

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 May 2001 (25.05.2001)

PCT

(10) International Publication Number
WO 01/36632 A2

(51) International Patent Classification⁷: **C12N 15/12**,
15/57, C07K 14/47, 14/705, C12N 9/48, C12Q 1/68,
G01N 33/68, 33/50, A61K 38/17, 38/48

46490 Herzliya (IL). **BERNSTEIN, Jeanne** [IL/IL]; 23
Harimon Street, 40300 Kfar Yona (IL).

(21) International Application Number: PCT/IL00/00766

(74) Agent: **REINHOLD COHN AND PARTNERS**; P.O.B.
4060, 61040 Tel Aviv (IL).

(22) International Filing Date:
17 November 2000 (17.11.2000)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
132978 17 November 1999 (17.11.1999) IL
133455 10 December 1999 (10.12.1999) IL

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **COMPU-
GEN LTD.** [IL/IL]; 72 Pinchas Rozen Street, 69512 Tel
Aviv (IL).

Published:

— Without international search report and to be republished
upon receipt of that report.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **LEVINE, Zurit**
[IL/IL]; 5 Hakozrim Street, 46360 Herzliya (IL). **DAVID,**
Anat [IL/IL]; 11 Afner Street, 53292 Givatayim (IL).
AZAR, Idit [IL/IL]; 2 Hankin Street, 76354 Rehovot (IL).
KHOSRAVI, Rami [IL/IL]; 36 Yehuda Halevy Street,

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: VARIANTS OF ALTERNATIVE SPLICING

(57) Abstract: The present invention concerns novel variants, amino acid and nucleic acid sequences obtained by alternative splicing of known sequences, expression vectors and host cells containing the variants' nucleic acid sequence, and antibodies reactive with the variants' products. The invention also concerns pharmaceutical compositions containing any of the above as well as methods of detection. A preferred example is the angiotensin converting enzyme (ACE) variant.

WO 01/36632 A2

1/103

VARIANTS OF ALTERNATIVE SPLICING

FIELD OF THE INVENTION

The present invention concerns novel nucleic acid sequences, vectors and host cells containing them, amino acid sequences encoded by said sequences, and antibodies reactive with said amino acid sequences, as well as pharmaceutical compositions comprising any of the above. The present invention further concerns methods for screening for candidate activators or deactivators utilizing said amino acid sequences.

BACKGROUND OF THE INVENTION

Alternative splicing (AS) is an important regulatory mechanism in higher eukaryotes (P.A. Sharp, *Cell* 77, 805-8152 (1994)). It is thought to be one of the most important mechanisms for differential expression related to tissue or development stage specificity. It is known to play a major role in numerous biological systems, including human antibody responses, and sex determination in *Drosophila*, (S. Stamm, M.Q. Zhang, T.G. Marr and D.M. Helfman, *Nucleic Acids Research* 22, 1515-1526 (1994); B. Chabot, *Trends Genet.* 12, 472-478 (1996); R.E. Breitbart, A. Andreadis, B. Nadal-Ginard, *Annual Rev. Biochem.*, 56, 467-495 (1987); C.W. Smith, J.G. Patton, B. Nadal-Ginard, *Annu. Rev. Genet.*, 27, 527-577 (1989)).

Until recently it was commonly believed that alternative splicing existed in only a small fraction of genes (about 5%). A recent observation based on literature survey of known genes revises this conservative estimate to as high as an estimate that at least 30% of human genes are alternatively spliced (M.S. Gelfand, I. Dubchak, I. Draluk and M. Zorn, *Nucleic Acids Research* 27, 301-302 (1999)). The importance of the actual frequency of this phenomenon lies not only

in the direct impact on the number of proteins created (100,000 human genes, for example, would be translated to a much higher number of proteins), but also in the diversity of functionality derived from the process.

Several mechanisms at different stages may be held responsible for the
5 complexity of higher eukaryote which include: alternative splicing at the transcription level, RNA editing at the post-transcriptional level, and post-translational modifications are the ones characterized to date.

Angiotensin I-converting enzyme (ACE) is a peptidyl dipeptide hydrolase that is located mainly on the luminal surface of vascular endothelial cells but also
10 in cells derived from the monocyte-macrophage system. Physiologically, ACE is a key enzyme in the renin-angiotensin system, converting angiotensin I into the potent vasopressor angiotensin II and also inactivating the vasodilator bradykinin.

Increased serum ACE activity (SACE) has been reported in pathologies involving stimulation of the monocytic cell line, primarily granulomatous
15 diseases. Sarcoidosis is the most frequent and the better studied of these diseases; high SACE is not only a well-established marker for the diagnosis but is also a useful tool for following its course and evaluating the effect of therapy of this disease.

SACE can also be increased in nonsarcoidotic pulmonary granulomatous
20 diseases such as silicosis and asbestosis, in extrathoracic granulomatous pathologies such as Gauchers disease and leprosis, and, to a lesser extent, in nongranulomatous disorders such as hyperthyroidism or cholestasis.

Decreased SACE has been reported in vascular pathologies involving an endothelial abnormality, such as deep vein thrombosis, and in endothelium
25 dysfunctions related to the toxicity of chemo- and radiotherapy used in cancers, leukemias, and hematopoietic or organ transplantations.

SACE is also of interest for monitoring arterial hypertension treated with specific synthetic ACE inhibitors.

Various methods have been developed for determining SACE activities. The most widely used is the spectrophotometric assay using hippuryl-histidyl-leucine as substrate. Fluorimetric and radiochemical assays using both classic and novel substrates have been proposed, but they are time consuming, require special apparatus, and are not suited to automation. Kinetic spectrophotometry of furylacryloyl-phenylalanyl-glycyl-glycine hydrolysis is now used extensively because it is easy to automatize.

Information obtained in the last decade indicates that angiotensin II increases the production of several autocrine factors, including transforming growth factor beta1 (TGF-beta1), tumor necrosis factor-alpha (TNF-alpha), and platelet-derived growth factor A chain (PDGF). Angiotensin also increases the release of other growth factors such as endothelin, platelet-activating factor (PAF), and interleukin 6. In addition, it increases the "activity" of nuclear factor-kappaB (NF-kappaB) and the synthesis of angiotensinogen. The emerging picture indicates that the actions of angiotensin II may be related to factors that are released or upregulated by angiotensin II, possibly through NF-kappaB.

GLOSSARY

In the following description and claims use will be made, at times, with a variety of terms, and the meaning of such terms as they should be construed in accordance with the invention is as follows:

"Variant nucleic acid sequence" – the sequence shown in any one of SEQ ID NO: 1 to SEQ ID NO: 87, native and known genes. It should be emphasized that the novel variants of the present invention are naturally occurring sequences resulting from alternative splicing of genes and not merely truncated, mutated or fragmented forms of known sequences which are artificially produced.

"Angiotensin converting enzyme variant (ACEV)" - a sequence shown in SEQ ID NO: 57 or 85 sequences having at least 90% identity (see below) to said sequence and *fragments* (see below) of the above sequences of least 20 b.p. long. These sequences are sequences coding for a novel, naturally occurring, alternative splice variants of the mouse angiotensin converting enzyme which convert angiotensin I to angiotensin II by release of the terminal His-Leu resulting in increase of vasoconstrictor activity of angiotensin.

"Variant product - also referred at times as the "variant protein" or "variant polypeptide" - is an amino acid sequence encoded by the variant nucleic acid sequence SEQ ID NO: 88 to SEQ ID NO: 174.

"ACEV product or ACEV protein" - amino acid coded by the ACEV nucleic acid which is a naturally occurring mRNA sequence obtained as a result of alternative splicing of the ACE gene. The amino acid sequence may be a peptide, a protein, as well as peptides or proteins having *chemically modified* amino acids (see below) such as a glycopeptide or glycoprotein. The variant products are shown in SEQ ID NO: 144 or 172. The term also includes *homologies* (see below) of said sequences in which one or more amino acids has been added, deleted, *substituted* (see below) or *chemically modified* (see below) as well as *fragments* (see below) of this sequence having at least 10 amino acids. The above two products may be secreted.

"Nucleic acid sequence" - a sequence composed of DNA nucleotides, RNA nucleotides or a combination of both types and may include natural nucleotides, chemically modified nucleotides and synthetic nucleotides.

"Amino acid sequence" - a sequence composed of any one of the 20 naturally appearing amino acids, amino acids which have been *chemically modified* (see below), or composed of synthetic amino acids.

"Fragment of variant nucleic acid sequence" and **"fragment of ACEV nucleic acid sequence"** - novel short stretch of nucleic acid sequences of at least 20 b.p., which does not appear as a continuous stretch in the *original nucleic acid sequence* (see below). The fragment may be a sequence which was previously
5 undescribed in the context of the published RNA and which affects the amino acid sequence encoded by the known gene. For example, where the variant nucleic includes a sequence which was not included in the original sequence (for example a sequence which was an intron in the original sequence) the fragment may contain said additional sequence. The fragment may also be a region which
10 is not an intron, which was not present in the original sequence. For example where the variant lacks a non-terminal region which was present in the original sequence. The two stretches of nucleotides spanning this region (upstream and downstream) are brought together by splicing in the variant, but are spaced from each by the spliced out region in the original sequence and are thus not
15 continuous in the original sequence. A continuous stretch of nucleic acids comprising said two splicing stretches of nucleotides is not present in the original sequence and thus falls under the definition of fragment.

"Fragments of variant products" - novel amino acid sequences coded by the
20 **"fragment of variant nucleic acid sequence"** or **"fragment of ACEV nucleic acid sequence"** defined above.

"Homologues of variants" - amino acid sequences of variants in which one or more amino acids has been added, deleted or replaced. The addition, deletion or
25 replacement should be in the regions or adjacent to regions where the variant differs from the *original sequence* (see below).

"Conservative substitution" - refers to the substitution of an amino acid in one class by an amino acid of the same class, where a class is defined by common
30 physicochemical amino acid side chain properties and high substitution

frequencies in homologous proteins found in nature, as determined, for example, by a standard Dayhoff frequency exchange matrix or BLOSUM matrix. [Six general classes of amino acid side chains have been categorized and include: Class I (Cys); Class II (Ser, Thr, Pro, Ala, Gly); Class III (Asn, Asp, Gln, Glu); Class IV (His, Arg, Lys); Class V (Ile, Leu, Val, Met); and Class VI (Phe, Tyr, Trp). For example, substitution of an Asp for another class III residue such as Asn, Gln, or Glu, is a conservative substitution.

"Non-conservative substitution" - refers to the substitution of an amino acid in one class with an amino acid from another class; for example, substitution of an Ala, a class II residue, with a class III residue such as Asp, Asn, Glu, or Gln.

"Chemically modified" - when referring to the product of the invention, means a product (protein) where at least one of its amino acid residues is modified either by natural processes, such as processing or other post-translational modifications, or by chemical modification techniques which are well known in the art. Among the numerous known modifications typical, but not exclusive examples include: acetylation, acylation, amidation, ADP-ribosylation, glycosylation, GPI anchor formation, covalent attachment of a lipid or lipid derivative, methylation, myristylation, pegylation, prenylation, phosphorylation, ubiquitination, or any similar process.

"Biologically active" - refers to the variant product having some sort of biological activity, for example, some physiologically measurable effect on target cells, molecules or tissues.

"Immunologically active" defines the capability of a natural, recombinant or synthetic variant product, or any fragment thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies. Thus, for example, an immunologically active fragment of variant product

denotes a fragment which retains some or all of the immunological properties of the variant product, e.g. can bind specific anti-variant product antibodies or which can elicit an immune response which will generate such antibodies or cause proliferation of specific immune cells which produce variant.

5

"Optimal alignment" - is defined as an alignment giving the highest percent identity score. Such alignment can be performed using a variety of commercially available sequence analysis programs, such as the local alignment program LALIGN using a ktup of 1, default parameters and the default PAM. A preferred
10 alignment is the one performed using the CLUSTAL-W program from MacVector (TM), operated with an open gap penalty of 10.0, an extended gap penalty of 0.1, and a BLOSUM similarity matrix. If a gap needs to be inserted into a first sequence to optimally align it with a second sequence, the percent identity is calculated using only the residues that are paired with a corresponding
15 amino acid residue (i.e., the calculation does not consider residues in the second sequences that are in the "gap" of the first sequence). In case of alignments of known gene sequences with that of the new variant, the optimal alignment invariably included aligning the identical parts of both sequences together, then keeping apart and unaligned the sections of the sequences that differ one from the
20 other.

"Having at least 90% identity" - with respect to two amino acid or nucleic acid sequence sequences, refers to the percentage of residues that are identical in the two sequences when the sequences are optimally aligned. Thus, 90% amino acid
25 sequence identity means that 90% of the amino acids in two or more optimally aligned polypeptide sequences are identical, however this definition explicitly excludes sequences which are 100% identical with the original sequence from which the variant of the invention was varied.

"Isolated nucleic acid molecule having an variant nucleic acid sequence" - is a nucleic acid molecule that includes the coding variant nucleic acid sequence. Said isolated nucleic acid molecule may include the variant nucleic acid sequence as an independent insert; may include the variant nucleic acid sequence fused to an additional coding sequences, encoding together a fusion protein in which the variant coding sequence is the dominant coding sequence (for example, the additional coding sequence may code for a signal peptide); the variant nucleic acid sequence may be in combination with non-coding sequences, e.g., introns or control elements, such as promoter and terminator elements or 5' and/or 3' untranslated regions, effective for expression of the coding sequence in a suitable host; or may be a vector in which the variant protein coding sequence is a heterologous.

"Expression vector" - refers to vectors that have the ability to incorporate and express heterologous DNA fragments in a foreign cell. Many prokaryotic and eukaryotic expression vectors are known and/or commercially available. Selection of appropriate expression vectors is within the knowledge of those having skill in the art.

"Deletion" - is a change in either nucleotide or amino acid sequence in which one or more nucleotides or amino acid residues, respectively, are absent.

"Insertion" or "addition" - is that change in a nucleotide or amino acid sequence which has resulted in the addition of one or more nucleotides or amino acid residues, respectively, as compared to the naturally occurring sequence.

"Substitution" - replacement of one or more nucleotides or amino acids by different nucleotides or amino acids, respectively. As regards amino acid sequences the substitution may be conservative or non- conservative.

"**Antibody**" – refers to IgG, IgM, IgD, IgA, or IgG antibody. The definition includes polyclonal antibodies or monoclonal antibodies. This term refers to whole antibodies or fragments of the antibodies comprising the antigen-binding domain of the anti-variant product antibodies, e.g. antibodies without the Fc portion, single chain antibodies, fragments consisting of essentially only the variable, antigen-binding domain of the antibody, etc.

"Distinguishing antibody" – an antibody capable of binding to the variant product and not the original amino acid sequence from which it has been varied, or an antibody capable of binding to the original nucleic acid sequence and not to the variant production.

"Activator" - as used herein, refers to a molecule which mimics the effect of the natural variant product or at times even increases or prolongs the duration of the biological activity of said product, as compared to that induced by the natural product. The mechanism may be by any mechanism known to prolonging activities of biological molecules such as binding to receptors; prolonging the lifetime of the molecules; increasing the activity of the molecules on its target; increasing the affinity of molecules to its receptor; inhibiting degradation or proteolysis of the molecules, or mimicking the biological activity of the variants on their targets, etc. Activators may be polypeptides, nucleic acids, carbohydrates, lipids, or derivatives thereof, or any other molecules which can bind to and activate the variant product.

"Deactivator" or ("**Inhibitor**") - refers to a molecule which modulates the activity of the variant product in an opposite manner to that of the activator, by decreasing or shortening the duration of the biological activity of the variant product. This may be done by any mechanism known to deactivate or inhibit biological molecules such as block of the receptor, block of active site, competition on binding site in target, enhancement of degradation, etc.

Deactivators may be polypeptides, nucleic acids, carbohydrates, lipids, or derivatives thereof, or any other molecules which bind to and modulate the activity of said product.

- 5 *"Treating a disease"* - refers to administering a therapeutic substance effective to ameliorate symptoms associated with a disease, to lessen the severity or cure the disease, or to prevent the disease from occurring.

"Detection" - refers to a method of detection of a disease, disorder, pathological
10 or normal condition. This term may refer to detection of a predisposition to a disease as well as for establishing the prognosis of the patient by determining the severity of the disease.

"Probe" - the variant nucleic acid sequence, or a sequence complementary
15 therewith, when used to detect presence of other similar sequences in a sample. The detection is carried out by identification of hybridization complexes between the probe and the assayed sequence. The probe may be attached to a solid support or to a detectable label.

20 *"Original sequence"* - the amino acid or nucleic acid sequence from which the variant of the invention have been varied as a result of alternative slicing.

SUMMARY OF THE INVENTION

The present invention is based on the finding of several novel, naturally occurring splice variants, which are naturally occurring sequences obtained by
25 alternative splicing of known genes. The novel splice variants of the invention are not merely truncated forms, fragments or mutations of known genes, but rather novel sequences which naturally occur within the body of individuals.

In particular the present invention concerns variants of alternative splice variants of angiotensin converting enzyme (ACEV).

The term "*alternative splicing*" in the context of the present invention and claims refers to: intron inclusion, exon exclusion, addition or deletion of terminal sequences in the variant as compared to the original sequences, as well as to the possibility of "*intron retention*". Intron retention is an intermediate stage in the
5 processing of RNA transcripts, where prior to production of fully processed mRNA the intron (naturally spliced in the original sequence) is retained in the variant. These intermediately processed RNAs may have physiological significance and are also within the scope of the invention.

The novel variant products of the invention, including the ACEV-variant
10 (ACEV), may have the same physiological activity as the original peptide from which they have been varied (although perhaps at a different level); may have an opposite physiological activity from the activity featured by the original peptide from which they are varied; may have a completely different, unrelated activity to the activity of the original from which they are varied; or alternatively may have no
15 activity at all and this may lead to various diseases or pathological conditions. The novel variants of the invention may differ from the original sequence, from which they were varied by alternative splicing, by physiological properties not relating directly to their activities such as: tissue localization, temporal pattern of expression, rate of clearance, rate of degradation, manner of up- or down
20 regulation, association with co-factors and cellular elements etc.

The novel variants may also serve for detection purposes, i.e. their presence or level may be indicative of a disease, disorder, pathological or normal condition or alternatively the ratio between the level variants and the level original peptide from which they were varied, or the ratio to other variants may be indicative to a
25 disease, disorder, pathological or normal condition.

For example, for detectional purposes, it is possible to establish differential expression of various variants in various tissues. A certain variant may be expressed mainly in one tissue, while the original sequence from which it has been varied, or another variant may, be expressed mainly in another tissue.
30 Understanding of the distribution of the variants in various tissues may be helpful

in basic research, for understanding the physiological function of the genes as well as may help in targeting pharmaceuticals or developing pharmaceuticals.

The study of the variants may also be helpful to distinguish various stages in the life cycles of the same type of cells which may also be helpful for development of pharmaceuticals for various pathological conditions in which cell cycles is non-normal, notably cancer.

Detection of various diseases in accordance with the invention is especially useful for detection of diseases which are associated with the function, (over function, under function, or malfunction) of proteins of the original sequence from which each variant of the invention has been obtained by alternative splicing. A list of the original proteins are given in the "Detailed Description" part of the specification. Thus, for example, if variant of SEQ ID NO: 3 is obtained from an original sequence which is coagulation factor XII, this sequence may be used to detect diseases involving excessive or diminished blood coagulation.

Thus the detection may be by determination of the presence or the level of expression of the variant within a specific cell population, comprising said presence or level between various cell types in a tissue, between different tissues and between individuals.

Where the variant in the angiotensin converting enzyme (ACEV) the detection may be used for detection (including disposition) of one of the following diseases.

Cardiovascular diseases:

Including hypertension, neurological damage due to cerebral circulatory disorders, peripheral vascular diseases, arteriosclerosis, heart and kidney diseases relating to blood pressure, erection problems and migraine problems relating to circulation functions, heart failures (including recurrent infraction in patients with left ventricular dysfunction), acute phase of myocardial infarction, coronary arterial thrombosis and cardiac insufficiency.

Renal diseases:

Hypertension adrenal injury (particularly in patients with type I or II diabetes), diabetic nephropathy, renal function deterioration in glomerular diseases

Muscular diseases:

5 Diseases involving growth of smooth muscle cells such as hypertrophy.

Immune disorders:

Various autoimmune diseases and diseases involving inflammatory mechanisms, for example, autoimmune manifestation affects in sarcoidosis, generation of immune complex nephritis, autoimmune encephatomyelitis, marker
10 for chronic fatigue-immune dysfunction syndrome.

Multiple sclerosis:Cancer:

Especially those cancers effected by different growth factors including endothelia, platelet-activating factor (PAF) and interleukin 6. Examples of such
15 cancers are tumors of the vascular system, and leukemias.

Diabetes:

Sarcoidosis – a disease of unknown origin characterized by the formation of granulomatous lesions that appear especially in the liver, lungs, skin and lymph nodes.

20 Nonaroidotic Pulmonary Granulomatous Diseases:

Such as silicosis and asbestosis, in extrathoracic granulomatous pathologies such as Gauchers disease and leprosis, and, to a lesser extent, in nongranulomatous disorders such as hyperthyroidism or cholestasis. (increased sACE)

25 Vascular Pathologies Involving An Endothelial Abnormality:

Deep vein thrombosis, and in endothelium dysfunctions related to the toxicity of chemo- and radiotherapy used in cancers, leukemias, and hematopoietic or organ transplantations.

Thus the present invention provides by its first aspect, a novel isolated
30 nucleic acid molecule comprising or consisting of any one of the coding sequence

SEQ ID NO: 1 to SEQ ID NO: 87, fragments of said coding sequence having at least 20 nucleic acids (provided that said fragments are continuous stretches of nucleotides not present in the original sequence from which the variant was varied), or a molecule comprising a sequence having at least 90% identity to SEQ ID
5 NO: 1 to SEQ ID NO: 87, provided that the molecule is not completely identical to the original sequence from which the variant was varied. In particular, the above variant is that of SEQ ID NO: 57 or SEQ ID NO: 85 being the ACEV nucleic acid sequence.

The present invention further provides a protein or polypeptide comprising
10 or consisting of an amino acid sequence encoded by any of the above nucleic acid sequences, termed herein "*variant product*", for example, an amino acid sequence having the sequence as depicted in any one of SEQ ID NO: 88 to SEQ ID NO: 174, fragments of the above amino acid sequence having a length of at least 10 amino acids coded by the above fragments of the nucleic acid sequences, as well as
15 homologues of the above amino acid sequences in which one or more of the amino acid residues has been substituted (by conservative or non-conservative substitution) added, deleted, or chemically modified. In particular, the product is the amino acid sequence of the ACEV as depicted in SEQ ID NO: 144 or 172.

The deletions, insertions and modifications should be in regions, or adjacent
20 to regions, wherein the variant differs from the original sequence.

For example, where the variant is different from the original sequence by addition of a short stretch of 10 amino acids, in the terminal or non-terminal portion of the peptide, the invention also concerns homologues of that variant where the additional short stretch is altered for example, it includes only 8
25 additional amino acids, includes 13 additional amino acids, or it includes 10 additional amino acids, however some of them being conservative or non-conservative substitutes of the original additional 10 amino acids of the novel variants. In all cases the changes in the homolog, as compared to the original sequence, are in the same regions where the variant differs from the original
30 sequence, or in regions adjacent to said region.

Another example is where the variant lacks a non-terminal region (for example of 20 amino acids) which is present in the original sequence (due for example to exon exclusion). The homologues may lack in the same region only 17 amino acids or 23 amino acids. Again the deletion is in the same region where the
5 variant lacks a sequence as compared to the original sequence, or in a region adjacent thereto.

It should be appreciated that once a man versed in the art's attention is directed to the importance of a specific region, due to the fact that this region differs in the variant as compared to the original sequence, there is no problem in
10 derivating said specific region by addition to it, deleting from it, or substituting some amino acids in it. Thus homologues of variants which are derivated from the variant by changes (deletion, addition, substitution) only in said region as well as in regions adjacent to it are also a part of the present invention. Generally, if the variant is distinguished from the original sequence by some sort of physiological
15 activity, then the homolog is distinguished from the original sequence in essentially the same manner.

The present invention further provides nucleic acid molecule comprising or consisting of a sequence which encodes the above amino acid sequences, (including the fragments and homologues of the amino acid sequences and in
20 particular the ACEV amino acid sequence). Due to the degenerative nature of the genetic code, a plurality of alternative nucleic acid, beyond those depicted in any one of SEQ ID NO: 1 to SEQ ID NO: 87, can code for the amino acid sequence of the invention. Those alternative nucleic acid sequences which code for the same amino acid sequences codes by the sequence SEQ ID NO: 1 to SEQ ID NO: 87 are
25 also an aspect of the of the present invention.

The present invention further provides expression vectors and cloning vectors comprising any of the above nucleic acid sequences, as well as host cells transfected by said vectors.

The present invention still further provides pharmaceutical compositions comprising, as an active ingredient, said nucleic acid molecules, said expression vectors, or said protein or polypeptide.

These pharmaceutical compositions are suitable for the treatment of diseases
5 and pathological conditions, which can be ameliorated or cured by raising the level of any one of the variant products of the invention. In particular, those diseases are diseases which are associated with malfunction or under function of the original sequence (for example, given in the "Detailed Description" part of the specification). Thus for example, SEQ ID NO: 3 and sequences encoded thereby
10 may be used to treat diseases associated with coagulation of blood.

By a second aspect, the present invention provides a nucleic acid molecule comprising or consisting of a non-coding sequence which is complementary to that of any one of SEQ ID NO: 1 to SEQ ID NO: 87, or complementary to a sequence having at least 90% identity to said sequence (with the proviso added above) or a
15 fragment of said two sequences (according to the above definition of fragment). The complementary sequence may be a DNA sequence which hybridizes with any one of SEQ of ID NO: 1 to SEQ ID NO: 87 or hybridizes to a portion of that sequence having a length sufficient to inhibit the transcription of the complementary sequence. The complementary sequence may be a DNA sequence
20 which can be transcribed into an mRNA being an antisense to the mRNA transcribed from any one of SEQ ID NO: 1 to SEQ ID NO: 87 or into an mRNA which is an antisense to a fragment of the mRNA transcribed from any one of SEQ ID NO: 1 to SEQ ID NO: 87 which has a length sufficient to hybridize with the mRNA transcribed from SEQ ID NO: 1 to SEQ ID NO: 87, so as to inhibit its
25 translation. The complementary sequence may also be the mRNA or the fragment of the mRNA itself.

The nucleic acids of the second aspect of the invention may be used for therapeutic or diagnostic applications for example as probes used for the detection of the variants of the invention. The presence of the variant transcript or the level of
30 the variant transcript may be indicative of a multitude of diseases, disorders and

various pathological as well as normal conditions for example, as indicated above for the variants in general, and for the ACEV in particular. In addition or alternatively, the ratio of the level of the transcripts of the variants of the invention may also be compared to that of the transcripts of the original sequences from which have been varied, or to the level of transcript of other variants, and said ratio may be indicative to a multitude of diseases, disorders and various pathological and normal conditions.

The present invention also provides expression vectors comprising any one of the above defined complementary nucleic acid sequences and host cells transfected with said nucleic acid sequences or vectors, being complementary to those specified in the first aspect of the invention.

The invention also provides anti-variant product antibodies, namely antibodies directed against the variant product which specifically bind to said variant product. Said antibodies are useful both for diagnostic and therapeutic purposes. For example said antibody may be as an active ingredient in a pharmaceutical composition as will be explained below.

The present invention also provides pharmaceutical compositions comprising, as an active ingredient, the nucleic acid molecules which comprise or consist of said complementary sequences, or of a vector comprising said complementary sequences. The pharmaceutical composition thus provides pharmaceutical compositions comprising, as an active ingredient, said anti-variant product antibodies.

The pharmaceutical compositions comprising said anti-variant product antibodies or the nucleic acid molecule comprising said complementary sequence, are suitable for the treatment of diseases and pathological conditions where a therapeutically beneficial effect may be achieved by neutralizing the variant (either at the transcript or product level) or decreasing the amount of the variant product or blocking its binding to its target, for example, by the neutralizing effect of the antibodies, or by the effect of the antisense mRNA in decreasing the expression level of the variant sequence.

Examples of diseases which can be treated either with ACEV sequence, an expression vector comprising that sequence, a sequence complementary to the ACEV sequence, an expression vector comprising said complementary sequence, ACEV product or an antibody to the product is any one of the diseases mentioned
5 in connection with the detection aspect above.

According to the third aspect of the invention the present invention provides methods for detecting the level of the transcript (mRNA) of said variant product in a body fluid sample, or in a specific tissue sample, for example by use of probes comprising or consisting of said coding sequences; as well as methods for detecting
10 levels of expression of said product in tissue, e.g. by the use of antibodies capable of specifically reacting with the variant products of the invention. Detection of the level of the expression of the variant of the invention in particular as compared to that of the original sequence from which it was varied or compared to other variant sequences all varied from the same original sequence may be indicative of a
15 plurality of physiological or pathological conditions. A preferred example is the detection of ACEV nucleic acid sequence, ACEV product or anti-ACEV antibody.

The method, according to this latter aspect, for detection of a nucleic acid sequence which encodes the variant product in a biological sample, comprises the steps of:

- 20 (a) providing a probe comprising at least one of the nucleic acid sequences defined above;
- (b) contacting the biological sample with said probe under conditions allowing hybridization of nucleic acid sequences thereby enabling formation of hybridization complexes;
- 25 (c) detecting hybridization complexes, wherein the presence of the complexes indicates the presence of nucleic acid sequence encoding the variant product in the biological sample.

The method as described above is qualitative, i.e. indicates whether the transcript is present in or absent from the sample. The method can also be
30 quantitative, by determining the level of hybridization complexes and then

calibrating said levels to determining levels of transcripts of the desired variant in the sample.

Both qualitative and quantitative determination methods can be used for diagnostic, prognostic and therapy planning purposes.

5 By a preferred embodiment the probe is part of a nucleic acid chip used for detection purposes, i.e. the probe is a part of an array of probes each present in a known location on a solid support.

The nucleic acid sequence used in the above method may be a DNA sequence an RNA sequence, etc; it may be a coding or a sequence or a sequence
10 complementary thereto (for respective detection of RNA transcripts or coding-DNA sequences). By quantization of the level of hybridization complexes and calibrating the quantified results it is possible also to detect the level of the transcript in the sample.

Methods for detecting mutations in the region coding for the variant product
15 are also provided, which may be methods carried-out in a binary fashion, namely merely detecting whether there is any mismatches between the normal variant nucleic acid sequence of the invention and the one present in the sample, or carried-out by specifically detecting the nature and location of the mutation.

The present invention also concerns a method for detecting variant product
20 in a biological sample, comprising the steps of:

(a) contacting with said biological sample the antibody of the invention, thereby forming an antibody-antigen complex; and

(b) detecting said antibody-antigen complex

wherein the presence of said antibody-antigen complex correlates with the
25 presence of variant product in said biological sample.

Many diseases are diagnosed by detecting the presence of antibodies against a protein characterizing the disease in the blood, serum or any other body fluid of the patient. The present invention also concerns a method for detecting anti-variant antibody in a biological sample, comprising:

(a) contacting said sample with the variant product of the invention, thereby forming an antibody-antigen complex; and

(b) detecting said antibody-antigen complex

wherein the presence of said antibody-antigen complex correlates with the
5 presence of anti-variant antibody in the sample.

As indicated above, both methods (for detection of variant product and for detection of the anti-variant antibody) can be quantitized to determine the level or the amount of the variant or antibody in the sample, alone or in comparison to the level of the original amino acid sequence from which it was varied or compared to
10 the level of antibodies against the original amino acid sequence, and qualitative and quantitative results may be used for diagnostic, prognostic and therapy planning purposes.

The invention also concerns distinguishing antibodies, i.e. antibodies capable of binding either to the variant product or to the original sequence from
15 which the variant has been varied, while not binding to the original sequence or the variant product respectively. These distinguishing antibodies may be used for detection purposes.

By yet another aspect the invention also provides a method for identifying candidate compounds capable of binding to the variant product and modulating its
20 activity (being either activators or deactivators). The method includes:

(i) providing a protein or polypeptide comprising an amino acid sequence substantially as depicted in any one of SEQ ID NO: 88 to 174, or a fragment of such a sequence;

(ii) contacting a candidate compound with said amino acid sequence;

25 (iii) measuring the physiological effect of said candidate compound on the activity of the amino acid sequences and selecting those compounds which show a significant effect on said physiological activity.

The present invention also concerns compounds identified by the above methods described above, which compound may either be an activator of the
30 variant product or a deactivator thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

In order to understand the invention and to see how it may be carried out in practice, a preferred embodiment will now be described, by way of non-limiting example only, with reference to the accompanying drawings, in which:

5 **Fig. 1** is a comparison between the amino acid sequence of SEQ ID NO: 88 and the original sequence from which it has been varied;

Fig. 2 is a comparison between the amino acid sequence of SEQ ID NO: 89 and the original sequence from which it has been varied;

Fig. 3 is a comparison between the amino acid sequence of SEQ ID NO: 90
10 and the original sequence from which it has been varied;

Fig. 4 is a comparison between the amino acid sequence of SEQ ID NO: 91 and the original sequence from which it has been varied;

Fig. 5 is a comparison between the amino acid sequence of SEQ ID NO: 92 and the original sequence from which it has been varied;

15 **Fig. 6** is a comparison between the amino acid sequence of SEQ ID NO: 93 and the original sequence from which it has been varied;

Fig. 7 is a comparison between the amino acid sequence of SEQ ID NO: 94 and the original sequence from which it has been varied;

Fig. 8 is a comparison between the amino acid sequence of SEQ ID NO: 95
20 and the original sequence from which it has been varied;

Fig. 9 is a comparison between the amino acid sequence of SEQ ID NO: 96 and the original sequence from which it has been varied;

Fig. 10 is a comparison between the amino acid sequence of SEQ ID NO: 97 and the original sequence from which it has been varied;

25 **Fig. 11** is a comparison between the amino acid sequence of SEQ ID NO: 98 and the original sequence from which it has been varied;

Fig. 12 is a comparison between the amino acid sequence of SEQ ID NO: 99 and the original sequence from which it has been varied;

Fig. 13 is a comparison between the amino acid sequence of SEQ ID
30 NO: 100 and the original sequence from which it has been varied;

Fig. 14 is a comparison between the amino acid sequence of SEQ ID NO: 101 and the original sequence from which it has been varied;

Fig. 15 is a comparison between the amino acid sequence of SEQ ID NO: 102 and the original sequence from which it has been varied;

5 **Fig. 16** is a comparison between the amino acid sequence of SEQ ID NO: 103 and the original sequence from which it has been varied;

Fig. 17 is a comparison between the amino acid sequence of SEQ ID NO: 104 and the original sequence from which it has been varied;

Fig. 18 is a comparison between the amino acid sequence of SEQ ID
10 NO: 105 and the original sequence from which it has been varied;

Fig. 19 is a comparison between the amino acid sequence of SEQ ID NO: 106 and the original sequence from which it has been varied;

Fig. 20 is a comparison between the amino acid sequence of SEQ ID NO: 107 and the original sequence from which it has been varied;

15 **Fig. 21** is a comparison between the amino acid sequence of SEQ ID NO: 108 and the original sequence from which it has been varied;

Fig. 22 is a comparison between the amino acid sequence of SEQ ID NO: 109 and the original sequence from which it has been varied;

Fig. 23 is a comparison between the amino acid sequence of SEQ ID
20 NO: 110 and the original sequence from which it has been varied;

Fig. 24 is a comparison between the amino acid sequence of SEQ ID NO: 111 and the original sequence from which it has been varied;

Fig. 25 is a comparison between the amino acid sequence of SEQ ID NO: 112 and the original sequence from which it has been varied;

25 **Fig. 26** is a comparison between the amino acid sequence of SEQ ID NO: 113 and the original sequence from which it has been varied;

Fig. 27 is a comparison between the amino acid sequence of SEQ ID NO: 114 and the original sequence from which it has been varied;

Fig. 28 is a comparison between the amino acid sequence of SEQ ID
30 NO: 115 and the original sequence from which it has been varied;

Fig. 29 is a comparison between the amino acid sequence of SEQ ID NO: 116 and the original sequence from which it has been varied;

Fig. 30 is a comparison between the amino acid sequence of SEQ ID NO: 117 and the original sequence from which it has been varied;

5 Fig. 31 is a comparison between the amino acid sequence of SEQ ID NO: 118 and the original sequence from which it has been varied;

Fig. 32 is a comparison between the amino acid sequence of SEQ ID NO: 119 and the original sequence from which it has been varied;

10 Fig. 33 is a comparison between the amino acid sequence of SEQ ID NO: 120 and the original sequence from which it has been varied;

Fig. 34 is a comparison between the amino acid sequence of SEQ ID NO: 121 and the original sequence from which it has been varied;

Fig. 35 is a comparison between the amino acid sequence of SEQ ID NO: 122 and the original sequence from which it has been varied;

15 Fig. 36 is a comparison between the amino acid sequence of SEQ ID NO: 123 and the original sequence from which it has been varied;

Fig. 37 is a comparison between the amino acid sequence of SEQ ID NO: 124 and the original sequence from which it has been varied;

20 Fig. 38 is a comparison between the amino acid sequence of SEQ ID NO: 125 and the original sequence from which it has been varied;

Fig. 39 is a comparison between the amino acid sequence of SEQ ID NO: 126 and the original sequence from which it has been varied;

Fig. 40 is a comparison between the amino acid sequence of SEQ ID NO: 127 and the original sequence from which it has been varied;

25 Fig. 41 is a comparison between the amino acid sequence of SEQ ID NO: 128 and the original sequence from which it has been varied;

Fig. 42 is a comparison between the amino acid sequence of SEQ ID NO: 129 and the original sequence from which it has been varied;

30 Fig. 43 is a comparison between the amino acid sequence of SEQ ID NO: 130 and the original sequence from which it has been varied;

Fig. 44 is a comparison between the amino acid sequence of SEQ ID NO: 131 and the original sequence from which it has been varied;

Fig. 45 is a comparison between the amino acid sequence of SEQ ID NO: 132 and the original sequence from which it has been varied;

5 **Fig. 46** is a comparison between the amino acid sequence of SEQ ID NO: 133 and the original sequence from which it has been varied;

Fig. 47 is a comparison between the amino acid sequence of SEQ ID NO: 134 and the original sequence from which it has been varied;

Fig. 48 is a comparison between the amino acid sequence of SEQ ID
10 NO: 135 and the original sequence from which it has been varied;

Fig. 49 is a comparison between the amino acid sequence of SEQ ID NO: 136 and the original sequence from which it has been varied;

Fig. 50 is a comparison between the amino acid sequence of SEQ ID NO: 137 and the original sequence from which it has been varied;

15 **Fig. 51** is a comparison between the amino acid sequence of SEQ ID NO: 138 and the original sequence from which it has been varied;

Fig. 52 is a comparison between the amino acid sequence of SEQ ID NO: 139 and the original sequence from which it has been varied;

Fig. 53 is a comparison between the amino acid sequence of SEQ ID NO:
20 140 and the original sequence from which it has been varied;

Fig. 54 is a comparison between the amino acid sequence of SEQ ID NO: 141 and the original sequence from which it has been varied;

Fig. 55 is a comparison between the amino acid sequence of SEQ ID NO: 142 and the original sequence from which it has been varied;

25 **Fig. 56** is a comparison between the amino acid sequence of SEQ ID NO: 143 and the original sequence from which it has been varied;

Fig. 57 is a comparison between the amino acid sequence of SEQ ID NO: 144 and the original sequence from which it has been varied;

Fig. 58 is a comparison between the amino acid sequence of SEQ ID NO:
30 145 and the original sequence from which it has been varied;

Fig. 59 is a comparison between the amino acid sequence of SEQ ID NO: 146 and the original sequence from which it has been varied;

Fig. 60 is a comparison between the amino acid sequence of SEQ ID NO: 147 and the original sequence from which it has been varied;

5 **Fig. 61** is a comparison between the amino acid sequence of SEQ ID NO: 148 and the original sequence from which it has been varied;

Fig. 62 is a comparison between the amino acid sequence of SEQ ID NO: 149 and the original sequence from which it has been varied;

Fig. 63 is a comparison between the amino acid sequence of SEQ ID NO: 10 150 and the original sequence from which it has been varied;

Fig. 64 is a comparison between the amino acid sequence of SEQ ID NO: 151 and the original sequence from which it has been varied;

Fig. 65 is a comparison between the amino acid sequence of SEQ ID NO: 152 and the original sequence from which it has been varied;

15 **Fig. 66** is a comparison between the amino acid sequence of SEQ ID NO: 153 and the original sequence from which it has been varied;

Fig. 67 is a comparison between the amino acid sequence of SEQ ID NO: 154 and the original sequence from which it has been varied;

Fig. 68 is a comparison between the amino acid sequence of SEQ ID NO: 20 155 and the original sequence from which it has been varied;

Fig. 69 is a comparison between the amino acid sequence of SEQ ID NO: 156 and the original sequence from which it has been varied;

Fig. 70 is a comparison between the amino acid sequence of SEQ ID NO: 157 and the original sequence from which it has been varied;

25 **Fig. 71** is a comparison between the amino acid sequence of SEQ ID NO: 158 and the original sequence from which it has been varied;

Fig. 72 is a comparison between the amino acid sequence of SEQ ID NO: 159 and the original sequence from which it has been varied;

Fig. 73 is a comparison between the amino acid sequence of SEQ ID NO: 30 160 and the original sequence from which it has been varied;

Fig. 74 is a comparison between the amino acid sequence of SEQ ID NO: 161 and the original sequence from which it has been varied;

Fig. 75 is a comparison between the amino acid sequence of SEQ ID NO: 162 and the original sequence from which it has been varied;

5 **Fig. 76** is a comparison between the amino acid sequence of SEQ ID NO: 163 and the original sequence from which it has been varied;

Fig. 77 is a comparison between the amino acid sequence of SEQ ID NO: 164 and the original sequence from which it has been varied;

Fig. 78 is a comparison between the amino acid sequence of SEQ ID NO: 10 165 and the original sequence from which it has been varied;

Fig. 79 is a comparison between the amino acid sequence of SEQ ID NO: 166 and the original sequence from which it has been varied;

Fig. 80 is a comparison between the amino acid sequence of SEQ ID NO: 167 and the original sequence from which it has been varied;

15 **Fig. 81** is a comparison between the amino acid sequence of SEQ ID NO: 168 and the original sequence from which it has been varied;

Fig. 82 is a comparison between the amino acid sequence of SEQ ID NO: 169 and the original sequence from which it has been varied;

Fig. 83 is a comparison between the amino acid sequence of SEQ ID NO: 20 170 and the original sequence from which it has been varied;

Fig. 84 is a comparison between the amino acid sequence of SEQ ID NO: 171 and the original sequence from which it has been varied;

Fig. 85 is a comparison between the amino acid sequence of SEQ ID NO: 172 and the original sequence from which it has been varied;

25 **Fig. 86** is a comparison between the amino acid sequence of SEQ ID NO: 173 and the original sequence from which it has been varied;

Fig. 87 is a comparison between the amino acid sequence of SEQ ID NO: 174 and the original sequence from which it has been varied;

Fig. 88 shows immunohistochemical staining with antibodies against a fragment of the ACEV product of SEQ ID NO: 144; expressed in ductal epitelus in salivatory gland (magnification X 100);

Fig. 89 shows the same as in Fig. 89 (magnification X 400);

5 Fig. 90 shows immunohistochemical staining with antibodies against a fragment of ACEV product of SEQ ID NO: 144 expressed in salivary glands surrounding the lymph nodes; and

Fig. 91 shows RT-PCR results of the ACEV sequence expressed in salivary glands.

10

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Example I: Comparison of variants with original sequences

Original sequences were obtained from GenBank Version 110. Comparison between the original sequences and the novel variant sequences was
15 made using the Pileup application from the GCG suite version 10.0 (January 1999), with the default values:

Gap creation penalty (GapWeight): 8

Gap extension penalty (GapLengthWeight): 2

The comparison is shown in Fig. 1 to 87 which show the comparison of
20 each of the variant products depicted in SEQ ID NO: 88 to 174 with the original sequence from which it was varied.

The following is a list which gives the name and the description of each original sequence from which the alternative splice variant has been varied by alternative splicing. The description is followed by the internal reference to the
25 novel variant (NV-NV... or NV-... etc.) and a short comparison between the variant and the original sequence. It should be noticed that several splice variants may have been originated from the same parent sequence by several different alternative splicings. The following table summarizes the accession number of the original sequence, the terminology of the new variant (RN-NV... or NV-...) and
30 the description of the difference between the new variant and the original sequence.

Table

Accession	SEQ ID NO:	Description of the New Variant
AA2A_HUMAN	88	Gap between amino acids at the positions 237-247 of the original protein. Missing 6th transmembrane loop of the original Adenosine A2 receptor.
ASM_HUMAN	89	Insertion of 2 amino acids after amino acid at the position 34 and insertion of 54 amino acids after amino acid at the position 492 of the original SPHINGOMYELIN PHOSPHODIESTERASE protein.
FA12_HUMAN	90	Alternative 10 C-terminal amino acids. Has part of catalytic domain missing 1 active site.
GCSR_HUMAN	91	Deletion of 62 amino acids between the positions 320-382 of the original GRANULOCYTE COLONY STIMULATING FACTOR receptor. The deletion is in the EXTRACELLULAR domain in one of the FIBRONECTIN TYPE-III domains R1.
GCSR_HUMAN	92	Insertion of 37 amino acids in the extracellular domain after the position 574 of the original GRANULOCYTE COLONY STIMULATING FACTOR receptor.
GLR2_HUMAN	93	Replacement of 88 C-terminal amino acids of the original glutamate receptor 2 by alternative 42 amino acids. Has most of domains, might be missing 4th transmembrane domain.
GLUC_HUMAN	94	Gap; 156aa compared to 180aa; exact 1-108; gap 108-132; exact 132-180. Missing almost whole GLUCAGON-LIKE PEPTIDE 1
IHBA_HUMAN	95	Replacement of 128 N-terminal amino acids of the original inhibin protein by alternative 5 amino acids. The deleted part contains propep and glycosylation site of the original protein. The resulting new variant sustains the inhibin beta chain.
IL6_HUMAN	96	Deletion of 17 amino acids between the positions 79-96 of the original interleukin 6 protein. Has all necessary domains.
IL6_HUMAN	97	Deletion of 55 amino acids between the positions 6-61 of the original protein. Has only the beginning of signal peptide; has disulfide bonds and carbohydrate region.
REL1_HUMAN	98	Insertion of 35 amino acids after the amino acid

		at the position 70 of the original relaxin protein. The insertion is in the connecting peptide.
SY04_HUMAN	99	Deletion of 5 amino acids between the positions 65-69 of the original protein. Replacement of the amino acid at the position 70 of the original protein by an alternative amino acid. Missing part of strand.
TSP1_HUMAN	100	Truncated: exact 1-722 (731aa long compared to 1170aa), last 9 amino acids are different. Missing 7 X TSP TYPE-3-REPEATS CA-BINDING domain C-TERMINAL, missing CELL ATTACHMENT SITE, missing 1 out of 4 glycosylation sites. Has all other components including signal peptide.
TSP1_HUMAN	101	Truncated exact 1-548 (555aa long compared to 1170) last 7aa different. Missing 3 X EGF-TYPE REPEATS, missing 7 X TSP TYPE-3 REPEATS Ca-BINDING domain C-TERMINAL missing CELL ATTACHMENT SITE, missing all diSulfide bonds, missing 2 out of 4 glycosylation sites. Has all other domains (including signal peptide).
TSP1_HUMAN	102	Truncated: exact 1-490 (546aa long compared to 1170) last 56 amino acids are different. Missing 1 out of 3 X TXP TYPE-1 REPEATS (CS-LIKE), Missing 3 X EGF-TYPE REPEATS, missing 7 X TSP TYPE-3 REPEATS CA-BINDING domain C-TERMINAL missing CELL ATTACHMENT SITE, missing all diSulfide bonds, missing 2 out of 4 glycosylations. Has all other domains (including signal peptide).
TSP1_HUMAN	103	Truncated: exact 1-431aa (459aa long compared to 1170) last 28 amino acids are different. Missing 2 out of 3 X TSP TYPE-1 REPEATS (CS-LIKE), Missing 3 X EGF-TYPE REPEATS, missing 7 X TSP TYPE-3 REPEATS CA-BINDING domain C-TERMINAL missing CELL ATTACHMENT SITE, missing all disulfide bonds, missing 2 out of 4 glycosylations. Has all other domains (including signal peptide).
TYPH_HUMAN	104	Deletion of 119 amino acids between the positions 33-452 of the original protein. The resulting new variant is missing the 3 rd repeat of the original protein.

TYPH_HUMAN	105	Replacement of 48 amino acids between the positions 216-264 of the original protein by alternative 9 amino acids.
TYPH_HUMAN	106	Deletion of 119 amino acids between the positions 333-452, missing 3 rd repeat of the original protein. Replacement of 48 amino acids between the positions 216-264 of the original protein by alternative 9 amino acids.
IC1_HUMAN	107	Deletion of 19 amino acids between the positions 29-48 of the original protein. Missing 1 glycosylation out of 14.
PT16_HUMAN	108	Deletion of 261 N-terminal amino acids of the original protein (the first possible Met is at the position 261). The new variant has 116 amino acids compared to 376 in the original protein (exact 261-376), including the active site.
PT16_HUMAN	109	Deletion of 57 amino acids between the positions 267-325 of the original protein. The resulting new variant contains the active site.
PT16_HUMAN	110	Deletion of 189 amino acids between the positions 89-278 of the original protein. The resulting new variant contains the active site.
PT16_HUMAN	111	Replacement of 376 C-terminal amino acids of the original protein by alternative 5 amino acids. The resulting new variant doesn't contain the active site.
IAP2_HUMAN	112	Truncated: 305 amino acids compared to 618 aa (protein 2). The new variant contains exact positions 1-299, last 6 amino acids are different. Two SNIPs in position 235 and 241 of the original protein. The new variant is missing Zn Finger and half of 3 rd BIR repeat.
SET_HUMAN	113	Extra 83 amino acids in the N-terminus of the protein. The added sequence has predicted potential transmembrane domain (probable signal peptide?)
SET_HUMAN	114	Replacement of 24 C-terminal amino acids of the original protein by alternative 8 amino acids. Missing part of ASP/GLU-RICH and BREAKPOINT FOR TRANSLOCATION TO FORM SET-CAN ONCOGENE.
CDNC_HUMAN	115	Deletion of 178 amino acids at the positions 97-275 of the original protein. Insertion of 121 amino acids at the N-terminus. The resulting new variant is missing PAPA repeats.
F13B_MOUSE	116	Deletion of 87 C-terminal amino acids of the original protein. SNIP at position 236 (L->V). The resulting new variant is missing the last

		shushi repeat.
EGF_MOUSE	117	Deletion of 641 amino acids between the positions 67-708 of the original protein. Missing 4 EGF-like domains, 2 glycosylations, 9 diSulfide bonds.
EGF_MOUSE	118	Deletion of 641 amino acids between the positions 67-708, and deletion of 45 amino acids between the positions 1020-1065 of the original protein. Missing 4 EGF-like domains, 2 glycosylations, 9 diSulfide bonds. Missing transmembrane domain.
EGF_MOUSE	119	Deletion of 641 amino acids between the positions 67-708 of the original protein. Missing 4 EGF-like domains, 2 glycosylations, 9 diSulfide bonds. Replacement of 419 C-terminal amino acids by 5 amino acids.
EGF_MOUSE	120	Deletion of 841 amino acids between the positions 18-859 of the original protein. Missing 5 EGF-like domains and 2 glycosylation sites.
EGF_MOUSE	121	Deletion of 774 amino acids between the positions 5-779 of the original protein. Missing signal peptide, 5 EGF-like domains, and 2 glycosylation sites.
P53_MOUSE	122	Deletion of 336 N-terminal amino acids of the original protein. Missing ASP/GLU-RICH (ACIDIC), missing hydrophobic domain, missing NUCLEAR LOCALIZATION SIGNAL, missing 1 out of 2 PHOSPHORYLATION sites.
NME3_HUMAN	123	Deletion of 381 N-terminal amino acids of the original protein. Missing 2 out of 4 glycosylation sites.
TRFE_HUMAN	124	Deletion of 34 amino acids between the positions 654-689 of the original protein. Loss of disulfide bond.
TRFE_HUMAN	125	Deletion of 52 amino acids between the positions 447-499 of the original protein. Loss of disulfide bond.
BAA23795	126	Replacement of 83 C-terminal amino acids from probable cytoplasmic domain of the original protein by alternative 4 amino acids. Resulting in truncated new variant: 4787 compared to 4866, exact 1-4783 with last 4 amino acids different.
VIPS_HUMAN	127	Replacement of 64 C-terminal amino acids of the original protein by alternative 7 amino acids. The resulting new variant is missing the

		last transmembrane and the cytoplasmic domains.
PACR_HUMAN	128	Deletion of 22 amino acids between the positions 88-110 of the original protein. The deletion is an extracellular loop.
NRP_HUMAN	129	Deletion of 540 C-terminal amino acids of the original protein, resulting in truncated new variant (383 compared to 923 amino acids). The new variant is missing part of the extracellular domain, the cytoplasmic and the transmembrane domains.
NRP_HUMAN	130	Replacement of 595 C-terminal amino acids of the original protein by alternative 11 amino acids. The resulting new variant is truncated (339 compared to 923 amino acids, exact 1-328 with last 11 amino acids different), and is missing part of the extracellular domain, the cytoplasmic and the transmembrane domains.
gi1899200	131	Deletion of 114 amino acids between the positions 1257-1372 of the original N-METHYL D-ASPARTATE RECEPTOR SUBTYPE 2A protein.
VIPS_HUMAN	132	Replacement of 56 C-terminal amino acids from the cytoplasmic domain of the original protein by alternative 73 amino acids.
VIPS_HUMAN	133	Replacement of 56 C-terminal amino acids from the cytoplasmic domain of the original protein by alternative 70 amino acids.
IG1R_HUMAN	134	Deletion of 22 amino acids between the positions 1268-1291 of the original protein. The deleted fragment is part of the cytoplasmic domain of INSULIN-LIKE GROWTH FACTOR I RECEPTOR, BETA-CHAIN.
NRP_HUMAN	135	Replacement of 282 C-terminal amino acids of the original protein, including the transmembrane domain and the MAM domain, by alternative 3 amino acids.
NRP_HUMAN	136	Deletion of 83 amino acids between the positions 538-622 of the original protein. The deleted region includes part of the F5/8 TYPE C 2 domain and part of the MAM domain.
NRP_HUMAN	137	Deletion of 385 C-terminal amino acids of the original protein, including the transmembrane domain and the MAM domain.
FGR3_HUMAN	138	Replacement of 496 C-terminal amino acids of the original protein by alternative 79 amino acids.. The deleted region includes the C-terminal part of the extracellular domain, the

		transmembrane domain, the cytoplasmic domain, the protein kinase domain and the two ATP binding domains.
F13B_MOUSE	139	Replacement of 340 aa of the c-terminus of the original protein in 3aa deletion of sushi 6-10 domain
EGF_MOUSE	140	Deletion of 144 amino acids between the positions 1020-1165, including the transmembrane domain and part of the cytoplasmic domain of the original protein.
EGF_MOUSE	141	Replacement of 418 C-terminal amino acids of the original protein by alternative 5 amino acids. The deleted region includes the EGF active chain, 4 out of 9 EGF-like domains within the extracellular region of the protein, the transmembrane and the cytoplasmic regions.
EGF_MOUSE	142	Deletion of 641 amino acids between the positions 66-707 of the original protein. The deleted region is in the extracellular part of the protein and it includes 4 out of 9 EGF-like domains. NV-20 contains the original signal peptide, part of the extracellular domain, the epidermal growth factor chain (located between the positions 977-1029 of the original protein), and the original transmembrane and the cytoplasmic domains.
EGF_MOUSE	143	Deletion of 842 amino acids between the positions 17-859 of the original protein (including replacement of the amino acid in the position 859 by an alternative one). The deleted region is in the extracellular part of the protein and it includes 5 out of 9 EGF-like domains. NV-20 contains the original signal peptide, part of the extracellular domain, the epidermal growth factor chain (located between the positions 977-1029 of the original protein), and the original transmembrane and the cytoplasmic domains.
ACE_MOUSE	144	Replacement of 77 C-terminal amino acids of the original protein, including the entire transmembrane and cytoplasmic domains, by alternative 14 amino acids.
ESR1_MOUSE	145	Replacement of 229 C-terminal amino acids of the original protein, including part of the steroid-binding domain, by alternative 12 amino acids.
FA7_MOUSE	146	Deletion of 101 amino acids, between the positions 119-220 of the original protein. The

		deleted region contains 74 amino acids from the C-terminal end of the factor VII light chain, and 26 amino acids from the N-terminal end of the factor VII heavy catalytic chain. The deleted region includes EGF-like 2 domain and the cleavage site (by factor XA, factor XIIA, factor IXA, or thrombin) of the original protein.
CAL0_MOUSE	147	Deletion of 33 amino acids, spanning the positions 18-50, between the signal and the calcitonin peptide in the original precursor protein.
Gi 2826776	148	Replacement of the last 7 C-terminal amino acids of the original protein by alternative 11 amino acids.
PTI6_HUMAN	149	Replacement of the last 4 C-terminal amino acids of the original protein by alternative 28 amino acids.
PTI6_HUMAN	150	Replacement of the last 16 C-terminal amino acids of the original protein by alternative 12 amino acids.
_RIN1_HUMAN	151	Replacement of 158 last C-terminal amino acids of the original protein by alternative 71 amino acids with probable transmembrane region.
CDNC_HUMAN	152	Addition of 121 amino acids at the N-terminus of the protein.
CDN2_HUMAN	153	Replacement of 5 amino acids at the positions 18, 24, 27, 30, 37 of the original protein by alternative amino acids. Replacement of last 4 C-terminal amino acids of the original protein by alternative 20 amino acids.
CDN5_HUMAN	154	Replacement of the last 6 C-terminal amino acids of the original protein by alternative 52 amino acids.
HEP2_HUMAN	155	Deletion of 150 amino acids, between the positions 334-485, of the original protein. The deleted region includes the reactive bond (the active site) of the original protein. NV-33 does contain the chemotactic activity domain, the glycosaminoglycan-binding site and the hirudin-like 2 x 11 AA approximate repeats, Asp/Glu rich.
TFP2_HUMAN	156	Replacement of 36 C-terminal amino acids of the original protein by alternative 12 amino acids. The deleted region includes part of the BPTI/KUNITZ inhibitor domain-3 and the poly-Lysine domain of the original protein.
TFP2_HUMAN	157	Deletion of 25 amino acids, between the positions 153-178 of the original protein, and

		replacement of the amino acid at the position 179 by alternative one. The deleted region includes the active site and part of the BPTI/KUNITZ inhibitor domain-3.
TFPI_HUMAN	158	Replacement of 95 C-terminal amino acids of the original protein, containing the entire BPTI/KUNITZ inhibitor-3 domain, by alternative 16 amino acids.
IC1_HUMAN	159	Insertion of 136 aa at position 227 of the original protein.
PTI6_HUMAN	160	Replacement of last 15 aa in the original protein in 28 aa, the cds of the NV has no stop codon.
PTI6_HUMAN	161	Replacement of last 185 aa of the original protein in 13 aa. The NV lacks the ACT site.
PTI6_HUMAN	162	Replacement of last 230 aa of the original protein in 10 aa. The NV lacks the ACT site.
TYPH_HUMAN	163	Insertion of 35 aa at position 387 of the original protein.
CDNC_HUMAN	164	Replacement of 220 aa of the c-terminus of the original protein in 47 aa. Deletion of all 9 x 4 aa repeats of p-a-p-a. Deletion of the potential nuclear localization signal (278-281 in the original protein).
FGR3_HUMAN	165	Replacement of 264 aa of the c-terminus of the original protein in 19 aa. Deletion of part of the potential cytoplasmatic protein (397-806 in the original protein), part of the protein kinase domain (472-761), deletion of the ACT site (617).
TFP2_HUMAN	166	Replacement of 58 aa of the c-terminus of the original protein in 12 aa. Deletion of part of the bpti/kunitz inhibitor 3 domain (158-208 in the original protein).
TRFE_HUMAN	167	Insertion of 32 aa at position 366 of the original protein.
VIPS_HUMAN	168	Replacement of 388 aa of the c-terminus of the original protein in 27 aa. Deletion of all potential 7 trans membrena domain.
TFPI_HUMAN	169	Replacement of 180 aa of the n-terminus of the original protein in 37 aa. Deletion of the signal peptide and deletion of the bpti/kunitz inhibitor 1 and 2 domains.
P53_MOUSE	170	Replacement of 246 aa of the n-terminus of

- 36 -

		the original protein in 13 aa. Deletion of the asp/glu-rich (acidic) domain.
P53_MOUSE	171	Replacement of 246 aa of the n-terminus of the original protein in 13 aa. Deletion of the asp/glu-rich (acidic) domain.
ACE_MOUSE	172	Replacement of 77 aa of the c-terminus of the original protein in 17 aa. Deletion of the entire transmembrane and cytoplasmatic domains.
ESR1_MOUSE	173	Deletion of 225 aa of the c-terminus of the original protein. Deletion of most of the steroid binding domain (315-599 in the original protein). RT-PCR results implies that the NV exhibits similarity to thr somatic ACE (results not shown).
vesicular GABA and glycine transporter (mouse), gi 2826776	174	Replacement of 73 aa of the c-terminus of the original protein in 21 aa.

Identification of the original sequence from which the novel Variant was variant

5 The following is the explanation of the definition to be used in the following:

Accession: Accession number of the original sequence in the GeneBank database
 10 Name: Name of the original sequence in the database
 Function: Physiological activity.

SEQ ID NO : Sequence number of variant

15 Description: the difference between the variant and the original sequence.

Accession: AA2A_HUMAN
 Name: Adenosine A2 receptor
 20 Function: Receptor for adenosine.

SEQ ID 1

- 37 -

Description: Gap between amino acids at the positions 237-247 of the original protein. Missing 6th transmembrane loop of the original Adenosine A2 receptor.

5 **Accession:** ASM_HUMAN
Name: SPHINGOMYELIN PHOSPHODIESTERASE
Function: Converts sphingomyelin to ceramide.

SEQ ID : 2

10

Description: Insertion of 2 amino acids after amino acid at the position 34 and insertion of 54 amino acids after amino acid at the position 492 of the original SPHINGOMYELIN PHOSPHODIESTERASE protein.

15 **Accession:** FA12_HUMAN
Name: COAGULATION FACTOR XII
Function: Factor XII is a serum glycoprotein that participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin.

20

SEQ ID : 3

Description: Alternative 10 C-terminal amino acids. Has part of catalytic domain missing 1 active site.

25

Accession: GCSR_HUMAN
Name: GRANULOCYTE COLONY STIMULATING FACTOR receptor
Function: Receptor for granulocyte colony-stimulating factor (g- csf). In addition it may function in some adhesion or recognition events at the cell surface.

30

SEQ ID : 4

35 **Description:** Deletion of 62 amino acids between the positions 320-382 of the original GRANULOCYTE COLONY STIMULATING FACTOR receptor.

- 38 -

The deletion is in the EXTRACELLULAR domain in one of the FIBRONECTIN TYPE-III domains R1.

Accession: GCSR_HUMAN
5 **Name:** GRANULOCYTE COLONY STIMULATING FACTOR
receptor
Function: Receptor for granulocyte colony-stimulating factor (g- csf).
In addition it may function in some adhesion or recognition
events at the cell surface.

10

SEQ ID : 5

Description: Insertion of 37 amino acids in the extracellular domain after the
position 574 of the original GRANULOCYTE COLONY STIMULATING
15 **FACTOR** receptor.

Accession: GLR2_HUMAN
Name: Glutamate receptor 2
Function: L-glutamate acts as an excitatory neurotransmitter at many
20 synapses in the central nervous system. the postsynaptic
actions of Glu are mediated by a variety of receptors are
named according to their selective agonists

SEQ ID : 6

25

Description: Replacement of 88 C-terminal amino acids of the original
glutamate receptor 2 by alternative 42 amino acids. Has most of domains, might
be missing 4th transmembrane domain.

30 **Accession:** GLUC_HUMAN
Name: Glucagon
Function: Promotes hydrolysis of glycogen and lipids, and raises the
blood sugar level.

35 **SEQ ID : 7**

- 39 -

Description Gap; 156aa compared to 180aa; exact 1-108; gap 108-132; exact 132-180. Missing almost whole GLUCAGON-LIKE PEPTIDE 1

Accession: IHBA_HUMAN

5 **Name:** Inhibin; erythroid differentiation factor

Function: Inhibin is a gonadal glycopeptide that inhibits the secretion of follitropin by the pituitary gland. On the other hand activin activates the secretion of follitropin. Activin is also important in embryonic axial development.

10

SEQ ID : 8

Description: Replacement of 128 N-terminal amino acids of the original inhibin protein by alternative 5 amino acids. The deleted part contains propep and
15 glycosylation site of the original protein. The resulting new variant sustains the inhibin beta chain.

Accession: IL6_HUMAN

Name: Interleukin 6

20 **Function:** IL-6 is a cytokine with a wide variety of biological functions: it plays an essential role in the final differentiation of B-cells into Ig-secreting cells, it induces myeloma and plasmacytoma growth, it induces nerve cells differentiation.

25 **SEQ ID : 9**

Description: Deletion of 17 amino acids between the positions 79-96 of the original interleukin 6 protein. Has all necessary domains.

30 **Accession:** IL6_HUMAN

Name: Interleukin 6

Function: IL-6 is a cytokine with a wide variety of biological functions: it plays an essential role in the final differentiation of B-cells into Ig-secreting cells, it induces myeloma
35 and plasmacytoma growth, it induces nerve cells differentiation.

- 40 -

SEQ ID : 10

Description: Deletion of 55 amino acids between the positions 6-61 of the original protein. Has only the beginning of signal peptide; has disulfide bonds and carbohydrate region.

Accession: REL1_HUMAN

Name: Relaxin

Function: Relaxin is an ovarian hormone that acts with estrogen to produce dilatation of the birth canal in many mammals.

SEQ ID : 11

Description: Insertion of 35 amino acids after the amino acid at the position 70 of the original relaxin protein. The insertion is in the connecting peptide.

Accession: SY04_HUMAN

Name: SMALL INDUCIBLE CYTOKINE A4, MACROPHAGE INFLAMMATORY PROTEIN 1-BETA

Function: Monokine with inflammatory and chemokinetic properties

SEQ ID : 12

Description: Deletion of 5 amino acids between the positions 65-69 of the original protein. Replacement of the amino acid at the position 70 of the original protein by an alternative amino acid. Missing part of strand.

Accession: TSP1_HUMAN

Name: Thrombospondin adhesive glycoprotein

Function: Adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions. Can bind to fibrinogen, fibronectin, laminin and type v collagen

SEQ ID : 13

Description: Truncated exact 1-722 (731aa long compared to 1170aa), last 9 amino acids are different. Missing 7 X TSP TYPE-3 REPEATS CA-BINDING

- 41 -

domain C-TERMINAL, missing CELL ATTACHMENT SITE, missing 1 out of 4 glycosylation sites. Has all other components including signal peptide

Accession: TSP1_HUMAN

5 **Name:** Thrombospondin adhesive glycoprotein

Function: Adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions. Can bind to fibrinogen, fibronectin, laminin and type v collagen

10 **SEQ ID : 14**

Description: Truncated exact 1-548 (555aa long compared to 1170) last 7aa different. Missing 3 X EGF-TYPE REPEATS, missing 7 X TSP TYPE-3 REPEATS Ca-BINDING domain C-TERMINAL missing CELL
15 ATTACHMENT SITE, missing all diSulfide bonds, missing 2 out of 4 glycosylation sites. Has all other domains (including signal peptide).

Accession: TSP1_HUMAN

Name: Thrombospondin adhesive glycoprotein

20 **Function:** Adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions. Can bind to fibrinogen, fibronectin, laminin and type v collagen

SEQ ID : 15

25 **Description:** Truncated exact 1-490 (546aa long compared to 1170) last 56 amino acids are different. Missing 1 out of 3 X TSP TYPE-1 REPEATS (CS-LIKE), Missing 3 X EGF-TYPE REPEATS, missing 7 X TSP TYPE-3 REPEATS CA-BINDING domain C-TERMINAL missing CELL
30 ATTACHMENT SITE, missing all diSulfide bonds, missing 2 out of 4 glycosylations. Has all other domains (including signal peptide).

Accession: TSP1_HUMAN

Name: Thrombospondin adhesive glycoprotein

35 **Function** Adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions. Can bind to fibrinogen, fibronectin, laminin and type v collagen

- 42 -

SEQ ID : 16

Description: Truncated: exact 1-431aa (459aa long compared to 1170) last 28
5 amino acids are different. Missing 2 out of 3 X TSP TYPE-1 REPEATS
(CS-LIKE), Missing 3 X EGF-TYPE REPEATS, missing 7 X TSP TYPE-3
REPEATS CA-BINDING domain C-TERMINAL missing CELL
ATTACHMENT SITE, missing all diSulfide bonds, missing 2 out of 4
glycosylations. Has all other domains (including signal peptide).

10

Accession: TYPH_HUMAN

Name: PLATELET-DERIVED ENDOTHELIAL CELL GROWTH
FACTOR

15

Function: May have a role in maintaining the integrity of the blood
vessels. Has growth promoting activity on endothelial cells,
angiogenic activity in vivo and chemotactic activity on
endothelial cells *in vitro*.

20

CATALYSES THE REVERSIBLE PHOSPHOROLYSIS
OF THYMIDINE. THE PRODUCED MOLECULES ARE
THEN UTILIZED AS CARBON AND ENERGY
SOURCES OR IN THE RESCUE OF PYRIMIDINE
BASES FOR NUCLEOTIDE SYNTHESIS.

25

SIMILARITY: BELONGS TO THYMIDINE/
PYRIMIDINE-NUCLEOSIDE PHOSPHORYLASES
FAMILY.

SEQ ID : 17

30 **Description:** Deletion of 119 amino acids between the positions 333-452 of
the original protein. The resulting new variant is missing the 3rd repeat of the
original protein.

Accession: TYPH_HUMAN

35 **Name:** PLATELET-DERIVED ENDOTHELIAL CELL GROWTH
FACTOR

- 43 -

Function:

May have a role in maintaining the integrity of the vessels.
Has growth promoting activity on endothelial cells,
angiogenic activity in vivo and chemotactic activity on
endothelial cells *in vitro*.

5

CATALYSES THE REVERSIBLE PHOSPHOROLYSIS
OF THYMIDINE. THE PRODUCED MOLECULES ARE
THEN UTILIZED AS CARBON AND ENERGY
SOURCES OR IN THE RESCUE OF PYRIMIDINE
BASES FOR NUCLEOTIDE SYNTHESIS.

10

SIMILARITY: BELONGS TO THYMIDINE/
PYRIMIDINE-NUCLEOSIDE PHOSPHORYLASES
FAMILY.

SEQ ID : 18

15

Description: Replacement of 48 amino acids between the positions 216-264
of the original protein by alternative 9 amino acids.

Accession:

TYPH_HUMAN

20

Name:PLATELET-DERIVED ENDOTHELIAL CELL GROWTH
FACTOR**Function:**

May have a role in maintaining the integrity of the vessels.
Has growth promoting activity on endothelial cells,
angiogenic activity in vivo and chemotactic activity on
endothelial cells *in vitro*.

25

CATALYSES THE REVERSIBLE PHOSPHOROLYSIS
OF THYMIDINE. THE PRODUCED MOLECULES ARE
THEN UTILIZED AS CARBON AND ENERGY
SOURCES OR IN THE RESCUE OF PYRIMIDINE
BASES FOR NUCLEOTIDE SYNTHESIS.

30

SIMILARITY: BELONGS TO THYMIDINE/
PYRIMIDINE-NUCLEOSIDE PHOSPHORYLASES
FAMILY.

- 44 -

SEQ ID : 19

Description: Deletion of 119 amino acids between the positions 333-452, missing 3rd repeat of the original protein. Replacement of 48 amino acids
5 between the positions 216-264 of the original protein by alternative 9 amino acids.

Accession: IC1_HUMAN

Name: PLASMA PROTEASE C1 INHIBITOR

10 **Function:** Activation of the c1 complex is under control of the c1-Inhibitor. IT FORMS A PROTEOLYTICALLY INACTIVE STOICHIOMETRIC COMPLEX WITH THE C1R OR C1S PROTEASES. MAY PLAY A POTENTIALLY CRUCIAL
15 ROLE IN REGULATING IMPORTANT PHYSIOLOGICAL PATHWAYS INCLUDING COMPLEMENT ACTIVATION, BLOOD COAGULATION, FIBRINOLYSIS AND THE GENERATION OF KININS.
PTM: HIGHLY GLYCOSYLATED (49%).
20 SIMILARITY: BELONGS TO THE SERPIN FAMILY.

SEQ ID NO : 20

Description: Deletion of 19 amino acids between the positions 29-48 of the
25 original protein. Missing 1 glycosylation out of 14.

Accession: PTI6_HUMAN

Name: PLACENTAL THROMBIN INHIBITOR

Function: Cytoplasmic antiproteinase.
30 SIMILARITY: BELONGS TO THE SERPIN FAMILY. OV-SERPIN SUBFAMILY.

SEQ ID : 21

35 **Description:** Deletion of 261 N-terminal amino acids of the original protein (the first possible Met is at the position 261). The new variant has 116 amino

- 45 -

acids compared to 376 in the original protein (exact 261-376), including the active site.

Accession: PTI6_HUMAN

Name: PLACENTAL THROMBIN INHIBITOR

5 **Function:** Cytoplasmic antiproteinase
SIMILARITY: BELONGS TO THE SERPIN FAMILY.
OV-SERPIN SUBFAMILY.

SEQ ID : 22

10

Description: Deletion of 57 amino acids between the positions 267-325 of the original protein. The resulting new variant contains the active site.

Accession: PTI6_HUMAN

Name: PLACENTAL THROMBIN INHIBITOR

15 **Function:** Cytoplasmic antiproteinase

SEQ ID : 23

20 **Description:** Deletion of 189 amino acids between the positions 89-278 of the original protein. The resulting new variant contains the active site.

Accession: PTI6_HUMAN

Name: PLACENTAL THROMBIN INHIBITOR

Function: Cytoplasmic antiproteinase

25

SEQ ID : 24

30 **Description:** Replacement of 376 C-terminal amino acids of the original protein by alternative 5 amino acids. The resulting new variant doesn't contain the active site.

Accession: IAP2_HUMAN

Name: INHIBITOR OF APOPTOSIS PROTEIN 2

35 **Function:** Apoptotic suppressor. The BIR motifs region interacts with TNF receptor associated factors 1 and 2 (traf1 and traf2) to form an heteromeric complex, which is then recruited to the tumor necrosis factor receptor 2 (TNFR2).

SEQ ID : 25

Description: Truncated: 305 amino acids compared to 618 aa(protein 2). The
5 new variant contains exact positions 1-299, last 6 amino acids are different. Two
SNIPs in positions 235 and 241 of the original protein. The new variant is
missing Zn Finger and half of 3rd BIR repeat.

Accession: SET_HUMAN
10 **Name:** PHOSPHATASE 2A INHIBITOR I2PP2A
Function: May be involved in the generation of intracellular signaling
events that lead to regulation of transcriptional activity after
binding of a ligand to HLA class II molecules. Potent
inhibitor of protein phosphatase 2a.

15

SEQ ID : 26

Description: Extra 83 amino acids in the N-terminus of the protein. The
added sequence has predicted potential transmembrane domain (probable signal
20 peptide?)

Accession: SET_HUMAN
Name: PHOSPHATASE 2A INHIBITOR I2PP2A
Function: May be involved in the generation of intracellular signaling
25 events that lead to regulation of transcriptional activity after
binding of a ligand to HLA class II molecules. Potent
inhibitor of protein phosphatase 2a.

SEQ ID : 27

30

Description: Replacement of 24 C-terminal amino acids of the original
protein by alternative 8 amino acids. Missing part of ASP/GLU-RICH and
BREAKPOINT FOR TRANSLOCATION TO FORM SET-CAN
ONCOGENE.

35

Accession: CDNC_HUMAN
Name: CYCLIN-DEPENDENT KINASE INHIBITOR 1C

- 47 -

Function: POTENT TIGHT-BINDING INHIBITOR OF SEVERAL
G1 CYCLIN/CDK COMPLEXES (CYCLIN E-CDK2,
CYCLIN D2-CDK4, AND CYCLIN A-CDK2) AND, TO
LESSER EXTENT, OF THE MITOTIC CYCLIN B-CDC2.
NEGATIVE REGULATOR OF CELL PROLIFERATION.
MAY PLAY A ROLE IN MAINTENANCE OF THE
NONPROLIFERATIVE STATE THROUGHOUT LIFE.
SUBCELLULAR LOCATION: NUCLEAR (BY
SIMILARITY).
DISEASE: CDKN1C MUTATIONS ARE INVOLVED IN
TUMOR FORMATION.

SEQ ID : 28

Description: Deletion of 178 amino acids at the positions 97-275 of the
original protein. Insertion of 121 amino acids at the N-terminus. The resulting
new variant is missing PAPA repeats.

Accession: F13B_MOUSE

Name: COAGULATION FACTOR XIII B CHAIN

Function: The B chain of factor XIII is not catalytically active, but is
thought to stabilize the a subunits and regulate the rate of
transglutaminase formation by thrombin

SEQ ID : 29**Description**

Deletion of 87 C-terminal amino acids of the original protein. SNIP at position
236 (L->V). The resulting new variant is missing the last shushi repeat.

Accession: EGF_MOUSE

Name: PRO-EPIDERMAL GROWTH FACTOR

Function: Stimulates the growth of various epidermal and epithelial
tissues.

SEQ ID : 30

- 48 -

Description: Deletion of 641 amino acids between the positions 67-708 of the original protein. Missing 4 EGF-like domains, 2 glycosylations, 9 diSulfide bonds.

5 **Accession:** EGF_MOUSE
Name: PRO-EPIDERMAL GROWTH FACTOR
Function: Stimulates the growth of various epidermal and epithelial Tissues

- 49 -

SEQ ID : 31

Description: Deletion of 641 amino acids between the positions 67-708, and deletion of 45 amino acids between the positions 1020-1065 of the original protein. Missing 4 EGF-like domains, 2 glycosylations, 9 diSulfide bonds. Missing transmembrane domain.

Accession: EGF_MOUSE

Name: PRO-EPIDERMAL GROWTH FACTOR

Function: Stimulates the growth of various epidermal and epithelial tissues

SEQ ID : 32

Description:

Deletion of 641 amino acids between the positions 67-708 of the original protein. Missing 4 EGF-like domains, 2 glycosylations, 9 diSulfide bonds. Replacement of 419 C-terminal amino acids by 5 amino acids.

Accession: EGF_MOUSE

Name: PRO-EPIDERMAL GROWTH FACTOR

Function: Stimulates the growth of various epidermal and epithelial Tissues

SEQ ID : 33

Description: Deletion of 841 amino acids between the positions 18-859 of the original protein. Missing 5 EGF-like domains and 2 glycosylation sites.

Accession: EGF_MOUSE

Name: PRO-EPIDERMAL GROWTH FACTOR

Function: Stimulates the growth of various epidermal and epithelial Tissues

- 50 -

SEQ ID : 34

Description: Deletion of 774 amino acids between the positions 5-779 of the original protein. Missing signal peptide, 5 EGF-like domains, and 2 glycosylation sites.

Accession: P53_MOUSE
Name: CELLULAR TUMOR ANTIGEN P53
Function: Acts as a tumor suppressor in many tumor types. Induces growth arrest or apoptosis depending on the physiological circumstances or cell type, but both activities are involved in tumor suppression.

SEQ ID : 35

Description: Deletion of 336 N-terminal amino acids of the original protein. Missing ASP/GLU-RICH (ACIDIC), missing hydrophobic domain, missing NUCLEAR LOCALIZATION SIGNAL, missing 1 out of 2 PHOSPHORYLATION sites.

Accession: NME3_HUMAN
Name: GLUTAMATE [NMDA] RECEPTOR SUBUNIT EPSILON 3
Function: NMDA receptor subtype of glutamate-gated ion channels possesses high calcium permeability and voltage-dependent sensitivity to magnesium and is mediated by glycine.

SEQ ID : 36

Description: Deletion of 381 N-terminal amino acids of the original protein. Missing 2 out of 4 glycosylation sites.

Accession: TRFE_HUMAN
Name: SEROTRANSFERRIN
Function: Iron binding transport proteins

- 51 -

SEQ ID : 37

Description: Deletion of 34 amino acids between the positions 654-689 of the original protein. Loss of disulfide bond.

5

Accession: TRFE_HUMAN
Name: SEROTRANSFERRIN
Function: Iron binding transport proteins

10 **SEQ ID : 38**

Description: Deletion of 52 amino acids between the positions 447-499 of the original protein. Loss of disulfide bond.

15 **Accession:** BAA23795
Name: Brain ryanodine receptor

SEQ ID : 39

20

Description: Replacement of 83 C-terminal amino acids from probable cytoplasmic domain of the original protein by alternative 4 amino acids. Resulting in truncated new variant: 4787 compared to 4866, exact 1-4783 with last 4 amino acids different.

25

Accession: VIPS_HUMAN
Name: VASOACTIVE INTESTINAL POLYPEPTIDE
RECEPTOR 2

30

Function: This is a receptor for VIP as well as PACAP-38 and -27, the activity of this receptor is mediated by G proteins which activate adenylyl cyclase. Can be coupled to phospholipase C.

SEQ ID : 40

35 **Description:** Replacement of 64 C-terminal amino acids of the original protein by alternative 7 amino acids. The resulting new variant is missing the last transmembrane and the cytoplasmic domains.

- 52 -

Accession: PACR_HUMAN
Name: PITUITARY ADENYLATE CYCLASE ACTIVATING
POLYPEPTIDE TYPE RECEPTOR

Function: This is a receptor for PACAP-27 and PACAP-38. The
5 activity of this receptor is mediated by G proteins which
activate adenylyl cyclase. May regulate the release of
adrenocorticotropin, luteinizing hormone, growth hormone,
prolactin, epinephrine.

10 **SEQ ID : 41**

Description: Deletion of 22 amino acids between the positions 88-110 of the
original protein. The deletion is in extracellular loop.

15 **Accession:** NRP_HUMAN
Name: NEUROPILIN VASCULAR ENDOTHELIAL CELL
GROWTH FACTOR 165 RECEPTOR

Function: Calcium-independent cell adhesion molecule that function
during the formation of certain neuronal circuits. Binds to
20 semaphorin III and to the VEGF165 isoform of VEGF

SEQ ID : 42

Description: Deletion of 540 C-terminal amino acids of the original protein,
25 resulting in truncated new variant (383 compared to 923 amino acids).
The new variant is missing part of the extracellular domain, the cytoplasmic and
the transmembrane domains.

Accession: NRP_HUMAN
30 **Name:** NEUROPILIN VASCULAR ENDOTHELIAL CELL
GROWTH FACTOR 165 RECEPTOR

Function: Calcium-independent cell adhesion molecule that during the
formation of certain neuronal circuits. Binds to semaphorin
III and to the VEGF165 isoform of VEGF

35

- 53 -

R2_NV43

Description: Replacement of 595 C-terminal amino acids of the original protein by alternative 11 amino acids. The resulting new variant is truncated (339 compared to 923 amino acids, exact 1-328 with last 11 amino acids different), and is missing part of the extracellular domain, the cytoplasmic and the transmembrane domains.

Accession: gi|1899200

Name: N-METHYL D-ASPARTATE RECEPTOR SUBTYPE 2A

Function: NMDA RECEPTOR SUBTYPE OF GLUTAMATE-GATED ION CHANNELS POSSESSES HIGH CALCIUM PERMEABILITY AND VOLTAGE-DEPENDENT SENSITIVITY TO MAGNESIUM AND IS MEDIATED BY GLYCINE.

SUBUNIT: HETERODIMER OF AN EPSILON SUBUNIT AND A ZETA SUBUNIT.

SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN.

SIMILARITY: BELONGS TO THE LIGAND-GATED IONIC CHANNELS FAMILY.

SEQ ID : 44:

Description: Deletion of 114 amino acids between the positions 1257-1372 of the original protein.

Accession: VIPS_HUMAN

Name: VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2

Function: THIS IS A RECEPTOR FOR VIP AS WELL AS PACAP-38 AND -27, THE ACTIVITY OF THIS RECEPTOR IS MEDIATED BY G PROTEINS WHICH ACTIVATE ADENYLYL CYCLASE. CAN BE COUPLED TO PHOSPHOLIPASE C.

SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN.

- 54 -

SIMILARITY: BELONGS TO FAMILY 2 OF
G-PROTEIN COUPLED RECEPTORS.

SEQ ID : 45:

5

Description: Replacement of 56 C-terminal amino acids from the
cytoplasmic domain of the original protein by alternative 73 amino acids.

10 **SEQ ID : 46**

Description: Replacement of 56 C-terminal amino acids from the
cytoplasmic domain of the original protein by alternative 70 amino acids.

15

Accession: IG1R_HUMAN
Name: INSULIN-LIKE GROWTH FACTOR I RECEPTOR
PRECURSOR

20

Function: THIS RECEPTOR BINDS INSULIN-LIKE GROWTH
FACTOR I (IGF I) WITH A HIGH AFFINITY AND IGF II
WITH A LOWER AFFINITY. IT HAS A
TYROSINE-PROTEIN KINASE ACTIVITY.
CATALYTIC ACTIVITY: ATP + A PROTEIN TYROSINE
= ADP + PROTEIN TYROSINE PHOSPHATE.

25

SUBUNIT: TETRAMER OF 2 ALPHA AND 2 BETA
CHAINS LINKED BY DISULFIDE BONDS. THE ALPHA
CHAINS

30

CONTRIBUTE TO THE FORMATION OF THE LIGAND-
BINDING DOMAIN, WHILE THE BETA CHAIN
CARRIES THE KINASE DOMAIN.

SUBCELLULAR LOCATION: TYPE I MEMBRANE
PROTEIN.

SIMILARITY: BELONGS TO THE INSULIN RECEPTOR
FAMILY OF TYROSINE- PROTEIN KINASES.

35

SIMILARITY: CONTAINS 2 FIBRONECTIN TYPE
III-LIKE DOMAINS.

- 55 -

SEQ ID : 47

Description: Deletion of 22 amino acids between the positions 1268-1291 of the original protein. The deleted fragment is part of the cytoplasmic domain of
5 INSULIN-LIKE GROWTH FACTOR I RECEPTOR, BETA-CHAIN.

Accession: NRP_HUMAN
Name: NEUROPILIN
10 **Function:** CALCIUM-INDEPENDENT CELL ADHESION
MOLECULE THAT FUNCTION DURING THE
FORMATION OF CERTAIN NEURONAL CIRCUITS.
BINDS TO SEMAPHORIN III AND TO THE VEGF165
ISOFORM OF VEGF.
15 SUBCELLULAR LOCATION: TYPE I MEMBRANE
PROTEIN.
SIMILARITY: CONTAINS 2 CUB DOMAINS.
SIMILARITY: CONTAINS 2 F5/8 TYPE C DOMAINS.
SIMILARITY: CONTAINS 1 MAM DOMAIN.

20

SEQ ID : 48

Description: Replacement of 282 C-terminal amino acids of the original protein, including the transmembrane domain and the MAM domain, by
25 alternative 3 amino acids.

SEQ ID : 49

Description: Deletion of 83 amino acids between the positions 538-622 of
30 the original protein. The deleted region includes part of the F5/8 TYPE C 2
domain and part of the MAM domain.

SEQ ID : 50

35 **Description:** Deletion of 385 C-terminal amino acids of the original protein, including the transmembrane domain and the MAM domain.

- 56 -

Accession: FGR3_HUMAN
Name: FIBROBLAST GROWTH FACTOR RECEPTOR 3
Function: SUBCELLULAR LOCATION: TYPE I MEMBRANE
5 PROTEIN.

10 DISEASE: DEFECTS IN FGFR3 ARE THE CAUSE OF THE AUTOMOSOMAL DOMINANT DISEASE ACHONDROPLASIA (ACH); THE MOST FREQUENT FORM OF SHORT-LIMB DWARFISM. ACH IS CHARACTERIZED BY A LONG, NARROW TRUNK, SHORT EXTREMITIES, PARTICULARLY IN THE PROXIMAL (RHIZOMELIC) SEGMENTS, A LARGE HEAD WITH FRONTAL BOSSING, HYPOPLASIA OF THE MIDFACE AND A TRIDENT CONFIGURATION
15 OF THE HANDS.

DISEASE: DEFECTS IN FGFR3 ARE A CAUSE OF CROUZON SYNDROME, ALSO CALLED CRANIOFACIAL DYSOSTOSIS TYPE I (CFD1). CHARACTERIZED BY CRANIOSYNOSTOSIS
20 (PREMATURE FUSION OF THE SKULL SUTURES), HYPERTELORISM, EXOPHTHALMOS AND EXTERNAL STRABISMUS, PARROT-BEAKED NOSE, SHORT UPPER LIP, HYPOPLASTIC MAXILLA, AND A RELATIVE MANDIBULAR PROGNATHISM.

25 DISEASE: DEFECTS IN FGFR3 ARE A CAUSE OF THANATOPHORIC DYSPLASIA (TD) (ALSO KNOWN AS THANATOPHORIC DWARFISM), THE MOST COMMON NEONATAL LETHAL SKELETAL DYSPLASIA, AFFECTED INDIVIDUALS DISPLAY
30 FEATURES SIMILAR TO THOSE SEEN IN HOMOZYGOUS ACHONDROPLASIA. IT CAUSES SEVERE SHORTENING OF THE LIMBS WITH MACROCEPHALY, NARROW THORAX AND SHORT RIBS. IN THE MOST COMMON SUBTYPE (TD1),
35 FEMUR ARE CURVED, WHILE IN TD2, STRAIGHT FEMURS ARE ASSOCIATED WITH CLOVERLEAF SKULL.

- 57 -

5 DISEASE: DEFECTS IN FGFR3 ARE A CAUSE OF
CRANIOSYNOSTOSIS ADELAIDE TYPE (CRS3), A
FORM OF CORONAL SYNOSTOSIS (CS)
CHARACTERIZED BY CRANIOSYNOSTOSIS,
MIDFACE HYPOPLASIA, DOWNSLANDING
PALPEBRAL FISSURES, PTOSIS, HIGHLY ARCHED
PALATE, MID-TO-MODERATE SENSORINEURAL
HEARING LOSS, NORMAL STATURE,
BRADYDACTYLY, BROAD BIG TOES.
10 RADIOLOGICALLY HANDS AND FEET SHOW
THIMBLE-LIKE MIDDLE PHALANGES, CONED
EPIPHYSES, AND CARPAL AND TARSAL FUSIONS.
DISEASE: DEFECTS IN FGFR3 ARE A CAUSE OF THE
AUTOSOMAL DOMINANT DISEASE HYPO-
15 CHONDROPLASIA CHARACTERIZED BY
DISPROPORTIONATE SHORT STATURE. IT
RESEMBLE ACHONDROPLASIA, BUT WITH A LESS
SEVERE PHENOTYPE.
SIMILARITY: BELONGS TO THE FIBROBLAST
20 GROWTH FACTOR RECEPTOR FAMILY.
SIMILARITY: CONTAINS 3 IMMUNOGLOBULIN-
LIKE DOMAINS.

SEQ ID : 51

25 **Description:** Replacement of 496 C-terminal amino acids of the original
protein by alternative 79 amino acids.. The deleted region includes the C-terminal
part of the extracellular domain, the transmembrane domain, the cytoplasmic
domain, the protein kinase domain and the two ATP binding domains.

30

EGF MOUSE**EPIDERMAL GROWTH FACTOR**

35

FUNCTION: THE GROWTH FACTOR STIMULATES THE GROWTH OF
VARIOUS EPIDERMAL AND EPITHELIAL TISSUES IN VIVO AND IN
VITRO AND OF SOME FIBROBLASTS IN CELL CULTURE.
SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.

- 58 -

SIMILARITY: CONTAINS 8 COMPLETE AND ONE INCOMPLETE EGF-LIKE DOMAINS.

SEQ ID NO : 52

5

Deletion of 144 amino acids between the positions 1020-1165, including the transmembrane domain and part of the cytoplasmic domain of the original protein.

10 **SEQ ID NO : 53**

Replacement of 418 C-terminal amino acids of the original protein by alternative 5 amino acids. The deleted region includes the EGF active chain, 4 out of 9 EGF-like domains within the extracellular region of the protein, the
15 transmembrane and the cytoplasmic regions.

SEQ ID NO : 54

Deletion of 641 amino acids between the positions 66-707 of the original protein.
20 The deleted region is in the extracellular part of the protein and it includes 4 out of 9 EGF-like domains. NV-20 contains the original signal peptide, part of the extracellular domain, the epidermal growth factor chain (located between the positions 977-1029 of the original protein), and the original transmembrane and the cytoplasmic domains.

25

SEQ ID NO : 55

Deletion of 842 amino acids between the positions 17-859 of the original protein
30 (including replacement of the amino acid in the position 859 by an alternative one). The deleted region is in the extracellular part of the protein and it includes 5 out of 9 EGF-like domains. NV-20 contains the original signal peptide, part of the extracellular domain, the epidermal growth factor chain (located between the positions 977-1029 of the original protein), and the original transmembrane and
35 the cytoplasmic domains.

ACE_MOUSE

40

ANGIOTENSIN-CONVERTING ENZYME

- 59 -

- FUNCTION: CONVERTS ANGIOTENSIN I TO ANGIOTENSIN II BY RELEASE OF THE TERMINAL HIS-LEU, THIS RESULTS IN AN INCREASE OF THE VASOCONSTRICTOR ACTIVITY OF ANGIOTENSIN.
- 5 CATALYTIC ACTIVITY: RELEASE OF A C-TERMINAL DIPEPTIDE, OLIGOPEPTIDE-|-XAA-XBB, WHEN XAA IS NOT PRO, AND XBB IS NEITHER ASP NOR GLU. CONVERTS ANGIOTENSIN I TO ANGIOTENSIN II.
- 10 COFACTOR: BINDS TWO ZINC IONS (BY SIMILARITY).
SUBCELLULAR LOCATION: TYPE I MEMBRANE PROTEIN.
ALTERNATIVE PRODUCTS: THE TESTICULAR ANGIOTENSIN-CONVERTING ENZYME IS TRANSCRIBED FROM THE SAME GENE AS THE SOMATIC ISOFORM, PROBABLY FROM AN ALTERNATIVE START
- 15 SITE.
SIMILARITY: BELONGS TO PEPTIDASE FAMILY M2 (ZINC METALLOPROTEASE).

20 **SEQ ID NO : 56**

Replacement of 77 C-terminal amino acids of the original protein, including the entire transmembrane and cytoplasmic domains, by alternative 14 amino acids.

25

ESR1_MOUSE

ESTROGEN RECEPTOR

- 30 FUNCTION: THE STEROID HORMONES AND THEIR RECEPTORS ARE INVOLVED IN THE REGULATION OF EUKARYOTIC GENE EXPRESSION AND AFFECT CELLULAR PROLIFERATION AND DIFFERENTIATION IN TARGET TISSUES.
SUBUNIT: HOMODIMER.
- 35 SUBCELLULAR LOCATION: NUCLEAR.
DOMAIN: COMPOSED OF THREE DOMAINS: A MODULATING N-TERMINAL DOMAIN, A DNA-BINDING DOMAIN AND A C-TERMINAL STEROID-BINDING DOMAIN.
MISCELLANEOUS: IN THE ABSENCE OF LIGAND, STEROID HORMONE
- 40 RECEPTORS ARE THOUGHT TO BE WEAKLY ASSOCIATED WITH NUCLEAR COMPONENTS; HORMONE BINDING GREATLY INCREASES RECEPTOR AFFINITY. THE HORMONE-RECEPTOR COMPLEX APPEARS TO RECOGNIZE DISCRETE DNA SEQUENCES UPSTREAM OF TRANSCRIPTIONAL START SITES.

- 60 -

SIMILARITY: BELONGS TO THE NUCLEAR HORMONE RECEPTORS
FAMILY. NR3 SUBFAMILY.

SEQ ID : 57

5

Replacement of 229 C-terminal amino acids of the original protein, including part of the steroid-binding domain, by an alternative 12 amino acids.

10

FA7_MOUSE**COAGULATION FACTOR VII PRECURSOR**

15 FUNCTION: CIRCULATES IN THE BLOOD IN A ZYMOGEN FORM.
FACTOR VII IS CONVERTED TO FACTOR VIIA BY FACTOR XA,
FACTOR XIIA, FACTOR IXA, OR THROMBIN BY MINOR PROTEOLYSIS.
IN THE PRESENCE OF TISSUE FACTOR AND CALCIUM IONS, FACTOR
VIIA THEN CONVERTS FACTOR X TO FACTOR XA BY LIMITED
20 PROTEOLYSIS. FACTOR VIIA WILL ALSO CONVERT FACTOR IX TO
FACTOR IXA IN THE PRESENCE OF TISSUE FACTOR AND CALCIUM
(BY SIMILARITY).

CATALYTIC ACTIVITY: HYDROLYSES ONE ARG-|-ILE BOND IN
FACTOR X TO FORM FACTOR XA.

25 SUBUNIT: HETERODIMER OF A LIGHT CHAIN AND A HEAVY CHAIN
LINKED BY A DISULFIDE BOND (BY SIMILARITY).

TISSUE SPECIFICITY: PLASMA.

PTM: THE VITAMIN K-DEPENDENT, ENZYMATIC CARBOXYLATION
OF SOME GLUTAMIC ACID RESIDUES ALLOWS THE MODIFIED
30 PROTEIN TO BIND CALCIUM (BY SIMILARITY).

SIMILARITY: CONTAINS 2 EGF-LIKE DOMAINS.

SIMILARITY: BELONGS TO PEPTIDASE FAMILY S1; ALSO KNOWN AS
THE TRYPSIN FAMILY.

35 SEQ ID : 58

Deletion of 101 amino acids, between the positions 119-220 of the original
protein. The deleted region contains 74 amino acids from the C-terminal end of
the factor VII light chain, and 26 amino acids from the N-terminal end of the
40 factor VII heavy catalytic chain. The deleted region includes EGF-like 2 domain
and the cleavage site (by factor XA, factor XIIA, factor IXA, or thrombin) of

- 61 -

the original protein.

CAL0_MOUSE

5

CALCITONIN PRECURSOR

FUNCTION: CAUSES A RAPID BUT SHORT-LIVED DROP IN THE LEVEL
OF CALCIUM AND PHOSPHATE IN BLOOD BY PROMOTING THE
INCORPORATION OF THOSE IONS IN THE BONES.

10 ALTERNATIVE PRODUCTS: THE CALCITONIN PRECURSOR AND THE
CALCITONIN RELATED PEPTIDE PRECURSOR ARE OBTAINED BY
TISSUE-SPECIFIC SPLICING OF THE SAME GENE.
SIMILARITY: BELONGS TO THE CALCITONIN FAMILY.

15

SEQ ID NO : 59

Deletion of 33 amino acids, spanning the positions 18-50, between the signal and
the calcitonin peptide in the original precursor protein.

20

gi 2826776

VESICULAR INHIBITORY AMINO ACID TRANSPORTER

25

function="uptake of GABA and glycine into synaptic vesicles"

SEQ ID NO : 60

30

Replacement of the last 7 C-terminal amino acids of the original protein by
alternative 11 amino acids.

35

PTI6_HUMAN

PLACENTAL THROMBIN INHIBITOR

40 CYTOPLASMIC ANTIPROTEINASE, PROTEASE INHIBITOR 6.
SIMILARITY: BELONGS TO THE SERPIN FAMILY. OV-SERPIN
SUBFAMILY.

- 62 -

SEQ ID NO : 61

Replacement of the last 4 C-terminal amino acids of the original protein by alternative 28 amino acids.

5

SEQ ID NO : 62

Replacement of the last 16 C-terminal amino acids of the original protein by alternative 12 amino acids.

10

RIN1_HUMAN

15

RAS INTERACTION/INTERFERENCE PROTEIN 1
(RAS INHIBITOR JC99)
(FRAGMENT)

SEQ ID NO : 63

20

Replacement of 158 last C-terminal amino acids of the original protein by alternative 71 amino acids with probable transmembrane region.

25

CDNC_HUMAN**CYCLIN-DEPENDENT KINASE INHIBITOR 1C P57**

30 FUNCTION: POTENT TIGHT-BINDING INHIBITOR OF SEVERAL G1
CYCLIN/CDK COMPLEXES (CYCLIN E-CDK2, CYCLIN D2-CDK4, AND
CYCLIN A-CDK2) AND, TO LESSER EXTENT, OF THE MITOTIC CYCLIN
B-CDC2. NEGATIVE REGULATOR OF CELL PROLIFERATION. MAY
PLAY A ROLE IN MAINTENANCE OF THE NONPROLIFERATIVE STATE
35 THROUGHOUT LIFE.
SUBCELLULAR LOCATION: NUCLEAR (BY SIMILARITY).
DISEASE: CDKN1C MUTATIONS ARE INVOLVED IN TUMOR
FORMATION.

40

SEQ ID NO : 64

Addition of 121 amino acids at the N-terminus of the protein.

- 63 -

CDN2_HUMAN

5 **CYCLIN-DEPENDENT KINASE 4 INHIBITOR A (CDK4I)**
 (MULTIPLE TUMOR SUPPRESSOR 1) (MTS1)

10 FUNCTION: INTERACTS STRONGLY WITH CDK4 AND CDK6. INHIBITS
 ITS ABILITY TO INTERACT WITH CYCLINS D. COULD ACT AS A
 NEGATIVE REGULATOR OF THE PROLIFERATION OF NORMAL
 CELLS.

 SUBUNIT: HETERODIMER WITH CDK4 OR CDK6.

15 DISEASE: CDKN2A MUTATIONS ARE INVOLVED IN TUMOR
 FORMATION IN A WIDE RANGE OF TISSUES.

 SIMILARITY: BELONGS TO THE CDKN2 FAMILY OF
 CYCLIN-DEPENDENT KINASE INHIBITORS.

 SIMILARITY: CONTAINS 4 ANK REPEATS.

20 **SEQ ID NO : 65**

 Replacement of 5 amino acids at the positions 18, 24, 27, 30, 37 of the original
 protein by alternative amino acids. Replacement of last 4 C-terminal amino acids
25 of the original protein by alternative 20 amino acids.

CDN5_HUMAN

30 **CYCLIN-DEPENDENT KINASE 4 INHIBITOR B**
 (MULTIPLE TUMOR SUPPRESSOR 2)

35 FUNCTION: INTERACTS STRONGLY WITH CDK4 AND CDK6. POTENT
 INHIBITOR. POTENTIAL EFFECTOR OF TGF-BETA INDUCED CELL
 CYCLE ARREST.

 SUBUNIT: HETERODIMER OF P14 WITH CDK4.

 DISEASE: CDKN2B MUTATIONS ARE INVOLVED IN TUMOR
 FORMATION.

40 SIMILARITY: BELONGS TO THE CDKN2 FAMILY OF
 CYCLIN-DEPENDENT KINASE INHIBITORS.

 SIMILARITY: CONTAINS 2 ANK REPEATS.

- 64 -

SEQ ID NO : 66

Replacement of the last 6 C-terminal amino acids of the original protein by alternative 52 amino acids.

5

HEP2_HUMAN**HEPARIN COFACTOR II PRECURSOR**
PROTEASE INHIBITOR LEUSERPIN 2

10

FUNCTION: THROMBIN INHIBITOR ACTIVATED BY THE GLYCOSAMINOGLYCANS, HEPARIN OR DERMATAN SULFATE. IN THE PRESENCE OF THE LATTER, HC-II BECOMES THE PREDOMINANT THROMBIN INHIBITOR IN PLACE OF ANTITHROMBIN III (AT). ALSO INHIBITS CHYMOTRYPSIN, BUT IN A GLYCOSAMINOGLYCAN-INDEPENDENT MANNER.

15

FUNCTION: PEPTIDES AT THE N-TERMINAL OF HC-II HAVE CHEMOTACTIC ACTIVITY FOR BOTH MONOCYTES AND NEUTROPHILS.

20

TISSUE SPECIFICITY: EXPRESSED PREDOMINANTLY IN LIVER.

DOMAIN: THE N-TERMINAL ACIDIC REPEAT REGION MEDIATES, IN PART, THE

GLYCOSAMINOGLYCAN-ACCELERATED THROMBIN INHIBITION.

25

DISEASE: DEFECTS IN HCF2 ARE ASSOCIATED WITH THROMBOSIS (THROMBOPHILIA).

SIMILARITY: BELONGS TO THE SERPIN FAMILY.

SEQ ID NO : 67

30

Deletion of 150 amino acids, between the positions 334-485, of the original protein. The deleted region includes the reactive bond (the active site) of the original protein. NV-33 does contain the chemotactic activity domain, the glycosaminoglycan-binding site and the hirudin-like 2 x 11 AA approximate repeats, Asp/Glu rich.

35

TFP2_HUMAN**TISSUE FACTOR PATHWAY INHIBITOR 2 PRECURSOR**

40

FUNCTION: SEEMS TO INHIBIT TRYPSIN, FACTOR VII(A)/TISSUE FACTOR, WEAKLY FACTOR XA. HAS NO EFFECT ON THROMBIN.

- 65 -

DOMAIN: THIS INHIBITOR CONTAINS THREE INHIBITORY DOMAINS.
SIMILARITY: BELONGS TO THE BPTI/KUNITZ FAMILY OF
INHIBITORS. HIGHLY SIMILAR TO TPFI.

5 **SEQ ID NO : 68**

Replacement of 36 C-terminal amino acids of the original protein by alternative
12 amino acids. The deleted region includes part of the BPTI/KUNITZ inhibitor
domain-3 and the poly-Lysine domain of the original protein.

10

SEQ ID NO : 69

Deletion of 25 amino acids, between the positions 153-178 of the original
15 protein, and replacement of the amino acid at the position 179 by alternative one.
The deleted region includes the active site and part of the BPTI/KUNITZ
inhibitor domain-3.

20

TFPI_HUMAN

TISSUE FACTOR PATHWAY INHIBITOR PRECURSOR (TFPI)

25 **SEQ ID NO : 70**

Replacement of 95 C-terminal amino acids of the original protein, containing the
entire BPTI/KUNITZ inhibitor-3 domain, by alternative 16 amino acids.

30

Example II: Variant nucleic acid sequence

The nucleic acid sequences of the invention include nucleic acid
sequences which encode variant product and fragments and analogs thereof. The
nucleic acid sequences may alternatively be sequences complementary to the
35 above coding sequence, or to a region of said coding sequence. The length of the
complementary sequence is sufficient to avoid the expression of the coding
sequence. The nucleic acid sequences may be in the form of RNA or in the form
of DNA, and include messenger RNA, synthetic RNA and DNA, cDNA, and
genomic DNA. The DNA may be double-stranded or single-stranded, and if

single-stranded may be the coding strand or the non-coding (anti-sense, complementary) strand. The nucleic acid sequences may also both include dNTPs, rNTPs as well as non naturally occurring sequences. The sequence may also be a part of a hybrid between an amino acid sequence and a nucleic acid
5 sequence.

In a general embodiment, the nucleic acid sequence has at least 90%, identity with any one of the sequence identified as SEQ ID NO: 1 to SEQ ID NO: 174 provided that this sequence is not completely identical with that of the original sequence.

10 The nucleic acid sequences may include the coding sequence by itself. By another alternative the coding region may be in combination with additional coding sequences, such as those coding for fusion protein or signal peptides, in combination with non-coding sequences, such as introns and control elements, promoter and terminator elements or 5' and/or 3' untranslated regions, effective
15 for expression of the coding sequence in a suitable host, and/or in a vector or host environment in which the variant nucleic acid sequence is introduced as a heterologous sequence.

The nucleic acid sequences of the present invention may also have the product coding sequence fused in-frame to a marker sequence which allows for
20 purification of the variant product. The marker sequence may be, for example, a hexahistidine tag to provide for purification of the mature polypeptide fused to the marker in the case of a bacterial host, or, the marker sequence may be a hemagglutinin (HA) tag when a mammalian host, e.g. COS-7 cells, is used. The HA tag corresponds to an epitope derived from the influenza hemagglutinin
25 protein (Wilson, I., *et al. Cell* 37:767 (1984)).

Also included in the scope of the invention are fragments as defined above also referred to herein as oligonucleotides, typically having at least 20 bases, preferably 20-30 bases corresponding to a region of the coding-sequence nucleic acid sequence. The fragments may be used as probes, primers, and when

complementary also as antisense agents, and the like, according to known methods.

As indicated above, the nucleic acid sequence may be substantially a depicted in any one of SEQ ID NO: 1 to SEQ ID NO: 87 or fragments thereof or
5 sequences having at least 90% identity to the above sequence as explained above. Alternatively, due to the degenerative nature of the genetic code, the sequence may be a sequence coding for any one of the amino acid sequence of SEQ ID NO: 88 to SEQ ID NO: 174, or fragments or analogs of said amino acid sequence.

10

A. Preparation of nucleic acid sequences

The nucleic acid sequences may be obtained by screening cDNA libraries using oligonucleotide probes which can hybridize to or PCR-amplify nucleic acid sequences which encode the variant products disclosed above. cDNA libraries
15 prepared from a variety of tissues are commercially available and procedures for screening and isolating cDNA clones are well-known to those of skill in the art. Such techniques are described in, for example, Sambrook *et al.* (1989) Molecular Cloning: A Laboratory Manual (2nd Edition), Cold Spring Harbor Press, Plainview, N.Y. and Ausubel FM *et al.* (1989) Current Protocols in Molecular
20 Biology, John Wiley & Sons, New York, N.Y.

The nucleic acid sequences may be extended to obtain upstream and downstream sequences such as promoters, regulatory elements, and 5' and 3' untranslated regions (UTRs). Extension of the available transcript sequence may be performed by numerous methods known to those of skill in the art, such as
25 PCR or primer extension (Sambrook *et al.*, *supra*), or by the RACE method using, for example, the Marathon RACE kit (Clontech, Cat. # K1802-1).

Alternatively, the technique of "restriction-site" PCR (Gobinda *et al.* *PCR Methods Applic.* 2:318-22, (1993)), which uses universal primers to retrieve flanking sequence adjacent a known locus, may be employed. First, genomic
30 DNA is amplified in the presence of primer to a linker sequence and a primer

- 68 -

specific to the known region. The amplified sequences are subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

5 Inverse PCR can be used to amplify or extend sequences using divergent primers based on a known region (Triglia, T. *et al.*, *Nucleic Acids Res.* 16:8186, (1988)). The primers may be designed using OLIGO(R) 4.06 Primer Analysis Software (1992; National Biosciences Inc, Plymouth, Minn.), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of
10 50% or more, and to anneal to the target sequence at temperatures about 68-72°C.

The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

Capture PCR (Lagerstrom, M. *et al.*, *PCR Methods Applic.* 1:111-19, (1991)) is a method for PCR amplification of DNA fragments adjacent to a
15 known sequence in human and yeast artificial chromosome DNA. Capture PCR also requires multiple restriction enzyme digestions and ligations to place an engineered double-stranded sequence into a flanking part of the DNA molecule before PCR.

20 Another method which may be used to retrieve flanking sequences is that of Parker, J.D., *et al.*, *Nucleic Acids Res.*, 19:3055-60, (1991)). Additionally, one can use PCR, nested primers and PromoterFinder™ libraries to "walk in" genomic DNA (PromoterFinder™; Clontech, Palo Alto, CA). This process avoids the need to screen libraries and is useful in finding intron/exon junctions. Preferred
25 libraries for screening for full length cDNAs are ones that have been size-selected to include larger cDNAs. Also, random primed libraries are preferred in that they will contain more sequences which contain the 5' and upstream regions of genes.

A randomly primed library may be particularly useful if an oligo d(T) library does not yield a full-length cDNA. Genomic libraries are useful for
30 extension into the 5' nontranslated regulatory region.

The nucleic acid sequences and oligonucleotides of the invention can also be prepared by solid-phase methods, according to known synthetic methods. Typically, fragments of up to about 100 bases are individually synthesized, then joined to form continuous sequences up to several hundred bases.

5

B. Use of variant nucleic acid sequence for the production of variant products

In accordance with the present invention, nucleic acid sequences specified
10 above may be used as recombinant DNA molecules that direct the expression of variant products.

As will be understood by those of skill in the art, it may be advantageous to produce variant product-encoding nucleotide sequences possessing codons other than those which appear in any one of SEQ ID NO: 1 to SEQ ID NO: 87
15 which are those which naturally occur in the human genome. Codons preferred by a particular prokaryotic or eukaryotic host (Murray, E. *et al. Nuc Acids Res.*, 17:477-508, (1989)) can be selected, for example, to increase the rate of variant product expression or to produce recombinant RNA transcripts having desirable properties, such as a longer half-life, than transcripts produced from naturally
20 occurring sequence.

The nucleic acid sequences of the present invention can be engineered in order to alter a variant product coding sequence for a variety of reasons, including but not limited to, alterations which modify the cloning, processing and/or expression of the product. For example, alterations may be introduced
25 using techniques which are well known in the art, e.g., site-directed mutagenesis, to insert new restriction sites, to alter glycosylation patterns, to change codon preference, etc.

The present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs
30 comprise a vector, such as a plasmid or viral vector, into which a nucleic acid sequence of the invention has been inserted, in a forward or reverse orientation.

- 70 -

In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. Appropriate cloning and
5 expression vectors for use with prokaryotic and eukaryotic hosts are also described in Sambrook, *et al.*, (*supra*).

The present invention also relates to host cells which are genetically engineered with vectors of the invention, and the production of the product of the invention by recombinant techniques. Host cells are genetically engineered (i.e.,
10 transduced, transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector. The vector may be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the
15 expression of the variant nucleic acid sequence. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to those skilled in the art.

The nucleic acid sequences of the present invention may be included in any one of a variety of expression vectors for expressing a product. Such vectors
20 include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. However, any other vector may be used as long as it is replicable and viable in the host.
25 The appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and related sub-cloning procedures are deemed to be within the scope of those skilled in the art.

The DNA sequence in the expression vector is operatively linked to an appropriate transcription control sequence (promoter) to direct mRNA synthesis. Examples of such promoters include: LTR or SV40 promoter, the *E.coli lac* or *trp* promoter, the phage lambda *PL* promoter, and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector also contains a ribosome binding site for translation initiation, and a transcription terminator. The vector may also include appropriate sequences for amplifying expression. In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in *E.coli*.

The vector containing the appropriate DNA sequence as described above, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the protein. Examples of appropriate expression hosts include: bacterial cells, such as *E.coli*, *Streptomyces*, *Salmonella typhimurium*; fungal cells, such as yeast; insect cells such as *Drosophila* and *Spodoptera Sf9*; animal cells such as CHO, COS, HEK 293 or Bowes melanoma; adenoviruses; plant cells, etc. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein. The invention is not limited by the host cells employed.

In bacterial systems, a number of expression vectors may be selected depending upon the use intended for the variant product. For example, when large quantities of variant product are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be desirable. Such vectors include, but are not limited to, multifunctional *E.coli* cloning and expression vectors such as *Bluescript*(R) (Stratagene), in which the variant polypeptide coding sequence may be ligated into the vector in-frame with sequences for the amino-terminal Met and the subsequent 7 residues of beta-galactosidase so that a hybrid protein is produced;

pIN vectors (Van Heeke & Schuster *J. Biol. Chem.* **264**:5503-5509, (1989)); *pET* vectors (Novagen, Madison WI); and the like.

In the yeast *Saccharomyces cerevisiae* a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase and
5 PGH may be used. For reviews, see Ausubel *et al.* (*supra*) and Grant *et al.*, (*Methods in Enzymology* **153**:516-544, (1987)).

In cases where plant expression vectors are used, the expression of a sequence encoding variant product may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of
10 *CaMV* (Brisson *et al.*, *Nature* **310**:511-514, (1984)) may be used alone or in combination with the omega leader sequence from TMV (Takamatsu *et al.*, *EMBO J.*, **6**:307-311, (1987)). Alternatively, plant promoters such as the small subunit of RUBISCO (Coruzzi *et al.*, *EMBO J.* **3**:1671-1680, (1984); Broglie *et al.*, *Science* **224**:838-843, (1984)); or heat shock promoters (Winter J and
15 Sinibaldi R.M., *Results Probl. Cell Differ.*, **17**:85-105, (1991)) may be used. These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. For reviews of such techniques, see Hobbs S. or Murry L.E. (1992) in McGraw Hill Yearbook of Science and Technology, McGraw Hill, New York, N.Y., pp 191-196; or Weissbach and Weissbach (1988)
20 *Methods for Plant Molecular Biology*, Academic Press, New York, N.Y., pp 421-463.

Variant product may also be expressed in an insect system. In one such system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes in *Spodoptera frugiperda* cells or in *Trichoplusia*
25 larvae. The variant product coding sequence may be cloned into a nonessential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of variant coding sequence will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein coat. The recombinant viruses are then used to infect *S. frugiperda* cells or

Trichoplusia larvae in which variant protein is expressed (Smith *et al.*, *J. Virol.* 46:584, (1983); Engelhard, E.K. *et al.*, *Proc. Nat. Acad. Sci.* 91:3224-7, (1994)).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, a
5 variant product coding sequence may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a nonessential E1 or E3 region of the viral genome will result in a viable virus capable of expressing variant protein in infected host cells (Logan and Shenk, *Proc. Natl. Acad. Sci.* 81:3655-59, (1984). In addition,
10 transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Specific initiation signals may also be required for efficient translation of a variant product coding sequence. These signals include the ATG initiation codon and adjacent sequences. In cases where variant product coding sequence,
15 its initiation codon and upstream sequences are inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only coding sequence, or a portion thereof, is inserted, exogenous transcriptional control signals including the ATG initiation codon must be provided. Furthermore, the initiation codon must be in the correct
20 reading frame to ensure transcription of the entire insert. Exogenous transcriptional elements and initiation codons can be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate to the cell system in use (Scharf, D. *et al.*, (1994) *Results Probl. Cell Differ.*, 20:125-62, (1994); Bittner *et al.*, *Methods in*
25 *Enzymol* 153:516-544, (1987)).

In a further embodiment, the present invention relates to host cells containing the above-described constructs. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell.
30 Introduction of the construct into the host cell can be effected by calcium

phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis, L., Dibner, M., and Battey, I. (1986) Basic Methods in Molecular Biology). Cell-free translation systems can also be employed to produce polypeptides using RNAs derived from the DNA constructs of the present
5 invention.

A host cell strain may be chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the protein include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation and
10 acylation. Post-translational processing which cleaves a "*pre-pro*" form of the protein may also be important for correct insertion, folding and/or function. Different host cells such as CHO, HeLa, MDCK, 293, WI38, etc. have specific cellular machinery and characteristic mechanisms for such post-translational activities and may be chosen to ensure the correct modification and processing of
15 the introduced, foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express variant product may be transformed using expression vectors which contain viral origins of replication or endogenous expression elements and a selectable marker gene.
20 Following the introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clumps of stably transformed cells can be
25 proliferated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler M., *et al.*, *Cell* 11:223-32, (1977)) and adenine phosphoribosyltransferase (Lowy I., *et al.*, *Cell* 22:817-23, (1980)) genes which
30 can be employed in *tk*- or *aprt*- cells, respectively. Also, antimetabolite,

antibiotic or herbicide resistance can be used as the basis for selection; for example, *dhfr* which confers resistance to methotrexate (Wigler M., *et al.*, *Proc. Natl. Acad. Sci.* 77:3567-70, (1980)); *npt*, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. *et al.*, *J. Mol. Biol.*, 5 150:1-14, (1981)) and *als* or *pat*, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, *supra*). Additional selectable genes have been described, for example, *trpB*, which allows cells to utilize indole in place of tryptophan, or *hisD*, which allows cells to utilize histinol in place of histidine (Hartman S.C. and R.C. Mulligan, *Proc. Natl. Acad. Sci.* 10 85:8047-51, (1988)). The use of visible markers has gained popularity with such markers as anthocyanins, beta-glucuronidase and its substrate, GUS, and luciferase and its substrates, luciferin and ATP, being widely used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes, C.A. *et al.*, 15 *Methods Mol. Biol.*, 55:121-131, (1995)).

Host cells transformed with a nucleotide sequence encoding variant product may be cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. The product produced by a recombinant cell may be secreted or contained intracellularly depending on the 20 sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing nucleic acid sequences encoding variant product can be designed with signal sequences which direct secretion of variant product through a prokaryotic or eukaryotic cell membrane.

The variant product may also be expressed as a recombinant protein with 25 one or more additional polypeptide domains added to facilitate protein purification. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS 30 extension/affinity purification system (Immunex Corp, Seattle, Wash.). The

inclusion of a protease-cleavable polypeptide linker sequence between the purification domain and variant product is useful to facilitate purification. One such expression vector provides for expression of a fusion protein comprising a variant polypeptide fused to a polyhistidine region separated by an enterokinase
5 cleavage site. The histidine residues facilitate purification on IMLAC (immobilized metal ion affinity chromatography, as described in Porath, *et al.*, *Protein Expression and Purification*, 3:263-281, (1992)) while the enterokinase cleavage site provides a means for isolating variant polypeptide from the fusion protein. *pGEX* vectors (Promega, Madison, Wis.) may also be used to express
10 foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to ligand-agarose beads (e.g., glutathione-agarose in the case of GST-fusions) followed by elution in the presence of free ligand.

Following transformation of a suitable host strain and growth of the host
15 strain to an appropriate cell density, the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period. Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification. Microbial cells employed in expression of proteins can
20 be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, or other methods, which are well known to those skilled in the art.

The variant products can be recovered and purified from recombinant cell cultures by any of a number of methods well known in the art, including
25 ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography, and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high

performance liquid chromatography (HPLC) can be employed for final purification steps.

C. Diagnostic applications utilizing nucleic acid sequences

5 The nucleic acid sequences of the present invention may be used for a variety of diagnostic purposes. The nucleic acid sequences may be used to detect and quantitate expression of the variant in patient's cells, e.g. biopsied tissues, by detecting the presence of mRNA coding for variant product. Alternatively, the assay may be used to detect soluble variant in the serum or blood. This assay
10 typically involves obtaining total mRNA from the tissue or serum and contacting the mRNA with a nucleic acid probe. The probe is a nucleic acid molecule of at least 20 nucleotides, preferably 20-30 nucleotides, capable of specifically hybridizing with a sequence included within the sequence of a nucleic acid molecule encoding variant product under hybridizing conditions, detecting the
15 presence of mRNA hybridized to the probe, and thereby detecting the expression of variant. This assay can be used to distinguish between absence, presence, and excess expression of variant product and to monitor levels of variant expression during therapeutic intervention. In addition, the assay may be used to compare the levels of the variant of the invention to the levels of the original sequence from
20 which it has been varied or to levels of other variants, which comparison may have some physiological meaning.

The invention also contemplates the use of the nucleic acid sequences as a diagnostic for diseases resulting from inherited defective variant sequences, or diseases in which the ratio of the amount of the original sequence from which the
25 variant was varied to the novel variants of the invention is altered. These sequences can be detected by comparing the sequences of the defective (i.e., mutant) variant coding region with that of a normal coding region. Association of the sequence coding for mutant variant product with abnormal variant product activity may be verified. In addition, sequences encoding mutant variant products
30 can be inserted into a suitable vector for expression in a functional assay system

(e.g., colorimetric assay, complementation experiments in a variant protein deficient strain of HEK293 cells) as yet another means to verify or identify mutations. Once mutant genes have been identified, one can then screen populations of interest for carriers of the mutant gene.

5 Individuals carrying mutations in the nucleic acid sequence of the present invention may be detected at the DNA level by a variety of techniques. Nucleic acids used for diagnosis may be obtained from a patient's cells, including but not limited to such as from blood, urine, saliva, placenta, tissue biopsy and autopsy material. Genomic DNA may be used directly for detection or may be amplified
10 enzymatically by using PCR (Saiki, *et al.*, *Nature* 324:163-166, (1986)) prior to analysis. RNA or cDNA may also be used for the same purpose. As an example, PCR primers complementary to the nucleic acid of the present invention can be used to identify and analyze mutations in the gene of the present invention. Deletions and insertions can be detected by a change in size of the amplified
15 product in comparison to the normal genotype.

Point mutations can be identified by hybridizing amplified DNA to radiolabeled RNA of the invention or alternatively, radiolabeled antisense DNA sequences of the invention. Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the
20 chemical cleavage method (e.g. Cotton, *et al.* *Proc. Natl. Acad. Sci. USA*, 85:4397-4401, (1985)), or by differences in melting temperatures. "Molecular beacons" (Kostrikis L.G. *et al.*, *Science* 279:1228-1229, (1998)), hairpin-shaped, single-stranded synthetic oligo- nucleotides containing probe sequences which are complementary to the nucleic acid of the present invention, may also be used
25 to detect point mutations or other sequence changes as well as monitor expression levels of variant product. Such diagnostics would be particularly useful for prenatal testing.

Another method for detecting mutations uses two DNA probes which are designed to hybridize to adjacent regions of a target, with abutting bases, where
30 the region of known or suspected mutation(s) is at or near the abutting bases.

The two probes may be joined at the abutting bases, e.g., in the presence of a ligase enzyme, but only if both probes are correctly base paired in the region of probe junction. The presence or absence of mutations is then detectable by the presence or absence of ligated probe.

5 Also suitable for detecting mutations in the variant product coding sequence are oligonucleotide array methods based on sequencing by hybridization (SBH), as described, for example, in U.S. Patent No. 5,547,839. In a typical method, the DNA target analyte is hybridized with an array of oligonucleotides formed on a microchip. The sequence of the target can then be
10 "read" from the pattern of target binding to the array.

D. Gene mapping utilizing nucleic acid sequences

The nucleic acid sequences of the present invention are also valuable for chromosome identification. The sequence is specifically targeted to and can
15 hybridize with a particular location on an individual human chromosome. Moreover, there is a current need for identifying particular sites on the chromosome. Few chromosome marking reagents based on actual sequence data (repeat polymorphisms) are presently available for marking chromosomal location. The mapping of DNAs to chromosomes according to the present
20 invention is an important first step in correlating those sequences with genes associated with disease.

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 20-30 bp) from the variant cDNA. Computer analysis of the 3' untranslated region is used to rapidly select primers that do not span more than
25 one exon in the genomic DNA, which would complicate the amplification process. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the primer will yield an amplified fragment.

PCR mapping of somatic cell hybrids or using instead radiation hybrids
30 are rapid procedures for assigning a particular DNA to a particular chromosome.

Using the present invention with the same oligonucleotide primers, sublocalization can be achieved with panels of fragments from specific chromosomes or pools of large genomic clones in an analogous manner. Other mapping strategies that can similarly be used to map to its chromosome include *in situ* hybridization, prescreening with labeled flow-sorted chromosomes and preselection by hybridization to construct chromosome specific-cDNA libraries.

Fluorescence *in situ* hybridization (FISH) of a cDNA clone to a metaphase chromosomal spread can be used to provide a precise chromosomal location in one step. This technique can be used with cDNA as short as 50 or 60 bases. For a review of this technique, see Verma *et al.*, *Human Chromosomes: a Manual of Basic Techniques*, (1988) Pergamon Press, New York.

Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, for example, in the OMIM database (Center for Medical Genetics, Johns Hopkins University, Baltimore, MD and National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD). The OMIM gene map presents the cytogenetic map location of disease genes and other expressed genes. The OMIM database provides information on diseases associated with the chromosomal location. Such associations include the results of linkage analysis mapped to this interval, and the correlation of translocations and other chromosomal aberrations in this area with the advent of polygenic diseases, such as cancer, in general and prostate cancer in particular.

E. Therapeutic applications of nucleic acid sequences

Nucleic acid sequences of the invention may also be used for therapeutic purposes. Turning first to the second aspect of the invention (i.e. inhibition of expression of variant), expression of variant product may be modulated through
5 antisense technology, which controls gene expression through hybridization of complementary nucleic acid sequences, i.e. antisense DNA or RNA, to the control, 5' or regulatory regions of the gene encoding variant product. For example, the 5' coding portion of the nucleic acid sequence sequence which codes for the product of the present invention is used to design an antisense
10 oligonucleotide of from about 10 to 40 base pairs in length. Oligonucleotides derived from the transcription start site, e.g. between positions -10 and +10 from the start site, are preferred. An antisense DNA oligonucleotide is designed to be complementary to a region of the nucleic acid sequence involved in transcription (Lee *et al.*, *Nucl. Acids, Res.*, 6:3073, (1979); Cooney *et al.*, *Science* 241:456,
15 (1988); and Dervan *et al.*, *Science* 251:1360, (1991)), thereby preventing transcription and the production of the variant products. An antisense RNA oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of the mRNA molecule into the variant products (Okano *J. Neurochem.* 56:560, (1991)). The antisense constructs can be delivered to cells by procedures known
20 in the art such that the antisense RNA or DNA may be expressed *in vivo*. The antisense may be antisense mRNA or DNA sequence capable of coding such antisense mRNA. The antisense mRNA or the DNA coding thereof can be complementary to the full sequence of nucleic acid sequences coding for the variant protein or to a fragment of such a sequence which is sufficient to inhibit
25 production of a protein product.

Turning now to the first aspect of the invention, i.e. expression of variant, expression of variant product may be increased by providing coding sequences for coding for said product under the control of suitable control elements ending its expression in the desired host.

The nucleic acid sequences of the invention may be employed in combination with a suitable pharmaceutical carrier. Such compositions comprise a therapeutically effective amount of the compound, and a pharmaceutically acceptable carrier or excipient. Such a carrier includes but is not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The
5 formulation should suit the mode of administration.

The products of the invention as well as any activators and deactivators compounds (see below) which are polypeptides, may also be employed in accordance with the present invention by expression of such polypeptides *in vivo*,
10 which is often referred to as "*gene therapy*." Cells from a patient may be engineered with a nucleic acid sequence (DNA or RNA) encoding a polypeptide *ex vivo*, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, cells may be engineered by procedures known in the art by use of a retroviral particle
15 containing RNA encoding a polypeptide of the present invention.

Similarly, cells may be engineered *in vivo* for expression of a polypeptide *in vivo* by procedures known in the art. As known in the art, a producer cell for producing a retroviral particle containing RNA encoding the polypeptide of the present invention may be administered to a patient for engineering cells *in vivo*
20 and expression of the polypeptide *in vivo*. These and other methods for administering a product of the present invention by such method should be apparent to those skilled in the art from the teachings of the present invention. For example, the expression vehicle for engineering cells may be other than a retrovirus, for example, an adenovirus which may be used to engineer cells *in*
25 *vivo* after combination with a suitable delivery vehicle.

Retroviruses from which the retroviral plasmid vectors mentioned above may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, retroviruses such as Rous Sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, gibbon ape leukemia virus, human immunodeficiency
30 virus, adenovirus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

- 83 -

The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the *PE501*, *PA317*, *psi-2*, *psi-AM*, *PA12*, *T19-14X*, *VT-19-17-H2*, *psi-CRE*, *psi-CRIP*, *GP+E-86*, *GP+envAm12*,
5 and *DAN* cell lines as described in Miller (*Human Gene Therapy*, Vol. 1, pg. 5-14, (1990)). The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation, the use of liposomes, and CaPO_4 precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a
10 lipid, and then administered to a host.

The producer cell line generates infectious retroviral vector particles which include the nucleic acid sequence(s) encoding the polypeptides. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express the nucleic
15 acid sequence(s) encoding the polypeptide. Eukaryotic cells which may be transduced include, but are not limited to, embryonic stem cells, embryonic carcinoma cells, as well as hematopoietic stem cells, hepatocytes, fibroblasts, myoblasts, keratinocytes, endothelial cells, and bronchial epithelial cells.

The genes introduced into cells may be placed under the control of
20 inducible promoters, such as the radiation-inducible *Egr-1* promoter, (Maceri, H.J., *et al.*, *Cancer Res.*, 56(19):4311 (1996)), to stimulate variant production or antisense inhibition in response to radiation, eg., radiation therapy for treating tumors.

25 **Example III. Variant product**

The substantially purified variant product of the invention has been defined above as the product coded from the nucleic acid sequence of the invention. Preferably the amino acid sequence is an amino acid sequence having at least 90% identity to any one of the sequences identified as SEQ ID NO: 88 to
30 SEQ ID NO: 174 provided that the amino acid sequence is not identical to that of

the original sequence from which it has been varied. The protein or polypeptide may be in mature and/or modified form, also as defined above. Also contemplated are protein fragments having at least 10 contiguous amino acid residues, preferably at least 10-20 residues, derived from the variant product, as well as homologues as explained above.

The sequence variations are preferably those that are considered conserved substitutions, as defined above. Thus, for example, a protein with a sequence having at least 90% sequence identity with any of the products identified as SEQ ID NO: 88 to SEQ ID NO: 174, preferably by utilizing conserved substitutions as defined above is also part of the invention, and provided that it is not identical to the original peptide from which it has been varied. In a more specific embodiment, the protein has or contains any one of the sequence identified as SEQ ID NO: 88 to SEQ ID NO: 174. The variant product may be (i) one in which one or more of the amino acid residues in a sequence listed above are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue), or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the variant product is fused with another compound, such as a compound to increase the half-life of the protein (for example, polyethylene glycol (PEG)), or a moiety which serves as targeting means to direct the protein to its target tissue or target cell population (such as an antibody), or (iv) one in which additional amino acids are fused to the variant product. Such fragments, variants and derivatives are deemed to be within the scope of those skilled in the art from the teachings herein.

25 A. Preparation of variant product

Recombinant methods for producing and isolating the variant product, and fragments of the protein are described above.

In addition to recombinant production, fragments and portions of variant product may be produced by direct peptide synthesis using solid-phase techniques (cf. Stewart *et al.*, (1969) Solid-Phase Peptide Synthesis, WH Freeman Co, San

Francisco; Merrifield J., *J. Am. Chem. Soc.*, **85**:2149-2154, (1963)). In vitro peptide synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer, Foster City, Calif.) in accordance with
5 the instructions provided by the manufacturer. Fragments of variant product may be chemically synthesized separately and combined using chemical methods to produce the full length molecule.

B. Therapeutic uses and compositions utilizing the variant product

10

The variant product of the invention is generally useful in treating diseases and disorders which are characterized by a lower than normal level of variant expression, and or diseases which can be cured or ameliorated by raising the level of the variant product, even if the level is normal.

15

Variant products or fragments may be administered by any of a number of routes and methods designed to provide a consistent and predictable concentration of compound at the target organ or tissue. The product-containing compositions may be administered alone or in combination with other agents, such as stabilizing compounds, and/or in combination with other pharmaceutical
20 agents such as drugs or hormones.

20

Variant product-containing compositions may be administered by a number of routes including, but not limited to oral, intravenous, intramuscular, transdermal, subcutaneous, topical, sublingual, or rectal means as well as by nasal application. Variant product-containing compositions may also be administered
25 via liposomes. Such administration routes and appropriate formulations are generally known to those of skill in the art.

25

The product can be given via intravenous or intraperitoneal injection. Similarly, the product may be injected to other localized regions of the body. The product may also be administered via nasal insufflation. Enteral administration is
30 also possible. For such administration, the product should be formulated into an

30

appropriate capsule or elixir for oral administration, or into a suppository for rectal administration.

The foregoing exemplary administration modes will likely require that the product be formulated into an appropriate carrier, including ointments, gels, 5 suppositories. Appropriate formulations are well known to persons skilled in the art.

Dosage of the product will vary, depending upon the potency and therapeutic index of the particular polypeptide selected.

A therapeutic composition for use in the treatment method can include the 10 product in a sterile injectable solution, the polypeptide in an oral delivery vehicle, the product in an aerosol suitable for nasal administration, or the product in a nebulized form, all prepared according to well known methods. Such compositions comprise a therapeutically effective amount of the compound, and a pharmaceutically acceptable carrier or excipient. Such a carrier includes but is not 15 limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The product of the invention may also be used to modulate endothelial differentiation and proliferation as well as to modulate apoptosis either *ex vivo* or *in vitro*, for example, in cell cultures.

20 **Example IV. Screening methods for activators and deactivators (inhibitors)**

The present invention also includes an assay for identifying molecules, such as synthetic drugs, antibodies, peptides, or other molecules, which have a modulating effect on the activity of the variant product, e.g. activators or 25 deactivators of the variant product of the present invention. Such an assay comprises the steps of providing an variant product encoded by the nucleic acid sequences of the present invention, contacting the variant protein with one or more candidate molecules to determine the candidate molecules modulating effect on the activity of the variant product, and selecting from the molecules a 30 candidate's molecule capable of modulating variant product physiological activity.

The variant product, its catalytic or immunogenic fragments or oligopeptides thereof, can be used for screening therapeutic compounds in any of a variety of drug screening techniques. The fragment employed in such a test may be free in solution, affixed to a solid support, borne on a cell membrane or
5 located intracellularly. The formation of binding complexes, between variant product and the agent being tested, may be measured. Alternatively, the activator or deactivator may work by serving as agonist or antagonist, respectively, of the variant receptor, binding entity or target site, and their effect may be determined in connection with any of the above.

10 Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the variant product is described in detail by Geysen in PCT Application WO 84/03564, published on Sep. 13, 1984. In summary, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic
15 pins or some other surface. The peptide test compounds are reacted with the full variant product or with fragments of variant product and washed. Bound variant product is then detected by methods well known in the art. Substantially purified variant product can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing
20 antibodies can be used to capture the peptide and immobilize it on a solid support.

Antibodies to the variant product, as described in Example VI below, may also be used in screening assays according to methods well known in the art. For example, a "*sandwich*" assay may be performed, in which an anti-variant
25 antibody is affixed to a solid surface such as a microtiter plate and variant product is added. Such an assay can be used to capture compounds which bind to the variant product. Alternatively, such an assay may be used to measure the ability of compounds to influence with the binding of variant product to the variant receptor, and then select those compounds which effect the binding.

Example V. Anti-variant antibodies

A. Synthesis

In still another aspect of the invention, the purified variant product is used to produce anti-variant antibodies which have diagnostic and therapeutic uses related to the activity, distribution, and expression of the variant product.

Antibodies to the variant product may be generated by methods well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, humanized, single chain, Fab fragments and fragments produced by an Fab expression library. Antibodies, i.e., those which inhibit dimer formation, are especially preferred for therapeutic use.

A fragment of the variant product for antibody induction does not require biological activity but have to feature immunological activity; however, the protein fragment or oligopeptide must be antigenic. Peptides used to induce specific antibodies may have an amino acid sequence consisting of at least five amino acids, preferably at least 10 amino acids of the sequences specified in any one of SEQ ID NO: 88 to SEQ ID NO: 174. Preferably they should mimic a portion of the amino acid sequence of the natural protein and may contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of variant protein amino acids may be fused with those of another protein such as keyhole limpet hemocyanin and antibody produced against the chimeric molecule. Procedures well known in the art can be used for the production of antibodies to variant product.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, etc may be immunized by injection with variant product or any portion, fragment or oligopeptide which retains immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include but are not limited to Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet

hemocyanin, and dinitrophenol. BCG (bacilli Calmette-Guerin) and *Corynebacterium parvum* are potentially useful human adjuvants.

Monoclonal antibodies to variant protein may be prepared using any technique which provides for the production of antibody molecules by continuous
5 cell lines in culture. These include but are not limited to the hybridoma technique originally described by Koehler and Milstein (*Nature* 256:495-497, (1975)), the human B-cell hybridoma technique (Kosbor *et al.*, *Immunol. Today* 4:72, (1983); Cote *et al.*, *Proc. Natl. Acad. Sci.* 80:2026-2030, (1983)) and the EBV-hybridoma technique (Cole, *et al.*, *Mol. Cell Biol.* 62:109-120, (1984)).

10 Techniques developed for the production of "*chimeric antibodies*", the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can also be used (Morrison *et al.*, *Proc. Natl. Acad. Sci.* 81:6851-6855, (1984); Neuberger *et al.*, *Nature* 312:604-608, (1984); Takeda *et al.*, *Nature* 314:452-454, (1985)).
15 Alternatively, techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778) can be adapted to produce single-chain antibodies specific for the variant protein.

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening recombinant immunoglobulin libraries or
20 panels of highly specific binding reagents as disclosed in Orlandi *et al.* (*Proc. Natl. Acad. Sci.* 86:3833-3837, 1989)), and Winter G and Milstein C., (*Nature* 349:293-299, (1991)).

Antibody fragments which contain specific binding sites for variant protein may also be generated. For example, such fragments include, but are not
25 limited to, the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse W.D. *et al.*, *Science*
30 256:1275-1281, (1989)).

B. Diagnostic applications of antibodies

A variety of protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the
5 formation of complexes between the variant product and its specific antibody and the measurement of complex formation. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two noninterfering epitopes on a specific variant product is preferred, but a competitive binding assay may also be employed. These assays are described in Maddox D.E., *et al.*,
10 (*J. Exp. Med.* 158:1211, (1983)).

Antibodies which specifically bind variant product are useful for the diagnosis of conditions or diseases characterized by expression of the novel variant of the invention (where normally it is not expressed) by over or under expression of variant as well as for detection of diseases in which the proportion
15 between the amount of the variants of the invention and the original sequence from which it varied is altered. Alternatively, such antibodies may be used in assays to monitor patients being treated with variant product, its activators, or its deactivators. Diagnostic assays for variant protein include methods utilizing the antibody and a label to detect variant product in human body fluids or extracts of
20 cells or tissues. The products and antibodies of the present invention may be used with or without modification. Frequently, the proteins and antibodies will be labeled by joining them, either covalently or noncovalently, with a reporter molecule. A wide variety of reporter molecules are known in the art.

A variety of protocols for measuring the variant product, using either
25 polyclonal or monoclonal antibodies specific for the respective protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescent activated cell sorting (FACS). As noted above, a two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on variant product is
30 preferred, but a competitive binding assay may be employed. These assays are

described, among other places, in Maddox, *et al.* (*supra*). Such protocols provide a basis for diagnosing altered or abnormal levels of variant product expression. Normal or standard values for variant product expression are established by combining body fluids or cell extracts taken from normal subjects, preferably human, with antibody to variant product under conditions suitable for complex formation which are well known in the art. The amount of standard complex formation may be quantified by various methods, preferably by photometric methods. Then, standard values obtained from normal samples may be compared with values obtained from samples from subjects potentially affected by disease. Deviation between standard and subject values establishes the presence of disease state.

The antibody assays are useful to determine the level of variant product present in a body fluid sample, in order to determine whether it is being expressed at all, whether it is being overexpressed or underexpressed in the tissue, or as an indication of how variant levels of variable products are responding to drug treatment.

By another aspect the invention concerns methods for determining the presence or level of various anti-variant antibodies in a biological sample obtained from patients, such as blood or serum sample using as an antigen the variant product. Determination of said antibodies may be indicative to a plurality of pathological conditions or diseases.

C. Therapeutic uses of antibodies

In addition to their diagnostic use the antibodies may have a therapeutical utility in blocking or decreasing the activity of the variant product in pathological conditions where beneficial effect can be achieved by such a decrease.

The antibody employed is preferably a humanized monoclonal antibody, or a human Mab produced by known globulin-gene library methods. The antibody is administered typically as a sterile solution by IV injection, although other parenteral routes may be suitable. Typically, the antibody is administered

- 92 -

in an amount between about 1-15 mg/kg body weight of the subject. Treatment is continued, e.g., with dosing every 1-7 days, until a therapeutic improvement is seen.

Although the invention has been described with reference to specific
5 methods and embodiments, it is appreciated that various modifications and changes may be made without departing from the invention.

Example VI. Expression of ACEV

(a) Immunohistochemical staining:

The immunohistochemical staining was performed using Histostain plus Kit
10 (Zymed Laboratories Inc.). Mouse salivary gland micron sections were prepared using a R. Gung microtome and fixed on superfrost plus slides with 2% Tespa. Deparaffinization was performed in xylene for 10 min. Dehydration was performed three times in absolute ethanol and once 95% ethanol. The slides were washed in DDW and then incubated with 3% H₂O for 5 min. Subsequently, the slide were washed in
15 DDW and twice in 0.05M TrisHCl pH 7.6 (Optimax wash Buffer, BioGenex). The rest of the procedure was performed following the manufacturer's instructions. The results are shown in Figs. 88 and 89.

The immunohistochemical staining was performed on mouse salivary gland
20 micron sections. The immunohistochemistry was done using specific polyclonal antibodies designed against the c-terminus of SEQ ID NO: 144 (12 amino-acids), which are unique to said ACEV product and lack in the original ACE protein (Fig 88-a,b,d magnification X 100; Fig 89-b magnification X 400) compared with the pre-immune rabbit's serum (Fig 88-c, Fig. 89-a).

25 ACE was found to express in ductal epifilus (Fig 88-a,b,d, Fig 89-b).

The same procedure was repeated for mouse lymph node sectors stained with pre-immune serum (Fig. 90a, 90c - magnifications X 100, X 200, respectively) and immune serum (Fig. 90b and 90c magnifications X 100, X 200 respectively).

The results show positive staining in salivary glands.

- 93 -

(b) RT - PCR

RNA Purification and cDNA Synthesis Total RNA was extracted from different mouse tissues using Tri-Reagent System (Molecular Research Center, Inc., Cincinnati, OH). Synthesis of first-strand cDNA was carried out using Oligo(dT)15 (Promega, 5 Madison, WI), Superscript II (Gibco/BRL, Gaithersburg, MD), Rnasin (Promega, Madison, WI) and dNTP's (Gibco/BRL, Gaithersburg, MD). + with Superscript II, - without Superscript II.

Polymerase Chain Reaction (PCR): PCR was performed using Expand Long Template PCR system (Roche). As a template cDNA from different tissues was used. 10 The PCR reaction on PTC-225 (MJ Research, Inc.). PCR products were analyzed on an automated DNA sequencer ABI Prizem 310 Genetic Analyzer (Perkin Elmer).

The results are shown in Fig. 91. As can be seen the ACEV of the invention was expressed in skin, lung, heart, thymus, spleen, bone marrow and brain tissue

CLAIMS:

1. An isolated nucleic acid sequence, of an alternative splicing variant, selected from the group consisting of:
 - (i) the nucleic acid sequence depicted in any one of SEQ ID NO: 1 to
5 SEQ ID NO: 87;
 - (ii) nucleic acid sequences having at least 90% identity with the sequence of (i) with the proviso that each sequence is different than the original nucleic acid sequence from which the sequences of (i) have been varied by alternative splicing; and
 - 10 (iii) fragments of (i) or (ii) of at least 20 b.p., provided that said fragment contains a sequence which is not present, as a continuous stretch of nucleotides, in the original nucleic acid sequence from which the sequences of (i) have been varied by alternative splicing.
2. An isolated nucleic acid sequence complementary to the nucleic acid
15 sequence of Claim 1.
3. An amino acid sequence selected from the group consisting of:
 - (i) an amino acid sequence coded by the isolated nucleic acid sequence of alternative splice variants of Claim 1;
 - (ii) homologues of the amino acid sequences of (i) in which one or more
20 amino acids has been added, deleted, replaced or chemically modified in the region or adjacent to the region where the amino acid sequences differs from the original amino acid sequence, coded by the original nucleic acid sequence from which the variant has been varied.
- 25 4. An amino acid sequence according to Claim 3, as depicted in any one of SEQ ID NO: 88 to SEQ ID NO: 174.
5. An isolated nucleic acid sequence coding for any one of the amino acid sequences of Claim 3 or 4.
6. A purified antibody which binds specifically to any of the amino acid
30 sequence of Claim 3 or 4.

7. An expression vector comprising any one of the nucleic acid sequences of Claim 1 or 5 and control elements for the expression of the nucleic acid sequence in a suitable host.
8. An expression vector comprising any one of the nucleic acid sequences of Claim 2, and control elements for the expression of the nucleic acid sequences in a suitable host.
9. A host cell transfected by the expression vector of Claim 7 or 8.
10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient an agent selected from the group consisting of:
 - (i) the expression vector of Claim 7; and
 - (ii) any one of the amino acid sequences of Claim 3 or 4.
11. A pharmaceutical composition according to Claim 10, for treatment of diseases which can be ameliorated or cured by raising the level of any one of the amino acid sequences depicted in SEQ ID NO: 88 to SEQ ID NO: 174.
12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient an agent selected from the group consisting of:
 - (i) any one of the nucleic acid sequences of Claim 2;
 - (ii) the expression vector of Claim 8; and
 - (iii) the purified antibody of Claim 6.
13. A pharmaceutical composition according to Claim 12, for treatment of diseases which can be ameliorated or cured by decreasing the level of any one of the amino acid sequences depicted in SEQ ID NO: 88 to SEQ ID NO: 174.
14. A method for detecting an variant nucleic acid sequence in a biological sample, comprising the steps of:
 - (a) hybridizing to nucleic acid material of said biological sample any one of the nucleic acid sequences of Claim 1 or 2; and
 - (b) detecting said hybridization complex;wherein the presence of said hybridization complex correlates with the presence of an variant nucleic acid sequence in the said biological sample.
15. A method for determining the level of variant nucleic acid sequences in a biological sample comprising the steps of:

(a) hybridizing to nucleic acid material of said biological sample any one of the nucleic acid sequences of Claim 1 or 2; and

(b) determining the amount of hybridization complexes and normalizing said amount to provide the level of the variant nucleic acid sequences in the sample.

16. A method for determining the ratio between the level of variant of the nucleic acid sequence in a first biological sample and the level of the original sequence from which the variant has been varied by alternative splicing in a second biological sample comprising:

10 (a) determining the level of the variant nucleic acid sequence in the first biological sample according to the method of Claim 15;

(b) determining the level of the original sequence in the second biological sample; and

(c) comprising the levels obtained in (a) and (b) to give said ratio.

15 17. A method according to Claim 16, wherein said first and said second biological samples are the same sample.

18. A method according to any of Claims 14 to 17, wherein the nucleic acid material of said biological sample are mRNA transcripts.

19. A method according to Claim 18, where the nucleic acid sequence is present in a nucleic acid chip.

20. A method for identifying candidate compounds capable of binding to the variant product and modulating its activity the method comprising:

(i) providing any one of the amino acid sequences as defined in Claim 3 or 4;

25 (ii) contacting a candidate compound with said amino acid sequence;

(iii) determining the effect of said candidate compound on the biological activity of said protein or polypeptide and selecting those compounds which show a significant effect on said biological activity.

21. A method according to Claim 20, wherein the compound is an activator and the measured effect is increase in the biological activity.

22. A method according to Claim 20, wherein the compound is an deactivator and the effect is decrease in the biological activity.
23. An activator of any one of the amino acid sequences of Claim 3 or 4.
24. An deactivator of any one of the amino acid sequences of Claims 3 or 4.
- 5 25. A method for detecting any one of the amino acid sequences of Claim 3 or 4 in a biological sample, comprising the steps of:
- (a) contacting with said biological sample the antibody of Claim 8, thereby forming an antibody-antigen complex; and
 - (b) detecting said antibody-antigen complex
- 10 wherein the presence of said antibody-antigen complex correlates with the presence of the desired amino acid in said biological sample.
26. A method for detecting the level of the amino acid sequence of any one of Claim 3 or 4 in a biological sample, comprising the steps of:
- (a) contacting with said biological sample the antibody of Claim 8,
- 15 thereby forming an antibody-antigen complex; and
- (b) detecting the amount of said antibody-antigen complex and normalizing said amount to provide the level of said amino acid sequence in the sample.
27. A method for determining the ratio between the level of any one of the
- 20 amino acid sequences of Claims 3 or 4 present in a first biological sample and the level of the original amino acid sequences from which they were varied by alternative splicing, present in a second biological sample, the method comprising:
- (a) determining the level of the amino acid sequences of Claims 3 or 4 into a first sample by the method of Claim 26;
- 25 (b) determining the level of the original amino acid sequence in the second sample; and
- (c) comparing the level obtained in (a) and (b) to give said ratio.
28. A method according to Claim 27, wherein said first and said second biological samples are the same sample.
- 30 29. A method for detecting any one of the antibodies of Claim 6 in a biological sample comprising the steps of:

(a) contacting said biological sample with any one of the amino acid sequences of Claim 3 or 4 thereby forming an antibody-antigen complex; and

(b) detecting said antibody-antigen complex

wherein the presence of said antibody-antigen complex correlates with the presence of the antibody in said biological sample.

30. A method for detecting the level of any one of the antibodies of Claim 6 in a biological sample comprising the steps of:

(a) contacting said biological sample with any one of the amino acid sequences of Claim 3;

(b) detecting the amount of said antibody-antigen complex and normalizing said amount to provide the levels of said antibody in the sample.

31. An isolated nucleic acid sequence according to Claim 1 of an alternative splicing variant of an angiotensin converting enzyme (ACEV) selected from the group consisting of:

(i) the nucleic acid sequence depicted in SEQ ID NO: 57 or SEQ ID NO: 85;

(ii) nucleic acid sequences having at least 90% identity with the sequence of (i) with the proviso that each sequence is different than the original nucleic acid sequence from which the sequences of (i) have been varied by alternative splicing; and

(iii) fragments of (i) or (ii) of at least 20 b.p., provided that said fragment contains a sequence which is not present, as a continuous stretch of nucleotides, in the original nucleic acid sequence from which the sequences of (i) have been varied by alternative splicing.

32. An isolated nucleic acid sequence complementary to the nucleic acid sequence of Claim 31.

33. An amino acid sequence selected from the group consisting of:

(i) an amino acid sequence coded by the isolated nucleic acid sequence of alternative splice variants of Claim 31;

(ii) homologues of the amino acid sequences of (i) in which one or more amino acids has been added, deleted, replaced or chemically modified in the region

or adjacent to the region where the amino acid sequences differs from the original amino acid sequence, coded by the original nucleic acid sequence from which the variant has been varied.

34. An amino acid sequence according to Claim 33, as depicted in SEQ ID NO:
5 144 or SEQ ID NO: 172.
35. An isolated nucleic acid sequence coding for any one of the amino acid sequences of Claim 33 or 34.
36. A purified antibody which binds specifically to any of the amino acid sequence of Claim 33 or 34.
- 10 37. An expression vector comprising any one of the nucleic acid sequences of Claim 31 or 35 and control elements for the expression of the nucleic acid sequence in a suitable host.
38. An expression vector comprising any one of the nucleic acid sequences of Claim 32, and control elements for the expression of the nucleic acid sequences in a
15 suitable host.
39. A host cell transfected by the expression vector of Claim 37 or 38.
40. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as an active ingredient an agent selected from the group consisting of:
- (i) the expression vector of Claim 37; and
 - 20 (ii) any one of the amino acid sequences of Claim 33 or 34.
41. A pharmaceutical composition according to Claim 40, for treatment of diseases which can be ameliorated or cured by raising the level of any one of the amino acid sequences depicted in SEQ ID NO: 144 or SEQ ID NO: 172.
42. A pharmaceutical composition comprising a pharmaceutically acceptable
25 carrier and as an active ingredient an agent selected from the group consisting of:
- (i) any one of the nucleic acid sequences of Claim 32;
 - (ii) the expression vector of Claim 38; and
 - (iii) the purified antibody of Claim 36.
43. A pharmaceutical composition according to Claim 42, for treatment of
30 diseases which can be ameliorated or cured by decreasing the level of the amino acid sequences depicted in SEQ ID NO: 144 or SEQ ID NO: 172.

44. A pharmaceutical composition according to Claim 40 or 42 for the treatment of a disease selected from: cardiovascular disorders, congestive heart failure, hypertension, renal hypertension, diabetes, multiple sclerosis, sarcoidosis, nonsarcoidotic pulmonary granulomatous diseases, vascular pathologies involving
5 an endothelial abnormality and cancer.

45. A method for detecting an variant nucleic acid sequence in a biological sample, comprising the steps of:

(a) hybridizing to nucleic acid material of said biological sample any one of the nucleic acid sequences of Claim 31 or 32; and

10 (b) detecting said hybridization complex;

wherein the presence of said hybridization complex correlates with the presence of an variant nucleic acid sequence in the said biological sample.

46. A method for determining the level of variant nucleic acid sequences in a biological sample comprising the steps of:

15 (a) hybridizing to nucleic acid material of said biological sample any one of the nucleic acid sequences of Claim 31 or 32; and

(b) determining the amount of hybridization complexes and normalizing said amount to provide the level of the variant nucleic acid sequences in the sample.

20 47. A method for determining the ratio between the level of variant of the nucleic acid sequence in a first biological sample and the level of the original sequence from which the variant has been varied by alternative splicing in a second biological sample comprising:

(a) determining the level of the variant nucleic acid sequence in the first
25 biological sample according to the method of Claim 46;

(b) determining the level of the original sequence in the second biological sample; and

(c) comprising the levels obtained in (a) and (b) to give said ratio.

48. A method according to Claim 47, wherein said first and said second
30 biological samples are the same sample.

49. A method according to any of Claims 45 to 48, wherein the nucleic acid material of said biological sample are mRNA transcripts.
50. A method according to Claim 49, where the nucleic acid sequence is present in a nucleic acid chip.
- 5 51. A method for identifying candidate compounds capable of binding to the variant product and modulating its activity the method comprising:
- (i) providing any one of the amino acid sequences as defined in Claim 33 or 34;
 - (ii) contacting a candidate compound with said amino acid sequence;
 - 10 (iii) determining the effect of said candidate compound on the biological activity of said protein or polypeptide and selecting those compounds which show a significant effect on said biological activity.
52. A method according to Claim 51, wherein the compound is an activator and the measured effect is increase in the biological activity.
- 15 53. A method according to Claim 51, wherein the compound is an deactivator and the effect is decrease in the biological activity.
54. An activator of any one of the amino acid sequences of Claim 33 or 34.
55. An deactivator of any one of the amino acid sequences of Claims 33 or 34.
56. A method for detecting any one of the amino acid sequences of Claim 33 or 20 34 in a biological sample, comprising the steps of:
- (a) contacting with said biological sample the antibody of Claim 38, thereby forming an antibody-antigen complex; and
 - (b) detecting said antibody-antigen complex
- wherein the presence of said antibody-antigen complex correlates with the 25 presence of the desired amino acid in said biological sample.
57. A method for detecting the level of the amino acid sequence of any one of Claim 33 or 34 in a biological sample, comprising the steps of:
- (a) contacting with said biological sample the antibody of Claim 38, thereby forming an antibody-antigen complex; and

(b) detecting the amount of said antibody-antigen complex and normalizing said amount to provide the level of said amino acid sequence in the sample.

58. A method for determining the ratio between the level of any one of the amino acid sequences of Claims 33 or 34 present in a first biological sample and the level of the original amino acid sequences from which they were varied by alternative splicing, present in a second biological sample, the method comprising:

(a) determining the level of the amino acid sequences of Claims 33 or 34 into a first sample by the method of Claim 57;

10 (b) determining the level of the original amino acid sequence in the second sample; and

(c) comparing the level obtained in (a) and (b) to give said ratio.

59. A method according to Claim 58, wherein said first and said second biological samples are the same sample.

15 60. A method for detecting any one of the antibodies of Claim 36 in a biological sample comprising the steps of:

(a) contacting said biological sample with any one of the amino acid sequences of Claim 3 or 4 thereby forming an antibody-antigen complex; and

(b) detecting said antibody-antigen complex

20 wherein the presence of said antibody-antigen complex correlates with the presence of the antibody in said biological sample.

61. A method for detecting the level of any one of the antibodies of Claim 36 in a biological sample comprising the steps of:

(a) contacting said biological sample with any one of the amino acid sequences of Claim 33;

25 (b) detecting the amount of said antibody-antigen complex and normalizing said amount to provide the levels of said antibody in the sample.

1/209

```

1  MPIMGSSVYITVELAIAVLAILGNVLVCWAVWLSNLQNVTNYFVVSLAA 50
   |||||
1  MPIMGSSVYITVELAIAVLAILGNVLVCWAVWLSNLQNVTNYFVVSLAA 50

51 ADIAVGVLAIPFAITISTGFCAACHGCLFIACFVLVLTQSSIFSLLAIAI 100
   |||||
51 ADIAVGVLAIPFAITISTGFCAACHGCLFIACFVLVLTQSSIFSLLAIAI 100

101 DRYIAIRIPLRYNGLVTGTRAKGIIAICWVLSFAIGLTPMLGWNNCQPK 150
   |||||
101 DRYIAIRIPLRYNGLVTGTRAKGIIAICWVLSFAIGLTPMLGWNNCQPK 150

151 EGKNHSQCGEGQVACLFEDVVPNMYVYFNFFACVLVPLLMLGVYLRI 200
   |||||
151 EGKNHSQCGEGQVACLFEDVVPNMYVYFNFFACVLVPLLMLGVYLRI 200

201 FLAARRQLKQMESQPLPGERARSTLQKEVHAAKSLA.....PLH 239
   |||||
201 FLAARRQLKQMESQPLPGERARSTLQKEVHAAKSLAIVGLFALCWLPLH 250

```

FIG. 1

3/209

```

1 MPRYGASLRQSCPRSGREQQDGTAGAPGLLWMGLVLALALALALALSDS 90
  |||||
1 MPRYGASLRQSCPRSGREQQDGTAGAPGLLWMG..LALALALALALSDS 48

91 RVLWAPAEAHPLSPQGHPARLHRIVPRLRDVFGWGNLTCPICKGLFTAIN 140
  |||||
49 RVLWAPAEAHPLSPQGHPARLHRIVPRLRDVFGWGNLTCPICKGLFTAIN 98

141 LGLKKEPNVARVGSVAIKLCNLLKIAPPAVCQSIVHLFEDDMVEVWRRSV 190
  |||||
99 LGLKKEPNVARVGSVAIKLCNLLKIAPPAVCQSIVHLFEDDMVEVWRRSV 148

191 LSPSEACGLLLGSTCGHWDIFSSWNISLPTVPKPPKPPSPAPGAPVSR 240
  |||||
149 LSPSEARGLLLGSTCGHWDIFSSWNISLPTVPKPPKPPSPAPGAPVSR 198

241 ILFLTDLHWDHDYLEGTDPPDCADPLCCRRGSLPPASRPGAGYWGEYSKC 290
  |||||
199 ILFLTDLHWDHDYLEGTDPPDCADPLCCRRGSLPPASRPGAGYWGEYSKC 248

```

FIG. 2

4/209

```

291 DLPLRTLESLLSGLGPAGPFDMVYWTGDIPAHDVWHQTRQDQLRALTTVT 340
    |||||
249 DLPLRTLESLLSGLGPAGPFDMVYWTGDIPAHDVWHQTRQDQLRALTTVT 298

341 ALVRKFLGPVPVYPVAVGNHSTPVNSFPFPFIEGNHSSRWLYEAMAKAWE 390
    |||||
299 ALVRKFLGPVPVYPVAVGNHSTPVNSFPFPFIEGNHSSRWLYEAMAKAWE 348

391 PWLPAAEALRTLRIIGGFYALSPYPGLRLISLNMNFCSENFWLLINSTDPA 440
    |||||
349 PWLPAAEALRTLRIIGGFYALSPYPGLRLISLNMNFCSENFWLLINSTDPA 398

441 GQLQWLVGELQAAEDRGDKVHIIGHIPPGHCLKSWSWNNYYRIVARYENTL 490
    |||||
399 GQLQWLVGELQAAEDRGDKVHIIGHIPPGHCLKSWSWNNYYRIVARYENTL 448

491 AAQFFGHTHVDEFEFYDEETLSRPLAVAF LAPSATYI GLNPLVSEAE G 540
    |||||
449 AAQFFGHTHVDEFEFYDEETLSRPLAVAF LAPSATYI GLNP ..... 491

```

FIG. 2 (CONT.¹)

5/209

```

541 SLPYPGVGGIGEGGWSQSLQSMGRMCGPSLELPLLAPPVSPVSTSLAGYRV 590
      ||||
492 .....GYRV 495

591 YQIDGNYSGSSHVVLDHETIILNLTQANIPGAIPHWQLLYRARETYGLPN 640
      |||||
496 YQIDGNYSGSSHVVLDHETIILNLTQANIPGAIPHWQLLYRARETYGLPN 545

641 TLP TAWHNLVYRMRGDMQLFQTFWFLYHKGHPPEPCGTPCRLATLCAQL 690
      |||||
546 TLP TAWHNLVYRMRGDMQLFQTFWFLYHKGHPPEPCGTPCRLATLCAQL 595

691 SARADSPALCRHLMMPDGS LPEAQSLWPRPLFC 722
      |||||
596 SARADSPALCRHLMMPDGS LPEAQSLWPRPLFC 627

```

FIG. 2 (CONT.²)

7/209

```

251 QARNWGLGGHAFCRNPNDIRPWCFLNRDRLSWEYCDLAQCQTPTQAAP 300
   |||||
254 QARNWGLGGHAFCRNPNDIRPWCFLNRDRLSWEYCDLAQCQTPTQAAP 303
   |||||

301 PTPVSPRLHVPLMPAQAPPKPQPTTRTPPQSQTPGALPAKREQPPSLTR 350
   |||||
304 PTPVSPRLHVPLMPAQAPPKPQPTTRTPPQSQTPGALPAKREQPPSLTR 353
   |||||

351 NGPLSCGQRLRKSLSSMTRVVGGGLVALRGAHPYIAALYWGHSHFCAGSLIA 400
   |||||
354 NGPLSCGQRLRKSLSSMTRVVGGGLVALRGAHPYIAALYWGHSHFCAGSLIA 403
   |||||

401 PCWVLTAAHCLQDRPAPEDLTVVLGQERRNHSCEPCQTLAVRSYRLHEAF 450
   |||||
404 PCWVLTAAHCLQDRPAPEDLTVVLGQERRNHSCEPCQTLAVRSYRLHEAF 453
   |||||

451 SPVSYQHDLALLRLQEDADGSCALLSPYVQPVCLPSGAARPSETTLCQVA 500
   |||||
454 SPVSYQHDLALLRLQEDADGSCALLSPYVQPVCLPSGAARPSETTLCQVA 503
   |||||

501 GWGHQFEAS 509
   |||||
504 GWGHQFEGA 512

```

FIG. 3 (CONT.¹)

9/209

```

251 LCWEPWQPGHLHINQKCELRHKPQGEASWALVGPLPLEALQYELCGLLPA 300
|||||
251 LCWEPWQPGHLHINQKCELRHKPQGEASWALVGPLPLEALQYELCGLLPA 300

301 TAYTLQIRCIRWPLPGHWS..... 320
|||||
301 TAYTLQIRCIRWPLPGHWSDSPSLELRTTERAPTVRLDTWWRQQLDPR 350

321 .....GAILPLCNTTELSCTFHLP 339
|||||
351 TVQLFWKVPLEEDSGRIQGYVVSWRPSGQAGAILPLCNTTELSCTFHLP 400

340 SEAQEVAlVAYNSAGTSRPTPVVFESESRGPALTRLHAMARDPHSLWVGWE 389
|||||
401 SEAQEVAlVAYNSAGTSRPTPVVFESESRGPALTRLHAMARDPHSLWVGWE 450

390 PPNPWPQGYVIEWGLGPPSASNSNKTWRMEQNGRATGFLLENIRPFQLY 439
|||||
451 PPNPWPQGYVIEWGLGPPSASNSNKTWRMEQNGRATGFLLENIRPFQLY 500

```

FIG. 4 (CONT.¹)

SIIRSTITITE SHEET (RII E 26)

440	EIIVTPLYQDTMGPSQHVYAYSQEMAPSHAPELHLKHIGKTWAQLEWVPE	489
501	EIIVTPLYQDTMGPSQHVYAYSQEMAPSHAPELHLKHIGKTWAQLEWVPE	550
490	PPELGKSP LTHYTI FWTNAQNQSFSA I L NASSRGFVLHGLEPASLYHIHL	539
551	PPELGKSP LTHYTI FWTNAQNQSFSA I L NASSRGFVLHGLEPASLYHIHL	600
540	MAASQAGATNSTVLTMTLTPEGSELHIILGLFGLLLLTCLCGTAWLCC	589
601	MAASQAGATNSTVLTMTLTPEGSELHIILGLFGLLLLTCLCGTAWLCC	650
590	SPNRKNPLWPSVDPAPAHSSLGSWVPTIMEEDAFQLPGLGTPPITKLTVLE	639
651	SPNRKNPLWPSVDPAPAHSSLGSWVPTIMEEDAFQLPGLGTPPITKLTVLE	700
640	EDEKKPVPWESHNSSETCGLPTLVQTYVLQGDPRAVSTQPPQSQSGTSDQV	689
701	EDEKKPVPWESHNSSETCGLPTLVQTYVLQGDPRAVSTQPPQSQSGTSDQV	750

FIG. 4 (CONT.²)

11/209

```

      . . . . .
690 LYGQLLGSTSPGPGHYLRCDSTQPLLAGLTPSPKSYENLWFQASPLGTL 739
      |||||
751 LYGQLLGSTSPGPGHYLRCDSTQPLLAGLTPSPKSYENLWFQASPLGTL 800
      . . . . .

      740 VTPAPSQEDDCVFGPLLNFPLLQGIRVHGMEALGSF 775
          |||||
      801 VTPAPSQEDDCVFGPLLNFPLLQGIRVHGMEALGSF 836

```

FIG. 4 (CONT. ³)

12/209

```

MARLGNCSLTWAALIILLPGSLEECGHISVSAPIVHLGDPITASCIKQ 50
|||||
1 MARLGNCSLTWAALIILLPGSLEECGHISVSAPIVHLGDPITASCIKQ 50

. . .
51 NCSHLDPEPQILWRLGAELQPGGRQQRSLSDGTQESIITLPHLNHTQAFLS 100
|||||
51 NCSHLDPEPQILWRLGAELQPGGRQQRSLSDGTQESIITLPHLNHTQAFLS 100

. . .
101 CCLNWGNSLQILDQVELRAGYPPIAPHNLSCLMNLTTSSLICQWEPGPET 150
|||||
101 CCLNWGNSLQILDQVELRAGYPPIAPHNLSCLMNLTTSSLICQWEPGPET 150

. . .
151 HLPTSFTLKSFKSRGNCQTQGDSILDCVPKDGQSHCCIPRKHLLLYQNMG 200
|||||
151 HLPTSFTLKSFKSRGNCQTQGDSILDCVPKDGQSHCCIPRKHLLLYQNMG 200

. . .
201 IWVQAENALGTSMSPQLCLDPMDVVKLEPPMLRTMDPSPEAAPQAGCLQ 250
|||||
201 IWVQAENALGTSMSPQLCLDPMDVVKLEPPMLRTMDPSPEAAPQAGCLQ 250

```

FIG. 5

15/209

```

      .      .      .      .      .
751 SSETCGLPTLVQTYVLQGDPRAVSTQPQSQSGTSDQVLYGQLLGSTSPG 800
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
714 SSETCGLPTLVQTYVLQGDPRAVSTQPQSQSGTSDQVLYGQLLGSTSPG 763

      .      .      .      .      .
801 PGHYLRCDSTQPLLAGLTPSPKSYENLWFQASPLGTLVTPAPSQEDDCVF 850
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
764 PGHYLRCDSTQPLLAGLTPSPKSYENLWFQASPLGTLVTPAPSQEDDCVF 813

      .      .
      851 GPLLNFPLLQGIRVHGMEALGSF 873
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
      814 GPLLNFPLLQGIRVHGMEALGSF 836

```

FIG. 5 (CONT.³)

16/209

```

1  MQKIMHISVLLSPVLWGLIFGVSSNSIQIGGLEPRGADQEYSAFRVGMVQ  50
   ||||||||||||||||||||||||||||||||||||||||||||||||
1  MQKIMHISVLLSPVLWGLIFGVSSNSIQIGGLEPRGADQEYSAFRVGMVQ  50

51  FSTSEFRLTPHIDNLEVANSFAVTNAFCQSFRGVYAI FGFYDKKSVNTI  100
   ||||||||||||||||||||||||||||||||||||||||||||||||
51  FSTSEFRLTPHIDNLEVANSFAVTNAFCQSFRGVYAI FGFYDKKSVNTI  100

101 TSFCGTLHVSFITPSFPTDGTGTHPFVIQMRPDLKGALLSLIEYYQWDKFAY  150
   ||||||||||||||||||||||||||||||||||||||||||||||||
101 TSFCGTLHVSFITPSFPTDGTGTHPFVIQMRPDLKGALLSLIEYYQWDKFAY  150

151 LYDSDRGLSTLQAVLDSAAEKKWQVTAINVGNINNDKKDEMYRSLFQDLE  200
   ||||||||||||||||||||||||||||||||||||||||||||||||
151 LYDSDRGLSTLQAVLDSAAEKKWQVTAINVGNINNDKKDEMYRSLFQDLE  200

201 LKKERRVILDCERDKVNDIVDQVITIGKHVKGYHYI IANLEFTDGDLLKI  250
   ||||||||||||||||||||||||||||||||||||||||||||||||
201 LKKERRVILDCERDKVNDIVDQVITIGKHVKGYHYI IANLEFTDGDLLKI  250

```

FIG. 6

251	QFGGANVSGFQIVDYDDSLVSKFIERWSTLEEKEYPGAHTTIKYTSALT	300
251	QFGGANVSGFQIVDYDDSLVSKFIERWSTLEEKEYPGAHTTIKYTSALT	300
301	YDAVQVMTEAFRNLRKQRIEISRRGNAGDCLANPAVPWGQGVIEIERALKQ	350
301	YDAVQVMTEAFRNLRKQRIEISRRGNAGDCLANPAVPWGQGVIEIERALKQ	350
351	VQVEGLSGNIKFDQNGKRINYTIMELKTNGPRKIGYWSEVDKMMVVTLT	400
351	VQVEGLSGNIKFDQNGKRINYTIMELKTNGPRKIGYWSEVDKMMVVTLT	400
401	ELPSGNDTSGLENKTVVVTTILESPYVMMKKNHEMLEGNERYEGYCVDLA	450
401	ELPSGNDTSGLENKTVVVTTILESPYVMMKKNHEMLEGNERYEGYCVDLA	450

FIG. 6 (CONT.)¹

18/209

```

451 AEIAKHCGFKYKLTIVGDGKYGARDADTKIWNMGVGVGELVYGKADIAIAPL 500
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
451 AEIAKHCGFKYKLTIVGDGKYGARDADTKIWNMGVGVGELVYGKADIAIAPL 500

501 TITLVREEVIDFSKPFMSLGISIMIKKPQKSKPGVFSFLDPLAYEIMCI 550
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
501 TITLVREEVIDFSKPFMSLGISIMIKKPQKSKPGVFSFLDPLAYEIMCI 550

551 VFAYIGVSVVFLVSRFSPYEWHTTEEFEDGRETQSSSESTNEFGIFNSLWF 600
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
551 VFAYIGVSVVFLVSRFSPYEWHTTEEFEDGRETQSSSESTNEFGIFNSLWF 600

601 SLGAFMRQGCDISPRSLSGRIVGGVWFFTLIIISSYTANLAFLTVERM 650
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
601 SLGAFMRQGCDISPRSLSGRIVGGVWFFTLIIISSYTANLAFLTVERM 650

651 VSPIESAEDLSKQTEIAYGTLDSGSTKEFFRRRSKIAVFDKMWTYMRSAEP 700
    | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
651 VSPIESAEDLSKQTEIAYGTLDSGSTKEFFRRRSKIAVFDKMWTYMRSAEP 700

```

FIG. 6 (CONT.²)

```

701 SVFVRTAEGVARVRKSKGYAYLLESTMNEYIEQRKPCDTMKVGGNLD 750
|||||
701 SVFVRTAEGVARVRKSKGYAYLLESTMNEYIEQRKPCDTMKVGGNLD 750

751 KGYGIATPKGSSLGTPVNLAVLKLSEQGVLDKLNKNWYDKGEXG 795
|||||
751 KGYGIATPKGSSLGTPVNLAVLKLSEQGVLDKLNKNWYDKGECG 795

```


20/209

```

1 MKSIYFVAGLFVMLVQGSWQSLQDTEEKSRFSASQADPLSDPDQMNED 50
  |||||
1 MKSIYFVAGLFVMLVQGSWQSLQDTEEKSRFSASQADPLSDPDQMNED 50
  . . . . .
51 KRHSQGTFTSDYSKYLDSTRRAQDFVQWLMNTKRNRRNNIAKRHDEFERHAE 100
  |||||
51 KRHSQGTFTSDYSKYLDSTRRAQDFVQWLMNTKRNRRNNIAKRHDEFERHAE 100
  . . . . .
101 GTFTSVI.....FPEEVAIVEELGRRHADGS 126
  ||||| : |||||
101 GTFTSDVSSYLEGQAAKEFIAWLVKGRGRDRDFPEEVAIVEELGRRHADGS 150
  . . . . .
127 FSDEMNTISDNLAARDFINWLIQTKITDRK 156
  |||||
151 FSDEMNTILDNLAARDFINWLIQTKITDRK 180

```

FIG. 7

21/209

6 SGTARKTLHFEISKEGSDLSVVERAEVWFLKVPKANRTRTKVTIRLFQQ 55
|||||
129 SGTARKTLHFEISKEGSDLSVVERAEVWFLKVPKANRTRTKVTIRLFQQ 178
56 QKHPQGS�DTGEEAEVGLKGERSELLSEKVVVDARKSTWHVFPVSSSIQ 105
|||||
179 QKHPQGS�DTGEEAEVGLKGERSELLSEKVVVDARKSTWHVFPVSSSIQ 228
106 RLDDQKGSSLDVRIACEQCQESGASVLLGKKKKKEEGEGKKKGEGG 155
|||||
229 RLDDQKGSSLDVRIACEQCQESGASVLLGKKKKKEEGEGKKKGEGG 278
156 AGADEEKEQSHRPFLMLQARQSEDPHRRRRRGLCDGKVNICKKQFFV 205
|||||
279 AGADEEKEQSHRPFLMLQARQSEDPHRRRRRGLCDGKVNICKKQFFV 328

FIG. 8

22/209

206 SFKDIGWNDWIIAPSGYHANYCEGECPSHIAGTSGSSLSFHSTVINHYRM 255
|||||
329 SFKDIGWNDWIIAPSGYHANYCEGECPSHIAGTSGSSLSFHSTVINHYRM 378

256 RGHSPFANLKSCCVPTKLRPMSMLYYDDGQNI IKKDIQNMIVEECGCS 303
|||||
379 RGHSPFANLKSCCVPTKLRPMSMLYYDDGQNI IKKDIQNMIVEECGCS 426

FIG. 8 (CONT.¹)

23/209

```

1 MNSFSTSAFGPVAFSLGLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSS 50
  |||||
1 MNSFSTSAFGPVAFSLGLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSS 50
  |||||

51 ERIDKQIRYILDGISA LRKETCNXSNMC.....EKDG 82
  |||||

51 ERIDKQIRYILDGISA LRKETCNKSNMCESSEKEALAE NNLPKMAEKDG 100
  |||||

83 CFQSGFNEETCLVKIITGLLEFEVYLEYLQNRFESEEEQARAVQMSTKVL 132
  |||||

101 CFQSGFNEETCLVKIITGLLEFEVYLEYLQNRFESEEEQARAVQMSTKVL 150
  |||||

133 IQFLQKKAKNLDAITTPDPPTTNASLLTKLQAQNQLQDMTTHLILRSFKE 182
  |||||

151 IQFLQKKAKNLDAITTPDPPTTNASLLTKLQAQNQLQDMTTHLILRSFKE 200
  |||||

183 FLQSSSLRALRQM 194
  |||||

201 FLQSSSLRALRQM 212
  |||||

```

FIG. 9

24/209

```

1 MNSFST..... 6
  |||||
1 MNSFSTAAGPVAFSLGLLLVLPAAFPAPVPPGEDSKDVAAPHRQPLTSS 50
  .
7 .....TCNKSNMCESSKEALAEANNLNLPKMAEKDG 36
  .
  |||||
51 ERIDKQIRYILDGISALRKETCNKSNMCESSKEALAEANNLNLPKMAEKDG 100
  .
  .
37 CFQSGFNEETCLVKIITGLLEFEVYLEYLQNRFESEEQARAVQMSTKVL 86
  |||||
101 CFQSGFNEETCLVKIITGLLEFEVYLEYLQNRFESEEQARAVQMSTKVL 150
  .
  .
87 IQFLQKKAKNLDAITTPDPPTNASLLTKLQANQWLQDMTTHLILRSFKE 136
  |||||
151 IQFLQKKAKNLDAITTPDPPTNASLLTKLQANQWLQDMTTHLILRSFKE 200
  .
  .
137 FLQSSLRALRQM 148
  |||||
201 FLQSSLRALRQM 212

```

FIG. 10

25/209

```

1  MPRLEFHLLEFCLLNQFSRAVAACKWKDDVIKLCGRELVRAQIAICGMS  50
   |||||
1  MPRLEFHLLEFCLLNQFSRAVAACKWKDDVIKLCGRELVRAQIAICGMS  50

51  TWSKRSLSQEDAPQTPRPVAAGDFIQTVSLGISPDGGKALRTGSCFTREF 100
   |||||
51  TWSKRSLSQEDAPQTPRPVA..... 70

101 LGALSKLVPSFINKDTETIIIMLEFIANLPPELKAALSERQPSLPQLQY 150
   .:|||||
71.... EIVPSFINKDTETIIIMLEFIANLPPELKAALSERQPSLPQLQY 115

151 VPALKDSSLLFEEFKKLIRNRQSEAADSNPSELKYLGLDTHSQKKRRPYV 200
   |||||. | |||||
116 VPALKDSNLSFEEFKKLIRNRQSEAADSNPSELKYLGLDTHSQKKRRPYV 165

201 ALFEKCCCLIGCTKRSLAKYC 220
   |||||
166 ALFEKCCCLIGCTKRSLAKYC 185

```

FIG. 11

26/209

```

1  MKLCVTVLSLLMLVAAFCSPALSAPMGSDPPTACCFSTARKLPRNFVVD 50
   |||||
1  MKLCVTVLSLLMLVAAFCSPALSAPMGSDPPTACCFSTARKLPRNFVVD 50

51 YYETSSLCSQPAVV...GKQVCADPSESWSVQYVYDLELN 87
   |||||
51 YYETSSLCSQPAVVFTKRSKQVCADPSESWSVQYVYDLELN 92

```

FIG. 12

27/209

```

1  MGLAWGLGVLFMLHVCGTNRIPESGGDNVFDIFELTGAARKGSGRRLVK  50
   |||||||
1  MGLAWGLGVLFMLHVCGTNRIPESGGDNVFDIFELTGAARKGSGRRLVK  50

51  GPDSPSPAFRIEDANLIPVPDDKFQDLVDVRAEKGFLLLASLRQMKT  100
   |||||||
51  GPDSPSPAFRIEDANLIPVPDDKFQDLVDVRAEKGFLLLASLRQMKT  100

101  RGTLLALERKDHSGQVFSVNSNGKAGTLDLSLTVQGKHVSVSEALLAT  150
   |||||||
101  RGTLLALERKDHSGQVFSVNSNGKAGTLDLSLTVQGKHVSVSEALLAT  150

151  GQWKSITLQVQEDRAQLYIDCEKMEAEALDVPIQSVFTRDLASIALRIA  200
   |||||||
151  GQWKSITLQVQEDRAQLYIDCEKMEAEALDVPIQSVFTRDLASIALRIA  200

201  KGGVNDNFQGVQLQNVRFVFGTTPEDILRNKGCSSSTSVLLTLDNNVVNGS  250
   |||||||
201  KGGVNDNFQGVQLQNVRFVFGTTPEDILRNKGCSSSTSVLLTLDNNVVNGS  250

```

FIG. 13

28/209

251	SPAIR	NYIGHKTKDLQAICGIS	DELSSMVLELRGLRTIV	TTLQDSIRK	300	
251	SPAIR	NYIGHKTKDLQAICGIS	DELSSMVLELRGLRTIV	TTLQDSIRK	300	
301	VTEEN	KELANELRRPPLCYHNGVQYRNNEE	WTVDSCTECHCQNSVTICKK		350	
301	VTEEN	KELANELRRPPLCYHNGVQYRNNEE	WTVDSCTECHCQNSVTICKK		350	
351	VSCPI	MPCSNATVPDGECCPRCWPSDSAD	DGWSPSEWTS	CSCTSCGNGIQ	400	
351	VSCPI	MPCSNATVPDGECCPRCWPSDSAD	DGWSPSEWTS	CSCTSCGNGIQ	400	
401	QRGR	SCDSLNNRCEGSSVQTRTCHI	QECDKR	FKQDGGWSHPWSSCSVT	450	
401	QRGR	SCDSLNNRCEGSSVQTRTCHI	QECDKR	FKQDGGWSHPWSSCSVT	450	
451	CGDGV	ITRILCN	SPSPQMNGKPC	EGARETKACKKD	ACPINGGWPWSP	500
451	CGDGV	ITRILCN	SPSPQMNGKPC	EGARETKACKKD	ACPINGGWPWSP	500

FIG. 13 (CONT.¹)

29/209

```

501 WDICSVTGGGVQKRSRLCINNPTPQFGGKDCVGDVTENQICNKQDCPIDG 550
   |||||
501 WDICSVTGGGVQKRSRLCINNPTPQFGGKDCVGDVTENQICNKQDCPIDG 550

551 CLSNPCFAGVKCTSYPDGSWKCGACPPGYSGNGIQCTDVDECKEVPDADF 600
   |||||
551 CLSNPCFAGVKCTSYPDGSWKCGACPPGYSGNGIQCTDVDECKEVPDADF 600

601 NHNGEHCENTDPGYNCLPCPPRFTGSQPFQGVGHATANKQVCKPRNPC 650
   |||||
601 NHNGEHCENTDPGYNCLPCPPRFTGSQPFQGVGHATANKQVCKPRNPC 650

651 TDGTHDCNKNAKCNLYLGHYSDEMPYRCECKPGYAGNGIICGEDTDLDGWPN 700
   |||||
651 TDGTHDCNKNAKCNLYLGHYSDEMPYRCECKPGYAGNGIICGEDTDLDGWPN 700

701 ENLVCVANATYHCKKDNCPNLP 722
   |||||
701 ENLVCVANATYHCKKDNCPNLP 722

```

FIG. 13 (CONT.²)

30/209

1 MGLAWGLGVLFMLHVCGTNRIPESGGDNSVFEDIFELTGAARKGSGRRLVK 50
|||||
1 MGLAWGLGVLFMLHVCGTNRIPESGGDNSVFEDIFELTGAARKGSGRRLVK 50
51 GPDSSPAFRIEDANLIPVPDDKFFQDLVDVRAEKGFLLLASLRQMKKT 100
|||||
51 GPDSSPAFRIEDANLIPVPDDKFFQDLVDVRAEKGFLLLASLRQMKKT 100
101 RGTLALERKDHSGQVFSVSNKGAGTLDLSLTVQKGQHVVSVVEALLAT 150
|||||
101 RGTLALERKDHSGQVFSVSNKGAGTLDLSLTVQKGQHVVSVVEALLAT 150
151 GQWKSITLQVQEDRAQLYIDCEKMENAEALDVPIQSVFTRDLASIALRIA 200
|||||
151 GQWKSITLQVQEDRAQLYIDCEKMENAEALDVPIQSVFTRDLASIALRIA 200
201 KGGVNDNFQGVNQVRFVFGTTPEDILRNKGCSSSTSVLLTLDNNVVNGS 250
|||||
201 KGGVNDNFQGVNQVRFVFGTTPEDILRNKGCSSSTSVLLTLDNNVVNGS 250

FIG. 14

31/209

251	SPAIR	NYIGHKTKDLQAICGIS	DELSSMVLELRGLRTIV	TTLQDSIRK	300
251	SPAIR	NYIGHKTKDLQAICGIS	DELSSMVLELRGLRTIV	TTLQDSIRK	300
301	VTEEN	KELANELRRPPLCYHN	GVQYRNNEE	WTVDSCTECHCQNSVTICKK	350
301	VTEEN	KELANELRRPPLCYHN	GVQYRNNEE	WTVDSCTECHCQNSVTICKK	350
351	VSCPI	MPCSNATVPDGECCPRC	WPSPDSAD	DGWSPSEWTSCSTSCGNGIQ	400
351	VSCPI	MPCSNATVPDGECCPRC	WPSPDSAD	DGWSPSEWTSCSTSCGNGIQ	400
401	QRGR	SCDSLNNRCEGSSVQ	TRTCHIQECDKRFKQD	GGWSHWPSSCSVT	450
401	QRGR	SCDSLNNRCEGSSVQ	TRTCHIQECDKRFKQD	GGWSHWPSSCSVT	450
451	CGDG	VITRIRLCNSPSPQMNGK	PCGEARETKACKKD	ACPINGGWGPWSP	500
451	CGDG	VITRIRLCNSPSPQMNGK	PCGEARETKACKKD	ACPINGGWGPWSP	500

FIG. 14 (CONT.¹)

33/209

```

1  MGLAWGLGVLFMLMHVCGTNRIPESGGDNSVFDIFELTGAARKSGRRLLVK  50
   |||||
1  MGLAWGLGVLFMLMHVCGTNRIPESGGDNSVFDIFELTGAARKSGRRLLVK  50

51  GPDSPSPAFRIEDANLIPVPDDKFDQDLVDVRAEKGFLLASLRQMKKT  100
   |||||
51  GPDSPSPAFRIEDANLIPVPDDKFDQDLVDVRAEKGFLLASLRQMKKT  100

101  RGTLLALERKDHSGQVFSVSNKGAGTLDLSLTVQKQHVVSVEEALLAT  150
   |||||
101  RGTLLALERKDHSGQVFSVSNKGAGTLDLSLTVQKQHVVSVEEALLAT  150

151  GQWKSITLFVQEDRAQLYIDCEKMENAEALDVPIQSVFTRDLASIALRIA  200
   |||||
151  GQWKSITLFVQEDRAQLYIDCEKMENAEALDVPIQSVFTRDLASIALRIA  200

201  KGGVNDNFQGVLFQNVRFVFGTTPEDILRNKGCSSSTSVLLTLDNNVVNGS  250
   |||||
201  KGGVNDNFQGVLFQNVRFVFGTTPEDILRNKGCSSSTSVLLTLDNNVVNGS  250

```

FIG. 15

34/209

```

251 SPAIRTN Y I G H K T K D L Q A I C G I S C D E L S S M V L E L R G L R T I V T T L Q D S I R K   300
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
251 SPAIRTN Y I G H K T K D L Q A I C G I S C D E L S S M V L E L R G L R T I V T T L Q D S I R K   300

301 V T E E N K E L A N E L R R P P L C Y H N G V Q Y R N N E E W T V D S C T E C H C Q N S V T I C K   350
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
301 V T E E N K E L A N E L R R P P L C Y H N G V Q Y R N N E E W T V D S C T E C H C Q N S V T I C K   350

351 V S C P I M P C S N A T V P D G E C C P R C W P S D S A D D G W S P S E W T S C S T S C G N G I Q   400
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
351 V S C P I M P C S N A T V P D G E C C P R C W P S D S A D D G W S P S E W T S C S T S C G N G I Q   400

401 Q R G R S C D S L N N R C E G S S V Q T R T C H I Q E C D K R F K Q D G G W S H W S P W S S C S V T   450
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
401 Q R G R S C D S L N N R C E G S S V Q T R T C H I Q E C D K R F K Q D G G W S H W S P W S S C S V T   450

451 C G D G V I T R I R L C N S P S P Q M N G K P C E G E A R E T K A C K K D A C P   490
   | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
451 C G D G V I T R I R L C N S P S P Q M N G K P C E G E A R E T K A C K K D A C P   490

```

FIG. 15 (CONT.¹)

```

1 MGLAWGLGVLFMLHVCGTNRIPESGGDNSVFDFELTGAARKGSGRRLVK 50
  |||||
1 MGLAWGLGVLFMLHVCGTNRIPESGGDNSVFDFELTGAARKGSGRRLVK 50

51 GPDSSPAFRIEDANLIPVPDDKFQDLVDVRAEKGFLLASLRQMKT 100
  |||||
51 GPDSSPAFRIEDANLIPVPDDKFQDLVDVRAEKGFLLASLRQMKT 100

101 RGTLLALERKDHSGQVFSVNSNGKAGTLDLSLTQVGKQHVSVVEEALLAT 150
  |||||
101 RGTLLALERKDHSGQVFSVNSNGKAGTLDLSLTQVGKQHVSVVEEALLAT 150

151 GQWKSITLQVQEDRAQLYIDCEKMENAEILDVPIQSVFTRDLASIALRIA 200
  |||||
151 GQWKSITLQVQEDRAQLYIDCEKMENAEILDVPIQSVFTRDLASIALRIA 200

201 KGGVNDNFQGVLQNVRFVFGTTPEDILRNKGCSSSTSVLLTLDNNVVNGS 250
  |||||
201 KGGVNDNFQGVLQNVRFVFGTTPEDILRNKGCSSSTSVLLTLDNNVVNGS 250

```

FIG. 16

SIIRSTITITE SHEET (RIIE E 26)

```

251 SPAIRTYIGHKTKDLQAICGISCDLSSMVLELRGLRTIVTTLQDSIRK 300
|||||
251 SPAIRTYIGHKTKDLQAICGISCDLSSMVLELRGLRTIVTTLQDSIRK 300
|||||
301 VTEENKELANELRRPPLCYHNGVQYRNNEEWTVDSCTECHCQNSVTICKK 350
|||||
301 VTEENKELANELRRPPLCYHNGVQYRNNEEWTVDSCTECHCQNSVTICKK 350
|||||
351 VSCPIMPCSNATVPDGECCPRCWPSDSADDDGWSPWSEWTSCSTSCGNGIQ 400
|||||
351 VSCPIMPCSNATVPDGECCPRCWPSDSADDDGWSPWSEWTSCSTSCGNGIQ 400
|||||
401 QGRSCDSLNNRCEGSSVQTRTCHIQECDKRCKHLSLGTW 441
|||||
401 QGRSCDSLNNRCEGSSVQTRTCHIQECDKRFKQ...DGGW 438

```

FIG. 16 (CONT.)¹

1	MAALMT	PGTGAPP	PAPGDF	SGEGSQ	GLPDP	SPPEPK	QLP	ELIRMK	RDDGRLS	50
1	MAALMT	PGTGAPP	PAPGDF	SGEGSQ	GLPDP	SPPEPK	QLP	ELIRMK	RDDGRLS	50
51	EADIRG	FVA	AVVNG	SAQGAQ	IGAMLM	AI	RLRGMD	LEETSV	LTAQAQSGQ	100
51	EADIRG	FVA	AVVNG	SAQGAQ	IGAMLM	AI	RLRGMD	LEETSV	LTAQAQSGQ	100
101	QLEWPE	AWRQ	QLV	DKHST	GGVG	DKVSL	VLAPALA	ACGCKV	PMSGRGLGH	150
101	QLEWPE	AWRQ	QLV	DKHST	GGVG	DKVSL	VLAPALA	ACGCKV	PMSGRGLGH	150
151	TGGTLD	KLESI	PGFN	VIQSP	EQMVLLDQ	AGCCIV	GQSEQL	VPADGILYA	200	
151	TGGTLD	KLESI	PGFN	VIQSP	EQMVLLDQ	AGCCIV	GQSEQL	VPADGILYA	200	
201	ARDVTAT	VD	SLPLIT	ASILSK	KLVEGL	SALVVD	VKFGGAA	VFPNQEQARE	250	
201	ARDVTAT	VD	SLPLIT	ASILSK	KLVEGL	SALVVD	VKFGGAA	VFPNQEQARE	250	

FIG. 17

SIIRSTITITE SHEET (RIII F 26)

FIG. 17 (CONT.¹)

39/209

[illegible]

FIG. 18

40/209

```

224 .....A...RVAAALTAMDKPLGRCVGHAVEEALLCMDGAGP 259
    |  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
250 ELAKTLVGVGASLGLRVAAALTAMDKPLGRCVGHAVEEALLCMDGAGP 299

    .      .      .      .      .      .      .      .
260 PDLRDLVTTLGGALLWLSGHAGTQAQGAARVAAALDDGSALGRFERMLAA 309
    |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
300 PDLRDLVTTLGGALLWLSGHAGTQAQGAARVAAALDDGSALGRFERMLAA 349

    .      .      .      .      .      .      .      .
310 QGVDPGLARALCSGSPAERRQLLPRAREQEELLAPADGTVELVRALPLAL 359
    |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
350 QGVDPGLARALCSGSPAERRQLLPRAREQEELLAPADGTVELVRALPLAL 399

    .      .      .      .      .      .      .      .
360 VLHELGAGRSRAGEPLRLGVGAELLDVDVGQRLRRGTPWLVRVHRDGPALSG 409
    |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
400 VLHELGAGRSRAGEPLRLGVGAELLDVDVGQRLRRGTPWLVRVHRDGPALSG 449

    .      .      .      .      .      .      .      .
410 PQSRALQEQALVLSDRAPFAAPSPFAELVLPPQQ 442
    |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
450 PQSRALQEQALVLSDRAPFAAPLPPFAELVLPPQQ 482

```

FIG. 18 (CONT.¹)

41/209

```

1  MAALMTPGTGAPPAPGDFSGEGSQGLPDPSPPEPKQLPELIRMKRDGGRLS  50
   |||||
1  MAALMTPGTGAPPAPGDFSGEGSQGLPDPSPPEPKQLPELIRMKRDGGRLS  50

51  EADIRGFVAADVNGSAQQAQIGAMLMAIRLRGMDLEETSVLTQALAQSGQ  100
   |||||
51  EADIRGFVAADVNGSAQQAQIGAMLMAIRLRGMDLEETSVLTQALAQSGQ  100

101 QLEWPEAWRQQLVDKHSTGGVGDKVSLVLAPALAAACGCKVPMISGRGLGH  150
   |||||
101 QLEWPEAWRQQLVDKHSTGGVGDKVSLVLAPALAAACGCKVPMISGRGLGH  150

151 TGGTLDKLESIPGFNVIQSPEQMQLLDQAGCCIVGQSEQLVPADGILYA  200
   |||||
151 TGGTLDKLESIPGFNVIQSPEQMQLLDQAGCCIVGQSEQLVPADGILYA  200

201 ARDVTATVDSLPLITG.....WRG.....SQPRA..  224
   |||||
201 ARDVTATVDSLPLITASILSKKLVEGLSALVVDVKFGGAAVFPNQEQARE  250

```

FIG. 19

```

225 .....RVAAALTAMDKPLGRCVGHAEVEEALLCMDGAGPP 260
    |||||
251 LAKTLVGVGASGLRVAAALTAMDKPLGRCVGHAEVEEALLCMDGAGPP 300
    .      .      .      .      .      .
261 DLRDLVTTLGGALLWLSGHAGTQAQGAARVAAA..... 293
    |||||
301 DLRDLVTTLGGALLWLSGHAGTQAQGAARVAAALDDGSALGRFERMLAAQ 350
    .      .      .
    .      .      .
    .      .      .
294 ..RALQEALVLSDRAPFAAPSPFAELVLPQQ 323
    |||||
451 QSRALQEALVLSDRAPFAAPLPPFAELVLPQQ 482

```

FIG. 19 (CONT.¹)

43/209

```

1 MASRLTLTLLTLLLAGDRASSNP NATSS.....VI 31
  |||||
1 MASRLTLTLLTLLLAGDRASSNP NATSSSQDPESLQDRGEGKVATTVI 50
  |||||
32 SKMLFVEPILEVSSLPTNSTNSATKITANTTDEPTTQPTTEPTTQPTI 81
  |||||
51 SKMLFVEPILEVSSLPTNSTNSATKITANTTDEPTTQPTTEPTTQPTI 100
  |||||
82 QPTQPTTQLPTDSPTQPTTGSCFCPGPVTLCSDLESHTAEVLGDALVDFS 131
  |||||
101 QPTQPTTQLPTDSPTQPTTGSCFCPGPVTLCSDLESHTAEVLGDALVDFS 150
  |||||
132 LKLYHAFSAMKKVETNMAFSPFSIASLLTQVLLGAGENTKTNLESILSYP 181
  |||||
151 LKLYHAFSAMKKVETNMAFSPFSIASLLTQVLLGAGENTKTNLESILSYP 200
  |||||
182 KDFTCVHQALKGETTKGVTSVSQIFHSPDLAIRDTFVNASRTLYSSSPRV 231
  |||||
201 KDFTCVHQALKGETTKGVTSVSQIFHSPDLAIRDTFVNASRTLYSSSPRV 250
  |||||

```

FIG. 20

FIG. 20 (CONT.¹)

[illegible]

FIG. 21

FIG. 22 (CONT.)¹)

[illegible]

FIG. 23

50/209

FIG. 25

51/209

83 MSAPAAKVSCKELNSNHDGADETSEKEQQAIEHIDEVQNEIDRLNEQAS 132
|||||
1 MSAPAAKVSCKELNSNHDGADETSEKEQQAIEHIDEVQNEIDRLNEQAS 50

133 EEILKVEQKYNKLRQPFQKRSELIAKIPNFWVTTFVNHPQVSALLGEED 182
|||||
51 EEILKVEQKYNKLRQPFQKRSELIAKIPNFWVTTFVNHPQVSALLGEED 100

183 EEALHYLTRVEVTEFFEDIKSGYRIDFYFDENPYFENKVLSEFHLNESGD 232
|||||
101 EEALHYLTRVEVTEFFEDIKSGYRIDFYFDENPYFENKVLSEFHLNESGD 150

233 PSSKSTEIKWKGKDLTKRSSQTQNKASRKQRQHEEPESFTWFTDHS DAG 282
|||||
151 PSSKSTEIKWKGKDLTKRSSQTQNKASRKQRQHEEPESFTWFTDHS DAG 200

283 ADELGEVIKDDIWPNPLOYYLVPMDDEEGEGEEDDDDDDEEEGLE DIDE 332
|||||
201 ADELGEVIKDDIWPNPLOYYLVPMDDEEGEGEEDDDDDDEEEGLE DIDE 250

333 EGDEDEGEDEDDDEGEDEGEDEGEDD 359
|||||
251 EGDEDEGEDEDDDEGEDEGEDEGEDD 277

FIG. 26


```

1 MSAPAAKVSKKELNSNHDGADETSEKEQQEAIEHIDEVQNEIDRLNEQAS 50  

| | | | | | | | | | | | | | | | | | | | | | | |  

1 MSAPAAKVSKKELNSNHDGADETSEKEQQEAIEHIDEVQNEIDRLNEQAS 50  

.  

51 EEILKV EQYNKL RQPFFQKRSELIAKIPNFWVTTFVNHPQVSALLGEED 100  

| | | | | | | | | | | | | | | | | | | | | | | |  

51 EEILKV EQYNKL RQPFFQKRSELIAKIPNFWVTTFVNHPQVSALLGEED 100  

.  

101 EEALHYLTRVEVFTEFEDIKSGYRIDFYFDENPYFENKVL SKEFHLNESGD 150  

| | | | | | | | | | | | | | | | | | | | | | | |  

101 EEALHYLTRVEVFTEFEDIKSGYRIDFYFDENPYFENKVL SKEFHLNESGD 150  

.  

151 PSSKSTEIKWKSGKDLTKRSSQTQN KASKRKQRHEEPESFFTWFTHSDAG 200  

| | | | | | | | | | | | | | | | | | | | | | | |  

151 PSSKSTEIKWKSGKDLTKRSSQTQN KASKRKQRHEEPESFFTWFTHSDAG 200  

.  

201 ADELGEVIKDDIWPNPL QYYLV PDM DDEEGEGEDDDD DEEEGLE IDE 250  

| | | | | | | | | | | | | | | | | | | | | | | |  

201 ADELGEVIKDDIWPNPL QYYLV PDM DDEEGEGEDDDD DEEEGLE IDE 250  


```

251 EGDGGG G 257

||| I
251 EGDE DEG 257

FIG. 27

FIG. 29

55/209

252	DLIQYNFGWYPESPICEGRRNRCP	PPVPLNSKIQPHSTTYRHGERVHI	301
251	DLIQYNFGWYPESPICEGRRNRCP	PPVPLNSKIQPHSTTYRHGERVHI	300
302	ECELNFVIQSEELLCENGKWT	PPKCIEEKEKVACEQPPSVENGVAHPH	351
301	ECELNFVIQSEELLCENGKWT	PPKCIEEKEKVACEQPPSVENGVAHPH	350
352	SEIYSGDKVTYRCGGGYSLRG	SSITTCNRRGWTLPPECVENIENCKPPP	401
351	SEIYSGDKVTYRCGGGYSLRG	SSITTCNRRGWTLPPECVENIENCKPPP	400
402	DIANGVVVDGLLAS	YTTGSSVEYRCNEYLLKGSETSRCEQGAWSPPVC	451
401	DIANGVVVDGLLAS	YTTGSSVEYRCNEYLLKGSETSRCEQGAWSPPVC	450
452	LEPCTIDVDHMNRN	NIQLKWKEYEGKILHGDLIDFVCKQGYNLSPSIPLSE	501
451	LEPCTIDVDHMNRN	NIQLKWKEYEGKILHGDLIDFVCKQGYNLSPSIPLSE	500

FIG. 29 (CONT.¹)

56/209

502 ISAQCNRGDVRYPMCIKESKGMCASPPVIRNGDIVSSAARTYENGSSVE 551
|||||
501 ISAQCNRGDVRYPMCIKESKGMCASPPVIRNGDIVSSAARTYENGSSVE 550
552 YRCFDNHFLQGSQNVYCVDGVTTPPSCLEP 582
|||||
551 YRCFDNHFLQGSQNVYCVDGVTTPPSCLEP 581

FIG. 29 (CONT.²)

58/209

160 LSKEVTSLSNSTQAEVPDDDGTESSLVAEIMVSGMNYEDDCGPGCGSH 209
|||||
801 LSKEVTSLSNSTQAEVPDDDGTESSLVAEIMVSGMNYEDDCGPGCGSH 850
210 ARCVSDGETAECQCLKGFARDGNLCSDIDECVLARSDCPSTSSRCINTEG 259
|||||
851 ARCVSDGETAECQCLKGFARDGNLCSDIDECVLARSDCPSTSSRCINTEG 900
260 GYVCRCEGYEGDGISCFDIDECQRGAHNCAENAACTNTEGGYNCTCAGR 309
|||||
901 GYVCRCEGYEGDGISCFDIDECQRGAHNCAENAACTNTEGGYNCTCAGR 950
310 PSSPGLSCPDPSTAPSLLGEDGHHLDRNSYPGCPSSYDGYCLNGGVCMHIE 359
|||||
951 PSSPGRSCPDPSTAPSLLGEDGHHLDRNSYPGCPSSYDGYCLNGGVCMHIE 1000
360 SLDSYTCNCVIGYSGDRCQTRDLRWELRHAGYGQKHDIMVVAVCMMVALV 409
|||||
1001 SLDSYTCNCVIGYSGDRCQTRDLRWELRHAGYGQKHDIMVVAVCMMVALV 1050

FIG. 30 (CONT.¹)

60/209

```

1 MPWGRRPTWLLAFLLVFLKISILSVTAWQTGNCQPGPLERSERSGTCAG 50
  |||||
1 MPWGRRPTWLLAFLLVFLKISILSVTAWQTGNCQPGPLERSERSGTCAG 50
  . . . . .
51 PAPFLVFSQGKKSISRI..... 66
  |||||
51 PAPFLVFSQGKKSISRIDPDGTNHQQQLVVDAGISADMDIHYYKKERLYWVDV 100
  . . .
67 ..... WAIPSVIRVNKRTGQNRVRLQGSMLKPSSLVVVHPLAKPGADP 109
  |||||
701 DHLWVSDWAIPSVIRVNKRTGQNRVRLQGSMLKPSSLVVVHPLAKPGADP 750
  . . .
110 CLYRNGGCEHICQESLGTARCLCREGFVKAWDGKMCPLPDYPILSGENAD 159
  |||||
751 CLYRNGGCEHICQESLGTARCLCREGFVKAWDGKMCPLPDYPILSGENAD 800
  . . .

```

FIG. 31

62/209

```

360 SLDSYTCNCVIGYSGDRCQT.....
      379
      |||||||
1001 SLDSYTCNCVIGYSGDRCQTRDLRWELRHAGYGQKHDIMVVAVCMVALV
      1050
      .
      .
      .
      .
380 .....PPSSDRGPEIEGNHSLPSYRPVGPEKLHSLQSANG 415
      |||||||
1151 PHIDGMGTGQSCWIPSSDRGPEIEGNHSLPSYRPVGPEKLHSLQSANG
      1200
      .
      416 SCHERAPDLPRQTEPVQ 432
      |||||||
      1201 SCHERAPDLPRQTEPVK 1217

```

FIG. 31 (CONT.²)

```

1 MPWGRPTWLLAFLVLKISILSVTAWTGNCQPGPLERSERSGTAG 50
| | | | | | | | | | | | | | | | | | | | | | | | | |
1 MPWGRPTWLLAFLVLKISILSVTAWTGNCQPGPLERSERSGTAG 50
. . . . .
51 PAPFLVFSQGKSISR.....AHNCA 66
| | | | | | | | | | | | | | | | | | | | | | | | | |
51 PAPFLVFSQGKSISRIDPDGTHHQQLVVDAGISADMDIHYKKERLYWVDV 100
. . .
67 ..... WAIPSVIRVNKRTGQNVRRLQGSMLKPSSLVVVHPLAKPGADP 109
| | | | | | | | | | | | | | | | | | | | | | | | | |
701 DHLWSDWAIPSVIRVNKRTGQNVRRLQGSMLKPSSLVVVHPLAKPGADP 750
. . .
110 CLYRNGGCEHICQESLGTARCLCREGFVKAWDGKMCLPQDYPILSGEN.. 157
| | | | | | | | | | | | | | | | | | | | | | | | | |
751 CLYRNGGCEHICQESLGTARCLCREGFVKAWDGKMCLPQDYPILSGENAD 800
. . .
158 .....AHNCA 162
| | | | |
901 GYVCRCSEGYEGDGISCFDIDECQRGAHNCA 931

```

FIG. 32

64/209

```

:      1 MPWRRPTWLLAFLV..... 17
      |||||
      1 MPWRRPTWLLAFLVFLKISILSVTAWQTGNCQPGPLERSERSGTCAG 50
      .
      .
      .
      .
      18 .....SAECQCLKGFARDGNLCSIDIECVLARSDCPSTSSRCINTEG 59
      .|||||
      851 ARCVSDGETAECQCLKGFARDGNLCSIDIECVLARSDCPSTSSRCINTEG 900
      .
      60 GYVRCSEGYEGDGISCFDIECQRGAHNCAENAACTNTEGGYNCTCAGR 109
      |||||
      901 GYVRCSEGYEGDGISCFDIECQRGAHNCAENAACTNTEGGYNCTCAGR 950
      .
      110 PSSPGLSCPDSTAPSLLGEDGHHLDRNSYPGCPSSYDGYCLNGVCMHIE 159
      |||||
      951 PSSPGRSCPDSTAPSLLGEDGHHLDRNSYPGCPSSYDGYCLNGVCMHIE 1000
      .
      .
      .
  
```

FIG. 33

65/209

```

160  SLDSTCNVCVIGSGDRCQTRDLRWELRHAGYGQKHDIMVAVCMVALV 209
    |||||||
1001 SLDSTCNVCVIGSGDRCQTRDLRWELRHAGYGQKHDIMVAVCMVALV 1050

    . . .
210  LLLLLGMWGTYYYRTRKQLSNPPKPCDEPSGVS SSSGPDSSSGAAVASC 259
    |||||||
1051 LLLLLGMWGTYYYRTRKQLSNPPKPCDEPSGVS SSSGPDSSSGAAVASC 1100

    . . .
260  PQWFFVLEKHQDPKNGSLPADGTNGAVVDAGLSPLQLGSHLT SWRQK 309
    |||||||
1101 PQWFFVLEKHQDPKNGSLPADGTNGAVVDAGLSPLQLGSHLT SWRQK 1150

    . . .
310  PHIDGMGTGQSCWIPPSSDRGPQEIEGN SHLPSYRPVGPEKLHSLQSANG 359
    |||||||
1151 PHIDGMGTGQSCWIPPSSDRGPQEIEGN SHLPSYRPVGPEKLHSLQSANG 1200

    .
360  SCHERAPDLPRQTEPVQ 376
    |||||||
1201 SCHERAPDLPRQTEPVK 1217
    
```

FIG. 33 (CONT.¹)

1 MPWGR..... 5
 |||||
 1 MPWGRPTWLLAFLLVFLKISILSVTAWQTGNCQPGPLERSERSGTCAG 50

6 KAWDGKMCLPQDYPILSGENAD 27
 |||||
 751 CLYRNGGCEHICQESLGTARCLCREGFVKAWDGKMCLPQDYPILSGENAD 800

28 LSKEVTSLSNSTQAEVPDDDGTESSLVAEIMVSGMNYEDDCGPGCGSH 77
 |||||
 801 LSKEVTSLSNSTQAEVPDDDGTESSLVAEIMVSGMNYEDDCGPGCGSH 850

78 ARCVSDGETAECQCLKGFARDGNLCSIDIECVLARSDCPSTSSRCINTEG 127
 |||||
 851 ARCVSDGETAECQCLKGFARDGNLCSIDIECVLARSDCPSTSSRCINTEG 900

66/209

FIG. 34

128 GYVCRCEGYEGDGI SCFDI DECQ RGAHNCAENAACTNTEGGYNCTCAGR 177
 |||||
 901 GYVCRCEGYEGDGI SCFDI DECQ RGAHNCAENAACTNTEGGYNCTCAGR 950
 |||||
 178 PSSPGLSCPDSTAPSL LGEDGHHLDRNSYPGCPSSYDGYCLNGGVCMHIE 227
 |||||
 951 PSSPGRSCPDSTAPSL LGEDGHHLDRNSYPGCPSSYDGYCLNGGVCMHIE 1000
 |||||
 228 SLDSYTCNCVIGYSGDRCQTRDLRWELRHAGYGQKHDIMVVAVCMVALV 277
 |||||
 1001 SLDSYTCNCVIGYSGDRCQTRDLRWELRHAGYGQKHDIMVVAVCMVALV 1050
 |||||
 278 LLLLGMWGTYYYRTRKQLSNPPKNPCDEPSGVS SSGPDSSSGAAVASC 327
 |||||
 1051 LLLLGMWGTYYYRTRKQLSNPPKNPCDEPSGVS SSGPDSSSGAAVASC 1100
 |||||
 328 PQPWFVVLEKHQDPKNGSLPADGTNGAVVDAGLSPLQLGSHLT SWRQK 377
 |||||
 1101 PQPWFVVLEKHQDPKNGSLPADGTNGAVVDAGLSPLQLGSHLT SWRQK 1150
 |||||

FIG. 34 (CONT. ¹)

378 PHIDGMGTGQSCWIPSSDRGPQIEGNHSLPSYRPVGPEKLHSLQ\$ANG 427
 |||||
 1151 PHIDGMGTGQSCWIPSSDRGPQIEGNHSLPSYRPVGPEKLHSLQ\$ANG 1200

FIG. 34 (CONT.²)

1 MFRELNEALELKDAHAATEESGDSRAHSSYLKTKKGQSTSRHKKTMTMVKKVG 50
|||||
337 MFRELNEALELKDAHAATEESGDSRAHSSYLKTKKGQSTSRHKKTMTMVKKVG 386

51 PDSD 54
;
||||
387 PDSD 390

FIG. 35

70/209

1 MKYPVWPARYSASLQPVVDSRHLTVATLEERPFIIVESPDGPGTGGCVPNTV 50
|||||
382 MKYPVWPARYSASLQPVVDSRHLTVATLEERPFIIVESPDGPGTGGCVPNTV 431
51 PCRRQSNHTFSSGDVAPYTKLCKGFCIDILKKLARVVKFSYDLYLVNTG 100
|||||
432 PCRRQSNHTFSSGDVAPYTKLCKGFCIDILKKLARVVKFSYDLYLVNTG 481
101 KHGKRVRGVWNGMIGEVYKRADMAIGSLTINEERSEIVDFSVPFVETGI 150
|||||
482 KHGKRVRGVWNGMIGEVYKRADMAIGSLTINEERSEIVDFSVPFVETGI 531
151 SVMVARSNGTVSPSAFLEPYSPAVWMMFVMCLTVVAITVFMFEYFSPVS 200
|||||
532 SVMVARSNGTVSPSAFLEPYSPAVWMMFVMCLTVVAITVFMFEYFSPVS 581
201 YNQNLTRGKKSGGPAFTIGKSVWLLWALVFNNNSVPIENPRGTTSKIMVLV 250
|||||
582 YNQNLTRGKKSGGPAFTIGKSVWLLWALVFNNNSVPIENPRGTTSKIMVLV 631

FIG. 36

71/209

251 WAFFAVIFLASYTANLAAFMIEQYIDTVSGLSDKKFQRPQDQYPPFRFG 300
 |||||
 632 WAFFAVIFLASYTANLAAFMIEQYIDTVSGLSDKKFQRPQDQYPPFRFG 681
 |||||
 301 TVPNGSTERNIRSNYRDMHMHVKNQSVEDALTSKMGKLDAFIYDAA 350
 |||||
 682 TVPNGSTERNIRSNYRDMHMHVKNQSVEDALTSKMGKLDAFIYDAA 731
 |||||
 351 VLNYMAGKDEGCKLVTIGSGKVFATTGYGIAMQKDSHWKRAIDLALLQFL 400
 |||||
 732 VLNYMAGKDEGCKLVTIGSGKVFATTGYGIAMQKDSHWKRAIDLALLQFL 781
 |||||
 401 GDGETQKLETVWLSGICQNEKNEVMSSKLDIDNMAGVFYMLLVAMGLALL 450
 |||||
 782 GDGETQKLETVWLSGICQNEKNEVMSSKLDIDNMAGVFYMLLVAMGLALL 831
 |||||
 451 VFAWEHLVYWKLRHSVPNSSQLDFLAFSRGIYSCFSGVQSLASPPRQAS 500
 |||||
 832 VFAWEHLVYWKLRHSVPNSSQLDFLAFSRGIYSCFSGVQSLASPPRQAS 881

FIG. 36 (CONT.¹)

501 PDLTASSAQASVLKMLQAARDMVTTAGVSSSLDRATRTIENWGGRRAPP 550
 |||||
 882 PDLTASSAQASVLKMLQAARDMVTTAGVSSSLDRATRTIENWGGRRAPP 931
 .
 551 PSPCPTPRSGSPCLPTPDRPEPSPTGWGPPDGGRAALVRRAPQPPGRP 600
 |||||
 932 PSPCPTPRSGSPCLPTPDRPEPSPTGWGPPDGGRAALVRRAPQPPGRP 981
 .
 601 PTPGPPLSDVSRVSRPPAWEARWPVRTGHCHLSASERPLSPARCHYSS 650
 |||||
 982 PTPGPPLSDVSRVSRPPAWEARWPVRTGHCHLSASERPLSPARCHYSS 1031
 .
 651 FPRADRSGRPFLPLFPPEPELEDLPLLGPQLARREALLHAAWARGSRPR 700
 |||||
 1032 FPRADRSGRPFLPLF...PELEDLPLLGPQLARREALLHAAWARGSRPR 1078
 .
 701 HASLPSSVAEAFARPSSLPAGCTGPACARPDGHSACRRLAQAQSMCLPIY 750
 |||||
 1079 HASLPSSVAEAFARPSSLPAGCTGPACARPDGHSACRRLAQAQSMCLPIY 1128
 .

FIG. 36 (CONT.²)

73/209

```

751 REACQEGEQAGAPAWQHRQHVCLHAHAHLPCWGAVCPHLPPCASHGWL 800
|||||
1129 REACQEGEQAGAPAWQHRQHVCLHAHAHLPCWGAVCPHLPPCASHGWL 1178
.
801 SGAWGPLGHRGRTLGLGTGYRDSGGLDEISXVARGTQGFPGPCTWRRISS 850
|||||
1179 SGAWGPLGHRGRTLGLGTGYRDSGGLDEISRVARGTQGFPGPCTWRRISS 1228
.
851 LESEV 855
|||||
1229 LESEV 1233

```

FIG. 36 (CONT.³)

74/209

```

1 1 MRLAVGALLVCAVLGLCLAVDPDKTVRWCAVSEHEATKCQSFDRHMKSVIP 50
  |||||
1 1 MRLAVGALLVCAVLGLCLAVDPDKTVRWCAVSEHEATKCQSFDRHMKSVIP 50

51 SDGPSVACVKKASYLDCIRAIANEADAVTLDAGLVYDAYLAPNNLKPVV 100
  |||||
51 SDGPSVACVKKASYLDCIRAIANEADAVTLDAGLVYDAYLAPNNLKPVV 100

101 AEFYGSKEDPQTFYYAVAVVKKDSGFQMNQLRGKKSCHTGLGRSAGWNIP 150
  |||||
101 AEFYGSKEDPQTFYYAVAVVKKDSGFQMNQLRGKKSCHTGLGRSAGWNIP 150

151 IGLLYCDLPEPRKPLEKAVANFFSGSCAPCADGTDFFPQLCQLCPGCGCST 200
  |||||
151 IGLLYCDLPEPRKPLEKAVANFFSGSCAPCADGTDFFPQLCQLCPGCGCST 200

201 LNQYFGYSGAFKCLKDGAGDVAFVKHSTIFENLANKADRQYELLCLDNT 250
  |||||
201 LNQYFGYSGAFKCLKDGAGDVAFVKHSTIFENLANKADRQYELLCLDNT 250

```

FIG. 37

251 RKPVDEYKDCHLAQVPSHTTVVARSMGKEDLIWELNQAQEHFGKDKSKE 300
 |||||
 251 RKPVDEYKDCHLAQVPSHTTVVARSMGKEDLIWELNQAQEHFGKDKSKE 300
 |||||
 301 FQLFSSPHGKDLLFKDSAAGFLKVPPRMDAKMYLGYEYVTAIRNLREGTC 350
 |||||
 301 FQLFSSPHGKDLLFKDSAAGFLKVPPRMDAKMYLGYEYVTAIRNLREGTC 350
 |||||
 351 PEPTDECKPVKWCALSHHERLKCDEWSVNSVGKIECVSAETTEDCIAKI 400
 |||||
 351 PEPTDECKPVKWCALSHHERLKCDEWSVNSVGKIECVSAETTEDCIAKI 400
 |||||
 401 MNGEADAMSLDGGFVYIAGKCGLVPVLAENYNKSDNCEDTPEAGYFAVAV 450
 |||||
 401 MNGEADAMSLDGGFVYIAGKCGLVPVLAENYNKSDNCEDTPEAGYFAVAV 450
 |||||
 451 VKKSASDLTWDNLKGKKSCHTAFGRTAGWNIPMGLLYNKINHCRFDEFFS 500
 |||||
 451 VKKSASDLTWDNLKGKKSCHTAFGRTAGWNIPMGLLYNKINHCRFDEFFS 500
 |||||

FIG. 37 (CONT.¹)

501 EGCA PGSKK DSSLCKLCMGSGNLNCEPNNKEGYGYTGAFRC LVEKGDVA 550
|||||
501 EGCA PGSKK DSSLCKLCMGSGNLNCEPNNKEGYGYTGAFRC LVEKGDVA 550
|||||
551 FVKHQ TVPQNTGGKNPDPWAKNLNEKDYELLCLDGT RKPVEEYANCHLAR 600
|||||
551 FVKHQ TVPQNTGGKNPDPWAKNLNEKDYELLCLDGT RKPVEEYANCHLAR 600
|||||
601 APNHAVVTRK DKEACVHKILRQQHLFGSNVTD CSGNFCLFRSETKD LLF 650
|||||
601 APNHAVVTRK DKEACVHKILRQQHLFGSNVTD CSGNFCLFRSETKD LLF 650
|||||
651 RDDT.....H.....LLEACTFRRP 665
||| |
651 RDDTVCLAKLH DRNTYEKYLGE EYVKA VGNLRK CSTSS LLEACTFRRP 698

FIG. 37 (CONT.²)

FIG. 38

78/209

```

251 RKPVDEYKDCHLAQVPSHTVVARSMGCKEDLIWELLNQAQEHFGKDKSKE 300
|||||
251 RKPVDEYKDCHLAQVPSHTVVARSMGCKEDLIWELLNQAQEHFGKDKSKE 300

301 FQLFSSPHGKDLLFKDSAHGFLKVPPRMDAKMYLGYEYVTAIRNLREGTC 350
|||||
301 FQLFSSPHGKDLLFKDSAHGFLKVPPRMDAKMYLGYEYVTAIRNLREGTC 350

351 PEAPTDECKPVKWCALSHHERLKCDEWSVNSVGKIECVSAETTEDCIAKI 400
|||||
351 PEAPTDECKPVKWCALSHHERLKCDEWSVNSVGKIECVSAETTEDCIAKI 400

401 MNGEADAMSLDGGFVYIAGKCGLVPVLAENYNKSDNCEDTPEAGYFA... 447
|||||
401 MNGEADAMSLDGGFVYIAGKCGLVPVLAENYNKSDNCEDTPEAGYFAVAV 450

448 .....E 448

451 VKKSASDLTWDNLKGKKSCHTAVGRTAGWNIPMGLLYNKINHCRFDEFFS 500

```

FIG. 38 (CONT.¹)

449 EGCAFGSKKDDSSLCCKMGSSGLNLCEPNNKEGYGYTGAFRCLVEKGDVA 498
 |||||
 501 EGCAFGSKKDDSSLCCKMGSSGLNLCEPNNKEGYGYTGAFRCLVEKGDVA 550

 499 FVKHQTVPQNTGGKNPDPWAKNLNEKDYELLCLDGTGTRKPVVEEYANCHLAR 548
 |||||
 551 FVKHQTVPQNTGGKNPDPWAKNLNEKDYELLCLDGTGTRKPVVEEYANCHLAR 600

 549 APNHAVVTRKDKEACVHKILRQQQHLFGSNVTDCSGNFCLEFRSETKDLLF 598
 |||||
 601 APNHAVVTRKDKEACVHKILRQQQHLFGSNVTDCSGNFCLEFRSETKDLLF 650

 599 RDDTVCLAKLHNRNTYEKYLGEYVKA VGNLRKCSTSSLLEACTFRRP 646
 |||||
 651 RDDTVCLAKLHNRNTYEKYLGEYVKA VGNLRKCSTSSLLEACTFRRP 698

FIG. 38 (CONT.²)

```

1 MAEGEGGEDEIQFLRTEDEVVLQCIATIHKEQRKFCCLAEGGLNRLCFL 50
  |||
1 MAEGEGGEDEIQFLRTEDEVVLQCIATIHKEQRKFCCLAEGGLNRLCFL 50

51 EPTSEAKYIPPDLCVCNFCVLEQSLSVRALQEMLANGTENGEGGAAQGGGH 100
  |||
51 EPTSEAKYIPPDLCVCNFCVLEQSLSVRALQEMLANGTENGEGGAAQGGGH 100

101 RTLLYGHAVLLRHVSFGMYLTCLTTSRSQTDKLAFDVGLREHATGEACWW 150
  |||
101 RTLLYGHAVLLRHVSFGMYLTCLTTSRSQTDKLAFDVGLREHATGEACWW 150

151 TIHPASKORSEGEKVRIGDDLILVSVSSERYLHLSVSNNGNIQVDASFMT 200
  |||
151 TIHPASKORSEGEKVRIGDDLILVSVSSERYLHLSVSNNGNIQVDASFMT 200

201 LWNVHPTCSGSSIEEGYLLGGHVVRFLFHGHDECLTIPSTDQNDQSQRRI 250
  |||
201 LWNVHPTCSGSSIEEGYLLGGHVVRFLFHGHDECLTIPSTDQNDQSQRRI 250

```

FIG. 39

81/209

```

251 YEAGGAGTRAXSLWRVEPLRISWGSNIRWGQAFRLRLTTGHY LALTED 300
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
251 YEAGGAGTRARSLWRVEPLRISWGSNIRWGQAFRLRLTTGHY LALTED 300

301 QGLILQDRAKSDTKSTAFSFRASKELKEKLDSSHKRDI EGMGVPEIKYGD 350
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
301 QGLILQDRAKSDTKSTAFSFRASKELKEKLDSSHKRDI EGMGVPEIKYGD 350

351 SVCFVQHIASGLWVTYKAQDAKTSRLGPLKRKVILHQEGHMD DGLTLQRC 400
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
351 SVCFVQHIASGLWVTYKAQDAKTSRLGPLKRKVILHQEGHMD DGLTLQRC 400

401 QREESQAARIIRNTTALFSQFVSGNNRTAAPITLPIEEVLQTLQD LIAFY 450
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
401 QREESQAARIIRNTTALFSQFVSGNNRTAAPITLPIEEVLQTLQD LIAFY 450

451 QPPEEEMRHEDKQNKLSLKNRQNLFKEEGMLALV LNCIDRLNXVNSVAH 500
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
451 QPPEEEMRHEDKQNKLSLKNRQNLFKEEGMLALV LNCIDRLNVNSVAH 500

```

FIG. 39 (CONT.¹)

82/209

```

501 FAGIAREESGMAWKEILNLLYKLLAALIRGNRNCAQFSNNLDWLISKLD 550
|||||
501 FAGIAREESGMAWKEILNLLYKLLAALIRGNRNCAQFSNNLDWLISKLD 550

551 RLESSSGILEVLHCILTESP EALNLIAEGHIKSIISLDDKHGRNHKVLDI 600
|||||
551 RLESSSGILEVLHCILTESP EALNLIAEGHIKSIISLDDKHGRNHKVLDI 600

601 LCSLCLCNGVAVRANQNLCIDNLLPRRNLLQLTRLINDVTSIRPNIFLG V 650
|||||
601 LCSLCLCNGVAVRANQNLCIDNLLPRRNLLQLTRLINDVTSIRPNIFLG V 650

        651 AEGSAQYKKWFELIIDQVDPFLTAEP THLRVGWASSSGYAPXPGGEG W 700
|||||
        651 AEGSAQYKKWFELIIDQVDPFLTAEP THLRVGWASSSGYAPXPGGEG W 700

701 GGNGVGDDLYSYGFDGLHLWSGRIPRAVASXNQHLLRSDDVVSCCL.DLG 749
|||||
701 GGNGVGDDLYSYGFDGLHLWSGRIPRAVASINQHLLRSDDV GKLLPGRP G 750

```

FIG. 39 (CONT.²)

83/209

750 CPASHASMGSPCRGCLRNFTDGLFFPVMFSAGVKVFLMGGRHGEFK 799
||||| 751 CPASHASMGSPCRGCLRNFTDGLFFPVMFSAGVKVFLMGGRHGEFK 800
800 FLPPSGYAPCYEALLPKEKMRLEPVKEYKRDADGIRDLLGTTQFLSQASF 849
||||| 801 FLPPSGYAPCYEALLPKEKMRLEPVKEYKRDADGIRDLLGTTQFLSQASF 850
850 IPCPVDTSQVILPPHLEKIRDRLAENIHELWGMNKKIELGWTFGKIRDDNK 899
||||| 851 IPCPVDTSQVILPPHLEKIRDRLAENIHELWGMNKKIELGWTFGKIRDDNK 900
900 RQHPCLVEFSKLPETEKNYNLQMSTETLKTLLXLGCHIAHVNPAEEEDLK 949
||||| 901 RQHPCLVEFSKLPETEKNYNLQMSTETLKTLLXLGCHIAHVNPAEEEDLK 950
950 KVKLPKNYMSNGYKPAPLDLSDVKLLPPQEILVDKLAENAHNVWAKDRI 999
||||| 951 KVKLPKNYMSNGYKPAPLDLSDVKLLPPQEILVDKLAENAHNVWAKDRI 1000

FIG. 39 (CONT.³)

1000 KQGWTYGIQQDLKNKRNPRLVPYALLDERTKKSNRDSLREAVRTFVGYG 1049
 |||||
 1001 KQGWTYGIQQDLKNKRNPRLVPYALLDERTKKSNRDSLREAVRTFVGYG 1050
 |||||
 1050 NIEPSDQELADSAVEKVSIDKIRFFRVERSYXVRSGKWYFEFEVVTGGDM 1099
 |||||
 1051 NIEPSDQELADSAVEKVSIDKIRFFRVERSYXVRSGKWYFEFEVVTGGDM 1100
 |||||
 1100 RVGWARPGCRPDVELGADDQAFVFEENRGQRWHQSGYFGRTWQPGDVVG 1149
 |||||
 1101 RVGWARPGCRPDVELGADDQAFVFEENRGQRWHQSGYFGRTWQPGDVVG 1150
 |||||
 1150 CMINLDDASMIFTLNGELLITNKGSELAFAADYEIENG FVPI CCLGLSQIG 1199
 |||||
 1151 CMINLDDASMIFTLNGELLITNKGSELAFAADYEIENG FVPI CCLGLSQIG 1200
 |||||
 1200 RMNLGTDASTFKFYTMCGLQEGFEFVAVNMNRDVAMWFSKR LPTFVNVPK 1249
 |||||
 1201 RMNLGTDASTFKFYTMCGLQEGFEFVAVNMNRDVAMWFSKR LPTFVNVPK 1250

FIG. 39 (CONT. 4)

85/209

1250 DPHIEVMRIDGTMDSPCLKVTHKTFGTQNSNADMIYCRLSMPVECHSS 1299
|||||
1251 DPHIEVMRIDGTMDSPCLKVTHKTFGTQNSNADMIYCRLSMPVECHSS 1300

1300 FSHSPCLDSEAFQKRKQMQEILSHTTTQCYAIRIFXGQDPSCVWVGWVT 1349
|||||
1301 FSHSPCLDSEAFQKRKQMQEILSHTTTQCYAIRIFGGQDPSCVWVGWVT 1350

1350 PDYHLYSEKFDLNKNCTVTTLGDERGRVHESVKRSNCYMWVGDI VASS 1399
|||||
1351 PDYHLYSEKFDLNKNCTVTTLGDERGRVHESVKRSNCYMWVGDI VASS 1400

1400 QRSNRSNVDLEIGCLVDLAMGMLSF SANGKELGTCYQVEPNTKVFPVFL 1449
|||||
1401 QRSNRSNVDLEIGCLVDLAMGMLSF SANGKELGTCYQVEPNTKVFPVFL 1450

1450 QPTSTSLFQFELGKLKNAMPLSAAIFRSEEXNPVPQCPRLDVQTIQPVL 1499
|||||
1451 QPTSTSLFQFELGKLKNAMPLSAAIFRSEEXNPVPQCPRLDVQTIQPVL 1500

FIG. 39 (CONT.⁵)

```

. . . . .
1500 WSRMPNSFLKVETERVSRHGWVQCLEPLQMMALHIPEENRCVDILELC 1549
|||||
1501 WSRMPNSFLKVETERVSRHGWVQCLEPLQMMALHIPEENRCVDILELC 1550
. . . . .
1550 EQEDLMRFHYHTLRLYSAVCALGNSRVAYALCSHVDSLQLFYAIDNKYLP 1599
|||||
1551 EQEDLMRFHYHTLRLYSAVCALGNSRVAYALCSHVDSLQLFYAIDNKYLP 1600
. . . . .
1600 GLLRSGFYDLLISIHLSAKERKLMMKNEYIIPITSTTRNICLFPDESKR 1649
|||||
1601 GLLRSGFYDLLISIHLSAKERKLMMKNEYIIPITSTTRNICLFPDESKR 1650
. . . . .
1650 HGLPGVGLRTCLKPGFRFSTPCFVVTGEDHQKQSP EIPLES LRTKALSML 1699
|||||
1651 HGLPGVGLRTCLKPGFRFSTPCFVVTGEDHQKQSP EIPLES LRTKALSML 1700
. . . . .

```

FIG. 39 (CONT.⁶)

```

1700 TEAVQCSGAHIRDPVGGSVFQFVPLKLTLLVMGVFDDDDVRQILL 1749
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
1701 TEAVQCSGAHIRDPVGGSVFQFVPLKLTLLVMGVFDDDDVRQILL 1750

      .
1750 IDPSVFGEHSAGTEEGAEKEEVTQVEEKAVEAGEKAGKEAPVKGLLQTRL 1799
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
1751 IDPSVFGEHSAGTEEGAEKEEVTQVEEKAVEAGEKAGKEAPVKGLLQTRL 1800

      .
1800 PESVKLQMCCELLSYLCDCELQHRVEAIVAFGDIYVSKLQANQKFRYNELM 1849
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
1801 PESVKLQMCCELLSYLCDCELQHRVEAIVAFGDIYVSKLQANQKFRYNELM 1850

      .
1850 QALNMSAALTARKTKEFRSPPEQINMLNLFQLGENCPCEEIREELYDF 1899
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
1851 QALNMSAALTARKTKEFRSPPEQINMLNLFQLGENCPCEEIREELYDF 1900

      .
1900 HEDLLHCGVPLEEEEEEDTSWTGKLCALVYKIKGPPKPEKEQPTEEE 1949
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
1901 HEDLLHCGVPLEEEEEEDTSWTGKLCALVYKIKGPPKPEKEQPTEEE 1950

```

FIG. 39 (CONT.)

88/209

1950 ERCPTTLKELISQTMICWAQEDQIQDSELVRMMFNLLRRQYDSIGELLQA 1999
|||||
1951 ERCPTTLKELISQTMICWAQEDQIQDSELVRMMFNLLRRQYDSIGELLQA 2000
2000 LRKTYTISHTSVSDTINLLAALGQIRSLLSVRMGKEEELLMINGLGDIMN 2049
|||||
2001 LRKTYTISHTSVSDTINLLAALGQIRSLLSVRMGKEEELLMINGLGDIMN 2050
2050 NKVFYQHPNLMRVLGMHETVMEVMVNVLGTEKSQIAFPKMVASCCFELCY 2099
|||||
2051 NKVFYQHPNLMRVLGMHETVMEVMVNVLGTEKSQIAFPKMVASCCFELCY 2100
2100 FCRISRQNKAMFEHLSYLLENSSVGLASPSMRGSTPLDVAASSVMDNNE 2149
|||||
2101 FCRISRQNKAMFEHLSYLLENSSVGLASPSMRGSTPLDVAASSVMDNNE 2150
2150 LALSLEEPDLEKVVVTYLAGCGLQSCPMLLAKGYPDVGWNPIEGERYLSFL 2199
|||||
2151 LALSLEEPDLEKVVVTYLAGCGLQSCPMLLAKGYPDVGWNPIEGERYLSFL 2200

FIG. 39 (CONT.⁸)

89/209

2200 RFAVFNSESVENASVVVKLLIRRPECFGPALRGEGNGLLAAMQGAIK 2249
|||||
2201 RFAVFNSESVENASVVVKLLIRRPECFGPALRGEGNGLLAAMQGAIK 2250
|||||
2250 ISENPALDLP SQGYKREVSTEDDEEEEEIVHMGNAIMSFYSALIDLLGRC 2299
|||||
2251 ISENPALDLP SQGYKREVSTEDDEEEEEIVHMGNAIMSFYSALIDLLGRC 2300
|||||
2300 APEMHLIQTGKGEAIRIRSIILRSIVPTEDLVGIIISIPKLPSLNKDGVS 2349
|||||
2301 APEMHLIQTGKGEAIRIRSIILRSIVPTEDLVGIIISIPKLPSLNKDGVS 2350
|||||
2350 EPDMAXNFCPDHKA PMVLF LDRVYGIKQDTFLHLLEVGFLPD LRASASL 2399
|||||
2351 EPDMAGNFCPDHKA PMVLF LDRVYGIKQDTFLHLLEVGFLPD LRASASL 2400
|||||
2400 DTVSLSTTEAALALNRYICS AVLP LLTRCAPLFXGTEHCTSLIDSTLQTI 2449
|||||
2401 DTVSLSTTEAALALNRYICS AVLP LLTRCAPLFXGTEHCTSLIDSTLQTI 2450

FIG. 39 (CONT.)

90/209

2450 YRLSKGRSLTKAQRDTIEECLLAICNHLRPSMLQQLRRLVFDVDPQLNEY 2499
|||||
2451 YRLSKGRSLTKAQRDTIEECLLAICNHLRPSMLQQLRRLVFDVDPQLNEY 2500
.
2500 CKMPLKLLTNHYEQCWKYCYCLPSGWGSYGLAVEEEHLHLTEKLFWGI XD SL 2549
|||||
2501 CKMPLKLLTNHYEQCWKYCYCLPSGWGSYGLAVEEEHLHLTEKLFWGI ID SL 2550
.
2550 SHKKYDPPDLFRMALPCLSAIAGALPPDYLDXRITATLEKQISVDADGNFD 2599
|||||
2551 SHKKYDPPDLFRMALPCLSAIAGALPPDYLDXRITATLEKQISVDADGNFD 2600
.
2600 PKPINTMNFSLPEKLEYIVTKYAEHSHDKWACDKSQSGWKYGISLDENVK 2649
|||||
2601 PKPINTMNFSLPEKLEYIVTKYAEHSHDKWACDKSQSGWKYGISLDENVK 2650
.
2650 THPLIRPFKTLTEKEKEIYRWPARESLKTMLAVGWTVERTKEGEALVQQR 2699
|||||
2651 THPLIRPFKTLTEKEKEIYRWPARESLKTMLAVGWTVERTKEGEALVQQR 2700

FIG. 39 (CONT.¹⁰)

2700	ENEKLRVSQANQNSYSPAPLDLSNVVLSRELQGMVEVVAENYHNIWAK	2749
2701	ENEKLRVSQANQNSYSPAPLDLSNVVLSRELQGMVEVVAENYHNIWAK	2750
2750	KKKLELESKGGGSHPLLVPYDTLTAAKEKFKDREKAQDLFKFLQVNGIIVS	2799
2751	KKKLELESKGGGSHPLLVPYDTLTAAKEKFKDREKAQDLFKFLQVNGIIVS	2800
2800	RGMKDMELDASSMEKRFXYKFLKKILKYVDSAQEFIAHLEAIVSSGKTEK	2849
2801	RGMKDMELDASSMEKRFYKFLKKILKYVDSAQEFIAHLEAIVSSGKTEK	2850
2850	SPRDQEIKEFFAKVLLPLVDQYFTSHCLYFLSSPLKPLSSSGYASHKEKEM	2899
2851	SPRDQEIKEFFAKVLLPLVDQYFTSHCLYFLSSPLKPLSSSGYASHKEKEM	2900
2900	VAGLFCKLAALVRHRISLFGSDSTTMVSC LHILAQTLDTRTVMKSGSELV	2949
2901	VAGLFCKLAALVRHRISLFGSDSTTMVSC LHILAQTLDTRTVMKSGSELV	2950

FIG. 39 (CONT.¹¹)

92/209

2950 KAGLRAFFENAAEDLEKTS[.]ENLKL[.]GKFTHSRTQIKGVSQNIN[.]YTTVALLP 2999
|||||
2951 KAGLRAFFENAAEDLEKTS[.]ENLKL[.]GKFTHSRTQIKGVSQNIN[.]YTTVALLP 3000
|||||
3000 ILTSIFEHV[.]TQH[.]QFGMDLL[.]LGDVQ[.]ISCYHILCSLYSLGTGKNIYVERQ[.]RP 3049
|||||
3001 ILTSIFEHV[.]TQH[.]QFGMDLL[.]LGDVQ[.]ISCYHILCSLYSLGTGKNIYVERQ[.]RP 3050
|||||
3050 ALGECLASLAAAI[.]PVAFLEPTLNRYNPLSVFNTKTPRERSILGMPDTVED 3099
|||||
3051 ALGECLASLAAAI[.]PVAFLEPTLNRYNPLSVFNTKTPRERSILGMPDTVED 3100
|||||
3100 MCPDIPQLEGLMKEINDLAESGARYTEMPHVIEVILPMLCN[.]YLSYW[.]WERG 3149
|||||
3101 MCPDIPQLEGLMKEINDLAESGARYTEMPHVIEVILPMLCN[.]YLSYW[.]WERG 3150
|||||
3150 PENLPPSTGPPCCTKVTSEHLSLILGNILKIINN[.]NLGI[.]DEASW[.]MKRIA[.]VYA 3199
|||||
3151 PENLPPSTGPPCCTKVTSEHLSLILGNILKIINN[.]NLGI[.]DEASW[.]MKRIA[.]VYA 3200
|||||

FIG. 39 (CONT.¹²)

93/209

3200 QPIISKARPDLLRSHFIPTLEKLLKKKAVKTVQEEEEQLKADGKGDTQEAEL 3249
|||||
3201 QPIISKARPDLLRSHFIPTLEKLLKKKAVKTVQEEEEQLKADGKGDTQEAEL 3250
|||||
3250 LILDEFVLCRDLYAFYPMLIRYVDNRRSNWLKSPDADSDQLFRMVAEVF 3299
|||||
3251 LILDEFVLCRDLYAFYPMLIRYVDNRRSNWLKSPDADSDQLFRMVAEVF 3300
|||||
3300 ILWCKSHNFKREEQNFVIQNEINNLAFLTGDSKSKMSKSGGQDQERKKTK 3349
|||||
3301 ILWCKSHNFKREEQNFVIQNEINNLAFLTGDSKSKMSKSGGQDQERKKTK 3350
|||||
3350 RRGDLYSIQTSLIVAALKKMLPIGLNMCTPGDQELISLAKSRYSHRDTDE 3399
|||||
3351 RRGDLYSIQTSLIVAALKKMLPIGLNMCTPGDQELISLAKSRYSHRDTDE 3400
|||||
3400 EVREHLRNNLHLQEKSDDDPAVKWQLNLYKDVCLKSEEPFNPEKTVERVQRI 3449
|||||
3401 EVREHLRNNLHLQEKSDDDPAVKWQLNLYKDVCLKSEEPFNPEKTVERVQRI 3450
|||||

FIG. 39 (CONT.¹³)

94/209

3450 SAAVFHLEQVEQLRSKKA VWHKLLSKQKR AVVACFRMAPLYNLPRHRS 3499
|||||
3451 SAAVFHLEQVEQLRSKKA VWHKLLSKQKR AVVACFRMAPLYNLPRHRS 3500
|||||
3500 INFLHGYQRFWIETEEYSFEEKLVQDLAKSPKVEEEEEETEKQPDPLH 3549
|||||
3501 INFLHGYQRFWIETEEYSFEEKLVQDLAKSPKVEEEEEETEKQPDPLH 3550
|||||
3550 QIILYFSRNALTERSKLEDDPLYTSYSSMMAKSCQSGEDEDEDEKETF 3599
|||||
3551 QIILYFSRNALTERSKLEDDPLYTSYSSMMAKSCQSGEDEDEDEKETF 3600
|||||
3600 EEKEMEKOQKTLYQQARLHERGAAEMVLQ MISASKGEMSPMVVETLKL GIA 3649
|||||
3601 EEKEMEKOQKTLYQQARLHERGAAEMVLQ MISASKGEMSPMVVETLKL GIA 3650
|||||
3650 ILNGGNAGVQQKMLDYLKEKKDAGFFQSLXGLMQSCSVLDLNAXERQNK A 3699
|||||
3651 ILNGGNAGVQQKMLDYLKEKKDAGFFQSLPGLMQSCSVLDLNASERQNK A 3700
|||||

FIG. 39 (CONT.¹⁴)

FIG. 39 (CONT.¹⁶)

97/209

4200 GIFQILWSTVFGGGLVEGAKNIRVTKILGDMPTQFGIHDDTMEAEAE 4249
|||||
4201 GIFQILWSTVFGGGLVEGAKNIRVTKILGDMPTQFGIHDDTMEAEAE 4250
|||||
4250 VMEPGITTEL VHF I KGEKGD TDIMSDLFGLHPKKEGSLKHGPEVGLDLS 4299
|||||
4251 VMEPGITTEL VHF I KGEKGD TDIMSDLFGLHPKKEGSLKHGPEVGLDLS 4300
|||||
4300 EIIGKDEPPTLESTVQKKRKAQAAEMKAANEAEKGKVESEKADMEDGEKED 4349
|||||
4301 EIIGKDEPPTLESTVQKKRKAQAAEMKAANEAEKGKVESEKADMEDGEKED 4350
|||||
4350 KDKEEEQAEYLWTEVTKKKKRRRCGQKVEKPEAFTANFFKGLEIYQTKLLH 4399
|||||
4351 KDKEEEQAEYLWTEVTKKKKRRRCGQKVEKPEAFTANFFKGLEIYQTKLLH 4400
|||||
4400 YLARNFYNLRFLALFVAFAINFILLFYKVTETEEPLEEETEDVANLWNSFND 4449
|||||
4401 YLARNFYNLRFLALFVAFAINFILLFYKVTETEEPLEEETEDVANLWNSFND 4450

FIG. 39 (CONT.¹⁷)

99/209

4700 PDMKCDDMMTCYLFHMYVGVRRAGGGIGDEIEDPAGDPYEMYRIVFDITFF 4749
|||||
4701 PDMKCDDMMTCYLFHMYVGVRRAGGGIGDEIEDPAGDPYEMYRIVFDITFF 4750
|||||
4750 FFVIVILLAI IQGLI IDAFGELRDQQEQVREDME 4783
|||||
4751 FFVIVILLAI IQGLI IDAFGELRDQQEQVREDME 4784

FIG. 39 (CONT.¹⁹)

100/209

1 MRTLLPPALLTCWLLAPVNSIHPECRHFHLEIQEEETKCXELLRSQTEKHK 50
|||||
1 MRTLLPPALLTCWLLAPVNSIHPECRHFHLEIQEEETKCAELLRSQTEKHK 50

51 ACSGVWDNITCWRPANVGETVTPCPKFVSNFYSKAGNISKNCTSDGWSE 100
|||||
51 ACSGVWDNITCWRPANVGETVTPCPKFVSNFYSKAGNISKNCTSDGWSE 100

101 TFPDFVDACGYSDPEDESKITFYILVKAIYTLGYSVSLMSLATGSIILCL 150
|||||
101 TFPDFVDACGYSDPEDESKITFYILVKAIYTLGYSVSLMSLATGSIILCL 150

151 FRKLHCTRNYIHLNLFSLFILRAISVLVKDDVLYSSSGTLHCPDQPSWV 200
|||||
151 FRKLHCTRNYIHLNLFSLFILRAISVLVKDDVLYSSSGTLHCPDQPSWV 200

201 GCKLSLVFLQCYCIMANFFWLLVEGLYLHTLLVAMLPPrRCFLAYLLIGWG 250
|||||
201 GCKLSLVFLQCYCIMANFFWLLVEGLYLHTLLVAMLPPrRCFLAYLLIGWG 250

FIG. 40

[illegible]

FIG. 41

103/209

230 LFTLLVETFFPERRYFYWYTIIGWGTPPTVCVTWATLRLYFDDTGCWDMN 279
|||||
251 LFTLLVETFFPERRYFYWYTIIGWGTPPTVCVTWATLRLYFDDTGCWDMN 300
|||||
280 DSTALWWVIKGPVVGSIMVNFVLFIGIIVILVQKLQSPDMGGNESSIYLR 329
|||||
301 DSTALWWVIKGPVVGSIMVNFVLFIGIIVILVQKLQSPDMGGNESSIYLR 350
|||||
330 LARSTLLLIPLFGIHYTVFAFSPENVSKRERLVFELGLGSFQGFVVAVLY 379
|||||
351 LARSTLLLIPLFGIHYTVFAFSPENVSKRERLVFELGLGSFQGFVVAVLY 400
|||||
380 CFLNGEVQAEIKRKWRSWKVNRYFAVDEKHRHPSLASSGVNGGTQLSILS 429
|||||
401 CFLNGEVQAEIKRKWRSWKVNRYFAVDEKHRHPSLASSGVNGGTQLSILS 450
|||||
430 KSSSQIRMSGGLPADNLAT 447
|||||
451 KSSSQIRMSGGLPADNLAT 468

FIG. 41 (CONT.¹)

104/209

1 MERGLPLLCAVLALVAPAGAFNRDKCGDTIKIESPGYLTSPPGYPHSYHP 50
|||||
1 MERGLPLLCAVLALVAPAGAFNRDECGDTIKIESPGYLTSPPGYPHSYHP 50
51 SEKCEWLIQAPDPYQRIMINFPHFDLEDRCCKYDYVEVFDGENENGHER 100
|||||
51 SEKCEWLIQAPDPYQRIMINFPHFDLEDRCCKYDYVEVFDGENENGHER 100
101 GKFCGKIAPPPVSSGPFLLFIKFVSDYETHGAGFSIRYEIFKRGPECSQN 150
|||||
101 GKFCGKIAPPPVSSGPFLLFIKFVSDYETHGAGFSIRYEIFKRGPECSQN 150
151 YTPSGVIKSPGFPEKYPNSLECTYIVFAPKMSEIILEFESFDLEPDSNP 200
|||||
151 YTPSGVIKSPGFPEKYPNSLECTYIVFAPKMSEIILEFESFDLEPDSNP 200
201 PGGMFCRYDRLEIWDGFPDVGPHIGRYCGQKTPGRIRSSSGILSMVFYTD 250
|||||
201 PGGMFCRYDRLEIWDGFPDVGPHIGRYCGQKTPGRIRSSSGILSMVFYTD 250

FIG. 42

105/209

```

251  SAIKEGFSANYSVLQSSVSEDFKCM EALGMESGEIHSDQITASSQYSTN 300
    |||||
251  SAIKEGFSANYSVLQSSVSEDFKCM EALGMESGEIHSDQITASSQYSTN 300

301  WSAERSRLNYPENGWTPGEDSYREWIQVDLGLLRFVTA VGTQGAISKETK 350
    |||||
301  WSAERSRLNYPENGWTPGEDSYREWIQVDLGLLRFVTA VGTQGAISKETK 350

      .      .      .
351  KKYVVKTYKIDVSSNGEDWITIKEGNKPVV 380
    |||||
351  KKYVVKTYKIDVSSNGEDWITIKEGNKPV L 380

```

FIG. 42 (CONT.)

106/209

1 MERGLPLLCAVLALVAPAGAFRNDECGDTIKIESPGYLTPGYPHSYHP 50
51 SEKCEWLIQAPDPYQRIMINFNPHFDLED RDCKYDYVEFDGENENGHFR 100
51 SEKCEWLIQAPDPYQRIMINFNPHFDLED RDCKYDYVEFDGENENGHFR 100
101 GKFCGKIAPPPVSSGPFLEIKFVSDYETHGAGFSIRYEIFKRGPECSQN 150
101 GKFCGKIAPPPVSSGPFLEIKFVSDYETHGAGFSIRYEIFKRGPECSQN 150
151 YTPSGVIKSPGFPEKYPNSLECTYIVFAPKMSEIILEFESFDLEPDSNP 200
151 YTPSGVIKSPGFPEKYPNSLECTYIVFAPKMSEIILEFESFDLEPDSNP 200
201 PGMFCRYDRLEIWDGFPDVGPHIGRYCGQKTPGRIRSSSGILSMVFYTD 250
201 PGMFCRYDRLEIWDGFPDVGPHIGRYCGQKTPGRIRSSSGILSMVFYTD 250

FIG. 43

107/209

251 SAIKEGFSANYSVLQSSVSEDFKCMALGMESGEIHSDQITASSQYSTN 300
|||||
251 SAIKEGFSANYSVLQSSVSEDFKCMALGMESGEIHSDQITASSQYSTN 300
|||||
301 WSAERSRLNYPENGWTPGEDSYREWIQV 328
|||||
301 WSAERSRLNYPENGWTPGEDSYREWIQV 328

FIG. 43 (CONT.¹)

108/209

1 MGRVGYWTLVLPALLVWRGPAPSAAAEKGPALNIAVMLGSHDVTRE 50
|||||
1 MGRVGYWTLVLPALLVWRGPAPSAAAEKGPALNIAVMLGSHDVTRE 50

51 LRTLWGPEQAAGLPLDVNVVALLMNRTPKSLITHVCDLMSGARIHGLVF 100
|||||
51 LRTLWGPEQAAGLPLDVNVVALLMNRTPKSLITHVCDLMSGARIHGLVF 100

101 GDDTDQEAQAQMLDFISSHTFVPILGIHGGASMIMADKDPSTFFQFGAS 150
|||||
101 GDDTDQEAQAQMLDFISSHTFVPILGIHGGASMIMADKDPSTFFQFGAS 150

151 IQQQATVMLKIMQDYDWHVFSLVTTIFPGYREFISFVKTTVDNSFVGWDM 200
|||||
151 IQQQATVMLKIMQDYDWHVFSLVTTIFPGYREFISFVKTTVDNSFVGWDM 200

201 QNVITLDTSEDAKTQVQLKKIHSSVILLYCSKDEAVLILSEARSLGLTG 250
|||||
201 QNVITLDTSEDAKTQVQLKKIHSSVILLYCSKDEAVLILSEARSLGLTG 250

FIG. 44

501	VYQRAVMAVGSLTINEERSEVVD	FSVPFVETGISVMVSR	NGTVSPSAFL	550
501	VYQRAVMAVGSLTINEERSEVVD	FSVPFVETGISVMVSR	NGTVSPSAFL	550
551	EPFSASVWVMFVMLLIVSAIAV	FVEYFSPVGYNRNLAKGAP	HGPSET	600
551	EPFSASVWVMFVMLLIVSAIAV	FVEYFSPVGYNRNLAKGAP	HGPSET	600
601	IGKAIWLLWGLVFNN	SVPVQNPKGTTSKIMSVWA	FFAVIFLAS	650
601	IGKAIWLLWGLVFNN	SVPVQNPKGTTSKIMSVWA	FFAVIFLAS	650
651	AFMIQEEFVDQVTGLSDKKFQ	RPHDYSPPFRFGTVPNG	STERNIRNNYPY	700
651	AFMIQEEFVDQVTGLSDKKFQ	RPHDYSPPFRFGTVPNG	STERNIRNNYPY	700

FIG. 44 (CONT. 2)

701	MQYMTKFNQKVEDALVSLKTGKLDAFIYDAAVLNYKAGRDEGCKLVTI	750
701	MQYMTKFNQKVEDALVSLKTGKLDAFIYDAAVLNYKAGRDEGCKLVTI	750
751	GSYIFATTGYGIALQKGSPWKQRQIDLALLQFVGDGEMEELETWLWTGIC	800
751	GSYIFATTGYGIALQKGSPWKQRQIDLALLQFVGDGEMEELETWLWTGIC	800
801	HNEKNEVMSSQLDIDNMAGVFYMLAAAMALSITFIWEHLFYWKLRFCFT	850
801	HNEKNEVMSSQLDIDNMAGVFYMLAAAMALSITFIWEHLFYWKLRFCFT	850
851	GVCSDRPGLLFSISRGIYSCIHGVIHIEKKKSPDNLTGSQSNMLKLLRS	900
851	GVCSDRPGLLFSISRGIYSCIHGVIHIEKKKSPDNLTGSQSNMLKLLRS	900
901	AKNISSMSNMNSSRMDSPKRAADFIQRGSLIMDMVSDKGNLMYSDNRSFQ	950
901	AKNISSMSNMNSSRMDSPKRAADFIQRGSLIMDMVSDKGNLMYSDNRSFQ	950

FIG. 44 (CONT.³)

112/209

951 GKESIFGDNMNELQTFVANRQKDNLNYYVFQGGHPLTLNESNPNTVEVAV 1000
|||||
951 GKESIFGDNMNELQTFVANRQKDNLNYYVFQGGHPLTLNESNPNTVEVAV 1000
1001 STESKANSRPRQLWKKSVD SIRQDSLSQNPVSQRDEATAENRTHSLKSPR 1050
|||||
1001 STESKANSRPRQLWKKSVD SIRQDSLSQNPVSQRDEATAENRTHSLKSPR 1050
1051 YLPEEMAHSDISETSNRATCHREPDNSKNHKTKDNFKRSVASKYPKDCSE 1100
|||||
1051 YLPEEMAHSDISETSNRATCHREPDNSKNHKTKDNFKRSVASKYPKDCSE 1100
1101 VERTYLTKSSSPRDKIYTI DGEKEPGFHLDPQFVENVTLPENVDFFDP 1150
|||||
1101 VERTYLTKSSSPRDKIYTI DGEKEPGFHLDPQFVENVTLPENVDFFDP 1150
1151 YQDPSENF RKGDSTLPMNRNPLHNEEGLSNNDQYKLYSKHFTLKDKGSPH 1200
|||||
1151 YQDPSENF RKGDSTLPMNRNPLHNEEGLSNNDQYKLYSKHFTLKDKGSPH 1200

FIG. 44 (CONT. ⁴)

114/209

```

1  MRTLLPPALLTCWLLAPVNSIHPECRFHLEIQEEETKCXELLRSQTEKHK 50
  |||||
1  MRTLLPPALLTCWLLAPVNSIHPECRFHLEIQEEETKCAELLRSQTEKHK 50
  |||||

51  ACSGVWDNITCWRPANVGETVTVPCPKVFSNFYSKAGNISKNCTSDGWSE 100
  |||||
51  ACSGVWDNITCWRPANVGETVTVPCPKVFSNFYSKAGNISKNCTSDGWSE 100
  |||||

101  TFPDFVDACGYSDPEDESKITFYILVKAIYTLGYSVLSMLSLATGSIILCL 150
  |||||
101  TFPDFVDACGYSDPEDESKITFYILVKAIYTLGYSVLSMLSLATGSIILCL 150
  |||||

151  FRKLHCTRNYIHLNLFSLFILRAISVLVKDDVLYSSSGLHCPDQPSSWV 200
  |||||
151  FRKLHCTRNYIHLNLFSLFILRAISVLVKDDVLYSSSGLHCPDQPSSWV 200
  |||||

201  GCKLSLVFLQYCIMANFFWLLVEGLYLHTLLVAMLPPrRCFLAYLLIGWG 250
  |||||
201  GCKLSLVFLQYCIMANFFWLLVEGLYLHTLLVAMLPPrRCFLAYLLIGWG 250
  |||||

```

FIG. 45

115/209

251 LPTVCIGAWTAARLYLEDTCGWDNDHSDVPWWVIRIPILISIIVNFVLF 300
|||||
251 LPTVCIGAWTAARLYLEDTCGWDNDHSDVPWWVIRIPILISIIVNFVLF 300
301 SIIIRILLQKLTSPDVGGNDQSQYKRLAKSTLLLIPLFGVHYMVFAVFPIS 350
|||||
301 SIIIRILLQKLTSPDVGGNDQSQYKRLAKSTLLLIPLFGVHYMVFAVFPIS 350
351 ISSKYQILFELCLGSGFQGLVVAVLYCFLNSEV 382
|||||
351 ISSKYQILFELCLGSGFQGLVVAVLYCFLNSEV 382

FIG. 45 (CONT.¹)

116/209

1 MRTLLPPALLTCWLLAPVNSIHPECFHFLEIQEEETKCXELLRSQTEKHK 50
|||||
1 MRTLLPPALLTCWLLAPVNSIHPECFHFLEIQEEETKCAELLRSQTEKHK 50
51 ACSGVWDNITCWRPANVGETVTPCPKVFSNFYSKAGNISKNCTSDGWSE 100
|||||
51 ACSGVWDNITCWRPANVGETVTPCPKVFSNFYSKAGNISKNCTSDGWSE 100
101 TFPDFVDACGYSDPEDESKITFYILVKAIYTLGYSVLSMLATGSIILCL 150
|||||
101 TFPDFVDACGYSDPEDESKITFYILVKAIYTLGYSVLSMLATGSIILCL 150
151 FRKLHCTRNYIHLNLFSLFILRAISVLVKDDVLYSSSGTLHCPDQPSSWV 200
|||||
151 FRKLHCTRNYIHLNLFSLFILRAISVLVKDDVLYSSSGTLHCPDQPSSWV 200
201 GCKLSLVFLQCYCIMANFFWLLVEGLYLHTLLVAMPLPPRRCFLAYLLIGWG 250
|||||
201 GCKLSLVFLQCYCIMANFFWLLVEGLYLHTLLVAMPLPPRRCFLAYLLIGWG 250

FIG. 46

117/209

```

      .      .      .      .      .
251 LPTVCIGAWTAARLYLEDTCGWDTNDHSPVWVIRIPILISIIVNFVLEFI 300
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
251 LPTVCIGAWTAARLYLEDTCGWDTNDHSPVWVIRIPILISIIVNFVLEFI 300

      .      .      .      .      .
301 SIIRILLQKLTSPPDVGNDQSQYKRLAKSTLLLIPLFGVHYMVFAVFPIS 350
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
301 SIIRILLQKLTSPPDVGNDQSQYKRLAKSTLLLIPLFGVHYMVFAVFPIS 350

      .      .      .      .      .
351 ISSKYQILFELCLGSFQGLVVAVLYCFLNSEV 382
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
351 ISSKYQILFELCLGSFQGLVVAVLYCFLNSEV 382
    
```

FIG. 46 (CONT.¹)

118/209

1 MKSGSGGSPTSLWGLFLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLE 50
|||||
1 MKSGSGGSPTSLWGLFLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLE 50

51 NCTVIEGYLHILLISKAEDYRSYRFPKLTVITEYLLLFVAGLESGLDLF 100
|||||
51 NCTVIEGYLHILLISKAEDYRSYRFPKLTVITEYLLLFVAGLESGLDLF 100

101 PNLTVIRGWKLFYNYALVIFEMTNLKDIGLYNLRNITRGAIRIEKNADLC 150
|||||
101 PNLTVIRGWKLFYNYALVIFEMTNLKDIGLYNLRNITRGAIRIEKNADLC 150

151 YLSTVDWSLILDVSNNNYIVGNKPPKECGDLCPGTMEEKPMCEKTTINNE 200
|||||
151 YLSTVDWSLILDVSNNNYIVGNKPPKECGDLCPGTMEEKPMCEKTTINNE 200

201 YNYRCWTTNRCQKMCPSCTCGKRACTENNECCHPECLGSCSAPDNDTACVA 250
|||||
201 YNYRCWTTNRCQKMCPSCTCGKRACTENNECCHPECLGSCSAPDNDTACVA 250

FIG. 47

119/209

251	CRHYYAGVCPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHD	300
251	CRHYYAGVCPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHD	300
301	GECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEKTKTIDSVTSAQML	350
301	GECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEKTKTIDSVTSAQML	350
351	QGCTIFKGNLLINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLS	400
351	QGCTIFKGNLLINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLS	400
401	FLKNLRLILGEEQLEGNYSFYVLDNQNLQQLWDWDHRNLTIKAGKMYFAF	450
401	FLKNLRLILGEEQLEGNYSFYVLDNQNLQQLWDWDHRNLTIKAGKMYFAF	450
451	NPKLCVSEIYRMEEVGTGKGRQSKGDINTRNNGERASCESDVLHFTSTTT	500
451	NPKLCVSEIYRMEEVGTGKGRQSKGDINTRNNGERASCESDVLHFTSTTT	500

FIG. 47 (CONT.)

120/209

501 SKNRIITWHRYRPPDYRDLSFTVYYKEAFKNVTEYDGGQDACGSNSWN 550
|||||
501 SKNRIITWHRYRPPDYRDLSFTVYYKEAFKNVTEYDGGQDACGSNSWN 550
551 MVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAATLTMVENDHIRGAKSE 600
|||||
551 MVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAATLTMVENDHIRGAKSE 600
601 ILYIRTNASVPSIPLDVLASNSSSQLIVKWNPPSLPENGNSYYIVRWQR 650
|||||
601 ILYIRTNASVPSIPLDVLASNSSSQLIVKWNPPSLPENGNSYYIVRWQR 650
651 QPQDGYLYRHNYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEGPCC 700
|||||
651 QPQDGYLYRHNYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEGPCC 700
701 ACPKTEAEKQAEKEEAEYRKVFENFLHNSIFVPRPERKRRDVMQVANTTM 750
|||||
701 ACPKTEAEKQAEKEEAEYRKVFENFLHNSIFVPRPERKRRDVMQVANTTM 750

FIG. 47 (CONT.²)

122/209

```

      . . . . .
1001 MSRELQGGSFGMVYEGVAKGVVKDEPETRVAIKTVNEAASMRRERIEFLNE 1050
      |||||
1001 MSRELQGGSFGMVYEGVAKGVVKDEPETRVAIKTVNEAASMRRERIEFLNE 1050

      . . . . .
1051 ASVMKEFNCHHVRLGLGVVSQGQPTLVIMELMTRGDLKSYLSLRPEMEN 1100
      |||||
1051 ASVMKEFNCHHVRLGLGVVSQGQPTLVIMELMTRGDLKSYLSLRPEMEN 1100

      . . . . .
1101 NPVLAPPSLSKMIQAGEIADGMAYLNANKFVHRDLAARNCMVAEDFTVK 1150
      |||||
1101 NPVLAPPSLSKMIQAGEIADGMAYLNANKFVHRDLAARNCMVAEDFTVK 1150

      . . . . .
1151 IGDFGMTRDIYETDYRKGGKGLLPVRWMSPESLKDGVFTTYSVDVWSFGV 1200
      |||||
1151 IGDFGMTRDIYETDYRKGGKGLLPVRWMSPESLKDGVFTTYSVDVWSFGV 1200

      . . . . .
1201 VLWEIATLAEQPYQGLSNEQVLRVFMEGGLLDKPDNCPDMLFELMRMCWQ 1250
      |||||
1201 VLWEIATLAEQPYQGLSNEQVLRVFMEGGLLDKPDNCPDMLFELMRMCWQ 1250

```

FIG. 47 (CONT.⁴)

123/209

1251 YNP[.]KMR[.]PSFLEIISSIK.....EELDLEPENM 1277
|||||
1251 YNP[.]KMR[.]PSFLEIISSIK[.]EME[.]PGFREV[.]SFY[.]SEEN[.]KLPE[.]PEELDLEPENM 1300
1278 E[.]SVPLD[.]PSASS[.]SLPL[.]DRH[.]SGHKA[.]ENG[.]PG[.]VL[.]VRAS[.]FDERQ[.]PYA[.]HMN 1327
|||||
1301 E[.]SVPLD[.]PSASS[.]SLPL[.]DRH[.]SGHKA[.]ENG[.]PG[.]VL[.]VRAS[.]FDERQ[.]PYA[.]HMN 1350
1328 GGRK[.]NERALPL[.]PQS[.]STC 1344
|||||
1351 GGRK[.]NERALPL[.]PQS[.]STC 1367

FIG. 47 (CONT.⁵)

124/209

1 MERGLPLLCVLA LVLAPAGAFRNDKCGDTIKIESPGYLTSPGYPHSYHP 50
|||||
1 MERGLPLLCVLA LVLAPAGAFRNDKCGDTIKIESPGYLTSPGYPHSYHP 50
51 SEKCEWLIQAPDPYQ RIMINFNPHFDLED RDCKYDYVEVFDGENENGHFR 100
|||||
51 SEKCEWLIQAPDPYQ RIMINFNPHFDLED RDCKYDYVEVFDGENENGHFR 100
101 GKFCGKIAPPV VSSGPF LFIKFVSDYETHGAGFSIRYE IFKRGPECSQN 150
|||||
101 GKFCGKIAPPV VSSGPF LFIKFVSDYETHGAGFSIRYE IFKRGPECSQN 150
151 YTPSGVIKSPGFPEKYPNSLECTYIVFAPKMSEI ILEFESFDLEPDSNP 200
|||||
151 YTPSGVIKSPGFPEKYPNSLECTYIVFAPKMSEI ILEFESFDLEPDSNP 200
201 PGGMFCRYDRLEIWDGFPDVGP HIGRYCGQKTPGRIRSSSGILSMVFYTD 250
|||||
201 PGGMFCRYDRLEIWDGFPDVGP HIGRYCGQKTPGRIRSSSGILSMVFYTD 250

FIG. 48

125/209

```

251  SAIKEGFSANYSVLQSSVSEDFKCMALGMESGEIHSDQITASSQYSTN  300
      |||||
251  SAIKEGFSANYSVLQSSVSEDFKCMALGMESGEIHSDQITASSQYSTN  300

301  WSAERSRLNYPENGWTPGEDSYREWIQVDLGLLRFVTAVGTQGAISKETK  350
      |||||
301  WSAERSRLNYPENGWTPGEDSYREWIQVDLGLLRFVTAVGTQGAISKETK  350

351  KKYVVKTYKIDVSSNGEDWITIKEGNKPVLFQGNTPD VVAVFPKPLI  400
      |||||
351  KKYVVKTYKIDVSSNGEDWITIKEGNKPVLFQGNTPD VVAVFPKPLI  400

401  TRFVRIKPATWETGISMRFEVYGCKITDYPCSGMLGMVSLISDSQITSS  450
      |||||
401  TRFVRIKPATWETGISMRFEVYGCKITDYPCSGMLGMVSLISDSQITSS  450

451  NQGDRNWMPENIRLVTSRSGWALPPAPHSYINEWLQIDLGEKIVRGII  500
      |||||
451  NQGDRNWMPENIRLVTSRSGWALPPAPHSYINEWLQIDLGEKIVRGII  500

```

FIG. 48 (CONT.¹)

126/209

501 QGKHKRENKVFMRKFKIGYSNNGSDWKIMDDSKRKAKSFEGNNNYDTPE 550
|||||
501 QGKHKRENKVFMRKFKIGYSNNGSDWKIMDDSKRKAKSFEGNNNYDTPE 550
551 LRTFPALSTRFIRIYPERATHGGGLGRMELLGCEVEAPTAGPTTPNGNLV 600
|||||
551 LRTFPALSTRFIRIYPERATHGGGLGRMELLGCEVEAPTAGPTTPNGNLV 600
601 DECDDDDQANCHSGTGDDFQLTGGTTVLATEKPTVIDSTIQS 641
|||||
601 DECDDDDQANCHSGTGDDFQLTGGTTVLATEKPTVIDSTIQS 641

FIG. 48 (CONT.²)

127/209

1 MERGLPLLCAVLALVAPAGAFRNDKCGDTIKIESPGYLTSPGYPHSYHP 50
|||||
1 MERGLPLLCAVLALVAPAGAFRNDKCGDTIKIESPGYLTSPGYPHSYHP 50

51 SEKCEWLIQAPDPYQIRIMINFNPHFDLED RDCKYDYVEVFDGENENGHFR 100
|||||
51 SEKCEWLIQAPDPYQIRIMINFNPHFDLED RDCKYDYVEVFDGENENGHFR 100

101 GKFCGKIAPPPVSSGPFLLFIKFVSDYETHGAGFSIRYEIFKRGPECSQN 150
|||||
101 GKFCGKIAPPPVSSGPFLLFIKFVSDYETHGAGFSIRYEIFKRGPECSQN 150

151 YTPSGVIKSPGFPEKYPNSLECTYIVFAPKMSEIILEFESFDLEPDSNP 200
|||||
151 YTPSGVIKSPGFPEKYPNSLECTYIVFAPKMSEIILEFESFDLEPDSNP 200

201 PGMFCRYDRLEIWDGFDPVGP HIGRYCGQKTPGRIRSSSGILSMVFYTD 250
|||||
201 PGMFCRYDRLEIWDGFDPVGP HIGRYCGQKTPGRIRSSSGILSMVFYTD 250

FIG. 49

251	SAIAKEGFSANYSVLQSSVSEDFKCMALGMESGEIHSDQITASSQYSTN	300
251	SAIAKEGFSANYSVLQSSVSEDFKCMALGMESGEIHSDQITASSQYSTN	300
301	WSAERSRLNYPENGWTPGEDSYREWIQVDLGLLRFVTA VGTQGAISKETH	350
301	WSAERSRLNYPENGWTPGEDSYREWIQVDLGLLRFVTA VGTQGAISKETH	350
351	KKYYVKTYKIDVSSNGEDWITIKEGNKPVL FQGNTNPTDVVAVFPKPLI	400
351	KKYYVKTYKIDVSSNGEDWITIKEGNKPVL FQGNTNPTDVVAVFPKPLI	400
401	TRFVRIKPATWETGISMRFEVYGCKITDYPCSGMLGMVSLDSQITSS	450
401	TRFVRIKPATWETGISMRFEVYGCKITDYPCSGMLGMVSLDSQITSS	450
451	NQGDNRNWPENIRLVTSRSGWALPPAPHSYINEWLQIDLGE EKIVRGII	500
451	NQGDNRNWPENIRLVTSRSGWALPPAPHSYINEWLQIDLGE EKIVRGII	500

FIG. 49 (CONT.¹)

```

501 QGKHRENKVFMRKFKIGYSNNGSDWKIMDDSKRKAK..... 538
      | | | | | | | | | | | | | | | | | | | | | | | |
501 QGKHRENKVFMRKFKIGYSNNGSDWKIMDDSKRKAKSFE GNNNYDTPE 550
      .
      .
      .
      .
539 .....GGTTVLATEKPTVIDSTIQSEFFPTYGFNC 567
      | | | | | | | | | | | | | | | | | | | | | | | |
601 DECDDQANCHSGTGDDFQLTGGTTVLATEKPTVIDSTIQSEFFPTYGFNC 650
      .
      .
      .
      .
568 EFGWGSHKTFCHWEHDNHVQLKWSVLTSKTGPIQDHTGDGNFIYSQADEN 617
      | | | | | | | | | | | | | | | | | | | | | | | |
651 EFGWGSHKTFCHWEHDNHVQLKWSVLTSKTGPIQDHTGDGNFIYSQADEN 700
      .
      .
      .
      .
618 QKGKVARLVSPVVYSQNSAHCMTFWYHMSGSHVGTLRVKLRYPKPEEYDQ 667
      | | | | | | | | | | | | | | | | | | | | | | | |
701 QKGKVARLVSPVVYSQNSAHCMTFWYHMSGSHVGTLRVKLRYPKPEEYDQ 750

```

FIG. 49 (CONT.²)

130/209

668 LVWMAIGHQGDHWKEGRVLLHKSLKLYQVIFEGEIGKGNLGGIAVDDISI 717
|||||
751 LVWMAIGHQGDHWKEGRVLLHKSLKLYQVIFEGEIGKGNLGGIAVDDISI 800
718 NNHISQEDCAKPADLDKKNPEIKIDETGSTPGYEGEGEDKNISRKPGENV 767
|||||
801 NNHISQEDCAKPADLDKKNPEIKIDETGSTPGYEGEGEDKNISRKPGENV 850
768 LKTLXPILITIIAMSALGVLLGAVCGVVLYCACWHNGMSENLNLSALENYN 817
|||||
851 LKTLXPILITIIAMSALGVLLGAVCGVVLYCACWHNGMSENLNLSALENYN 900
818 FELVDGVKLLKKDKLNTQSTYSEA 840
|||||
901 FELVDGVKLLKKDKLNTQSTYSEA 923

FIG. 49 (CONT.³)

```

1 MERGLPLLCVALLVAPAGAFRNDKCGDTIKIESPGYLTPGYPHSYHP 50
  |||||
1 MERGLPLLCVALLVAPAGAFRNDKCGDTIKIESPGYLTPGYPHSYHP 50
  |||||
51 SEKCEWLIQAPDPYQIMINFNPHFDLEDRCCKYDYVEVFDGENENGHFR 100
  |||||
51 SEKCEWLIQAPDPYQIMINFNPHFDLEDRCCKYDYVEVFDGENENGHFR 100
  |||||
101 GKFCGKIAPPPVVSSGPFLLFIKFVSDYETHGAGFSIRYEIIFKRGPECSQN 150
  |||||
101 GKFCGKIAPPPVVSSGPFLLFIKFVSDYETHGAGFSIRYEIIFKRGPECSQN 150
  |||||
151 YTPSGVIKSPGFPEKYPNSLECTYIVFAPKMSIILEFESFDLEPDSNP 200
  |||||
151 YTPSGVIKSPGFPEKYPNSLECTYIVFAPKMSIILEFESFDLEPDSNP 200
  |||||
201 PGGMFCRYDRLEIWDGFPDVGPHIGRYCGQKTPGRIRSSSGILSMVFYTD 250
  |||||
201 PGGMFCRYDRLEIWDGFPDVGPHIGRYCGQKTPGRIRSSSGILSMVFYTD 250
  |||||
251 SAIAKEGFSANYSVLQSSVSEDFKCMALGMESGEIHSDQITASSQYSTN 300
  |||||
251 SAIAKEGFSANYSVLQSSVSEDFKCMALGMESGEIHSDQITASSQYSTN 300
  |||||

```

FIG. 50

132/209

301 WSAERSRLNYPENGWTPGEDSYREWIQVDLGLLRFTAVGTQGAISKETK 350
|||||
301 WSAERSRLNYPENGWTPGEDSYREWIQVDLGLLRFTAVGTQGAISKETK 350
351 KKYVVKTYKIDVSSNGEDWITIKEGNKPVLFGQNTNPTDVVAVFPKPLI 400
|||||
351 KKYVVKTYKIDVSSNGEDWITIKEGNKPVLFGQNTNPTDVVAVFPKPLI 400
401 TRFVRIKPATWETGISMRFEVYGCKITDYPCSGMLGMVSLISDSQITSS 450
|||||
401 TRFVRIKPATWETGISMRFEVYGCKITDYPCSGMLGMVSLISDSQITSS 450
451 NQGDRNWMPENIRLVTSRSGWALPPAPHSYINNEWLQIDLGEKIVRGII 500
|||||
451 NQGDRNWMPENIRLVTSRSGWALPPAPHSYINNEWLQIDLGEKIVRGII 500
501 QGGKHRENKVFMRKFKIGYSNNGSDWKIMDDSKRKAR 538
|||||
501 QGGKHRENKVFMRKFKIGYSNNGSDWKIMDDSKRKAR 538

FIG. 50 (CONT.¹)

133/209

1 MGAPACALALCVAVAI VAGASSESLGTEQRRVVGRAAEVPGPEGGQEQLV 50
|||||
1 MGAPACALALCVAVAI VAGASSESLGTEQRRVVGRAAEVPGPEGGQEQLV 50
51 FGSGDAVELSCPPPGGGPMGPTVWVKDGTGLVPSE RVLVGPQRLQVLNAS 100
|||||
51 FGSGDAVELSCPPPGGGPMGPTVWVKDGTGLVPSE RVLVGPQRLQVLNAS 100
101 HEDSGAYSCRQRLTQ RVLCHF SVRVTDAPSSGDD EDEAE DTGVDTGA 150
|||||
101 HEDSGAYSCRQRLTQ RVLCHF SVRVTDAPSSGDD EDEAE DTGVDTGA 150
151 PYWTRPERMDKKLLAVPAANTVRFRC PAAGNPTPSISWLKNGREFRGEHR 200
|||||
151 PYWTRPERMDKKLLAVPAANTVRFRC PAAGNPTPSISWLKNGREFRGEHR 200
201 IGGIKLRHQQWSLVME SVVPSPDRGN YTCVVENKFGSIRQTYTLDV LERSP 250
|||||
201 IGGIKLRHQQWSLVME SVVPSPDRGN YTCVVENKFGSIRQTYTLDV LERSP 250

FIG. 51

134/209

```

      .      .      .      .      .
251 HRPILQAGLPANQTAVLGSDVEFHCKVYSDAQPHIQWLKHVEVNGSKVGP 300
      |||||
251 HRPILQAGLPANQTAVLGSDVEFHCKVYSDAQPHIQWLKHVEVNGSKVGP 300

      .      .      .      .      .
301 DGTPYVTVLKSWISESVEADVR.LRLANVSERDGGEYLCRATNFIGVAEK 349
      |||||
301 DGTPYVTVLKTAGANTTDKELEVLSLHNVTFFEDAGEYTCLAGNSIGFSHH 350

      .      .      .      .      .
350 AFWLSV 355
      . |||
351 SAWLVV 356

```

FIG. 51 (CONT.¹)

```

1 MTLRHLPFILLILSGELYAEKQCDPFTVENGRIAQYYTTFKSFYFPMS 50
  |||||
1 MTLRHLPFILLILSGELYAEKQCDPFTVENGRIAQYYTTFKSFYFPMS 50
  |||||
51 VDKKLSFFCLAGYATESGKQEEQIRCTAEGWSPNPRCYKKCLKPDLRNGY 100
  |||||
51 VDKKLSFFCLAGYATESGKQEEQIRCTAEGWSPNPRCYKKCLKPDLRNGY 100
  |||||
101 VSNDKVLVKLQERMSYGCSSGYKTTGGKDEEVHCLSAGWSSQPSCRKEQ 150
  |||||
101 VSNDKVLVKLQERMSYGCSSGYKTTGGKDEEVHCLSAGWSSQPSCRKEQ 150
  |||||
151 ETCLAPELEHGNYSTTQRTFKVKDIAVYCTAGYTTTGKQTGEAECQAN 200
  |||||
151 ETCLAPELEHGNYSTTQRTFKVKDIAVYCTAGYTTTGKQTGEAECQAN 200
  |||||
201 GWSLTPQC�KLMCSSLRLIENGYFHPVKQTYEEGDVVQFFCHENYYLSGS 250
  |||||
201 GWSLTPQC�KLMCSSLRLIENGYFHPVKQTYEEGDVLVQFFCHENYYLSGS 250
  |||||

```

FIG. 52

136/209

251 DLIQCYNFGWYPESPICEGRRNRCPPPPVPLNSKIQPHSTTYRHGERVHI 300
|||||
251 DLIQCYNFGWYPESPICEGRRNRCPPPPVPLNSKIQPHSTTYRHGERVHI 300
301 ECELNFVIQGSSEELLCEGKWKTEPPKCI 328
|||||
301 ECELNFVIQGSSEELLCEGKWKTEPPKCI 328

FIG. 52 (CONT.¹)

1	MPWGRRPTWLLAFLLVFLKISILSVTAWQTGNCQPGPLERSERSGTCAG	50
1	MPWGRRPTWLLAFLLVFLKISILSVTAWQTGNCQPGPLERSERSGTCAG	50
51	PAPFLVFSQKKSIRIDPDGTGNHQQLVVDAGISADMDIHYKKERLYWVDV	100
51	PAPFLVFSQKKSIRIDPDGTGNHQQLVVDAGISADMDIHYKKERLYWVDV	100
101	ERQVLLRVFLNGTGLEKVCNVERKVSGLAIDWIDDEVLWVDQQNGVITVT	150
101	ERQVLLRVFLNGTGLEKVCNVERKVSGLAIDWIDDEVLWVDQQNGVITVT	150
151	DMTGKNSRVLLSSLKHPNSIAVDPIERLMFWSSEVTGSLHRAHLKGVDVK	200
151	DMTGKNSRVLLSSLKHPNSIAVDPIERLMFWSSEVTGSLHRAHLKGVDVK	200
201	TLLETGGISVLTLDVLDKRLFWVQDSGEGSHAYIHSCDYEGGSVRLIRHQ	250
201	TLLETGGISVLTLDVLDKRLFWVQDSGEGSHAYIHSCDYEGGSVRLIRHQ	250
251	ARHSLSSMAFFGDRIFYSVLKSKAIWIANKHTGKDTVRLNHLPSFVTPGK	300
251	ARHSLSSMAFFGDRIFYSVLKSKAIWIANKHTGKDTVRLNHLPSFVTPGK	300

FIG. 53

138/209

301 LMVVHPRAQPRTEAAKDPPELLKQGRGPCRFGLCERDPKSHSSACAEG 350
|||||
301 LMVVHPRAQPRTEAAKDPPELLKQGRGPCRFGLCERDPKSHSSACAEG 350
|||||
351 YTLRDRKYCEDVNECATQNHGCTLGCENTPGSYHCTCPTGFVLLPDGKQ 400
|||||
351 YTLRDRKYCEDVNECATQNHGCTLGCENTPGSYHCTCPTGFVLLPDGKQ 400
|||||
401 CHELVSCPNGVSKCSHGCVLTSDGPRCICPAGSVLGRDGKTCTGCSSPDN 450
|||||
401 CHELVSCPNGVSKCSHGCVLTSDGPRCICPAGSVLGRDGKTCTGCSSPDN 450
|||||
451 GGCSQICLPLRPGSWECD CFPGYDLQSDRKSCAASGPQPLL FANSQDIR 500
|||||
451 GGCSQICLPLRPGSWECD CFPGYDLQSDRKSCAASGPQPLL FANSQDIR 500
|||||
501 HMFHDGTDYKVLLSRQMGVMFALDYDPVESKIYFAQTALKWIERANMDGS 550
|||||
501 HMFHDGTDYKVLLSRQMGVMFALDYDPVESKIYFAQTALKWIERANMDGS 550
|||||
551 QRLITEGVDTLEGLALDWIGRRIYWTDSGKSVVGGSDLGKHHRIIQ 600
|||||
551 QRLITEGVDTLEGLALDWIGRRIYWTDSGKSVVGGSDLGKHHRIIQ 600

FIG. 53 (CONT. ¹)

139/209

601 ERISRPRGIAVHPRARRLFWTDVGMSPRIESASLQGS DRVLIASSNLLEP 650
|||||
601 ERISRPRGIAVHPRARRLFWTDVGMSPRIESASLQGS DRVLIASSNLLEP 650
651 SGITIDYLTDTLYWC DTKRSV IEMANLDGSKRRRLIQNDVGH PFS LAVFE 700
|||||
651 SGITIDYLTDTLYWC DTKRSV IEMANLDGSKRRRLIQNDVGH PFS LAVFE 700
701 DHLVSDWAIPSVIRVNKRTGQNRVRLQGSMLKPSSLVVVHPLAKPGADP 750
|||||
701 DHLVSDWAIPSVIRVNKRTGQNRVRLQGSMLKPSSLVVVHPLAKPGADP 750
751 CLYRNGGCEHICQESLGTARCLCREGFVKAWDGKMC L PQDYPILSGENAD 800
|||||
751 CLYRNGGCEHICQESLGTARCLCREGFVKAWDGKMC L PQDYPILSGENAD 800
801 LSKEVTSLSNSTQAEVPDDDGTESS TLVAEIMVSGMNYEDDCGPGCGSH 850
|||||
801 LSKEVTSLSNSTQAEVPDDDGTESS TLVAEIMVSGMNYEDDCGPGCGSH 850
851 ARCVSDGETAECQCLKGFARDGNLCSDIDECVLARSDCPSTSSRCINTEG 900
|||||
851 ARCVSDGETAECQCLKGFARDGNLCSDIDECVLARSDCPSTSSRCINTEG 900

FIG. 53 (CONT.²)

140/209

```

851  ARCVDGETAECQCLKGFA RDGNLCSDIDECVLARSDCPSTSSRCINTEG 900
      |||||
851  ARCVDGETAECQCLKGFA RDGNLCSDIDECVLARSDCPSTSSRCINTEG 900

901  GYVCRCEGYEGDGISCFDIDECQ RGAHNCAENAACTNTEGGYNCTCAGR 950
      |||||
901  GYVCRCEGYEGDGISCFDIDECQ RGAHNCAENAACTNTEGGYNCTCAGR 950

951  PSSPGLSCP DSTAPSL LGEDGHHLDRNSYPGCPSSYDGYCLNGGVCMHIE 1000
      |||||
951  PSSPGRSCP DSTAPSL LGEDGHHLDRNSYPGCPSSYDGYCLNGGVCMHIE 1000

1001 SLDSYTCNCVIGYSGDRCQT..... 1020
      |||||
1001 SLDSYTCNCVIGYSGDRCQTRDLRWWE L RHAGYQKHDIMVVAVCMVALV 1050

1021 ..... PPSSDRGPQEIEGNSHLPSYR PVGPEKLHSLQSANG 1056
      |||||
1151 PHIDGMGTGQSCWIPPSSDRGPQEIEGNSHLPSYR PVGPEKLHSLQSANG 1200

      1057 SCHERAPDLPRQTEPVQ 1073
          |||||
      1201 SCHERAPDLPRQTEPVK 1217

```

Fig. 53 (Cont.)³

[illegible]

FIG. 54

142/209

251 ARHSLSSMAFFGDRIFYVLKSKAIWANKHTGKDTVRLNHPSEFVTPGK 300
|||||
251 ARHSLSSMAFFGDRIFYVLKSKAIWANKHTGKDTVRLNHPSEFVTPGK 300
301 LMVVHPRAQPRTEAAKDPDPPELLKQGRGPCRFGLCERDPKSHSSACAEG 350
|||||
301 LMVVHPRAQPRTEAAKDPDPPELLKQGRGPCRFGLCERDPKSHSSACAEG 350
351 YTLSDRKYCEDVNECATQNHGCTLGCENTPGSYHCTCPTGFVLLPDGKQ 400
|||||
351 YTLSDRKYCEDVNECATQNHGCTLGCENTPGSYHCTCPTGFVLLPDGKQ 400
401 CHELVSCPGNVSKCSHGCVLTSDGPRCICPAGSVLGRDGKCTCGCSSPDN 450
|||||
401 CHELVSCPGNVSKCSHGCVLTSDGPRCICPAGSVLGRDGKCTCGCSSPDN 450
451 GGCSQICLPLRPGSWECDCEPGYDLQSDRKSCAASGPQPLL FANSQDIR 500
|||||
451 GGCSQICLPLRPGSWECDCEPGYDLQSDRKSCAASGPQPLL FANSQDIR 500

FIG. 54 (CONT. ¹)

143/209

501 HMFHFDGTDYKVLRSRQMGVMFALDYPDVESKIYFAQTALKWIERANMDGS 550
|||||
501 HMFHFDGTDYKVLRSRQMGVMFALDYPDVESKIYFAQTALKWIERANMDGS 550
|||||
551 QRERLITEGVDTLEGLALDWIGRRRIYWTDSGKSVVGGSDLGKHHRIIQ 600
|||||
551 QRERLITEGVDTLEGLALDWIGRRRIYWTDSGKSVVGGSDLGKHHRIIQ 600
|||||
601 ERISRPRGIAVHPRARRLFWTDVGMSPRIESASLQGS DRVLIASSNLLPEP 650
|||||
601 ERISRPRGIAVHPRARRLFWTDVGMSPRIESASLQGS DRVLIASSNLLPEP 650
|||||
651 SGITIDYLTDTLYWC DTKR SVIEMANLDGSKRRRLIQNDVGH PFS LAVFE 700
|||||
651 SGITIDYLTDTLYWC DTKR SVIEMANLDGSKRRRLIQNDVGH PFS LAVFE 700
|||||
701 DHLWVSDWAI PSVIRVNKR TGQNRVR LQGSMLK PSSLVVVHPLAKPGADP 750
|||||
701 DHLWVSDWAI PSVIRVNKR TGQNRVR LQGSMLK PSSLVVVHPLAKPGADP 750
|||||
751 CLYRNGGCEHICQESLGTARCLCREGFVKAWDGKMC L PQDYPILSGENA 799
|||||
751 CLYRNGGCEHICQESLGTARCLCREGFVKAWDGKMC L PQDYPILSGENA 799
|||||

FIG. 54 (CONT. ²)

```

1 MPWRRPTWLLAFLVLKISILSVTAWQTGNCQPGPLERSERSGTCAG 50
  |||||
1 MPWRRPTWLLAFLVLKISILSVTAWQTGNCQPGPLERSERSGTCAG 50
  |||||
51 PAPFLVFSQGKSI SRI..... 66
  |||||
51 PAPFLVFSQGKSI SRI DP DGT NH Q Q LV VD AG I S AD MD I H Y K K E R L Y W V D V 100
  |||||
67 ..... W A I P S V I R V N K R T G Q N R V R L Q G S M L K P S S L V V V H P L A K P G A D P 109
  |||||
701 D H L W V S D W A I P S V I R V N K R T G Q N R V R L Q G S M L K P S S L V V V H P L A K P G A D P 750
  |||||
110 CLYRNGGCEHICQESLGTARCLCREGFVKAWDGKMC L P Q D Y P I L S G E N A D 159
  |||||
751 CLYRNGGCEHICQESLGTARCLCREGFVKAWDGKMC L P Q D Y P I L S G E N A D 800
  |||||
160 LSKEVTSLSNSTQAEV P D D D G T E S S T L V A E I M V S G M N Y E D D C G P G C G S H 209
  |||||
801 LSKEVTSLSNSTQAEV P D D D G T E S S T L V A E I M V S G M N Y E D D C G P G C G S H 850
  |||||

```

FIG. 55

210	ARCUSDGETAECQCLKGFARDGNLCSIDIECVLARSDCPSTSSRCINTEG	259
851	ARCUSDGETAECQCLKGFARDGNLCSIDIECVLARSDCPSTSSRCINTEG	900
260	GYVCRCEGYEGDGISCFDIEDECQRGAHNCAENAACTNTEGGYNCTCAGR	309
901	GYVCRCEGYEGDGISCFDIEDECQRGAHNCAENAACTNTEGGYNCTCAGR	950
310	PSSPGLSCPDESTAPSLLEDGHHLDRNSYPGCPSSYDGYCLNGGVCMHIE	359
951	PSSPGRSCPDESTAPSLLEDGHHLDRNSYPGCPSSYDGYCLNGGVCMHIE	1000
360	SLDSTCNVCVIGSGDRCQTRDLRWWEILRHAGYGQKHDIMVVAVCMVALV	409
1001	SLDSTCNVCVIGSGDRCQTRDLRWWEILRHAGYGQKHDIMVVAVCMVALV	1050
410	LLLLLMWGTYYRTRKQLSNPPKNPCDEPSGSVSSSGPDSSSGA AVASC	459
1051	LLLLLMWGTYYRTRKQLSNPPKNPCDEPSGSVSSSGPDSSSGA AVASC	1100

FIG. 55 (CONT. 1)

146/209

460 PQPWFVVLEKHQDPKNGSLPADGTNGAVVDAGLSPSLQLGSVHLTSWRQK 509
 11101 PQPWFVVLEKHQDPKNGSLPADGTNGAVVDAGLSPSLQLGSVHLTSWRQK 1150
 510 PHIDGMGTGQSCWIPPSSDRGPQOEIEGNHLSYRYPVGPEKHLHLSQSANG 559
 11151 PHIDGMGTGQSCWIPPSSDRGPQOEIEGNHLSYRYPVGPEKHLHLSQSANG 1200
 560 SCHERAPDLPRQTEPVQ 576
 1201 SCHERAPDLPRQTEPVK 1217

FIG. 55 (CONT. 2)

```

1 MPWGRPTWLLAFLLV..... 17  

  |||||  

1 MPWGRPTWLLAFLLVFKISILSVTAWTGNCQPGPLERSERSGT CAG 50  

18 ..... SAECQLKFARDGNLCSDIDECVLARSDCPSTSSRCINTEG 59  

   |||||  

851 ARCVSDGETAECQLKFARDGNLCSDIDECVLARSDCPSTSSRCINTEG 900  

60 GYVCRCEGYEGDGISCFDIDECQRGAHNCAENAACTNTEGGYNCTCAGR 109  

   |||||  

901 GYVCRCEGYEGDGISCFDIDECQRGAHNCAENAACTNTEGGYNCTCAGR 950  

110 PSSPGLSCPDPSTAPSLLEDGHHLDRNSYPGCPPSSYDGYCLNGVCMHIE 159  

   |||||  

951 PSSPGRSCPDPSTAPSLLEDGHHLDRNSYPGCPPSSYDGYCLNGVCMHIE 1000  

160 SLDSYTCNCVICYSGDRCQTRDLRWELRHAGYGQKH DIMVVA VCMVALV 209  

   |||||  

1001 SLDSYTCNCVICYSGDRCQTRDLRWELRHAGYGQKH DIMVVA VCMVALV 1050

```

FIG. 56


```

210 LLLLGMWGTYYYRTRKQLSNPPKNPCDEPSGVSSSGPDSSSGAAVASC 259
    |||||
1051 LLLLGMWGTYYYRTRKQLSNPPKNPCDEPSGVSSSGPDSSSGAAVASC 1100
    |||||

260 PQPWFVLEKHQDPKNGSLPADGTNGAVVDAGLSPSLQLGSHLTSWRQK 309
    |||||
1101 PQPWFVLEKHQDPKNGSLPADGTNGAVVDAGLSPSLQLGSHLTSWRQK 1150
    |||||

310 PHIDGMGTQSCWIPPSSDRGPQIEGNSHLPSYRPVGPEKLHSLQSANG 359
    |||||
1151 PHIDGMGTQSCWIPPSSDRGPQIEGNSHLPSYRPVGPEKLHSLQSANG 1200
    |||||

360 SCHERAPDLPRQTEPVQ 376
    |||||
1201 SCHERAPDLPRQTEPVK 1217

```

FIG. 56 (CONT.)¹

[illegible]

FIG. 57

251	QLEPLYNLHAYVRRALHRRYGDKYVNLRGPIPAHLLGDMWAQSWENIYD	300
251	QLEPLYNLHAYVRRALHRRYGDKYVNLRGPIPAHLLGDMWAQSWENIYD	300
301	MVVPFPDKPNLDVTSTMVQKGNATHMFRVSEEFFTSLGLSPMPPEFWAE	350
301	MVVPFPDKPNLDVTSTMVQKGNATHMFRVSEEFFTSLGLSPMPPEFWAE	350
351	SMLEKPTDGREVVCHASAWDFYNRKDFRIKQCTRVTMEOQLATVHHMGHV	400
351	SMLEKPTDGREVVCHASAWDFYNRKDFRIKQCTRVTMEOQLATVHHMGHV	400
401	QYYLQYKDLHVSRLRGANPGFHEAIGDVLALSVPAPHLHKIGLLDHVTN	450
401	QYYLQYKDLHVSRLRGANPGFHEAIGDVLALSVPAPHLHKIGLLDHVTN	450
451	DIESDINYLKMALEKIAFLPFGYLVDDQWRWGVFSGRTPPSRYNFDWWYL	500
451	DIESDINYLKMALEKIAFLPFGYLVDDQWRWGVFSGRTPPSRYNFDWWYL	500

FIG. 57 (CONT.)

151/209

501 RTKYQGICPPVARNETHFDAGAKFHIPNVTPIRYFVSFVLQFQFHQALC 550
|||||
501 RTKYQGICPPVARNETHFDAGAKFHIPNVTPIRYFVSFVLQFQFHQALC 550
551 KEAGHQGPLHQCDIYQSQAGAKLKQVLQAGCSRPPWQEVKDLVGSDALD 600
|||||
551 KEAGHQGPLHQCDIYQSTQAGAKLKQVLQAGCSRPPWQEVKDLVGSDALD 600
601 AKALLEYFQPVSQWLEEQNRNGEVLGWPENQWRPPLPDNYPEGIDLETD 650
|||||
601 AKALLEYFQPVSQWLEEQNRNGEVLGWPENQWRPPLPDNYPEGIDLETD 650
651 EAKADRFVEEYDRTAQVLLNEYAEANWQYNTNITIEGSKILLEKSTEVS 700
|||||
651 EAKADRFVEEYDRTAQVLLNEYAEANWQYNTNITIEGSKILLEKSTEVS 700
701 HTLKYGTRAKTFDVSNFQNSSIKRIKKLQNLDRVLPKPKELEEYNQIILL 750
|||||
701 HTLKYGTRAKTFDVSNFQNSSIKRIKKLQNLDRVLPKPKELEEYNQIILL 750

FIG. 57 (CONT. ²)

751	DMETYSLSNICYTNGTCMPLEPDLTNMMATSRKYEELLWAWKSWRDKVG	800
751	DMETYSLSNICYTNGTCMPLEPDLTNMMATSRKYEELLWAWKSWRDKVG	800
801	RAILPFFPKYVEFSNKIAKLNGYTDAGDSWRSLYESDNLEQDLEKLYQEL	850
801	RAILPFFPKYVEFSNKIAKLNGYTDAGDSWRSLYESDNLEQDLEKLYQEL	850
851	QPLYLNLHAYVRRSLHRHYGSEYINLDGPIPAHLLGNMWAQTWSNIYDLV	900
851	QPLYLNLHAYVRRSLHRHYGSEYINLDGPIPAHLLGNMWAQTWSNIYDLV	900
901	APFPSAPNIDATEAMIKQGWTPRRIFKEADNFTSLGLLPVPPEFWNKSM	950
901	APFPSAPNIDATEAMIKQGWTPRRIFKEADNFTSLGLLPVPPEFWNKSM	950
951	LEKPTDGREVVCHPSAWDFYNGKDFRIKQCTSVNMEDLVIAHHEMGIQY	1000
951	LEKPTDGREVVCHPSAWDFYNGKDFRIKQCTSVNMEDLVIAHHEMGIQY	1000

FIG. 57 (CONT.)

153/209

1001 FMQYKDLPVTFREGANPGFHEAIGDIMALSVSTPKHLYSLNLLSTEGSY 1050
|||||
1001 FMQYKDLPVTFREGANPGFHEAIGDIMALSVSTPKHLYSLNLLSTEGSY 1050

1051 EYDINFLMKMALDKIAFIPFSYLIDQWRWRVFDGSGITKENYNQEWWSLRL 1100
|||||
1051 EYDINFLMKMALDKIAFIPFSYLIDQWRWRVFDGSGITKENYNQEWWSLRL 1100

1101 KYQGLCPPVPRSQGDGDFGSKFHV PANVPYVRYFVSFIIQFQFHEALCRA 1150
|||||
1101 KYQGLCPPVPRSQGDGDFGSKFHV PANVPYVRYFVSFIIQFQFHEALCRA 1150

1151 AGHTGPLHKCDIYQSKEAGKLLADAMKLGYSKPWPEAMKLITGQPNMSAS 1200
|||||
1151 AGHTGPLHKCDIYQSKEAGKLLADAMKLGYSKPWPEAMKLITGQPNMSAS 1200

1201 AMMNYFKPLTEWLVTENRRRHGETL GWPEYNWAPNT 1235
|||||
1201 AMMNYFKPLTEWLVTENRRRHGETL GWPEYNWAPNT 1235

FIG. 57 (CONT. 4)

154/209

1 MTMTLHTKASGMALLHQIQGNELEPLNRPQLKMPMERALGEVYVDNSKPT 50
|||||
1 MTMTLHTKASGMALLHQIQGNELEPLNRPQLKMPMERALGEVYVDNSKPT 50

51 VFNYPEGAAYEFNAAAAAASAPVYGQSGIAYGPGSEAAAFSANS LG A 100
|||||
51 VFNYPEGAAYEFNAAAAAASAPVYGQSGIAYGPGSEAAAFSANS LG A 100

101 FPQLNSVSPSPLMLLHPPQLSPFLHPHGQQVPYYLENEPSAYAVRDTGP 150
|||||
101 FPQLNSVSPSPLMLLHPPQLSPFLHPHGQQVPYYLENEPSAYAVRDTGP 150

151 PAFYRSNSDNRNQGRERLSSSNEKGNMIMESAKETRYCAVCNDYASGYH 200
|||||
151 PAFYRSNSDNRNQGRERLSSSNEKGNMIMESAKETRYCAVCNDYASGYH 200

FIG. 58

201	YGVWSCEGCKAFFKRSIQGHNDYMC	PATNQCTIDKNRRKSCQACRLRKY	250
201	YGVWSCEGCKAFFKRSIQGHNDYMC	PATNQCTIDKNRRKSCQACRLRKY	250
251	EVGMMKGGIRKDRRGGRMLKHKRQRDDLEGRNEMGASGDMRAANLWPSP	L	300
251	EVGMMKGGIRKDRRGGRMLKHKRQRDDLEGRNEMGASGDMRAANLWPSP	L	300
301	VIKHTTKNSPALSILTADQMVSALLDAEPPMIYSEYDPSRPFSEASMMGLL		350
301	VIKHTTKNSPALSILTADQMVSALLDAEPPMIYSEYDPSRPFSEASMMGLL		350
	351	TNLADRELVHMINWAKRVPG	370
	351	TNLADRELVHMINWAKRVPG	370

FIG. 58 (CONT.¹)

156/209

1 MVPQAHGLLLCFLLQLQGLGTAVFITQEEAHGVLHRQRANSLLLEELW 50
|||||
1 MVPQAHGLLLCFLLQLQGLGTAVFITQEEAHGVLHRQRANSLLLEELW 50
|||||
51 PGSLERECNEEQCSFEEAREIFKSPERTKQFWIVYSDGDQCASNPCQNGG 100
|||||
51 PGSLERECNEEQCSFEEAREIFKSPERTKQFWIVYSDGDQCASNPCQNGG 100
|||||
101 TCQDHLKSYVCFCLLDFE..... 118
|||||
101 TCQDHLKSYVCFCLLDFEGRNCESKNEQLICANENGDCDQYCRDHVGTK 150
|||||
119GAVLLDARWIVTAAHCFDNIRYWGNI TVVMG 149
|||||
201 PKGECPWQAVLKINGLLCGAVLLDARWIVTAAHCFDNIRYWGNI TVVMG 250
|||||
150 EHDFSEKDGDEQVRRVTQVIMPDKYIRGKINHDIALLRLHRPVTF TDYVV 199
|||||
251 EHDFSEKDGDEQVRRVTQVIMPDKYIRGKINHDIALLRLHRPVTF TDYVV 300
|||||

FIG. 59

157/209

200 PLCLPEKSFSENTLARIFSRVSGWGQLLDRGATALELMSIEVPRMTQD 249
|||||
301 PLCLPEKSFSENTLARIFSRVSGWGQLLDRGATALELMSIEVPRMTQD 350
250 CLEHAKHSSNTPKITTENMFCAGYMDGTDACKGDSGGPHATHYHGTWYLT 299
|||||
351 CLEHAKHSSNTPKITTENMFCAGYMDGTDACKGDSGGPHATHYHGTWYLT 400
300 GVVSWGEGCAAIGHIGVYTRVSQYIDWLVRHMDSKLQGVFRLPLL 345
|||||
401 GVVSWGEGCAAIGHIGVYTRVSQYIDWLVRHMDSKLQGVFRLPLL 446

FIG. 59 (CONT. ¹)

```

1 MGFLKFSPLVVSILL..... 17
  |||||
1 MGFLKFSPLVVSILLYQACSLQAVPLRSILESSPGMATLSEEEVRLA 50

18 ALVQDYMQMKA RELEQEEEEQEAEGSSLDSPRSKRCGNLSTCMLGTYTQDL 67
  |||||
51 ALVQDYMQMKA RELEQEEEEQEAEGSSLDSPRSKRCGNLSTCMLGTYTQDL 100

      .
68 NKFHTFPQTSIGVEAPGKKRDVAKDLETNHQSHFGN 103
  |||||
101 NKFHTFPQTSIGVEAPGKKRDVAKDLETNHQSHFGN 136

```

FIG. 60

159/209

1 MATLLRSKLTNVATSVSNKSQAKVSGMFARMGFQAATDEEAVGFACDDDL 50
|||||
1 MATLLRSKLTNVATSVSNKSQAKVSGMFARMGFQAATDEEAVGFACDDDL 50
51 DFEHRQGLQMDILKSEGEPCGDEGAEPVEGDIHYQRGGAPLPPSGSKDQ 100
|||||
51 DFEHRQGLQMDILKSEGEPCGDEGAEPVEGDIHYQRGGAPLPPSGSKDQ 100
101 AVGAGGEFGGHDKPKITAWAEGWNVNTNAIQGMFVLGLPYAILHGGYLGFL 150
|||||
101 AVGAGGEFGGHDKPKITAWAEGWNVNTNAIQGMFVLGLPYAILHGGYLGFL 150
151 LIIFAAVVCCYTGKILIACLYEENEDGEVVRVDRDSYVAIANACCAPRFPT 200
|||||
151 LIIFAAVVCCYTGKILIACLYEENEDGEVVRVDRDSYVAIANACCAPRFPT 200
201 LGGRVVNVAQIIELVMTCILYVVVSGNLMYNSFPGLPVSQKSWSIITAV 250
|||||
201 LGGRVVNVAQIIELVMTCILYVVVSGNLMYNSFPGLPVSQKSWSIITAV 250
251 LLPCAFLKNLKA VSKFSLCTLAHFVINILVIA YCLSRARDWAW EKVKFY 300
|||||
251 LLPCAFLKNLKA VSKFSLCTLAHFVINILVIA YCLSRARDWAW EKVKFY 300

FIG. 61

160/209

301 IDVKKFPISIGIIVFSYTSQIFLPSLEGNMQQPSEFHCMMNWTHIAACVL 350
|||||
301 IDVKKFPISIGIIVFSYTSQIFLPSLEGNMQQPSEFHCMMNWTHIAACVL 350
|||||
351 KGLFALVAYLTWADETKEVITDNLPGSIRAVVNFLVAKALLSYPLPFFA 400
|||||
351 KGLFALVAYLTWADETKEVITDNLPGSIRAVVNFLVAKALLSYPLPFFA 400
|||||
401 AVEVLEKSLFQEGSRAFFPACYGGDGRILKSWELTLRCALVVFTLLMAIYV 450
|||||
401 AVEVLEKSLFQEGSRAFFPACYGGDGRILKSWELTLRCALVVFTLLMAIYV 450
|||||
451 PHFALLMGLTGSLTGAGLCFLLPSLFHLRLLWRKLLWHQVFFDVAFVIG 500
|||||
451 PHFALLMGLTGSLTGAGLCFLLPSLFHLRLLWRKLLWHQVFFDVAFVIG 500
|||||
501 GICSVSGFVHSLEGLIEAYRT 521
|||||
501 GICSVSGFVHSLEGKFAGLET 521

FIG. 61 (CONT.¹)

161/209

1 MDVLAEANGTFALNLLKTLGKDNSKNVFFSPMSMICALAMVYMGAKGNTA 50
|||||
1 MDVLAEANGTFALNLLKTLGKDNSKNVFFSPMSMICALAMVYMGAKGNTA 50
51 AQMAQILSFNKSGGGDIHQGFQSLLTEVNKTGTQYLLRVANRLFGEKSC 100
|||||
51 AQMAQILSFNKSGGGDIHQGFQSLLTEVNKTGTQYLLRVANRLFGEKSC 100
101 DFLSSFRDSCQKFYQAEMEELDFISAVEKSRKHINTWVAEKTGKIAELL 150
|||||
101 DFLSSFRDSCQKFYQAEMEELDFISAVEKSRKHINTWVAEKTGKIAELL 150
151 SPGSVDPLTRLVLVNAVYFRGNWDEQFDKENTEERLFKVSKNEEKPVQMM 200
|||||
151 SPGSVDPLTRLVLVNAVYFRGNWDGQFDKENTEERLFKVSKNEEKPVQMM 200
201 FKQSTFKKTYIGEIFTQILVLPYVGKELNMIIMLPDETTDLRTVEKELTY 250
|||||
201 FKQSTFKKTYIGEIFTQILVLPYVGKELNMIIMLPDETTDLRTVEKELTY 250

FIG. 62

163/209

```

1 MDVLAEANGTFALNLLKTLGKDNSKNVFFSPMSMSCALAMVYMGAKGNTA 50
  |||||
1 MDVLAEANGTFALNLLKTLGKDNSKNVFFSPMSMSCALAMVYMGAKGNTA 50

51 AQMAQILSFNKSGGGDIHQGFQSLLTEVNKTGTQYLLRVANRLFGEKSC 100
  |||||
51 AQMAQILSFNKSGGGDIHQGFQSLLTEVNKTGTQYLLRVANRLFGEKSC 100

101 DFLSSFRDSCQKFYQAEEMEELDFISAVEKSRKHINTWVAEKTGKIAELL 150
  |||||
101 DFLSSFRDSCQKFYQAEEMEELDFISAVEKSRKHINTWVAEKTGKIAELL 150

151 SPGSVDPLTRLVLVNAVYFRGNWDEQFDKENTEERLFKVSKNEEKPVQMM 200
  |||||
151 SPGSVDPLTRLVLVNAVYFRGNWDGQFDKENTEERLFKVSKNEEKPVQMM 200

201 FKQSTFKKTYIGEIFTQILVLPYVGKELNMIIMLPDETTDLRTVEKELTY 250
  |||||
201 FKQSTFKKTYIGEIFTQILVLPYVGKELNMIIMLPDETTDLRTVEKELTY 250

```

FIG. 63

164/209

FIG. 63 (CONT.¹)

165/209

157 VGYRVPAGSGPSLPPMPSLQEVDCGSPSSSEEEGVPGSRGSPATSPHLGR 206
:|||||
1 IGYRVPAGSGPSLPPMPSLQEVDCGSPSSSEEEGVPGSRGSPATSPHLGR 50

207 RRPLLRMSA AFCSL LAPERQV GRAAAALMQDRHTAAGQLVQDLLTQVRD 256
|||||
51 RRPLLRMSA AFCSL LAPERQV GRAAAALMQDRHTAAGQLVQDLLTQVRD 100

257 GORPQEEGIRQALSRARAMLSAELGPEKLVSPKRLEHVLEKSLHCSVLK 306
|||||
101 GORPQEEGIRQALSRARAMLSAELGPEKLVSPKRLEHVLEKSLHCSVLK 150

307 PLRPILAARLRRRLAADGSLGR LAEGLRLARAQGPAGFSGHLSLSPVEL 356
|||||
151 PLRPILAARLRRRLAADGSLGR LAEGLRLARAQGPAGFSGHLSLSPVEL 200

357 EQVRQKLLQLV R T Y S P S A Q V K R L L Q A C K L L Y M A L R T Q E G E G S G A D G F L P L 406
|||||
201 EQVRQKLLQLV R T Y S P S A Q V K R L L Q A C K L L Y M A L R T Q E G E G S G A D G F L P L 250

FIG. 64

166/209

407 LSLVLAHCDLPELLLEAEYMSLELPSLLTGE GGYLTSLASLALLSGL 456
|||||
251 LSLVLAHCDLPELLLEAEYMSLELPSLLTGE GGYLTSLASLALLSGL 300
457 GQAHTLPLSPVQELRRSLSLWEQRRLPATHCFQ 489
|||||
301 GQAHTLPLSPVQELRRSLSLWEQRRLPATHCFQ 333

FIG. 64 (CONT. ¹)

167/209

122 MSDASLRSTMERLVARGTFPVLVRTSACRSLFGPVDHEELSRELQARL 171
|||||
1 MSDASLRSTMERLVARGTFPVLVRTSACRSLFGPVDHEELSRELQARL 50

172 AELNAEDQNRWDYDFQQDMPLRGPGRLQWTEVDSVPAFYRETQVGRC 221
|||||
51 AELNAEDQNRWDYDFQQDMPLRGPGRLQWTEVDSVPAFYRETQVGRC 100

222 RLLAPRPVAVAVAVSPPLEPAAESLDGLEEAPQLPSVPVPAPASTPPP 271
|||||
101 RLLAPRPVAVAVAVSPPLEPAAESLDGLEEAPQLPSVPVPAPASTPPP 150

272 VPVLAPAPAPAPAPVAAAPVAVPVLAPAPAPAPAPAPVAAAPAP 321
|||||
151 VPVLAPAPAPAPVAAAPVAVAVLAPAPAPAPAPAPVAAAPAP 200

322 APAPAPAPAPAPAPDAAPQESAEQGANQGQEQEPLADQLHSGISGRP 371
|||||
201 APAPAPAPAPAPAPDAAPQESAEQGANQGQEQEPLADQLHSGISGRP 250

FIG. 65

168/209

372 AAGTAAASANGAAIKKLSGPLISDFFAKRKRSAPEKSSGSDVPAPCPSPSA 421
|||||
251 AAGTAAASANGAAIKKLSGPLISDFFAKRKRSAPEKSSGSDVPAPCPSPSA 300
422 APGVGSVEQTPRKRLR 437
|||||
301 APGVGSVEQTPRKRLR 316

FIG. 65 (CONT.¹)

169/209

1 MEPAAGSSMEPSADWLASAAARGLVEKVRQLLEAGADPNAPNSYGRRPIQ 50
|||||
1 MEPAAGSSMEPSADWLATAAARGRVEEVRALEAGALPNAPNSYGRRPIQ 50
|||||
51 VMMGSRVAE L L L L H G A E P N C A D P A T L T R P V H D A A R E G F L D T L V V L H R A 100
|||||
51 VMMGSRVAE L L L L H G A E P N C A D P A T L T R P V H D A A R E G F L D T L V V L H R A 100
|||||
101 GARLDV R D A W G R L P V D L A E E L G H R D V A R Y L R A A A G G T R G S N H A R I D A A E G 150
|||||
101 GARLDV R D A W G R L P V D L A E E L G H R D V A R Y L R A A A G G T R G S N H A R I D A A E G 150
151 PS 152
||
151 PS 152

FIG. 66

```

1 MREENKGMPSGGSGDEGLASAAARGLVEKVRQLLLEAGADPNGVNRFGRR 50
  | | | | | | | | | | | | | | | | | | | | | | | | | | | |
1 MREENKGMPSGGSGDEGLASAAARGLVEKVRQLLLEAGADPNGVNRFGRR 50

51 IQVMMMG SARVAELLLHGAEPNCADPATLTRPVHDAAREGEFDTLVVLH 100
  | | | | | | | | | | | | | | | | | | | | | | | | | | | |
51 IQVMMMG SARVAELLLHGAEPNCADPATLTRPVHDAAREGEFDTLVVLH 100

      .      .      .      .
101 RAGARLDVRDAWGRLPVDLAEEELGHRDVARYLRAAAG 137
   | | | | | | | | | | | | | | | | | | | | | |
101 RAGARLDVRDAWGRLPVDLAEEERGH RDVAGYLRTATG 137

```

FIG. 67

[illegible]

89. FIF.


```

251 ADESDPAFISKTNHMKLTKGLIKDALENIDPATQMMILNCIYFKGSWV 300
    | | | | | | | | | | | | | | | | | | | | | | | | | | | |
251 ADESDPAFISKTNHMKLTKGLIKDALENIDPATQMMILNCIYFKGSWV 300

301 NKFPVEMTHNHNRLNEREVVKVSMMQTKGNFLA..... 334
    | | | | | | | | | | | | | | | | | | | | | | | | | | | |
301 NKFPVEMTHNHNRLNEREVVKVSMMQTKGNFLAANDQELDCDILQLEYV 350

335 ..... SCLLFMGRVANPSRS 349
    | | | | | | | | | | | | | | | | | | | | | | | | | | | |
451 QATTVTTVGFMPLSTQVRFTVDRPFLFLIYEHRTSCLLFMGRVANPSRS 499

```

FIG. 68 (CONT.¹)

173/209

1 MDPARPLGLSILLFLTEAALGDAAQEPTGNNAEICLLPLDYGPCRALLL 50
|||||
1 MDPARPLGLSILLFLTEAALGDAAQEPTGNNAEICLLPLDYGPCRALLL 50

51 RYYDRYTQSCRQFLYGGCEGNANNFYTWEACDDACWRIEKVPKVCRLQV 100
|||||
51 RYYDRYTQSCRQFLYGGCEGNANNFYTWEACDDACWRIEKVPKVCRLQV 100

101 SVDDQCEGSTEKYFFNLSSMTCEKFFSGGCHRNRIENRFPDEATCMGFCA 150
|||||
101 SVDDQCEGSTEKYFFNLSSMTCEKFFSGGCHRNRIENRFPDEATCMGFCA 150

151 PKKIPSFYCSPKDEGLCSANVTRYFNPRTCDATYTGCGGNDNNFVT 200
|||||
151 PKKIPSFYCSPKDEGLCSANVTRYFNPRTCDATYTGCGGNDNNFVS 200

201 VQK.MRDCA 208
: | ||
201 REDCKRACA 209

FIG. 69

```

1 MDPARPLGLSILLFLTEAALGDAAQPTGNNAEICLLPLDYGPCRALLL 50
  |||||
1 MDPARPLGLSILLFLTEAALGDAAQPTGNNAEICLLPLDYGPCRALLL 50
  |||||
51 RYYYDRYTQSCRQFLYGGCEGNANNFYTWACDDACWRIEKVPKVCRLQV 100
  |||||
51 RYYYDRYTQSCRQFLYGGCEGNANNFYTWACDDACWRIEKVPKVCRLQV 100
  |||||
101 SVDDQCEGSTKEYFFNLSSMTCEKFFSGGCHRNRIENRFPDEATCMGFCA 150
  |||||
101 SVDDQCEGSTKEYFFNLSSMTCEKFFSGGCHRNRIENRFPDEATCMGFCA 150
  |||||
151 PKK.....KYRTCDAFTYTGCGGNDNNFVS 175
  |||:|||||
151 PKKIPSFYCSPKDEGLCSANVTRYFNPYRRTCDAFYTGCGGNDNNFVS 200
  |||||
176 REDCKRACAKALKKKKMPKILRFASIRKIRKKQF 210
  |||||
201 REDCKRACAKALKKKKMPKILRFASIRKIRKKQF 235
  |||||

```

FIG. 70


```

1 MASRLTLTLLLLLAGDRASSNP NATSSSSQDPESLQDRGEGKVATTVI 50
  |||||
1 MASRLTLTLLLLLAGDRASSNP NATSSSSQDPESLQDRGEGKVATTVI 50

51 SKMLFVEPILEVSSLPTTNSTNSATKITANTTDEPTTQPTTEPTTQPTI 100
  |||||
51 SKMLFVEPILEVSSLPTTNSTNSATKITANTTDEPTTQPTTEPTTQPTI 100

101 QPTQPTTQLPTDSPTQPTTGSCFCPGPVTLCSDLESHSTEAVLGDALVDFS 150
  |||||
101 QPTQPTTQLPTDSPTQPTTGSCFCPGPVTLCSDLESHSTEAVLGDALVDFS 150

1151 LKLYHAFSAMKKVETNMAFSPFSIASLLTQVLLGAGENTKTNLESILSYP 200
  |||||
1151 LKLYHAFSAMKKVETNMAFSPFSIASLLTQVLLGAGENTKTNLESILSYP 200

```

FIG. 72

177/209

201 KDFTCVHQALKGFTTKGVTSVSQIFHSPVDWRLLQSKSQEVLSQTSTKAR 250

|||||

201 KDFTCVHQALKGFTTKGVTSVSQIFHS..... 227

.

351 VERTYCFPELKYPPDLAIRDTFVNASRTLYSSSPRVLSNNSDANLELINT 400

|||||

228 PDLAIRDTFVNASRTLYSSSPRVLSNNSDANLELINT 264

401 WVAKNTNNKISRLLDSPDTRLVLLNAIYLSAKWKTFDPPKTRMEPFH 450

|||||

265 WVAKNTNNKISRLLDSPDTRLVLLNAIYLSAKWKTFDPPKTRMEPFH 314

451 FKNSVIKVPMMNSKKYPVAHFIDQTLKAKVGQLQLSHNLSLVLPQNLK 500

|||||

315 FKNSVIKVPMMNSKKYPVAHFIDQTLKAKVGQLQLSHNLSLVLPQNLK 364

FIG. 72 (CONT. ¹)

178/209

501 HRLEDMEQALSPSVFKAIMKLEMSKFQPTLLTLPRIKVTTSQDMLTIME 550
|||||
365 HRLEDMEQALSPSVFKAIMKLEMSKFQPTLLTLPRIKVTTSQDMLTIME 414

551 KLEFFDFSVDLNLCCGLTEDPDLQVSAMQHQTIVLELTETGVEAAAASV 600
|||||
415 KLEFFDFSVDLNLCCGLTEDPDLQVSAMQHQTIVLELTETGVEAAAASV 464

601 ARTLLVFEVQQPFLEVLWDQQHKFPVFMGRVYDPRA 636
|||||
465 ARTLLVFEVQQPFLEVLWDQQHKFPVFMGRVYDPRA 500

FIG. 72 (CONT. ²)

[illegible]

FIG. 73

251 EKFEWTRLDMMDEEEVSLPRFKLEESYDMESVLRLNLGMTDAFELGKA 300
| | | | | | | | | | | | | | | | | | | | | |
251 EKFEWTRLDMMDEEEVSLPRFKLEESYDMESVLRLNLGMTDAFELGKA 300

301 DFSGMSQTDLSLSKVVKHSFVEVN EEGTEAAAATAAIMMRCAREVP RFC 350
| | | | | | | | | | | | | | | | | | | | | |
301 DFSGMSQTDLSLSKVVKHSFVEVN EEGTEAAAATAAIMMRCAREVP RFC 350

351 ADHPFLFFIQH 361
| | | | | | | | | |
351 ADHPFLFFIQH 361

FIG. 73 (CONT. ¹)

182/209

FIG. 75

```

1 MAALMTPGTGAPPAPGDFSGEGSQGLPDPSPPEPKQLPELIRMKRDGGRLS 50
  |||||
1 MAALMTPGTGAPPAPGDFSGEGSQGLPDPSPPEPKQLPELIRMKRDGGRLS 50

51 EADIRGFVAAVNGSAQGAQIGAMLMAIRLRGMDLEETSVLTQALAQSGQ 100
  |||||
51 EADIRGFVAAVNGSAQGAQIGAMLMAIRLRGMDLEETSVLTQALAQSGQ 100

101 QLEWPEAWRQQLVDKXSTGGVGDKVSLVLAPALAACGCKVPMISGRGLGH 150
  |||||
101 QLEWPEAWRQQLVDKXSTGGVGDKVSLVLAPALAACGCKVPMISGRGLGH 150

151 TGGTLDKLESIPGFNVIQSPEQMOVLLDQAGCCIVGQSEQLVPADGILYA 200
  |||||
151 TGGTLDKLESIPGFNVIQSPEQMOVLLDQAGCCIVGQSEQLVPADGILYA 200

201 ARDVTATVDSLPLITASILSKKLVEGLSALVVDVKFEGAAVFPNQEARE 250
  |||||
201 ARDVTATVDSLPLITASILSKKLVEGLSALVVDVKFEGAAVFPNQEARE 250

251 LAKTLVGVGASLGLRVAAALTAMDKPLGRCVGHAEVEEALLCMDGAGPP 300
  |||||
251 LAKTLVGVGASLGLRVAAALTAMDKPLGRCVGHAEVEEALLCMDGAGPP 300

```

FIG. 76

184/209

301 DLRDLVTTLGGALLWLSGHAGTQAQGAARVAAALDDGSALGRFERMLAAQ 350
|||||
301 DLRDLVTTLGGALLWLSGHAGTQAQGAARVAAALDDGSALGRFERMLAAQ 350
351 GVDPGALARALCSGSPAERRQLLPRAREQEELLAPADGERSGESPSFRLRH 400
|||||
351 GVDPGALARALCSGSPAERRQLLPRAREQEELLAPAD..... 386
401 PLPFRPRPFPSRPLSAPLPAGTVELVRALPLALVLHELGAAGRSRAGEPL 450
||||| GTVELVRALPLALVLHELGAAGRSRAGEPL 415
387
451 RLGVGAEILLVDVGQRLRRGTPWLRVHRDGPALSGPQSRALQEALVLSdra 500
|||||
416 RLGVGAEILLVDVGQRLRRGTPWLRVHRDGPALSGPQSRALQEALVLSdra 465
501 PFAAPSPFAELVLPPQQ 517
|||||
466 PFAAPSPFAELVLPPQQ 482

FIG. 76 (CONT.¹)

FIG. 77

1 MSDASLRSTSTMERLVARGTFPVLVRTSACRSLEFGPVDHEELSRELQARL 50
 1 MSDASLRSTSTMERLVARGTFPVLVRTSACRSLEFGPVDHEELSRELQARL 50
 51 AELNAEDQNRWDYDFQQDMPLRGPGRLQWTEVDSVPAFYRETVQ 96
 51 AELNAEDQNRWDYDFQQDMPLRGPGRLQWTEVDSVPAFYRETVQ 96

187/209

301 DGTPYVTVLKTAGANTTDKELEVLSLHNVTFFEDAGEYTCLAGNSIGFSHH 350
|||||
301 DGTPYVTVLKTAGANTTDKELEVLSLHNVTFFEDAGEYTCLAGNSIGFSHH 350
|||||
351 SAWLVVLPAAEEELVEADEAGSVYAGILSYGVGFFLFILVVAAVTXCRLRS 400
|||||
351 SAWLVVLPAAEEELVEADEAGSVYAGILSYGVGFFLFILVVAAVTXCRLRS 400
|||||
401 PPKKGLGSPTVHKISRFPPLKRQVSLESNASMSSNTPLVRIARLSSGEGPT 450
|||||
401 PPKKGLGSPTVHKISRFPPLKRQVSLESNASMSSNTPLVRIARLSSGEGPT 450
|||||
451 LANVSELELPADPKWELSRARLTTLGKPLGEGCFGQVVMMAEIGIDKDRAA 500
|||||
451 LANVSELELPADPKWELSRARLTTLGKPLGEGCFGQVVMMAEIGIDKDRAA 500
|||||
501 KPVTVAVKMLKDDATDKDLSDLVSEMEMMKMIGKHKNIINLL 542
|||||
501 KPVTVAVKMLKDDATDKDLSDLVSEMEMMKMIGKHKNIINLL 542

FIG. 78 (CONT. ¹)


```

1  MNQLRGKKSCHTGLGRSAGWNIPIGLLYCDLPEPRKPLEKAVANFFSGSC  50
   |||||
1  MNQLRGKKSCHTGLGRSAGWNIPIGLLYCDLPEPRKPLEKAVANFFSGSC  50

51  APCADGTDFPQLCQLCPGCGCSTLNQYFGYSGAFKCLKDGAGDVAFKHS  100
   |||||
51  APCADGTDFPQLCQLCPGCGCSTLNQYFGYSGAFKCLKDGAGDVAFKHS  100

101  TIFENLANKADRDQYELLCLDNTRKPVDEYKDKCHLAQVPSHTVVARSMSG  150
   |||||
101  TIFENLANKADRDQYELLCLDNTRKPVDEYKDKCHLAQVPSHTVVARSMSG  150

151  KEDLIWELLNQAQEHFGKDKSKEFQLFSSPHGKDLLFKDSAHGFLKVP  200
   |||||
151  KEDLIWELLNQAQEHFGKDKSKEFQLFSSPHGKDLLFKDSAHGFLKVP  200

201  MDAKMYLGYEYVTAIRNLREGTCPEAPTDECKPVKWCALSHHERLKCDEW  250
   |||||
201  MDAKMYLGYEYVTAIRNLREGTCPEAPTDECKPVKWCALSHHERLKCDEW  250

```

FIG. 80

190/209

251	SVNSVGKIECVSAETTEDCIAKIMNGEADAMSLDGGFVYIAGKCGLVPVL	300
251	SVNSVGKIECVSAETTEDCIAKIMNGEADAMSLDGGFVYIAGKCGLVPVL	300
301	AENYNKSDNCEDTPEAGYFAVAVVKKSASDLTWDNLKGKKSCHTAVGRTA	350
301	AENYNKSDNCEDTPEAGYFAVAVVKKSASDLTWDNLKGKKSCHTAVGRTA	350
351	GWNIPMGLLYNKINH.....CEP	368
351	GWNIPMGLLYNKINCRFEFFSEGCAPGSKKDSLCKLCMGSGLNLCEP	400
369	NNKEGYGYTGAFRCLVEKGDVAFVKHQTVPQNTGGKNPDPWAKNLNEKD	418
401	NNKEGYGYTGAFRCLVEKGDVAFVKHQTVPQNTGGKNPDPWAKNLNEKD	450
419	YELLCLDGTRKPVVEEYANCHLARAPNHAVVTRKDKACVHKILRQQQHLF	468
451	YELLCLDGTRKPVVEEYANCHLARAPNHAVVTRKDKACVHKILRQQQHLF	500

FIG. 80 (CONT.¹)

469 GSNVTDCSGNFC LFRSETKD L LFRDDTVCLAKLHNRNTYEKYLGE EYVKA 518
|||||
501 GSNVTDCSGNFC LFRSETKD L LFRDDTVCLAKLHNRNTYEKYLGE EYVKA 550
.
519 VGNLRKCSTSS LLEACTFRRP 539
|||||
551 VGNLRKCSTSS LLEACTFRRP 571

FIG. 80 (CONT. ²)

193/209

37 NGFQVDNYGTQLNAVNNSLTPQSTKVPSLFEFHGPSWCLTPADRGGLCRAN 86
|||||
180 NGFQVDNYGTQLNAVNNSLTPQSTKVPSLFEFHGPSWCLTPADRGGLCRAN 229
87 ENRFYNSVIGKCRPFKYSGCGGNENNFTSKQECLRACKKGFIQRISKGG 136
|||||
230 ENRFYNSVIGKCRPFKYSGCGGNENNFTSKQECLRACKKGFIQRISKGG 279
137 LIKTKRKRKKQVRVKIAYEEIFVKNM 161
|||||
280 LIKTKRKRKKQVRVKIAYEEIFVKNM 304

FIG. 82

```

13 RPILTIITLEDSSGNLLGRDSFEVRVCASPGRDPRTTE 50
   | | | | | | | | | | | | | | | | | | | | | |
246 RPILTIITLEDSSGNLLGRDSFEVRVCACPGRRRTTE 283

   .
51 ENFRKKEVLCPELPPGSAKRALPTCTASPPQKKKPLDGEYFTLKIRGRK 100
   | | | | | | | | | | | | | | | | | | | | | |
284 ENFRKKEVLCPELPPGSAKRALPTCTASPPQKKKPLDGEYFTLKIRGRK 333

   .
101 RFEMFRELNEALELKDAHATEESGDSRAHSSYLKTKKGQSTSRHKKTMVK 150
   | | | | | | | | | | | | | | | | | | | | | |
334 RFEMFRELNEALELKDAHATEESGDSRAHSSYLKTKKGQSTSRHKKTMVK 383

   .
151 KVGPDSD 157
   | | | | |
384 KVGPDSD 390

```

FIG. 83

```

13 RPILTIITLEDSSGNLLGRDSFEVRVCASGRDPRTTEE 50
|||||
246 RPILTIITLEDSSGNLLGRDSFEVRVCACGRDRRTTEE 283

51 ENFRKKEVLCPELPPGSAKRALPTCTASPPQKKKPLDGEYFTLKIRGRK 100
|||||
284 ENFRKKEVLCPELPPGSAKRALPTCTASPPQKKKPLDGEYFTLKIRGRK 333

101 RFEMFRELNEALELKDAHATEESGDSRAHSSYLKTKKGQSTSRHKKTMTVK 150
|||||
334 RFEMFRELNEALELKDAHATEESGDSRAHSSYLKTKKGQSTSRHKKTMTVK 383

151 KVGPDSD 157
|||||
384 KVGPDSD 390

```

FIG. 84

196/209

```

1 MGAASGQGRWPLSPPLMLSLVLLQSPAPALDPGLQPGNFSPDEAG 50
  |||||
1 MGAASGQGRWPLSPPLMLSLVLLQSPAPALDPGLQPGNFSPDEAG 50

51 AQLFAESYNSSAEVVFQSTVASWAHDTNITEENARRQEEAALVSQEEFAE 100
  |||||
51 AQLFAESYNSSAEVVFQSTVASWAHDTNITEENARRQEEAALVSQEEFAE 100

101 VWGKKAKELYESIWQNFTDSKLRRIIGSIRTLGPANLPLAQRQQYNSLLS 150
  |||||
101 VWGKKAKELYESIWQNFTDSKLRRIIGSIRTLGPANLPLAQRQQYNSLLS 150

151 NMSRIYSTGKVCFPNKTATCWSLDPELTNILASSRSYAKLLFAWEGWHDA 200
  |||||
151 NMSRIYSTGKVCFPNKTATCWSLDPELTNILASSRSYAKLLFAWEGWHDA 200

201 VGIPLKPLYQDFTAISNEAYRQDDFSDTGAFWRSWYESPSFEESLEHIYH 250
  |||||
201 VGIPLKPLYQDFTAISNEAYRQDDFSDTGAFWRSWYESPSFEESLEHIYH 250

```

FIG. 85

197/209

251	QLEPLYNLHAYVRRALHRRYGDKYVNLRGPIPAHLLGDMWAQSWENIYD	300
251	QLEPLYNLHAYVRRALHRRYGDKYVNLRGPIPAHLLGDMWAQSWENIYD	300
301	MVVPFPDKPNLDVTSTMVQKGWNATHMFRVSEEFFTSGLSPMPPEFWAE	350
301	MVVPFPDKPNLDVTSTMVQKGWNATHMFRVSEEFFTSGLSPMPPEFWAE	350
351	SMLEKPTDGREVVCHASAWDFYNRKDFRIKQCTRVTEQATVHHHEMGHV	400
351	SMLEKPTDGREVVCHASAWDFYNRKDFRIKQCTRVTEQATVHHHEMGHV	400
401	QYYLQYKDLHVSLRRGANPGFHEAIGDVLALSVSTPAHLHKIGLLDHVTN	450
401	QYYLQYKDLHVSLRRGANPGFHEAIGDVLALSVSTPAHLHKIGLLDHVTN	450
451	DIESDINYLKMALEKIAFLPFGYLVLDQWRWGVFSGRTPPSRYNFDWWYL	500
451	DIESDINYLKMALEKIAFLPFGYLVLDQWRWGVFSGRTPPSRYNFDWWYL	500

FIG. 85 (CONT.¹)

198/209

501 RTKYQGICPPVARNETHFDAGAKFHIPNVTPYIRYFVSFVLQFHFQALC 550
|||||
501 RTKYQGICPPVARNETHFDAGAKFHIPNVTPYIRYFVSFVLQFHFQALC 550
|||||

551 KEAGHQGPLHQCDIYQSAQAGAKLKQVLQAGCSRQWQEVVKDLVGSDALD 600
|||||
551 KEAGHQGPLHQCDIYQSAQAGAKLKQVLQAGCSRQWQEVVKDLVGSDALD 600
|||||

601 AKALLEYFQVPVSQWLEEQNQRNGEVLGWPENQWRPPLPDNYPEGIDLETD 650
|||||
601 AKALLEYFQVPVSQWLEEQNQRNGEVLGWPENQWRPPLPDNYPEGIDLETD 650
|||||

651 EAKADRFVEEYDRTAQVLLNEYAEANWQYNTNITIEGSKILLEKSTEVSN 700
|||||
651 EAKADRFVEEYDRTAQVLLNEYAEANWQYNTNITIEGSKILLEKSTEVSN 700
|||||

701 HTLKYGTRAKTFDVSNFQNSSIKRIKKLQNLDRVLPKPKELEEYNQIILL 750
|||||
701 HTLKYGTRAKTFDVSNFQNSSIKRIKKLQNLDRVLPKPKELEEYNQIILL 750
|||||

751 DMETTYSLSNICYTNGTCMPLEPDLTNMMATSRKYEEELLWAWKSWRDKVG 800
|||||
751 DMETTYSLSNICYTNGTCMPLEPDLTNMMATSRKYEEELLWAWKSWRDKVG 800
|||||

FIG. 85 (CONT. ²)

199/209

```

      . . . . .
801 RAILPEFPKYVEFSNKIAKLNQYTDAGDSWRSLYESDNLEQDLEKLYQEL 850
      |||||
801 RAILPEFPKYVEFSNKIAKLNQYTDAGDSWRSLYESDNLEQDLEKLYQEL 850

      . . . . .
851 QPLYNLHAYVRRSLHRHYGSEYINLDGPIPAHLLGNMWAQTWSNIYDLV 900
      |||||
851 QPLYNLHAYVRRSLHRHYGSEYINLDGPIPAHLLGNMWAQTWSNIYDLV 900

      . . . . .
901 APFPSAPNIDATEAMIKQGWTPRRIFKEADNFFTSGLLLPVPPEFWNKSM 950
      |||||
901 APFPSAPNIDATEAMIKQGWTPRRIFKEADNFFTSGLLLPVPPEFWNKSM 950

      . . . . .
951 LEKPTDGREVVCHPSAWDFYNGKDFRIKQCTSVNMEDLVIAHHEMIGHIQY 1000
      |||||
951 LEKPTDGREVVCHPSAWDFYNGKDFRIKQCTSVNMEDLVIAHHEMIGHIQY 1000

      . . . . .
1001 FMQYKDLPVTFREGANPGFHEAIGDIMALSVSTPKHLYSLNLLSTEGSGY 1050
      |||||
1001 FMQYKDLPVTFREGANPGFHEAIGDIMALSVSTPKHLYSLNLLSTEGSGY 1050

```

FIG. 85 (CONT. ³)

200/209

1051 EYDINFLMKMALDKIAFIPFSYLIDQWRWRVFDGSITKENYNQEWWSLRL 1100
|||||
1051 EYDINFLMKMALDKIAFIPFSYLIDQWRWRVFDGSITKENYNQEWWSLRL 1100
1101 KYQGLCPPVPRSQGFDPGSKFHV PANVPYRVYFVSFIIQFQFHEALCRA 1150
|||||
1101 KYQGLCPPVPRSQGFDPGSKFHV PANVPYRVYFVSFIIQFQFHEALCRA 1150
1151 AGHTGPLHKCDIYQSK EAGKLLADAMKLGYSKPWPEAMKLLITGQPNMSAS 1200
|||||
1151 AGHTGPLHKCDIYQSK EAGKLLADAMKLGYSKPWPEAMKLLITGQPNMSAS 1200
1201 AMMNYFKPLTEWLVTENRRRHGETL GWPEYNWAPNT 1235
|||||
1201 AMMNYFKPLTEWLVTENRRRHGETL GWPEYNWAPNT 1235

FIG. 85 (CONT. ⁴)

201/209

1 MTMTLHTKASGMALLHQIQGNELEPLNRPQLKMPMERALGEVYVDNSKPT 50
|||||
1 MTMTLHTKASGMALLHQIQGNELEPLNRPQLKMPMERALGEVYVDNSKPT 50

51 VFNYPEGAAYEFNAAAAAASAPVYQGSGIAYGPGSEAAAFSANSLSGA 100
|||||
51 VFNYPEGAAYEFNAAAAAASAPVYQGSGIAYGPGSEAAAFSANSLSGA 100

101 FPQLNSVSPSPMLLLHPPPLSPFLHPHGQQVPYYLENEPSAYAVRDTGP 150
|||||
101 FPQLNSVSPSPMLLLHPPPLSPFLHPHGQQVPYYLENEPSAYAVRDTGP 150

151 PAFYRSNSDNRRQNGRERLSSSNEKGNMIMESAKETRYCAVCNDYASGYH 200
|||||
151 PAFYRSNSDNRRQNGRERLSSSNEKGNMIMESAKETRYCAVCNDYASGYH 200

201 YGVWSCEGCKAFFKRSIQGHNDYMCNATNQCTIDKNRRKSCQACRLRKCY 250
|||||
201 YGVWSCEGCKAFFKRSIQGHNDYMCNATNQCTIDKNRRKSCQACRLRKCY 250

FIG. 86


```

1 MATLLRSKLTNVATSVSNKSOAKVSGMFARMGFQAATDEEAVGFAHCDDL 50
  |||||
1 MATLLRSKLTNVATSVSNKSOAKVSGMFARMGFQAATDEEAVGFAHCDDL 50

51 DFEHRQGLQMDILKSEGEPCGDEGAEPVEGDIHYQRGGAPLPPSGSKDQ 100
  |||||
51 DFEHRQGLQMDILKSEGEPCGDEGAEPVEGDIHYQRGGAPLPPSGSKDQ 100

101 AVGAGGEFGGHDKPKITAEAGWNVTNAIQGMFVLGLPYAILHGGYLGFL 150
  |||||
101 AVGAGGEFGGHDKPKITAEAGWNVTNAIQGMFVLGLPYAILHGGYLGFL 150

151 LIIFAAVVCCYTGKILIACLYEENEDGEVVRVRDSYVAIANACCAPRFT 200
  |||||
151 LIIFAAVVCCYTGKILIACLYEENEDGEVVRVRDSYVAIANACCAPRFT 200

201 LGGRVVNVVAQIIELVMTCILYVVVSGNLMYNSFPGLPVSKSWSIIATAV 250
  |||||
201 LGGRVVNVVAQIIELVMTCILYVVVSGNLMYNSFPGLPVSKSWSIIATAV 250

```

FIG. 87

204/209

```

251  LLPCAFLKNLKAVSKFSLCTLAHFVINILVIAYCLSRARDWAEKVKFY 300
    |||||
251  LLPCAFLKNLKAVSKFSLCTLAHFVINILVIAYCLSRARDWAEKVKFY 300

301  IDVKKFPISIGIIVFSYTSQIFLPSLEGNMQQPSEFFHCMNWNTHIAACVL 350
    |||||
301  IDVKKFPISIGIIVFSYTSQIFLPSLEGNMQQPSEFFHCMNWNTHIAACVL 350

351  KGLFALVAYLTWADETKEVITDNLPGSIRAVVNFLVAKALLSYPLPFFA 400
    |||||
351  KGLFALVAYLTWADETKEVITDNLPGSIRAVVNFLVAKALLSYPLPFFA 400

401  AVEVLEKSLFQEGSRAFFPACYGGDGRLLKSWGLTLRCALVVFLLMAI 448
    |||||
401  AVEVLEKSLFQEGSRAFFPACYGGDGRLLKSWGLTLRCALVVFLLMAI 448

```

FIG. 87 (CONT.¹)

205/209






FIG. 88

206/209



89B



89A

FIG. 89

207/209




FIG. 90

208/209





FIG. 91A

209/209



Liver RT+
Liver RT-
Skin RT+
Skin RT-
Thyroid RT+
Thyroid RT-
Bone marrow
RT+
Bone marrow RT-
Salivary gland
RT+
Salivary gland
RT-
Lung RT+
Lung RT-
Heart RT+
Heart RT-
Thymus RT+
Thymus RT-
Spleen RT+
Spleen RT-
Brain RT+
Brain RT-

FIG. 91B

SEQUENCE LISTING

<110> COMPUGEN LTD

<120> VARIANTS OF ALTERNATIVE SPLICING

<130> 1293240-COMPUGEN

<140>

<141>

<150> IL132978

<151> 1999-11-17

<150> IL133455

<151> 1999-12-10

<160> 174

<170> PatentIn Ver. 2.1

<210> 1

<211> 2567

<212> DNA

<213> Homo sapiens

<400> 1

```

aattttcagc tgttctttgc tcaataataa cttttttatc accaagatat ctctctaagt 60
ttttgacata ttcttcattt gttttgataa aagttttctt attttcttag aaaaataagt 120
tactaaaagt catatatcat tgtatatctt caaaatattg cttaaaacta ggacttgtat 180
ttaaatgttt tttcttctta aagacaattt gcaggtgcct caggaaccct gaagctgggc 240
tgagccatga tgctgctgcc agaaccctg cagagggcct ggtttcagga gactcagagt 300
cctctgtgaa aaagcccttg gagagcgccc cagcagggct gcacttggct cctgtgagga 360
aggggctcag gggctctggc ccctccgctt gggccgggct gggagccagg cgggcgggctg 420
ggctgcagca atggaccgtg agctggccca gccgcgctcc gtgctgagcc tgcctgtcgt 480
ctgtggccat gcccatcatg ggctcctcgg tgtacatcac ggtggagctg gccattgctg 540
tgctggccat cctgggcaat gtgctggtgt gctgggccgt gtggctcaac agcaacctgc 600
agaacgtcac caactacttt gtggtgtcac tggcggcggc cgacatcgca gtgggtgtgc 660
tcgccatccc ctttgccatc accatcagca ccgggttctg cgctgcctgc cacggctgcc 720
tcttcattgc ctgcttcgtc ctggtcctca cgcagagctc catcttcagt ctctggcca 780
tcgccattga ccgtacatt gccatccgca tcccgcctcg gtacaatggc ttggtgaccg 840
gcacgagggc taagggcatc attgccatct gctgggtgct gtcgtttgcc atcgccctga 900
ctcccatgct aggttgaac aactgcggtc agccaaagga gggcaagaac cactcccagg 960
gctgcgggga gggccaagtg gcctgtctct ttgaggatgt ggtcccatg aactacatgg 1020
tgtacttcaa cttctttgcc tgtgtgctgg tgccctgct gctcatgctg ggtgtctatt 1080
tgcggtatct cctggcgggc cgacgacagc tgaagcagat ggagagccag cctctgccgg 1140
gggagcgggc acggtccaca ctgcagaagg aggtccatgc tgccaagtca ctggctgccc 1200
ctacacatca tcaactgctt cactttcttc tgccccgact gcagccacgc ccctctctgg 1260
ctcatgtacc tggccatcgt cctctccac accaattcgg ttgtgaatcc ctctcatctac 1320
gcctaccgta tccgcgagtt ccgccagacc ttccgcaaga tcattcgag ccacgtcctg 1380
aggcagcaag aacctttcaa ggcagctggc accagtgcct gggctctggc agctcatggc 1440
agtgcaggag agcaggtcag cctccgtctc aacggccacc cgccaggagt gtgggccaac 1500
ggcagtgctc cccaccctga gcggaggccc aatggctatg ccctggggct ggtgagtggg 1560
gggagtgcct aagagtccca ggggaacacg ggcctcccag acgtggagct ccttagccat 1620
gagctcaagg gagtgtgccc agagccccct ggcctagatg accccctggc ccaggatgga 1680
gcaggagtgt cctgatgatt catggagttt gcccttctct aagggaagga gatctttatc 1740
tttctggttg gcttgaccag tcacgttggg agaagagaga gagtgccagg agaccctgag 1800
ggcagccggt tctacttttg gactgagaga agggagcccc aggtggagc agcatgaggc 1860
ccagcaagaa gggcttgggt tctgaggaag cagatgtttc atgctgtgag gccttgcacc 1920
aggtgggggc cacagcacca gcagcatctt tgctgggcag ggccagccc tccactgcag 1980
aagcatctgg aagcaccacc ttgtctccac agagcagctt gggcacagca gactggcctg 2040

```

gccctgagac	tggggagtg	ctccaacagc	ctcctgccac	ccacacacca	ctctccctag	2100
actctcctag	ggttcaggag	ctgctgggcc	cagaggtgac	atttgacttt	tttccaggaa	2160
aaatgtaagt	gtgaggaaac	cctttttatt	ttattacctt	tcactctctg	gctgctgggt	2220
ctgccgtcgg	tctgtctgct	aacctggcac	cagagcctct	gcccggggag	cctcaggcag	2280
tctctctctg	ctgtcacagc	tgccatccac	ttctcagtc	cagggccatc	tcttgagtg	2340
acaaagctgg	gatcaaggac	agggagtgtg	aacagagcag	tgccagagca	tgggccagg	2400
tcccagggga	gaggttgggg	ctggcaggcc	actggcatgt	gctgagtagc	gcagagctac	2460
ccagtgagag	gccttgtcta	actgcctttc	cttctaaagg	gaatgttttt	ttctgagata	2520
aaataaaaac	gagccacatc	gtgttttaag	cttgtccaaa	tgagaaa		2567

<210> 2

<211> 2562

<212> DNA

<213> Homo sapiens

<400> 2

gggccgacta	cagagaaggg	taatcgggtg	tccccggcgc	cgccccgggc	cctgagggct	60
ggctagggtc	caggccgggg	gggacgggac	agacgaacca	gccccgtgta	ggaagcgcca	120
caatgccccg	ctacggagcg	tactccgcc	agagctgccc	caggtccggc	cgggagcagg	180
gacaagacgg	gaccgccgga	gccccgggac	tctttggat	gggcctgggt	ctggcgctgg	240
cgctggcgct	ggcgctggct	ctgtctgact	ctcgggttct	ctgggctccg	gcagaggctc	300
acctcttttc	tccccaaaggc	catcctgcca	ggttacatcg	catagtgcgc	cggctccgag	360
atgtcttttg	gtgggggaac	ctcacctgcc	caatctgcaa	aggtctattc	accgcatca	420
acctcgggct	gaagaaggaa	cccaatgtgg	ctcgcgtggg	ctccgtggcc	atcaagctgt	480
gcaatctgct	gaagatagca	ccacctgccg	tgtgccaatc	cattgtccac	ctctttgagg	540
atgacatggt	ggaggtgtgg	agacgctcag	tgtgagccc	atctgaggcc	tgtggcctgc	600
tcttgggctc	cacctgtggg	cactgggaca	ttttctcatc	ttggaacatc	tctttgccta	660
ctgtgccgaa	gcccgcctccc	aaaccccccta	gccccccagc	cccagggtgcc	cctgtcagcc	720
gcacctctct	cctcactgac	ctgcactggg	atcatgacta	cctggagggc	acggacctg	780
actgtgcaga	cccactgtgc	tgcgcgggg	gttctggcct	gcccgcgcga	tcccggccag	840
gtgccggata	ctggggcgaa	tacagcaagt	gtgacctgcc	cctgaggacc	ctggagagcc	900
tgttgagtgg	gctggggccca	gcccggccctt	ttgatatggt	gtactggaca	ggagacatcc	960
ccgcacatga	tgtctggcac	cagactcgtc	aggaccaact	gcggggccctg	accaccgtca	1020
cagcacttgt	gaggaagttc	ctggggccag	tgccagtgtg	ccctgctgtg	ggttaaccatg	1080
aaagcacacc	tgtcaatagc	ttccctcccc	ccttcattga	gggcaaccac	tcctcccgtc	1140
ggctctatga	agcgatggcc	aaggcttggg	agccctggct	gcctgccgaa	gccctgcgca	1200
ccctcagaat	tgggggggttc	tatgctcttt	ccccataccc	cggctctccgc	ctcatctctc	1260
tcaatatgaa	tttttgttcc	cgtgagaact	tctggctctt	gatcaactcc	acggatcccc	1320
caggacagct	ccagtggctg	gtgggggagc	ttcaggctgc	tgaggatcga	ggagacaaa	1380
tgcataata	tggccacatt	ccccagggc	actgtctgaa	gagctggagc	tggattatt	1440
accgaattgt	agccagggtat	gagaacaccc	tggctgtca	gttctttggc	cacactcatg	1500
tggatgaatt	tgaggtcttc	tatgatgaag	agactctgag	ccggcccgctg	gctgtagcct	1560
tcttggcacc	cagtgcact	acctacatcg	gccttaatcc	tggtagtgta	ggcagaagg	1620
agcctccctt	atcctggagt	tgggtgggata	ggggaaggag	gttggagcca	gagcctgcaa	1680
agcatgggca	ggatgtgtgg	ccccctccctg	gagttaccct	tgtctcttgc	ccctccagtc	1740
agccccacat	ccttgcagg	taccgtgtgt	accaaataga	tggaaactac	tccgggagct	1800
ctcacgtggt	cctggaccat	gagacctaca	tctgaatct	gacccaggca	aacataccgg	1860
gagccatacc	gcactggcag	cttctctaca	gggctcgaga	aacctatggg	ctgccaaca	1920
cactgcctac	cgctggcac	aacctggtat	atcgcatgcg	ggcgacatg	caacttttcc	1980
agaccttctg	gtttctctac	cataagggcc	accacccctc	ggagccctgt	ggcacgcct	2040
gccgtctggc	tactctttgt	gcccagctct	ctgcccgtgc	tgacagccct	gctctgtgcc	2100
gccacctgat	gccagatggg	agcctcccag	aggcccagag	cctgtggcca	aggccactgt	2160
tttgctaggg	ccccagggcc	cacatttggg	aaagtctctg	atgtaggaaa	gggtgaaaa	2220
gcccacatgc	tgtgtgtggt	caaccaggca	agatcatccg	gtgaaagaa	cagtccctgg	2280
gcccacagga	tggcggggaa	acaggacctt	ctcctttcct	ggagctggtt	tagctggata	2340
tgggaggggg	tttggctgcc	tgtgcccagg	agctagactg	ccttgaggct	gctgtccttt	2400
cacagccatg	gagtagaggc	ctaagttgac	actgccttgg	gcagacaaga	caggagctgt	2460
cgccccaggc	ctgtgctgcc	cagccaggaa	ccctgtactg	ctgctgcgac	ctgatgctgc	2520
cagtctgtta	aaataaagat	aagagacttg	gactccaaaa	aa		2562

<210> 3
<211> 2158
<212> DNA
<213> Homo sapiens

<400> 3
ctgctgctcc tgggggttcc gctgggtgagc ttggagtgcaa cacttttcgat tccaccttgg 60
gaagccccca aggagcataa gtacaaagct gaagagcaca cagtgcgttct cactgtcacc 120
ggggagccct gccacttccc cttccagtac caccggcagc tgtaccacaa atgtaccac 180
aagggcgggc caggccctca gccctggtgt gctaccaccc ccaactttga tcaggaccag 240
cgatggggat actgttttga gcccaagaaa gtgaaagacc actgcagcaa acacagcccc 300
tgccagaaag gagggacctg tgtgaacatg ccaagcggcc cccactgtct ctgtccacaa 360
cacctcactg gaaaccactg ccagaaagag aagtgccttg agcctcagct tctccggttt 420
ttccacaaga atgagatatg gtatagaact gagcaagcag ctgtggccag atgccagtgc 480
aagggctctg atgcccactg ccagcggctg gccagccagg cctgccgcac caaccctgtc 540
ctccatgggg gtcgctgcct agaggtggag ggccaccgcc tgtgccactg cccggtgggc 600
tacaccggac ccttctgcga cgtggacacc aaggcaagct gctatgatgg ccgcgggctc 660
agctaccgcg gcctggccag gaccacgctc tcgggtgcgc cctgtcagcc gtgggcctcg 720
gaggccacct accggaacgt gactgccgag caagcgcgga actggggact gggcgggcac 780
gccttctgcc ggaaccggga caacgacatc cgcccgtggt gcttcgtgct gaaccgcgac 840
cggctgagct gggagtactg cgacctggca cagtgcaga ccccaacca ggcggcgcc 900
ccgaccccg ggtcccttag gttcatgtc ccactcatgc ccgcgcagcc ggcaccgccc 960
aagcctcagc ccacgaccgc gaccccgct cagtcccaga ccccgggagc cttgccggcg 1020
aagcgggagc agccgccttc cctgaccagg aacggcccac tgagctgcgg gcagcggctc 1080
cgcaagagtc tgtcttcgat gaccgcgctc gttggcgggc tgggtggcgt acgcggggcg 1140
caccctaca tcgcgcgct gtactggggc cacagtttct gcgcggcag cctcatcgcc 1200
ccctgctggg tgcctgacggc cgctcactgc ctgcaggacc ggcccgcacc cgaggatctg 1260
acggtgggtg tcggccagga acgcgtaac cacagctgtg agccgtgcca gacgttgcc 1320
gtgcgctcct accgcttgca cgaggccttc tcgcccgtca gctaccagca cgacctggct 1380
ctgttgccgc ttcaggagga tgcggacggc agctgcgcgc tctgtcgc ttaacttcag 1440
ccggtgtgcc tgccaagcgg ccgcgcgca ccctccgaga ccacgctctg ccagggtggc 1500
ggctggggcc accagttcga ggctccttg cctatgaaat tgaattaatg gcacctcnct 1560
tccttcgggc ttgctgcgag agaggaaggg catgagtggg tttacaagcg cctggagcag 1620
ctttgtccat cgtccggggc gcaagcgttg tcagatgggg tgtgaagaag gcgctctgtg 1680
ttcgcagggg cggaggaata tgccagcttc ctgcaggagg cgcaggtacc gttcctctcc 1740
ctggagcgct gctcagcccc ggacgtgcac ggatcctcca tctccccg catgctctgc 1800
gcagggttcc tcgaggggcg caccgatgcg tgccagggtg attccggagg cccgctggtg 1860
tgtgaggacc aagctgcaga gcgcgggctc accctgcaag gcatcatcag ctgggggatcg 1920
ggctgtgggt accgcaacaa gccaggcgtc tacacbgatg tggcctacta cctggcctgg 1980
atccgggagc acaccgtttc ctgattgctc agggactcat ctttccctcc ttgggtgatc 2040
cgcagtgaga gagtggctgg ggcattggaag gcaagattgt gtccattcc cccagtgcgg 2100
ccagctccgc gccaggatgg cgcaggaact caataaagtg ctttgaatg gctgagaa 2158

<210> 4
<211> 2816
<212> DNA
<213> Homo sapiens

<400> 4
gaagctggac tgcagctggt ttcaggaact tctcttgacg agaagagaga ccaaggaggc 60
caagcagggg ctgggcccaga ggtgccaaca tggggaaact gaggctcggc tcggaaaggt 120
gaagtaactt gtccaagatc acaaagctgg tgaacatcaa gttggtgcta tggcaaggct 180
gggaaactgc agcctgactt gggctgccct gatcctctg ctgctccccg gaagtctgga 240
ggagtgcggg cacatcagtg tctcagcccc catcgtccac ctgggggatc ccatcacagc 300
ctcctgcatc atcaagcaga actgcagcca tctggaccgc gagccacaga ttctgtggag 360
actgggagca gagcttcagc ccggggggcag gcagcagcgt ctgtctgatg ggaccagga 420
atctatcatc accctgcccc acctcaacca cactcaggcc tttctctcct gctgcctgaa 480
ctggggcaac agcctgcaga tcttgacca ggttgagctg cgcgcaggct accctccagc 540
cataccccac aacctctcct gcctcatgaa cctcacaacc agcagcctca tctgccagt 600

ggagccagga	cctgagaccc	acctacccac	cagcttcact	ctgaagagtt	tcaagagccg	660
gggcaactgt	cagacccaag	gggactccat	cctggactgc	gtgccaagg	acgggcagag	720
ccactgctgc	atcccacgca	aacacctgct	gttgtagcag	aatatgggca	tctgggtgca	780
ggcagagaat	gcgctgggga	ccagcatgtc	cccacaactg	tgtcttgatc	ccatggatgt	840
tgtgaaactg	gagcccccca	tgtgctggac	catggacccc	agccctgaag	cggccccctc	900
ccaggcaggc	tgcctacagc	tgtgctggga	gccatggcag	ccaggcctgc	acataaatca	960
gaagtgtgag	ctgcgccaca	agccgcagcg	tggagaagcc	agctgggcac	tgggtggccc	1020
cctccccctg	gaggcccttc	agtatgaget	ctgcgggctc	ctcccagcca	cggcctacac	1080
cctgcagata	cgtgcacatc	gctggcccc	gcctggccac	tggagcgact	ggggccatcc	1140
tgcctctctg	caacaccaca	gagctcagct	gcaccttcca	cctgccttca	gaagcccagg	1200
aggtggccct	tgtggcctat	aactcagccg	ggacctctcg	ccccaccccg	gtggtcttct	1260
cagaaagcag	aggcccagct	ctgaccagac	tccatgccat	ggcccagac	cctcacagcc	1320
tctgggtagg	ctgggagccc	cccaatccat	ggcctcaggg	ctatgtgatt	gagtggggcc	1380
tgggcccccc	cagcgcgagc	aatagcaaca	agacctggag	gatggaacag	aatgggagag	1440
ccacgggggt	tctgctgaag	gagaacatca	ggccttttca	gctctatgag	atcatcgtga	1500
ctcccttgta	ccaggacacc	atgggaccct	cccagcatgt	ctatgcctac	tctcaagaaa	1560
tggctccctc	ccatgcccc	gagctgcac	taaagcacat	tggcaagacc	tgggcacagc	1620
tggagtgggt	gcctgagccc	cctgagctgg	ggaagagccc	ccttaccac	tacaccatct	1680
tctggaccaa	cgctcagaac	cagtccttct	ccgccatcct	gaatgcctcc	tcccgtggct	1740
ttgtctctca	tggcctggag	cccgccagtc	tgtatcacat	ccacctcatg	gctgccagcc	1800
aggttggggc	caccaacagt	acagtcctca	cctgatgac	cttgacccca	gaggggtcgg	1860
agctacacat	catectgggc	ctgttcggcc	tctgctgtt	gtcacctgc	ctctgtggaa	1920
ctgectggct	ctgttgagc	cccaacagga	agaatccct	ctggccaagt	gtcccagacc	1980
cagctcacag	cagcctgggc	tcttgggtgc	ccacaatcat	ggaggaggat	gccttccagc	2040
tgcctggcct	tggcacgcca	cccatcacca	agctcacagt	gctggaggag	gatgaaaaga	2100
agccggtgcc	ctgggagtc	cataacagct	cagagacctg	tggcctcccc	actctggtcc	2160
agacctatgt	gctccagggg	gacccaagag	cagtttccac	ccagcccaa	tcccagtctg	2220
gcaccagcga	ttaggtcctt	tatgggcagc	tgttgggcag	ccccacaagc	ccagggccag	2280
ggcactatct	ccgctgtgac	tccactcagc	ccctcttggc	gggcctcacc	cccagcccca	2340
agtcctatga	gaacctctgg	ttccaggcca	gccccttggg	gaccttggtg	accccagccc	2400
caagccagga	ggacgactgt	gtctttgggc	cactgctcaa	cttccccctc	ctgcagggga	2460
tccgggtcca	tgggatggag	gcgctgggga	gcttctaggg	cttctctggg	ttcccttctt	2520
gggctgctct	cttaaaggcc	tgagctagct	ggagaagagg	ggagggtcca	taagcccatg	2580
actaaaaact	accccagccc	aggtctctac	catctccagt	caccagcatc	tccctctcct	2640
cccaatctcc	ataggctggg	cctcccaggc	gatctgcata	ctttaaggac	cagatcatgc	2700
tccatccagc	cccacccaat	ggccttttgt	gcttgtttcc	tataacttca	gtattgtaaa	2760
ctagtttttg	gtttgcagtt	tttgttgttg	tttatagaca	ctcttgggtg	taaaca	2816

<210> 5

<211> 3050

<212> DNA

<213> Homo sapiens

<400> 5

gaagctggac	tgcagctggt	ttcaggaact	tctcttgacg	agaagagaga	ccaaggaggc	60
caagcagggg	ctgggccaga	ggtgccaa	tggggaaact	gaggctcggc	tcggaagggt	120
gaagtaactt	gtccaagatc	acaaagctgg	tgaacatcaa	gttggtgcta	tggcaaggct	180
gggaaactgc	agcctgactt	gggctgccc	gatcactctg	ctgctccccg	gaagtctgga	240
ggagtgcggg	cacatcagtg	tctcagcccc	catcgtccac	ctgggggatc	ccatcacagc	300
ctcctgcac	atcaagcaga	actgcagcca	tctggacccc	gagccacaga	ttctgtggag	360
actgggagca	gagcttcagc	ccgggggcag	gcagcagcgt	ctgtctgatg	ggaccagga	420
atctatcacc	accctgcccc	acctcaacca	cactcaggcc	tttctctcct	gctgcctgaa	480
ctggggcaac	agcctgcaga	tcttgacca	ggttgagctg	cgcgcaggct	accctccagc	540
cataccccc	aacctctcct	gcctcatgaa	cctcacaacc	agcagcctca	tctgccagtg	600
ggagccagga	cctgagaccc	acctacccac	cagcttcact	ctgaagagtt	tcaagagccg	660
gggcaactgt	cagacccaag	gggactccat	cctggactgc	gtgccaagg	acgggcagag	720
ccactgctgc	atcccacgca	aacacctgct	gttgtagcag	aatatgggca	tctgggtgca	780
ggcagagaat	gcgctgggga	ccagcatgtc	cccacaactg	tgtcttgatc	ccatggatgt	840
tgtgaaactg	gagcccccca	tgtgctggac	catggacccc	agccctgaag	cggccccctc	900
ccaggcaggc	tgcctacagc	tgtgctggga	gccatggcag	ccaggcctgc	acataaatca	960

```

gaagtgtgag ctgcgccaca agccgcagcg tggagaagcc agctggggcac tgggtgggccc 1020
cctcccccttg gagggcccttc agtatgagct ctgcgggctc ctcccagcca cggcctacac 1080
cctgcagata cgctgcatcc gctggccctt gcctggccac tggagcgact ggagccccag 1140
cctggagctg agaactaccg aacgggcccc cactgtcaga ctggacacat ggtggcggca 1200
gaggcagctg gaccccagga cagtgcagct gttctggaag ccagtgcccc tggaggaaga 1260
cagcggacgg atccaaggtt atgtggtttc ttggagaccc tcaggccagg ctggggccat 1320
cctgcccctc tgcaacacca cagagctcag ctgcaccttc cacctgcctt cagaagccca 1380
ggaggtggcc cttgtggcct ataactcage cgggacctct cggcccaccc cgggtgtctt 1440
ctcagaaagc agaggcccag ctctgaccag actccatgcc atggcccag accctcacag 1500
cctctgggta ggctgggagc ccccacatcc atggcctcag ggctatgtga ttgagtggg 1560
cctgggcccc ccagcgcga gcaatagcaa caagacctgg aggatggaac agaatgggag 1620
agccacgggg tttctgctga aggagaacat caggcccttt cagctctatg agatcatcgt 1680
gactcccttg taccaggaca ccatgggacc ctcccagcat gtctatgcct actctcaaga 1740
aatggctccc tcccatgccc cagagctgca tctaaagcac attggcaaga cctgggcaca 1800
gctggagtgg gtgcctgagc cccctgagct ggggaagagc ccccttacct actacaccat 1860
cttctggacc aacgctcaga accagtcctt ctgtgagtct ancctcagtt ccccacagc 1920
cccagaaggc ctggaagggg gtgctcagct gccacggagg cantttacca tccaggccta 1980
tgctgaccgt acacccctcc cagccgccat cctgaatgcc tccctccgtg gctttgtcct 2040
ccatggcctg gagcccgcga gtctgtatca catccacctc atggctgcca gccaggctgg 2100
ggccaccaac agtacagtc taccctgat gaccttgacc ccagaggggt cggagctaca 2160
catcactctg ggctgttctg gctcctgct gttgtctacc tgctctgtg gaactgctg 2220
gctctgttgc agccccaaca ggaagaatcc cctctggcca agtgctccag acccagctca 2280
cagcagcctg ggctcctggg tgcccacaat catggaggag gatgccttcc agctgcccgg 2340
ccttggcacg ccacccatca ccaagctcac agtgctggag gaggatgaaa agaagccggt 2400
gcccctggag tcccataaca gctcagagac ctgtggcctc cccactctgg tccagaccta 2460
tgtctccag ggggacccaa gagcagtttc caccagccc caatcccagt ctggcaccag 2520
cgatcaggtc ttttatgggc agctgctggg cagccccaca agcccagggc cagggcacta 2580
tctccgctgt gactccactc agccctctt ggcgggcctc acccccagcc ccaagtcccta 2640
tgagaacctc tggttccagg ccagcccctt ggggacctg gtaaccccag cccaagcca 2700
ggaggacgac tgtgtctttg ggccactgct caacttcccc ctctgcagg ggatccgggt 2760
ccatgggatg gaggcgctgg ggagcttcta gggcttctg gggttccctt cttgggctg 2820
cctcttaaag gctgagcta gctggagaag aggggagggt ccataagccc atgactaaaa 2880
actaccccag ccaggtctc caccatctcc agtcaccagc atctccctc cctcccaatc 2940
tccataggct gggcctccca ggcgatctgc atactttaag gaccagatca tgtcccatcc 3000
agccccaccc aatggccttt tgtcttgtt tcctataact tcagtattgt 3050

```

<210> 6

<211> 2752

<212> DNA

<213> Homo sapiens

<400> 6

```

agggattctt ctgcctccac ttcaggtttt agcagcttgg tgctaaattg ctgtctcaaa 60
atgcagagga tctaatttgc agaggaaaac agccaaagaa ggaagaggag gaaaaggaaa 120
aaaaaagggg tatattgtgg atgctctact tttcttgga atgcaaaaga ttatgcatat 180
ttctgtctc ctttctctg ttttatggg actgattttt ggtgtctctt ctaacagcat 240
acagataggg gggctatttc ctaggggcgc cgatcaagaa tacagtgcac ttcgagtagg 300
gatggttcag ttttccactt cggagtccag actgacaccc cacatcgaca atttggaggt 360
ggcaaacagc ttgcagtcga ctaatgcttt ctgctcccag ttttcgagag gagtctatgc 420
tatttttggg ttttatgaca agaagtctgt aaataccatc acatcatttt gcggaacact 480
ccacgtctcc ttcactactc ccagcttccc aacagatggc acacatccat ttgtcattca 540
gatgagaccc gacctcaaag gagctctcct tagcttgatt gaatactatc aatgggacaa 600
gtttgcatac ctctatgaca gtgacagagg cttatcaaca ctgcaagctg tgctggattc 660
tgctgctgaa aagaaatggc aagtgactgc tatcaatgtg ggaaacatta acaatgacaa 720
gaaagatgag atgtaccgat cactttttca agatctggag ttaaaaaagg aacggcgtgt 780
aattctggac tgtgaaaggg ataaagtaaa cgacattgta gaccagggtt ttaccattgg 840
aaaacacgtt aaagggtacc actacatcat tgcaaactg gaatttactg atggagacct 900
attaaaaatc cagtttggag gtgcaaagt ctctggattt cagatagtgg actatgatga 960
ttcgttggta tctaaattta tagaaagatg gtcaacactg gaagaaaaag aataccctgg 1020
agctcacaca acaacaatta agtatacttc tgctctgacc tatgatgccg ttcaagtgat 1080

```

```

gactgaagcc ttccgcaacc taaggaagca aagaattgaa atctcccgaa gggggaatgc 1140
aggagactgt ctggcacaacc cagcagtgcc ctggggacaa ggtgtagaaa tagaaagggc 1200
cctcaaacag gttcagggtg aaggtctctc aggaaatata aagtttgacc agaatggaaa 1260
aagaataaac tatacaatta acatcatgga gctcaaaact aatgggcccc ggaagattgg 1320
ctactggagt gaagtggaca aaatggttgt tacccttact gagctccctt ctggaaatga 1380
cacctctggg cttgagaata agactgttgt tgtcaccaca attttggaat ctccgtatgt 1440
tatgatgaag aaaaatcatg aaatgcttga aggcaatgag cgctatgagg gctactgtgt 1500
tgacctggct gcagaaatcg ccaaacattg tgggttcaag tacaagttga caattgttgg 1560
tgatggcaag tatggggcca gggatgcaga cacgaaaatt tggaaatggga tgggtggaga 1620
acttgatatat gggaaaagctg atattgcaat tgcctcatta actattaccc ttgtgagaga 1680
agaggtgatt gacttctcaa agcccttcat gagcctcggg atatctatca tgatcaagaa 1740
gcctcagaag tccaaaccag gagtgttttc ctttcttgat ctttagcct atgagatctg 1800
gatgtgcatt gtttttgcct acattggggg cagtgtagtt ttattcctgg tcagcagatt 1860
tagcccctac gagtggcaca ctgaggagtt tgaagatgga agagaaacac aaagtagtga 1920
atcaactaat gaatttggga tttttaatag tctctggttt tccttgggtg ctttatgctg 1980
gcaaggatgc gatatttgcg caagatccct ctctgggcgc attgttggag gtgtgtgtgt 2040
gttctttacc ctgatcataa tctcctccta cacggctaac ttagctgcct tcctgactgt 2100
agagaggatg gtgtctccca tcgaaagtgc tgaggatctt tctaagcaaa cagaaattgc 2160
ttatggaaca ttagactctg gctccactaa agagttttcc aggagatcta aaattgcagt 2220
gtttgataaa atgtggacct acatgcggag tgcggagccc tctgtgtttg tgaggactac 2280
ggccgaaggg gtggctagag tgcggaagtc caaagggaaa tatgcctact tgttggagtc 2340
cacgatgaac gactacattg agcaaaggaa gccttgcgac accatgaaag ttggtggaaa 2400
cctgatttcc aaaggctatg gcatcgcaac acctaaagga tcctcattag gaacccagtc 2460
aaatcttgca gtattgaaac tcagtgaagc aggcgtctta gacaagctga aaaacaaatg 2520
gtggtacgat aaaggagagt ncggcanggg ggaggtgatt ccaaggtcag cccagtgag 2580
aaaagtaatg ggtaactcaa tgcaaaacaa agtaagcagc agctatgcac agtgtgggca 2640
ctcgtccac ccaagtttcc aacgcttaag ctgaagagtg caattggatg accaggacac 2700
ttgacttctt ctttctttct tcctctactt ctctttccct ctctttctcc at 2752

```

<210> 7

<211> 1056

<212> DNA

<213> Homo sapiens

<400> 7

```

agcttaggac acagagcaca tcaaaagtcc ccaaagaggg cttgctctct cttcacctgc 60
tctgttctac agcacactac cagaagacag cagaaatgaa aagcatttac tttgtggctg 120
gattatttgt aatgctggta caaggcagct ggcaacgttc cttcaagac acagaggaga 180
aatccagatc attctcagct tcccaggcag acctctcag tgatcctgat cagatgaacg 240
aggacaagcg ccattcacag ggcacattca ccagtacta cagcaagtat ctggactcca 300
ggcgtgccca agattttgtg cagtgggtga tgaataccaa gaggaacagg aataacattg 360
ccaaacgtca cgatgaattt gagagacatg ctgaaggagc cttaccagt gattttccca 420
gaagaggtcg ccattgttga agaacttggc cgcagacatg ctgatggttc tttctctgat 480
gagatgaaca ccatttcttg ataacttgc cgccaggagc tttataaaact ggttgattca 540
gacaaaaatc actgacagga aataactata tcactattca agatcatctt cacaacatca 600
cctgctagcc acgtgggatg tttgaaatgt taagtctgt aaatttaaga ggtgtattct 660
gaggccacat tgctttgcat gccaaataat aaattttctt ttagtggtgt gtagccaaaa 720
attacaaatg gaataaagt ttatcaaaat attgctaaaa tatcagcttt aaaatatgaa 780
agtgtagat tctgttattt tcttcttatt ttggatgaag taccccaacc tgtttacatt 840
tagcgataaa attatttttc tatgatataa tttgtaaagt taaattattc cgatctgaca 900
tatctgcatt ataataatag gagaatagaa gaactggtag ccacagtggg gaaattggaa 960
agagaacttt ctctctgaaa ctttctgtct aaaaatactc agctttcaat gtatcaaaga 1020
tacaattaaa taaaattttc aagcttcttt aaaaaa 1056

```

<210> 8

<211> 1700

<212> DNA

<213> Homo sapiens

<400> 8

```

gtaaaagtat aaaagccatt cttagtttgc aggcagtaca gaaacagttt cagcccatgg 60
ntgtncattt gttgacccct attcaagagg gtctgtcaca gaagactcct gcttgcctga 120
aattttacgag tgcattgtaa tgttggaatt aacagggtgt cctgttttct cttatgctgt 180
ctttcatctt caggaacagc caggaagacg ctgcacttcg agatttccaa ggaaggcagt 240
gacctgtcag tgggtggagc tgcagaagtc tggctcttcc taaaagtccc caaggccaac 300
aggaccagga ccaaagtcac catccgcctc ttccagcagc agaagcaccg gcagggcagc 360
ttggacacag gggaagaggc cgaggaagtg ggcttaaagg gggagaggag tgaactgttg 420
ctctctgaaa aagtagtaga cgctcggaag agcacctggc atgtcttccc tgtctccagc 480
agcatccagc ggttgctgga ccagggaag agtcctctgg acgttcggat tgcctgtgag 540
cagtgccagg agagtggcgc cagcttggtt ctcttgggca agaagaagaa gaaagaagag 600
gagggggaag ggaaaaagaa gggcgagggt gaaggtgggg caggagcaga tgaggaaaag 660
gagcagtcgc acagaccttt cctcatgctg caggcccggc agtctgaaga ccacctcat 720
cgccggcgct ggccggggct ggagtgtgat ggcaaggcca acatctgctg taagaaacag 780
ttctttgtca gtttcaagga catcggtctg aatgactgga tcattgctcc ctctggctat 840
catgccaact actgcgaggg tgagtgcctg agccatatag caggcacgtc cgggtcctca 900
ctgtccttcc actcaacagt catcaaccac taccgcatgc ggggccatag cccctttgcc 960
aacctcaaat cgtgctgtgt gcccaccaag ctgagaccca tgtccatgtt gtactatgat 1020
gatggtcaaa acatcatcaa aaaggacatt cagaacatga tcgtggagga gtgtgggtgc 1080
tcatagagtt gccagccca gggggaagg gagcaagagt tgtccagaga agacagtggc 1140
aaaatgaaga aatttttaag gtttctgagt taaccagaaa aatagaaatt aaaaacaaaa 1200
caaaaaaaaa aaacaaaaaa aaacaaaagt aaattaaaaa caaacctga tgaacagat 1260
gaaggaagat gtggaaaaaa tccttagcca gggctcagag atgaagcagt gaaagagaca 1320
ggaattggga gggaaaggga gaatggtgta ccttttattt cttctgaaat cactctgatg 1380
acatcagttg tttaaacggg gtattgtcct tccccctt gaggttccct tgtgagcctt 1440
gaatcaacca atctagtctg cagtagtgtg gactagaaca acccaaatag catctagaaa 1500
gccatgagtt tgaaagggcc catcacaggc actttcctac ccaattacc aggtcataag 1560
gtatgtctgt gtgacactta tctctgtgta tatcagcata cacacacaca cacacacaca 1620
cacacacaca ggcatttcca cacattacat atatacacat actggtaaaa gaacaatcgt 1680
gtgcaggtgg tcacacttcc

```

<210> 9

<211> 1104

<212> DNA

<213> Homo sapiens

<400> 9

```

aggactggag atgtctgagg ctcatctctg cctcgagccc accgggaacg aaagagaagc 60
tctatctccc ctccaggagc ccagctatga actccttctc cacaagcgcc ttcggtccag 120
ttgccttctc cctggggctg ctctggtgtg tgctgtctgc cttccctgcc ccagtacccc 180
caggagaaga ttccaaagat gtagccgccc cacacagaca gccactcacc tcttcagaac 240
gaattgacaa acaaattcgg tacatcctcg acggcatctc agccctgaga aaggagacat 300
gtaacangag taacatgtgt gaaaaagatg gatgcttcca atctggattc aatgaggaga 360
cttgctggtg gaaaatcatc actggtcttt tggagtttga ggtataccta gagtacctcc 420
agaacagatt tgagagtagt gaggaacaag ccagagctgt gcagatgagt acaaaagtcc 480
tgatccagtt cctgcagaaa aaggcaaaga atctagatgc aataaccacc cctgacccaa 540
ccacaaatgc cagcctgctg acgaagctgc aggcacagaa ccagtggctg caggacatga 600
caactcatct cattctgctg agctttaagg agttcctgca gtccagcctg agggctcttc 660
ggcaaatgta gcatgggcac ctgagattgt tgttggtaat gggcattcct tcttctggct 720
agaaacctgt ccactgggca cagaacttat gttgttctct atggagaact aaaagtatga 780
gcgttaggac actattttta ttatttttaa tttattaata tttaaatatg tgaagctgag 840
ttaatttatg taagtcatat ttatattttt aagaagtacc acttgaaaca ttttatgtat 900
tagttttgaa ataataatgg aaagtggcta tgcagtttga atatcctttg tttcagagcc 960
agatcatttc ttggaaagtg taggcttacc tcaataaat ggctaactta tacatatatt 1020
taaagaaata tttatattgt atttatataa tgtataaatg gtttttatac caataaatgg 1080
cattttaaaa aattcagcaa aaaa

```

<210> 10

<211> 967

<212> DNA

<213> Homo sapiens

<400> 10

```

aggactggag atgtctgagg ctcatctctgc cctcgagccc accgggaacg aaagagaagc 60
tctatctccc ctccaggagc ccagctatga actccttctc cacaacatg taacaagagt 120
aacatgtgtg aaagcagcaa agaggcactg gcagaaaaca acctgaacct tccaaagagt 180
gctgaaaaag atggatgctt ccaatctgga ttcaatgagg agacttgctt ggtgaaaatc 240
atcactggtc ttttgagggt tgaggtatac cttagagtacc tccagaacag atttgagagt 300
agtgaggaac aagccagagc tgtgcagatg agtacaaaag tcctgatcca gttcctgcag 360
aaaaaggcaa agaattctaga tgcaataacc acccctgacc caaccacaaa tgccagcctg 420
ctgacgaagc tgcaggcaca gaaccagtgg ctgcaggaca tgacaactca tctcattctg 480
cgcagcttta aggagttcct gcagtcacgc ctgagggctc ttcggcaaat gtagcatggg 540
cacctcagat tgttgttgtt aatgggcatt ccttcttctg gtcagaaacc tgtccactgg 600
gcacagaact tatgttgttc tctatggaga actaaaagta tgagcgtagg gacactatct 660
taattatttt taatttatta atattttaat atgtgaagct gagttaattt atgtaagtca 720
tatttatatt ttttaagaagt accacttgaa acattttatg tattagtttt gaaataataa 780
tggaagtggt ctatgcagtt tgaatatcct ttgtttcaga gccagatcat ttcttggaaa 840
gtgtaggctt acctcaaata aatggctaac ttatacatat ttttaaagaa atatttatat 900
tgtatttata taatgtataa atgggtttta taccaataaa tggcatttta aaaaattcag 960
caaaaaaa

```

<210> 11

<211> 948

<212> DNA

<213> Homo sapiens

<400> 11

```

atgcctcgcc tgttcttggt ccacctgcta graktctgtt tactactgaa ccaattttcc 60
agagcagtcg cggmcwmatg gawggasgaw gttattaaat tatgcggccg cgaattagtt 120
cgcgcgcaga ttgccatttg cggcatgagc acctggagca aaaggtctct gagccaggaa 180
gatgctcctc agacacctag accagtggca ggtgatttta ttcaaacagt ctactggga 240
atctcaccgg acggagggaa agcactgaga acaggaagct gcttcaccgg agagttcctt 300
ggtgcccttt ccaaattgta ccaccttca tcaacaaaga tacagaaact ataattatca 360
tgttgaattt yrttgctaatt ttgccacmgy agctgaagky arccctrtct gagakgcagc 420
caccattacc asagctacar caryatgtac ctgyattaaa agattccagt cttctctttg 480
aagaatttaa gaaacttatt cgcaataggc aaagtgaagc cgcagacagc aatccttcag 540
aattaaaafa cttaggcttg gatactcatt ctcaaaaaaa gagacgacct tacgtggcac 600
tgtttgagaa atgttgccca attggttgta ccaaaaggct tcttgctaaa tattgctgag 660
atgaagctaa ttgtgcacat cttgtcctaat ttccacacat agtcttgatg acatttcact 720
gatgcttctg tcagggtccca ctaattatta gaatataaga aatctttatt aatgtttaga 780
tttttcattt ggtgtgtaag aaaatattct ttgtatgatt gtagtttctg taaatgacac 840
tttctatgct gaagtctttt tgtcttttta ttaacagtat aattgtgttg attcttttta 900
atgctgttaa cttaaaatta caataaaacc tttgccactt taaccata 948

```

<210> 12

<211> 703

<212> DNA

<213> Homo sapiens

<400> 12

```

ttcccccccc ccccccccc ccccgccccg gcacaggaca cagctgggtt ctgaagcttc 60
tgagttctgc agcctcacct ctgagaaaac ctcttttcca ccaataccat gaagctctgc 120
gtgactgtcc tgtctctcct catgctagta gctgccttct gctctccagc gctctcagca 180
ccaatgggct cagaccctcc caccgcctgc tgettttctt acaccgcgag gaagcttcct 240
cgcaactttg tggtagatta ctatgagacc agcagcctct gctcccagcc agctgtgggtg 300
gcaagcaagt ctgcgctgac cccagttagt cctgggtcca ggagtacgtg tatgacctgg 360
aactgaactg agctgctcag agacaggaag tcttcaggga aggtcacctg agcccggatg 420
cttctccatg agacacatct cctccatact caggactcct ctccgcagtt cctgtccctt 480

```

```

ctcttaattt aatctttttt atgtgccgtg ttattgtatt aggtgtcatt tccattattt 540
atattagttt agccaaagga taagtgtccc ctatggggat ggtccactgt cactgtttct 600
ctgctgttgc aaatacatgg ataacacatt tgattctgtg tgttttcata ataaaacttt 660
aaaataatgg aatgaacaa cctaatacaa taacacggca cat 703

```

<210> 13

<211> 2468

<212> DNA

<213> Homo sapiens

<400> 13

```

gcacgagcng aggtagaggt tgctcctgac gcacaggcat tccccgcgcc cctccagccc 60
tcgccgccct cgccaccgct cccggccgcc gcgctccggt acacacagga tccctgctgg 120
gcaccaacag ctccaccatg gggctggcct ggggactagg cgctcctgtt ctgatgcatg 180
tgtgtggcac caaccgcatt ccagagtctg gcggagacaa cagcgtgttt gacatctttg 240
aactcaccgg ggccgcccgc aaggggtctg ggcgccgact ggtgaagggc cccgaccctt 300
ccagcccagc tttccgcata gaggatgcc aacctgatccc cctgtgcct gatgacaagt 360
tccaagacct ggtggatgct gtgcgggcag aaaagggttt cctccttctg gcacccctga 420
ggcagatgaa gaagaccgg ggcacgctgc tggccctgga gcggaaagac cactctggcc 480
aggtcttcag cgtggtgtcc aatggcaagg cgggcaccct ggacctcagc ctgaccgtcc 540
aaggaaagca gcacgtggtg tctgtggaag aagctctcct ggcaaccggc cagtgggaaga 600
gcatcacccct gtttgtgcag gaagacaggg ccagctgta catcgactgt gaaaagatgg 660
agaatgctga gttggacgtc cccatccaaa gcgtcttcac cagagacctg gccagcatcg 720
ccagactccg catcgcaaaag gggggcgctca atgacaattt ccagggggtg ctgcagaatg 780
tgaggtttgt ctttggaaac acaccagaag acatcctcag gaacaaaggc tgetccagct 840
ctaccagtgt cctcctcacc cttgacaaca acgtggtgaa tggttccagc cctgccatcc 900
gcactaacta cattggccac aagacaaagg acttgcaagc catctgcggc atctcctgtg 960
atgagctgtc cagcatggtc ctggaactca ggggcctgcg caccattgtg accacgtgc 1020
aggacagcat ccgcaaagtg actgaagaga acaaagagtt ggccaatgag ctgaggcggc 1080
ctcccctatg ctatcacaac ggagttcagt acagaaataa cgaggaaatg actggtgata 1140
gctgcactga gtgtcactgt cagaactcag ttaccatctg caaaaagggtg tctgccccca 1200
tcatgccctg ctccaatgcc acagttcctg atggagaatg ctgtcctcgc tgttgccccca 1260
gcgactctgc ggacgatggc tgggtctccat ggtccgagtg gacctcctgt tctacgagct 1320
gtggcaatgg aattcagcag cgcggccgct cctgcgatag cctcaacaac cgatgtgagg 1380
gctcctcggc ccagacacgg acctgccaca ttcaggagtg tgacaagaga tttaaacagg 1440
atggtggctg gagccactgg tccccgtggt catcttgttc tgtgacatgt ggtgatggtg 1500
tgatcacaag gatccggctc tgcaactctc ccagccccc gatgaacggg aaacctgtgt 1560
aaggcgaagc gcgggagacc aaagcctgca agaaagacgc ctgccccatc aatggaggct 1620
ggggtccttg gtcaccatgg gacatctgtt ctgtcacctg tggaggaggg gtacagaaac 1680
gtagtctgtc ctgcaacaac cccacacccc agtttggagg caaggactgc gttggtgatg 1740
taacagaaaa ccagatctgc aacaagcagg actgtccaat tgatggatgc ctgtccaatc 1800
cctgctttgc cggcgtgaag tgtactagct accctgatgg cagctggaaa tgtggtgctt 1860
gtccccctgg ttacagtgga aatggcatcc agtgcacaga tgttgatgag tgcaaagaag 1920
tgctgatgc ctgcttcaac cacaatggag agcaccgggtg tgagaacacg gaccccggt 1980
acaactgcct gccctgcccc ccacgcttca cgggctcaca gcccttcggc caggggtgctg 2040
aacatgccac ggccaacaaa caggtgtgca agccccgtaa cccctgcacg gatgggaccc 2100
acgactgcaa caagaacgcc aagtgaact acctgggcca ctatagcgac cccatgtacc 2160
gctgcgagtg caagcctggc tacgctggca atggcatcat ctgcggggag gacacagacc 2220
tggatggctg gcccaatgag aacctggtgt gcgtggccaa tgcgacttac cactgcaaaa 2280
aggataattg ccccaacctt ccgcaggatc cagctccctg cccgagggtca tgactgtcgc 2340
cacatacagt gctttgacct ggagtcgtac ctgcagctca actgtgagcg ggggacttgg 2400
aggtgtcctg tgtgcaacaa gacagctttg ctggaggggc tggagggtga ccagtacatg 2460
ctgggcat 2468

```

<210> 14

<211> 1850

<212> DNA

<213> Homo sapiens

<400> 14

```

gcacgagcng aggtagaggt tgctcctgac gcacaggcat tccccgcgcc cctccagccc 60
tcgccgccct cgccaccgct cccggcgccc gcgctccggt acacacagga tccctgctgg 120
gcaccaacag ctccaccatg gggctggcct ggggactagg cgtcctgttc ctgatgcatg 180
tgtgtggcac caaccgcatt ccagagtctg gcggagacaa cagcgtgttt gacatctttg 240
aactcaccgg ggccgcccgc aaggggtctg ggcgcgcact ggtgaagggc cccgaccctt 300
ccagcccagc ttccgcgcatc gaggatgcc aacctgatccc ccctgtgcct gatgacaagt 360
tccaagacct ggtggatgct gtgcgggcag aaaagggttt cctccttctg gcatccctga 420
ggcagatgaa gaagaccggg ggcacgctgc tggccctgga gcgaaagac cactctggcc 480
aggtcttcag cgtggtgtcc aatggcaagg cgggcaccct ggacctcagc ctgaccgtcc 540
aaggaaagca gcacgtggtg tctgtggaag aagctctcct ggcaaccggc cagtgaaga 600
gcatcaccct gtttgtgcag gaagacaggg ccagctgta catcgactgt gaaaagatgg 660
agaatgctga gttggacgtc cccatccaaa gcgtcttcac cagagacctg gccagcatcg 720
ccagactccg catcgcaaag gggggcgta atgacaattt ccagggggtg ctgcagaatg 780
tgaggtttgt ctttggaacc acaccagaag acatcctcag gaacaaaggc tgctccagct 840
ctaccagtgt cctcctcacc cttgacaaca acgtggtgaa tggttccagc cctgccatcc 900
gcactaacta cattggccac aagacaaagg acttgcaagc catctgcggc atctcctgtg 960
atgagctgtc cagcatggtc ctggaactca ggggcctgcg caccattgtg accacgtgc 1020
aggacagcat ccgcaaagtg actgaagaga acaaagagtt ggccaatgag ctgaggcggc 1080
ctcccctatg ctatcacaac ggagttcagt acagaaataa cgaggaatgg actgttgata 1140
gctgcactga gtgtcactgt cagaactcag ttaccatctg caaaaagggtg tcctgcccc 1200
tcatgccctg ctccaatgcc acagttcctg atggagaatg ctgtcctcgc tgttgcccc 1260
gcgactctgc ggacgatggc tggctccat ggtccgagtg gacctcctgt tctacgagct 1320
gtggcaatgg aattcagcag cgcggccgct cctgcgatag cctcaacaac cgatgtgagg 1380
gctcctcggt ccagacacgg acctgccaca ttcaggagtg tgacaagaga ttaaacagg 1440
atggtggctg gagccactgg tccccgtggt catcttggtc tgtgacatgt ggtgatggtg 1500
tgatcacaag gatccggctc tgcaactctc ccagcccca gatgaacggg aaacctgtg 1560
aaggcgaagc gcgggagacc aaagcctgca agaaagacgc ctgccccatc aatggaggct 1620
ggggctcctg gtcaccatgg gacatctgtt ctgtcacctg tggaggaggg gtacagaaac 1680
gtagtctct ctgcaacaac cccacacccc agtttgagg caaggactgc gttggtgatg 1740
taacagaaaa ccagatctgc aacaagcagg actgtccaat tggtagacca cgcagcccag 1800
gatgaaacga cccaggagct ttgctctttt actgaatgct gcagtcagca 1850

```

<210> 15

<211> 1771

<212> DNA

<213> Homo sapiens

<400> 15

```

gcacgagcng aggtagaggt tgctcctgac gcacaggcat tccccgcgcc cctccagccc 60
tcgccgccct cgccaccgct cccggcgccc gcgctccggt acacacagga tccctgctgg 120
gcaccaacag ctccaccatg gggctggcct ggggactagg cgtcctgttc ctgatgcatg 180
tgtgtggcac caaccgcatt ccagagtctg gcggagacaa cagcgtgttt gacatctttg 240
aactcaccgg ggccgcccgc aaggggtctg ggcgcgcact ggtgaagggc cccgaccctt 300
ccagcccagc ttccgcgcatc gaggatgcc aacctgatccc ccctgtgcct gatgacaagt 360
tccaagacct ggtggatgct gtgcgggcag aaaagggttt cctccttctg gcatccctga 420
ggcagatgaa gaagaccggg ggcacgctgc tggccctgga gcgaaagac cactctggcc 480
aggtcttcag cgtggtgtcc aatggcaagg cgggcaccct ggacctcagc ctgaccgtcc 540
aaggaaagca gcacgtggtg tctgtggaag aagctctcct ggcaaccggc cagtgaaga 600
gcatcaccct gtttgtgcag gaagacaggg ccagctgta catcgactgt gaaaagatgg 660
agaatgctga gttggacgtc cccatccaaa gcgtcttcac cagagacctg gccagcatcg 720
ccagactccg catcgcaaag gggggcgta atgacaattt ccagggggtg ctgcagaatg 780
tgaggtttgt ctttggaacc acaccagaag acatcctcag gaacaaaggc tgctccagct 840
ctaccagtgt cctcctcacc cttgacaaca acgtggtgaa tggttccagc cctgccatcc 900
gcactaacta cattggccac aagacaaagg acttgcaagc catctgcggc atctcctgtg 960
atgagctgtc cagcatggtc ctggaactca ggggcctgcg caccattgtg accacgtgc 1020
aggacagcat ccgcaaagtg actgaagaga gtgtcactgt cagaactcag ttaccatctg 1080
caaaaagggtg tcctgcccc 1140
ctgtcctcgc tgttgcccc 1200
gacctcctgt tctacgagct gtggcaatgg aattcagcag cgcggccgct cctgcgatag 1260

```



```

cctcaacaac cgatgtgagg gctcctcggt ccagacacgg acctgccaca ttcaggagtg 1320
tgacaagaga tttaaacagg atggtggctg gagccactgg tccccgtggt catcttggtc 1380
tgtgacatgt ggtgatggtg tgatcacaag gatccggctc tgcaactctc ccagccccc 1440
gatgaacggg aaacctgtg aaggcgaagc gcgggagacc aaagcctgca agaaagacgc 1500
ctgccccagt aagtgtgagg tccgctgcaa gggtagcat gggcagcagc tctgcccagc 1560
tggttgcctg ggcactctgca gctgcagtt tcagtggggg cataggagca ggaagggttac 1620
ctaattagga gaaacaaaca gaaggcaaag tccctgcagg tcagcaactt ctttttaatt 1680
gaaaaacaaa ttcacctttt cccagctttt ttttccttgt gttcagggga ggcagagggt 1740
ttttgaacgg gttaggggat ttttgcaagt t 1771

```

<210> 16

<211> 1750

<212> DNA

<213> Homo sapiens

<400> 16

```

gcacgagcng aggttagaggt tgctcctgac gcacaggcat tccccgcgcc cctccagccc 60
tcgccgccct cgccaccgct cccggccgcc gcgtccgggt acacacagga tccctgctgg 120
gcaccaacag ctccaccatg gggctggcct ggggactagg cgctctgttc ctgatgcatg 180
tgtgtggcac caaccgcatt ccagagtctg gcggagacaa cagcgtgttt gacatctttg 240
aactcaccgg ggccgccccg aaggggtctg ggcgcgact ggtgaagggc cccgaccctt 300
ccagcccagc tttccgcate gaggatgcc aactgatccc cctgtgctt gatgacaagt 360
tccaagacct ggtggatgct gtgcgggcag aaaagggttt cctccttctg gcatccctga 420
ggcagatgaa gaagaccggg ggcacgctgc tggccctgga gcggaaagac cactctggcc 480
aggtcttcag cgtggtgtcc aatggcaagg cgggaccctt ggacctcagc ctgaccgtcc 540
aaggaaaagc gcacgtggtg tctgtggaag aagctctcct ggcaaccggc cagtgggaaga 600
gcatcacctt gtttgtgcag gaagacaggg cccagctgta catcgactgt gaaaagatgg 660
agaatgctga gttggacgtc cccatccaaa gcgtcttcac cagagacctg gccagcatcg 720
ccagactccg catcgcaaaag gggggcgta atgacaattt ccagggggtg ctgcagaatg 780
tgaggtttgt ctttgaacc acaccagaag acatcctcag gaacaaaggc tgctccagct 840
ctaccagtgt cctcctcacc cttgacaaca acgtggtgaa tggttccagc cctgccatcc 900
gcactaacta cattggccac aagacaaagg acttgcaagc catctgcggc atctcctgtg 960
atgagctgtc cagcatggct ctggaactca ggggcctgcg caccattgtg accacgtgc 1020
aggacagcat ccgcaaagtg actgaagaga acaaagagtt ggccaatgag ctgaggcggc 1080
ctcccctatg ctatcacaaac ggagttcagt acagaaataa cgaggaatgg actgttgata 1140
gctgcaactga gtgtcactgt cagaactcag ttaccatctg caaaaagggt tctgcccc 1200
tcatgcctg ctccaatgcc acagttcctg atggagaatg ctgtcctcgc tgttgcccc 1260
gagactctgc ggacgatggc tggctccat ggtccgagtg gacctcctgt tctacgagct 1320
gtggcaatgg aattcagcag cgcggccgct cctgcgatag cctcaacaac cgatgtgagg 1380
gctcctcggt ccagacacgg acctgccaca ttcaggagtg tgacaagaga tgtaagcatc 1440
ttagcctctc agggacgtgg agaactgacc tgtccttgtt gtcgtcacca agggcagctc 1500
cacagcatgt atattaagaa cacgggttct aggatctctg gatcccaatc cactgtctta 1560
gctgtgcacc cttgaacaca acttacctc tctgaggctc tttcctcatt tgcaacttgg 1620
agataataat agttcttgat aagtttatct tgagcatttt atttagatac tgcatgtaaa 1680
gcagttagca ctgagttttg gtttatggta agcaccctgt aaatgttagg atattaacag 1740
caaccataa 1750

```

<210> 17

<211> 2101

<212> DNA

<213> Homo sapiens

<400> 17

```

agggttgggc agctctggcc ctgttttgag tgaggcctgt gcaccagcaa cccgccctgg 60
gccgtccgcy ttttcacagc aaccggccct gggcccgctt gcgtttggt tatgctgggg 120
tgtctccggg cccgcagcac cggaagcccc gcggctggag ttccgggata cggcactcgg 180
actacctggc cccgctgggt accgacggc acaactgacc cgccaggcgg gagcgggccc 240
acacgtgttt gcttaaagtc tgcgagtcg catcgtgtcc gctctctct ctctctctct 300
gcgcgtcctg gcgcaaggcc tgggggtggag ccacggctgg ggccgtgtcc caactccgaa 360

```

```

cccagcggggg cggggccccga gcgtcgggcg aggccgggac cccagcgctg cgcgcgctcc 420
gaacgtcgag accccaccga gggcgggagg gggactctcg ggagccacag acgcccgaga 480
cccacgcggg gcgggaccgg ccagggatca cccccgccga cggccccggg ccccgacggc 540
ccggaagttc cgcgtgtccg ggggcaccgg gggattggcc ggggcgcggc gtgcaaggct 600
tcccgggggc ggcgactgcc gagctccgcc ctccaggcgg cccacccgc ctgccgtcct 660
ggggcgccgc cgcgcccgcg ccggcagtgg accgctgtgc gcgaaccctg aaccctacgg 720
tcccgaaccg cgggcgaggc cgggtacctg ggctgggac cggagcaagc gggcgagggc 780
agcgccctaa gcaggtacgg gcggggctca agtcgcgagg cggggaagcg ggaggcagac 840
acggacgagg gcgacacaga cacgggaccg aggggcggac accggagaga cacgggaaag 900
gggtcgggac aggagcacgt ggctcagaca ccgacgccg gaggcgcag accccggacg 960
tgtcaggcat ccccgaggc ccggagcgat ggcagccttg atgaccccg gaaccggggc 1020
cccacccgcg cctggtgact tctccgggga agggagccag ggacttccc acccttcgcc 1080
agagcccaag cagctcccgg agctgatccg catgaagcga gacggaggcc gcctgagcga 1140
agcggacatc aggggcttcg tggccgctgt ggtgaatggg agcgcgcagg gcgcacagat 1200
cggggccatg ctgatggcca tccgacttcg gggcatggat ctggaggaga cctcgggtgt 1260
gacccaggcc ctggctcagt cgggacagca gctggagtgg ccagaggcct ggcgccagca 1320
gcttgtggac aagcattcca cagggggtgt gggtgacaag gtcagcctgg tcctcgcacc 1380
tgccctggcg gcatgtggct gcaaggtgcc aatgatcagc ggacgtggtc tggggcacac 1440
aggaggcacc ttggataagc tggagtctat tcctggattc aatgtcatcc agagcccaga 1500
gcagatgcaa gtgctgctgg accaggcggg ctgctgtatc gtgggtcaga gtgagcagct 1560
ggttctctcg gacggaatcc tatatgcagc cagagatgtg acagccaccg tggacagcct 1620
gccactcatc acagctcca ttctcagtaa gaaactcgtg gaggggctgt ccgctctggt 1680
ggtggacgtt aagttcggag gggcgccgct cttccccaac caggagcagg cccgggagct 1740
ggcaaagacg ctggttggcg tgggagccag cctagggctt cgggtcgcgg cagcgtgac 1800
cgccatggac aagcccttg gtgctgctg gggccacgcc ctggagggtg aggaggcgt 1860
gctctgcatg gacggcgag gcccgccaga cttaaggag ctggtcacca cgctcggggg 1920
cgccctgctc tggctcagcg gacacgcggg gactcaggct cagggcgctg cccgggtggc 1980
cgcggcgcgc gccctgcagg aggcgctcgt actctccgac cgcgcgccat tcgcccccc 2040
ctcgcccttc gcagagctcg ttctgcgcgc gcagcaataa agctcctttg ccgcgaaaaa 2100
a 2101

```

<210> 18

<211> 2339

<212> DNA

<213> Homo sapiens

<400> 18

```

agggttgggc agctctggcc ctgttttgag tgaggcctgt gcaccagcaa cccgccctgg 60
gccgtccgcg ttttcacagc aaccgcctt gggcccgctt gcgtttggct tatgctggg 120
tgtctccggg cccgcagcac cgggaagccc gcggtggag ttccgggac cggcactcgg 180
actacctggc cccgctgggt accgacgcgg acaactgacc cgcaggcgg gagcggcccc 240
acacgtgttt gcttaaagtc tgcgagtcg catcgtgtcc gcctctctct ctctctctct 300
gcgcgtcctg gcgcaaggcc tggggtggag ccacggctgg ggcggtgtcc caactccgaa 360
cccagcgggg cggggccgga gcgtcgggag aggccgggac cccagcgctg cgcgcgctcc 420
gaacgtcgag accccaccga gggcgggagg gggactctcg ggagccacag acgcccgaga 480
cccacgcccg gcgggaccgg ccagggatca cccccgccga cggccccggg ccccgacggc 540
ccggaagttc cgcgtgtccg ggggcaccgg gggattggcc ggggcgcggc gtgcaaggct 600
tcccgggggc ggcgactgcc gagctccgcc ctccaggcgg cccacccgc ctgccgtcct 660
ggggcgccgc cgcgcccgcg ccggcagtgg accgctgtgc gcgaaccctg aaccctacgg 720
tcccgaaccg cgggcgaggc cgggtacctg ggctgggac cggagcaagc gggcgagggc 780
agcgccctaa gcaggtacgg gcggggctca agtcgcgagg cggggaagcg ggaggcagac 840
acggacgagg gcgacacaga cacgggaccg aggggcggac accggagaga cacgggaaag 900
gggtcgggac aggagcacgt ggctcagaca ccgacgccg gaggcgcag accccggacg 960
tgtcaggcat ccccgaggc ccggagcgat ggcagccttg atgaccccg gaaccggggc 1020
cccacccgcg cctggtgact tctccgggga agggagccag ggacttccc acccttcgcc 1080
agagcccaag cagctcccgg agctgatccg catgaagcga gacggaggcc gcctgagcga 1140
agcggacatc aggggcttcg tggccgctgt ggtgaatggg agcgcgcagg gcgcacagat 1200
cggggccatg ctgatggcca tccgacttcg gggcatggat ctggaggaga cctcgggtgt 1260
gacccaggcc ctggctcagt cgggacagca gctggagtgg ccagaggcct ggcgccagca 1320
gcttgtggac aagcattcca cagggggtgt gggtgacaag gtcagcctgg tcctcgcacc 1380

```

tgccctggcg gcatgtggct gcaaggtgcc aatgatcagc ggacgtggtc tggggcacac 1440
 aggaggcacc ttggataagc tggagtctat tcttgattc aatgtcatcc agagcccaga 1500
 gcagatgcaa gtgctgctgg accaggcggg ctgctgtatc gtgggtcaga gtgagcagct 1560
 ggttcctgcg gacggaatcc tatatgcagc cagagatgtg acagccaccg tggacagcct 1620
 gccactcadc acaggttgge gtgggagcca gcctagggtc tcgggtcgcg gcagcgctga 1680
 ccgccatgga caagcccctg ggtcgctgcg tgggccacgc cctggaggtg gaggaggcgc 1740
 tgctctgcat ggacggcgca ggcccgccag acttaaggga cctggtcacc acgctcgggg 1800
 gcgccctgct ctggctcagc ggacacgcgg ggactcaggc tcagggcgct gcccggttg 1860
 ccgcggcgct ggacgacggc tcggcccttg gccgcttcga gcggatgctg gcggcgagg 1920
 gcgtggatcc cgtctggcc cgagccctgt gctcggaag tcccgagaa cgcggcagc 1980
 tgctgcctcg cggcgaggag caggaggagc tgctggcgcc cgcagatggc accgtggagc 2040
 tggtcggggc gctgcgctg gcgctggtgc tgcacgagct cggggccggg cgcagcccg 2100
 ctggggagcc gctccgctg ggggtggcg cagagctgct ggtcgacgtg ggtcagaggc 2160
 tgcgcgtgg gacccctgg ctccgctgc accgggacgg ccccgcgctc agcgcccg 2220
 agagccgccc cctgcaggag gcgctcgtag tctccgacc cgcgccattc gccgcccct 2280
 cgcccttcgc agagctcgtt ctgcccgcgc agcaataaag ctcccttgcc gcgaaaaa 2339

<210> 19

<211> 1982

<212> DNA

<213> Homo sapiens

<400> 19

aggggtgggc agctctggcc ctgttttgag tgaggcctgt gcaccagcaa cccgccttg 60
 gccgtccgcy ttttcacagc aaccgcctt gggccgctt gcgtttggct tatgctggg 120
 tgtctccggg cccgcagcac cggaaagccc gcggctggag tttcgggac cggcactcg 180
 actacctggc cccgctggtg accgacgcgg acaactgacc cgcagggcg gagcgcccc 240
 acacgtgttt gcttaaagtc tgcgagtcgg catcgtgtcc gcctctctct ctctctctct 300
 gcgctgctg gcgcaaggcc tgggtggag ccacggctgg ggccgtgtcc caactccgaa 360
 cccagcgggg cggggccga gcgtcggggc aggcggggac cccagcgctg cgcgcgctc 420
 gaacgtcgag accccaccga gggcgggagg gggactctcg ggagccacag acgcccaga 480
 cccacgcccg gcgggacgg ccagggatca ccccgccga cggccccgg ccccgacggc 540
 ccggaagtcc cgcgtgtccg ggggacccg gggattggcc gggcgcgggc gtgcaaggct 600
 tcccgggggc ggagactgcc gagctccgcc ctccaggcg cccacccgc ctgcccctc 660
 gggcgcgccg cgcgccgccc ccggcagtg accgctgtgc gcgaacctg aacctacgg 720
 tcccgacccg cgggcgaggc cgggtacctg ggtgggac cggagcaagc gggcgaggc 780
 agcgccctaa gcaggtacgg gcggggctca agtcgcgagg cggggaagcg ggagggagac 840
 acggacgagg gcgacacaga cacgggaccg agggggcgac accggagaga caccggaaa 900
 gggtcgggac agggacacgt ggctcagaca ccgacgcccg gaggcccgag accccggacg 960
 tgtcaggcat ccccgaggc ccggagcgat ggcagcctt atgaccccg gaaccggggc 1020
 cccacccgcy cctggtgact tctccgggga agggagccag ggacttccc acccttcgccc 1080
 agagcccaag cagctcccgg agctgatccg catgaagcga gacggaggcc gcctgagcga 1140
 agcgacatc aggggcttcg tggccgctgt ggtgaatgg agcgcgagg gcgcacagat 1200
 cggggccatg ctgatggcca tccgacttcg gggcatggat ctggaggaga cctcgtgct 1260
 gaccagggc ctggctcagt cgggacagca gctggagtgg ccagaggcct ggcgccagca 1320
 gcttggtgac aagcattcca cagggggtgt ggtgacaag gtcagcctg tcctcgacc 1380
 tgccctggcg gcatgtggct gcaaggtgcc aatgatcagc ggacgtggtc tggggcacac 1440
 aggaggcacc ttggataagc tggagtctat tcttgattc aatgtcatcc agagcccaga 1500
 gcagatgcaa gtgctgctgg accaggcggg ctgctgtatc gtgggtcaga gtgagcagct 1560
 ggttcctgcy gacggaatcc tatatgcagc cagagatgtg acagccaccg tggacagcct 1620
 gccactcadc acaggttgge gtgggagcca gcctagggtc tcgggtcgcg gcagcgctga 1680
 ccgccatgga caagcccctg ggtcgctgcy tgggccacgc cctggaggtg gaggaggcgc 1740
 tgctctgcat ggacggcgca ggcccgccag acttaaggga cctggtcacc acgctcgggg 1800
 gcgccctgct ctggctcagc ggacacgcgg ggactcaggc tcagggcgct gcccggttg 1860
 ccgcgcgcg cgcctgcag gaggcgctc tactctccga ccgcgcgcca ttcgcccgc 1920
 cctcgccctt cgcagagctc gttctgccgc cgcagcaata aagctcctt gcccgaaaa 1980
 aa

<210> 20

<211> 1804

<212> DNA

<213> Homo sapiens

<400> 20

```

ccgaggctgg ctggctccgc aggtccgctg acgtcgccgc ccagatggcc tccaggctga 60
ccctgctgac cctcctgctg ctgctgctgg ctggggatag agcctcctca aatccaaatg 120
ctaccagcag ttatctccaa gatgctattc gttgaaccca tcctggaggt ttccagcttg 180
ccgacaacca actcaacaac caattcagcc accaaaataa cagctaatac cactgatgaa 240
cccaccacac aaccaccac agagcccacc acccaaccca ccatccaacc caccacaacca 300
actaccacag tcccaacaga ttctcctacc cagcccacta ctgggtcctt ctgcccagga 360
cctgttactc tctgctctga cttggagagt cattcaacag aggccgtgtt gggggatgct 420
ttggtagatt tctcctgaa gctctaccac gccttctcag caatgaagaa ggtggagacc 480
aacatggcct tttcccatt cagcatcgcc agcctcctta cccaggctct gctcggggct 540
ggggagaaca ccaaaacaaa cctggagagc atcctctctt accccaagga cttcacctgt 600
gtccaccagg ccctgaaggg cttcacgacc aaaggtgtca cctcagtctc tcagatcttc 660
cacagcccag acctggccat aagggacacc tttgtgaatg cctctcggac cctgtacagc 720
agcagcccca gagtectaag caacaacagt gacgccaact tggagctcat caacacctgg 780
gtggccaaga acaccaacaa caagatcagc cggctgctag acagtctgcc ctccgatacc 840
cgccttgtcc tctcaatgc tatctacctg agtgccaagt ggaagacaac atttgatccc 900
aagaaaacca gaatggaacc ctttcacttc aaaaactcag ttataaaagt gccatgatg 960
aatagcaaga agtaccctgt ggcccatttc attgacccaa ctttgaaagc caaggtgggg 1020
cagctgcagc tctcccacaa tctgagtttg gtgatcctgg taccacagaa cctgaaacat 1080
cgtcttgaag acatggaaca ggctctcagc ccttctgttt tcaaggccat catggagaaa 1140
ctggagatgt ccaagttcca gccactctc ctaacactac cccgcatcaa agtgacgacc 1200
agccaggata tgctctcaat catggagaaa ttggaattct tcgatttttc ttatgacctt 1260
aacctgtgtg ggctgacaga ggaccagat cttcaggttt ctgcatgca gcaccagaca 1320
gtgctggaac tgacagagac tgggggtggag gcggtgcag cctccgccat ctctgtggcc 1380
cgcaccctgc tggctcttga agtgacagcag ccctcctctc tcgtgctctg ggaccagcag 1440
cacaagttcc ctgtctcat ggggcagta tatgaccca gggcctgaga cctgcaggat 1500
caggttaggg cgagcgctac ctctccagcc tcagctctca gttgcagccc tgetgtgcc 1560
tgccctggact tggccctgc cacctcctgc ctcagggtgc cgctatccac caaaagggct 1620
ccctgagggt ctgggcaagg gacctgcttc tattagccct tctccatggc cctgccatgc 1680
tctccaaacc actttttgca gctttctcta gttcaagttc accagactct ataaataaaa 1740
cctgacagac catgtaaagc ggcagatatt ttagtagtag taggctagta gtagtagcgg 1800
ccgc 1804

```

<210> 21

<211> 682

<212> DNA

<213> Homo sapiens

<400> 21

```

atagccacgc tgccactggt gtctggcatc cacagcatag cacagggccc tgctgggcag 60
cagcacctta ggtcttanag tcttcaactg tctccctcta ggtggagaaa gaactcactt 120
acgagaagtt cgtagaatgg acgaggctgg acatgatgga tgaagaggag gtggaagtgt 180
ccctcccgcg gtttaaaacta gaggaaagct acgacatgga gagtgtcctg cgcaacctgg 240
gcatgactga tgccttcgag ctgggcaagg cagacttctc tggaaatgtcc cagacagacc 300
tgtctctgtc caaggtcgtg cacaagtctt ttgtggaggt caatgaggaa ggcacggagg 360
ctgcagccgc cacagctgcc atcatgatga tgcggtgtgc cagattcgtc ccccgcttct 420
gcgccgacca ccccttcctt ttcttcatcc agcacagcaa gaccaacggg attctcttct 480
gcgccgctt ttcctctccg tgaggacagg gcagtcttgg tgtgcagccc ctctcctctc 540
tgtccctga cactccacag tgtgcctgca acccaagtgg ccttatccgt gcagtgggtg 600
cagttcagaa ataaagggcc catttgggg atgccgcatt caaaaaaag ttaccaatct 660
gaagtgggag cgattttttt tt 682

```

<210> 22

<211> 1349

<212> DNA

<213> Homo sapiens

<400> 22

```

cagggcagca tgtgattgac tgcgaattcg ggtctcgagc aggaagtacc aagggaggat 60
ggagatggta ataatcaggg ttgggtggag aatatctgag gaaactgcac ttgatttggg 120
ccttgaagag taattgactg gatttagatt tatctagaaa ggtcgttccc agcagaagca 180
acaagaacaa caagcttgga ctgccatcat ggatgttctc gcagaagcaa atggcacctt 240
tgccttaaac cttttgaaaa cgctgggtaa agacaactcg aagaatgtgt ttttctcacc 300
catgagcatg tectgtgccc tggccatggg ctacatgggg gcaaaggga acaccgctgc 360
acagatggcc cagatacttt cttcaataa aagtggcggg ggtggagaca tccaccaggg 420
cttccagtct cttctcaccg aagtgaacaa gactggcacg cagtacttgc ttaggggtggc 480
caacaggctc tttggggaaa agtcttgtga tttcctctca tcttttagag attcctgcca 540
aaaattctac caagcagaga tggaggagct tgactttatc agcgccgtag agaagtccag 600
aaaacacata aacacctggg tagctgaaaa gacagaaggt aaaattgcgg agttgtcttc 660
tccgggctca gtggatccat tgacaaggct ggttctgggt aatgtgtctc atttcagagg 720
aaactgggat gaacagtttg acaaggagaa caccgaggag agactgttta aagtcagcaa 780
gaatgaggag aaacctgtgc aaatgatgtt taagcaatct acttttaaga agacctatat 840
aggagaaata tttacccaaa tcttgggtct tccatatgtt ggcaaggaa tgaatatgat 900
catcatgctt ccggacgaga cactgactt gagaacgggt gagaaagaac tcaactacga 960
gaagtctgta gaatggacga ggctggacat gatggatgaa gaggagggtg aagggaaaggc 1020
acggaggctg cagccgccac agctgccatc atgatgatgc ggtgtgccag attcgtcccc 1080
cgcttctgcg ccgaccaccc cttccttttc ttcattccagc acagcaagac caacgggatt 1140
ctcttctgcg gccgcttttc ctctccgtga ggacagggca gtcttgggtg gcagcccctc 1200
tctctctgt cccctgacac tccacagtgt gcctgcaacc caagtggcct tatccgtgca 1260
gtggtggcag ttcagaaata aagggcccat ttgtgggatg ccgcattcaa aaaaaagtta 1320
ccaatctgaa gtgggagcga tttttttt 1349

```

<210> 23

<211> 953

<212> DNA

<213> Homo sapiens

<400> 23

```

cagggcagca tgtgattgac tgcgaattcg ggtctcgagc aggaagtacc aagggaggat 60
ggagatggta ataatcaggg ttgggtggag aatatctgag gaaactgcac ttgatttggg 120
ccttgaagag taattgactg gatttagatt tatctagaaa ggtcgttccc agcagaagca 180
acaagaacaa caagcttgga ctgccatcat ggatgttctc gcagaagcaa atggcacctt 240
tgccttaaac cttttgaaaa cgctgggtaa agacaactcg aagaatgtgt ttttctcacc 300
catgagcatg tectgtgccc tggccatggg ctacatgggg gcaaaggga acaccgctgc 360
acagatggcc cagatacttt cttcaataa aagtggcggg ggtggagaca tccaccaggg 420
cttccagtct cttctcaccg aagtgaacaa gactggcacg cagtacttgc ttaggaaagc 480
tacgacatgg agagtgtcct gcgcaacctg ggcatgactg atgccttcca gctgggcaag 540
gcagacttct ctggaatgtc ccagacagac ctgtctctgt ccaagggtcgt gcacaagtct 600
tttgtggagg tcaatgagga aggcacggag gctgcagccg ccacagctgc catcatgatg 660
atgcggtgtg ccagattcgt cccccgcttc tgcgccgacc accccttctc tttcttcatc 720
cagcacagca agaccaacgg gattctcttc tgcggccgct tttcctctcc gtgaggacag 780
ggcagtcttg gtgtgcagcc cctctcctct ctgtcccctg acactccaca gtgtgcctgc 840
aaccctaagt gccttatccg tgcagtgggt gcagttcaga aataaagggc ccatttgggtg 900
gatgccgcat tcaaaaaaaaaa gttaccaatc tgaagtggga gcgatttttt ttt 953

```

<210> 24

<211> 498

<212> DNA

<213> Homo sapiens

<400> 24

```

cagggcagca tgtgattgac tgcgaattcg ggtctcgagc aggaagtacc aagggaggat 60
ggagatggta ataatcaggg ttgggtggag aatatctgag gaaactgcac ttgatttggg 120
ccttgaagag taattgactg gatttagatt tatctagaaa ggtcgttccc agcagaagca 180

```

acaagaacaa caagcttgga ctgccatcat ggatgtttct gcagaagcaa atggcacctt 240
 tgccttaaac cttttgaaaa cgctgggttaa agacaactcg aagaatgtgt tttctcacc 300
 catgagcatg tctgtgccc tggccatggt ctacatgggg gcaaagggaa acaccgctgc 360
 acagatggcc cagcgttttc aaaagggtta aggcaaaggt gccatttgct tctgcgagaa 420
 catccatgat ggcagacctg gaacaagatt taaaatcagt atcacttaag cagcttcac 480
 gcgactgcat ctcacgcg 498

<210> 25

<211> 2291

<212> DNA

<213> Homo sapiens

<400> 25

ccgggctgat ccgagccgag cgggccgtat ctecttgtcg gcgccgctga ttcccggctc 60
 tgcggaggcc tctaggcagc cgcgagctt ccgtgtttgc tgcgcccga ctgcgattta 120
 caaccctgaa gaatctccct atccctattt tgtccccctg cagtaataaa tcccattatg 180
 gagatctcga aactttataa agggatatag tttgaattct atggagtgtg attttgtgta 240
 tgaattatat ttttaaaaca ttgaagagtt ttcagaaaga aggctagtag agttgattac 300
 tgatacttta tgctaagcag tacttttttg gtagtacaat attttgttag gcgtttctga 360
 taacactaga aaggacaagt tttatcttgt gataaattga ttaatgttta caacatgact 420
 gataattata gctgaatagt ccttaaatga tgaacagggt atttagtttt taaatgcagt 480
 gtaaaaagtg tgctgtggaa attttatggc taactaagtt tatggagaaa ataccttcag 540
 ttgatcaaga ataatagtgg tatacaaagt taggaagaaa gtcaacatga tgctgcagga 600
 aatggaaaca aatacaaatg atatttaaca aagatagagt ttacagtttt tgaactttaa 660
 gccaaattca tttgacatca agcactatag caggcacagg ttcaacaaag cttgtgggta 720
 ttgacttccc ccaaaagtgg tcagctgaag taatttagcc cacttaagta aatactatga 780
 tgataagctg tgtgaactta gcttttaaat agtgtgacca tatgaagggt ttaattactt 840
 ttgtttattg gaataaaatg agattttttg ggttgtcatg ttaaagtgtt tatagggaaa 900
 gaagcctgca tataattttt taccttgtgg cataatcagt aattgggtctg ttattcaggc 960
 ttcatagctt gtaaccaa ataaataaaa ggcataattt aggtattcta tagttgctta 1020
 gaattttgtt aatataaatc tctgtgaaaa atcaaggagt ttaatatatt tcagaagtgc 1080
 atccaccttt cagggtctta agttagtatt actcaagatt atgaacaaat agcacttagg 1140
 ttacctgaaa gagttactac aaccccaaa agttgtgttc taagtagtat cttggtaatt 1200
 cagagagata ctcatctac ctgaatataa actgagataa atccagtaaa gaaagtgtag 1260
 taaattctac ataagagtct atcattgatt tctttttgtg gtaaaaaatct tagttcatgt 1320
 gaagaaattt catgtgaatg ttttagctat caaacagtag tgctcacctac tcatgcacaa 1380
 aactgcctcc caaagacttt tcccagggtc ctcgatatcaa aacattaaga gtataatgga 1440
 agatagcacg atcttgtcag attggacaaa cagcaacaaa caaaaaatga agtatgactt 1500
 ttctgtgtaa ctctacagaa tgtctacata ttcaaatttc cccgccgggg tgctgtctc 1560
 agaaaggagt cttgctcggt ctggtttcta ttatactgggt gtgaatgaca aggtcaaatg 1620
 cttctgttgt ggctgatgc tggataactg gaaactagga gacagtccta ttcaaaagca 1680
 taaacagcta tatcctagct gtagctttat tcagaatctg gtttcagcta gtctgggatc 1740
 cacctctaag aatacgtctc caatgagaaa cagttttgca cattcattat ctcccacctt 1800
 ggaacatagt agcttgttca gtggttctta ctccagcctt tctccaaacc ctcttaattc 1860
 tagagcagtt gaagacatct ctcatcgag gactaacccc tacagttatg caatgagtac 1920
 tgaagaagcc agatttctta cctaccatat gtggccatta acttttttgt caccatcaga 1980
 attggcaaga gctggttttt attatatagg acctggagat agggtagcct gctttgcctg 2040
 tgggtgggaag ctcaagtaact gggaaccgaa ggataatgct atgtcagaac acctgagaca 2100
 ttttcccaac tgtccatttt tggaaaattc tctagaaact ctgaggttta gcatttcaaa 2160
 tctgagcatg cagacacatg cagctcgaat gagaacattt atgtactggc catctagtgt 2220
 tccagttcag cctgagcagc ttgcaagtgc tgggttttat tatgtgggta agaaactgaa 2280
 tctgctaatt a 2291

<210> 26

<211> 3450

<212> DNA

<213> Homo sapiens

<400> 26

atacactcca agaatactgg gcttatgggt ggggttggtt tttgtttgt tttgtttgt 60
 tttcaagtca tgtctttatc cccatataat ggagaatgtg ccacttggct aataatgtgt 120
 tttcaaaact acaagttcag tgatgacagg aaagagggtt aaagtagtcc cacagaggct 180
 ggtagaaaag gcgaatcaca cttaagcacc agcagggtta aaacctgaaa ggggtggccct 240
 gacaattcag actataggtt ttacagcatg ccacttgtgc aataggaggt ctagggttga 300
 aactttcaag aacgagagga ggtgaaggaa ggagacgttt actgctcaaa tgccatgcat 360
 ttcactgctt gccactgaac ttgtatttga atgacttagt aatgcttaat ataattgggc 420
 aactttttta gcactttgga aagagtcac aatctttctg gtaaattata aaagttttct 480
 gagtgagaaa aggtgtgttt ggagtttgtt tgacttttta tattattatt gttattaata 540
 aagaaaaaaa tctacagcat ttttcagact ccaccctaga aaatatgtac ccctgaattt 600
 gggttgcagt ttgatactca gggaaggatg tattccatag atatcctttc cgtataaaac 660
 actaacatct ttgagaaatt cactaccata ctaacttcaa ttgttgtcac tatgcattct 720
 tcaatgaaaa ctagtctatt tttccatata gtaatgcagt tagggttctc agcactttct 780
 ttcttctatc ctttttttaa ctcttcatat tatgttcaga tgatcatact gtcaaggttt 840
 ggggtgcccgg accaaaatgg ggaccgtgta gagcgggtgt acagtaaagc gctggacagg 900
 gtcattngcc ttcccttctc tccccctccc cgctccccc ccgaccgagg agagcaccat 960
 gtcggcgccg gcggccaaaag tcagtaaaaa ggagctcaac tccaaccacg acggggccga 1020
 cgagacctca gaaaaagaac agcaagaagc gattgaacac attgatgaag taaaaatga 1080
 aatagacaga cttaatgaac aagccagtga ggagattttg aaagtagaac agaaatataa 1140
 caaactccgc caaccatttt ttcagaagag gtcagaattg atcgccaaaa tcccaaattt 1200
 ttgggtaaca acatttgtca accatccaca agtgtctgca ctgcttgggg aggaagatga 1260
 agaggcactg cattatttga ccagagttga agtgacagaa tttgaagata ttaaatacagg 1320
 ttacagaata gatttttatt ttgatgaaaa tcttacttt gaaaataaag ttctctccaa 1380
 agaatttcat ctgaatgaga gtggtgatcc atcttcgaag tccaccgaaa tcaaattgaa 1440
 atctggaag gatttgacga aacgttcgag tcaaacgcag aataaagcca gcaggaagag 1500
 gcagcatgag gaaccagaga gcttctttac ctgggttact gaccattctg atgcaggtgc 1560
 tgatgagtta ggagaggatg aagaaggaga agggagatg gatgaaggtg aagaagatga 1620
 gggtcccgat atggatgatg ttgacgaaga aggggatgag gatgaaggtg aaatagaaca 1680
 ggaggaagga ttagaagata ttgacgaaga aggggatgag gatgaaggtg aaatagaaca 1740
 agatgatgat gaaggggagg aaggagagga ggatgaagga gaagatgact caagttgcag 1800
 ctgatggatt ccaaccttcc tttttttaaa ttttctccag tccctgggag caagttgcag 1860
 tctttttttt tttttttttt ttccctcttg tgctcagtcg ccctgttctt gaggtctctt 1920
 ttctctactc catggttctc aatttatttg gggggaaata ccttgagcag aatacaatgg 1980
 gaaaagagtc tctacccctt tctgttcgaa gttcattttt atcccttctt gtctgaacaa 2040
 aaactgtatg gaatcaacac caccgagctc tgtgggaaaa aagaaaaacc tgctcccttc 2100
 gctctgctgg aagctggagg gtgctaggcc cctgtgtagt agtgcataga attctagctt 2160
 ttttctctct ttctctgtat attgggctca gagagtacac tgtgtctcta tgtgaatatg 2220
 gacagttagc atttaccac atgtatctgt ctactttctc ttgtttaaaa aaagaaaaaa 2280
 aaacttaaaa aaatggggtt atagaagggt agcaaagggt gggtttgaga tgtttgggtg 2340
 ggtaagtgg gcattttgac aacatggctt ctcccttggc atgtttaatt gtgatatttg 2400
 acagacatcc ttgcagttta agatgacact tttaaaataa attctctcct aatgatgact 2460
 tgagccctgc cactcaatgg gagaatcagc agaacctgta ggatcttatt tggaattgac 2520
 attctctatt gtaattttgt tctgttttat ttttaaattt tctttttgtt tcaactgaaa 2580
 ggaaagatga tgctcagttt taaacgttaa aagtgtacaa gttgctttgt tacaataaaa 2640
 ctaaatgtgt acacaaagga tttgatgctt ttctctcagc ataggtatgc ttactatgac 2700
 cttccaagtt tgacttgtat aacatcactg tcaaactttg tcaccctaac ttcgtatttt 2760
 ttgatacgca ctttgcagga tgacctcagg gctatgtgga ttgagtaatg ggatttgaat 2820
 caatgtatta atatctccat agctgggaaa cgtgggttca atttgccatt ggtttctgaa 2880
 agtattcaca tcatttggga taccagatag ctcaatactc tctgagtaca ttgtgccctt 2940
 gattttttat tccaagtggc agttttttaa attggccttt tacctggata taaattaatt 3000
 gtgctgcca ccaccatcca acagacctgg tgctctaatt ccaagttata cacgggacag 3060
 ttgctggcat gtcttcattg gctatataaa atgtggccaa gaagataggc tctcagtaag 3120
 aagtctgatg gtgagcagta actgtccctg ctttctggta taaagctctc aaatgtgacc 3180
 atgtgaatct ggggtgggata atggactcag ctctgtctgc tcaatgccat tgtgcagaga 3240
 agcaccctaa tgcataagct ttttaatgct gtaaaatata gtcgctgaaa ttaaatgcca 3300
 ctttttcaga ggtgaattaa tggacagtct ggtgaacttc aaaagctttt tgatgtataa 3360
 aacttgataa atggaactat tccatcaata ggcaaaagtg taacaacctt tctagatgga 3420
 tagtatgtaa tttctgcaca ggtctctgtt 3450

<211> 917
 <212> DNA
 <213> Homo sapiens

<400> 27
 agcgagcgcc gggaggaggc ggccggaccg agcggggcgc cgcgcggtgtg gcgtgagggg 60
 aagccgcttn nccnnccctc tcgccttccc ttctctcccc ctccccgctc cccccccgac 120
 cgcgagagagc accatgtcgg cgccggcggc caaagtcagt aaaaaggagc tcaactccaa 180
 ccacgacggg gccgacgaga cctcagaaaa agaacagcaa gaagcgattg aacacattga 240
 tgaagtacaa aatgaaatag acagacttaa tgaacaagcc agtgaggaga ttttgaaagt 300
 agaacagaaa tatacaaac tccgcccaacc attttttcag aagagggtcag aattgatcgc 360
 caaaatccca aatttttggg taacaacatt tgtcaaccat ccacaagtgt ctgcaactgct 420
 tggggaggaa gatgaagagg cactgcatta tttgaccaga gttgaagtga cagaatttga 480
 agatattaaa tcaggttaca gaatagattt ttattttgat gaaaatcctt actttgaaaa 540
 taaagtcttc tccaaagaat ttcattctgaa tgagagtggg gatccatctt cgaagtcac 600
 cgaaatcaaa tggaaatctg gaaaggattt gacgaaacgt tcgagtcaaa cgcagaataa 660
 agccagcagg aagaggcagc atgaggaacc agagagcttc tttacctggt ttactgacca 720
 ttctgatgca ggtgctgatg agttaggaga ggtcatcaaa gatgatattt ggccaaaccc 780
 attacagtac tacttggttc ccgatatgga tgatgaagaa ggagaaggag aagaagatga 840
 tgatgatgat gaagaggagg aaggattaga agatattgac gaagaagggg atggaggcgg 900
 aggtggaag ggcccg 917

<210> 28
 <211> 1112
 <212> DNA
 <213> Homo sapiens

<400> 28
 gcacgaggcc ctggtgccgt ntgcactgag tttcagcaga gattaaacat tttatataaa 60
 tgactcttaa agctttacac cttgggacca gtgtaccttc tcgtgcagaa tacatttaga 120
 tataaaaaaga cgttattaat acattgcaca gttttcaaaa tttaaaaaca aaaccgaacg 180
 ctgctctgcg gcagccgccg ccggttgctg ctacatgaac ggtcccagcc gaggcccagc 240
 gcccttccaa cgctcgctgc cccggcaggt tccctcgggg ctctttgggg tctaaattgg 300
 ctcaccgcag cctcttgccg ggggtctgct ccaccgagcc cacgccaggg gcggcgcttg 360
 gagagggaca cggcgcgggg acatcgcccg acgacttctc aggcgctgat ctcttgccgt 420
 tggcgaagaa atctgcaccg tctcgcggtg gaacgcgggc accgagtcgc tgtccacttc 480
 ggtccactgc aggcgtccag ggcccgcag cggcatgtcc tgctggaagt cgtaatccca 540
 gcggttcttg tctcgcggt tcagctcgcc caggcgggcc tgcagctcgc ggctcagctc 600
 ctggtgttcc accggcccga agaggctcgc gcaggcgctg gtgcgacta gtactgggaa 660
 ggtccacagg gcgacaagac gctccatcgt ggatgtgctg cggaggagac cgctcgacat 720
 ggcccggggc tgcgcaaacg cgggcagcga gagaggagag gacagcgaga agaaggggaa 780
 aggagaggag gagaggcgcg aggcggggcg caaggagagc ccgcgcgcgc ccgactctgc 840
 gtgtgcgagg gacgcggcgg ctacctggt gtccgggtgt ggactcttct gcgtcgggtt 900
 cgcctgtctc gtccggacgg cagccgcgcc ccctcgatgc ctgctggcta gctcgtcgcg 960
 tcmrgcctgg ccggcaccgc tcgagcacag cgcacttgcc ctgtggaacg ccagcccgcg 1020
 ctgcgcccc tttatacgcg cgggccccac ccccgctgcgc gcggggcccg ccgcgattag 1080
 cataatgtag tattttcagt ttcaacaaca cc 1112

<210> 29
 <211> 1929
 <212> DNA
 <213> Homo sapiens

<400> 29
 ctttagagct gtaaaaatct tcatgagaca cactgatgat gacgctgaga cacttgccat 60
 ttattctttt attaatcttc tcaggagaac tctatgcaga agagaaacag tgtgattttc 120
 ctaccgtgga aaatggaagg attgcccaat attattatac gtttaaaagc ttttacttcc 180
 ccattgagct agacaaaaaa ctatcattct tctgtttggc tggctatgca accgaaagtg 240
 ggaagcaaga agagcaaatc aggtgcacag cagaaggctg gtctccaaac ccaagggtgct 300

acaagaaatg tctgaagcct gacctaagga atggctacgt ctccaatgac aaagtactgt 360
 acaaacttca agagaggatg agctacgggt gctcttcagg atacaaaacc actgggggaa 420
 aggacgagga ggtgggtccac tgtctttctg caggggtggc ttctcaaccg tctgcagga 480
 aagaacaaga gacatgtttg gcccctgagt tggaacatgg aaattactcc acgacgcaga 540
 gaacattcaa agtgaaggac atagtggctt acacatgcac tgcaggctac tacaccacta 600
 caggggaagca gactggggaa gcagagtggc aggtcaatgg ctgggtccctc acaccacagt 660
 gcaacaaatt aatgtgctct tctttgagat taatagaaaa tggctatttt catcctgtaa 720
 agcaaacata tgaagaagga gatgtagttc aatttttctg tcatgaaaat tattatctaa 780
 gtggatctga ttttaattcag tgctataact ttggctggta tccagaatct cccatattgtg 840
 aaggaagaag aaatcgatgt cctcctccac ctgtgcctct aaattctaaa attcaaccac 900
 attcaacaac ttaccgtcac ggagaaagag tgcatataga atgtgaactt aatttgtgat 960
 tcagggttca gaagaactgc tctgtgaaaa tgggaagtgg acagaacctc caaatgtat 1020
 tgaggaagag gagaaggtag cctgcgagca accaccctcc gttgagaatg gtgttgaca 1080
 cccacactct gagatttact acagtgggga taaagtgaca tacagggtgtg gagggggcta 1140
 cagtctcaga ggatcaagta cgataacttg caatcgtggc cgatggacac tgccccctga 1200
 gtgtgttgaa aatattgaga attgtaagcc tctcctgac atagcaaacg gtgtggttgt 1260
 tgatgggtta ctggcaagtt acacaacagg atcttctgtg gagtaccgat gcaatgagta 1320
 ttacttattg aaggggtcgg aaacatctcg ctgtgaacaa ggagcgtggg catctccacc 1380
 tgtctgcttg gagccctgca ctattgatgt ggatcacatg aacaggaata acatacagtt 1440
 gaagtggaaa tatgagggca agattttaca tggagacctc atagattttg tgtgtaagca 1500
 gggatataac ttgtcaccat caatcccact gtggagata tctgcgcagt gcaatagagg 1560
 cgatgtgagg taccatcatgt gcattagaaa agaactctaaa gggatgtgtg catctcctcc 1620
 agtgataaga aatggagata ttgttagttc agcagcccg cactatgaaa acggctcctc 1680
 agtagaatac cgggtgtttg ataactattt cctacaaggg tcccagaatg tctattgtgt 1740
 cgatggagtg tggactacac caccatcgtg tctagagcct taaactacac atggaataga 1800
 gggcacaaca cactaataca gcatgtggaa gaagacaatg tacaagtgtc ccagaggcct 1860
 ggagagttaa ggaatcactt cataaaggag tgacatcata aagaaatgac atcataaatg 1920
 aatgacttc

<210> 30

<211> 1679

<212> DNA

<213> Homo sapiens

<400> 30

acggcgagcc tcatcctccg ggtgcggcgc tgagcagcga gtencgactg tgctcgctgc 60
 tcagcgccgc acccgagga tgaggctcgc cgtgggagcc ctgctggtct gcgcgctcct 120
 ggggctgtgt ctggctgtcc ctgataaaac tgtgagatgg tgtgcagtgt cggagcatga 180
 ggccactaag tgccagagtt tccgcgacca tatgaaaagc gtcattccat ccgatggctc 240
 cagtgttgct tgtgtgaaga aagcctccta ccttgattgc atcagggccca ttgcggcaaa 300
 cgaagcggat gctgtgacac tggatgcagg tttggtgtat gatgcttacc tggctcccaa 360
 taacctgaag cctgtggtgg cagagttcta tgggtcaaaa gaggatccac agactttcta 420
 ttatgctgtt gctgtggtga agaaggatag tggcttccag atgaaccaag agtggagtgt 480
 gcctgtgaag tgggtgtgcgc tgagccacca cgagaggctc aagtgtgatg gcatcgccaa 600
 taacagtgtg gggaaaatag agtgtgtatc agcagagacc accgaagact acatagcggg 660
 gatcatgaat ggagaagctg atgccatgag cttggatgga gggtttgtct acatagcggg 720
 caagtgtggt ctggtgcctg tcttggcaga aaactacaat aagagcgata attgtgagga 780
 tacaccagag gcagggtatt ttgctgtagc agtgggtgaag aaatcagctt ctgacctcac 840
 ctgggacaat ctgaaaggca agaagtcctg ccatacggca tttggcagaa ccgctggctg 900
 gaacatcccc atgggcctgc tctacaataa gatcaaccac tgcagatttg atgaattttt 960
 cagtgaaggt tgtgcccctg ggtctaagaa agactccagt ctctgtaagc tgtgtatggg 1020
 ctcaggccta aacctgtgtg aacccaacaa caaagaggga tactacggct acacaggcgc 1080
 tttcagggtg ctggttgaga agggagatgt ggcctttgtg aaacaccaga ctgtccaca 1140
 gaacactggg ggaaaaaacc ctgatccatg ggctaagaat ctgaatgaaa aagactatga 1200
 gttgctgtgc cttgatggtg ccaggaaacc tgtggaggag tatgcgaact gccacctggc 1260
 cagagccccc aatcacgctg tggtcacacg gaaagataag gaagcttgcg tccacaagat 1320
 attacgtcaa cagcagcacc tatttggaag caacgtaact gactgctcgg gcaacttttg 1380
 tttgttccgg tcggaaacca aggaccttct gttcagagat gacacagtat gtttgccaa 1440
 acttcatgac agaaacacat atgaaaaata cttaggagaa gaatatgtca aggtgtgtg 1500
 taacctgaga aaatgctcca cctcatcact cctggaagcc tgcactttcc gtagacctta

aaatctcaga ggtagggctg ccaccaaggt gaagatggga acgcagatga tccatgagtt 1560
tgccctgggt tcaactggccc aagtggtttg tgctaaccac gtctgtcttc acagctctgt 1620
gttgccatgt gtgctgaaca aaaaataaaa attattattg attttatatt tcakkrrea 1679

<210> 31

<211> 2410

<212> DNA

<213> Homo sapiens

<400> 31

aaaaaawwaa aaaaggagaa gggattccta tctgtatata gggaaggaat cctatctgca 60
tatttcgttg ttagcaccat ccctcatccc ggtggggctt ggaactttcc atcaattctt 120
tctgtctcg tttctctttc atcctttgcc tgggtgtgcc tgtctcaggg agaaatcagt 180
cacctgcagg ccttgcaggg ctcttaggct ctgggaaatt tgcatacagg gtgtcaggta 240
cttcttattg ctgtccaaag ggaaaaaaa agtgagacaa agaactctcc cggagccttt 300
ccggctgcac tcagaggctc tcgagagggt cagaaggacc tggaaaggca gctaaataaa 360
agatgccctg gggccgaagg ccaacctggc tgttgctcgc ctctctgctg gtgtttttaa 420
agattagcat actcagcgtc acagcatggc agaccgggaa ctgtcagcca ggtcctctcg 480
agagaagcga gagaagcggg acttgtgccg gtccctgcccc ctccctagtt ttctcacaag 540
gaaagagcat ctctcggatt gggctatccc atcggtaata aggggaaca agaggactgg 600
ccaaaacagg gtacgtcttc aaggcagcat gctgaagccc tegtcaactg ttgtgggtcca 660
tccattggca aaaccagggt cagatccctg cttatacagg aatggaggct gtgaacacat 720
ctgccaagag agcctgggca cagctcgggt tttgtgtcgt gaaggttttg tgaaggcctg 780
ggatgggaaa atgtgtctcc ctccaggatta tccaatcctg tcagggtgaa atgtgatct 840
tagtaaagag gtgacatcac tgagcaactc cactcaggct gaagtaccag acgatgatgg 900
gacagaatct tccacactag tggctgaaat catgggtgtc agcatgaact atgaagatga 960
ctgtgggtccc ggggggtgtg gaagccatgc tcgatgcgtt tcagacggag agactgctga 1020
gtgtcagtggt ctgaaagggg ttgccaggga tggaaacctg tgttctgata tagatgagtg 1080
tgtgtcgtggt agatcggact gccccagcac ctctcctcagg tgcatacaac ctgaagggtg 1140
ctacgtctgc agatgctcag aaggctacga aggagacggg atctcctgtt tcgatattga 1200
cgagtgccag cggggggcgc acaactgcgc tgagaatgcc gcctgcacca acacggaggg 1260
aggctacaac tgcacctgcg caggccgccc atcctcgcgc ggactgagtt gccctgactc 1320
taccgcaccc tctctccttg gggaagatgg ccaccatttg gaccgaaata gttatccagg 1380
atgcccatcc tcatatgatg gatactgcct caatgggtgg gtgtgcatgc atattgaatc 1440
actggacagc tacacatgca actgtgttat tggctattct ggggatcgat gtcagactcc 1500
accatcaagt gacagaggac cccaggaaat agagggaac tcccacctac cctcctacag 1560
acctgtgggg ccggagaagc tgcattctct ccagtcagct aatggatcgt gtcacgaaag 1620
ggctccagac ctgccacggc agacagagcc agttcagtag aaactgggag tagacagaag 1680
gtacagaagg gaaaataaca aaccaggctg atgatggtag agtgctacag acttgggtact 1740
ccagtttcca cggctaatac ctgctcgtc agggctcctg agatagctgc acagctgcag 1800
agctgcacag cgggatatgt gcgacttttg cttcttgctt taagcagttc cactgaagat 1860
actcaaaaga gaagtggaga aaatcattag aaaccaaagt caagacattc atatataagc 1920
tgtgtcttct tcaactggacg gtttgctct tttccttttg cctcagaagg agtgggttaa 1980
agcaggtgac cccatgctct gtcaaccctt gaataaatga tgtgatctac atagaagctc 2040
tagctcactc tcaggaacgc ttggaacact ataacttttg ctatgatata ctgccaagtg 2100
tggcccacgc tcataattgt gctttctgaa ttgtgataaa ttagtgaaaa aactgtaact 2160
tagaatctga tttattcagg attagatcat ctttttatac tataaaaaatc ttcgaatgaa 2220
aatatttaac tttaaaaaca ttaccttaat cattgtcttt tcttcttgaa gtctttccca 2280
gtgaaaacgc tcaattctgc tgtttccata gaatttttaa tttattttaa gacatgagat 2340
tgtaaacaaa ttgcttgatt tattttatcc taattattta aataaaatca ccctaaagca 2400
tcagcatttt 2410

<210> 32

<211> 1134

<212> DNA

<213> Homo sapiens

<400> 32

aaaaaawwaa aaaaggagaa gggattccta tctgtatata gggaaggaat cctatctgca 60

tatttcgttg ttagcaccat cctcatccc ggtggggctt ggaactttcc atcaattctt 120
 tcctgtctcg tttctctttc atcctttgcc tgggtgtgcc tgtctcagg agaaatcagt 180
 cacctgcagg ccttgcagg ctcttaggct ctgggaaatt tgcatacgg gtgtcaggta 240
 cttcttattg ctgtccaaag ggaaaaaaa agtgagacaa agaactctcc cggagccttt 300
 ccggctgcac tcagaggctc tcgagagggtg cagaaggacc tggaaaggca gctaaataaa 360
 agatgccctg gggccgaagg ccaacctggc tgttgctcgc cttcctgctg gtgtttttaa 420
 agattagcat actcagcgtc acagcatggc agaccgggaa ctgtcagcca ggtcctctcg 480
 agagaagcga gagaagcggg acttgtgccc gtcttgcccc cttcctagtt ttctcacaag 540
 gaaagagcat ctctcggatt gggtatccc atcggttaata aggggtgaaca agaggactgg 600
 ccaaaacagg gtacgtcttc aaggcagcat gctgaagccc tcgtcactgg ttgtgggtcca 660
 tccattggca aaaccagggt cagatccctg cttatacagg aatggaggct gtgaacacat 720
 ctgccaaag agcctgggca cagctcgggt tttgtgtcgt gaaggttttg tgaaggcctg 780
 ggatgggaaa atgtgtctcc ctcaggatta tccaatcctg tcaggtgaaa atgctcataa 840
 ttgtgctttc tgaattgtga taaatttagt aaaaaactgt aacttagaat ctgatttatt 900
 caggattaga tcactctttt atactataaa aatcttcgaa tgaaaatatt taactttaaa 960
 aacattacct taatcattgt cttttcttct tgaagtcttt ccagtgaaa acgctcaatt 1020
 ctgctgtttc catagaattt ttaatttatt ttaagacatg agattgtaaa caaattgctt 1080
 gatttatttt atcctaatta tttaaataaa atcacctaa agcatcagca tttt 1134

<210> 33

<211> 2243

<212> DNA

<213> Homo sapiens

<400> 33

aaaaaawaa aaaaggagaa gggattccta tctgtatata gggaaggaaat cctatctgca 60
 tatttcgttg ttagcaccat cctcatccc ggtggggctt ggaactttcc atcaattctt 120
 tcctgtctcg tttctctttc atcctttgcc tgggtgtgcc tgtctcagg agaaatcagt 180
 cacctgcagg ccttgcagg ctcttaggct ctgggaaatt tgcatacgg gtgtcaggta 240
 cttcttattg ctgtccaaag ggaaaaaaa agtgagacaa agaactctcc cggagccttt 300
 ccggctgcac tcagaggctc tcgagagggtg cagaaggacc tggaaaggca gctaaataaa 360
 agatgccctg gggccgaagg ccaacctggc tgttgctcgc cttcctgctg gtgtctgctg 420
 agtgcagtg tctgaaaggg tttgccaggg atggaaacct gtgttctgat atagatgagt 480
 gtgtgctggc tagatcggac tgccccagca cctcgtccag gtgcatcaac actgaagggt 540
 gctacgtctg cagatgctca gaaggctacg aaggagacgg gatctcctgt ttcgatattg 600
 acgagtgccg gcggggggcg cacaactgcg ctgagaatgc cgcctgcacc aacacggagg 660
 gaggctacaa ctgcacctgc gcaggccgcc cactcctcgc cggactgagt tgccctgact 720
 ctaccgcacc ctctctcctt ggggaagatg gccaccattt ggaccgaaat agttatccag 780
 gatgcccatc ctcatatgat ggatactgcc tcaatgggtg cgtgtgcatg catattgaat 840
 cactggacag ctacacatgc aactgtgtta ttggctattc tggggatcga tgtcagactc 900
 gagacctacg atggtgggag ctgcgtcatg ctggctacgg gcagaagcat gacatcatgg 960
 tgggtggctgt ctgcatgggt gcaactggct tgctgtcctt cttggggatg tgggggactt 1020
 actactacag gactcgggag cagctatcaa acccccaaaa gaaccttgt gatgagccaa 1080
 gcggaagtgt gagcagcagc gggcccgaca gcagcagcg ggcagctgtg gcttctgtc 1140
 cccaaccttg gtttgtggtc ctagagaaac accaagacct caagaatggg agtctgcctg 1200
 cggatggtag gaattgtgca gtagtagatg ctggcctgtc tccctccctg cagctcgggt 1260
 cagtgcattc gacttcatgg agacagaagc cccacataga tggaaatggg acagggcaaa 1320
 gctgctggat tccaccatca agtgacagag gacccagga aatagaggga aactcccacc 1380
 taccctccta cagacctgtg gggccggaga agctgcattc tctccagtca gctaatggat 1440
 cgtgtcacga aagggtcca gacctgccac ggcagacaga gccagtccag tagaaactgg 1500
 gagtagacag aaggtagaga agggaaaata acaaaccagg ctgatgatgg tagagtgtca 1560
 cagacttggg actccagttt ccacggctaa tcaactgctg ctcagggtcc tgaagatagc 1620
 tgcacagctg cagagctgca cagcgggata gctgcgactt ttgcttcttg ctttaagcag 1680
 ttccactgaa gatactcaaa agagaagtgg agaaaatcat tagaaaccaa agtcaagaca 1740
 ttcatatata agctgtgtct tcttactggg acggtttgcc tcttttctt ttgcctcaga 1800
 aggagtgggt taaagcagg gacccatgc tctgtcaacc cctgaataaa tgatgtgatc 1860
 tacatagaag tcttagctca ctctcaggaa cgcttggaa actataactt ttgctatgat 1920
 atactgccaa gtgtggccca tgcataaat tgtgctttct gaattgtgat aaattagtga 1980
 aaaaactgta acttagaatc tgatttattc aggattagat catcttttta tactataaaa 2040
 atcttcgaat gaaaatattt aactttaaaa acattacctt aatcattgtc ttttcttctt 2100

gaagtctttc ccagtgaaaa cgtcaattc tgctgtttcc atagaatttt taattttattt 2160
taagacatga gattgtaaac aaattgcttg attttattta tcctaattat ttaaataaaa 2220
tcaccctaaa gcatacagcat ttt 2243

<210> 34

<211> 2446

<212> DNA

<213> Homo sapiens

<400> 34

aaaaaawwaa aaaaggagaa gggattccta tctgtatata gggaaggaat cctatctgca 60
tatttcgttg ttagcaccat ccctcatccc ggtggggctt ggaactttcc atcaattctt 120
tctgtctcg tttctctttc atcctttgcc tgggtgtgcc tgtctcaggg agaaatcagt 180
cacctgcagg ccttgcaggg ctcttaggct ctgggaaatt tgtcatcagg gtgtcaggta 240
cttcttattg ctgtccaaag ggaaaaaaa agtgagacaa agaactctcc cggagccttt 300
ccggctgcac tcagaggctc tcgagagggtg cagaaggacc tggaaaggca gctaaataaa 360
agatgccctg gggccgaagg cctgggatgg gaaaatgtgt ctccctcagg attatccaat 420
cctgtcaggt gaaaatgtg atcttagtaa agaggtgaca tcaactgagca actccactca 480
ggctgaagta ccagacgatg atgggacaga atcttcaca ctagtggctg aaatcatggg 540
gtcaggcatg aactatgaag atgactgtgg tcccgggggg tgtggaagcc atgtcagtg 600
cgtttcagac ggagagactg ctgagtgtca gtgtctgaaa gggtttgcca gggatggaaa 660
cctgtgttct gatatagatg agtgtgtgct ggctagatcg gactgcccc gcacctctgc 720
cagggtgcac aacactgaag gtggctacgt ctgcagatgc tcagaaggct acgaaggaga 780
cgggatctcc tgtttcgata ttgacgagtg ccagcggggg gcgcacaact gcgctgagaa 840
tgccgcctgc accaacacgg agggaggcta caactgcacc tgcgcaggcc gccatcctc 900
gcccggactg agttgccctg actctaccgc accctctctc cttggggaag atggccacca 960
tttgaccga aatagttatc caggatgccc atcctcatat gatggatact gcctcaatgg 1020
tggcgtgtgc atgcatattg aatcactgga cagctacaca tgcaactgtg ttattggcta 1080
ttctggggat cgatgtcaga ctcgagacct acgatgggtg gagctgcgtc atgtctgcta 1140
cgggcagaag catgacatca tgggtgtggc tgtctgcatg gtggcactgg tctgtctgct 1200
cctcttgggg atgtggggga cttactacta caggactcgg aagcagctat caaaccctcc 1260
aaagaacctt tgtgatgagc caagcgggaag tgtgagcagc agcggggccc acagcagag 1320
cggggcagct gtggtctctt gtccccaacc ttgggtttgt gtcttagaga aacaccaaga 1380
ccccaagaat gggagtctgc ctgaggatgg tacgaatggg gcagtagtag atgctggcct 1440
gtctccctcc ctgcagctcg ggtcagtgc tctgacttca tggagacaga agccccacat 1500
agatggaatg ggcacagggc aaagctgctg gattccacca tcaagtgaca gaggacccca 1560
ggaaatagag ggaaactccc acctaccctc ctacagacct gtggggcccg agaagctgca 1620
ttctctccag tcagctaatt gatcgtgtca cgaagggtc ccagacctgc cacggcagac 1680
agagccagtt cagtagaaac tgggagtaga cagaagggtac agaagggaaa ataacaaacc 1740
aggctgatga tggtagagt ctacagactt ggtactccag tttccacggc taactactgc 1800
tcgctcaggg tctgaagat agctgcacag ctgcagagct gcacagcggg atagctgcga 1860
cttttgcttc ttgctttaag cagttccact gaagatactc aaaagagaag tggagaaaat 1920
cattagaaac caaagtcaag acattcatat ataagctgtg tcttcttcac tggacggttt 1980
gcctcttttc cttttgcctc agaaggagtg ggttaagca ggtgacccca tgctctgtca 2040
acctctgaat aaatgatgtg atctacatag aagtcttagc tcaactctcg gaacgcttg 2100
aacactataa cttttgctat gatatactgc caagtgtggc ccatgctcat aattgtgctt 2160
tctgaattgt gataaattag tgaaaaaact gtaacttaga atctgattta ttcaggatta 2220
gatcatcttt ttatactata aaaatcttcg aatgaaaata ttttaactta aaaacattac 2280
cttaatcatt gtcttttctt cttgaagtct ttcccagtga aaacgctcaa ttctgtgtt 2340
tccatagaat ttttaattta ttttaagaca tgagattgta aacaaattgc ttgatttatt 2400
ttatcctaatt tatttaataa aaatcaccct aaagcatcag cttttt 2446

<210> 35

<211> 886

<212> DNA

<213> Homo sapiens

<400> 35

ccccccccc cccccccct tcactctacac tggaagattc cgagtgggaa ctttctggga 60

cgggacagct ttgaggttcg tgtttgtgcc tgccctggga gagaccgccc tacagaagaa 120
 gaaaatttcc gcaaaaagga agtcctttgc cctgaactgc cccagggag cgcaaagaga 180
 gcgctgcccc cctgcacaag cgccctctccc ccgcaaaaaga aaaaaccact tgatggagag 240
 tatttcacccc tcaagatccg cgggcgtaaa cgcttcgaga tgttccggga gctgaatgag 300
 gccttagagt taaaggatgc ccattgctaca gaggagtctg gagacagcag ggctcactcc 360
 agctacctga agaccaagaa gggccagtct acttcccgc ataaaaaac aatgggtcaag 420
 aaagtggggc ctgactcaga ctgactgcct ctgcatccc tccccatcac cagcctcccc 480
 ctctccttgc tgtcttatga cttcagggct gagacacaat cctcccggtc ccttctgctg 540
 ccttttttac cttgtagcta gggtcagcc cctctctga gtagtgggtc ctggcccaag 600
 ttgggggaata ggttgatagt tgtcaggtct ctgctggccc agcgaaattc tatccagcca 660
 gttgttggac cctggcacct acaatgaaat ctcacctac cccacacct gtaagattct 720
 atcttgggccc ctcatagggc ccatactctc cagggcctac tttccttcca ttctgcaaag 780
 cctgtctgca tttatccacc cccacacctg tctcctctt ttttttttt ttacccttt 840
 ttatatatca atttctatt ttacaataaa attttgttat cactta 886

<210> 36

<211> 3050

<212> DNA

<213> Homo sapiens

<400> 36

cccttaataa gatttgccac gtacactcga gccatcgaga gtgtccttga gccgcgggtg 60
 acggtggctc tcgtgctcg cgccccctcc tcccgcgggg ggagcctgat gccacgttcc 120
 ctatgaatta tttatcgccg gcctaaaaat acccgaact tcacagccc agtgtggggc 180
 gctgggagca tggcgctcta tacatgaagt acccgtgtg gcctcgctac agtgccctc 240
 tgcagcctgt ggtggacagt cggcacctga cgggtggccac gctggaagag cggcccttg 300
 tcatcgaggga gagccctgac cctggcacag gaggctgtgt ccccaacacc gtgccctgcc 360
 gcaggcagag caaccacacc ttcagcagcg gggacgtggc cccctacacc aagctctgct 420
 gtaagggatt ctgcatcgac atcctcaaga agctggccag agtgggtcaaa ttctcctacg 480
 acctgtacct ggtgaccaac ggcaagcatg gcaagcgggt gcgcggcgta tggaacggca 540
 tgattgggga ggtgtactac aagcgggcag acatggccat cggtccctc accatcaatg 600
 aggaacgctc cgagatcgta gacttctctg taccctttgt ggagacgggc atcagtgtga 660
 tgggtggctc cagcaatggc accgtctccc cctcgccctt ctggagcca tatagccctg 720
 cagtgtgggt gatgatgttt gtcattgtcc tcactgtggt ggccatcac gtcttcatgt 780
 tcgagtactt cagccctgtc agctacaacc agaacctcac cagaggcaag aagtcgggg 840
 gccagcttt cactatcggc aagtcctgtg ggctgctgtg ggcgctggtc ttcaacaact 900
 cagtgcccat cgagaacccg cggggcacca ccagcaagat catggttctg gtctgggccc 960
 tctttgctgt catcttctc gccagctaca cggccaacct ggccgcttc atgatccaag 1020
 agcaatacat cgacactgtg tcgggcctca gtgacaaaga gtttcagcgg cctcaagatc 1080
 agtaccaccc tttccgcttc ggcaacgggtg ccaacggcag cagggagcgg aacatccgca 1140
 gtaactaccg tgacatgcac accacatgg tcaagtcaa ccagcgctcg gtggaggacg 1200
 cgctcaccag cctcaagatg gggaagctgg atgcctcat ctatgatgct gctgtcctca 1260
 actacatggc aggcaaggac gagggtgca agctgggtc cattgggtct ggcaaggtct 1320
 ttgctaccac tggctacggc atcgccatgc agaaggact ccactggaag cgggcatag 1380
 acctggcgct cttgcagttc ctgggggacg gagagacaca gaaactggag acagtgtggc 1440
 tctcagggat ctgccagaat gagaagaacg aggtgatgag cagcaagctg gacatcgaca 1500
 acatggcagg cgtcttctac atgtctgtgg tggccatggg gctggccctg ctggtcttcg 1560
 cctgggagca cctgggtctac tggaagctgc gccactcggg gcccactca tcccagctgg 1620
 acttctctgt ggctttcagc aggggcattt acagctgctt cagcgggggtg cagagcctcg 1680
 ccagcccacc gcggcaggcc agcccggacc tcacggccag ctcgccccag gccagcgtgc 1740
 tcaagatgct gcaggcagcc cgcgacatgg tgaccacggc gggcgtaagc agctccctgg 1800
 accgcgccac tcgcaccatc gagaattggg gtggcgcccg ccgtgcgccc ccaccgtccc 1860
 cctgcccagc cccgcgggtc ggccccagcc catgcctgcc ccccccgac ccgccccag 1920
 agccgagccc cacgggctgg ggaccgccag acgggggtcg cgcggcgctt gtgcgcaggg 1980
 ctccgcagcc cccgggccgc ccccgacgc cggggccgccc cctgtccgac gtctcccgag 2040
 tgtcgcgccc cccagcctgg gaggcgggtt ggccggtgcg gaccgggcac tgcgggaggg 2100
 acctctcggc ctccgagcgg cccctgtcgc ccgcgcgctg tcaactacagc tctttctc 2160
 gagccgaccg atccggccgc ccttctctcc cgctcttccc ggagcccccg gagctggagg 2220
 acctgcccgt gctcggtccg gacgagctgg cccggcgagg ggcctgctg cagcggcct 2280
 gggcccgggg ctgcgcggcc cgtcacgctt cctgcccag ctccgtggcc gaggccttcg 2340

ctcggccag ctcgctgccc gctgggtgca cccggcccgc ctgcgcccgc cccgacggcc 2400
actcggcctg caggcgcttg gcgcaggcgc agtcgatgtg cttgcgcatc taccgggagg 2460
cctgccagga gggcgagcag gcagggggccc ccgcctggca gcacagacag cacgtctgcc 2520
tgcaagccca cgcacacctg ccattttgct ggggggctgt ctgtcctcac ctccaccct 2580
gtgccagcca cggtccttg ctctccgggg cctggggggc tctggggcac aggggcagga 2640
ctctggggct gggcacaggc tacagagaca gtgggggact ggacgagatc agcagkgtag 2700
cccgtgggac gcaaggcttc ccgggaccct gcacctggag acggatctcc agtctggagt 2760
cagaagtgtg agttatcagc cactcaggct ccgagccagc tggattctct gcctgccact 2820
gtcagggtta agcggcaggc aggtattggc tttctggct tctaccatga aatcctggcc 2880
atgggacccc agtgacagat gatgtcttcc atggtcacga gtgacctcag tagcctcaaa 2940
tcatggtgag ggctgggctt ttgctgtcct cttctcacgc agagttctgc caggagggtg 3000
tgctgtgggg gtcagactcc tgaggctctc cttccctgg ggctagccag 3050

<210> 37

<211> 2254

<212> DNA

<213> Homo sapiens

<400> 37

acggcgagcc tcacccctcc ggtgcggcgc tgagcagcga gtncgactg tgctcgtgc 60
tcagcgccgc acccgaggga tgaggctcgc cgtgggagcc ctgctggtct gcgccgtcct 120
ggggctgtgt ctggctgtcc ctgataaaac tgtgagatgg tgtgcagtgt cggagcatga 180
ggccactaag tgccagagtt tccgcgacca tatgaaaagc gtcattccat ccgatggctc 240
cagtgttgct tgtgtgaaga aagcctccta ccttgattgc atcaggggcca ttgcggcaaa 300
cgaagcggat gctgtgacac tggatgcagg tttgtgtat gatgcttacc tggctcccaa 360
taacctgaag cctgtggtgg cagagttcta tgggtcaaaa gaggatccac agactttcta 420
ttatgctgtt gctgtggtga agaaggatag tggctccag atgaaccagc ttcgaggcaa 480
gaagtccctgc cacacgggtc taggcaggctc cgctgggtgg aacatcccca taggcttact 540
ttactgtgac ttacctgagc cacgtaaaacc tcttgagaaa gcagtggcca atttcttctc 600
gggcagctgt gcccttgtg cggatgggac ggacttcccc cagctgtgtc aactgtgtcc 660
aggggtgtgg tgctccaccc ttaaccaata cttcggctac tccgggagcct tcaagtgtct 720
gaaggatggt gctggggatg tggcctttgt caagcactcg actatatttg agaacttggc 780
aaacaaggct gacagggacc agtatgagct gctttgcctg gacaacaccc ggaagccggt 840
agatgaatac aaggactgcc acttggccca ggctccctct cataccgtcg tggcccgaag 900
tatgggcccgc aaggaggact tgatctggga gcttctcaac caggcccagg aacatttttg 960
caaagacaaa tcaaaagaat tccaactatt cagctctcct catgggaagg acctgctgtt 1020
taaggactct gccacgggt ttttaaaagt ccccccagg atggatgcca agatgtacct 1080
gggctatgag tatgtcactg ccacccggaa tctacgggaa ggcacatgcc cagaagcccc 1140
aacagatgaa tgcaagcctg tgaagtgggtg tgcgtgagc caccacgaga ggctcaagt 1200
tgatgagtgg agtgtaaca gtgtaggaa aatagagtgt gtatcagcag agaccaccga 1260
agactgcac gccaaatca tgaatggaga agctgatgcc atgagcttgg atggagggtt 1320
tgtctacata gcgggcaagt gtggtctggt gcctgtcttg gcagaaaact acaataagag 1380
cgataattgt gaggatacac cagaggcagg gtattttgct gtagcagtgg tgaagaaatc 1440
agcttctgac ctcacctggg acaatctgaa aggcaagaag tctgcccata cggcatttgg 1500
cagaaccgct ggctggaaca tccc'catggg cctgctctac aataagatca accactgcag 1560
atttgatgaa tttttcagtg aaggttgtgc ccctgggtct aagaaagact ccagtctctg 1620
taagctgtgt atgggctcag gcctaaacct gtgtgaacct aacaacaaag agggatacta 1680
cggctacaca ggcgctttca ggtgtctggt tgagaaggga gatgtggcct ttgtgaaaca 1740
ccagactgtc ccacagaaca ctgggggaaa aaacctgat ccatgggcta agaactctgaa 1800
tgaaaaagac tatgagttgc tgtgccttga tgggtaccag aaacctgtgg aggagtatgc 1860
gaactgccac ctggccagag ccccgaatca cgctgtggtc acacggaaaag ataaggaagc 1920
ttgcgtccac aagatattac gtcaacagca gcacctattt ggaagcaacg taactgactg 1980
ctcgggcaac ttttgtttgt tccggtcgga aaccaaggac cttctgttca gagatgacac 2040
acactcctgg aagcctgcac tttccgtaga ccttaaaatc tcagaggtag ggctgccacc 2100
aaggtgaaga tgggaacgca gatgatccat gagtttggc tggtttctact ggcccaagt 2160
gtttgtgcta accacgtctg tcttcacagc tctgtgttgc catgtgtgct gaacaaaaaa 2220
taaaaattat tattgatttt atatttcakk rraa 2254

<210> 38

<211> 2199

<212> DNA

<213> Homo sapiens

<400> 38

```
acggcgagcc tcatacctccg ggtgcggcgc tgagcagcga gtcncgactg tgctcgctgc 60
tcagcgccgc acccggaagga tgaggctcgc cgtgggagcc ctgctgggtct gcgccgtcct 120
ggggctgtgt ctggctgtcc ctgataaaac tgtgagatgg tgtgcagtgt cggagcatga 180
ggccactaag tgccagagtt tccgcgacca tatgaaaagc gtcattccat ccgatgggtcc 240
cagtgttgct tgtgtgaaga aagcctccta ccttgattgc atcagggccca ttgcggcaaa 300
cgaagcggat gctgtgacac tggatgcagg tttgggtgat gatgcttacc tggctcccaa 360
taacctgaag cctgtggtgg cagagttcta tgggtcaaaa gaggatccac agactttcta 420
ttatgctggt gctgtggtga agaaggatag tggcttccag atgaaccagc ttcgaggcaa 480
gaagtccctgc cacacgggtc taggcaggtc cgtgggtgg aacatcccca taggcttact 540
ttactgtgac ttacctgagc cacgtaaac tcttgagaaa gcagtggcca atttcttctc 600
gggcagctgt gccccttgtg cggatgggac ggacttcccc cagctgtgtc aactgtgtcc 660
aggggtgtgc tgctccaccc ttaaccaata cttcggtac tcgggagcct tcaagtgtct 720
gaaggatggt gctggggatg tggcctttgt caagcactcg actatatttg agaacttggc 780
aaacaaggct gacagggacc agtatgagct gctttgctg gacaacaccc ggaagccggt 840
agatgaatac aaggactgcc acttgccca ggtcccttct cataccgtcg tggcccgaag 900
tatgggcggc aaggaggact tgatctggga gcttctcaac caggcccagg aacatttttg 960
caaagacaaa tcaaaagaat tccaactatt cagctctcct catgggaagg acctgtgtt 1020
taaggactct gccacgggt ttttaaaagt cccccccagg atggatgcca agatgtacct 1080
gggctatgag tatgtcactg ccatccggaa tctacgggaa ggcacatgcc cagaagcccc 1140
aacagatgaa tgcaagcctg tgaagtgggt tgcgtgagc caccacgaga ggctcaagt 1200
tgatgagtggt agtggttaaca gtgtaggaa aatagagtgt gtatcagcag agaccaccga 1260
agactgcac tcgcaagatca tgaatggaga agctgatgcc atgagcttgg atggagggtt 1320
tgtctacata gcgggcaagt gtggtctggt gcctgtcttg gcagaaaact acaataagag 1380
cgataaattgt gaggatacac cagaggcagg gtattttgct gagtgaagggt tgtgcccctg 1440
ggtctaagaa agactccagt ctctgtaagc tgtgtatggg ctcaggccta aacctgtgtg 1500
aaccacaaca caaagaggga tactacggct acacaggcgc tttcagggtg ctggttgaga 1560
agggagatgt ggcctttgtg aaacaccaga ctgtcccaca gaacactggg ggaaaaaacc 1620
ctgatccatg ggctaagaat ctgaatgaaa aagactatga gttgctgtgc cttgatggta 1680
ccaggaaacc tgtggaggag tatgcgaact gccacctggc cagagccccg aatcacgctg 1740
tggtcacacg gaaagataag gaagcttgcg tccacaagat attacgtcaa cagcagcacc 1800
tatttggaag caacgtaact gactgctcgg gcaactttt tttgttccg tcggaaacca 1860
aggaccttct gttcagagat gacacagtat gtttgcccaa acttcatgac agaaacacat 1920
atgaaaaata cttaggagaa gaatatgtca aggtgtttg taacctgaga aaatgctcca 1980
cctcatcact cctggaagcc tgcactttcc gtagacctta aaatctcaga ggtagggctg 2040
ccaccaaggt gaagatggga acgcagatga tccatgagtt tgccctggtt tcaactggcc 2100
aagtgtttg tgctaaccac gtctgtcttc acagctctgt gttgccatgt gtgctgaaca 2160
aaaaataaaa attattattg attttatatt tcakkrrea 2199
```

<210> 39

<211> 14800

<212> DNA

<213> Homo sapiens

<400> 39

```
gggcagcagc agtcagcga cgccgagcgg ctgccggggg aagcagaggc gccggaggct 60
ggggcaccgc cgacgcctcg ggagccatgg ccgaaggggg agaaggaggc gaggacgaga 120
tccagtttct gaggactgag gatgaagtgg tactccagt catcgccacc attcataagg 180
agcagaggaa gttctgcctg gcagccgagg gacttgggaa tcgcctgtgc ttcttggaac 240
ccacttcaga agccaagtac attcctccag atctctcgt ctgcaatttt gtgctggaac 300
agtccttatc tgtcagagcc ctgcaggaaa tgcttgccaa cacagggtgaa aatggcgggc 360
aaggggcagc acaaggagggt ggccacagga ccctgttata cggccatgca gttctcctga 420
ggcactcttt cagcggaatg tatctaact gcttgactac atcaagatcc cagacagaca 480
aacttgctt tgatgtaggt ctacgggaac atgccacagg agaagcctgt tgggtgacta 540
tacatcctgc ttccaaacag aggtccgaag gagagaaagt tcgaattggc gatgacctca 600
tcctcgtcag cgtgtcctct gaaagatacc ttcattcttc agtatcaaat ggtaacatac 660
```

aagtggatgc ctcccttatg caaacactct ggaatgtaca tectacgtgc tcaggaagta 720
gcatcgaaaga aggataccta cttggtgggc atgtagtacg tcttttccat ggtcatgatg 780
aatgtttgac gataccatct acagaccaga atgattccca gcacaggagg atattctacg 840
aagctggggg agctgggact cgagccaagt ctctttggag agtggaaacc cttcggataa 900
gctggagtgg cagtaacatc agatggggcc aggttttccg actccggcat ctcaccacag 960
gccactacct ggccttgaca gaagaccaag gccttatact gcaagaccgg gcaaagtcag 1020
acaccaagtc cacagctttc tctttccggg catcaaagga actcaaggag aaattagact 1080
ccagtcacaa gcgagacata gaaggcatgg gagttccaga aatcaagtat ggagattctg 1140
tctgctttgt gcagcatata gccagtggtc tgtgggtgac ctacaaagca caagacgcca 1200
aaacttccc cctgggacct ctaaaaagaa aggtcatact ccacaggaa ggccacatgg 1260
atgatggatt aacactgcag agatgccarc gtgaggagtc ccaggctgct cggatcatcc 1320
ggaacactac agccttattc agccagtttg tcagtggaaa caatcgaca gctgccccca 1380
tcaccctgcc tatagaagaa gtcctgcaga cctacagga cttgatcgcc tacttccagc 1440
ccccagagga ggagatgcga catgaagaca agcagaacaa gctccgctca ctcaaaaaa 1500
gacaaaatct tttcaaggaa gagggaaatgt tggcccttgt cttaaattgc attgaccgct 1560
taaatrctta caatagcgtg gcacactttg cagggattgc aagggaagag agtggcatgg 1620
cctggaaaga aattctgaac ctctctaca aattgctggc tgctctcatt cgcggaaaca 1680
gaaacaattg cgtcaattc tccaataacc ttgattggct catcagtaaa ttggacagac 1740
tagaattctt ctcaggatct ttggaagttt tgcactgcat cttaactgaa agcccagaag 1800
ccttaaatct gatagcggag ggccacatca agtcgatcat ctccctgttg gataagcag 1860
ggcggaatca caaggttctg gatatcctgt gctccctctg tctctgcaat ggggttgacg 1920
tgagagccaa ccagaatctg atctgtgaca acttgctgcc ccggagaaac ctactcctgc 1980
agacacgact gattaacgat gtaaccagta tccggccaaa catcttcctg ggagtgcgg 2040
agggctcagc ccagtacaag aagtggact tcgagctgat tatcgaccag gtggaccct 2100
tcctaacagc agagcccaca catctgcggg tgggctgggc ctcttcttca ggctatgcc 2160
catrccagg aggtggagaa ggatggggag gcaatggtgt tggtagcagc ctgtactcct 2220
atggctttga tggacttcac ctttggtcag gccggatacc cagagctgtg gcttccrtca 2280
accagcacct cctgagatcg gatgacgtg taagctgctg cctggacctc ggggtgccc 2340
gcatctcatt ccgcatcaat gggcagcccg tgcaggggat gtttgagaac ttcaacacag 2400
acgggctctt ctccctgtg atgagctttt cagcaggtgt caaagtacgt ttcctgatgg 2460
gtggacgtca tggagagttt aagtctctgc ctccctctgg ctatgcccct tgctatgaag 2520
ccttacttcc aaaagagaag atgagattgg agcctgtcaa agaataaaa cgtgatgctg 2580
atggcattag agatctcttg ggtaccaccc agttcctctc ccaagcctct ttcattccat 2640
gccccgtaga caccagtcag gttatcttgc cacctcacct agaaaagatc cgagacagac 2700
tagctgaaaa catccatgag ctttggggaa tgaataaaat agaacttggc tggactttcg 2760
gcaagatacg agatgacaat aaaagacaac acccttgcc tgtggagttt tcaaagctcc 2820
cagaaactga gaagaactat aacctgcaaa tgtcaactga aaccttaaaa accctcttgr 2880
ccctgggktg ccacattgct catgttaacc cagctgctga ggaggatctc aagaaggtca 2940
aactgccc aaactatat atgtccaacg gctataagcc agcccctttg gatttgtctg 3000
atgtgaagct gttacctct caagaaattt tagtggataa gcttgacaga aatgcacaca 3060
atgtttgggc aaaagacaga ataaaaaag gatggaccta tggcatccaa caggatttga 3120
agaacaaaag aaatcccgt ctggtgccat atgcattact ggatgagcgt accaagaagt 3180
caaacaggga cagcctgcgg gaagctgtgc gcacttttgt tggttacggg tataacattg 3240
agccatcaga ccaagaacta gctgactcgg ctgtggagaa ggtagcagata gacaagatcc 3300
gatttttccg ggtagagcga tcttatscag tgagatctgg aaagtggat tttgagttg 3360
aagtgggtgac tggaggagac atgcgagtcg gctggcgag gccaggctgt cgacctgatg 3420
tcgagctggg ggccgatgac caagcctttg tgtttgaagg caacaggggc cagcgttggc 3480
atcaagggaag tgggtatttt gggcgtaact ggcagccagg ggatgtggtc ggatgtatga 3540
ttaacctgga tgatgcttca atgatcttca cactgaatgg ggagctgctg atcaccaaca 3600
aaggctctga acttgccctc gctgactacg agattgagaa tggcttcgtg cccatctgct 3660
gtctgggtct atctcagatc ggccgcatga atctcgggac agatgccagt accttcaagt 3720
tttataccat gtgcggtctc caagagggct ttgagcctt tgcgtcaac atgaacagag 3780
atgttgctat gtggttcagc aagcgcctcc cgacgtttgt caacgtgcca aaggatcatc 3840
cacacataga ggtcatgagg attgatggca ccatggacag ccctccgtgt ctcaaggtga 3900
cgcataagac atttggcaca cagaatagca atgccgacat gatctattgc cgcttgagca 3960
tgccctgtcga gtgccactcc tccctcagyc acagcccctg tctggacagt gaagctttcc 4020
agaaaaggaa acagatgcaa gaaatactct ctcatacaac aacacagtgc tactacgcca 4080
tccgcatctt tgstggacag gatccatcct gtgtctgggt cggatgggtg actccagact 4140
atcacttgta cagtgaagaa tttgacctga ataaaaactg cacagtgaact gtcacctag 4200
gggatgaaag aggcgggtc catgaaagtg tgaacgcag caactgctac atggtctggg 4260
gtggagacat tgtagccagt tcccagagat caaatcgag caacgtggac ctggagatcg 4320

gctgtctcgt ggatctggcc atgggcatgt tgtccttctc agccaatgga aaggaactgg 4380
gcacctgcta ccagggtggag cctaataacca aagtgtttcc agcagtcttc ctgcagccta 4440
caagtacttc tttgtttcag tttgaacttg gaaagctgaa gaacgcaatg cccctgtcag 4500
cggccatatt caggagttaa gagragaac cagtcacaca gtgtccacct cggctggacg 4560
tccaaacccat ccagcccgtg ctctggagcc gcatgcccac cagcttcctg aaggtggaga 4620
ccgagcgtgt gagcgagcgc cacggctggg tgggtgagtg cctggagccc ctgcagatga 4680
tggcgctcca catccccgag gagaacaggt gtgtggatat cctggagctc tgtgagcagg 4740
aggacctgat gcggttccat taccacacgc tgaggctcta cagcgcggtg tgcgccctgg 4800
gaaacagccg cgtggcctac gccctgtgca gccacgtgga cctctcccag ctcttctatg 4860
ccattgacaa caagtacctc cccggcctcc ttcgatctgg tttctatgac ctgctcatca 4920
gcacccacct ggccagcgcc aaggagagga agctgatgat gaagaacgag tacatcatcc 4980
ccattaccag caccaccagg aatatctgcc tcttcccga cgagtccaag aggcattggac 5040
tgcttggggg gggcctgaga acatgtctca agcccgggtt caggttctcc accccttgct 5100
ttgttgtgac tgggtgagat caccaaaagc agagccccga gattcccttg gagagtctca 5160
ggacgaaggc tctgagtatg ctgacagagg cagtgcagtg cagcggggcc cacatccgag 5220
accctgtagg ggggtctgtg gagggtccag ttgtgcctgt gctgaaactc attggaaccc 5280
tgctgtgcat gggcgtgttt gatgatgat atgttcggca gatectcttc ctgattgatc 5340
cctctgtggt tggggagcat agtgcgggga cagaggaggg agcagaaaag gaggaagtga 5400
cccagggtga ggagaaggct gtggaggctg gggagaaggc gcagatgtgt gagctctca 5460
aaggcttgtt gcagactcga ttaccggaat ccgtcaagct cattgtggca tttggtgaca 5520
gctatctctg cgactgtgag ctgcagcacc gagtggaggc caatgagctc atgcaggccc 5580
tttatgtctc caagctgcag gcaaatcaga agttccgcta caatgagctc ccccccacagg 5640
tgaacatgtc tgcggccctg actgcccgga agaccaagga gttccgctca ccccccacagg 5700
agcagatcaa catgctgctt aactttcaac tgggagagaa ctgcccctgc ccagaggaga 5760
ttcgggagga gctgtatgat ttccatgagg accttctcct tcaactgtgg gttcctttgg 5820
aagaagagga agaggaggag gaggacacct cctggacagg aaaactctgt gccttggttt 5880
acaaaatcaa agggccaccc aagccagaga aggagcagcc gacggaggag gaggagagat 5940
gccccacaac attgaaggaa ctcatctcac agacgatgat ctgctgggccc caggaggacc 6000
agatccagga ttcagagctg gtccgaatga tgttcaacct cctccggagg cagtatgaca 6060
gcattgggga gctgctgcag gcgctgcgga agacctacac catcagccac acctctgtaa 6120
gcgacacccat caacctgctg gctgccctgg gccaaatccg ctccctctc agtgtcagga 6180
tgggcaagga agaggagttg ctcatgatca atgggctggg agacataatg aacaacaagg 6240
tgtttttacca gcatcccaac ctcatgagag tcctgggcat gcacgagac gtgatggagg 6300
tgatggtgaa cgtgttgggt acagagaaat ctcatgagag atttccaaag atggttgcta 6360
gctgctgccg tttcctttgc tatttctgtc gaattagccg gcaaaatcag aaggccatgt 6420
ttgagcatct gagttatctt ctggagaata cagagtgttg cctagcctcc ccgtcgatga 6480
gggagtcac cccgctggat gtggcagctt cctctgtgat ggacaacaat gagttagcgc 6540
tgagcttaga ggaaccagac ctcgagaagg tggtagccta cttggcaggc tgtggcctac 6600
agagctgccc catgcttctg gccaaaggat accctgatgt cgtgctctct gaacagttag agtgaggaa 6660
gggaacgcta cctgtccttc ctgaggtttg ctgtctctct agagtgttc agagtgttc 6720
aaaacgccag cgttgtggtc aagctgctca tcagacgccc agagtgttc agagtgttc 6780
tgccgggtga ggggggaaac ggrctcttg cagccatgca ggggtgccatt aagatctctg 6840
agaacccagc gctcgacctc ccctctcaag gatacaaaag agaagtcagc acggaggacg 6900
atgaagagga agaagaaatc gtgcatatgg gcaatgcaat catccagaca ggaaagggg 7020
ttatagatct actgggcgc tgtgctctc aaatgcacct catccagaca ctggttgga 7080
aagccatccg catcaggtcc atcctgcgct cctgtgtccc cacagaagac agtgagccag 7140
tcacagcat ccccttgaaa ctgcccctcc tcaacaaaga tgggtcggtc agtgagccag 7200
atatggcggs caatttctgc cctgaccaca aggcacctat ggtgctgttc ttggaccgag 7260
tttatggcat taaggatcaa acttttctgc tccacttct ggaggttgga tttttacctg 7320
acctaagagc ttctgcctct ctgatacag tttccctaag caccacagag gctgcgcttg 7380
cactaaatag gtatatatgt tctgctgtgc tccgctcct cacaagatgt gcccctctct 7440
ttgscggaac agaactgc accctctga ttgattccac actgcagaca atatacaggc 7500
tatccaagg acgttccctc accaaagcac aaaggacac tatagaagaa tgtttgcttg 7560
ccatttgcaa tcaactgagg ccttccatgt tacagcaact cctgcgacgc ctggtttttg 7620
atgtgcccga actcaatgaa tactgaaaa tgcctctcaa gcttctgacg aatcactatg 7680
aacagtgttg gaagtattac tgcctgcctt caggatggg gagctacgg ctagctgtgg 7740
aagaagagct gcacctaacg gagaagcttt tctgggggat tctcagtgct atagctggg 7800
agaaatatga cccagatctt ttccgaatgg cctgccttg tctcagtgct atagctggg 7860
ccttgccacc agattattta gatwccagaa tcacagccac rttggagaaa cagatctcag 7920
tggatgcgga tggcaacttt gacccaaaac ctattaacac catgaatttt tcttgccctg 7980
aaaaattgga atacatcgtc accaagtatg ctgagcattc acatgataaa tgggcctgtg 7980

acaagagtca gaggatgg aaatatggga tttccctgga tgaaaatgtg aagaccacc 8040
cactgataag gcctttcaag acattaacgg agaaggagaa ggaaatttat cgctggcctg 8100
cgcgagagtc cctgaaaacc atgctggctg tgggctggac tgtggagagg accaaagagg 8160
gagaagcttt ggttcaacag cgggaaaatg agaagcttcg aagtgtgtcc caggccaacc 8220
agggcaacag ctacagtcct gctccctcgc acctctcaaa cgttgtgtcc tccagagagc 8280
tccagggat ggtggaggtc gtggctgaga actatcaca tatctgggcc aagaagaaga 8340
agctggagct ggagagcaaa ggtgggtggca gccaccctct tctggtacca tatgacacct 8400
tgactgcca ggaaaagttc aaggaccggg agaaggcaca ggacctgttt aagttcctcc 8460
aagtgaatgg catcatagtt tccaggggta tgaaggatat ggagctggat gcctcctcca 8520
tgagagaag gtttgscat aagttcttga agaagatcct gaaatacgtt gattctgctc 8580
aagaatttat tgcccattta gaagccattg tcagcagtgg gaaaactgaa aagttcctccc 8640
gtgaccagga gatcaaatc tttgccaaag ttctcctccc gctgggtgac cagtacttca 8700
ccagtcattg cctctacttc ttgtcatccc ctctgaagcc ccttagcagc agcggatatg 8760
cctcccataa ggagaaagaa atggtggccg gcctgttctg caaacttgcc gctctcgtta 8820
gacacagaat ttcctcttt gtagtgatt ctactacaat ggtgagctgt cttcacatct 8880
tagctcagac acttgacaca aggactgtca tgaagtcagg ctacagagctg gtgaaggctg 8940
ggttacgagc attctttgaa aatgctgcag aagatttgga gaagacttca gaaaacctga 9000
aacttgaggaa gttcacccat tcccgaacgc agattaaagg cgtttctcag aatattaact 9060
acactacagt ggctctgctc cccatcctga cgtccatctt tgagcacgct actcagcatc 9120
agtttggaat ggtctactc ttgggtgatg tgcagatttc atgctaccac atactgtgca 9180
gcctctactc ccttgggacg ggaaagaaca tttatgttga aaggcaacgc cctgcccttg 9240
gagaatgtct ggcctcgcgt gcagctgcca taccagtgcc attcctggag cccaccctta 9300
atcgctacaa tccactctcg gtcttcaaca ccaaaacccc caggagagg tctattctgg 9360
ggatgccaga cacggtagaa gacatgtgtc cccgttacac agagatgcc catgtcatcg 9420
aggaaatcaa cgacctggcc gagtccggg tgcactact gtgggagcgg ggtcctgaga 9480
aggtgatctt acccatgctc tgcaactact tgcctactg gtgggagcgg ggtcctgaga 9540
acctgcccc cagcacagg ccattctgaaa ccatgctgca ccaaggtcac ctctgaacac ctcagtctca 9600
tcctgggcaa cattctgaaa atcatcaaca acaacctgg catcgatgag gcctcctgga 9660
tgaagcgcat tgcagtgtat gcacagccca tcatcagcaa agccaggccc gacctgctga 9720
gaagccactt catcccaact ctggagaagc tgaagaaaaa ggctgtcaag acggtgcagg 9780
aggagagca gttgaaagcc gatggcaaa gggacacca ggaggcagaa ctctcatcc 9840
tgagcaggt cgcggtcctc tgcagagatc tctatgcct ctaccccatg ctgatccgct 9900
acgtggacaa caacagatct aactggctga aaagtctga tctgattct gaccagctct 9960
tccgcatggt ggcagaagtc ttcattctgt ggtgtaaatc tcataacttc aagagagaag 10020
agcaaaattt tgtgattcag aatgaaatta ataatttggc atttttaact ggagacagca 10080
aaagcaagat gtcaaaatct ggaggacaag accaggagcg actcaagaaa atgtgcccc 10140
gagacttgta tccatccag acctccctca tctgtgctgc actcaagaaa atgtgcccc 10200
ttggttgaa tatgtgtact ccaggcgacc aggagctgat ctccctcgca aaatcgcat 10260
acagccatag ggacacagat gaagaggtca gagaacatct gcggaacaac ttgcaattgc 10320
aggaaaagtc tgatgaccca gctgtaaaat ggcaactgaa cctctacaag gatgttctga 10380
agagtgaaga acctttcaat ccgaaaaaga cagtggagcg tgtgcagaga atttcagcag 10440
ctgtcttcca cctggaacag gtggaacagc ctttgaggtc caagaaggcc gtctggcaca 10500
aactgttatc aaagcaacgg aaacgggcag tgggtggctg ttccaggatg gccctctct 10560
acaacctgcc caggcaccgc tctattaacc tcttctcca tggctatcag agattttgga 10620
tagaaacaga ggagtattcc tttgaagaga aactagtaca ggatttggct aaatctccaa 10680
aggtggaaga ggaggaggag gaagagacag aaaaacaacc tgaccacta catcagatca 10740
ttctctatt tagccgcaac gctctcacgg agaggagcaa attggaagac gacctttgt 10800
acacctccta tccagcatg atggccaaga gttgtcaaag tggtaggat gaagaagaag 10860
atgaagacaa ggaaaaaaca ttygaagaga aagagatgga ccttcagatg ataagcgcta 10920
agcaagctcg gctgcatgag cgtggtgctg crgagatggt ccttcagatg ataagcgcta 10980
gcaaaggtga gatgagcccc atggtggtg agacgctgaa gctggggatc gccattctga 11040
acggaggcaa tgcgtgtgtg caacagaaaa tgctagatta cctaaaggag aaaaaggatg 11100
ctggattctt tcaaagcctt yctggtctta tgcagtcttg cagygtcctt gatttgaatg 11160
catytagag gcagaataaa gctgaaggcc tggggatggt gactgaagaa ggaacactca 11220
ttgttcggga acgtggtgaa aaagtactcc agaagacga gttcacgct gatctcttta 11280
gattcctaca gttactttgt gagggacata acagtgact tcagaacttc ctgaggactc 11340
agatgggcaa caccaccacc gtgaatgtca tcatcagcac tgtggactac cttctgcgtc 11400
tgagggaatc aatcagtgat ttctactggt attattcagg gaaggacatc attgatgaat 11460
ctggacagca caatttttcc aaagctctgg cagtcaccaa gcagatttcc aattctctta 11520
cagaatacat ccagggccct tgcattggt atcaacagag cctggctcac agcaggctgt 11580
gggacgcagt ggttggcttc tccatgtct ttgctaatat gcagatgaaa ctctctcagg 11640

attccagtc gatcgagctg ctgaaggaac tcttgatct ccttcaggac atgggtggtga 11700
tgcttctgtc cctcctggaa gggaatgtgg taaatggcac cattggcaag cagatggttg 11760
acacactggt agaactatct accaatgtag aaatgatctt gaaattcttt gacatgttct 11820
tgaaacttaa agacttaacc agctcagaca ccttcaaaga atatgaccca gatggtaaag 11880
gaattatctc caaaaaagaa ttccagaagg ccattggaagg gcaaaaacag tacacgcagt 11940
cagagattga ctttctcctg tcgtgtgcag aagctgatga gaatgacatg ttttaattacg 12000
ttgattttgt agaccgggtc catgagccag ccaaggacat agggtttaat gtggctgtgt 12060
tattgacaaa tctttctgaa cacatgccaa acgattcccc cctgaagtgt ctgttggacc 12120
cagcagaaag tgtgctaaat tacttcgrac cctacctagg acgcacagag atcatgggtg 12180
gggccaagaa gattgagcgt gtttattttg agatcagtga atccagtcgc actcagtggg 12240
agaagcccca ggtgaaggaa tctaagcgac agttcatttt tgatgttgtc aatgaagggtg 12300
gggagcagga aaagatggrg ctgtttgtga acttctgtga ggacaccatc tttgaaatgc 12360
agtttagcatc tcagatctct gaatccgatt cagctgacag gccagaagag gaggaagaag 12420
atgaagattc ttcttacgtg ttagaaattg cgggtgaaga ggaagaagac gggctctctg 12480
agccggcctc tgcatttgct atggcctgtg cctctgtgaa gaggaatgtc accgacttcc 12540
tgaagagagc aaccctgaag aacctcagga agcagtacag gaacgtgaaa aagatgactg 12600
cgaaggagct ggtgaagggt ctcttctcct ttttctggat gctgttcgtg gggctatttc 12660
agttgctctt caccatcctg ggaggaatct ttcagatcct ctggagcaca gtgtttggag 12720
ggggcctggt agaaggggca aagaacatca gagtgaccaa gatcctgggt gacatgcctg 12780
acccaaccca atttggtatc catgatgaca ctatggaggc tgagagggca gaggtgatgg 12840
agccaggtat caccactgaa ctagtacact tcataaaggg ggagaaggga gatacagata 12900
tcatgtcaga cctcttttga ctccacccaa agaaagaggg cagcttaaaag catgggcctg 12960
aagtgggttt ggggtgacctc tcagaaatta ttggcaagga tgaacccctt acattagaga 13020
gtactgtaca gaagaagagg aaagctcagg cagcagaaat gaaagcagca aatgaagcag 13080
aaggaaaagt agaatccgag aaggcagaca tggaagatgg agagaaggaa gacaaagaca 13140
aagaagagga gcaagctgag tacctgtgga cagaagtgc aaaaaagaag aagcggcggg 13200
gtggtcagaa ggttgagaag ccggaagctt tcacagccaa tttctttaa gggctggaaa 13260
tctatcagac caagtactg cattacctgg ccaggaattt ctacaacctg aggttccttg 13320
ctctgtttgt agccttcgct atcaacttca tctgctttt ttataaggct actgaagaac 13380
ctttagaaga agagacagag gatgttgcaa acctatggaa ttcctttaat gacgaggaag 13440
aggaagaagc gatggtatc tttgtccttc aggagagcac cgggtatatg gcaccaacct 13500
tgctgcccct ggccatcatc cataccatca tctctctagt ctgtgtggtg ggctactact 13560
gcctgaagggt gcctttgggt gttttcaaaa gggaaaaaga aatcgccagg cagtgggacc 13620
ttgatggcct atatatcacc gaacagccat ctgaagatga catcaagggt gtaaagagaa 13740
scttggtgat caacacacca tcttttcta ataactactg ggacaagttt cttctgggtt 13800
aggtgatcaa caagtatgga gatctctacg gagcagaacg caaagcagaa gcggcttctc 13860
tggaacaaaa tgctcttgac tttagcccag tagaagagac ctggaagctt ggagttgttt 13920
tggtgtcatg gctaagttcc wtagacatga agtaccatat catgtcagtc ctgggccact 13980
ttactgacaa ctcccttctc gctcacctat tggacatcgc aatgggcttc aagacactga 14040
acaataactt cttctttgct gctcacatg gcaaacagtt ggttctgact gtcggtctcc 14100
ggaccattct gtcactgtga actcacaatg gcaaacagtt cttcttccgc aagttctaca 14160
tgccggtggt ggtttatctc tatactgtgg tggctttcaa cttcttccgc aagttctaca 14220
acaaaagcga agacgatgac gagcccagata tgaagtgcga cgacatgatg acgtgttacc 14280
ttttccacat gtacgtggga gtgagagcag gaggtggcat tggatgata attgaagacc 14340
ctgctggtga tccttatgaa atgtatcgca ttgtctttga cattaccttt ttcttcttcg 14400
tcattgtcat cttgctggcc atcattcaag gtcttattat tgatgctttc ggagagctaa 14460
gagaccagca ggaacaagta cgagaagata tggaggtaat gttactctaa ctactaatcc 14520
cagctctatt ttaatatccc cagaagcaaa tagatttttt atgcctgtt ctctgcaccc 14580
acttagggcc agtactaagc aagaacgcag tttgttttcc cactgtccca caataggagg 14640
tgccataccc ctgccaggcc ggccactctg ctgcccctc cactgtccca caataggagg 14700
gagcagtatc ctcagctaag caggagctaa gtgtatggca ctactgagt aatgactaat 14760
agccaaaagc attagaaaga aagttttcat tctcttcaa ttcgatagaa tcatgacagt 14800
tttctctcct gcctatatta tgccaacaaa tgccttttct

<210> 40

<211> 1309

<212> DNA

<213> Homo sapiens

<400> 40

```

gtgcattgag cgcgctccag ctgccgggac gagggggcgg cccccgcgct cggggcgctc 60
ggctacagct gcggggcccc aggtctccgc gcaactcgct ccggcccatg ctggaggcgg 120
cggaaccessg gggacctagg acggaggcgg cggggcgctg gcggcccccg gcacgctgag 180
ctcgggatgc ggacgctgct gcctcccgcg ctgctgacct gctggctgct cgcctccgctg 240
aacagcattc acccagaatg ccgatttcat ctggaaatac aggaaggaaga aacaaaatgt 300
rcagagcttc tgaggcttca aacagaaaaa cacaagcctt gcagtggcgt ctgggacaac 360
atcacgtgct ggcggcctgc caatgtggga gagaccgtca cgggtgccctg cccaaaagtc 420
ttcagcaatt ttacagcaa agcaggaaac ataagcaaaa actgtacgag tgacggatgg 480
tcagagacgt tcccagattt cgtcgatgcc tgtggctaca gcgaccgga ggatgagagc 540
aagatcacgt tttatattct ggtgaaggcc atttataccc tgggctacag tgtctctctg 600
atgtctcttg caacaggaag cataattctg tgctcttca ggaagctgca ctgcaccagg 660
aattacatcc acctgaacct gttcctgtcc ttcctcctga gagccatctc agtgctggtc 720
aaggacgacg ttctctactc cagctctggc acgttgcact gccctgacca gccatcctcc 780
tggtgtgggt gcaagctgag cctgggtctt ctgcagtact gcatcatggc caacttcttc 840
tggtgctggg tggaggggct ctacctccac acctcctggg tggccatgct cccccctaga 900
aggtgcttcc tggcctacct cctgatcgga tggggcctcc ccaccgtctg catcggtgca 960
tggaactgcg ccaggctcta cttagaagac accggttgct gggatacaaa cgaccacagt 1020
gtgccctggg gggctatacg aataccgatt ttaatttcca tcatcgtaaa tttgtcctt 1080
ttcattagta ttatacgaat tttgtgcag aagttaacat cccagatgt cggcggaac 1140
gaccagtctc agtacaagag gctggccaag tccacgctcc tgcttatccc gctgttcggc 1200
gtccactaca tgggttttgc cgtgtttccc atcagcatct cctccaaata ccagatactg 1260
tttgagctgt gcctcgggtc gttccaggta ggtgtgcgga ggcggccgc 1309

```

<210> 41

<211> 1500

<212> DNA

<213> Homo sapiens

<400> 41

```

agcccagaga cacattgggg ctgacctgcc gctgctgtca gtgggaggcc agtggtgctg 60
gccaaagaag gtcattggct gtgtcgtgca cgtttccctg gctgctcact gcggggcctg 120
tccgtggggc cggggcgagc tccgcaaagg acgcgcagcc tgcaagtccg cggcccagag 180
acacattggg gctgacctgc cgtgctgtc agtgggaggc cagtgggtgct ggccaagaag 240
tgtcatggct ggtgtcgtgc acgtttccct ggctgctctc ctctgctgc ctatggcccc 300
tgccatgcat tctgactgca tottcaagaa ggagcaagcc atgtgcctgg agaagatcca 360
gagggccaat gagctgatgg gcttcaatga ttcctctcca ggctgtcctg ggatgtggga 420
caacatcacg tgttggaagc ccgcccagtg ggtgagatg gtctgtgca gctgccctga 480
gctcttcoga atcttcaacc cagaccaaga catgggagtg gtgagccgga actgcacgga 540
ggatggctgg tcggaacctt tccctcatta ctttgatgcc tgtgggtttg atgaatatga 600
atctgagact ggggaccagg attattacta cctgtcagtg aaggccctct acacggttgg 660
ctacagcaca tccctcgtca ccctcaccac tgcctatggtc atcctttgtc gcttccgga 720
gctgcactgc aacgcgaact tcatccacat gaacctgtt gtgtcgttca tgcctgagggc 780
gatctccgtc ttcataaag actggattct gtatgcggag caggacagca accactgctt 840
catctccact ttggaatgta aggccgtcat ggttttcttc cactactgtg ttgtgtccaa 900
ctacttctgg ctgttcacg agggcctgta cctcttcaact ctgctgggtg agaccttctt 960
ccctgaaagg agatacttct actggtacac catcattggc tgggggaccc caactgtgtg 1020
tgtgacagtg tgggctacgc tgagactcta ctttgatgac acaggctgct gggatatgaa 1080
tgacagcaca gctctgtggg gggatgacaa aggcctgtg gttggctcta tcatggttaa 1140
ctttgtgctt tttattggca ttatcgtcat cctgtgagc aaacttcagt ctccagacat 1200
gggaggcaat gagtccagca tctacttgcg actggcccg tccacctgc tgctcatccc 1260
actattcgga atccactaca cagtatttgc cttctccca gagaatgtca gcaaaaggga 1320
aagactcgtg tttgagctgg ggctgggctc cttccagggc tttgtgggtg ctgttctcta 1380
ctgttttctg aatggtgagg tacaagcgga gatcaagcga aaatggcgaa gctggaagggt 1440
gaaccgttac ttcgctgtgg acttcaagca ccgacaccgc tctctggcca gcagtggggt 1500

```

<210> 42

<211> 1550

<212> DNA

<213> Homo sapiens

<400> 42
gagacatggc ccgggcagtg gctcctggaa gaggaacaag tgtgggaaaa gggagaggaa 60
gccggagcta aatgacagga tgcaggcgac ttgagacaca aaaagagaag cgttcctctc 120
ggatccaggc attgcctcgc tgctttcttt tctccaagac gggctgagga ttgtacagct 180
ctaggcggag ttggggctct tggatcgct tagattctcc tctttgctgc atttcccccc 240
acgtcctcgt tctcccgct ctgcctgcgg acccgagaa gggagaatgg agagggggct 300
gccgtcctc tgcgcctgc tgcctcgt cctcgccccg gccggcgctt ttcgcaacga 360
taaattgtggc gatactataa aaattgaaag ccccggtac cttacatctc ctggttatcc 420
tcattcttat cacccaagtg aaaaatgcga atggctgatt caggctccgg acccatacca 480
gagaattatg atcaacttca accctcactt cgatttggag gacagagact gcaagtatga 540
ctacgtggaa gtcttcgatg gagaaaatga aaatggacat tttaggggaa agttctgtgg 600
aaagatagcc cctcctcctg ttgtgtcttc agggccattt ctttttatca aatttgtctc 660
tgactacgaa acacatggtg caggattttc catacgttat gaaattttca agagagggtcc 720
tgaatgttcc cagaactaca caacacctag tggagtata aagtcccccg gattccctga 780
aaaatatccc aacagccttg aatgcactta tattgtcttt gcgcaaaaga tgtagagat 840
tactctggaa tttgaaagct ttgacctgga gcctgactca aatcctccag gggggatgtt 900
ctgtcgctac gaccggctag aaatctggga tggattccct gatgttggcc ctcacattgg 960
gcgttactgt ggacagaaaa caccaggctg aatccgatcc tcatcgggca ttctctccat 1020
ggttttttac accgacagcg cgatagcaaa agaagggttc tcagcaaaact acagtgtctt 1080
gcagagcagt gtctcagaag atttcaaatg tatggaagct ctgggcatgg aatcaggaga 1140
aattcattct gaccagatca cagcttcttc ccagtatagc accaactggf ctgcagagcg 1200
ctcccgctg aactaccctg agaatgggtg gactcccgga gaggattcct accgagagtg 1260
gatacaggta gacttgggccc ttctgcgctt tgtcaggct gtcgggacac agggcgccat 1320
ttcaaaagaa accaagaaga aatattatgt caagacttac aagatcgacg ttagctccaa 1380
cggggaagac tggatcacca taaaagaagg aaacaaacct gttgtaagtt aggtgccac 1440
cgtggcaaac naatttggtc ttttaaatgg atgatcaatt tttacttgtt tgtttggtag 1500
ctttctgtct ggcctggttt atnnttgaat tgatttgaaa tgaaangtgc 1550

<210> 43
<211> 1550
<212> DNA
<213> Homo sapiens

<400> 43
gagacatggc ccgggcagtg gctcctggaa gaggaacaag tgtgggaaaa gggagaggaa 60
gccggagcta aatgacagga tgcaggcgac ttgagacaca aaaagagaag cgttcctctc 120
ggatccaggc attgcctcgc tgctttcttt tctccaagac gggctgagga ttgtacagct 180
ctaggcggag ttggggctct tggatcgct tagattctcc tctttgctgc atttcccccc 240
acgtcctcgt tctcccgct ctgcctgcgg acccgagaa gggagaatgg agagggggct 300
gccgtcctc tgcgcctgc tgcctcgt cctcgccccg gccggcgctt ttcgcaacga 360
taaattgtggc gatactataa aaattgaaag ccccggtac cttacatctc ctggttatcc 420
tcattcttat cacccaagtg aaaaatgcga atggctgatt caggctccgg acccatacca 480
gagaattatg atcaacttca accctcactt cgatttggag gacagagact gcaagtatga 540
ctacgtggaa gtcttcgatg gagaaaatga aaatggacat tttaggggaa agttctgtgg 600
aaagatagcc cctcctcctg ttgtgtcttc agggccattt ctttttatca aatttgtctc 660
tgactacgaa acacatggtg caggattttc catacgttat gaaattttca agagagggtcc 720
tgaatgttcc cagaactaca caacacctag tggagtata aagtcccccg gattccctga 780
aaaatatccc aacagccttg aatgcactta tattgtcttt gcgcaaaaga tgtagagat 840
tactctggaa tttgaaagct ttgacctgga gcctgactca aatcctccag gggggatgtt 900
ctgtcgctac gaccggctag aaatctggga tggattccct gatgttggcc ctcacattgg 960
gcgttactgt ggacagaaaa caccaggctg aatccgatcc tcatcgggca ttctctccat 1020
ggttttttac accgacagcg cgatagcaaa agaagggttc tcagcaaaact acagtgtctt 1080
gcagagcagt gtctcagaag atttcaaatg tatggaagct ctgggcatgg aatcaggaga 1140
aattcattct gaccagatca cagcttcttc ccagtatagc accaactggf ctgcagagcg 1200
ctcccgctg aactaccctg agaatgggtg gactcccgga gaggattcct accgagagtg 1260
gatacaggta tgcagcataa gatcaagcct atctaggatt gaataagttt ttgacctct 1320
agagagggtg ttgaaagaaa gtggtactgt gccaaatggc ctccaatgag aagatagggt 1380
cacggcgctc agtataaatc actgcaagag aagatagggt cacggccatc aggtataaat 1440
cactgcaaaa tgagcccatc gctacacgat cagagaaaag caggcccaag atgacatccc 1500

tgaaaaacgct ttatcttttc agttacttat tatactaactc tttccgrgga

1550

<210> 44

<211> 5948

<212> DNA

<213> Homo sapiens

<400> 44

atcatgggac	cgggtgagcg	ctgagaatcg	cggccgcagc	catcagccct	ggagatgacc	60
aggagcggcc	actgctgaga	actatgtgga	gagaggctgc	gagccctgct	gcagagcctc	120
cggctgggat	agccgcccc	cgtggggcg	atgcggacag	cgcgggacag	ccaggggagc	180
gcgctggggc	cgcagcatgc	gggaaccgc	taaaccgggt	ggctgctgag	gcggccgaga	240
tgctcgtgcg	cgcagcgcgc	cccactgcat	cctcgacctt	ctcgggctac	agggaccgtc	300
agtggcgact	atgggcagag	tgggctattg	gacctgctg	gtgctgccgg	cccttctggt	360
ctggcgcggt	ccggcgccga	gcgcggcggc	ggagaaggg	ccccccgcgc	taaataattgc	420
ggtgatgctg	ggtcacagcc	acgacgtgac	agagcgcgaa	cttcgaacac	tgtggggccc	480
cgaacaggcg	gcggggctgc	ccctggacgt	gaacgtggta	gctctgctga	tgaaccgcac	540
cgaccccaag	agcctcatca	cgcacgtgtg	cgacctcatg	tccggggcac	gcattccacg	600
cctcgtgttt	ggggacgaca	cggaccagga	ggccgtagcc	cagatgctgg	attttatctc	660
ctccacacac	ttcgtcccca	tcttgggcat	tcatgggggc	gcattctatga	tcatggctga	720
caaggatccg	acgtctacct	tcttccagtt	tggagcgctc	atccagcagc	aagccacgg	780
catgctgaag	atcatgcagg	attatgactg	gcattgtctc	tccctggtga	ccactatctt	840
ccctggctac	agggattca	tcagcttctg	caagaccaca	gtggacaaca	gctttgtggg	900
ctgggacatg	cagaatgtga	tcacactgga	cacttccttt	gaggatgcaa	agacacaagt	960
ccagctgaag	aagatccact	cttctgtcat	cttgtctctac	tggtccaaag	acgaggctgt	1020
tctcattctg	agtgaggccc	gctcccttgg	cctcaccggg	tatgatttct	tctggattgt	1080
ccccagcttg	gtctctggga	acacggagct	catcccaaaa	gagtttccat	cgggactcat	1140
ttctgtctcc	tacgatgact	gggactacag	cctggaggcg	agagtgagg	acggcattgg	1200
catcctaacc	accgctgcat	cttctatgct	ggagaagttc	tcctacatcc	ccgaggccaa	1260
ggccagctgc	tacgggcaga	tggagaggcc	agaggtcccg	atgcacacct	tgcacccatt	1320
tatggtcaat	gttacatggg	atggcaaaga	cttatccttc	actgaggaag	gctaccaggt	1380
gcacccagag	ctgggtgtga	ttgtgctgaa	caaagaccgg	gaatgggaaa	aggtgggcaa	1440
gtgggagaac	catacgtgta	gcctgaggca	cgcctgtgtg	cccaggtaga	agtccttctc	1500
cgactgtgag	ccggatgaca	accatctcag	catcgtcacc	ctggaggagg	ccccattcgt	1560
catcgtggaa	gacatagacc	ccctraccga	gacgtgtgtg	aggaacaccg	tgccatgtcg	1620
gaagtctgtc	aaaatcaaca	attcaaccaa	tgaggggatg	aatgtgaaga	aatgctgcaa	1680
gggttctctg	attgatattc	tgaagaagct	ttccagaact	gtgaagttta	cttacgacct	1740
ctatctggtg	accaatggga	agcatggcaa	gaaagttaac	aatgtgtgga	atggaatgat	1800
cgggtgaagt	gtctatcaac	gggcagtcac	ggcagttggc	tcgtccacca	tcaatgagga	1860
acgttctgaa	gtgggtgact	tctctgtgcc	ctttgtggaa	acgggaatca	gtgtcatggt	1920
ttcaagaagt	aatggcaccg	tctcaccttc	tgcttttcta	gaaccattca	gcgcctctgt	1980
ctgggtgatg	atgtttgtga	tgtgtctcat	tgtttctgcc	atagctgttt	ttgtctttga	2040
atacttcagc	cctgttggat	acaacagaaa	cttagccaaa	gggaaagcac	cccatgggccc	2100
ttcttttaca	attggaaaag	ctatatggct	tctttggggc	ctgggtgtta	ataactccgt	2160
gcctgtccag	aatcctaaag	ggaccaccag	caagatcatg	gtatctgtat	gggccttctt	2220
cgtgttcata	ttcctggcta	gctacacagc	caatctggct	gccttcatga	tccaagagga	2280
atttgtggac	caagtgaccg	gcctcagtga	caaaaagttt	cagagacctc	atgactattc	2340
cccacctttt	cgatttggga	cagtgcctaa	tggaagcacg	gagagaaaca	ttcgggaataa	2400
ctatccctac	atgcatcagt	acatgaccaa	atttaatcag	aaaggagtag	aggacgcctt	2460
ggtcagcctg	aaaacgggga	agctggacgc	tttcatctac	gatgccgcag	tcttgaatta	2520
caaggctggg	agggatgaag	gctgcaagct	ggtgaccatc	gggagtgggt	acatctttgc	2580
caccaccggg	tatggaattg	cccttcagaa	aggctctcct	tggaagaggc	agatcgacct	2640
ggccttgctt	cagtttgtgg	gtgatggtga	gatggaggag	ctggagaccc	tgtggctcac	2700
tgggatctgc	cacaacgaga	agaacgaggt	gatgagcagc	cagctggaca	ttgacaacat	2760
ggcgggcgta	ttctacatgc	tggctgccgc	catggccctt	agcctcatca	ccttcatctg	2820
ggagcacctc	ttctactgga	agctgcgctt	ctgtttcacg	ggcgtgtgct	ccgaccggcc	2880
tgggttgctc	ttctccatca	gcaggggcat	ctacagctgc	attcatggag	tgcacattga	2940
agaaaagaag	aagtctccag	acttcaatct	gacgggatcc	cagagcaaca	tgttaaaact	3000
cctccgggtca	gccaaaaaca	tttccagcat	gtccaacatg	aactcctcaa	gaatggactc	3060
acccaaaaga	gctgctgact	tcatccaaag	aggttccttc	atcatggaca	tggtttcaga	3120

taaggggaat ttgatgtact cagacaacag gtcctttcag gggaaagaga gcatttttgg 3180
 agacaacatg aacgaactcc aaacatttgt ggccaaccgg cagaaggata acctcaataa 3240
 ctatgtattc cagggacaac atcctcttac tctcaatgag tccaacccta acacgggtga 3300
 ggtggccgtg agcacagaat ccaaagcgaa ctctagaccc cggcagctgt ggaagaaatc 3360
 cgtrgattcc atacgccagg attcactatc ccagaatcca gtctcccaga gggatgaggg 3420
 aacagcagag aataggaccc actccctaaa gagccctagg tatcttccag aagagatggc 3480
 ccaactctgac atttcagaaa cgtcaaactc ggccacgtgc cacagggaac ctgacaacag 3540
 taagaaccac aaaaccaagg acaactttta aaggtcagtg gcctccaaat accccaagga 3600
 ctgtagttag gtcgagcgca cctacctgaa aaccaaacta agctccccta gagacaagat 3660
 ctacactata gatggtgaga aggagcctgg ttccactta gatccacccc agtttgttga 3720
 aaatgtgacc ctgcccgaga acgtggactt cccggacccc taccaggatc ccagtgaata 3780
 cttccgcaag ggggactcca cgtgcgaat gaaccgggaa cccttgcata atgaagaggg 3840
 gctttccaac aacgaccagt ataaactcta ctccaagcac ttcaccttga aagacaaggg 3900
 ttccccgcac agtgagacca gcgagcgata ccggcagaac tccacgcact gcagaagctg 3960
 cctttccaac atgccacact attcaggcca cttcaccatg aggtccccct tcaagtgcga 4020
 tgccctgctg cggatgggga aytcttatga catcgatgaa gaccagatgc ttcaggagac 4080
 agggatgacc aacgcttggg tattgggaga tgccctcgg acccttacia acactcgttg 4140
 ccatcccagg cgggtgaatga cagctatctt cggctgcctt tgaggtcaac ggcatcgtac 4200
 tgttccaggg acagtcgggg ccacaatgat gtgtatat tt cggagcatgt tatgccttat 4260
 gctgcaataa agaataatat gtactctacc cccaggggtt taaattcctg cagcaataga 4320
 cgcgtgtaca agaaaatgcc tagtatcgaa tctgatgttt aaaaatcttc cattaatgtt 4380
 ttatctatag ggaaatayac gtaatggcca atgttctgga gggtaaattg tggatgtcca 4440
 atagtgcctt gctaagagga agaagatgta gggaggtatt ttgttgttgt tgttgttggc 4500
 tcttttgcac acggttcat gccataatct tccactcaag gaatcttgtg aggtgtgtgc 4560
 tgagcatggc agacaccaga taggtgagtc ctttaaccaa aataactaac tacataaggg 4620
 caagtctccg ggacatgcct actgggtatg ttggcaataa tgatgcattg gatgccaatg 4680
 gtgatgttat gatttccat attccaaatt ccattaaggc cagcccacca tgtaattttc 4740
 tcatcagaaa tgcctaattg tttctcta atcagaataag caatatgggtg tgcattgaaa 4800
 cctgacacag acaaaataaa aacagttaag aatgcattct cactgtagtc ggatttgaac 4860
 atgtgcaaga gattaggaag tttggctcgt aacagtttca gctttcttgt tatgccttcc 4920
 atcacagccc aggtccacc caagaactcc aggtccctt aaagaatagc aaatcagtgt 4980
 gttcgtgatg actgtgctac cttcattata gttcatttcc aagacacatc tggagccaaa 5040
 ggcccgaggg accctcaggt ggggagagct acaggaatct ctttgatgtg tgatgtgtgt 5100
 ttctctcacc ctccgcttct atggtcttgt tcagagctgc ataaactaac acatttatgt 5160
 ctccgagatc taagtgtgga tcttctgtct gtgacacagt ggccattgta gtttatccc 5220
 aagacgccta tgtacgtaag tttgcatttc ctcccttctg gtgatgactc agggttgtat 5280
 agtatctgtt acccttccc tcccagagta accataactc gttccgttcc caaacagcca 5340
 tgggtggtgc caattagctg tgtatcgctc ttcccagagt tgtaaatgtg gtgacatgca 5400
 ccaacagccg tatgtgtact gtgatctgta agaagtacaa tgccatctgt ctgccgaagg 5460
 ctagcatggt ttaggttta tcttcttcca catccagaaa ttctgttggga cactcacttc 5520
 caccaccaac tctcaaactc aaaagccttc aaaaacagag gcactcttgg atctaccctg 5580
 agtatcctcc aaactgtgga tacagtttag tgagacaagc aatttctccc ttctgagtta 5640
 ttctctctgt tgggtgcaaa ccacttcata gcaccaacag agatgtagga aaaattcctc 5700
 aaagtatttg tcatttctga gtgcctgca ttatcccatt cttattctcc tcaaacctgt 5760
 gcataatga catgaaatga tatccatttt ttttttaagt tagaaacaga gaggggaata 5820
 cttatgcctg gggagcctgt tagcacagt cctgccacaa aaacaagtgc ccccgacaag 5880
 atagttgcta tgttatgaca ctttctcaga tcaggatttt ctagtttaaa aattaaatat 5940
 cataaaac 5948

<210> 45

<211> 1862

<212> DNA

<213> Homo sapiens

<400> 45

gtgcattgag cgcgctccag ctgccgggag gagggggcgg cccccgcgtc cggggcgctc 60
 ggctacagct gcggggcccg aggtctccgc gcactcgctc cgggcccatt ctggaggcgg 120
 cggaaccssg ggacactagg acggaggcgg cgggcgctgg gcggcccccg gcacgctgag 180
 ctccggatgc ggacgtgct gcctcccgcg ctgctgacct gctggctgct cggcccccgtg 240
 aacagcattc acccagaatg ccgatttcat ctggaaatag agggaggaaga acaaaaatgt 300

```

rcagagcttc tgagggtctca aacagaaaaa cacaaagcct gcagtggcgt ctgggacaac 360
atcacgtgct ggcggcctgc caatgtggga gagaccgtca cgggtgccctg cccaaaagtc 420
ttcagcaatt tttacagcaa agcaggaaac ataagcaaaa actgtacgag tgacggatgg 480
tcagagacgt tcccagattt cgtcgatgcc tgtggctaca gcgaccggga ggatgagagc 540
aagatcacgt tttatattct ggtgaaggcc atttataccc tgggctacag tgtctctctg 600
atgtctcttg caacaggaag cataattctg tgccctctca ggaagctgca ctgcaccagg 660
aattacatcc acctgaacct gttcctgtcc ttcctcctga gagccatctc agtgctggtc 720
aaggacgacg ttctctactc cagctctggc acgttgcaact gccctgacca gccatcctcc 780
tgggtgggct gcaagctgag cctggctctc ctgcagtact gcatcatggc caacttcttc 840
tggtgctggg tggaggggct ctacctccac accctcctgg tggccatgct cccccctaga 900
aggtgcttcc tggcctacct cctgatcgga tggggcctcc ccaccgtctg catcggtgca 960
tggactgcgg ccaggctcta cttagaagac accggttgct gggatacaaa cgaccacagt 1020
gtgccctggt gggtcatacg aataccgatt ttaatttcca tcatcgtaa ttttgtcctt 1080
ttcattagta ttatacgaat tttgctgcag aagttaacat cccagatgt cgggcgcaac 1140
gaccagtctc agtacaagag gctggccaag tccacgtccc tgcttatccc gctgttcggc 1200
gtccactaca tgggtgtttgc cgtgtttccc atcagcatct cctccaaata ccagatactg 1260
tttgagctgt gcctcgggtc gttccagggc ctgggtgggg ccgtcctcta ctgtttcctg 1320
aacagtgagg taagttcatg gccgccttgg aaccaagcac aggtactcac ttgcttctctg 1380
agatgctgcc cagcctgggt cgcagcccc cacacatgcc tgtcttccgc gggctcgagt 1440
tactgcccgg gacccacag ttctgtgtcc ccatcagaga acccacaacg acacaggcaa 1500
acccactctt ctgggcccag cttccaaacc ccgccgtcct tccgtccacc ctaagttagca 1560
tcgactgccg tccgtctcgg agccctctcg ggaagctccc cggccgggtc tagacagaat 1620
ctgtttttcc ccatggtcgg cgtctcgtcc ctgaccatag cttgtgagtc ccagaaagcc 1680
gggcctgggt tgggggggtg ggtgcacag cgtcctgtga gtccctgggg aggaagcccc 1740
gagccgagct ctgccctgcg ttcattccca gccaggagg ctgtctccgg gctgtccaa 1800
cggcctggcc ccgtcccctg acccctgacc ctcgccccc acgtgcgggt tgctggcgt 1860
tt

```

<210> 46

<211> 1687

<212> DNA

<213> Homo sapiens

<400> 46

```

gtgcattgag cgcgtccag ctgccgggac gagggggcgg cccccgcgt cggggcgctc 60
ggctacagct gcggggcccc aggtctccgc gcactcgtc ccggcccatg ctggaggcgg 120
cggaaccssg gggacctagg acggaggcgg cgggcgtgg gcggcccccg gcacgctgag 180
ctcgggatgc ggacgtgct gccctcccg cgtctgacct gctggctgct cgtccccgtg 240
aacagcattc acccagaatg ccgatttcat ctggaataac aggaggaaga aacaaaatgt 300
rcagagcttc tgagggtctca aacagaaaaa cacaaagcct gcagtggcgt ctgggacaac 360
atcacgtgct ggcggcctgc caatgtggga gagaccgtca cgggtgccctg cccaaaagtc 420
ttcagcaatt tttacagcaa agcaggaaac ataagcaaaa actgtacgag tgacggatgg 480
tcagagacgt tcccagattt cgtcgatgcc tgtggctaca gcgaccggga ggatgagagc 540
aagatcacgt tttatattct ggtgaaggcc atttataccc tgggctacag tgtctctctg 600
atgtctcttg caacaggaag cataattctg tgccctctca ggaagctgca ctgcaccagg 660
aattacatcc acctgaacct gttcctgtcc ttcctcctga gagccatctc agtgctggtc 720
aaggacgacg ttctctactc cagctctggc acgttgcaact gccctgacca gccatcctcc 780
tgggtgggct gcaagctgag cctggctctc ctgcagtact gcatcatggc caacttcttc 840
tggtgctggg tggaggggct ctacctccac accctcctgg tggccatgct cccccctaga 900
aggtgcttcc tggcctacct cctgatcgga tggggcctcc ccaccgtctg catcggtgca 960
tggactgcgg ccaggctcta cttagaagac accggttgct gggatacaaa cgaccacagt 1020
gtgccctggt gggtcatacg aataccgatt ttaatttcca tcatcgtaa ttttgtcctt 1080
ttcattagta ttatacgaat tttgctgcag aagttaacat cccagatgt cgggcgcaac 1140
gaccagtctc agtacaagag gctggccaag tccacgtccc tgcttatccc gctgttcggc 1200
gtccactaca tgggtgtttgc cgtgtttccc atcagcatct cctccaaata ccagatactg 1260
tttgagctgt gcctcgggtc gttccagggc ctgggtgggg ccgtcctcta ctgtttcctg 1320
aacagtgagg taagttcatg gccgccttgg aaccaagcac aggtactcac ttgcttctctg 1380
agatgctgcc cagcctgggt cgcagcccc cacacatgcc tgtcttccgc gggctcgagt 1440
tactgcccgg gacccacag ttctgtgtcc ccatcagaga acccacaacg acacaggcaa 1500
acccactctt ctgggtgggg ggtggggctg cacagcgtcc tgtgagtcct tggggaggaa 1560

```


gccccgagcc gagctctgcc ctgcgttcat tcccagccag ggaggctgtc tccgggctgc 1620
tccaacggcc tggccccgtc ccttgacccc tgacctccc gccccacgct gcggttgctg 1680
gcgcttt 1687

<210> 47

<211> 6486

<212> DNA

<213> Homo sapiens

<400> 47

ttgagaaagg gaatttcac ccaaataaaa ggaatgaagt ctggctccgg aggaggggtcc 60
ccgacctcgc tgtgggggct cctgtttctc tccgccgcgc tctcgctctg gccgacgagt 120
ggagaaatct gcgggccagg catcgacatc cgcaacgact atcagcagct gaagcgcctg 180
gagaactgca cgggtgatga gggctacctc cacatcctgc tcatctccaa ggccgaggac 240
taccgcagct accgcttccc caagctcacg gtcattaccg agtacttgct gctgttccga 300
gtggctggcc tcgagagcct cggagacctc ttccccaacc tcacggtcat ccgcggtgg 360
aaactcttct acaactacgc cctggtcatc ttcgagatga ccaatctcaa ggatattggg 420
ctttacaacc tgaggaacat tactcggggg gccatcagga ttgagaaaaa tgctgacctc 480
tgttacctct ccaactgtgga ctggctccctg atcctggatg cgggtgtccaa taactacatt 540
gtggggaata agccccaaaa ggaatgtggg gacctgtgtc cagggacctat ggaggagaag 600
ccgatgtgtg agaagaccac catcaacaat gagtacaact accgctgctg gaccacaaac 660
cgctgccaga aaatgtgccc aagcacgtgt gggaagcggg cgtgcaccga gaacaatgag 720
tgctgccacc ccgagtgcct gggcagctgc agcgcgctg acaacgacac ggctgtgta 780
gcttgccggc actactacta tgcoggtgtc tgtgtgcctg cctgcccgcc caacacctac 840
aggtttgagg gctggcgctg tgtggaccgt gacttctgcg ccaacatcct cagcgccgag 900
agcagcgact ccgaggggtt tgtgatccac gacggcgagt gcatgcagga gtgcccctcg 960
ggcttcatcc gcaacggcag ccagagcatg tactgcatcc cttgtgaagg tccttgcccg 1020
aaggtctgtg aggaagaaaa gaaaacaaag accattgatt ctgttacttc tgctcagatg 1080
ctccaaggat gcaccatctt caagggcaat ttgctcatta acatccgacg ggggaataac 1140
attgcttcag agctggagaa cttcatgggg ctcacagagg ttgtgacggg ctacgtgaag 1200
atccgccatt ctcatgcctt ggtctccttg tccttcctaa aaaaccttcg cctcatccta 1260
ggagaggagc agctagaagg gaattactcc ttctacgtcc tcgacaacca gaacttgca 1320
caactgtggg actgggacca ccgcaacctg accatcaaaag cagggaaaaat gtactttgct 1380
ttcaatccca aattatgtgt ttccgaaatt taccgcatgg aggaagtgc ggggactaaa 1440
gggcgcaaaa gcaaagggga cataaacacc aggaacaacg gggagagagc ctctgtgaa 1500
agtgcagctc tgcatttcac ctccaccacc acgtcgaaga atcgcatcat cataacctg 1560
caccggtacc ggccccctga ctacagggat ctcacagct tcaccgttta ctacaaggaa 1620
gcacccttta agaattgcac agagtatgat gggcaggatg cctgcccgtc caacagctgg 1680
aacatggtgg acgtggacct cccgcccaac aaggacgtgg agcccggcat cttactacat 1740
gggtgaagc cctggactca gtacgccgtt tacgtcaagg ctgtgacct caccatggtg 1800
gagaacgacc atatccgtgg ggccaagagt gagatcttgt acattcgac caatgcttca 1860
gttcttccca ttcccttgga cgttctttca gcacgaaact cctcttctca gttaatcgtg 1920
aagtgaacc ctccctctct gcccaacggc aacctgagtt actacattgt gcgctggcag 1980
cggcagcctc aggacggcta cctttaccgg cacaattact gtcctaaaaga caaaatcccc 2040
atcaggaagt atgccgacgg caccatcgac attgaggagg tcacagagaa ccccaagact 2100
gaggtgtgtg gtggggagaa agggccttgc tgcgctgcc ccaaaaactga agccgagaag 2160
caggccgaga aggaggaggc tgaataccgc aaagtctttg agaatttct gcacaactcc 2220
atcttcgtgc ccagacctga aaggaagcgg agagatgtca tgcaagtggc caacaccacc 2280
atgtccagcc gaagcaggaa caccacggcc gcagacacct acaacatcac cgaccggaa 2340
gagctggaga cagagtacct tttctttgag agcagagtgg ataacaagga gagaactgtc 2400
atttctaacc ttccggcctt cacattgtac cgcacgata tccacagctg caaccacgag 2460
gctgagaagc tgggctgcag cgcctccaac ttctgtttt caaggactat gcccgagaa 2520
ggagcagatg acattcctgg gccagtgacc tgggagccaa ggctgaaaa ctccatcttt 2580
ttaaagtggc cggaaacctga gaatcccaat ggattgattc taatgtatga aataaaatac 2640
ggatcacaag ttgaggatca gcgagaatgt gtgtccagac aggaatacag gaagtatgga 2700
ggggccaagc taaaccggct aaaccgggg aactacacag cccgattca ggccacatct 2760
ctctctggga atgggtcgtg gacagatcct gtgttcttct atgtccaggc caaaacagga 2820
tatgaaaact tcatccatct gatcatcgct ctgcccgtcg ctgtcctgtt gatcgtggga 2880
gggttggtga ttatgctgta cgtcttccat agaaagagaa ataacagcag gctggggaat 2940
ggagtgtgt atgcctctgt gaaccggag tacttcagcg ctgctgatgt gtacgttct 3000

gatgagtggg aggtggctcg ggagaagatc accatgagcc gggaaacttg gcaggggtcg 3060
tttgggatgg tctatgaagg agttgccaag ggtgtggtga aagatgaacc tgaaccaga 3120
gtggccatta aaacagtga cgaggccgca agcatgcgtg agaggattga gtttctcaac 3180
gaagcttctg tgatgaagga gttcaattgt caccatgtgg tgcgattgct ggggtggtg 3240
tcccaaggcc agccaacact ggtcatcatg gaactgatga caccgggcca tctcaaaagt 3300
tatctccggt ctctgagggc agaaatggag aataatccag tcttagcacc tccaagcctg 3360
agcaagatga ttcagatggc cggagagatt gcagacggca tggcatacct caacgccaat 3420
aagtctgtcc acagagacct tgcgtcccgg aattgcatgg tagccgaaga tttcacagtc 3480
aaaatcggag attttggtat gacgcgagat atctatgaga cagactatta ccggaaggga 3540
ggcaaagggc tgcgtcccgt gcgtggtatg tctctgagt ccctcaaggga tggagtcttc 3600
accacttact cggacgtctg gtccttcggg gtcgtcctct gggagatcgc cacactggcc 3660
gagcagccct accagggtt gtccaacgag caagtccttc gcttcgtcat ggaggcgcc 3720
cttctggaca agccagacaa ctgtcctgac atgctgttg aactgatgcg catgtgctgg 3780
cagtataacc ccaagatgag gccttccttc ctggagatca tcagcagcat caaagaggag 3840
ctggacctgg agccagagaa catggagagc gtccccctgg acccctcggc ctctcgtcc 3900
tccctgccac tgcgcgacag acaactcagga cacaaggccg agaacggccc cgccctggg 3960
gtgctggtcc tccgcgccag cttcgacgag agacagcctt acgcccacat gaacggggg 4020
cgcaagaacg agcgggcctt gccgtgccc cagtcttcga cctgctgac ctggatcct 4080
gaatctgtgc aaacagtaac gtgtgcgcac gcgcagcggg gtgggggggg agagagagt 4140
ttaacaatcc attcacaagc ctctgttacc tcagtggatc ttcagaactg cccttgtgc 4200
ccgcgggaga cagcttctct gcagtaaaac acatttgga tgttctttt tcaaatatgc 4260
aagcagcttt ttattccctg cccaaaccct taactgacat gggcctttaa gaaccttaat 4320
gacaacactt aatagcaaca gagcacttga gaaccagtct cctcactctg tccctgtct 4380
tccctgttct cccttctct ctctctctg ctccataacg gaaaaataat tgcacaaagt 4440
ccagctggga agccctttt atcagtttga ggaagtggct gtccctgtgg ccccatccaa 4500
ccactgtaca caccgcctg acaccgtggg tcattacaaa aaaacacgtg gagatggaaa 4560
tttttacctt tatctttcac ctctctaggg acatgaaatt taaaaagggc catcgttcat 4620
ccaaggctgt taccatttta acgctgccta attttgcaa aatcctgaac tttctccctc 4680
atcgcccgcg cgtgattcc tegtgtccg aggcattggg gagcatggca gctggtgct 4740
ccatttgaga gacacgtgg cgacacactc cgtccatccg actgcccctg ctgtgctgct 4800
caaggccaca ggcacacagg tctcattgct tctgactaga ttattatttg ggggaactgg 4860
acacaatagg tcttctctc agtgaagggt gggagaagct gaaccggctt ccctgccctg 4920
cctcccccag cccctgcccc acccccaga atctggtggc catggggccc gaagcagtct 4980
ggcgagacag cttggagtca aggggcccc tgcctgcttc tctcccagcc ccagctcccc 5040
cgcccgcccc caaggacaca gatgggaagg ggtttccagg gactcagccc cactgttgat 5100
gcaggttgca aaggaaagaa attcaaacac cacaacagca gtaagaagaa aagcagtcaa 5160
tggtattcaag cattctaagc tttgttgaca ttttctctgt tcttaggact tcttcatggg 5220
tcttacagtt ctatgttaga ccatgaaaca tttgcataca catcgtcttt aatgtcactt 5280
ttataacttt ttacgggtc agatattcat ctatacgtct gtacagaaaa aaaaaagctg 5340
ctattttttt tgttcttgat ctttgtggat ttaattctatg aaaaccttca ggtccacctt 5400
ctcccccttc tgcctactcc aagaaacttc ttaatgctttg tactagagtg cgtgactttc 5460
ttctctttt cccggtaatg gatacttcta tcacataatt tgccatgaac tgttgatgc 5520
ctttttataa atacatcccc catccctgct cccacctgcc cctttagtgt ttttctaacc 5580
cgtaggctct ctggggcacg aggcagaaag cagggccggg gcaccccatc ctgaggaggg 5640
ccgcgctcct ctccccagcc tgcctcaca gcattggagc ctgttacagt gcaagacatg 5700
atacaaaactc aggtcagaaa aacaaagggt aaatatttca cactgtttt ttcatgttt 5760
ccactcacg tggttgagaa gcctcaccct ctctttccct tgcctttgct taggttgta 5820
cacacatata tatatatatt ttaattctt ggttacaaca gcagtgttaa ccgcagacac 5880
taggcatttg gattactatt tttcttaatt gctatttaat ccttccatcc cagcaaaaac 5940
agctgctgag tccaaggag cagcagagcg tggctcggca gggcctgttg tggcctcgc 6000
cacccccctc accggaccga ctgacctgtc tttggaacca gaacatccca aggaactcc 6060
ttcgcactgg cgttgagtgg gaccccgga tccaggctgg ccaggggcg caccctcagg 6120
gctgtgccc ctggagtgt aggtggaggc agcacagac ccacggtggc ccaagagccc 6180
ctttgcttct tgcgtgggga ccagggtgt ggtgctggcc cactttccct cggccaggaa 6240
tccaggtcct tggggcccag gggcttctg ctctctggat ttttttctt ttagcactt ctaccagag 6300
agatgacagc acaagagttg ctctctggat agaaatgttt aggagtaaga acaaagctgg 6360
gatacggtga ttgctagtgt tgcactgaaga ttcaacacag aaaagaaagt ttatacggct 6420
ttttgtctgg tcagcagttt gtcccactgc tttctctagt ctctatccca tagcgtgttc 6480
ccttta

<210> 48
 <211> 2241
 <212> DNA
 <213> Homo sapiens

<400> 48

```

gagacatggc ccgggcagtg gctcctggaa gaggaacaag tgtgggaaaa gggagaggaa 60
gccggagcta aatgacagga tgcaggcgac ttgagacaca aaaagagaag cgttcctctc 120
ggatccaggc attgcctcgc tgctttcttt tctccaagac gggctgagga ttgtacagct 180
ctaggcggag ttggggctct tcggatcgct tagattctcc tctttgctgc atttcccccc 240
acgtcctcgt tctcccgcgt ctgcctgcgg acccgagaa gggagaatgg agagggggct 300
gccgtcctc tgcgccgtgc tcgccctcgt cctcgccccg gccggcgctt ttcgcaacga 360
taaattgtggc gatactataa aaattgaaag ccccggttac cttacatctc ctggttatcc 420
tcattcttat cacccaagtg aaaaatgcga atggctgatt caggctccgg acccatacca 480
gagaattatg atcaacttca accctcactt cgatttggag gacagagact gcaagtatga 540
ctacgtggaa gtcttcgatg gagaaaatga aaatggacat tttaggggaa agttctgtgg 600
aaagatagcc cctcctcctg ttgtgtcttc agggccattt ctttttatca aatttgtctc 660
tgactacgaa acacatgggt caggattttc catacgttat gaaattttca agagagggtcc 720
tgaatgttcc cagaactaca caacacctag tggagtata aagtcccccg gattccctga 780
aaaatatccc aacagccttg aatgcactta tattgtcttt gcgccaaaga tgtcagagat 840
tatcctggaa tttgaaagct ttgacctgga gcctgactca aatcctccag gggggatgtt 900
ctgtcgctac gaccggctag aaatctggga tggattccct gatgttggcc ctcacattgg 960
gcgttactgt ggacagaaaa caccaggtcg aatccgatcc tcacgggca ttctctccat 1020
ggttttttac accgacagcg cgatagcaaa agaaggtttc tcagcaaact acagtgtctt 1080
gcagagcagt gtctcagaag atttcaaagt tatggaagct ctgggcatgg aatcaggaga 1140
aattcattct gaccagatca cagcttcttc ccagtatagc accaactggt ctgcagagcg 1200
ctcccgctg aactaccctg agaatgggtg gactcccga gaggattcct accgagagtg 1260
gatacaggta gacttgggccc ttctgcgctt tgtcacggct gtcgggacac agggcgccat 1320
ttcaaaagaa accaagaaga aatattatgt caagacttac aagatcgacg ttagctccaa 1380
cggggaagac tggatcacca taaaagaagg aaacaaacct gttctctttc agggaaacac 1440
caaccccaca gatgttgtgg ttgcagtatt ccccaaacca ctgataactc gatttgtccg 1500
aatcaagcct gcaacttggg aaactggcat atctatgaga tttgaagtat acggttgcaa 1560
gataacagat tatccttgc tgggaatgtt gggtatggtg tctggactta tttctgactc 1620
ccagatcaca tcatccaacc aaggggacag aaactggatg cctgaaaaca tccgcctggt 1680
aaccagtgcg tctggtctgg cacttccacc cgcacctcat tcctacatca atgagtggct 1740
ccaaatagac ctgggggagg agaagatcgt gaggggcata atcattcagg gtgggaagca 1800
ccgagagaac aaggtgttca tgaggaagtt caagatcggg tacagcaaca acggctcggg 1860
ctggaagatg atcatggatg acagcaaacg caaggcgaag tcttttgagg gcaacaacaa 1920
ctatgataca cctgagctgc ggacttttcc agctctctcc acgcgattca tcaggatcta 1980
ccccgagaga gccactcatg gcggactggg gctcagaatg gagctgctgg gctgtgaagt 2040
ggaagccccct acagctggac cgaccactcc caacgggaac ttggtggatg aatgtgatga 2100
cgaccaggcc aactgccaca gtggaacagg tgatgacttc cagctcacag gtggcaccac 2160
tgtgctggcc acagaaaagc ccacggtcat agacagcacc atacaatcag gtatcaaata 2220
aaatacgaat tgtgacagat t 2241

```

<210> 49
 <211> 2808
 <212> DNA
 <213> Homo sapiens

<400> 49

```

gagacatggc ccgggcagtg gctcctggaa gaggaacaag tgtgggaaaa gggagaggaa 60
gccggagcta aatgacagga tgcaggcgac ttgagacaca aaaagagaag cgttcctctc 120
ggatccaggc attgcctcgc tgctttcttt tctccaagac gggctgagga ttgtacagct 180
ctaggcggag ttggggctct tcggatcgct tagattctcc tctttgctgc atttcccccc 240
acgtcctcgt tctcccgcgt ctgcctgcgg acccgagaa gggagaatgg agagggggct 300
gccgtcctc tgcgccgtgc tcgccctcgt cctcgccccg gccggcgctt ttcgcaacga 360
taaattgtggc gatactataa aaattgaaag ccccggttac cttacatctc ctggttatcc 420
tcattcttat cacccaagtg aaaaatgcga atggctgatt caggctccgg acccatacca 480
gagaattatg atcaacttca accctcactt cgatttggag gacagagact gcaagtatga 540

```

ctacgtggaa gtcttcgatg gagaaaatga aaatggacat tttaggggaa agttctgtgg 600
 aaagatagcc cctcctcctg ttgtgtcttc agggccattt ctttttatca aatttgtctc 660
 tgactacgaa acacatggtg caggattttc catacgttat gaaattttca agagaggtcc 720
 tgaatgttcc cagaactaca caacacctag tggagtata aagtcctccg gattccctga 780
 aaaatatccc aacagccttg aatgcactta tattgtcttt gcgccaaaga tgtcagagat 840
 tatectggaa ttgaaagct ttgacctgga gcctgactca aatcctccag gggggatgtt 900
 ctgtcgctac gaccggctag aaatctggga tggattccct gatgttggcc ctcacattgg 960
 gcgttactgt ggacagaaaa caccaggtcg aatccgatcc tcacgggca ttctctccat 1020
 ggttttttac accgacagcg cgatagcaaa agaagggttc tcagcaaaact acagtgtctt 1080
 gcagagcagt gtctcagaag atttcaaatg tatggaagct ctgggcatgg aatcaggaga 1140
 aattcattct gaccagatca cagcttcttc ccagtatagc accaactggt ctgcagagcg 1200
 ctcccgcctg aactaccctg agaatgggtg gactcccgga gaggattcct accgagagt 1260
 gatacaggta gacttggggc ttctgcgctt tgtcacggct gtcgggacac agggcgccat 1320
 ttcaaaagaa accaagaaga aatattatgt caagacttac aagatcgacg ttagctccaa 1380
 cggggaagac tggatcacca taaaagaagg aaacaaacct gttctctttc agggaaacac 1440
 caaccccaaca gatgttgtgg ttgcagtatt ccccaaacca ctgataactc gatttgtccg 1500
 aatcaagcct gcaacttggg aaactggcat atctatgaga tttgaagtat acggttgcaa 1560
 gataacagat tatecttgct ctggaatgtt gggatgtgtg tctggactta tttctgactc 1620
 ccagatcaca tcacccaacc aaggggacag aaactggatg cctgaaaaca tccgcctggg 1680
 aaccagtgcg tctggctggg cacttccacc cgcacctcat tcctacatca atgagtggct 1740
 ccaaataagac ctgggggagg agaagatcgt gaggggcatc atcattcagg gtgggaagca 1800
 ccgagagaac aaggtgttca tgaggaagtt caagatcggg tacagcaaca acggctcgga 1860
 ctggaagatg atcatggatg acagcaaacg caaggcgaaag gtggcaccac tgtgctggcc 1920
 acagaaaagc ccacggtcat agacagcacc atacaatcag agtttccaac atatggtttt 1980
 aactgtgaat ttggctgggg ctctcacaag accttctgcc actgggaaca tgacaatcac 2040
 gtgcagctca agtggagtgt gttgaccagc aagacgggac ccattcagga tcacacagga 2100
 gatggcaact tcactattc ccaagctgac gaaaatcaga agggcaaagt ggctcgctg 2160
 gtgagccctg tgggtttatt ccagaactct gccactgca tgaccttctg gtatcacatg 2220
 tctgggtccc acgtcggcac actcagggtc aaactgcgct accagaagcc agaggagtac 2280
 gatcagctgg tctggatggc cattggacac caaggtgacc actggaagga agggcgtgtc 2340
 ttgtctccaca agtctctgaa actttatcag gtgattttcg agggcgaaat cggaaaagga 2400
 aaccttgggt ggattgtgtt ggatgacatt agtattaata accacatttc acaagaagat 2460
 tgtgcaaaac cagcagacct ggataaaaaa aaccagaaa ttaaaattga tgaacagggt 2520
 agcacgccag gatacgaagg tgaaggagaa ggtgacaaga acatctccag gaagccaggc 2580
 aatgtgttga agaccttaga mccccctc atcaccatca tagccatgag ygccctgggg 2640
 gtctcctcgg gggctgtctg tggggtcgtg ctgtactgtg cctgttggca taatgggatg 2700
 tcagaaagaa acttgtctgc cctggagaac tataactttg aacttgtgga tgggtggaag 2760
 ttgaaaaaag acaaactgaa taacacagat acttattcgg aggcata 2808

<210> 50

<211> 1922

<212> DNA

<213> Homo sapiens

<400> 50

gagacatggc cggggcagtg gctcctggaa gaggaacaag tgtgggaaaa gggagaggaa 60
 gccggagcta aatgacagga tgcaggcgac ttgagacaca aaaagagaag cgttcctctc 120
 ggatccaggc attgcctcgc tgctttcttt tctccaagac gggctgagga ttgtacagct 180
 ctaggcggag ttggggctct tcggatcgct tagattctcc tctttgctgc atttcccccc 240
 acgtcctcgt tctcccgcgt ctgcctgcgg acccgagaa gggagaatgg agagggggct 300
 gccgtcctc tgccgcgtgc tgcctcctc cctcgccccg gccggcgctt ttcgcaacga 360
 taaatgtggc gatactataa aaattgaaag ccccggtac cttacatctc ctggttatcc 420
 tcattcttat caccgaagtg aaaaatgcga atggctgatt caggctccgg acccatacca 480
 gagaattatg atcaacttca accctcactt cgatttggag gacagagact gcaagtatga 540
 ctacgtggaa gtcttcgatg gagaaaatga aaatggacat tttaggggaa agttctgtgg 600
 aaagatagcc cctcctcctg ttgtgtcttc agggccattt ctttttatca aatttgtctc 660
 tgactacgaa acacatggtg caggattttc catacgttat gaaattttca agagaggtcc 720
 tgaatgttcc cagaactaca caacacctag tggagtata aagtcctccg gattccctga 780
 aaaatatccc aacagccttg aatgcactta tattgtcttt gcgccaaaga tgtcagagat 840
 tatectggaa ttgaaagct ttgacctgga gcctgactca aatcctccag gggggatgtt 900

ctgtcgctac gaccggctag aaatctggga tggattcct gatgttggcc ctcacattgg 960
 gcgttactgt ggacagaaaa caccaggtcg aatccgatcc tcatcgggca ttctctccat 1020
 ggttttttac accgacagcg cgatagcaaa agaaggtttc tcagcaaaact acagtgtctt 1080
 gcagagcagt gtctcagaag atttcaaattg tatggaagct ctgggcatgg aatcaggaga 1140
 aattcattct gaccagatca cagcttcttc ccagtatagc accaactggt ctgcagagcg 1200
 ctcccgcctg aactaccctg agaatgggtg gactcccgga gaggattcct accgagagt 1260
 gatacaggta gacttggggc ttctgcgctt tgtcacggct gtcgggacac agggcgccat 1320
 ttcaaaagaa accaagaaga aatattatgt caagacttac aagatcgacg ttagctccaa 1380
 cggggaagac tggatcacca taaaagaagg aaacaaacct gttctcttcc agggaaacac 1440
 caaccccaaca gatgttggg ttgcagtatt ccccaaacca ctgataactc gatttgtccg 1500
 aatcaagcct gcaacttggg aaactggcat atctatgaga tttgaagtat acggttgcaa 1560
 gataacagat tatecttgct ctggaatgtt gggatgtgtg tctggactta tttctgactc 1620
 ccagatcaca tcatccaacc aaggggacag aaactggatg cctgaaaaca tccgcttggg 1680
 aaccagtcgc tctggctggg cacttccacc cgcacctcat tctacatca atgagtggct 1740
 ccaaatagac ctgggggagg agaagatcgt gaggggcatc atcattcagg gtgggaagca 1800
 ccgagagaac aaggtgttca tgaggaaagt caagatcggg tacagcaaca acggctcggg 1860
 ctggaagatg atcatggatg acagcaaacg caaggcgagg tgagggctgg ggactgggag 1920
 ga 1922

<210> 51

<211> 1208

<212> DNA

<213> Homo sapiens

<400> 51

cgcgcgctgc ctgaggacgc cgcggccccc gccccgccca tgggcgcccc tgctgcgccc 60
 ctgcgctct gcgtggccgt gccatcgtg gccggcgcc cctcggagtc cttggggacg 120
 gagcagcgcg tcgtggggcg agcggcagaa gtcccgggcc cagagcccg ccagcaggag 180
 cagttggctct tcggcagcgg ggatgctgtg gagctgagct gtcccccgcc cgggggtggt 240
 cccatggggc ccaactgtctg ggtcaaggat ggcacagggc tgggtgccctc ggagcgtgtc 300
 ctggtggggc cccagcggct gcaggtgctg aatgcctccc acgaggactc cggggcctac 360
 agctgcccgc agcggctcac gcagcgcgta ctgtgccact tcagtgtgcy ggtgacagac 420
 gctccatcct cgggagatga cgaagacggg gaggacgagg ctgaggacac aggtgtggac 480
 acagggggccc cttactggac acggcccag cggatggaca agaagctgct ggccgtgccg 540
 gccgccaaca ccgtccgctt ccgtgccca gccgtggca acccactcc ctccatctcc 600
 tggctgaaga acggcagggg gtcccgccgc gagcaccgca ttggaggcat caagctgcgg 660
 catcagcagt ggagcctggt catggaaagc gtggtgccct cggaccgcg caactacacc 720
 tgcgctcgtg agaacaagt tggcagcctc cggcagacgt acacgctgga cgtgctggag 780
 cgctccccgc accggcccat cctgcaggcg gggctgcccg ccaaccagac ggcgtgctg 840
 ggcagcgacg tggagttcca ctgcaagggtg tacagtgcg cacagcccca catccagtgg 900
 ctcaagcacg tggaggtgaa tggcagcaag gtgggcccgc acggcacacc ctacgttacc 960
 gtgctcaagt cctggatcag tgagagtgtg gaggccgacg tgcgcctccg cctggccaat 1020
 gtgtcggagc gggacggggg cgagtacctc tgtcgagcca ccaatttcat aggcgtggcc 1080
 gagaaggcct tttgctgag cgttcacggg ccccgagcag gtaacgactc tgtcccatgc 1140
 cggccggcac aagagctcca gctccaaggc cctggccgcg cgccctgcac gccccgcag 1200
 cccagccc 1208

<210> 52

<211> 1194

<212> DNA

<213> Mouse

<400> 52

ggtgcttttag agctgtaaaa atcttcatga gacacactga tgatgacgct gagacacttg 60
 ccatttattc ttttattaat cctctcagga gaactctatg cagaagagaa acagtgtgat 120
 tttcctaccg tggaaaaatgg aaggattgcc caatattatt atacgtttta aagcttttac 180
 ttccccatga gcgtagacaa aaaactatca ttcttctgtt tggctggcta tgcaaccgaa 240
 agtgggaagc aagaagagca aatcaggtgc acagcagaag gctggctctc aaacccaagg 300
 tgctacaaga aatgtctgaa gcctgacctt aggaatggct acgtctccaa tgacaaagta 360

ctgtacaaac ttcaagagag gatgagctac gggtgctctt caggatacaa aaccactggg 420
 ggaaaggacg aggaggtggg ccactgtctt tctgcagggt ggtcttctca accgtcctgc 480
 aggaaagaac aagagacatg tttggccctt gagttggaac atggaaatta ctccacgacg 540
 cagagaacat tcaaagtga gacatagtg gcttacacat gcactgcagg ctactacacc 600
 actacaggga agcagactgg ggaagcagag tgccaggcta atggctgggc cctcacacca 660
 cagtgcaca aattaatgtg ctcttctttg agattaatag aaaatggcta ttttcatect 720
 gtaaagcaaa catatgaaga aggagatgta gttcaatttt tctgtcatga aaattattat 780
 ctaagtggat ctgatttaac tcagtgttat aactttggct ggtatccaga atctcccata 840
 tgtgaaggaa gaagaaatcg atgtcctcct ccacctgtgc ctctaaattc taaaattcaa 900
 ccacattcaa caacttaccg tcacggagaa agagtgcata tagaatgtga acttaatttt 960
 gtgattcagg gttcagaaga actgctctgt gaaaatggga agtggacaga acctccaaaa 1020
 tgtattgggt ggtaaaatct tttaaagtta gctttcatta atattttaat ttgtgtattt 1080
 aatagtgaat tttattgtgn catttccaga catgtttatt gttgtccttg ctctcattca 1140
 caatcctccc atgtactac tctccctact ttattatctt gaataagcct ctcc 1194

<210> 53

<211> 4334

<212> DNA

<213> Mouse

<400> 53

aaaaaawaa aaaaggagaa gggattccta tctgtatata gggaaggaaat cctatctgca 60
 tttttcgttg ttagcaccat ccctcatccc ggtggggctt ggaactttcc atcaattctt 120
 tcctgtctcg tttctctttc atcctttgccc tgggtgtgcc tgtctcaggg agaaatcagt 180
 cacctgcagg ccttgacagg ctcttaggct ctgggaaatt tgtcatacgg gtgtcaggtg 240
 cttcttattg ctgtccaaag ggaaaaaaa agtgagacaa agaactctcc cggagccttt 300
 ccggctgcac tcagaggctc tcgagaggtg cagaaggacc tggaaggca gctaaataaa 360
 agatgccctg gggtccgaagg ccaacctggc tgttgcctgc ctctctgctg gtgtttttta 420
 agattagcat actcagcgtc acagcatggc agaccgggaa ctgtcagcca ggtcctctcg 480
 agagaagcga gagaagcggg acttgtgccg gtccctgccc ctctctagtt ttctcacaag 540
 gaaagagcat ctctcggatt gacctagatg gaacaaatca ccagcaattg gtgggtggatg 600
 ctggcatctc agcagacatg gatattcatt ataaaaaga gagactctat tgggtggatg 660
 tagaaagaca agttttgcta agagttttcc ttaacgggac aggactagag aaagtgtgca 720
 atgtagagag gaaggtgtct gggctggcca tagactggat agatgatgaa gttctctggg 780
 tagaccaaca gaacggagtc atcacctgaa cagatatgac agggaaaaat tcccgagttc 840
 ttctaagttc cttaaaacat ccgtcaaaata tagcagtgga tccaatagag aggttgatgt 900
 tttgggtctc agaggtgacc ggcagccttc acagagcaca cctcaaagggt gttgatgtaa 960
 aaacactgct ggagacaggg ggaatatcgg tgcctgactc ggatgtcctg gacaaacggc 1020
 tcttctgggt tcaggacagt ggcgaaggaa gccacgctta cattcattcc tgtgattatg 1080
 aggggtggctc cgtccgtctt atcaggcact tgaaaagcaa ggcgatttgg atagccaaca 1200
 tttttgtgta tcggatcttc tactcagtgt tgaaaagcaa ggcgatttgg atagccaaca 1200
 aacacacggg gaaggacacg gtcaggatta acctccatcc atcctttgtg acacctggaa 1260
 aactgatggt agtacacct cgtgcacagc ccaggacaga ggacgctgct aaggatcctg 1320
 accccgaact tctcaaacag aggggaagac catgccgctt cggctctctg gagcgagacc 1380
 ccaagtccca ctgcagcgca tgcgctgagg gctacacggt aagccgagac cggaaagtact 1440
 gcgaagatgt caatgaatgt gccactcaga atcacggctg tactcttggg tgtgaaaaca 1500
 cccctggatc ctatcactgc acatgcccc caggatttgt tctgcttctt gatgggaaac 1560
 aatgtcacga acttgtttcc tgcccaggca acgtatcaaa gtgcagtcac agagtgtggg 1620
 tgacatcaga tgggtcccg tgcactctgc ctgcaggctc agtgcttggg agagatggga 1680
 agacttgca tgggtgttca tcgcctgaca atgggtggatg tgacctacag tcagaccgaa 1740
 tcaggccagg atcctgggaa tgtgattgct ttcttggtta tgcaaatcc caggacatcc 1800
 agagctgtgc agcttcagga ccacagccac ttttactgtt tgcaaatcc caggacatcc 1860
 gacacatgca ttttgatgga acagactaca aagttctgct cagccggcag atgggaatgg 1920
 tttttgcctt ggattatgac cctgtggaaa gcaagatata ttttgacag acagccctga 1980
 agtggataga gagggctaat atggatgggt ccagcgaga aagactgac acagaaggag 2040
 tagatacgt tgaaggtctt gccctggact ggattggccg gagaatctac tggacagaca 2100
 gtgggaagtc tgttgttgga gggagcgatc tgagcgggaa gcatcatcga ataactatcc 2160
 aggagagaat ctgcaggccg cgaggaatag ctgtgcaccc aaggccagg agactgttct 2220
 ggacggacgt agggatgtct ccacggattg aaagcgcttc cttcaagggt tccgaccggg 2280
 tqctgatagc cagctccaat ctactggaac ccagtggaaat cacgattgac tacttaacag 2340

```

acactttgta ctggtgtgac accaagaggt ctgtgattga aatggccaat ctggatggct 2400
ccaaacgccc aagacttata cagaacgacg taggtcacc cttctctcta gccgtgtttg 2460
aggatcacct gtgggtctcg gattgggcta tcccatcggt aataagggtg aacaagagga 2520
ctggccaaaa cagggtagct cttcaaggca gcatgctgaa gccctcgtca ctggttgtgg 2580
tccatccatt ggcaaaacca ggtgcagatc cctgcttata caggaatgga ggctgtgaac 2640
acatctgcca agagagcctg ggcacagctc ggtgtttgtg tctgtaagggt tttgtgaagg 2700
cctgggatgg gaaaatgtgt ctcctcagg attatccaat cctgtcagggt gaaaatgctg 2760
atcttagtaa agaggtgaca tcaactgagca actccactca ggctgaagta ccagacgatg 2820
atgggacaga atcttccaca ctagtggctg aaatcatggg gtcaggcatg aactatgaag 2880
atgactgtgg tcccgggggg tgtggaagcc atgctcgatg cgtttcagac ggagagactg 2940
ctgagtgtca gtgtctgaaa gggtttgcca gggatggaaa cctgtgttct gatatagatg 3000
agtgtgtgct ggctagatcg gactgcccc gacactcgtc cagggtgcac aacactgaag 3060
gtggctacgt ctgcagatgc tcagaaggct acgaaggaga cgggatctcc tgtttcgata 3120
ttgaccagtg ccagcggggg gcgcacaact gcgctgagaa tgccgcctgc accaacacgg 3180
agggaggcta caactgcacc tgcgcaggcc gcccatcctc gcccgactg agttgccctg 3240
actctaccgc accctctctc cttggggaag atggccacca tttggaccga aatagttatc 3300
caggatggcc acctcatat gatggatact gcctcaatgg tggcgtgtgc atgcatattg 3360
aatcactgga cagctacaca tgcaactgtg ttattggcta ttctggggat cgatgtcaga 3420
ctccaccatc aagtgcaga ggaccccagg aaatagaggg aaactccac ctaccctcct 3480
acagacctgt ggggccggag aagctgcatt ctctccagtc agctaattga tctgtctacg 3540
aaagggtccc agacctgcca cggcagacag agccagttca gtagaaactg ggagtagaca 3600
gaaggtagag aagggaat aacaaaccag gctgatgatg gtagagtgtc acagacttgg 3660
tactccagtt tccacggcta atcactgtc gctcagggtc ctgaagatag ctgcacagct 3720
gcagagctgc acagcgggat agctgcgact tttgcttctt gctttaagca gttccactga 3780
agatactcaa aagagaagtg gagaaaatca ttgaaaacca aagtcaagac attcatatat 3840
aagctgtgtc ttcttcactg gacggtttgc ctcttttctt tttgcctcag aaggagtggg 3900
ttaaagcagg tgaccccatg ctctgtcaac ccctgaataa atgatgtgat ctacatagaa 3960
gtcttagctc actctcagga acgcttgga cactataact tttgctatga tatactgcca 4020
agtgtggccc atgctcataa ttgtgcttct tgaattgtga taaattagtg aaaaaactgt 4080
aacttagaat ctgatttatt caggattaga tcactctttt atactataaa aatcttcgaa 4140
tgaaaatatt taactttaaa aacattacct taatcattgt cttttcttct tgaagtcttt 4200
cccagtgaag acgctcaatt ctgctgtttc catagaattt ttaatttatt ttaagacatg 4260
agattgtaaa caaattgctt gatttatatt atcctaatta tttaaataaa atcacccata 4320
agcatcagca tttt 4334

```

<210> 54

<211> 3058

<212> DNA

<213> Homo sapiens

<400> 54

```

aaaaaawaa aaaaggagaa gggattccta tctgtatata ggaaggaat cctatctgca 60
tatttcgttg ttagcaccat cctcatccc ggtggggctt ggaactttcc atcaattctt 120
tcctgtctcg tttctctttc atcctttgcc tgggtgtgcc tgtctcaggg agaaatcagt 180
cactgcagcg ccttgcaggg ctcttaggct ctgggaaatt tgtcatcagg gtgtcaggta 240
cttcttattg ctgtccaaag ggaaaaaaa agtgagacaa agaactctcc cggagccttt 300
ccggtgtcac tcagaggctc tcgagagggt cagaaggacc tggaaaggca gctaaataaa 360
agatgccctg gggccgaagg ccaacctggc tgttgctcgc cttcctgctg gtgtttttaa 420
agattagcat actcagcgtc acagcatggc agaccgggaa ctgtcagcca ggtcctctcg 480
agagaagcga gagaagcggg acttgtgccg gtctgcctcc cttcctagt tctccacaag 540
gaaagagcat ctctcggatt gaccagatg gaacaaatca ccagcaattg gtgggtggatg 600
ctggcatctc agcagacatg gatattcatt ataaaaaaga gagactctat tgggtggatg 660
tagaaagaca agttttgcta agagttttcc ttaacgggac aggactagag aaagtgtgca 720
atgtagagag gaaggtgtct gggctggcca tagactggat agatgatgaa gttctctggg 780
tagaccaaca gaacggagtc atcacgtaa cagatatgac agggaaaaat tcccaggttc 840
ttctaagttc cttaaaacat ccgtcaaata tagcagtggg tccaatagag aggttgatgt 900
tttggctctc agaggtgacc ggcagccttc acagagcaca cctcaaagggt gttgatgtaa 960
aaacactgct ggagacaggg ggaatatcgg tgctgactct ggatgtcctg gacaaacggc 1020
tcttctgggt tcaggacagt ggcgaaggaa gccacgctta cattcattcc tgtgattatg 1080
aggggtggctc cgtccgtctt atcaggcatc aagcacggca cagtttgtct tcaatggcct 1140

```

```

tttttgggtga tcggatcttc tactcagtggt tgaaaagcaa ggcgatttgg atagccaaca 1200
aacacacggg gaaggacacg gtcaggatta acctccatcc atcctttgtg acacctggaa 1260
aactgatggg agtacacctt cgtgcacagc ccaggacaga ggacgctgct aaggatcctg 1320
accccgaaact tctcaaacag aggggaagac catgccgctt cgtctctgtg gagcgagacc 1380
ccaaagtccca ctcgagcgca tgcgtgagg gctacacggt aagccgagac cggaagtact 1440
gcgaagatgt caatgaatgt gccactcaga atcacggctg tactcttggg tgtgaaaaca 1500
cccctggatc ctatcactgc acatgcccca caggatttgt tctgcttccg gatgggaaac 1560
aatgtcacga acttgtttcc tgcccaggca acgtatcaaa gtgcagtcac ggctgtgtcc 1620
tgacatcaga tgggtccccg tgcatctgtc ctgcagggtc agtgcttggg agagatggga 1680
agacttgac tggttgttca tgcctgaca atggtggatg cagccagatc tgtcttctc 1740
tcaggccagg atcctgggaa tgtgattgct ttctgggta tgacctacag tcagaccgaa 1800
agagctgtgc agcttcagga ccacagccac aagtctctgt cagccggcag atgggaatgg 1920
gacacatgca ttttgatgga acagactaca aagtctctgt cagccggcag atgggaatgg 1920
tttttgccct ggattatgac cctgtggaaa gcaagatata ttttgacag acagccctga 1980
agtggataga gagggttaat atggatgggt ccacgcgaga aagactgac acagaaggag 2040
tagatacgct tgaaggtctt gccctggact ggattggccg gagaatctac tggacagaca 2100
gtgggaagtc tgttgttggg gggagcgatc tgagcgggaa gcatcatcga ataactatcc 2160
aggagagaat ctcgaggccg cgaggaatag ctgtgcatcc aaggggccagg agactgttct 2220
ggacggacgt agggatgtct ccacggattg aaagcgcttc ccttcaagg tccgaccggg 2280
tgctgatagc cagctccaat ctactggaac ccagtggat cagcattgac tacttaacag 2340
acactttgta ctggtgtgac accaagaggt ctgtgattga aatggccaat ctggatggct 2400
ccaaacgccc aagacttctc cagaacgacg taggtcacc cttctctcta gccgtgtttg 2460
aggatcacct gtgggtctcg gattgggcta tcccatcggt aataagggtg aacaagagga 2520
ctggccaaaa cagggtacgt cttcaaggca gcatgctgaa gccctcgtc ctggttgtgg 2580
tccatccatt ggcaaaaacca ggtgcagatc cctgcttata caggaatgga ggctgtgaac 2640
acatctgcca agagagcctg ggcacagctc ggtgtttgtg tcgtgaaggt tttgtgaagg 2700
cctgggatgg gaaaatgtgt ctccctcagg attatccaat cctgtcaggt gaaaatgctc 2760
ataattgtgc tttctgaatt gtgataaatt agtgaaaaaa ctgtaactta gaatctgatt 2820
tattcaggat tagatcatct ttttatacta taaaaatctt cgaatgaaaa tatttaactt 2880
taaaaacatt accttaatca ttgtcttttc ttcttgaagt ctttccaggt gaaaacgctc 2940
aattctgctg tttccataga atttttaatt tattttaaga catgagattg taaacaaatt 3000
gcttgattta ttttatccta attatttaaa taaaatcacc ctaaagcatc agcatttt 3058

```

<210> 55

<211> 2842

<212> DNA

<213> Homo sapiens

<400> 55

```

aaaaaawwaa aaaaggagaa gggattccta tctgtatata gggaaggaaat cctatctgca 60
tatttcgttg ttagcaccat cctcatccc ggtggggctt ggaactttcc atcaattctt 120
tcctgtctcg tttctcttcc atcctttgcc tgggtgtgoc tgtctcagg agaaatcagt 180
cacctgcagg ccttgcagg ctcttaggct ctgggaaatt tgtcataccg gtgtcaggta 240
cttcttattg ctgtccaaag ggaaaaaaa agtgagacaa agaactctcc cggagccttt 300
ccggctgcac tcagaggtc tcgagaggtg cagaaggacc tggaaaggca gctaaataaa 360
agatgccctg gggccgaagg ccaacctggc tgttgcctgc cttcctgctg gtgtttttaa 420
agattagcat actcagctc acagcatggc agaccgggaa ctgtcagcca ggtcctctcg 480
agagaagcga gagaagcggg acttgtgccg gtccctgccc cttcctagtt ttctcacaag 540
gaaagagcat ctctcgatt gggctatccc atcggttaata aggggtgaaca agaggactgg 600
ccaaaacagg gtacgtcttc aaggcagcat gctgaagccc tgcactgg ttgtgggtcca 660
tccattggca aaaccagggt cagatccctg cttatacagg aatggaggct gtgaacacat 720
ctgccaagag agcctgggca cagctcgggt tttgtgctg gaaggttttg tgaaggcctg 780
ggatgggaaa atgtgtctcc ctacaggatta tccaatcctg tcaggtgaaa atgctgatct 840
tagtaaagag gtgacatcac tgagcaactc cactcaggct gaagtaccag acgatgatgg 900
gacagaatct tccacactag tggctgaaat catggtgtca ggcataact atgaagatga 960
ctgtgggtccc ggggggtgtg gaagccatgc tcgatgcgtt tcagacggag agactgctga 1020
gtgtcagtgct ctgaaagggt ttgccaggga tggaaacctg tgttctgata tagatgagtg 1080
tgtgtcggct agatcggaact gccccagcac ctgcctcagg tgcatcaaca ctgaagggtg 1140
ctacgtctgc agatgctcag aaggctacga aggagacggg atctcctgtt tcgatattga 1200
cgatgcccag cggggggcgc acaactgcgc tgagaatgcc gcctgcacca acacggaggg 1260

```



```

aggctacaac tgcacctgcg caggccgccc atcctcgccc ggactgagtt gccctgactc 1320
taccgcaccc tctctccttg gggaagatgg ccaccatttg gaccgaaata gttatccagg 1380
atgcccaccc tcatatgatg gatactgcct caatgggtggc gtgtgcatgc atattgaatc 1440
actggacagc tacacatgca actgtgttat tggctattct ggggatcgat gtcagactcg 1500
agacctacga tgggtgggagc tgcgtcatgc tggctacggg cagaagcatg acatcatggt 1560
ggtggctgtc tgcattggtg cactggctct gctgctctc ttggggatgt gggggactta 1620
ctactacagg actcggaagc agctatcaaa ccccccaaag aacccttggt atgagccaa 1680
cggaagtgtg agcagcagcg ggcccagacag cagcagcggg gcagctgtgg cttcttgctc 1740
ccaaccttggt tttgtggtcc tagagaaaca ccaagacccc aagaatggga gtctgcctgc 1800
ggatggtacg aatggtgcag tagtagatgc tggcctgtct cctccctgc agctcgggtc 1860
agtgcattct acttcattgga gacagaagcc ccacatagat ggaatgggca cagggcaaag 1920
ctgctggatt ccaccatcaa gtgacagagg accccaggaa atagagggaa actcccacct 1980
acctccttac agacctgtgg ggccggagaa gctgcattct ctccagtcag ctaatggatc 2040
gtgtcacgaa agggctccag acctgccacg gcagacagag ccagttcagt agaaactggg 2100
agtagacaga aggtacagaa gggaaaataa caaaccaggc tgatgatggt agagtgttac 2160
agacttggtt ctccagtttc cacggctaata cactgctcgc tcagggtcct gaagatagct 2220
gcacagctgc agagctgcac agcgggatag ctgcgacttt tgcttcttgc ttttaagcagt 2280
tccactgaag atactcaaaa gagaagtggg gaaaatcatt agaaaccaa gtcaagacat 2340
tcatatataa gctgtgtctt cttcactgga cggtttgctt ctttctctt tgccctagaa 2400
ggagtgggtt aaagcaggtg accccatgct ctgtcaaccc ctgaataaat gatgtgatct 2460
acatagaagt cttagctcac tctcaggaac gcttggaaca ctataacttt tgctatgata 2520
tactgccaag tgtggcccat gctcataatt gtgctttctg aattgtgata aattagttaa 2580
aaaactgtaa cttagaattct gatttattca ggattagatc atctttttat actataaaaa 2640
tcttcgaatg aaaatatatta acttttaaaaa cattacctta atcattgtct tttcttcttg 2700
aagtctttcc cagtgaaaac gctcaattct gctgtttcca tagaattttt aatttatttt 2760
aagacatgag attgtaaaca aattgcttga tttattttat cctaattatt taaataaaat 2820
caccctaaag catcagcatt tt 2842

```

<210> 56

<211> 2243

<212> DNA

<213> Homo sapiens

<400> 56

```

aaaaawwaa aaaaggagaa gggattccta tctgtatata gggaaggaa cctatctgca 60
tatttcgttg ttagcaccat cctcatccc ggtggggctt ggaactttcc atcaattctt 120
tctgtctcgt tttctcttcc atcctttgccc tgggtgtgcc tgtctcaggg agaaatcagt 180
cacctgcagg ccttgccagg ctcttaggct ctgggaaatt tgcatacagg gtgtcaggta 240
cttcttattg ctgtccaaag ggaaaaaaa agtgagacaa agaactctcc cggagccttt 300
ccggctgcac tcagaggctc tgcagagggt cagaaggacc tggaaaggca gctaaataaa 360
agatgccctg gggccgaagg ccaacctggc tgttgctcgc cttcctgctg gtgtctgctg 420
agtgtcagtg tctgaaaggg tttgccaggg atggaaacct gtgttctgat atagatgagt 480
gtgtgctggc tagatcggac tgccccagca cctcgtccag gtgcatcaac actgaagggtg 540
gctacgtctg cagatgctca gaaggctacg aaggagacgg gatctcctgt ttcgatattg 600
acgagtgcca gcggggggcg cacaactgcg ctgagaatgc cgcctgcacc aacacggagg 660
gaggctacaa ctgcacctgc gcaggccgcc catcctcgcc cggactgagt tgccctgact 720
ctaccgcacc ctctctcctt gggaagatg gccaccattt ggaccgaaat agttatccag 780
gatgcccatc ctcatatgat ggatactgcc tcaatgggtg cgtgtgcatg catattgaat 840
cactggacag ctacacatgc aactgtgtta ttggctatc tggggatcga gtcagactc 900
gagacctacg atggtgggag ctgcgtcatg ctggctacgg gcagaagcat gacatcatgg 960
tgggtggctgt ctgcatggtg gcaactggcc tgctgtcctt cttggggatg tgggggactt 1020
actactacag gactcggaag cagctatcaa acccccaaaa gaaccttggt gatgagccaa 1080
gcggaagtgt gagcagcagc gggcccagca gcagcagcg ggcagctgtg gcttctgtgc 1140
cccaaccttg gtttgtggtc ctagagaaac accaagaccc caagaatggg agtctgcctg 1200
cggatggtac gaatggtgca gtagtagatg ctggcctgtc tccctccctg cagctcgggt 1260
cagtgcattt gacttcattg agacagaagc ccacataga tggaaatggg acagggcaaa 1320
gctgctggat tccaccatca agtgacagag gacccagga aatagagggg aactcccacc 1380
tacctccta cagacctgtg gggccggaga agctgcattc tctccagtc gctaattgat 1440
cgtgtcacga aagggtcca gacctgccac ggcagacaga gccagttcag tagaaactgg 1500
gagtagacag aaggtacaga agggaaaata acaaacagg ctgatgatgg tagagtgtta 1560

```

cagacttggt actccagttt ccacggctaa tcaactgctcg ctcaggggtcc tgaagatagc 1620
 tgcacagctg cagagctgca cagcgggata gctgcgactt ttgcttcttg ctttaagcag 1680
 ttccactgaa gatactcaaa agagaagtgg agaaaatcat tagaaaccaa agtcaagaca 1740
 ttcataatata agctgtgtct tcttcaactgg acggtttgccc tcttttcctt ttgcctcaga 1800
 aggagtgggt taaagcaggt gaccccatgc tctgtcaacc cctgaataaa tgatgtgatc 1860
 tacatagaag tcttagctca ctctcaggaa cgcttggaaac actataactt ttgctatgat 1920
 atactgcaa gtgtggccca tgctcataat tgtgctttct gaattgtgat aaattagtga 1980
 aaaaactgta acttagaatc tgattttatc aggattagat catcttttta tactataaaa 2040
 atcttcgaat gaaaatattt aactttaaaa acattacctt aatcattgtc ttttcttctt 2100
 gaagtctttc ccagtgaata cgctcaattc tgcgttttcc atagaatttt taattttattt 2160
 taagacatga gattgtaaac aaattgcttg attttattta tcttaattat ttaaataaaa 2220
 tcaccctaaa gcatcagcat ttt 2243

<210> 57

<211> 4563

<212> DNA

<213> Homo sapiens

<400> 57

gaattcgggg cgcacccgcg cgcacccgcg catggggggc gcgtccggcc agcgggggcg 60
 gtggccgttg tgcctccgc tcttgatgct gtcgtgctg gtgctgttg tgcagccgtc 120
 gccgcgcccg gcaactcgacc ctggattgca gccgggcaac ttttcccgag acgaggcagg 180
 ggcgcagctt ttcgctgaaa gctataactc gactgcccag gtggtgatgt tccagagcac 240
 cgtggccagt tgggcgcacg acaccaacat caccggaggag aacgcgcgac gccaggagga 300
 agcggccctg gtcagccagg agtttgacga ggtctggggc aagaaggcca aggagtgtga 360
 tgagtccatt tggcagaact ttactgactc aaagctgcga aggatcatcg gatctattcg 420
 gaccctagga cctgccaatc tgcccctggc ccagcggcag cagtacaact ctctgctaag 480
 caacatgagc agaattctact ccactggcaa ggtctgcttc cccaacaaga ctgccacctg 540
 ctggctccctg gaccagagc tcaccaacat cctggcttcc tcacgaagct atgccaaagt 600
 gttgtttgccc tgggagggct ggcattgatgc tgtgggtatc ccactgaaac ccctctatca 660
 agactttact gccatcagta acgaagccta cagacaagac gacttctcag acacaggagc 720
 cttctggcgc tcttggtatg agtccccctc ctttgaggag agtctggaac atatctacca 780
 ccaactagag cccctctacc tgaacctcca tgcctacgtc cgccgcgcac tgcaccgccc 840
 ctatggggac aaatacgtca atctcagggg gcctattcct gccatttgc tgggagacat 900
 gtgggcccag agctgggaga acatctacga catggtagtg cctttcccag acaaacccaa 960
 cctcgatgtc accagtacaa tggtagacaa gggctggaac gccacacaca tgttccgggt 1020
 atcagaggaa ttcttcacct cgctggggct ctcacccatg cctcctgagt tctgggcgga 1080
 gtcaatgtcg gagaaaccaa cggatggacg ggaggtggtg tgccacgcct ctgcctggga 1140
 cttctacaac cggaaggact tccggattaa gcaatgcaca cgggtcacga tggaaacagct 1200
 ggccacagta caccacgaga tgggcccagc cgagtactac ctccagtaca aggacctgca 1260
 cgtctctctg cgtagagggtg ccaaccctgg cttccatgag gccattgggg atgtgcttgc 1320
 actctccgtc tctacccctg cacatctgca caaaatcgcc ctactggacc atgttaccaa 1380
 tgacatagag agtgacatca attacctgct aaagatggcc ctagagaaaa tgccttctt 1440
 gccctttggc tacctggttg accagtggcg ttggggggct ttcagtggac ggacccacc 1500
 ctctcgctac aacttcgact ggtggtatct tcgaaccaag tatcagggga tctgccacc 1560
 agttgcccg aatgaaaccc attttgatgc tggagccaag tttcacatcc caaacgtgac 1620
 accgtacatc aggtacttcg tgagctttgt gctgcagttc cagttccatc aagcactgtg 1680
 caaggaggca ggccaccagg gccactaca ccagtgtgac atctaccagt ccroccaggc 1740
 gggggccaaag ctcaagcagg tgttgacagg tggctgctcc aggccttggc aggaggtact 1800
 gaaggacctg gtaggctcag atgccctgga tgccaaggca ctgctggagt acttccaacc 1860
 ggtcagccag tggctggaag agcagaatca gcggaatggc gaagtcctag gctggccaga 1920
 gaatcagtgg cgtccaccgt taccgacaa ctatccagag ggcattgacc tagagactga 1980
 tgaagccaag gctgacaggt tcgtggaaga gtatgaccgg acagcccaag tgttgttgaa 2040
 cgagtacgca gaggccaact ggcaatataa caccaacatt accatagagg gcagcaagat 2100
 cctgcttgag aaaagcacgg aggtatccaa tcacaccctg aaatatggca cccggggcaa 2160
 gacatttgat gtgagcaact ttcaaaactc ttccatcaag cggatcataa agaagcttca 2220
 gaacctggac cgggcagtg tgcctcccaa ggaattagaa gactacaacc agatcctgct 2280
 agacatggag acaacttaca gcttatccaa catttgctac acaaattggc cttgtatgcc 2340
 cctggaacct gatctaaca acatgatggc cacatcccg aaatatgaag aattgctatg 2400
 ggcattggaag agctggagag acaagggtgg gagagccatc ctctctttt tcccaaagta 2460

tgtggagttc tccaacaaga ttgccaagct caatggctac acggatgcag gggattcatg 2520
 gagatcctta tacgagtctg acaacctgga gcaagacctg gaaaaactgt accaggagct 2580
 gcagccactc tacctgaacc tgcagccta tgtgcgtcgt tcctgcacc gccactatgg 2640
 gtccgagtag atcaacctgg atggccccat tcctgccccat ctgctaggga acatgtgggc 2700
 gcagacctgg tccaacatct atgatttggt ggcgcccttc ccttccgccc ccaatataga 2760
 tgccacggaa gccatgataa agcaggagtg gacacccaga aggatattta aggaagctga 2820
 caatttcttt acctccctgg ggctgttacc tgtgccccct gagttctgga acaagtcgat 2880
 gttagagaag cccaccgatg gaagggaggt ggtgtgccat ccctcagcct gggacttcta 2940
 caacggcaag gacttcagga tcaagcagtg tacctctgtg aacatggagg acttggtgat 3000
 agcgcaaccac gaaatgggccc acatccagta ttctatgcag tacaagact taccctgac 3060
 ttcccgaggag ggtgccaaacc ctggttttca tgaagctatt ggagatataa tggctctctc 3120
 agtgtctacc cccaagcacc tatacagctc caacctgctt agcactgagg gcagtggcta 3180
 cgagtatgac atcaactttc taatgaagat ggccctcgac aagatcgccct ttatccccctt 3240
 cagctacctc atcgaccagt ggcgctggag ggtctttgat ggaagcatca ccaaggagaa 3300
 ctataaccag gagtgggtgga gcctcaggct gaagtatcag ggtctgtgcc cccagtgcc 3360
 aagatcccaa ggtgactttg acccaggggtc caagttccac gttcctgcga acgtgccata 3420
 cgtcaggtac tttgtcagct tcatcatcca gttccagttc cagcaggcgc tgtgtcgcgc 3480
 agccgggacac acgggtccccc tgcacaagtg tgacatctac caatccaagg aagcagggaa 3540
 gctcctggcg gatgccatga agctgggcta cagtaagccg tggccagagg ccatgaagct 3600
 gatcacaggc cagcctaaca tgtcagcctc cgccatgatg aattacttca agccactgac 3660
 agaatggctc gtcaccgaga acaggagaca tggagagaca ctgggctggc cggagtacaa 3720
 ctgggcgcca aacaccggtc ctacacccac cctgcctcca gccccgggc ccagctccta 3780
 gagctcatat agggctgaac cccattccca gtccagacag tctccagtct gacctcagag 3840
 caagaacagg gacgccagga cgcaagaccc cagcccttgt gggaagccag ggacaggacc 3900
 ggctgcttgc ctgtctcctg acagtccag cagcaccctt tactggttgt cttcgcagtc 3960
 ttccctccaag caggaaagta atcccaattc ctctggaccc catccccac aacctttccc 4020
 accagccttc ctaacagccc aggtgaggtg gctcctgtct tgcagaccca tgaacttgcc 4080
 agggaggagc ctaggaaaca gaggggaagg aagcaggtag gctgcctcct ttatgtgtgg 4140
 atacactata gatggctcat cctgtcccat gtgacctctc tgtggctggg tgtcttggag 4200
 gaaggctctg gatgcccttc cctgctacag ggtgagggcc ctggaaggcc gtgcctcact 4260
 gagcatgctg aagcggccag tatataagtg gacagcctgg gttccctgac ggagccacgt 4320
 aggctctgcc cacaggaaag agcattaatc cgtgaccaca cagtgggttc actgctactg 4380
 cccacctcct catcccgga cacatccctc cagcctcagc catcctttgg aaggcctatt 4440
 tggatttttag ggggtgtcac ttgaagtaac tttttatcta catatttatg tagtaaat 4500
 ggaaaaatctg aataaaaagc ccattggtagc aacattaaga aatataagcm ctgttgaagt 4560
 tta 4563

<210> 58

<211> 1630

<212> DNA

<213> Homo sapiens

<400> 58

cagctctgc cttgatcaca caccgcgcca ctgcgacatt cgagcacatt ccttccttcc 60
 gtcttactgt ctacgccctt gacttctaca aacctatgga acatttctgg aaagacgtc 120
 ttgaaccagc aggggtggccc acgcgctgct gagccctctg cgtgcgcggg gagccagtct 180
 gtaactcgcc ggctgccact taccatgacc atgaccttc acaccaaagc ctcggaatg 240
 gccttgctgc accagatcca agggaaacgag ctggagcccc tcaaccgccc gcagctcaag 300
 atgccccatg agagggccct ggcgaggtga tacgtggaca acagcaagcc cactgtgttc 360
 aactaccccg agggcgccgc ctacgagttc aacgcgcgcg ccgcccgcgc cgccgcgcgc 420
 tcggcgccgg tctacggcca gtccggcctc gcctacggcc ccgggtcgga ggccggccgc 480
 ttcagtggca acagcctggg ggctttcccc cagctcaaca gcgtgtcgcc tagcccgtg 540
 atgctgctgc accgcgcgcc gcagctgtct cctttcctgc acccgcacgg ccagcaggtg 600
 cctactacc tggagaacga gccagcgcc tacgcctgac ggcacaccgg ccctcccgc 660
 ttctacaggt ctaattctga caatcgacgc cagaatggcc gagagagact gtccagcagt 720
 aacgagaaaag gaaacatgat catggagtct gccaggaga ctgcgtactg tgccgtgtg 780
 aatgactatg cctctggcta ccattatggg gtctggctct gcgaaggctg caagcctttc 840
 ttttaagagaa gcattcaagg acacaatgac tacatgtgtc cagctacaaa ccaatgcacc 900
 attgacaaga accggaggaa gaggttgccg gcctgtcggc tgcgcaagtg ttacgaagtg 960
 ggcattgatga aaggcgccat acggaaagac cgccgaggag ggagaatgtt gaagcacaag 1020

```

cgtcagagag atgacttggg aggccgaaat gaaatgggtg cttcaggaga catgaggggt 1080
gccaaccttt ggccaagccc tcttgtgatt aagcacacta agaagaatag coctgccttg 1140
tccttgacag ctgaccagat ggtcagtgcc ttgttggatg ctgaaccgcc catgacttat 1200
tctgaatatg atccttctag acccttcagt gaagcctcaa tgatgggctt attgaccaac 1260
ctagcagata gggagctggg tcatatgatc aactgggcaa agagagtgcc aggttaaggat 1320
gctaaactca acttctatgt taagagtga taactttcaa cagtcagctg tggtagctg 1380
gggggaaagt agtagtgtgc tatgggatta gggagatggc tgtattggga tttgtcaatt 1440
gtcaatatta acccgctgta tttctcttga aactaggaaa tagcctttaa aattaaactc 1500
ccagcagact aaaaccttgg acatgcta at tttggccgt ctttgcctca aacacttgg 1560
tgaacacttc attacaacat gcccatgtgt tctgtcatca aatgtcatat attaaaagta 1620
cttaatgctc 1630

```

<210> 59

<211> 1551

<212> DNA

<213> Homo sapiens

<400> 59

```

aaagaagcca cagtctcatc atggttccac aggcgcagtg gctgctgctt ctctgctttc 60
tgctccagct ccagggacct ctagggactg cagttttcat aaccaggag gaagcacatg 120
gtgtcctaca caggcaaagg cgtgccaaact cactcctgga ggagctttgg cccggctctc 180
tgagagagaga gtgcaatgag gaacagtgct cctttgagga ggcccgagg atcttcaaga 240
gccctgagag gaccaagcag ttctggattg ttacagtga tggggaccag tgtgcctcga 300
atccatgtca gaacggaggt acctgccagg atcatctcaa gtcttacgtc tgttctgcc 360
tcctagactt tgagggccgt cctgctggac gccagatgga tagtgaccgc agcccactgc 420
ttcgataata tccgctactg gggaaacatc acagtgggta tgggtgaaca tgacttcagt 480
gagaaggatg gggatgagca agtacgacgg gtgacacagg tcatcatgcc cgacaagtac 540
atccgcgga agatcaacca cgacattgcc ctgctccgcc ttcaccggcc tgtgaccttc 600
actgactacg tgggtgccct gtgtctgcct gaaaagtcct tctccgagaa caccctagcc 660
agaatccgct tctcaagggt cagtggctgg ggccagctac tggaccgtgg tgccacagcc 720
ctggaactca tgtccatcga ggtgccccgg ctgatgacct aggactgtct ggagcacgcc 780
aagcacagct ctaacacccc caaaatcaca gagaacatgt tctgcgctgg ctacatggat 840
ggtagcaagg acgcctgcaa gggtagacgc ggtggccac atgccacgca ctaccatggc 900
acatggtatc tgacaggtgt ggtcagctgg ggggagggct gtgcagctat tggtcacatt 960
ggggtgtaca ccagggtctc ccagtagata gactggctgg tcagacacat ggactccaag 1020
ctccagggtt ggggttttccg actcccacta ctgtagctcc ttggatagcc caaccgtcc 1080
caagaaggaa gctacggcct gtgaagctgt tctatggact ttctgtctat tcttgtgtaa 1140
gggaagagaa tgagataaag agagagtga gaaagcagag ggggaggtaa atgagagagg 1200
ctgggaaagg ggaaacagaa agcagggcgg ggggaagagt ctaagttaga gactcaciaa 1260
gaaactcaag aggggctggg cagtgcagtc acagtcaagg agctgagggg cagggtgtcc 1320
ctgagggagg cgaggtcag gccttgcctc cgtctccccg tagctgcctc ctgtctgcat 1380
gcattcggtc tgcagtacta cacagttagt atgcacatga gcacgtagga cacgtgaatg 1440
tgccgcatgc atgtgcgtgc ctgtgtgtcc atcattggca ctgttgctca cttgtgcttc 1500
ctgtgagcac cctgtcttgg tttcaattaa atgagaaaca tgggtctcaa a 1551

```

<210> 60

<211> 732

<212> DNA

<213> Homo sapiens

<400> 60

```

tcgagcggcc gcccgggcag gtccaggatc aagagtcacc gcttcgcaag cactgcctgg 60
ctccatcagg atccccgcag gctcagctcc aaggcaccgc tcaccaggaa ggcacatagg 120
gcttcttgaa gttctccccct ttcttggttg tcagcatctt gctcctgcac tgggtgcagg 180
ctatatgca atgaaagcca gggagctgga gcaggaggaa gagcaggagg ctgagggctc 240
tagcttggac agccccagat ctaagcgggt tgggaatctg agtacctgca tgctgggcac 300
gtacacacaa gacctcaaca agtttcacac cttcccccaa acttcaattg ggggtgaagc 360
acctggcaag aaaagggatg tggccaagga cttggagaca aaccaccaat cccattttgg 420
caactaagct ccttctctcc tttctagttt ccttcttctt ttcttctat aacttgatgc 480

```

atgtagttcc tctctggttg ctctccaggc tattactggt tgctttcctg aggcaaagaa 540
 tggatctga aatccccagt gggtagagg aaagtccac aggctaaaag agaatacccc 600
 aggaagatgg cagagagcaa gggcacactc aggaagatgg cagagagcaa ggcagtcac 660
 ctggcttcct agtagagctt ctagtcttgc ttctggaagt gttggttgtt tgggaaataa 720
 aactatTTTT ta 732

<210> 61

<211> 1648

<212> DNA

<213> Homo sapiens

<400> 61

ccccagaccc ttctgtcctt ttctcccgcc ccgcccgcgc catggccacc ctgctccgca 60
 gcaagctgac caatgtggcc acctccgtgt ccaacaagtc ccaggccaag gtgagcggca 120
 tggttgccag gatggggttt caggcgcca ccgatgagga agcgtgggc ttgcgcact 180
 ggcagatct cgactttgag catcgccagg gcctgcagat ggacatcctg aaatcggaag 240
 gcgagccctg cggagacgag ggcgcagaag ctcccgtcga gggagacatt cattatcagc 300
 gcggcgccgc tctctgcca cctctggct ccaaggacca ggccgtggga gctggtggg 360
 agttcggggg tcacgacaaa cccaagatca cggcggtggga agcgggctgg aacgtgacaa 420
 atgccattca gggcatgttc gtgctgggccc taccctacgc catcctccac ggcggctacc 480
 tggggttgtt cctcatcatc ttccgcccag tgggtgtctg ctacaccggc aagatcctca 540
 tcgcgtgcct gtacgaggag aacgaagacg gggaggtggt gcgcgtgcg gactcgtatg 600
 tggccatagc taacgcagtc tgcgtcctc gattccccc cctggcgcc gcgcgtgtca 660
 atgtggcgca gatcatcgag ctggtgatga cgtgtatctt gtacgtcgtg gtgagcggca 720
 acctcatgta caacagtttc ccggggctgc ccgtgtcgca gaagtcctgg tccatcatag 780
 ccacagcggg gctgctgccc tgcgccttc tgaagaatct caaggccgtg tccaagttca 840
 gtctgctgtg tacgctggcc cacttcgtca tcaacatcct ggtcatcgt tactgtctct 900
 ctgcgcgcgc tgattgggc tgggagaagg tgaagttcta catcgacgtc aagaagtttc 960
 ccatctccat tggcatcatc gtgttcagct acacgtcgca gatcttcctg ccctctctcg 1020
 aaggcaacat gcagcagccc agcgaatttc actgcatgat gaactggaca cacatcgccg 1080
 cctgcgtgct caagggcttc ttgcgcctgc tgcctacct cacctgggccc gacgagacca 1140
 aggaagtcac caccgataac ctgcccggct ccacccgcgc cgtggtcaac ctcttcttg 1200
 tggccaaggc gctgctgtcc tatccgttgc ccttcttcgc ggccgtcgaa gtgctggaga 1260
 agtctctctt ccaggaaggc agtcgcgcct tcttccccgc ctgctatgga ggcgacggtc 1320
 gccttaagtc ctgggagctg acgctgcgct gcgcgtggt ggtcttcacg ctgctcatgg 1380
 ccacttacgt gccacacttc gcgctgctca tgggcctcac gggcagcctc acaggcgccg 1440
 gcctctgctt cctgctgccc agcctcttcc acttgcgcct tctctggcgc aagctgctgt 1500
 ggcaccaggt cttcttcgat gtggccatct tegtcatcgg cggcatctgc agcgtgtccg 1560
 gcttctgtgca ttactcagag ggtctcatcg aggcctaccg aaccaacgca gaggactagg 1620
 ggggtggggac cctgccccca gctccatc 1648

<210> 62

<211> 1410

<212> DNA

<213> Homo sapiens

<400> 62

cagggcagca tgtgattgac tgcgaattcg ggtctcgagc aggaagtacc aaggaggat 60
 ggagatggta ataatacagg ttgggtggag aatatctgag gaaactgcac ttgatttggg 120
 ccttgaagag taattgactg gatttagatt tatctagaaa ggtcgttccc agcagaagca 180
 acaagaacaa caagcttgga ctgccatcat ggatgttctc gcagaagcaa atggcacctt 240
 tgccttaaac cttttgaaaa cgtggtgtaa agacaactcg aagaatgtgt ttttctcacc 300
 catgagcatg tctgtgccc tggccatggt ctacatggg gcaaaggaa acaccgctgc 360
 acagatggcc cagatacttt ctttcaataa aagtggcgt gactggcacg cagtacttgc ttaggtggc 420
 cttccagtct cttctcaccg aagtgaacaa gactggcacg tttctctca tcttttagag attcctgcca 540
 caacaggctc tttggggaaa agtcttgtga tttctctca tcttttagag attcctgcca 540
 aaaattctac caagcagaga tggaggagct tgactttatc agcgcgtag agaagtccag 600
 aaaacacata aacacctggg tagctgaaaa gacagaaggt aaaattgcgg agttgtctc 660
 tccgggctca gtggatccat tgacaaggct ggttctggtg aatgctgtct atttcagagg 720

aaactgggat gaacagtttg acaaggagaa caccgaggag agactgttta aagtcagcaa 780
 gaatgaggag aaacctgtgc aaatgatgtt taagcaatct acttttaaga agacctatat 840
 aggagaaata tttacccaaa tcttggtgct tccatatgtt ggcaaggaaac tgaatatgat 900
 catcatgctt ccggacgaga ccactgactt gagaacggtg gagaaagaac tcacttacga 960
 gaagttcgta gaatggacga ggctggacat gatggatgaa gaggaggtgg aagtgtccct 1020
 cccgcggttt aaactagagg aaagctacga catggagagt gtcctgcgca acctgggcat 1080
 gactgatgcc ttcgagctgg gcaaggcaga cttctctgga atgtcccaga cagacctgtc 1140
 tctgtccaag gtcgtgcaca agtcttttgt ggaggtcaat gaggaaggca cggagggtgc 1200
 agccgccaca gctgccatca tgatgatgcg gtgtgccaga ttcgtccccc gcttctgcgc 1260
 cgaccacccc ttccttttct tcatccagca cagcaagacc aacgggattc tcttctgcgc 1320
 ccgccagctt atgaacttta gtccggattc ctctgccggc tgctgcaatg ttntgctgtt 1380
 tccctctccg tggggggggg gggggggggg 1410

<210> 63

<211> 1324

<212> DNA

<213> Homo sapiens

<400> 63

cagggcagca tgtgattgac tgcgaattcg ggtctcgagc aggaagtacc aaggaggat 60
 ggagatggta ataatacaggg ttgggtggag aatatctgag gaaactgcac ttgatttggg 120
 ccttgaagag taattgactg gatttagatt tatctagaaa ggtcgttccc agcagaagca 180
 acaagaacaa caagcttga ctgccatcat ggatgttctc gcagaagcaa atggcacctt 240
 tgccttaaac cttttgaaaa cgctgggtaa agacaactcg aagaatgtgt ttttctcacc 300
 catgagcatg tccgtgccc tggccatggt ctacatgggg gcaaaggga acaccgctgc 360
 acagatggcc cagatacttt ctttcaataa aagtggcggg ggtggagaca tccaccaggg 420
 cttccagctt cttctcaccg aagtgaacaa gactggcacg cagtacttgc ttaggggtggc 480
 caacaggctc tttggggaaa agtcttgtga tttctctca tcttttagag attcctgcca 540
 aaaattctac caagcagaga tggaggagct tgactttatc agcgcctag agaagtccag 600
 aaaacacata aacacctggg tagctgaaaa gacagaaggt aaaattgcgg agttgctctc 660
 tccgggctca gtggatccat tgacaaggct ggttctggtg aatgctgtct atttcagagg 720
 aaactgggat gaacagtttg acaaggagaa caccgaggag agactgttta aagtcagcaa 780
 gaatgaggag aaacctgtgc aaatgatgtt taagcaatct acttttaaga agacctatat 840
 aggagaaata tttacccaaa tcttggtgct tccatatgtt ggcaaggaaac tgaatatgat 900
 catcatgctt ccggacgaga ccactgactt gagaacggtg gagaaagaac tcacttacga 960
 gaagttcgta gaatggacga ggctggacat gatggatgaa gaggaggtgg aagtgtccct 1020
 cccgcggttt aaactagagg aaagctacga catggagagt gtcctgcgca acctgggcat 1080
 gactgatgcc ttcgagctgg gcaaggcaga cttctctgga atgtcccaga cagacctgtc 1140
 tctgtccaag gtcgtgcaca agtcttttgt ggaggtcaat gaggaaggca cggagggtgc 1200
 agccgccaca gctgccatca tgatgatgcg gtgtgccaga ttcgtccccc gcttctgcgc 1260
 cgaccacccc ttccttttct tcatccagca gagaatcccg ttggtcttgc tgtgctggtc 1320
 gacc 1324

<210> 64

<211> 2235

<212> DNA

<213> Homo sapiens

<400> 64

gtggacacac aagagttaac tggcgggtgt gacaggcgga ccgcctcag gaagtgttac 60
 tcaactgggga tgtgcgtgcc ttgccttggg actggattct cttcctgaag cgaaggggct 120
 cccagccatg gaaagccctg gagagtcagg cgcgggctct cctggagccc ccagcccgtc 180
 cagcttcaact actgggcacc tggcgagaga aaagccagcc caggaccac tgtatgacgt 240
 gcccaatgcc agcggcgggc aggcaggcgg gccgcagcgg ccggggcgcg ttgtgagcct 300
 gcgggagcgc ctgctgtca cccggcccgt gtggctgcag ctgcaagcca acgcagcggc 360
 cgactgcac atgctgagga ccgagccccc ggggacgttc ctgtgcgga aatctaacac 420
 ccgccagtgc caggccctgt gcatgcgggt gcctgaagcc agtggccctc cttcgtctcc 480
 agccactaca tccctggagag ccctggcggc gtctccttgg agggctcgga gctcatgttc 540
 ccagacctag tccagctcat ctgtgcctac tgccacaccc gggacatcct tctcctccc 600

ctgcagctcc ccagagccat ccaccacgca gccactcaca aagagctgga ggccatctcc 660
 catctgggca ttgagttctg gagctcctcc ctcaacatca aggctcagcg gggcccggct 720
 ggaggccag tgttgccca gctgaaggcc cggccccctc aagagctgga ccaggccacc 780
 ggagccgct tgtgcttctt caacccccctg ttccccgggg acctagggcc caccaagcgg 840
 gagaaattca agagaagctt caaagtgcgc gtgtccacag agacctccag cccctgtct 900
 ccacctgccg tgccacctcc ccccgctccc gtgctgccag gggcagctcc cagccagaca 960
 gaggcgctgc ccccttgcca gctgctacgg agggagagct cagtgggta ccgctgcca 1020
 gcaggcagtg gccctagcct tccgctatg cctccctcc aagaggtgga ctgctgctcc 1080
 cccagcagct ccgaggagga ggggtgcca ggggtccggg ggagcccagc gacctacccc 1140
 cacctgggccc gccgacgacc tctgcttcgg tccatgagcg ccgcttctg ctccctactg 1200
 gcacccgagc ggcaggtggg ccgggctgcg gcagcactga tgcaggaccg acacacagcc 1260
 gcggggcagc tgggtgcagga cctactgacc cagggtgcggg atgggcagag gcccaggag 1320
 ctcgagggca tccgtcaggc gctgagccgg gcccgggcca tgcctgagtc ggagctgggc 1380
 cctgagaagc tctgtgcgc taagaggctg gaacatgtcc tggagaagtc attgcattgc 1440
 tctgtgctca agcctctccg gccatcctg gcagcccgcg tgcggcgccg gcttgccga 1500
 gacggctccc tgggcgcct agctgaggcg ctccgcctgg cccgggcccga gggcccggga 1560
 gccttcgggt cccacctgag cctgccctcc ccagtagagt tggagcaagt gcgccagaag 1620
 ctgctgcagc tctccgcac ctactacccc agcggccagg tcaagcggt cctgcaggcc 1680
 tgcaagctgc tctacatggc cctgaggacc cagggaaggg agggctcggg tgccgacggg 1740
 ttctgcctc tgcctgagcct cgtcttgccc cactgtgacc ttctgagct gctgctggag 1800
 gccagtagca tgcctgagct gctggagccc agcctgctta ctggagaggg tggctactac 1860
 ctgaccagcc tctctgccag cctggccctg ctgagtgccc tgggtcaggc ccacaccctc 1920
 ccactgagcc ccgtgcagga gctacggcg tccctcagcc tctgggagca gcgcccctg 1980
 cctgccaccc actgcttcca ggtaacagc cctccaccgt gtcctcagag ccagacgcca 2040
 tccccgcct tnccttccct gtccttggtg aagagtccag actctgtaga cagatcctgg 2100
 gttctaattc ttgctctgca ctgggttggt gggacttggg cgagttactt aactacttcg 2160
 tgccctcagtt ttctcatcag taaaatgggg gtaataggac ctacctctg gggttgaggt 2220
 gaagattaaa tgagt 2235

<210> 65

<211> 1643

<212> DNA

<213> Homo sapiens

<400> 65

ggtgttggtg aaactgaaaa tactacatta tgctaattcg gcccgggccc gcgcgcacgg 60
 ggggtggggc cgcgcgata aagggggcgc aggggggctg ggcgttcac aggccaaagt 120
 cgctgtgctc gagggggtgcc ggccaggcyk gagcgagcga gctagccagc aggcacgag 180
 ggggcgcggc tgccgtccgg acgagacagg cgaacccgac gcagaagagt ccaccaccgg 240
 acagccaggt agcgcgcg tccctcgcac acgcagagtc gggcggcgcg ggggtctcct 300
 tgcgcccggc ctccgccctc tctctctctc ctttccccct cttctcgtg tctctctctc 360
 tctcgtgccc cgcggttgcg cagccccggg ccatgtccga cgcgctccctc cgcagcacat 420
 ccacgatgga gcgtcttgct gcccggtggg ccttcccagt actagtgcgc accagcgct 480
 gccgcagcct ctccggggcg gtggaccacg aggaagtgcg ccgcgagctg caggcccggc 540
 tggccgagct gaacgcccag gaccagaacc gctgggatta cgacttccag caggacatgc 600
 cgctgcgggg ccttgacgc ctgcagtgga ccgaagtgga cagcgactcg gtgcccgcgt 660
 tctaccgca gacggtgcag gtggggcgct gccgctgct gctggcgccg cggcccgtcg 720
 cggctcgcggt ggctgtcagc ccgcccctcg agccggccgc tgagtcctc gacggcctag 780
 aggaggcgcc ggagcagctg cctagtgtcc cggctccggc cccggcgctc actccgcccc 840
 cagtcgccgt cctggctcca gccccggccc cggtccggc tccggtcgcg gctccggctg 900
 cggctccggt cgcggtccgg tcttgcccc ggccccggcc ccggctccgg ctccggctcc 960
 ggccccggct ccagtcgcgg cccccggccc agccccggcc ccggccccgg cccccggccc 1020
 cgccccggcc ccggccccgg acgcggcgc tcaagagagc gccgagcagg gcgcgaacca 1080
 ggggcagcgc ggccaggagc ctctcgctga ccagctgcac tccgggattt cgggacgtcc 1140
 cgcgccgggc accgcggccg ccagcgccaa cggcgcgggc atcaagaagc tgtccgggccc 1200
 tctgatctcc gatttcttcg ccaagcgcaa gagatcagcg cctgagaagt cgtcgggcca 1260
 tgtccccgag ccgtgtccct ctccaagcgc cggccctggc gtgggctcgg tggagcagac 1320
 cccgcgcaag aggtgcgggt gagccaattt agagcccaaa gagccccgag ggaacctgcc 1380
 ggggcagcgc acgttggaag ggcgctgggc ctcggttggg accgttcatg tagcagcaac 1440
 cggcgcgcgcc tgccgcagag cagcgcttcgg tttgttttt aaattttgaa aactgtgcaa 1500

tgtattaata acgtcttttt atatctaaat gtattctgca cgagaaggta cactgggtccc 1560
 aagggtgtaaa gctttaagag tcattttatat aaaatgttta atctctgctg aaactcagtg 1620
 canacggcac gagggcctcg tgc 1643

<210> 66
 <211> 722
 <212> DNA
 <213> Homo sapiens

<400> 66
 cggagagggg gagaacagac aacgggcggc ggggagcagc atggagccgg cggcggggag 60
 cagcatggag ccttcggctg actggctggc cagcgccgcg gcgcggggac tagtgagaa 120
 ggtgcgacag ctccctggaag cgggcgcgga tcccaacgca ccgaatagtt acggtcggag 180
 gccgatccag gtcattgatg tgggcagcgc ccgagtggcg gagctgctgc tgctccacgg 240
 cgcgagagccc aactgcgccc accccgccac tctcaccgga cccgtgcacg acgtgcccg 300
 ggagggcttc ctggacacgc tgggtggtgct gcaccggggc ggggcgcggc tggacgtgcg 360
 cgatgcctgg ggccgtctgc ccgtggacct ggctgaggag ctgggccatc gcgatgtcgc 420
 acggtacctg cgcgcggtg cggggggcac cagaggcagt aacctatgcc gcatagatgc 480
 cgcggaaggt cctcagttta cagctagcat ccaggtcccg ggaggtgaag aaggagactt 540
 cggctccagt tacagctagc atccgggtcc cgatttagaa ggagctgcca attacagcgc 600
 ggttccaggg ctgagcaaaa agcctgagga gccaaagtgg agagggagta aaactactga 660
 attgggccac aagyaaatga ataaactgaa cgactcttaa ccaaactaa tatattta 720
 cc 722

<210> 67
 <211> 1008
 <212> DNA
 <213> Homo sapiens

<400> 67
 ccgcgacgcg tccgcaccct gcggccagag cggctttgag ctcggtgctg tccgcgctag 60
 gcgctttttc ccagaagcaa tccaggcgcg cccgctggtt cttgagcgcc aggaaaagcc 120
 cggagctaac gaccggccgc tcggccactg cacggggccc caagccgag aaggacgacg 180
 gggagggtaa tgaagctgag cccaggtctc cttaggaagga gagagtgcgc cggagcagcg 240
 tgggaaagaa gggaagagtg tcgttaagtt tacggccaac ggtggattat ccgggccgct 300
 gcgcgtctg gggctgcgga atgcgcgagg agaacaagg catgcccagt gggggcggca 360
 gcgatgaggg tctggccagc gccgcggcgc ggggactagt ggagaagggt cgacagctcc 420
 tggaagcccg cgcgatccc aacggagtca accgtttcgg gaggcgcgcg atccaggtca 480
 tgatgatggg cagcgcccga gtggcgagc tgcgtgctgc ccacggcgcg gagcccaact 540
 gcgccgaccc cgccactctc accgacccg tgacagacgc tgcccgggag ggcttccctg 600
 acacgttgtt ggtgctgcac cgggcggggg cgcggtgga cgtgcgcgat gcctggggcc 660
 gtctgcccgt ggacctggct gaggagctgg gccatcgca tgcgcacag tacctgcgcg 720
 cggctgcggg gggcaccaga ggcagtaacc atgcccgcat agatgcccg gaaggtccct 780
 cagttacagc tagcatccag gtcccgggag gtgaagaagg agacttcggc tccagttaca 840
 gctagcatcc ggtcccgat ttagaaggag ctgccaatca cagcgcggtt ccagggtga 900
 gcaaaaagcc tgaggagcca agtgggagag ggagtaaaac tactgaattg ggccacaagy 960
 aaatgaataa actgaacgac tcttaaccaa acctaataa tttaatcc 1008

<210> 68
 <211> 1738
 <212> DNA
 <213> Homo sapiens

<400> 68
 cgaaacacag agcttttagct ccgcaaaaat gaaacactca ttaaaccgac ttctcatttt 60
 cctcatcata acatctgcgt ggggtgggag caaaggcccc ctggatcagc tagagaaagg 120
 aggggaaact gctcagctg cagatcccca gtgggagcag ttaaataaca aaaacctgag 180
 catgcctctt ctccctgccc acttccacaa ggaaaacacc gtcaccaacg actggattcc 240

agaggggggag gaggacgacg actatctgga cctggagaaag atattcagtg aagacgacga 300
 ctacatcgac atcgtcgaca gtctgtcagt ttccccgaca gactctgatg tgagtgtg 360
 gaacatcctc cagctttttc atggcaagag ccggatccag cgtcttaaca tcctcaacgc 420
 caagttcgct ttcaacctct accgagtgtg gaaagaccag gtcaacactt tcgataacat 480
 cttcatagca cccgttggca tttctactgc gatgggtatg atttcccttag gtctgaagg 540
 agagacccat gaacaagtgc actcgatttt gcattttaaa gactttgtta atgccagcag 600
 caagtatgaa atcacgacca ttcataatct cttccgtaag ctgactcatc gcctcttcag 660
 gaggaatttt ggttacacac tgcggtcagt caatgacctt tatatccaga agcagtttcc 720
 aatcctgctt gacttcaaaa ctaaagttaag agagtattac tttgctgagg ccagatagc 780
 tgactttctc gacctgctt tcatatcaaa aaccaacaac cacatcatga agctcaccaa 840
 gggcctcata aaagatgctc tggagaatat agaccctgct acccagatga tgattctcaa 900
 ctgcatctac ttcaaaggat cctgggtgaa taaattccca gtggaaatga cacacaacca 960
 caacttccgg ctgaatgaga gagaggtagt taaggtttcc atgatgcaga ccaaggggaa 1020
 cttctcgca gctgctgct cttcatggga agagtggcca accccagcag gtcctagagg 1080
 tggaggtcta ggtgtctgaa gtgccttggg ggcacctca ttttgtttcc attccaacaa 1140
 cgagaacaga gatgttctgg catcatttac gtagtttacg ctaccaatct gaattcgagg 1200
 cccatagtag aggagcttag aaacgaccaa gaagagaggc ttgttggaat caattctgca 1260
 caatagccca tgctgtaagc tcatagaagt cactgtaact gtagtgtgtc tgctgttacc 1320
 tagagggtct cacctcccca ctcttcacag caaacctgag cagcgcgtcc taagcacctc 1380
 ccgctccggt gaccccatcc ttgcacacct gactctgtca ctcaagcctt tctccaccag 1440
 gcccctcatc tgaataccaa gcacagaaat gagtgggtgt actaattcct tacctctccc 1500
 aaggagggtg cacaactagc accatttctg atgtccagg aagaagccac ctcaagacat 1560
 atgaggggtg ccctgggcta atgttagggc ttaattttct caaagcctga cttttcaa 1620
 ccatgatgaa tgccatcagt cctcctgct gttgcctccc tgtgacctgg aggacagtgt 1680
 gtgccatgtc tcccatacta gagataaata aatgtagcca catttactgt gaataann 1738

<210> 69

<211> 2308

<212> DNA

<213> Homo sapiens

<400> 69

ggcacgagct cctcccccca ggcgctttct cggacgcctt gccagcggg ccgcccagc 60
 cctgcacca tggaccccg cgcgccctg gggctgtcga ttctgtgct tttcctgacg 120
 gaggtgcac tgggcgatgc tgetcaggag ccaacaggaa ataacgcgga gatctgtctc 180
 ctgcccctag actacggacc ctgcccggcc ctacttctcc gttactacta cgacaggtag 240
 acgcagagct gccgccagtt cctgtacggg ggctgcgagg gcaacgcaa caatttctac 300
 acctgggagg cttgcgacga tgcttgtgagg aggatagaaa aagttcccaa agtttgccgg 360
 ctgcaagtga gtgtggacga ccagtgtgag ggtgccacag aaaagtattt ctttaactca 420
 agttccatga catgtgaaaa attcttttcc ggtgggtgtc accggaaccg gattgagaac 480
 aggtttccag atgaagctac ttgtatgggc ttctgcgcac caaagaaaat tccatcattt 540
 tgctacagtc caaaagatga gggactgtgc tctgccaatg tgactcgcta ttattttaat 600
 ccaagataca gaacctgtga tgctttcacc tatactggct gtggagggaa tgacaataac 660
 tttgttacag tccaaaagat gagggactgt gctctgccaa tgtgactcgc tattatttta 720
 atccaagata cagaacctgt gatgctttca cctatactgg ctgtggaggg aatgacaata 780
 actttgttag cagggaggat tgcaaacgtg catgtgcaaa agctttgaaa aagaaaaaga 840
 agatgcaaaa gcttcgcttt gccagtagaa tccggaaaaat tcggaagaag caatttttaa 900
 cattcttaat atgtcatctt gtttgtcttt atggttatt tgcctttatg gttgtatctg 960
 aagaataata tgacagcatg aggaacaaaa tcattgtgga tttattcacc agtttttatt 1020
 aatacaagtc acttttttaa aaatttggat ttttttatat ataactagct gctattcaaa 1080
 tgtgagtcta ccatttttaa tttatgggtc aactgtttgt gagactgaat tcttgcaatg 1140
 cataagatca aaaagcaaat atgactcact catttcttgg ggtcgtattc ctgatttcag 1200
 aagaggatca taactgaaac aacataagac aatataatca tgtgctttta acatatttga 1260
 gaataaaaaag gactagcaaa taaaactcat tttgcattta aaagtggat tatatttttag 1320
 tcccaagaag acaaaagtcg agattaacaa cactttaaaa atattactcc cattttattg 1380
 tgttagattg cagtacaatg aatgaataag gggatttatt tgttctctc tgggaaagca 1500
 gactgattta aaaagctaat caatttatta aagccagaaa atgtttgtgt ttacatagag 1560
 atttctatct atttatctac caatccccac tcacatgtat atgtttgtgt gtgggttgga 1620
 atagatggtt ttaagggttt tctattgtt aaattatttc ctaagacatt gtgggttgga 1680
 gaccactaaa cttataaaaa accaaggaaa gtaaaagttt tcaaatgttt atactgttta 1680

aggtgtttat ttatataaac catgcatgag aaaccatgca taaatttaatt aatttaaatt 1740
 tcaccagtaa attatcattg attaaatatg gtcataccaa tgaaataggt tttttctttc 1800
 tctgtaataa aacaattttt cttaaattctt atgttttcat agcaagatta acatatttaa 1860
 ttacaaatta aatatgcaaa atgacaaatg cgtttacctt ttgcttgaac aatctttcat 1920
 ttaaaaaattt atcccagtta ttttgacaaa tgtatatgcc tgagaacttt gaatgatgct 1980
 gaaagctaga agcaaaccag gtactcttca gtcagggact ggttgaagat tttatggatg 2040
 aggagttagc aaaatatcta tatatgcata tcttctgact cccmr ggata cataagaaac 2100
 acagggccta gaacagtatg aataaacaca catatacaca aacatcacag aagatactaa 2160
 agatattaaa aatgtttacc tatagaggtt tggagagaac agaggggtgg acagttgtgg 2220
 agataatatt tgtgtaaata taactgtgat atagttttta tcttgggcca tgtaaattatt 2280
 tgacataatt aataatcaaa attaaata 2308

<210> 70

<211> 2110

<212> DNA

<213> Homo sapiens

<400> 70

ggacagagct cctcccgcga ggcgctttct cggacgcctt gccagcggg ccgcccgcacc 60
 cctgcacca tggacccgcg tcgccccctg gggctgtcga ttctgtgct tttcctgacg 120
 gaggtgcac tgggcgatgc tgctcaggag ccaacaggaa ataacgcgga gatctgtctc 180
 ctgcccctag actacggacc ctgcccggcc ctacttctcc gttactacta cgacaggtag 240
 acgcagagct gccgccagtt cctgtacggg ggctgcgagg gcaacgccaa caatttctac 300
 acctgggagg cttgcgacga tgcttgctgg aggatagaaa aagttcccaa agtttgccgg 360
 ctgcaagtga gtgtggacga ccagtgtgag ggtccacag aaaagtattt ctttaattcta 420
 agttccatga catgtgaaaa attcttttcc ggtgggtgtc accggaaccg gattgagaac 480
 aggtttccag atgaagctac ttgtatgggc ttctgcgcac caaagaaaaa tacagaacct 540
 gtgatgcttt cacctatact ggctgtggag ggaatgacaa taactttgtt agcaggagg 600
 attgcaaacg tgcattgtga aaagctttga aaaagaaaaa gaagatgcca aagcttcgct 660
 ttgcccagtag aatccggaaa attcgggaaga agcaatttta aacattctta atatgtcatc 720
 ttgtttgtct ttatggctta tttgccttta tgggtgtatc tgaagaataa tatgacagca 780
 tgaggaaaca aatcattggg gatatttcca ccagttttta ttaatacaag tcacttttta 840
 aaaaatttgg atttttttat atataactag ctgctattca aatgtgagtc taccattttt 900
 aatttatggg tcaactgttt gtgagactga attcttgcaa tgcataagat ataaaagcaa 960
 atatgactca ctcatcttct ggggtcgtat tctgtatttc agaagaggat cataactgaa 1020
 acaacataag acaatataat catgtgcttt taacataatt gagaataaaa aggactagca 1080
 aataaaactc attttgcatt taaaagtgg attatattt agtcccaaga agacaaagtc 1140
 gcagattaac aacactttaa aaatattact cccattttat tgtgttagat tgcagtacaa 1200
 tgaatgaata aggggattta tttaaaagat cttaactttc ttgactgatt taaaaagcta 1260
 atcaatttat taaagccaga aatgttctcc tctgggaaag caatttctat ctatttatct 1320
 accaatcccc actcacatgt atatgtttgt gtttacatag agatagatgg ttttaagggt 1380
 tttcctattg ttaaatattt tcctaagaca ttgtgggttg gagaccacta aacttataaa 1440
 aaaccaagga aagtaaagtt tttcaaagt ttatactgtt taagggtgtt atttatataa 1500
 accatgcag agaaaccatg cataaattta ataatttaa tttcaccagt aaattatcat 1560
 tgattaaata tggtcatacc aatgaaatag gtttttctt tctctgtaat aaaacaattt 1620
 ttctaaattc ttatgttttc atagcaagat taacatattt aattacaaat taaatatgca 1680
 aaatgacaaa tgcgtttacc tttgtctga acaatcttcc atttaaaaat ttatcccagt 1740
 tattttgaca aatgtatatg cctgagaact ttgaatgatg ctgaaagcta gaagcaaacc 1800
 aggtactctt cagtcaggga ctggttgaag attttatgga tgaggagtta gcaaaatatt 1860
 tatatatgca tatcttctga ctccmr gga tacataagaa acacagggcc tagaacagta 1920
 tgaataaaca cacatataca caaacatcac agaagatact aaagatatta aaaatgttta 1980
 cctatagagg tttggagaga acagaggggt ggagataata tttgtgtaaa 2040
 tataactgtg atatagtttt tatcttgggc catgtaaata tttgacataa ttaataatca 2100
 aaattaaata 2110

<210> 71

<211> 1091

<212> DNA

<213> Homo sapiens

<400> 71

```

nactcctga ggctccctct ttgctctaac agacagcagc gacttttaggc tggataatag 60
tcaaattctt acctcgctct ttcactgcta gtaagatcag attgcgcttc tttcagttac 120
tcttcaatcg ccagtttctt gatctgcttc taaaagaaga agtagagaag ataaatcctg 180
tcttcaatac ctggaaggaa aaacaaaata acctcaactc cgttttgaaa aaaacattcc 240
aagaactttc atcagagatt ttacttagat gatttacaca atgaagaaag tacatgcact 300
ttgggcttct gtatgcctgc tgcttaatct tgcccctgcc cctcttaatg ctgattctga 360
ggaagatgaa gaacacacaa ttatcacaga tacggagtgt ccaccactgg aaacttatgc 420
attcattttg tgcattcaag gcggatgatg gcccatgtaa agcaatcatg aaaagatttt 480
tcttcaatat tttcactcga cagtgcgaag aatttatata tgggggatgt gaaggaaatc 540
agaatcgatt tgaaagtctg gaagagtgc aaaaaatgtg tacaagagat aatgcaaaca 600
ggattataaa gacaacattg caacaagaaa agccagattt ctgctttttg gaagaagatc 660
ctggaatatg tcgaggttat attaccaggt atttttataa caatcagaca aaacagtgtg 720
aacgtttcaa gtatggtgga tgctgggcca atatgaacaa ttttgagaca ctggaagaat 780
gcaagaacat ttgtgaagat ggtccgaatg gtttccaggt ggataattat ggaacccagc 840
tcaatgctgt gaataactcc ctgactccgc aatcaaccaa ggttcccagc ctttttggtg 900
agaatcttgt ggattttatt gcttccagga aactattatc atgctaacaa tgaagtggat 960
tgtgtattag aagtatgtct ttaaataatat atatatacct gcgttggtgc ttaataatgt 1020
gtttgttgaa atactgagat tcaaattggt taagacattt aatctcataa aagcamcmat 1080
tttctaatc t 1091

```

<210> 72

<211> 2267

<212> DNA

<213> Homo sapiens

<400> 72

```

ccgaggctgg ctggctccgc aggtccgctg acgtcgcgcg ccagatggcc tccaggctga 60
ccctgctgac cctcctgctg ctgctgctgg ctggggatag agcctcctca aatccaaatg 120
ctaccagctc cagctcccag gatccagaga gtttgcaaga cagaggcgaa gggaaggctg 180
caacaacagt tatctccaag atgctattcg ttgaacccat cctggagggt tccagcttgc 240
cgacaaccaa ctcaacaacc aattcagcca ccaaataac agctaatacc actgatgaac 300
ccaccacaca acccaccaca gagcccacca cccaaccac catccaacc acccaaccaa 360
ctaccagct cccaacagat tctcctaccc agcccactac tgggtccttc tgcccaggac 420
ctgttactct ctgctctgac ttggagagtc attcaacaga ggccgtgttg ggggatgctt 480
tggtagattt ctccctgaag ctctaccaag ccttctcagc aatgaagaag gtggagacca 540
acatggcctt ttccccattc agcatcgcca gcctccttac ccaggtcctg ctgggggctg 600
gggagaacac caaaacaaac ctggagagca tctctctta cccaaggac ttcacctgtg 660
tccaccaggc cctgaagggc ttacgacca aaggtgtcac ctcagtctct cagatcttcc 720
acagcccagt ggactgaagg cttttgcaga gcaaaagcca ggaagttttg tcacaaactt 780
ccaccaaggc caggaagcag agtctattcc gtgccaaaat taagggaaga aaagagggaa 840
aatctaggca aatggaattt aatatctcaa aaagattatc ttgccgagcc atagtcacat 900
agcaagctga ggcagcggag gcttggggct acttctcttg ttcttggttc tgggtttacc 960
ttctttgggc cttatttgcc acatctgtaa gaggagtggg ctggaccgag ctccaccatg 1020
ccgtattcac taagtgaagc gatagaacca tagaaagcat gctcactctc aaattgtgct 1080
catggaaaga acgacgtgtt caggacttat gcttccttt tttaaaatac ccccagacc 1140
tgcccataag ggacacctt gtgaatgect ctggaccct gtacagcagc agccccagag 1200
tctaagcaa caacagtgc gccaaacttg agctcatcaa cacctgggtg gccaagaaca 1260
ccaacaacaa gatcagccgg ctgctagaca gtctgccctc cgataccgac cttgtcctcc 1320
tcaatgctat ctacctgagt gccaaagtga agacaacatt tgatcccaag aaaaccagaa 1380
tggaaccctt tcacttcaaa aactcagtta taaaagtgcc catgatgaat agcaagaagt 1440
accctgtggc ccatttcatt gaccaaactt tgaaagccaa ggtggggcag ctgcagctct 1500
cccacaatct gagtttggtg atcctggtao cccagaacct gaaacatcgt cttgaagaca 1560
tggaacaggc tctcagccct tctgttttca aggccatcat ggagaaactg gagatgtcca 1620
agttccagcc cactctccta aactacccc gcatacaagt gacgaccagc caggatatgc 1680
tctcaatcat ggagaaattg gaattcttcg atttttctta tgacctaac ctgtgtgggc 1740
tgacagagga cccagatctt caggtttctg cgatgcagca ccagacagtg ctggaactga 1800
cagagactgg ggtggaggcg gctgcagcct ccgccatctc tgtggccgac accctgctgg 1860
tctttgaagt gcagcagccc tctctcttcg tgctctggga ccagcagcac aagttccctg 1920

```

tcttcatggg gcgagtatat gaccccaggg cctgagacct gcaggatcag gttagggcga 1980
 gcgctacctc tccagcctca gctctcagtt gcagccctgc tgetgcctgc ctggacttgg 2040
 cccctgccac ctctgcctc aggtgtccgc tatccacca aagggtccc tgagggctcg 2100
 ggcaagggac ctgcttctat tagcccttct ccatggccct gccatgctct ccaaaccact 2160
 ttttgagct ttctctagtt caagttcacc agactctata aataaaacct gacagaccat 2220
 gaaaamakaw atttttagtag tagtaggcta gtagtagtag cggccgc 2267

<210> 73

<211> 1302

<212> DNA

<213> Homo sapiens

<400> 73

ctcgctcgct ccccgctctg gagtacgtgt ctggcttggg agccgctcgg acacgctggc 60
 ttgggtctgc catcatggat gttctcgcag aagcaaatgg cacctttgcc ttaaaccttt 120
 tgaaaacgct gggtaaagac aactcgaaga atgtgttttt ctaccccatg agcatgtcct 180
 gtgccctggc catggtctac atgggggcaa agggaaacac cgctgcacag atggcccaga 240
 tactttcttt caataaaagt ggcggtggtg gagacatcca ccagggttc cagtctcttc 300
 tcaccgaagt gaacaagact ggcacgcagt acttgcttag gatggccaac aggtcttttg 360
 gggaaaagtc ttgtgatttc ctctcatctt ttagagattc ctgccaaaaa ttctaccaag 420
 cagagatgga ggagcttgac tttatcagcg ccgtagagaa gtccagaaaa cacataaaca 480
 cctgggtagc tgaaaagaca gaaggtaaaa ttgcggagtt gctctctccg ggctcagtgg 540
 atccattgac aaggctggtt ctggtgaatg ctgtctatct cagaggaaac tgggatgaac 600
 agtttgacaa ggagaacacc gaggagagac tgtttaaagt cagcaagaat gaggagaaac 660
 ctgtgcaaat gatgtttaag caatctactt ttaagaagac ctatatagga gaaatattta 720
 cccaaatctt ggtgcttcca tatgttggca aggaactgaa tatgatcatc atgcttccgg 780
 acgagaccac tgacttgaga acggttgaga aagaactcac ttacgagaag ttcgtagaat 840
 ggacgaggct ggacatgatg gatgaagagg aggtggaagt gtccctcccg cggtttaaac 900
 tagaggaaag ctacgacatg gagagtgtcc tgcccaacct gggcatgact gatgccttcg 960
 agctgggcaa ggcagacttc tctggaatgt cccagacaga cctgtctctg tccaagggtcg 1020
 tgcacaagtc ttttgtggag gtcaatgagg aaggcacgga ggctgcagcc gccacagctg 1080
 ccatcatgat gatgcggtgt gccagattcg tccccgctt ctgcgccgac cacccttcc 1140
 ttttcttcat ccagcacagc tgtccctga cactccacag tgtgcctgca acccaagtgg 1200
 ccttatccgt gcagtggtgg cagttcagaa ataaagggcc catttgtggg atgccgcatt 1260
 caaaaaaag ttaccaatct gaagtgggag cgattttttt tt 1302

<210> 74

<211> 868

<212> DNA

<213> Homo sapiens

<400> 74

ctcgctcgct ccccgctctg gagtacgtgt ctggcttggg agccgctcgg acacgctggc 60
 ttgggtctgc catcatggat gttctcgcag aagcaaatgg cacctttgcc ttaaaccttt 120
 tgaaaacgct gggtaaagac aactcgaaga atgtgttttt ctaccccatg agcatgtcct 180
 gtgccctggc catggtctac atgggggcaa agggaaacac cgctgcacag atggcccaga 240
 tactttcttt caataaaagt ggcggtggtg gagacatcca ccagggttc cagtctcttc 300
 tcaccgaagt gaacaagact ggcacgcagt acttgcttag gatggccaac aggtcttttg 360
 gggaaaagtc ttgtgatttc ctctcatctt ttagagattc ctgccaaaaa ttctaccaag 420
 cagagatgga ggagcttgac tttatcagcg ccgtagagaa gtccagaaaa cacataaaca 480
 cctgggtagc tgaaaagaca gaaggtaaaa ttgcggagtt gctctctccg ggctcagtgg 540
 atccattgac aaggctggtt ctggtgaatg ctgtctatct cagaggaaac tgggatgaac 600
 agtttgacaa ggagaacacc gaggagagac tgtttaaagt cagcaagacc aacgggattc 660
 tcttctgcgg ccgcttttcc tctccgtgag gacagggcag tcttggtgtg cagccccctc 720
 cctctctgtc ccctgacact ccacagtgtg cctgcaacct aagtggcctt atccgtgcag 780
 tgggtggcagt tcagaaataa agggcccat tgtgggatgc cgcattcaaa aaaaagttac 840
 caatctgaag tgggagcgat tttttttt 868

<210> 75
<211> 695
<212> DNA
<213> Homo sapiens

<400> 75
ctcgcctcgt ccccgctctg gactacgtgt ctggcttggg agccgctcgg acacgctggc 60
ttgggtctgc catcatggat gttctcgcag aagcaaatgg cacctttgcc ttaaacccttt 120
tgaaaacgct gggtaaagac aactcgaaga atgtgttttt ctcacccatg agcatgtcct 180
gtgccctggc catggtctac atgggggcaa agggaaacac cgctgcacag atggcccaga 240
tactttcttt caataaaagt ggcggtgggt gagacatcca ccagggttc cagtctcttc 300
tcaccgaagt gaacaagact ggcacgcagt acttgcttag gatggccaac aggtcttttg 360
gggaaaagtc ttgtgatttc ctctcatctt ttagagattc ctgccaaaaa ttctaccaag 420
cagagatgga ggagcttgac tttatcagcg ccgtagagaa gtccagaaaa cacataaaca 480
cctgggtagc tgaaaagaca gaaggtaaaa tgtattgtta ttctactttt gtaataacct 540
cttaatccat tttattgtca gttccttcac aagactgtca attgtaaaca ggaatgattt 600
ttttttctct gaataactgc aaacttaaaa aatctgcttc tgaaatcagt tgccattatt 660
tgacattttg gaaatgctca actgtgttgc tcttt 695

<210> 76
<211> 3294
<212> DNA
<213> Homo sapiens

<400> 76
atggggcttg gggctgggag gccagacgct aactcggatg ctcccaggct acgccttggc 60
catgacccgt gggcccgccg gcccccgcct tcaccttcgg cgcgcgcttc cccacgcagc 120
agacgacgtg cggccccggg ccaggccacc tgggtgcccg tcgcatgacc gtgcgcggca 180
ccgacggcgc cccgcctac tccatctacg gccgcccacg ccgctcagcg ccttccctca 240
ctccgggagc tggtcaggac ccccgggccc ctggcacccc aacgccgaac tgccctcagg 300
gaggccacc tgggaacccc cgacctgaac cccgagtcct cctcggatac cctaaccagg 360
catattcggg acccccatat ccgcatctca aatccaaaac cccgaacccc acggggcttt 420
gataaatcgt ggctcagact cccactagt cccaggaccc catctcgggt acccaccagg 480
ctcccacgca gttctagccc cccacaccct tgatccgccc cgcaggcagg tacttcccg 540
agcgagcggg gaacgcgacg taccccagtg cgcctcggca caccattgct ccccgaaact 600
ggggtgtcca ggccgaacag cagagcccag gtcccgcggc ctatacgggt cctcgcctct 660
tgggtccgag cgtcatcggc aaagtctccg ccccaacttg ctccatctac ggccgcagag 720
cggctggcag tttcttcgag gacctcagca aggtcgtgag tccaggggtc tacaagtccc 780
gggcccccca gttcacgatt ctggcgcgga cttcgtctcc ccaagacaac actcgggaagc 840
caggggccgc ggccctacaac gtggatcagc accggaagcc ccgcggttg agtttcggga 900
tccggcactc ggactacctg gcccgcgtgg tgaccgacgc ggacaactga cccgccaggc 960
gggagcggcc ccacacgtgt ttgcttaaag tctgcgagtc cgcacagagt ccgctctct 1020
ctctctctct ctgcgcgtcc tggcgcaagg cctggggttg agccacgggt ggggcggtgt 1080
cccaactccg aaccacgagg ggccggggcc gagegtcggg cgaggccggg accccagcgc 1140
tgccgcccgt ccgaacgtcg agaccccacc gagggcgagg gggggactct cgggagccac 1200
agacgcccga gacccacgcc gggcgggacc ggccagggat cacccccgcg gacggccccg 1260
ggccccgacg gcccgggaagt tccgcgtgtc cgggggcacc gggggatttg ccggggcgcg 1320
gcgtgcaagg cttcccgggg gcggcgactg ccgagctccg ccctccaggc ggccccaccc 1380
gcctgccgtc ctggggcgcc gccgcccgcg cgcgggcagt ggaccgctgt gcgcgaaccc 1440
tgaaccctac ggtcccgaac cgcggggcag gccgggtacc tgggctggga tccggagcaa 1500
gcgggagcag gcagcgccct aagcaggtac gggcggggct caagtgcgca ggcggggaag 1560
cgggagggcag acacggacga gggcgacaca gacacgggac cgaggggagg acaccggaga 1620
gacacgggaa aggggtcggg acaggagcac gtggctcaga caccgacgcc gggaggccgc 1680
agaccccggg cgtgtcaggc atccccgcag gcccgagcg atggcagcct tgatgacccc 1740
gggaaccggg gccccacccg gcctggtga cttctccggg gaaggagacc agggacttcc 1800
cgacccttcg ccagagccca agcagctccc ggagctgac cgcaggaagc gagcggagg 1860
ccgctgagc gaagcggaca tcaggggctt cgtggccgct gtggtgaatg ggagcgcgca 1920
gggagcagc atcggggcca tgctgatggc catccgactt cggggcagtg atctggagga 1980
gacctcggty ctgacccagg ccctggctca gtcgggacag cagctggagt ggccagaggc 2040
ctggcgccag cagcttgttg acaagcattc cacagggggg gtgggtgaca aggtcagcct 2100

```

ggtcctcgca cctgccctgg cggcatgtgg ctgcaaggtg ccaatgatca gcggacgtgg 2160
tctggggcac acaggaggca ccttgataa gctggagtct attcctggat tcaatgtcat 2220
ccagagccca gagcagatgc aagtgtgtct ggaccaggcg ggctgtgtga tctgtgggtca 2280
gagtgagcag ctggttctctg cggacggaat cctatatgca gccagagatg tgacagccac 2340
cgtggacagc ctgccactca tcacagcctc cattctcagt aagaaactcg tggaggggct 2400
gtccgctctg gtggtggacg ttaagtctgg aggggcccgc gtcttcccca accaggagca 2460
ggcccgggag ctggcaaaga cgctggttgg cgtgggagcc agcctagggc ttcgggtcgc 2520
ggcagcgctg accgccatgg acaagccctt gggtcgtctg gtgggccacg ccctggaggt 2580
ggaggaggcg ctgctctgca tggacggcgc agggcccgca gacttaaggg acctggtcac 2640
cacgtcggg ggccgcccgc tctggctcag cggacacgcg gggactcagg ctacggggcg 2700
tgcccgggtg gccgcggcgc tggacgacgg ctccggccctt ggccgcttcg agcggatgct 2760
ggcggcgcaag ggcgtggatc ccggtctggc ccgagccctg tgctcgggaa gtcccgcaga 2820
acgccggcag ctgctgcctc gcgcccggga gcaggaggag ctgctggcgc ccgcagatgg 2880
tgagcgtcgg gggagtcccc gtcttccgc ctccgccatc cccttccctt cccgaggccc 2940
cgcccttcc cgagcccgcg cctttcagcc cctctccccg caggcacctg ggagctggtc 3000
cgggcgctgc cgctggcgct ggtgctgcac gagctcgggg ccgggcgcag ccgcgtggg 3060
gagccgctcc gcctgggggt gggcgagag ctgctggtcg acgtgggtca gaggctgcgc 3120
cgtgggaccc cctggctccg cgtgcaccgg gacggccccg cgctcagcgg ccgcagagc 3180
cgcgccctgc aggaggcgct cgtactctcc gaccgcgcgc cattgcgcgc cccctcgccc 3240
ttcgagagc tcttctgcc gccgcagcaa taaagctcct ttgccgcgaa aaaa 3294

```

<210> 77
 <211> 902
 <212> DNA
 <213> Homo sapiens

```

<400> 77
gttgctgcta catgaacggt cccccaccgg acagccaggt agccgcgcgc tccctcgac 60
acgcagagtc gggcggcgcg ggggtctcct tgcccccgc ctccgcctc tctcctctc 120
ctttccctt cttctcgtg tctctcctc tctcgtgcc cgcgtttgc cagccccggg 180
ccatgtccga cgcgtccctc cgcagacat ccacgatgga gcgtctgtc gccgtggga 240
ccttcccagt actagtgcgc accagcgctt gccgcagcct cttcgggccc gtggaccacg 300
aggagctgag ccgogagctg caggcccgc tggccgagct gaacgccgag gaccagaacc 360
gctgggatta cgacttccag caggacatgc cgctgcgggg ccctggacgc ctgcagtgga 420
ccgaagtgga cagcgactcg gtgcccgcgt tctaccgca gacggtgcag atttcttcgc 480
caagcgcaag agatcagcgc ctgagaagtc gtcgggcgat gtccccgcgc cgtgtccctc 540
tccaagcgcc gccctggcg tgggtctcgt ggagcagacc ccgcgcaaga ggctgcggtg 600
agccaattta gagcccaaag agccccgagg gaacctgccg gggcagcgga cgttggaagg 660
gcgctgggcc tcggtggga ccgttcatgt agcagcaacc ggcggcggct gccgcagagc 720
agcgttcggt ttgttttta aattttgaaa actgtgcaat gtattaataa cgtcttttta 780
tatctaaatg tattctgcac gagaaggtag actggtccca aggtgtaaag ctttaagagt 840
catttatata aaatgttta tctctgctga aactcagtgc anacggcacg agggcctcgt 900
gc 902

```

<210> 78
 <211> 2052
 <212> DNA
 <213> Homo sapiens

```

<400> 78
ggggggcagc atgcccgcgc gcgctgcctg aggacgcgc ggccccgcgc cccgccatgg 60
gcgcccctgc ctgcgccctc gcgctctgcg tggcgcgtggc catcgtggcc ggccctcct 120
cggagtcctt ggggacggag cagcgcgtcg tggggcgagc ggcagaagtc ccgggcccag 180
agcccggcca gcaggagcag ttggtcttcg gcagcgggga tgctgtggag ctgagctgtc 240
ccccgccgg ggggtggtccc atggggccca ctgtctgggt caaggatggc acagggctgg 300
tgccctcgga gcgtgtcctg gtggggcccc agcggctgca ggtgctgaat gcctcccacg 360
aggactccgg ggcctacagc tgccggcagc ggctcacgca gcgcgtactg tgccacttca 420
gtgtgcgggt gacagacgct ccactctcgg gagatgacga agacggggag gacgaggctg 480
aggacacagg tgtggacaca ggggcccctt actggacacg gcccagcgcg atggacaaga 540

```

```

agctgctggc cgtgccggcc gccaacaccg tccgcttccg ctgcccagcc gctggcaacc 600
ccactccctc catctcctgg ctgaagaacg gcagggagtt ccgcggcgag caccgcattg 660
gagggcatcaa gctgcggcat cagcagtggg gcctgggtcat ggaaagcgtg gtgccctcgg 720
accgcggcaa ctacacctgc gtcgtggaga acaagtttgg cagcatccgg cagacgtaca 780
cgctggacgt gctggagcgc tccccgcacc ggcccactct gcaggcgggg ctgccggcca 840
accagacggc ggtgctgggc agcgacgtgg agttccactg caaggtgtac agtgacgcac 900
agccccacat ccagtggctc aagcacgtgg aggtgaacgg cagcaagggt ggcccggacg 960
gcacacccta cgttaccgtg ctcaagacgg cgggcgctaa caccaccgac aaggagctag 1020
aggttctctc cttgcacaac gtcacctttg aggacgcggg ggagtacacc tgcctggcgg 1080
gcaattctat tgggttttct catcactctg cgtggctggg ggtgctgcca gccgaggagg 1140
agctgggtgga ggctgacgag gcgggcagtg tgtatgcagg catcctcagc tacggggtgg 1200
gtttcttctt gttcatcctg gtggtggcgg ctgtgacsst ctgccgctg cgagccccc 1260
ccaagaaagg cctgggctcc cccaccgtgc acaagatctc ccgcttccc ctcaagcgac 1320
aggtgtccct ggagtccaac gcgtccatga gctccaacac accactggtg cgcacgcgaa 1380
ggctgtcctc aggggagggc cccacgctgg ccaatgtctc cgagctcgag ctgcctgccg 1440
accccaaatg ggagctgtct cgggcccggc tgaccctggg caagcccctt ggggagggct 1500
gcttcggcca ggtggtcatg gcggaggcca tcggcattga caaggaccgg gccgccaagc 1560
ctgtcacctg agccgtgaag atgctgaaag acgatgccac tgacaaggac ctgtcggacc 1620
tgggtgtctga gatggagatg atgaagatga tcgggaaaca caaaaacatc atcaacctgc 1680
tgacagttcc gatgttatta gatgttacia gtttatatat atctatatat ataatttatt 1740
gagtttttac aagatgtatt tggtgtagac ttaacacttc ttacgcaatg cttctagagt 1800
tttatagcct ggactgctac ctttcaaagc ttggagggaa gccgtgaatt cagttgggtc 1860
gttctgtact gttactgggc cctgagctct ggagctgtc ccttgcttgc ctgcagggcc 1920
atggctcagg gtggtctctt cttggggccc agtgcattgt ggccagaggt gtcacccaaa 1980
ccggcaggtg cgattttgtt aaccacgcga cgaactttcc gaaaaataaa gacacctggt 2040
tgctaacctg aa 2052

```

<210> 79

<211> 1057

<212> DNA

<213> Homo sapiens

<400> 79

```

ggcacgagct cctcccgcca ggcgctttct cggacgcctt gccagcggg ccgcccagcc 60
ccctgcacca tggaccccg ctcgcccctg gggctgtcga ttctgctgct tttcctgacg 120
gaggtgtcac tgggcgatgc tgcctcaggag ccaacaggaa ataacgcgga gatctgtctc 180
ctgcccctag actacggacc ctgccggggc ctacttctcc gttactacta cgacaggtac 240
acgcagagct gccgccagtt cctgtacggg ggctgcgagg gcaacgcaac aatttctaca 300
cctgggagggc ttgcgacgat gcttgcctgga ggataaaaa agttcccaa gtttgccggc 360
tgcaagttag tgtggacgac cagtgtgagg ggtccacaga aaagtatttc tttaatctaa 420
gttccatgac atgtgaaaaa ttcttttccg gtgggtgtca ccggaaccgg attgagaaca 480
ggtttccaga tgaagctact tgtatgggct tctgcgcacc aaagaaaatt ccatcatttt 540
gctacagtcc aaaagatgag ggactgtgct ctgccaatgt gactcgctat tattttaata 600
ttgatgtcag tatttcaact gctgtaaaat tataaacttt tatacttggg taagtcccc 660
aggggcgaggt tcctcgtctt gggatgcagg catgcttctc accgtgcaga gctgcacttg 720
gcctcagctg gctgtatgga aatgcacct cctcctgcc gctcctctct agaaccttct 780
agaacctggg ctgtgctgct tttgagcctc agaccccagg gcagcatctc ggttctgcgc 840
cacttcttt gtgtttatat ggcgttttgt ctgtgttgct gtttagagta aataaactgt 900
ttatataaag gttttggttg cattattatc attgaaagtg agaggaggcg gctcccaagt 960
gcccggccct cccacccac ctgcagcccc accgcggggc aggaccaggc tctccatctg 1020
cttcggatgc acgcaggctg tgaggctctg tcttgcc 1057

```

<210> 80

<211> 2256

<212> DNA

<213> Homo sapiens

<400> 80

```

acggcgagcc tcactctccg ggtgcggcgc tgagcagcga gtncgactg tgctcgtgctg 60

```

```

tcagcgccgc acccgaggga tgaggctcgc cgtgggagcc ctgctgggtct gcgcccgtcct 120
ggggctgtgt ctggctgtcc ctgataaaac tgtgagatgg tgtgcagtgt cggagcatga 180
ggccactaag tgccagagtt tccgcgacca tatgaaaagc gtcattccat ccgatgggcc 240
cagtgttgct tgtgtgaaga aagcctccta ccttgattgc atcagggcca ttgcggcaaa 300
cgaagcggat gctgtgacac tggatgcagg tttgggtgat gatgcttacc tggctcccaa 360
taacctgaag cctgtgggtg cagagttcta tgggtcaaaa gaggatccac agactttcta 420
ttatgctgtt gctgtgggtg agaaggatag tggcttccag atgaaccagc ttcgaggcaa 480
gaagtccctgc cacacgggtc taggcaggtc cgctgggtgg aacatcccca taggcttact 540
ttactgtgac ttacctgagc cacgtaaacc tcttgagaaa gcagtggcca atttcttctc 600
gggcagctgt gcccttctgt cggatgggac ggacttcccc cagctgtgtc aactgtgtcc 660
aggggtgtggc tgctccaccc ttaaccaata cttcggctac tcaggagcct tcaagtgtct 720
gaaggatggt gctggggatg tggcctttgt caagcactcg actatatattg agaacttggc 780
aaacaaggct gacagggacc agtatgagct gctttgctg gacaacaccc ggaagccggt 840
agatgaatac aaggactgcc acttggccca ggtcccttct cataccgtcg tggcccgaag 900
tatgggcggc aaggaggact tgatctggga gcttctcaac caggcccagg aacatttttg 960
caaagacaaa tcaaaagaat tccaactatt cagctctcct catgggaagg acctgtgtgt 1020
taaggactct gcccacgggt ttttaaaagt cccccccagg atggatgcca agatgtacct 1080
gggctatgag tatgtcactg ccacccgaa tctacgggaa ggcacatgcc cagaagcccc 1140
aacagatgaa tgcaagcctg tgaagtgtg tgcgctgagc caccacgaga ggctcaagt 1200
tgatgagtgg agtgtaaca gtgtaggaa aatagagtgt gtatcagcag agaccaccga 1260
agactgcac gccaagatca tgaatggaga agctgatgcc atgagcttgg atggaggggt 1320
tgtctacata gcgggcaagt gtggctctgt gcctgtcttg gcagaaaact acaataagag 1380
cgataattgt gaggatacac cagaggcagg gtattttgct gtagcagtgg tgaagaaatc 1440
agcttctgac ctcacctggg acaatctgaa aggcaagaag tcctgccata cggcagttgg 1500
cagaaccgct ggctggaaca tccccatggg cctgctctac aataagatca accactgtga 1560
acccaacaac aaagagggat actacggcta cacaggcgtc ttcaggtgtc tggttgagaa 1620
gggagatgtg gcctttgtga aacaccagac tgtcccacag aacactgggg gaaaaaaccc 1680
tgatccatgg gctaagaatc tgaatgaaaa agactatgag ttgctgtgcc ttgatggtag 1740
caggaaacct gtggaggagt atgcgaactg ccacctggcc agagccccga atcacgctgt 1800
ggtcacacgg aaagataagg aagcttgcgt ccacaagata ttacgtcaac agcagcacct 1860
atttggaagc aacgtaactg actgctcggg caacttttgt ttgttcoggt cggaacacaa 1920
ggaccttctg ttcagagatg acacagtatg tttggccaaa cttcatgaca gaaacacata 1980
tgaaaaatac ttaggagaag aatatgtcaa ggctgttggg aacctgagaa aatgtctcac 2040
ctcatcactc ctggaagcct gcactttccg tagaccttaa aatctcagag gtaggggtgc 2100
caccaagggt aagatgggaa cgcagatgat ccatgagttt gccctgggtt cactggccca 2160
agtgggttgt gctaaccacg tctgtcttca cagctctgtg ttgccatgtg tgctgaacaa 2220
aaaataaaaa ttattattga ttttatattt caaaaa 2256

```

<210> 81

<211> 632

<212> DNA

<213> Homo sapiens

<400> 81

```

gtgcattgag cgcgctccag ctgccgggac gagggggcgg cccccgcgtc cggggcgctc 60
ggctacagct gcggggcccg aggtctccgc gactcgctc ccggcccatg ctggaggcgg 120
cggaaccgcg gggacctagg acggaggcgg cgggcgtgg gcggcccccg gcacgctgag 180
ctcgggatgc ggacgtgct gctcccgcg ctgctgacct gctggctgct cgcctccgtg 240
aacagcattc acccagaatg ccgatttcat ctggaaatac aggaggaaag aacaaaatgt 300
gcagagcttc tgagggtctc aacagaaaaa cacaaaggcc atacaaaggg attcatcctc 360
attcacgcgg gaggtttaaa gaggatcctg gaccacata cctaccatt ggctccatga 420
ccagtgtctt tataattaca aaatcattga gaaattaagt cacaggaagc ctggtgtgtg 480
gtatacactg gtgataaagc aagtcccatg cagtctgaga tggcaaggga ccttctaggg 540
aaagggcagt gaccagaag cccgactgct cggctggctc ccgcactccg tctgtgtgtc 600
agagtgtgtt tctccctc tgtgaacctg gt 632

```

<210> 82

<211> 1388

<212> DNA

<213> Homo sapiens

<400> 82

```

ctgctacgct tttttgacca agaactacag ttactcatgg aaatattacc ttacaattat 60
atthaaagat tcaactgtttg ctaatttaac atagcaatgt gaatgaaatt gccagaagtc 120
tgctttttta actgttgtac gcttcatgag tccaaatatg agattgtgac aatgtttatc 180
tatttttaatt ggtgttattt ttttccagcg aatgggttcc aggtggataa ttatggaacc 240
cagctcaatg ctgtgaataa ctccctgact ccgcaatcaa ccaaggttcc cagccttttt 300
gaatttcacg gtccctcatg gtgtctcact ccagcagaca gaggattgtg tcgtgccaat 360
gagaacagat tctactacaa ttcagtcatt gggaaatgcc gccatttaa gtacagtgga 420
tgtgggggaa atgaaaacaa ttttacttcc aaacaagaat gtctgagggc atgtaaaaaa 480
ggtttcatcc aaagaatatc aaaaggaggc ctaattaaaa ccaaaagaaa aagaaagaag 540
cagagagtga aaatagcata tgaagaaatt tttgttaaaa atatgtgaat ttgttatagc 600
aatgtaacat taattctact aaatatatta tatgaaatgt ttcactatga ttttctattt 660
ttcttctaaa atgcttttaa ttaatatgtt cattaaattt tctatgctta ttgtacttgt 720
tatcaacacg tttgtatcag agttgctttt ctaatcttgt taaattgctt attctaggtc 780
tgtaatttat taactggcta ctgggaaatt acttattttc tggatctatc tgtattttca 840
tttaactaca aattatcata ctaccggcta catcaaatca gtcctttgat tccattttgt 900
gaccatctgt ttgagaatat gatcatgtaa atgattatct cctttatagc ctgtaaccag 960
attaaggaat acagctctta aaaaatcaag aacttcttga gtttcacata taaaatggtr 1020
acatgttacc attctgatgt aggaggtcat ctgttttctt cttttctctt cctctgactc 1080
ttaagccctt tcccattctc tttctcagga atggctgtta aaatgccaat atggctctgt 1140
aactttctctg tacttagtga acctccttat ttacaccctg tttgtgaagt ggctgtgttc 1200
accctgggtg gacacggaat gtttttgcca tgtacaaaga gaattttatg ctgcctgtgt 1260
acagttatta atttgtaagt acactcagct ttttgtatct gtaggtttta tatctgtgta 1320
tgtaagcaaa cttggatgca aaatatattga aataaaatca gatgcttgca tctgtagtga 1380
acataaaa

```

<210> 83

<211> 1015

<212> DNA

<213> Mouse

<400> 83

```

atttggacac acaactccaa aattttcttc cacaacctct tgttaccttt tcagccaccc 60
gtgcccctt tcatcatacc tcttccacta ctagtacatg tataatactt ccyyccatggs 120
ccccwcgaac ccccgacctt tctttaccat catcacactg gaagactcca gtgggaacct 180
tctgggacgg gacagctttg aggttcgtgt ttgtgcctcc cctgggagag acccccgtac 240
agaagaagaa aatttccgca aaaaggaagt cctttgccct gaactgcccc cagggagcgc 300
aaagagagcg ctgcccacct gcacaagcgc ctctcccccg caaaagaaaa aaccacttga 360
tgagaggtat ttcacctca agatccgcgg gcgtaaacgc ttcgagatgt tccgggagct 420
gaatgaggcc ttagagttaa aggatgcccc tgctacagag gagtctggag acagcagggc 480
tcaactccagc tacctgaaga ccaagaaggc ccagtctact tcccgcata aaaaaacaat 540
ggtcaagaaa gtggggcctg actcagactg actgcctctg catcccgctc ccatcaccag 600
cctccccctc tcttgcgtgt cttatgactt cagggctgag acacaatcct cccggtccct 660
tctgtgcct tttttacctt gtagctaggg ctgagcccc tctctgagta gtggttctctg 720
gcccaggttg ggggaatagg tgatagttgt caggtctctg ctggcccagc gaaattctat 780
ccagccagtt gttggacctt ggcacctaca atgaaatctc accctacccc acaccctgta 840
agattctatc ttgggcccctc atagggtcca tatcctccag ggctacttt ccttccattc 900
tgcaaagcct gtctgcattt atccaccccc caccctgtct cctctttttt tttttttta 960
ccccttttta tatatcaatt tctattttta caataaaatt ttgttatcac ttaaa 1015

```

<210> 84

<211> 969

<212> DNA

<213> Mouse

<400> 84

```

attgaccctc ctgatccccg ttatatctat accaccctcc tataactacta catgtttaat 60

```

agatcctgct tgcggggcat gaacccccga cctatcctta ccatcatcac actggaagac 120
 tccagtggga accttctggg acgggacagc tttgaggttc gtgtttgtgc ctcccctggg 180
 agagaccccc gtacagaaga agaaaatttc cgcaaaaagg aagtcctttg ccctgaactg 240
 cccccaggga gcgcaaagag agcgtgccc acctgcacaa gcgcctctcc cccgcaaaag 300
 aaaaaaccac ttgatggaga gtatttcacc ctcaagatcc gcgggcgtaa acgcttcgag 360
 atgttccggg agctgaatga ggccttagag ttaaaggatg cccatgctac agaggagtct 420
 ggagacagca gggctcactc cagctacctg aagaccaaga agggccagtc tacttcccgc 480
 cataaaaaaa caatgggtcaa gaaagtgggg cctgactcag actgactgcc tctgcatccc 540
 gtccccatca ccagcctccc cctctccttg ctgtcttatg acttcagggc tgagacacaa 600
 tcctcccggg cccttctgct gcctttttta cctttagctc agggctcagc cccctctctg 660
 agtagtggtt cctggcccaa gttggggaat aggttgatag ttgtcaggtc tctgctggcc 720
 cagcgaaatt ctatccagcc agttgttgga cctggcacc tacaatgaaa tctcacccta 780
 cccacacccc tgtaagattc tatcttgggc cctcataggg tccatctcct ccagggccta 840
 ctttccctcc attctgcaaa gcctgtctgc atttatccac cccccacct gtctccctct 900
 tttttttttt tttaccctt tttatatatc aatttctat tttacaataa aattttgtta 960
 tcacttaaa

<210> 85

<211> 3939

<212> DNA

<213> Mouse

<400> 85

gaattcgggg ccgcaccgcg cgcaccgcgc catggggggc gcgtccggcc agcggggggc 60
 gtggccggtt tgcctccgc tcttgatgct gtcgtgctg gtgctgttgc tgcagccgtc 120
 gcccgcctcg gactcgcacc ctggattgca gccgggcaac ttttccccg acgaggcagg 180
 ggcgcagctt ttcgctgaaa gctataactc gagtgcgag gtggtgatgt tccagagcac 240
 cgtggccagt tgggcgcacg acaccaacat cacggaggag aacgcgcgac gccaggagga 300
 agcggccctg gtcagccagg agtttgaga ggtctggggc aagaaggcca aggagtgtga 360
 tgagtcattt tggcagaact ttactgactc aaagctgcga aggatcatcg gatctattcg 420
 gaccctagga cctgccaatc tgcccctggc ccagcggcag cagtacaact ctctgctaag 480
 caacatgagc agaattact ccactggcaa ggtctgcttc cccaacaaga ctgccacctg 540
 ctggctccctg gaccagagc tcaccaacat cctggcttcc tcacgaagct atgccaaagt 600
 gttgttttgc tgggagggct ggcattgatgc tgtgggtatc ccactgaaac cctctatca 660
 agactttact gccatcagta acgaagccta cagacaagac gacttctcag acacaggagc 720
 cttctggcgc tcttggtatg agtccccctc ctttgaggag agtctggaac atatctacca 780
 ccaactagag cccctctacc tgaacctcca tgctacgtc cgccgcgcac tgcaccgccg 840
 ctatggggac aaatacgtca atctcagggg gcctattcct gccatttgc tgggagacat 900
 gtggggccag agctgggaga acatctacga catggttagt cctttcccag acaaacccaa 960
 cctcgatgtc accagtacaa tggtagagaa gggctggaac gccacacaca tgttccgggt 1020
 atcagaggaa ttcttcacct cgctggggct ctcacctatg cctcctgagt tctgggcgga 1080
 gtcaatgctg gagaaaccaa cggatggacg ggaggtggtg tgccacgcct ctgcttggga 1140
 cttctacaac cggaaggact tccggattaa gcaatgcaca cgggtcacga tggaaacagt 1200
 ggccacagta caccacgaga tgggccacgt gcagtactac ctccagtaca aggacctgca 1260
 cgtctctctg cgtagaggtg ccaaccctgg cttccatgag gccattgggg atgtgcttgc 1320
 actctccgtc tctaccctg cacatctgca caaaatcggc ctactggacc atgttaccaa 1380
 tgacatagag agtgacatca attacctgct aaagatggcc cttagagaaa tgccttctt 1440
 gccctttggc tacctgggtg accagtggcg ttgggggggtc ttcagtggac ggacccacc 1500
 ctctcgctac aacttcgact ggtggtatct tcgaaccaag tatcagggga tctgccacc 1560
 agttgcccgg aatgaaaccc attttgatgc tggagccaag tttcacatcc caaacgtgac 1620
 accgtacatc aggtacttgc tgagctttgt cgtgcagttc cagttccatc aagcactgtg 1680
 caaggaggca ggccaccagg gccactaca ccagtgtgac atctaccagt ccgcccaggc 1740
 gggggccaag ctcaagcagg tgttgaggc tggctgctcc aggcctggc agggagtact 1800
 gaaggacctg gtaggctcag atgccctgga tgccaaggca ctgctggagt acttccaacc 1860
 ggtcagccag tggctggaag agcagaatca gcggaatggc gaagtcctag gctggccaga 1920
 gaatcagtg cgtccaccgt taccgcacaa ctatccagag ggcattgacc tagagactga 1980
 tgaagccaag gctgacaggt tcgtggaaga gtatgaccg acagcccaag tgtgttgaa 2040
 cgagtacgca gaggccaact ggcaatataa caccaacatt accatagagg gcagcaagat 2100
 cctgcttgag aaaagcacgg aggtatccaa tcacaccctg aaatatggca cccgggcca 2160
 gacatttgat gtgagcaact ttcaaaactc ttccatcaag cggatcataa agaagcttca 2220

```

gaacctggac cgggcagtg tgcctcccaa ggaattagaa gagtacaacc agatcctgct 2280
agacatggag acaacttaca gcttatccaa catttgctac acaaatggca cttgtatgcc 2340
cctggaacct gatctaacaa acatgatggc cacatcccgg aaatatgaag aattgctatg 2400
ggcatggaaag agctggagag acaaggtggg gagagccatc cttccttttt tcccaaagta 2460
tgtggagtgc tccaacaaga ttgccaagct caatggctac acggatgcag gggattcatg 2520
gagatcctta tacgagtcgt acaacctgga gcaagacctg gaaaaactgt accaggagct 2580
gcagccactc tacctgaacc tgcattgcct tgtgcgtcgt tccctgcacc gccactatgg 2640
gtccgagtag atcaacctgg atggccccc tctgcccatt ctgctaggga acatgtgggc 2700
gcagacctgg tccaacatct atgatttggg ggccgcccct ccttccgccc ccaatataga 2760
tgccacggaa gccatgataa agcagggatg gacaccaga aggatattta aggaagctga 2820
caattttctt acctccctgg ggtgtttacc tgtgcccctt gagttctgga acaagtcgat 2880
gttagagaag cccaccgatg gaagggaggt ggtgtgccc atctcagcct gggacttcta 2940
caacggcaag gacttcagga tcaagcagtg tacctctgtg aacatggagg acttggtgat 3000
agcgaccac gaaatgggac acatccagta ttctatgcag tacaagact taccctgac 3060
tttccgggag ggtgccacc ctggttttca tgaagctatt ggagatataa tggctctctc 3120
agtgtctacc cccaagcatc tatacagtc caacctgctt agcactgagg gcagtggcta 3180
cgagtatgac atcaactttc taatgaagat ggccctcgac aagatcgctt ttatcccctt 3240
cagctacctc atcgaccagt ggctgtggag ggtctttgat ggaagcatca ccaaggagaa 3300
ctataaccag gagtgggtga gctcaggct gaagtatcag ggtctgtgcc cccagtgcc 3360
aagatcccaa ggtgactttg acccagggtc caagttccac gttctgcga acgtgccata 3420
cgtcaggtac tttgtcagct tcatcatcca gttccagttc cagcaggcgc tgtgtcgcgc 3480
agccgggcac acgggtcccc tgcacaagtg tgacatctac caatccaagg aagcaggaa 3540
gctcctggcg gatgccatga agctgggcta cagtaagccg tggccagagg ccatgaagct 3600
gatcacaggc cagcctaaca tgtcagcctc cgccatgatg aattacttca agccactgac 3660
agaatggctc gtcaccgaga acaggagaca tggagagaca ctgggctggc cggagtacaa 3720
ctgggcgcca aacaccggtg ctacaccac cctgcctcca gcccacattc tctggatacc 3780
cagtgtctaa caccgacttc cctgcccagt ctctgtgaat acaattaaag gtctcccc 3840
acacctgagt ctgtgtccct tgtgggaagc caggacagg accggctgct tgctgtctc 3900
ctgacagtc cagcaagacc ctttantggt tgcncannng 3939

```

<210> 86

<211> 1470

<212> DNA

<213> Mouse

<400> 86

```

cagctctgc cttgatcaca caccgcgcca ctcgatcatt cgagcacatt ccttccctcc 60
gtcttactgt ctcagccctt gacttctaca aacccatgga acatttctgg aaagacgctc 120
ttgaaccagc aggggtggccc acgcgtgct gagcctctctg cgtgcgcggg gagccagctc 180
gtaactcgcc ggctgccact taccatgacc atgacccttc acaccaaagc ctccgggaatg 240
gccttgctgc accgatccca agggaacgag ctggagcccc tcaaccgccc gcagctcaag 300
atgcccattg agagggccct gggcgaggta tacgtggaca acagcaagcc cactgtgttc 360
aactaccccc agggcgccgc ctacgagttc aacgcgcgc ccgcgcgcgc cgccgcgcgc 420
tcggcgccgg tctacggcca gtcgggcac gcctacggcc ccgggtcgga ggccggccgc 480
ttcagtgcca acagcctggg ggctttcccc cagctcaaca gcgtgtcgcc tagcccgctg 540
atgctgctgc accgcgcgc gcagctgtct cctttcctgc accgcacgg ccagcaggtg 600
ccctactacc tggagaacga gccagcgcc tacgcccgtgc gcgacacgg cctcccgc 660
ttctacaggt ctaattctga caatcgacgc cagaatggcc gagagagact gtccagcagt 720
aacgagaaag gaaacatgat catggagtct gccaggaga ctgcgtactg tgccgtgtgc 780
aatgactatg cctctggcta ccattatggg gtctggtcct gcgaaggctg caaggctttc 840
tttaagagaa gcattcaagg acacaatgac tacatgtgtc cagctacaaa ccaatgcacc 900
attgacaaga accggaggaa gaggttgccg gctgtcggc tgcgcaagtg ttacgaagtg 960
ggcatgatga aaggcgcat acggaaagac cgccgaggag ggagaatgtt gaagcacaag 1020
cgtcagagag atgacttga aggcggaat gaaatgggtg cttcaggaga catgagggtc 1080
gccaaccttt ggccaagccc tcttgtgatt aagcacacta agaagaatag cctgccttg 1140
tccttgacag ctgaccagat ggtcagtgcc ttgttggatg ctgaaccgcc catgatctat 1200
tctgaatatg atccttctag acccttcagt gaagcctcaa tgatgggctt attgaccaac 1260
ctagcagata gggagctggg tcatatgatc aactgggcaa agagagtgcc aggaggaaat 1320
agcctttaa attaaactcc cagcagacta aaaccttga catgctaatt ttggcccgctc 1380
ttgtctcaaa acacttggat gaacacttca ttacaacatg cccatgtgtt ctgtcatcaa 1440

```

1470

atgtcatata ttaaaagtac ttaatgctcg

<210> 87

<211> 1723

<212> DNA

<213> Mouse

<400> 87

```

gaacagaagg ccagagacgc ctttgtttct tctttatttg gggatataat tattatgcac 60
cgactcttaa attagagata gatttttttc tgatatacat ttcattcttat tcaccacgag 120
cacaccacac gcacagtata cagttccacg aacggataca ttgcacaaga tgagatggcc 180
atgagcagcg tgaagaccac cagcgcgcag cgcgcagtca gccccagga cttaaaggcg 240
ccgtcgcctc catagcaggc ggggaagaag gcgcgactgc cttcctggaa gagagacttc 300
tccagcactt cgacggccgc gaagaagggc aacggatagg acagcagcgc cttggccacc 360
aggaagaggt tgaccacggc gcggatggag ccgggcaggt tatccgtgat gacttccttg 420
gtctcgtcgg cccaggtgag gtaggcgacg agcgcgaaga gacccttgag cacgcaggcg 480
gcgatgtgtg tccagttcat catgcagtgg aattcgtcgg gctgctgcat gttgccttcg 540
agagagggca ggaagatctg cgacgtgtag ctgaacacga tgatgccaat ggagatggga 600
aacttcttga cgtcgtatga gaacttcacc ttctcccagg cccaatcacg cgcgcgagag 660
agacagtaag cgtatgaccg gatgttgatg acgaagtggg ccagcgtaca cagcagactg 720
aacttggaac cggccttgag attcttcagg aaggcgcagg gcagcagcac cgctgtggct 780
atgatggacc aggacttctg cgacacgggc agccccggga aactgttgta catgaggttg 840
ccgctcacca cgacgtacaa gatacacgtc atcaccagct cgatgatctg cgccacattg 900
accacgcggc cgcccagggt ggggaatcga ggagcgcagc atgcgttagc tatggccaca 960
tacgagtccc gcacgcgcac cacctccccg tcttcgttct cctcgtacag gcacgcgatg 1020
aggatcttgc cgggtgtagc gcacaccact gcggcgaaga tgatgaggaa caacccagg 1080
tagccgccgt ggaggatggc gtagggtagg cccagcacga acatgccctg aatggcattt 1140
gtcacgttcc agcccgttc gtccttggag ccagaggggtg gcagaggagc gccgccgcgc 1200
ccaccagctc ccacggcctg gtccttggag ccagaggggtg gcagaggagc gccgccgcgc 1260
tgataatgaa tgtctccctc gacgggagct tctgcgccct cgtctccgca gggctcgcct 1320
tccgatttca ggaatgccat ctgcaggccc tggcgtatgct caaagtcgag atcgtcgcag 1380
tgccggaagc ccaccgcttc ctcatcggtg gccgcctgaa accccatcct ggcaaacatg 1440
ccgctcacct tggcctggga cttgttggac acggaggtgg ccacattggt cagcttgcgtg 1500
cggagcaggg tggccatggc ggccggcggg cgggagaaaa ggacagaagg gtctggggac 1560
gcggcgggcg cgcgtcaagg cagcgaggac tgctatctcc gctgggtctc cgcgcggcgc 1620
cccagggcgc tctggctcat gaccctcgcg cctgacgttc gaggctggcc ccggtcacga 1680
cagtctggct cttggtggga ccggcccag aggcctcgtg ccg 1723

```

<210> 88

<211> 401

<212> PRT

<213> Homo sapiens

<400> 88

```

Met Pro Ile Met Gly Ser Ser Val Tyr Ile Thr Val Glu Leu Ala Ile
1         5         10         15

```

```

Ala Val Leu Ala Ile Leu Gly Asn Val Leu Val Cys Trp Ala Val Trp
20         25         30

```

```

Leu Asn Ser Asn Leu Gln Asn Val Thr Asn Tyr Phe Val Val Ser Leu
35         40         45

```

```

Ala Ala Ala Asp Ile Ala Val Gly Val Leu Ala Ile Pro Phe Ala Ile
50         55         60

```

```

Thr Ile Ser Thr Gly Phe Cys Ala Ala Cys His Gly Cys Leu Phe Ile
65         70         75         80

```

Ala Cys Phe Val Leu Val Leu Thr Gln Ser Ser Ile Phe Ser Leu Leu
85 90 95

Ala Ile Ala Ile Asp Arg Tyr Ile Ala Ile Arg Ile Pro Leu Arg Tyr
100 105 110

Asn Gly Leu Val Thr Gly Thr Arg Ala Lys Gly Ile Ile Ala Ile Cys
115 120 125

Trp Val Leu Ser Phe Ala Ile Gly Leu Thr Pro Met Leu Gly Trp Asn
130 135 140

Asn Cys Gly Gln Pro Lys Glu Gly Lys Asn His Ser Gln Gly Cys Gly
145 150 155 160

Glu Gly Gln Val Ala Cys Leu Phe Glu Asp Val Val Pro Met Asn Tyr
165 170 175

Met Val Tyr Phe Asn Phe Phe Ala Cys Val Leu Val Pro Leu Leu Leu
180 185 190

Met Leu Gly Val Tyr Leu Arg Ile Phe Leu Ala Ala Arg Arg Gln Leu
195 200 205

Lys Gln Met Glu Ser Gln Pro Leu Pro Gly Glu Arg Ala Arg Ser Thr
210 215 220

Leu Gln Lys Glu Val His Ala Ala Lys Ser Leu Ala Pro Leu His Ile
225 230 235 240

Ile Asn Cys Phe Thr Phe Phe Cys Pro Asp Cys Ser His Ala Pro Leu
245 250 255

Trp Leu Met Tyr Leu Ala Ile Val Leu Ser His Thr Asn Ser Val Val
260 265 270

Asn Pro Phe Ile Tyr Ala Tyr Arg Ile Arg Glu Phe Arg Gln Thr Phe
275 280 285

Arg Lys Ile Ile Arg Ser His Val Leu Arg Gln Gln Glu Pro Phe Lys
290 295 300

Ala Ala Gly Thr Ser Ala Arg Val Leu Ala Ala His Gly Ser Asp Gly
305 310 315 320

Glu Gln Val Ser Leu Arg Leu Asn Gly His Pro Pro Gly Val Trp Ala
325 330 335

Asn Gly Ser Ala Pro His Pro Glu Arg Arg Pro Asn Gly Tyr Ala Leu
340 345 350

Gly Leu Val Ser Gly Gly Ser Ala Gln Glu Ser Gln Gly Asn Thr Gly
355 360 365

Leu Pro Asp Val Glu Leu Leu Ser His Glu Leu Lys Gly Val Cys Pro
370 375 380

Glu Pro Pro Gly Leu Asp Asp Pro Leu Ala Gln Asp Gly Ala Gly Val
385 390 395 400

Ser

<210> 89
 <211> 682
 <212> PRT
 <213> Homo sapiens

<400> 89
 Met Pro Arg Tyr Gly Ala Ser Leu Arg Gln Ser Cys Pro Arg Ser Gly
 1 5 10 15
 Arg Glu Gln Gly Gln Asp Gly Thr Ala Gly Ala Pro Gly Leu Leu Trp
 20 25 30
 Met Gly Leu Val Leu Ala Leu Ala Leu Ala Leu Ala Leu Ser
 35 40 45
 Asp Ser Arg Val Leu Trp Ala Pro Ala Glu Ala His Pro Leu Ser Pro
 50 55 60
 Gln Gly His Pro Ala Arg Leu His Arg Ile Val Pro Arg Leu Arg Asp
 65 70 75 80
 Val Phe Gly Trp Gly Asn Leu Thr Cys Pro Ile Cys Lys Gly Leu Phe
 85 90 95
 Thr Ala Ile Asn Leu Gly Leu Lys Lys Glu Pro Asn Val Ala Arg Val
 100 105 110
 Gly Ser Val Ala Ile Lys Leu Cys Asn Leu Leu Lys Ile Ala Pro Pro
 115 120 125
 Ala Val Cys Gln Ser Ile Val His Leu Phe Glu Asp Asp Met Val Glu
 130 135 140
 Val Trp Arg Arg Ser Val Leu Ser Pro Ser Glu Ala Cys Gly Leu Leu
 145 150 155 160
 Leu Gly Ser Thr Cys Gly His Trp Asp Ile Phe Ser Ser Trp Asn Ile
 165 170 175
 Ser Leu Pro Thr Val Pro Lys Pro Pro Pro Lys Pro Pro Ser Pro Pro
 180 185 190
 Ala Pro Gly Ala Pro Val Ser Arg Ile Leu Phe Leu Thr Asp Leu His
 195 200 205
 Trp Asp His Asp Tyr Leu Glu Gly Thr Asp Pro Asp Cys Ala Asp Pro
 210 215 220
 Leu Cys Cys Arg Arg Gly Ser Gly Leu Pro Pro Ala Ser Arg Pro Gly
 225 230 235 240
 Ala Gly Tyr Trp Gly Glu Tyr Ser Lys Cys Asp Leu Pro Leu Arg Thr
 245 250 255
 Leu Glu Ser Leu Leu Ser Gly Leu Gly Pro Ala Gly Pro Phe Asp Met
 260 265 270
 Val Tyr Trp Thr Gly Asp Ile Pro Ala His Asp Val Trp His Gln Thr

275 280 285
 Arg Gln Asp Gln Leu Arg Ala Leu Thr Thr Val Thr Ala Leu Val Arg
 290 295 300
 Lys Phe Leu Gly Pro Val Pro Val Tyr Pro Ala Val Gly Asn His Glu
 305 310 315 320
 Ser Thr Pro Val Asn Ser Phe Pro Pro Pro Phe Ile Glu Gly Asn His
 325 330 335
 Ser Ser Arg Trp Leu Tyr Glu Ala Met Ala Lys Ala Trp Glu Pro Trp
 340 345 350
 Leu Pro Ala Glu Ala Leu Arg Thr Leu Arg Ile Gly Gly Phe Tyr Ala
 355 360 365
 Leu Ser Pro Tyr Pro Gly Leu Arg Leu Ile Ser Leu Asn Met Asn Phe
 370 375 380
 Cys Ser Arg Glu Asn Phe Trp Leu Leu Ile Asn Ser Thr Asp Pro Ala
 385 390 395 400
 Gly Gln Leu Gln Trp Leu Val Gly Glu Leu Gln Ala Ala Glu Asp Arg
 405 410 415
 Gly Asp Lys Val His Ile Ile Gly His Ile Pro Pro Gly His Cys Leu
 420 425 430
 Lys Ser Trp Ser Trp Asn Tyr Tyr Arg Ile Val Ala Arg Tyr Glu Asn
 435 440 445
 Thr Leu Ala Ala Gln Phe Phe Gly His Thr His Val Asp Glu Phe Glu
 450 455 460
 Val Phe Tyr Asp Glu Glu Thr Leu Ser Arg Pro Leu Ala Val Ala Phe
 465 470 475 480
 Leu Ala Pro Ser Ala Thr Thr Tyr Ile Gly Leu Asn Pro Leu Val Ser
 485 490 495
 Glu Ala Glu Gly Ser Leu Pro Tyr Pro Gly Val Gly Gly Ile Gly Glu
 500 505 510
 Gly Gly Trp Ser Gln Ser Leu Gln Ser Met Gly Arg Met Cys Gly Pro
 515 520 525
 Ser Leu Glu Leu Pro Leu Leu Leu Ala Pro Pro Val Ser Pro Thr Ser
 530 535 540
 Leu Ala Gly Tyr Arg Val Tyr Gln Ile Asp Gly Asn Tyr Ser Gly Ser
 545 550 555 560
 Ser His Val Val Leu Asp His Glu Thr Tyr Ile Leu Asn Leu Thr Gln
 565 570 575
 Ala Asn Ile Pro Gly Ala Ile Pro His Trp Gln Leu Leu Tyr Arg Ala
 580 585 590
 Arg Glu Thr Tyr Gly Leu Pro Asn Thr Leu Pro Thr Ala Trp His Asn
 595 600 605

Leu Val Tyr Arg Met Arg Gly Asp Met Gln Leu Phe Gln Thr Phe Trp
 610 615 620

Phe Leu Tyr His Lys Gly His Pro Pro Ser Glu Pro Cys Gly Thr Pro
 625 630 635 640

Cys Arg Leu Ala Thr Leu Cys Ala Gln Leu Ser Ala Arg Ala Asp Ser
 645 650 655

Pro Ala Leu Cys Arg His Leu Met Pro Asp Gly Ser Leu Pro Glu Ala
 660 665 670

Gln Ser Leu Trp Pro Arg Pro Leu Phe Cys
 675 680

<210> 90

<211> 515

<212> PRT

<213> Homo sapiens

<400> 90

Leu Leu Leu Leu Gly Phe Leu Leu Val Ser Leu Glu Ser Thr Leu Ser
 1 5 10 15

Ile Pro Pro Trp Glu Ala Pro Lys Glu His Lys Tyr Lys Ala Glu Glu
 20 25 30

His Thr Val Val Leu Thr Val Thr Gly Glu Pro Cys His Phe Pro Phe
 35 40 45

Gln Tyr His Arg Gln Leu Tyr His Lys Cys Thr His Lys Gly Arg Pro
 50 55 60

Gly Pro Gln Pro Trp Cys Ala Thr Thr Pro Asn Phe Asp Gln Asp Gln
 65 70 75 80

Arg Trp Gly Tyr Cys Leu Glu Pro Lys Lys Val Lys Asp His Cys Ser
 85 90 95

Lys His Ser Pro Cys Gln Lys Gly Gly Thr Cys Val Asn Met Pro Ser
 100 105 110

Gly Pro His Cys Leu Cys Pro Gln His Leu Thr Gly Asn His Cys Gln
 115 120 125

Lys Glu Lys Cys Phe Glu Pro Gln Leu Leu Arg Phe Phe His Lys Asn
 130 135 140

Glu Ile Trp Tyr Arg Thr Glu Gln Ala Ala Val Ala Arg Cys Gln Cys
 145 150 155 160

Lys Gly Pro Asp Ala His Cys Gln Arg Leu Ala Ser Gln Ala Cys Arg
 165 170 175

Thr Asn Pro Cys Leu His Gly Gly Arg Cys Leu Glu Val Glu Gly His
 180 185 190

Arg Leu Cys His Cys Pro Val Gly Tyr Thr Gly Pro Phe Cys Asp Val
 195 200 205

Asp Thr Lys Ala Ser Cys Tyr Asp Gly Arg Gly Leu Ser Tyr Arg Gly
 210 215 220
 Leu Ala Arg Thr Thr Leu Ser Gly Ala Pro Cys Gln Pro Trp Ala Ser
 225 230 235 240
 Glu Ala Thr Tyr Arg Asn Val Thr Ala Glu Gln Ala Arg Asn Trp Gly
 245 250 255
 Leu Gly Gly His Ala Phe Cys Arg Asn Pro Asp Asn Asp Ile Arg Pro
 260 265 270
 Trp Cys Phe Val Leu Asn Arg Asp Arg Leu Ser Trp Glu Tyr Cys Asp
 275 280 285
 Leu Ala Gln Cys Gln Thr Pro Thr Gln Ala Ala Pro Pro Thr Pro Val
 290 295 300
 Ser Pro Arg Leu His Val Pro Leu Met Pro Ala Gln Pro Ala Pro Pro
 305 310 315 320
 Lys Pro Gln Pro Thr Thr Arg Thr Pro Pro Gln Ser Gln Thr Pro Gly
 325 330 335
 Ala Leu Pro Ala Lys Arg Glu Gln Pro Pro Ser Leu Thr Arg Asn Gly
 340 345 350
 Pro Leu Ser Cys Gly Gln Arg Leu Arg Lys Ser Leu Ser Ser Met Thr
 355 360 365
 Arg Val Val Gly Gly Leu Val Ala Leu Arg Gly Ala His Pro Tyr Ile
 370 375 380
 Ala Ala Leu Tyr Trp Gly His Ser Phe Cys Ala Gly Ser Leu Ile Ala
 385 390 395 400
 Pro Cys Trp Val Leu Thr Ala Ala His Cys Leu Gln Asp Arg Pro Ala
 405 410 415
 Pro Glu Asp Leu Thr Val Val Leu Gly Gln Glu Arg Arg Asn His Ser
 420 425 430
 Cys Glu Pro Cys Gln Thr Leu Ala Val Arg Ser Tyr Arg Leu His Glu
 435 440 445
 Ala Phe Ser Pro Val Ser Tyr Gln His Asp Leu Ala Leu Leu Arg Leu
 450 455 460
 Gln Glu Asp Ala Asp Gly Ser Cys Ala Leu Leu Ser Pro Tyr Val Gln
 465 470 475 480
 Pro Val Cys Leu Pro Ser Gly Ala Ala Arg Pro Ser Glu Thr Thr Leu
 485 490 495
 Cys Gln Val Ala Gly Trp Gly His Gln Phe Glu Ala Ser Leu Pro Met
 500 505 510
 Lys Leu Asn
 515

<210> 91
 <211> 775
 <212> PRT
 <213> Homo sapiens

<400> 91

Met Ala Arg Leu Gly Asn Cys Ser Leu Thr Trp Ala Ala Leu Ile Ile
 1 5 10 15

Leu Leu Leu Pro Gly Ser Leu Glu Glu Cys Gly His Ile Ser Val Ser
 20 25 30

Ala Pro Ile Val His Leu Gly Asp Pro Ile Thr Ala Ser Cys Ile Ile
 35 40 45

Lys Gln Asn Cys Ser His Leu Asp Pro Glu Pro Gln Ile Leu Trp Arg
 50 55 60

Leu Gly Ala Glu Leu Gln Pro Gly Gly Arg Gln Gln Arg Leu Ser Asp
 65 70 75 80

Gly Thr Gln Glu Ser Ile Ile Thr Leu Pro His Leu Asn His Thr Gln
 85 90 95

Ala Phe Leu Ser Cys Cys Leu Asn Trp Gly Asn Ser Leu Gln Ile Leu
 100 105 110

Asp Gln Val Glu Leu Arg Ala Gly Tyr Pro Pro Ala Ile Pro His Asn
 115 120 125

Leu Ser Cys Leu Met Asn Leu Thr Thr Ser Ser Leu Ile Cys Gln Trp
 130 135 140

Glu Pro Gly Pro Glu Thr His Leu Pro Thr Ser Phe Thr Leu Lys Ser
 145 150 155 160

Phe Lys Ser Arg Gly Asn Cys Gln Thr Gln Gly Asp Ser Ile Leu Asp.
 165 170 175

Cys Val Pro Lys Asp Gly Gln Ser His Cys Cys Ile Pro Arg Lys His
 180 185 190

Leu Leu Leu Tyr Gln Asn Met Gly Ile Trp Val Gln Ala Glu Asn Ala
 195 200 205

Leu Gly Thr Ser Met Ser Pro Gln Leu Cys Leu Asp Pro Met Asp Val
 210 215 220

Val Lys Leu Glu Pro Pro Met Leu Arg Thr Met Asp Pro Ser Pro Glu
 225 230 235 240

Ala Ala Pro Pro Gln Ala Gly Cys Leu Gln Leu Cys Trp Glu Pro Trp
 245 250 255

Gln Pro Gly Leu His Ile Asn Gln Lys Cys Glu Leu Arg His Lys Pro
 260 265 270

Gln Arg Gly Glu Ala Ser Trp Ala Leu Val Gly Pro Leu Pro Leu Glu
 275 280 285

Ala Leu Gln Tyr Glu Leu Cys Gly Leu Leu Pro Ala Thr Ala Tyr Thr
 290 295 300
 Leu Gln Ile Arg Cys Ile Arg Trp Pro Leu Pro Gly His Trp Ser Asp
 305 310 315 320
 Gly Ala Ile Leu Pro Leu Cys Asn Thr Thr Glu Leu Ser Cys Thr Phe
 325 330 335
 His Leu Pro Ser Glu Ala Gln Glu Val Ala Leu Val Ala Tyr Asn Ser
 340 345 350
 Ala Gly Thr Ser Arg Pro Thr Pro Val Val Phe Ser Glu Ser Arg Gly
 355 360 365
 Pro Ala Leu Thr Arg Leu His Ala Met Ala Arg Asp Pro His Ser Leu
 370 375 380
 Trp Val Gly Trp Glu Pro Pro Asn Pro Trp Pro Gln Gly Tyr Val Ile
 385 390 395 400
 Glu Trp Gly Leu Gly Pro Pro Ser Ala Ser Asn Ser Asn Lys Thr Trp
 405 410 415
 Arg Met Glu Gln Asn Gly Arg Ala Thr Gly Phe Leu Leu Lys Glu Asn
 420 425 430
 Ile Arg Pro Phe Gln Leu Tyr Glu Ile Ile Val Thr Pro Leu Tyr Gln
 435 440 445
 Asp Thr Met Gly Pro Ser Gln His Val Tyr Ala Tyr Ser Gln Glu Met
 450 455 460
 Ala Pro Ser His Ala Pro Glu Leu His Leu Lys His Ile Gly Lys Thr
 465 470 475 480
 Trp Ala Gln Leu Glu Trp Val Pro Glu Pro Pro Glu Leu Gly Lys Ser
 485 490 495
 Pro Leu Thr His Tyr Thr Ile Phe Trp Thr Asn Ala Gln Asn Gln Ser
 500 505 510
 Phe Ser Ala Ile Leu Asn Ala Ser Ser Arg Gly Phe Val Leu His Gly
 515 520 525
 Leu Glu Pro Ala Ser Leu Tyr His Ile His Leu Met Ala Ala Ser Gln
 530 535 540
 Ala Gly Ala Thr Asn Ser Thr Val Leu Thr Leu Met Thr Leu Thr Pro
 545 550 555 560
 Glu Gly Ser Glu Leu His Ile Ile Leu Gly Leu Phe Gly Leu Leu Leu
 565 570 575
 Leu Leu Thr Cys Leu Cys Gly Thr Ala Trp Leu Cys Cys Ser Pro Asn
 580 585 590
 Arg Lys Asn Pro Leu Trp Pro Ser Val Pro Asp Pro Ala His Ser Ser
 595 600 605
 Leu Gly Ser Trp Val Pro Thr Ile Met Glu Glu Asp Ala Phe Gln Leu

610 615 620
 Pro Gly Leu Gly Thr Pro Pro Ile Thr Lys Leu Thr Val Leu Glu Glu
 625 630 635 640
 Asp Glu Lys Lys Pro Val Pro Trp Glu Ser His Asn Ser Ser Glu Thr
 645 650 655
 Cys Gly Leu Pro Thr Leu Val Gln Thr Tyr Val Leu Gln Gly Asp Pro
 660 665 670
 Arg Ala Val Ser Thr Gln Pro Gln Ser Gln Ser Gly Thr Ser Asp Gln
 675 680 685
 Val Leu Tyr Gly Gln Leu Leu Gly Ser Pro Thr Ser Pro Gly Pro Gly
 690 695 700
 His Tyr Leu Arg Cys Asp Ser Thr Gln Pro Leu Leu Ala Gly Leu Thr
 705 710 715 720
 Pro Ser Pro Lys Ser Tyr Glu Asn Leu Trp Phe Gln Ala Ser Pro Leu
 725 730 735
 Gly Thr Leu Val Thr Pro Ala Pro Ser Gln Glu Asp Asp Cys Val Phe
 740 745 750
 Gly Pro Leu Leu Asn Phe Pro Leu Leu Gln Gly Ile Arg Val His Gly
 755 760 765
 Met Glu Ala Leu Gly Ser Phe
 770 775

 <210> 92
 <211> 873
 <212> PRT
 <213> Homo sapiens

 <400> 92
 Met Ala Arg Leu Gly Asn Cys Ser Leu Thr Trp Ala Ala Leu Ile Ile
 1 5 10 15
 Leu Leu Leu Pro Gly Ser Leu Glu Glu Cys Gly His Ile Ser Val Ser
 20 25 30
 Ala Pro Ile Val His Leu Gly Asp Pro Ile Thr Ala Ser Cys Ile Ile
 35 40 45
 Lys Gln Asn Cys Ser His Leu Asp Pro Glu Pro Gln Ile Leu Trp Arg
 50 55 60
 Leu Gly Ala Glu Leu Gln Pro Gly Gly Arg Gln Gln Arg Leu Ser Asp
 65 70 75 80
 Gly Thr Gln Glu Ser Ile Ile Thr Leu Pro His Leu Asn His Thr Gln
 85 90 95
 Ala Phe Leu Ser Cys Cys Leu Asn Trp Gly Asn Ser Leu Gln Ile Leu
 100 105 110
 Asp Gln Val Glu Leu Arg Ala Gly Tyr Pro Pro Ala Ile Pro His Asn

115		120		125
Leu Ser Cys Leu Met Asn	Leu Thr Thr Ser Ser	Leu Ile Cys Gln Trp		
130	135	140		
Glu Pro Gly Pro Glu Thr His	Leu Pro Thr Ser Phe Thr	Leu Lys Ser		
145	150	155		160
Phe Lys Ser Arg Gly Asn Cys	Gln Thr Gln Gly Asp Ser	Ile Leu Asp		
	165	170		175
Cys Val Pro Lys Asp Gly Gln Ser	His Cys Cys Ile Pro Arg	Lys His		
	180	185		190
Leu Leu Leu Tyr Gln Asn Met	Gly Ile Trp Val Gln Ala	Glu Asn Ala		
	195	200		205
Leu Gly Thr Ser Met Ser Pro	Gln Leu Cys Leu Asp Pro	Met Asp Val		
	210	215		220
Val Lys Leu Glu Pro Pro Met	Leu Arg Thr Met Asp Pro	Ser Pro Glu		
	225	230		235
Ala Ala Pro Pro Gln Ala Gly	Cys Leu Gln Leu Cys Trp	Glu Pro Trp		
	245	250		255
Gln Pro Gly Leu His Ile Asn	Gln Lys Cys Glu Leu Arg	His Lys Pro		
	260	265		270
Gln Arg Gly Glu Ala Ser Trp	Ala Leu Val Gly Pro Leu	Pro Leu Glu		
	275	280		285
Ala Leu Gln Tyr Glu Leu Cys	Gly Leu Leu Pro Ala Thr	Ala Tyr Thr		
	290	295		300
Leu Gln Ile Arg Cys Ile Arg	Trp Pro Leu Pro Gly His	Trp Ser Asp		
	305	310		315
Trp Ser Pro Ser Leu Glu Leu	Arg Thr Thr Glu Arg Ala	Pro Thr Val		
	325	330		335
Arg Leu Asp Thr Trp Trp Arg	Gln Arg Gln Leu Asp Pro	Arg Thr Val		
	340	345		350
Gln Leu Phe Trp Lys Pro Val	Pro Leu Glu Glu Asp Ser	Gly Arg Ile		
	355	360		365
Gln Gly Tyr Val Val Ser Trp	Arg Pro Ser Gly Gln Ala	Gly Ala Ile		
	370	375		380
Leu Pro Leu Cys Asn Thr Thr	Glu Leu Ser Cys Thr Phe	His Leu Pro		
	385	390		395
Ser Glu Ala Gln Glu Val Ala	Leu Val Ala Tyr Asn Ser	Ala Gly Thr		
	405	410		415
Ser Arg Pro Thr Pro Val Val	Phe Ser Glu Ser Arg Gly	Pro Ala Leu		
	420	425		430
Thr Arg Leu His Ala Met Ala	Arg Asp Pro His Ser Leu	Trp Val Gly		
	435	440		445

Trp Glu Pro Pro Asn Pro Trp Pro Gln Gly Tyr Val Ile Glu Trp Gly
 450 455 460

Leu Gly Pro Pro Ser Ala Ser Asn Ser Asn Lys Thr Trp Arg Met Glu
 465 470 475 480

Gln Asn Gly Arg Ala Thr Gly Phe Leu Leu Lys Glu Asn Ile Arg Pro
 485 490 495

Phe Gln Leu Tyr Glu Ile Ile Val Thr Pro Leu Tyr Gln Asp Thr Met
 500 505 510

Gly Pro Ser Gln His Val Tyr Ala Tyr Ser Gln Glu Met Ala Pro Ser
 515 520 525

His Ala Pro Glu Leu His Leu Lys His Ile Gly Lys Thr Trp Ala Gln
 530 535 540

Leu Glu Trp Val Pro Glu Pro Pro Glu Leu Gly Lys Ser Pro Leu Thr
 545 550 555 560

His Tyr Thr Ile Phe Trp Thr Asn Ala Gln Asn Gln Ser Phe Cys Glu
 565 570 575

Ser Xaa Leu Ser Ser Pro Thr Ala Pro Glu Gly Leu Glu Gly Gly Ala
 580 585 590

Gln Leu Pro Arg Arg Xaa Phe Thr Ile Gln Ala Tyr Ala Asp Arg Thr
 595 600 605

Pro Leu Pro Ala Ala Ile Leu Asn Ala Ser Ser Arg Gly Phe Val Leu
 610 615 620

His Gly Leu Glu Pro Ala Ser Leu Tyr His Ile His Leu Met Ala Ala
 625 630 635 640

Ser Gln Ala Gly Ala Thr Asn Ser Thr Val Leu Thr Leu Met Thr Leu
 645 650 655

Thr Pro Glu Gly Ser Glu Leu His Ile Ile Leu Gly Leu Phe Gly Leu
 660 665 670

Leu Leu Leu Leu Thr Cys Leu Cys Gly Thr Ala Trp Leu Cys Cys Ser
 675 680 685

Pro Asn Arg Lys Asn Pro Leu Trp Pro Ser Val Pro Asp Pro Ala His
 690 695 700

Ser Ser Leu Gly Ser Trp Val Pro Thr Ile Met Glu Glu Asp Ala Phe
 705 710 715 720

Gln Leu Pro Gly Leu Gly Thr Pro Pro Ile Thr Lys Leu Thr Val Leu
 725 730 735

Glu Glu Asp Glu Lys Lys Pro Val Pro Trp Glu Ser His Asn Ser Ser
 740 745 750

Glu Thr Cys Gly Leu Pro Thr Leu Val Gln Thr Tyr Val Leu Gln Gly
 755 760 765

Asp Pro Arg Ala Val Ser Thr Gln Pro Gln Ser Gln Ser Gly Thr Ser
770 775 780

Asp Gln Val Leu Tyr Gly Gln Leu Leu Gly Ser Pro Thr Ser Pro Gly
785 790 795 800

Pro Gly His Tyr Leu Arg Cys Asp Ser Thr Gln Pro Leu Leu Ala Gly
805 810 815

Leu Thr Pro Ser Pro Lys Ser Tyr Glu Asn Leu Trp Phe Gln Ala Ser
820 825 830

Pro Leu Gly Thr Leu Val Thr Pro Ala Pro Ser Gln Glu Asp Asp Cys
835 840 845

Val Phe Gly Pro Leu Leu Asn Phe Pro Leu Leu Gln Gly Ile Arg Val
850 855 860

His Gly Met Glu Ala Leu Gly Ser Phe
865 870

<210> 93

<211> 837

<212> PRT

<213> Homo sapiens

<400> 93

Met Gln Lys Ile Met His Ile Ser Val Leu Leu Ser Pro Val Leu Trp
1 5 10 15

Gly Leu Ile Phe Gly Val Ser Ser Asn Ser Ile Gln Ile Gly Gly Leu
20 25 30

Phe Pro Arg Gly Ala Asp Gln Glu Tyr Ser Ala Phe Arg Val Gly Met
35 40 45

Val Gln Phe Ser Thr Ser Glu Phe Arg Leu Thr Pro His Ile Asp Asn
50 55 60

Leu Glu Val Ala Asn Ser Phe Ala Val Thr Asn Ala Phe Cys Ser Gln
65 70 75 80

Phe Ser Arg Gly Val Tyr Ala Ile Phe Gly Phe Tyr Asp Lys Lys Ser
85 90 95

Val Asn Thr Ile Thr Ser Phe Cys Gly Thr Leu His Val Ser Phe Ile
100 105 110

Thr Pro Ser Phe Pro Thr Asp Gly Thr His Pro Phe Val Ile Gln Met
115 120 125

Arg Pro Asp Leu Lys Gly Ala Leu Leu Ser Leu Ile Glu Tyr Tyr Gln
130 135 140

Trp Asp Lys Phe Ala Tyr Leu Tyr Asp Ser Asp Arg Gly Leu Ser Thr
145 150 155 160

Leu Gln Ala Val Leu Asp Ser Ala Ala Glu Lys Lys Trp Gln Val Thr
165 170 175

Ala Ile Asn Val Gly Asn Ile Asn Asn Asp Lys Lys Asp Glu Met Tyr
 180 185 190
 Arg Ser Leu Phe Gln Asp Leu Glu Leu Lys Lys Glu Arg Arg Val Ile
 195 200 205
 Leu Asp Cys Glu Arg Asp Lys Val Asn Asp Ile Val Asp Gln Val Ile
 210 215 220
 Thr Ile Gly Lys His Val Lys Gly Tyr His Tyr Ile Ile Ala Asn Leu
 225 230 235 240
 Glu Phe Thr Asp Gly Asp Leu Leu Lys Ile Gln Phe Gly Gly Ala Asn
 245 250 255
 Val Ser Gly Phe Gln Ile Val Asp Tyr Asp Asp Ser Leu Val Ser Lys
 260 265 270
 Phe Ile Glu Arg Trp Ser Thr Leu Glu Glu Lys Glu Tyr Pro Gly Ala
 275 280 285
 His Thr Thr Thr Ile Lys Tyr Thr Ser Ala Leu Thr Tyr Asp Ala Val
 290 295 300
 Gln Val Met Thr Glu Ala Phe Arg Asn Leu Arg Lys Gln Arg Ile Glu
 305 310 315 320
 Ile Ser Arg Arg Gly Asn Ala Gly Asp Cys Leu Ala Asn Pro Ala Val
 325 330 335
 Pro Trp Gly Gln Gly Val Glu Ile Glu Arg Ala Leu Lys Gln Val Gln
 340 345 350
 Val Glu Gly Leu Ser Gly Asn Ile Lys Phe Asp Gln Asn Gly Lys Arg
 355 360 365
 Ile Asn Tyr Thr Ile Asn Ile Met Glu Leu Lys Thr Asn Gly Pro Arg
 370 375 380
 Lys Ile Gly Tyr Trp Ser Glu Val Asp Lys Met Val Val Thr Leu Thr
 385 390 395 400
 Glu Leu Pro Ser Gly Asn Asp Thr Ser Gly Leu Glu Asn Lys Thr Val
 405 410 415
 Val Val Thr Thr Ile Leu Glu Ser Pro Tyr Val Met Met Lys Lys Asn
 420 425 430
 His Glu Met Leu Glu Gly Asn Glu Arg Tyr Glu Gly Tyr Cys Val Asp
 435 440 445
 Leu Ala Ala Glu Ile Ala Lys His Cys Gly Phe Lys Tyr Lys Leu Thr
 450 455 460
 Ile Val Gly Asp Gly Lys Tyr Gly Ala Arg Asp Ala Asp Thr Lys Ile
 465 470 475 480
 Trp Asn Gly Met Val Gly Glu Leu Val Tyr Gly Lys Ala Asp Ile Ala
 485 490 495
 Ile Ala Pro Leu Thr Ile Thr Leu Val Arg Glu Glu Val Ile Asp Phe

500	505	510
Ser Lys Pro Phe Met Ser Leu Gly Ile Ser Ile Met Ile Lys Lys Pro 515	520	525
Gln Lys Ser Lys Pro Gly Val Phe Ser Phe Leu Asp Pro Leu Ala Tyr 530	535	540
Glu Ile Trp Met Cys Ile Val Phe Ala Tyr Ile Gly Val Ser Val Val 545	550	555 560
Leu Phe Leu Val Ser Arg Phe Ser Pro Tyr Glu Trp His Thr Glu Glu 565	570	575
Phe Glu Asp Gly Arg Glu Thr Gln Ser Ser Glu Ser Thr Asn Glu Phe 580	585	590
Gly Ile Phe Asn Ser Leu Trp Phe Ser Leu Gly Ala Phe Met Arg Gln 595	600	605
Gly Cys Asp Ile Ser Pro Arg Ser Leu Ser Gly Arg Ile Val Gly Gly 610	615	620
Val Trp Trp Phe Phe Thr Leu Ile Ile Ile Ser Ser Tyr Thr Ala Asn 625	630	635 640
Leu Ala Ala Phe Leu Thr Val Glu Arg Met Val Ser Pro Ile Glu Ser 645	650	655
Ala Glu Asp Leu Ser Lys Gln Thr Glu Ile Ala Tyr Gly Thr Leu Asp 660	665	670
Ser Gly Ser Thr Lys Glu Phe Phe Arg Arg Ser Lys Ile Ala Val Phe 675	680	685
Asp Lys Met Trp Thr Tyr Met Arg Ser Ala Glu Pro Ser Val Phe Val 690	695	700
Arg Thr Thr Ala Glu Gly Val Ala Arg Val Arg Lys Ser Lys Gly Lys 705	710	715 720
Tyr Ala Tyr Leu Leu Glu Ser Thr Met Asn Glu Tyr Ile Glu Gln Arg 725	730	735
Lys Pro Cys Asp Thr Met Lys Val Gly Gly Asn Leu Asp Ser Lys Gly 740	745	750
Tyr Gly Ile Ala Thr Pro Lys Gly Ser Ser Leu Gly Thr Pro Val Asn 755	760	765
Leu Ala Val Leu Lys Leu Ser Glu Gln Gly Val Leu Asp Lys Leu Lys 770	775	780
Asn Lys Trp Trp Tyr Asp Lys Gly Glu Xaa Gly Xaa Gly Glu Val Ile 785	790	795 800
Pro Arg Ser Ala Pro Val Arg Lys Val Met Gly Asn Ser Met Gln Asn 805	810	815
Lys Val Ser Ser Ser Tyr Ala Gln Cys Gly His Ser Val His Pro Ser 820	825	830

Phe Gln Arg Leu Ser
835

<210> 94
<211> 156
<212> PRT
<213> Homo sapiens

<400> 94
Met Lys Ser Ile Tyr Phe Val Ala Gly Leu Phe Val Met Leu Val Gln
1 5 10 15
Gly Ser Trp Gln Arg Ser Leu Gln Asp Thr Glu Glu Lys Ser Arg Ser
20 25 30
Phe Ser Ala Ser Gln Ala Asp Pro Leu Ser Asp Pro Asp Gln Met Asn
35 40 45
Glu Asp Lys Arg His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys
50 55 60
Tyr Leu Asp Ser Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn
65 70 75 80
Thr Lys Arg Asn Arg Asn Asn Ile Ala Lys Arg His Asp Glu Phe Glu
85 90 95
Arg His Ala Glu Gly Thr Phe Thr Ser Val Ile Phe Pro Glu Glu Val
100 105 110
Ala Ile Val Glu Glu Leu Gly Arg Arg His Ala Asp Gly Ser Phe Ser
115 120 125
Asp Glu Met Asn Thr Ile Ser Asp Asn Leu Ala Ala Arg Asp Phe Ile
130 135 140
Asn Trp Leu Ile Gln Thr Lys Ile Thr Asp Arg Lys
145 150 155

<210> 95
<211> 303
<212> PRT
<213> Homo sapiens

<400> 95
Met Leu Ser Phe Ile Ser Gly Thr Ala Arg Lys Thr Leu His Phe Glu
1 5 10 15
Ile Ser Lys Glu Gly Ser Asp Leu Ser Val Val Glu Arg Ala Glu Val
20 25 30
Trp Leu Phe Leu Lys Val Pro Lys Ala Asn Arg Thr Arg Thr Lys Val
35 40 45
Thr Ile Arg Leu Phe Gln Gln Gln Lys His Pro Gln Gly Ser Leu Asp
50 55 60
Thr Gly Glu Glu Ala Glu Glu Val Gly Leu Lys Gly Glu Arg Ser Glu

65 70 75 80

Leu Leu Leu Ser Glu Lys Val Val Asp Ala Arg Lys Ser Thr Trp His
85 90 95

Val Phe Pro Val Ser Ser Ser Ile Gln Arg Leu Leu Asp Gln Gly Lys
100 105 110

Ser Ser Leu Asp Val Arg Ile Ala Cys Glu Gln Cys Gln Glu Ser Gly
115 120 125

Ala Ser Leu Val Leu Leu Gly Lys Lys Lys Lys Lys Glu Glu Glu Gly
130 135 140

Glu Gly Lys Lys Lys Gly Gly Gly Glu Gly Gly Ala Gly Ala Asp Glu
145 150 155 160

Glu Lys Glu Gln Ser His Arg Pro Phe Leu Met Leu Gln Ala Arg Gln
165 170 175

Ser Glu Asp His Pro His Arg Arg Arg Arg Arg Gly Leu Glu Cys Asp
180 185 190

Gly Lys Val Asn Ile Cys Cys Lys Lys Gln Phe Phe Val Ser Phe Lys
195 200 205

Asp Ile Gly Trp Asn Asp Trp Ile Ile Ala Pro Ser Gly Tyr His Ala
210 215 220

Asn Tyr Cys Glu Gly Glu Cys Pro Ser His Ile Ala Gly Thr Ser Gly
225 230 235 240

Ser Ser Leu Ser Phe His Ser Thr Val Ile Asn His Tyr Arg Met Arg
245 250 255

Gly His Ser Pro Phe Ala Asn Leu Lys Ser Cys Cys Val Pro Thr Lys
260 265 270

Leu Arg Pro Met Ser Met Leu Tyr Tyr Asp Asp Gly Gln Asn Ile Ile
275 280 285

Lys Lys Asp Ile Gln Asn Met Ile Val Glu Glu Cys Gly Cys Ser
290 295 300

<210> 96
<211> 194
<212> PRT
<213> Homo sapiens

<400> 96
Met Asn Ser Phe Ser Thr Ser Ala Phe Gly Pro Val Ala Phe Ser Leu
1 5 10 15
Gly Leu Leu Leu Val Leu Pro Ala Ala Phe Pro Ala Pro Val Pro Pro
20 25 30
Gly Glu Asp Ser Lys Asp Val Ala Ala Pro His Arg Gln Pro Leu Thr
35 40 45
Ser Ser Glu Arg Ile Asp Lys Gln Ile Arg Tyr Ile Leu Asp Gly Ile

50

55

60

Ser Ala Leu Arg Lys Glu Thr Cys Asn Xaa Ser Asn Met Cys Glu Lys
65 70 75 80

Asp Gly Cys Phe Gln Ser Gly Phe Asn Glu Glu Thr Cys Leu Val Lys
85 90 95

Ile Ile Thr Gly Leu Leu Glu Phe Glu Val Tyr Leu Glu Tyr Leu Gln
100 105 110

Asn Arg Phe Glu Ser Ser Glu Glu Gln Ala Arg Ala Val Gln Met Ser
115 120 125

Thr Lys Val Leu Ile Gln Phe Leu Gln Lys Lys Ala Lys Asn Leu Asp
130 135 140

Ala Ile Thr Thr Pro Asp Pro Thr Thr Asn Ala Ser Leu Leu Thr Lys
145 150 155 160

Leu Gln Ala Gln Asn Gln Trp Leu Gln Asp Met Thr Thr His Leu Ile
165 170 175

Leu Arg Ser Phe Lys Glu Phe Leu Gln Ser Ser Leu Arg Ala Leu Arg
180 185 190

Gln Met

<210> 97

<211> 148

<212> PRT

<213> Homo sapiens

<400> 97

Met Asn Ser Phe Ser Thr Thr Cys Asn Lys Ser Asn Met Cys Glu Ser
1 5 10 15

Ser Lys Glu Ala Leu Ala Glu Asn Asn Leu Asn Leu Pro Lys Met Ala
20 25 30

Glu Lys Asp Gly Cys Phe Gln Ser Gly Phe Asn Glu Glu Thr Cys Leu
35 40 45

Val Lys Ile Ile Thr Gly Leu Leu Glu Phe Glu Val Tyr Leu Glu Tyr
50 55 60

Leu Gln Asn Arg Phe Glu Ser Ser Glu Glu Gln Ala Arg Ala Val Gln
65 70 75 80

Met Ser Thr Lys Val Leu Ile Gln Phe Leu Gln Lys Lys Ala Lys Asn
85 90 95

Leu Asp Ala Ile Thr Thr Pro Asp Pro Thr Thr Asn Ala Ser Leu Leu
100 105 110

Thr Lys Leu Gln Ala Gln Asn Gln Trp Leu Gln Asp Met Thr Thr His
115 120 125

Leu Ile Leu Arg Ser Phe Lys Glu Phe Leu Gln Ser Ser Leu Arg Ala

130

135

140

Leu Arg Gln Met
145

<210> 98
<211> 220
<212> PRT
<213> Homo sapiens

<400> 98
Met Pro Arg Leu Phe Leu Phe His Leu Leu Glu Phe Cys Leu Leu Leu
1 5 10 15
Asn Gln Phe Ser Arg Ala Val Ala Ala Lys Trp Lys Asp Asp Val Ile
20 25 30
Lys Leu Cys Gly Arg Glu Leu Val Arg Ala Gln Ile Ala Ile Cys Gly
35 40 45
Met Ser Thr Trp Ser Lys Arg Ser Leu Ser Gln Glu Asp Ala Pro Gln
50 55 60
Thr Pro Arg Pro Val Ala Ala Gly Asp Phe Ile Gln Thr Val Ser Leu
65 70 75 80
Gly Ile Ser Pro Asp Gly Gly Lys Ala Leu Arg Thr Gly Ser Cys Phe
85 90 95
Thr Arg Glu Phe Leu Gly Ala Leu Ser Lys Leu Val Pro Ser Phe Ile
100 105 110
Asn Lys Asp Thr Glu Thr Ile Ile Ile Met Leu Glu Phe Ile Ala Asn
115 120 125
Leu Pro Pro Glu Leu Lys Ala Ala Leu Ser Glu Arg Gln Pro Ser Leu
130 135 140
Pro Glu Leu Gln Gln Tyr Val Pro Xaa Leu Lys Asp Ser Ser Leu Leu
145 150 155 160
Phe Glu Glu Phe Lys Lys Leu Ile Arg Asn Arg Gln Ser Glu Ala Ala
165 170 175
Asp Ser Asn Pro Ser Glu Leu Lys Tyr Leu Gly Leu Asp Thr His Ser
180 185 190
Gln Lys Lys Arg Arg Pro Tyr Val Ala Leu Phe Glu Lys Cys Cys Leu
195 200 205
Ile Gly Cys Thr Lys Arg Ser Leu Ala Lys Tyr Cys
210 215 220

<210> 99
<211> 87
<212> PRT
<213> Homo sapiens

<400> 99

Met Lys Leu Cys Val Thr Val Leu Ser Leu Leu Met Leu Val Ala Ala
 1 5 10 15
 Phe Cys Ser Pro Ala Leu Ser Ala Pro Met Gly Ser Asp Pro Pro Thr
 20 25 30
 Ala Cys Cys Phe Ser Tyr Thr Ala Arg Lys Leu Pro Arg Asn Phe Val
 35 40 45
 Val Asp Tyr Tyr Glu Thr Ser Ser Leu Cys Ser Gln Pro Ala Val Val
 50 55 60
 Gly Lys Gln Val Cys Ala Asp Pro Ser Glu Ser Trp Val Gln Glu Tyr
 65 70 75 80
 Val Tyr Asp Leu Glu Leu Asn
 85

<210> 100
 <211> 731
 <212> PRT
 <213> Homo sapiens

<400> 100

Met Gly Leu Ala Trp Gly Leu Gly Val Leu Phe Leu Met His Val Cys
 1 5 10 15
 Gly Thr Asn Arg Ile Pro Glu Ser Gly Gly Asp Asn Ser Val Phe Asp
 20 25 30
 Ile Phe Glu Leu Thr Gly Ala Ala Arg Lys Gly Ser Gly Arg Arg Leu
 35 40 45
 Val Lys Gly Pro Asp Pro Ser Ser Pro Ala Phe Arg Ile Glu Asp Ala
 50 55 60
 Asn Leu Ile Pro Pro Val Pro Asp Asp Lys Phe Gln Asp Leu Val Asp
 65 70 75 80
 Ala Val Arg Ala Glu Lys Gly Phe Leu Leu Leu Ala Ser Leu Arg Gln
 85 90 95
 Met Lys Lys Thr Arg Gly Thr Leu Leu Ala Leu Glu Arg Lys Asp His
 100 105 110
 Ser Gly Gln Val Phe Ser Val Val Ser Asn Gly Lys Ala Gly Thr Leu
 115 120 125
 Asp Leu Ser Leu Thr Val Gln Gly Lys Gln His Val Val Ser Val Glu
 130 135 140
 Glu Ala Leu Leu Ala Thr Gly Gln Trp Lys Ser Ile Thr Leu Phe Val
 145 150 155 160
 Gln Glu Asp Arg Ala Gln Leu Tyr Ile Asp Cys Glu Lys Met Glu Asn
 165 170 175
 Ala Glu Leu Asp Val Pro Ile Gln Ser Val Phe Thr Arg Asp Leu Ala
 180 185 190

Ser Ile Ala Arg Leu Arg Ile Ala Lys Gly Gly Val Asn Asp Asn Phe
 195 200 205
 Gln Gly Val Leu Gln Asn Val Arg Phe Val Phe Gly Thr Thr Pro Glu
 210 215 220
 Asp Ile Leu Arg Asn Lys Gly Cys Ser Ser Ser Thr Ser Val Leu Leu
 225 230 235 240
 Thr Leu Asp Asn Asn Val Val Asn Gly Ser Ser Pro Ala Ile Arg Thr
 245 250 255
 Asn Tyr Ile Gly His Lys Thr Lys Asp Leu Gln Ala Ile Cys Gly Ile
 260 265 270
 Ser Cys Asp Glu Leu Ser Ser Met Val Leu Glu Leu Arg Gly Leu Arg
 275 280 285
 Thr Ile Val Thr Thr Leu Gln Asp Ser Ile Arg Lys Val Thr Glu Glu
 290 295 300
 Asn Lys Glu Leu Ala Asn Glu Leu Arg Arg Pro Pro Leu Cys Tyr His
 305 310 315 320
 Asn Gly Val Gln Tyr Arg Asn Asn Glu Glu Trp Thr Val Asp Ser Cys
 325 330 335
 Thr Glu Cys His Cys Gln Asn Ser Val Thr Ile Cys Lys Lys Val Ser
 340 345 350
 Cys Pro Ile Met Pro Cys Ser Asn Ala Thr Val Pro Asp Gly Glu Cys
 355 360 365
 Cys Pro Arg Cys Trp Pro Ser Asp Ser Ala Asp Asp Gly Trp Ser Pro
 370 375 380
 Trp Ser Glu Trp Thr Ser Cys Ser Thr Ser Cys Gly Asn Gly Ile Gln
 385 390 395 400
 Gln Arg Gly Arg Ser Cys Asp Ser Leu Asn Asn Arg Cys Glu Gly Ser
 405 410 415
 Ser Val Gln Thr Arg Thr Cys His Ile Gln Glu Cys Asp Lys Arg Phe
 420 425 430
 Lys Gln Asp Gly Gly Trp Ser His Trp Ser Pro Trp Ser Ser Cys Ser
 435 440 445
 Val Thr Cys Gly Asp Gly Val Ile Thr Arg Ile Arg Leu Cys Asn Ser
 450 455 460
 Pro Ser Pro Gln Met Asn Gly Lys Pro Cys Glu Gly Glu Ala Arg Glu
 465 470 475 480
 Thr Lys Ala Cys Lys Lys Asp Ala Cys Pro Ile Asn Gly Gly Trp Gly
 485 490 495
 Pro Trp Ser Pro Trp Asp Ile Cys Ser Val Thr Cys Gly Gly Gly Val
 500 505 510
 Gln Lys Arg Ser Arg Leu Cys Asn Asn Pro Thr Pro Gln Phe Gly Gly

515 520 525
 Lys Asp Cys Val Gly Asp Val Thr Glu Asn Gln Ile Cys Asn Lys Gln
 530 535 540
 Asp Cys Pro Ile Asp Gly Cys Leu Ser Asn Pro Cys Phe Ala Gly Val
 545 550 555 560
 Lys Cys Thr Ser Tyr Pro Asp Gly Ser Trp Lys Cys Gly Ala Cys Pro
 565 570 575
 Pro Gly Tyr Ser Gly Asn Gly Ile Gln Cys Thr Asp Val Asp Glu Cys
 580 585 590
 Lys Glu Val Pro Asp Ala Cys Phe Asn His Asn Gly Glu His Arg Cys
 595 600 605
 Glu Asn Thr Asp Pro Gly Tyr Asn Cys Leu Pro Cys Pro Pro Arg Phe
 610 615 620
 Thr Gly Ser Gln Pro Phe Gly Gln Gly Val Glu His Ala Thr Ala Asn
 625 630 635 640
 Lys Gln Val Cys Lys Pro Arg Asn Pro Cys Thr Asp Gly Thr His Asp
 645 650 655
 Cys Asn Lys Asn Ala Lys Cys Asn Tyr Leu Gly His Tyr Ser Asp Pro
 660 665 670
 Met Tyr Arg Cys Glu Cys Lys Pro Gly Tyr Ala Gly Asn Gly Ile Ile
 675 680 685
 Cys Gly Glu Asp Thr Asp Leu Asp Gly Trp Pro Asn Glu Asn Leu Val
 690 695 700
 Cys Val Ala Asn Ala Thr Tyr His Cys Lys Lys Asp Asn Cys Pro Asn
 705 710 715 720
 Leu Pro Gln Asp Pro Ala Pro Cys Pro Arg Ser
 725 730

<210> 101
 <211> 555
 <212> PRT
 <213> Homo sapiens

<400> 101
 Met Gly Leu Ala Trp Gly Leu Gly Val Leu Phe Leu Met His Val Cys
 1 5 10 15
 Gly Thr Asn Arg Ile Pro Glu Ser Gly Gly Asp Asn Ser Val Phe Asp
 20 25 30
 Ile Phe Glu Leu Thr Gly Ala Ala Arg Lys Gly Ser Gly Arg Arg Leu
 35 40 45
 Val Lys Gly Pro Asp Pro Ser Ser Pro Ala Phe Arg Ile Glu Asp Ala
 50 55 60
 Asn Leu Ile Pro Pro Val Pro Asp Asp Lys Phe Gln Asp Leu Val Asp

65		70		75		80
Ala Val Arg Ala Glu Lys Gly Phe Leu Leu Ala Ser Leu Arg Gln						
	85			90		95
Met Lys Lys Thr Arg Gly Thr Leu Leu Ala Leu Glu Arg Lys Asp His						
	100			105		110
Ser Gly Gln Val Phe Ser Val Val Ser Asn Gly Lys Ala Gly Thr Leu						
	115			120		125
Asp Leu Ser Leu Thr Val Gln Gly Lys Gln His Val Val Ser Val Glu						
	130			135		140
Glu Ala Leu Leu Ala Thr Gly Gln Trp Lys Ser Ile Thr Leu Phe Val						
	145			150		155
Gln Glu Asp Arg Ala Gln Leu Tyr Ile Asp Cys Glu Lys Met Glu Asn						
				165		170
Ala Glu Leu Asp Val Pro Ile Gln Ser Val Phe Thr Arg Asp Leu Ala						
				180		185
Ser Ile Ala Arg Leu Arg Ile Ala Lys Gly Gly Val Asn Asp Asn Phe						
				195		200
Gln Gly Val Leu Gln Asn Val Arg Phe Val Phe Gly Thr Thr Pro Glu						
				210		215
Asp Ile Leu Arg Asn Lys Gly Cys Ser Ser Ser Thr Ser Val Leu Leu						
				225		230
Thr Leu Asp Asn Asn Val Val Asn Gly Ser Ser Pro Ala Ile Arg Thr						
				245		250
Asn Tyr Ile Gly His Lys Thr Lys Asp Leu Gln Ala Ile Cys Gly Ile						
				260		265
Ser Cys Asp Glu Leu Ser Ser Met Val Leu Glu Leu Arg Gly Leu Arg						
				275		280
Thr Ile Val Thr Thr Leu Gln Asp Ser Ile Arg Lys Val Thr Glu Glu						
				290		295
Asn Lys Glu Leu Ala Asn Glu Leu Arg Arg Pro Pro Leu Cys Tyr His						
				305		310
Asn Gly Val Gln Tyr Arg Asn Asn Glu Glu Trp Thr Val Asp Ser Cys						
				325		330
Thr Glu Cys His Cys Gln Asn Ser Val Thr Ile Cys Lys Lys Val Ser						
				340		345
Cys Pro Ile Met Pro Cys Ser Asn Ala Thr Val Pro Asp Gly Glu Cys						
				355		360
Cys Pro Arg Cys Trp Pro Ser Asp Ser Ala Asp Asp Gly Trp Ser Pro						
				370		375
Trp Ser Glu Trp Thr Ser Cys Ser Thr Ser Cys Gly Asn Gly Ile Gln						
				385		390
						395
						400

Gln Arg Gly Arg Ser Cys Asp Ser Leu Asn Asn Arg Cys Glu Gly Ser
 405 410 415
 Ser Val Gln Thr Arg Thr Cys His Ile Gln Glu Cys Asp Lys Arg Phe
 420 425 430
 Lys Gln Asp Gly Gly Trp Ser His Trp Ser Pro Trp Ser Ser Cys Ser
 435 440 445
 Val Thr Cys Gly Asp Gly Val Ile Thr Arg Ile Arg Leu Cys Asn Ser
 450 455 460
 Pro Ser Pro Gln Met Asn Gly Lys Pro Cys Glu Gly Glu Ala Arg Glu
 465 470 475 480
 Thr Lys Ala Cys Lys Lys Asp Ala Cys Pro Ile Asn Gly Gly Trp Gly
 485 490 495
 Pro Trp Ser Pro Trp Asp Ile Cys Ser Val Thr Cys Gly Gly Gly Val
 500 505 510
 Gln Lys Arg Ser Arg Leu Cys Asn Asn Pro Thr Pro Gln Phe Gly Gly
 515 520 525
 Lys Asp Cys Val Gly Asp Val Thr Glu Asn Gln Ile Cys Asn Lys Gln
 530 535 540
 Asp Cys Pro Ile Gly Glu Pro Arg Ser Pro Gly
 545 550 555

<210> 102

<211> 546

<212> PRT

<213> Homo sapiens

<400> 102

Met Gly Leu Ala Trp Gly Leu Gly Val Leu Phe Leu Met His Val Cys
 1 5 10 15
 Gly Thr Asn Arg Ile Pro Glu Ser Gly Gly Asp Asn Ser Val Phe Asp
 20 25 30
 Ile Phe Glu Leu Thr Gly Ala Ala Arg Lys Gly Ser Gly Arg Arg Leu
 35 40 45
 Val Lys Gly Pro Asp Pro Ser Ser Pro Ala Phe Arg Ile Glu Asp Ala
 50 55 60
 Asn Leu Ile Pro Pro Val Pro Asp Asp Lys Phe Gln Asp Leu Val Asp
 65 70 75 80
 Ala Val Arg Ala Glu Lys Gly Phe Leu Leu Leu Ala Ser Leu Arg Gln
 85 90 95
 Met Lys Lys Thr Arg Gly Thr Leu Leu Ala Leu Glu Arg Lys Asp His
 100 105 110
 Ser Gly Gln Val Phe Ser Val Val Ser Asn Gly Lys Ala Gly Thr Leu
 115 120 125

Asp Leu Ser Leu Thr Val Gln Gly Lys Gln His Val Val Ser Val Glu
 130 135 140
 Glu Ala Leu Leu Ala Thr Gly Gln Trp Lys Ser Ile Thr Leu Phe Val
 145 150 155 160
 Gln Glu Asp Arg Ala Gln Leu Tyr Ile Asp Cys Glu Lys Met Glu Asn
 165 170 175
 Ala Glu Leu Asp Val Pro Ile Gln Ser Val Phe Thr Arg Asp Leu Ala
 180 185 190
 Ser Ile Ala Arg Leu Arg Ile Ala Lys Gly Gly Val Asn Asp Asn Phe
 195 200 205
 Gln Gly Val Leu Gln Asn Val Arg Phe Val Phe Gly Thr Thr Pro Glu
 210 215 220
 Asp Ile Leu Arg Asn Lys Gly Cys Ser Ser Ser Thr Ser Val Leu Leu
 225 230 235 240
 Thr Leu Asp Asn Asn Val Val Asn Gly Ser Ser Pro Ala Ile Arg Thr
 245 250 255
 Asn Tyr Ile Gly His Lys Thr Lys Asp Leu Gln Ala Ile Cys Gly Ile
 260 265 270
 Ser Cys Asp Glu Leu Ser Ser Met Val Leu Glu Leu Arg Gly Leu Arg
 275 280 285
 Thr Ile Val Thr Thr Leu Gln Asp Ser Ile Arg Lys Val Thr Glu Glu
 290 295 300
 Asn Lys Glu Leu Ala Asn Glu Leu Arg Arg Pro Pro Leu Cys Tyr His
 305 310 315 320
 Asn Gly Val Gln Tyr Arg Asn Asn Glu Glu Trp Thr Val Asp Ser Cys
 325 330 335
 Thr Glu Cys His Cys Gln Asn Ser Val Thr Ile Cys Lys Lys Val Ser
 340 345 350
 Cys Pro Ile Met Pro Cys Ser Asn Ala Thr Val Pro Asp Gly Glu Cys
 355 360 365
 Cys Pro Arg Cys Trp Pro Ser Asp Ser Ala Asp Asp Gly Trp Ser Pro
 370 375 380
 Trp Ser Glu Trp Thr Ser Cys Ser Thr Ser Cys Gly Asn Gly Ile Gln
 385 390 395 400
 Gln Arg Gly Arg Ser Cys Asp Ser Leu Asn Asn Arg Cys Glu Gly Ser
 405 410 415
 Ser Val Gln Thr Arg Thr Cys His Ile Gln Glu Cys Asp Lys Arg Phe
 420 425 430
 Lys Gln Asp Gly Gly Trp Ser His Trp Ser Pro Trp Ser Ser Cys Ser
 435 440 445

Val Thr Cys Gly Asp Gly Val Ile Thr Arg Ile Arg Leu Cys Asn Ser
 450 455 460

Pro Ser Pro Gln Met Asn Gly Lys Pro Cys Glu Gly Glu Ala Arg Glu
 465 470 475 480

Thr Lys Ala Cys Lys Lys Asp Ala Cys Pro Ser Lys Cys Glu Val Arg
 485 490 495

Cys Lys Gly Glu His Gly Gln Gln Leu Cys Pro Ala Gly Cys Leu Gly
 500 505 510

Ile Cys Ser Leu Gln Phe Gln Trp Gly His Arg Ser Arg Lys Val Thr
 515 520 525

Tyr Leu Gly Glu Thr Asn Arg Arg Gln Ser Pro Ala Gly Ser Ala Thr
 530 535 540

Ser Phe
 545

<210> 103
 <211> 459
 <212> PRT
 <213> Homo sapiens

<400> 103
 Met Gly Leu Ala Trp Gly Leu Gly Val Leu Phe Leu Met His Val Cys
 1 5 10 15

Gly Thr Asn Arg Ile Pro Glu Ser Gly Gly Asp Asn Ser Val Phe Asp
 20 25 30

Ile Phe Glu Leu Thr Gly Ala Ala Arg Lys Gly Ser Gly Arg Arg Leu
 35 40 45

Val Lys Gly Pro Asp Pro Ser Ser Pro Ala Phe Arg Ile Glu Asp Ala
 50 55 60

Asn Leu Ile Pro Pro Val Pro Asp Asp Lys Phe Gln Asp Leu Val Asp
 65 70 75 80

Ala Val Arg Ala Glu Lys Gly Phe Leu Leu Leu Ala Ser Leu Arg Gln
 85 90 95

Met Lys Lys Thr Arg Gly Thr Leu Leu Ala Leu Glu Arg Lys Asp His
 100 105 110

Ser Gly Gln Val Phe Ser Val Val Ser Asn Gly Lys Ala Gly Thr Leu
 115 120 125

Asp Leu Ser Leu Thr Val Gln Gly Lys Gln His Val Val Ser Val Glu
 130 135 140

Glu Ala Leu Leu Ala Thr Gly Gln Trp Lys Ser Ile Thr Leu Phe Val
 145 150 155 160

Gln Glu Asp Arg Ala Gln Leu Tyr Ile Asp Cys Glu Lys Met Glu Asn
 165 170 175

Ala Glu Leu Asp Val Pro Ile Gln Ser Val Phe Thr Arg Asp Leu Ala
180 185 190

Ser Ile Ala Arg Leu Arg Ile Ala Lys Gly Gly Val Asn Asp Asn Phe
195 200 205

Gln Gly Val Leu Gln Asn Val Arg Phe Val Phe Gly Thr Thr Pro Glu
210 215 220

Asp Ile Leu Arg Asn Lys Gly Cys Ser Ser Ser Thr Ser Val Leu Leu
225 230 235 240

Thr Leu Asp Asn Asn Val Val Asn Gly Ser Ser Pro Ala Ile Arg Thr
245 250 255

Asn Tyr Ile Gly His Lys Thr Lys Asp Leu Gln Ala Ile Cys Gly Ile
260 265 270

Ser Cys Asp Glu Leu Ser Ser Met Val Leu Glu Leu Arg Gly Leu Arg
275 280 285

Thr Ile Val Thr Thr Leu Gln Asp Ser Ile Arg Lys Val Thr Glu Glu
290 295 300

Asn Lys Glu Leu Ala Asn Glu Leu Arg Arg Pro Pro Leu Cys Tyr His
305 310 315 320

Asn Gly Val Gln Tyr Arg Asn Asn Glu Glu Trp Thr Val Asp Ser Cys
325 330 335

Thr Glu Cys His Cys Gln Asn Ser Val Thr Ile Cys Lys Lys Val Ser
340 345 350

Cys Pro Ile Met Pro Cys Ser Asn Ala Thr Val Pro Asp Gly Glu Cys
355 360 365

Cys Pro Arg Cys Trp Pro Ser Asp Ser Ala Asp Asp Gly Trp Ser Pro
370 375 380

Trp Ser Glu Trp Thr Ser Cys Ser Thr Ser Cys Gly Asn Gly Ile Gln
385 390 395 400

Gln Arg Gly Arg Ser Cys Asp Ser Leu Asn Asn Arg Cys Glu Gly Ser
405 410 415

Ser Val Gln Thr Arg Thr Cys His Ile Gln Glu Cys Asp Lys Arg Cys
420 425 430

Lys His Leu Ser Leu Ser Gly Thr Trp Arg Thr Asp Leu Ser Leu Leu
435 440 445

Ser Ser Pro Arg Ala Ala Pro Gln His Val Tyr
450 455

<210> 104

<211> 363

<212> PRT

<213> Homo sapiens

<400> 104

Met Ala Ala Leu Met Thr Pro Gly Thr Gly Ala Pro Pro Ala Pro Gly
 1 5 10 15
 Asp Phe Ser Gly Glu Gly Ser Gln Gly Leu Pro Asp Pro Ser Pro Glu
 20 25 30
 Pro Lys Gln Leu Pro Glu Leu Ile Arg Met Lys Arg Asp Gly Gly Arg
 35 40 45
 Leu Ser Glu Ala Asp Ile Arg Gly Phe Val Ala Ala Val Val Asn Gly
 50 55 60
 Ser Ala Gln Gly Ala Gln Ile Gly Ala Met Leu Met Ala Ile Arg Leu
 65 70 75 80
 Arg Gly Met Asp Leu Glu Glu Thr Ser Val Leu Thr Gln Ala Leu Ala
 85 90 95
 Gln Ser Gly Gln Gln Leu Glu Trp Pro Glu Ala Trp Arg Gln Gln Leu
 100 105 110
 Val Asp Lys His Ser Thr Gly Gly Val Gly Asp Lys Val Ser Leu Val
 115 120 125
 Leu Ala Pro Ala Leu Ala Ala Cys Gly Cys Lys Val Pro Met Ile Ser
 130 135 140
 Gly Arg Gly Leu Gly His Thr Gly Gly Thr Leu Asp Lys Leu Glu Ser
 145 150 155 160
 Ile Pro Gly Phe Asn Val Ile Gln Ser Pro Glu Gln Met Gln Val Leu
 165 170 175
 Leu Asp Gln Ala Gly Cys Cys Ile Val Gly Gln Ser Glu Gln Leu Val
 180 185 190
 Pro Ala Asp Gly Ile Leu Tyr Ala Ala Arg Asp Val Thr Ala Thr Val
 195 200 205
 Asp Ser Leu Pro Leu Ile Thr Ala Ser Ile Leu Ser Lys Lys Leu Val
 210 215 220
 Glu Gly Leu Ser Ala Leu Val Val Asp Val Lys Phe Gly Gly Ala Ala
 225 230 235 240
 Val Phe Pro Asn Gln Glu Gln Ala Arg Glu Leu Ala Lys Thr Leu Val
 245 250 255
 Gly Val Gly Ala Ser Leu Gly Leu Arg Val Ala Ala Ala Leu Thr Ala
 260 265 270
 Met Asp Lys Pro Leu Gly Arg Cys Val Gly His Ala Leu Glu Val Glu
 275 280 285
 Glu Ala Leu Leu Cys Met Asp Gly Ala Gly Pro Pro Asp Leu Arg Asp
 290 295 300
 Leu Val Thr Thr Leu Gly Gly Ala Leu Leu Trp Leu Ser Gly His Ala
 305 310 315 320
 Gly Thr Gln Ala Gln Gly Ala Ala Arg Val Ala Ala Ala Arg Ala Leu

325 330 335

Gln Glu Ala Leu Val Leu Ser Asp Arg Ala Pro Phe Ala Ala Pro Ser
340 345 350

Pro Phe Ala Glu Leu Val Leu Pro Pro Gln Gln
355 360

<210> 105
<211> 442
<212> PRT
<213> Homo sapiens

<400> 105

Met Ala Ala Leu Met Thr Pro Gly Thr Gly Ala Pro Pro Ala Pro Gly
1 5 10 15

Asp Phe Ser Gly Glu Gly Ser Gln Gly Leu Pro Asp Pro Ser Pro Glu
20 25 30

Pro Lys Gln Leu Pro Glu Leu Ile Arg Met Lys Arg Asp Gly Gly Arg
35 40 45

Leu Ser Glu Ala Asp Ile Arg Gly Phe Val Ala Ala Val Val Asn Gly
50 55 60

Ser Ala Gln Gly Ala Gln Ile Gly Ala Met Leu Met Ala Ile Arg Leu
65 70 75 80

Arg Gly Met Asp Leu Glu Glu Thr Ser Val Leu Thr Gln Ala Leu Ala
85 90 95

Gln Ser Gly Gln Gln Leu Glu Trp Pro Glu Ala Trp Arg Gln Gln Leu
100 105 110

Val Asp Lys His Ser Thr Gly Gly Val Gly Asp Lys Val Ser Leu Val
115 120 125

Leu Ala Pro Ala Leu Ala Ala Cys Gly Cys Lys Val Pro Met Ile Ser
130 135 140

Gly Arg Gly Leu Gly His Thr Gly Gly Thr Leu Asp Lys Leu Glu Ser
145 150 155 160

Ile Pro Gly Phe Asn Val Ile Gln Ser Pro Glu Gln Met Gln Val Leu
165 170 175

Leu Asp Gln Ala Gly Cys Cys Ile Val Gly Gln Ser Glu Gln Leu Val
180 185 190

Pro Ala Asp Gly Ile Leu Tyr Ala Ala Arg Asp Val Thr Ala Thr Val
195 200 205

Asp Ser Leu Pro Leu Ile Thr Gly Trp Arg Gly Ser Gln Pro Arg Ala
210 215 220

Arg Val Ala Ala Ala Leu Thr Ala Met Asp Lys Pro Leu Gly Arg Cys
225 230 235 240

Val Gly His Ala Leu Glu Val Glu Glu Ala Leu Leu Cys Met Asp Gly

```
<210> 106
<211> 323
<212> PRT
<213> Homo sapiens
```

Met Ala Ala Leu Met Thr Pro Gly Thr Gly Ala Pro Pro Ala Pro Gly
1 5 .10 15

Asp Phe Ser Gly Glu Gly Ser Gln Gly Leu Pro Asp Pro Ser Pro Glu
20 25 30

Pro Lys Gln Leu Pro Glu Leu Ile Arg Met Lys Arg Asp Gly Gly Arg
35 40 45

Leu Ser Glu Ala Asp Ile Arg Gly Phe Val Ala Ala Val Val Asn Gly
50 55 60

Ser Ala Gln Gly Ala Gln Ile Gly Ala Met Leu Met Ala Ile Arg Leu
65 70 75 80

Arg Gly Met Asp Leu Glu Glu Thr Ser Val Leu Thr Gln Ala Leu Ala

85 90 95
 Gln Ser Gly Gln Gln Leu Glu Trp Pro Glu Ala Trp Arg Gln Gln Leu
 100 105 110
 Val Asp Lys His Ser Thr Gly Gly Val Gly Asp Lys Val Ser Leu Val
 115 120 125
 Leu Ala Pro Ala Leu Ala Ala Cys Gly Cys Lys Val Pro Met Ile Ser
 130 135 140
 Gly Arg Gly Leu Gly His Thr Gly Gly Thr Leu Asp Lys Leu Glu Ser
 145 150 155 160
 Ile Pro Gly Phe Asn Val Ile Gln Ser Pro Glu Gln Met Gln Val Leu
 165 170 175
 Leu Asp Gln Ala Gly Cys Cys Ile Val Gly Gln Ser Glu Gln Leu Val
 180 185 190
 Pro Ala Asp Gly Ile Leu Tyr Ala Ala Arg Asp Val Thr Ala Thr Val
 195 200 205
 Asp Ser Leu Pro Leu Ile Thr Gly Trp Arg Gly Ser Gln Pro Arg Ala
 210 215 220
 Arg Val Ala Ala Ala Leu Thr Ala Met Asp Lys Pro Leu Gly Arg Cys
 225 230 235 240
 Val Gly His Ala Leu Glu Val Glu Glu Ala Leu Leu Cys Met Asp Gly
 245 250 255
 Ala Gly Pro Pro Asp Leu Arg Asp Leu Val Thr Thr Leu Gly Gly Ala
 260 265 270
 Leu Leu Trp Leu Ser Gly His Ala Gly Thr Gln Ala Gln Gly Ala Ala
 275 280 285
 Arg Val Ala Ala Ala Arg Ala Leu Gln Glu Ala Leu Val Leu Ser Asp
 290 295 300
 Arg Ala Pro Phe Ala Ala Pro Ser Pro Phe Ala Glu Leu Val Leu Pro
 305 310 315 320
 Pro Gln Gln

<210> 107
 <211> 481
 <212> PRT
 <213> Homo sapiens

<400> 107
 Met Ala Ser Arg Leu Thr Leu Leu Thr Leu Leu Leu Leu Leu Ala
 1 5 10 15

Gly Asp Arg Ala Ser Ser Asn Pro Asn Ala Thr Ser Ser Val Ile Ser
 20 25 30

Lys Met Leu Phe Val Glu Pro Ile Leu Glu Val Ser Ser Leu Pro Thr

35	40	45
Thr Asn Ser Thr Thr Asn Ser Ala Thr Lys Ile Thr Ala Asn Thr Thr		
50	55	60
Asp Glu Pro Thr Thr Gln Pro Thr Thr Glu Pro Thr Thr Gln Pro Thr		
65	70	75 80
Ile Gln Pro Thr Gln Pro Thr Thr Gln Leu Pro Thr Asp Ser Pro Thr		
	85	90 95
Gln Pro Thr Thr Gly Ser Phe Cys Pro Gly Pro Val Thr Leu Cys Ser		
	100	105 110
Asp Leu Glu Ser His Ser Thr Glu Ala Val Leu Gly Asp Ala Leu Val		
	115	120 125
Asp Phe Ser Leu Lys Leu Tyr His Ala Phe Ser Ala Met Lys Lys Val		
	130	135 140
Glu Thr Asn Met Ala Phe Ser Pro Phe Ser Ile Ala Ser Leu Leu Thr		
	145	150 155 160
Gln Val Leu Leu Gly Ala Gly Glu Asn Thr Lys Thr Asn Leu Glu Ser		
	165	170 175
Ile Leu Ser Tyr Pro Lys Asp Phe Thr Cys Val His Gln Ala Leu Lys		
	180	185 190
Gly Phe Thr Thr Lys Gly Val Thr Ser Val Ser Gln Ile Phe His Ser		
	195	200 205
Pro Asp Leu Ala Ile Arg Asp Thr Phe Val Asn Ala Ser Arg Thr Leu		
	210	215 220
Tyr Ser Ser Ser Pro Arg Val Leu Ser Asn Asn Ser Asp Ala Asn Leu		
	225	230 235 240
Glu Leu Ile Asn Thr Trp Val Ala Lys Asn Thr Asn Asn Lys Ile Ser		
	245	250 255
Arg Leu Leu Asp Ser Leu Pro Ser Asp Thr Arg Leu Val Leu Leu Asn		
	260	265 270
Ala Ile Tyr Leu Ser Ala Lys Trp Lys Thr Thr Phe Asp Pro Lys Lys		
	275	280 285
Thr Arg Met Glu Pro Phe His Phe Lys Asn Ser Val Ile Lys Val Pro		
	290	295 300
Met Met Asn Ser Lys Lys Tyr Pro Val Ala His Phe Ile Asp Gln Thr		
	305	310 315 320
Leu Lys Ala Lys Val Gly Gln Leu Gln Leu Ser His Asn Leu Ser Leu		
	325	330 335
Val Ile Leu Val Pro Gln Asn Leu Lys His Arg Leu Glu Asp Met Glu		
	340	345 350
Gln Ala Leu Ser Pro Ser Val Phe Lys Ala Ile Met Glu Lys Leu Glu		
	355	360 365

Met Ser Lys Phe Gln Pro Thr Leu Leu Thr Leu Pro Arg Ile Lys Val
 370 375 380

Thr Thr Ser Gln Asp Met Leu Ser Ile Met Glu Lys Leu Glu Phe Phe
 385 390 395 400

Asp Phe Ser Tyr Asp Leu Asn Leu Cys Gly Leu Thr Glu Asp Pro Asp
 405 410 415

Leu Gln Val Ser Ala Met Gln His Gln Thr Val Leu Glu Leu Thr Glu
 420 425 430

Thr Gly Val Glu Ala Ala Ala Ala Ser Ala Ile Ser Val Ala Arg Thr
 435 440 445

Leu Leu Val Phe Glu Val Gln Gln Pro Phe Leu Phe Val Leu Trp Asp
 450 455 460

Gln Gln His Lys Phe Pro Val Phe Met Gly Arg Val Tyr Asp Pro Arg
 465 470 475 480

Ala

<210> 108

<211> 116

<212> PRT

<213> Homo sapiens

<400> 108

Met Met Asp Glu Glu Glu Val Glu Val Ser Leu Pro Arg Phe Lys Leu
 1 5 10 15

Glu Glu Ser Tyr Asp Met Glu Ser Val Leu Arg Asn Leu Gly Met Thr
 20 25 30

Asp Ala Phe Glu Leu Gly Lys Ala Asp Phe Ser Gly Met Ser Gln Thr
 35 40 45

Asp Leu Ser Leu Ser Lys Val Val His Lys Ser Phe Val Glu Val Asn
 50 55 60

Glu Glu Gly Thr Glu Ala Ala Ala Ala Thr Ala Ala Ile Met Met Met
 65 70 75 80

Arg Cys Ala Arg Phe Val Pro Arg Phe Cys Ala Asp His Pro Phe Leu
 85 90 95

Phe Phe Ile Gln His Ser Lys Thr Asn Gly Ile Leu Phe Cys Gly Arg
 100 105 110

Phe Ser Ser Pro
 115

<210> 109

<211> 319

<212> PRT

<213> Homo sapiens

<400> 109

Met Asp Val Leu Ala Glu Ala Asn Gly Thr Phe Ala Leu Asn Leu Leu
 1 5 10 15
 Lys Thr Leu Gly Lys Asp Asn Ser Lys Asn Val Phe Phe Ser Pro Met
 20 25 30
 Ser Met Ser Cys Ala Leu Ala Met Val Tyr Met Gly Ala Lys Gly Asn
 35 40 45
 Thr Ala Ala Gln Met Ala Gln Ile Leu Ser Phe Asn Lys Ser Gly Gly
 50 55 60
 Gly Gly Asp Ile His Gln Gly Phe Gln Ser Leu Leu Thr Glu Val Asn
 65 70 75 80
 Lys Thr Gly Thr Gln Tyr Leu Leu Arg Val Ala Asn Arg Leu Phe Gly
 85 90 95
 Glu Lys Ser Cys Asp Phe Leu Ser Ser Phe Arg Asp Ser Cys Gln Lys
 100 105 110
 Phe Tyr Gln Ala Glu Met Glu Glu Leu Asp Phe Ile Ser Ala Val Glu
 115 120 125
 Lys Ser Arg Lys His Ile Asn Thr Trp Val Ala Glu Lys Thr Glu Gly
 130 135 140
 Lys Ile Ala Glu Leu Leu Ser Pro Gly Ser Val Asp Pro Leu Thr Arg
 145 150 155 160
 Leu Val Leu Val Asn Ala Val Tyr Phe Arg Gly Asn Trp Asp Glu Gln
 165 170 175
 Phe Asp Lys Glu Asn Thr Glu Glu Arg Leu Phe Lys Val Ser Lys Asn
 180 185 190
 Glu Glu Lys Pro Val Gln Met Met Phe Lys Gln Ser Thr Phe Lys Lys
 195 200 205
 Thr Tyr Ile Gly Glu Ile Phe Thr Gln Ile Leu Val Leu Pro Tyr Val
 210 215 220
 Gly Lys Glu Leu Asn Met Ile Ile Met Leu Pro Asp Glu Thr Thr Asp
 225 230 235 240
 Leu Arg Thr Val Glu Lys Glu Leu Thr Tyr Glu Lys Phe Val Glu Trp
 245 250 255
 Thr Arg Leu Asp Met Met Asp Glu Glu Glu Val Glu Glu Gly Thr Glu
 260 265 270
 Ala Ala Ala Ala Thr Ala Ala Ile Met Met Met Arg Cys Ala Arg Phe
 275 280 285
 Val Pro Arg Phe Cys Ala Asp His Pro Phe Leu Phe Phe Ile Gln His
 290 295 300
 Ser Lys Thr Asn Gly Ile Leu Phe Cys Gly Arg Phe Ser Ser Pro
 305 310 315

<210> 110
 <211> 188
 <212> PRT
 <213> Homo sapiens

<400> 110
 Met Asp Val Leu Ala Glu Ala Asn Gly Thr Phe Ala Leu Asn Leu Leu
 1 5 10 15
 Lys Thr Leu Gly Lys Asp Asn Ser Lys Asn Val Phe Phe Ser Pro Met
 20 25 30
 Ser Met Ser Cys Ala Leu Ala Met Val Tyr Met Gly Ala Lys Gly Asn
 35 40 45
 Thr Ala Ala Gln Met Ala Gln Ile Leu Ser Phe Asn Lys Ser Gly Gly
 50 55 60
 Gly Gly Asp Ile His Gln Gly Phe Gln Ser Leu Leu Thr Glu Val Asn
 65 70 75 80
 Lys Thr Gly Thr Gln Tyr Leu Leu Arg Glu Ser Tyr Asp Met Glu Ser
 85 90 95
 Val Leu Arg Asn Leu Gly Met Thr Asp Ala Phe Glu Leu Gly Lys Ala
 100 105 110
 Asp Phe Ser Gly Met Ser Gln Thr Asp Leu Ser Leu Ser Lys Val Val
 115 120 125
 His Lys Ser Phe Val Glu Val Asn Glu Glu Gly Thr Glu Ala Ala Ala
 130 135 140
 Ala Thr Ala Ala Ile Met Met Met Arg Cys Ala Arg Phe Val Pro Arg
 145 150 155 160
 Phe Cys Ala Asp His Pro Phe Leu Phe Phe Ile Gln His Ser Lys Thr
 165 170 175
 Asn Gly Ile Leu Phe Cys Gly Arg Phe Ser Ser Pro
 180 185

<210> 111
 <211> 60
 <212> PRT
 <213> Homo sapiens

<400> 111
 Met Asp Val Leu Ala Glu Ala Asn Gly Thr Phe Ala Leu Asn Leu Leu
 1 5 10 15
 Lys Thr Leu Gly Lys Asp Asn Ser Lys Asn Val Phe Phe Ser Pro Met
 20 25 30
 Ser Met Ser Cys Ala Leu Ala Met Val Tyr Met Gly Ala Lys Gly Asn
 35 40 45
 Thr Ala Ala Gln Met Ala Gln Arg Phe Gln Lys Val

50

55

60

<210> 112
 <211> 306
 <212> PRT
 <213> Homo sapiens

<400> 112

Met His Lys Thr Ala Ser Gln Arg Leu Phe Pro Gly Pro Ser Tyr Gln
 1 5 10 15
 Asn Ile Lys Ser Ile Met Glu Asp Ser Thr Ile Leu Ser Asp Trp Thr
 20 25 30
 Asn Ser Asn Lys Gln Lys Met Lys Tyr Asp Phe Ser Cys Glu Leu Tyr
 35 40 45
 Arg Met Ser Thr Tyr Ser Thr Phe Pro Ala Gly Val Pro Val Ser Glu
 50 55 60
 Arg Ser Leu Ala Arg Ala Gly Phe Tyr Tyr Thr Gly Val Asn Asp Lys
 65 70 75 80
 Val Lys Cys Phe Cys Cys Gly Leu Met Leu Asp Asn Trp Lys Leu Gly
 85 90 95
 Asp Ser Pro Ile Gln Lys His Lys Gln Leu Tyr Pro Ser Cys Ser Phe
 100 105 110
 Ile Gln Asn Leu Val Ser Ala Ser Leu Gly Ser Thr Ser Lys Asn Thr
 115 120 125
 Ser Pro Met Arg Asn Ser Phe Ala His Ser Leu Ser Pro Thr Leu Glu
 130 135 140
 His Ser Ser Leu Phe Ser Gly Ser Tyr Ser Ser Leu Ser Pro Asn Pro
 145 150 155 160
 Leu Asn Ser Arg Ala Val Glu Asp Ile Ser Ser Ser Arg Thr Asn Pro
 165 170 175
 Tyr Ser Tyr Ala Met Ser Thr Glu Glu Ala Arg Phe Leu Thr Tyr His
 180 185 190
 Met Trp Pro Leu Thr Phe Leu Ser Pro Ser Glu Leu Ala Arg Ala Gly
 195 200 205
 Phe Tyr Tyr Ile Gly Pro Gly Asp Arg Val Ala Cys Phe Ala Cys Gly
 210 215 220
 Gly Lys Leu Ser Asn Trp Glu Pro Lys Asp Asn Ala Met Ser Glu His
 225 230 235 240
 Leu Arg His Phe Pro Asn Cys Pro Phe Leu Glu Asn Ser Leu Glu Thr
 245 250 255
 Leu Arg Phe Ser Ile Ser Asn Leu Ser Met Gln Thr His Ala Ala Arg
 260 265 270
 Met Arg Thr Phe Met Tyr Trp Pro Ser Ser Val Pro Val Gln Pro Glu

275

280

285

Gln Leu Ala Ser Ala Gly Phe Tyr Tyr Val Gly Lys Lys Leu Asn Leu
 290 295 300

Leu Ile
 305

<210> 113
 <211> 359
 <212> PRT
 <213> Homo sapiens

<400> 113
 Met His Ser Ser Met Lys Thr Ser Leu Phe Phe His Ile Val Met Gln
 1 5 10 15

Leu Gly Phe Ser Ala Leu Ser Phe Phe Tyr Pro Phe Phe Asn Ser Ser
 20 25 30

Tyr Tyr Val Gln Met Ile Ile Leu Ser Arg Phe Gly Cys Pro Asp Gln
 35 40 45

Asn Gly Asp Arg Val Glu Arg Cys Asp Ser Lys Ala Leu Asp Arg Val
 50 55 60

Ile Xaa Leu Pro Phe Ser Pro Pro Pro Arg Ser Pro Pro Asp Arg Gly
 65 70 75 80

Glu His Met Ser Ala Pro Ala Ala Lys Val Ser Lys Lys Glu Leu Asn
 85 90 95

Ser Asn His Asp Gly Ala Asp Glu Thr Ser Glu Lys Glu Gln Gln Glu
 100 105 110

Ala Ile Glu His Ile Asp Glu Val Gln Asn Glu Ile Asp Arg Leu Asn
 115 120 125

Glu Gln Ala Ser Glu Glu Ile Leu Lys Val Glu Gln Lys Tyr Asn Lys
 130 135 140

Leu Arg Gln Pro Phe Phe Gln Lys Arg Ser Glu Leu Ile Ala Lys Ile
 145 150 155 160

Pro Asn Phe Trp Val Thr Thr Phe Val Asn His Pro Gln Val Ser Ala
 165 170 175

Leu Leu Gly Glu Glu Asp Glu Glu Ala Leu His Tyr Leu Thr Arg Val
 180 185 190

Glu Val Thr Glu Phe Glu Asp Ile Lys Ser Gly Tyr Arg Ile Asp Phe
 195 200 205

Tyr Phe Asp Glu Asn Pro Tyr Phe Glu Asn Lys Val Leu Ser Lys Glu
 210 215 220

Phe His Leu Asn Glu Ser Gly Asp Pro Ser Ser Lys Ser Thr Glu Ile
 225 230 235 240

Lys Trp Lys Ser Gly Lys Asp Leu Thr Lys Arg Ser Ser Gln Thr Gln

```

<400> 114
Met Ser Ala Pro Ala Ala Lys Val Ser Lys Lys Glu Leu Asn Ser Asn
  1             5             10             15
His Asp Gly Ala Asp Glu Thr Ser Glu Lys Glu Gln Gln Glu Ala Ile
          20             25             30
Glu His Ile Asp Glu Val Gln Asn Glu Ile Asp Arg Leu Asn Glu Gln
          35             40             45
Ala Ser Glu Glu Ile Leu Lys Val Glu Gln Lys Tyr Asn Lys Leu Arg
          50             55             60
Gln Pro Phe Phe Gln Lys Arg Ser Glu Leu Ile Ala Lys Ile Pro Asn
          65             70             75             80
Phe Trp Val Thr Thr Phe Val Asn His Pro Gln Val Ser Ala Leu Leu
          85             90             95
Gly Glu Glu Asp Glu Glu Ala Leu His Tyr Leu Thr Arg Val Glu Val
          100             105             110
Thr Glu Phe Glu Asp Ile Lys Ser Gly Tyr Arg Ile Asp Phe Tyr Phe
          115             120             125
Asp Glu Asn Pro Tyr Phe Glu Asn Lys Val Leu Ser Lys Glu Phe His
          130             135             140
Leu Asn Glu Ser Gly Asp Pro Ser Ser Lys Ser Thr Glu Ile Lys Trp
          145             150             155             160
Lys Ser Gly Lys Asp Leu Thr Lys Arg Ser Ser Gln Thr Gln Asn Lys

```



```

<400> 115
Met Leu Ile Ala Ala Gly Pro Ala Arg Thr Gly Val Gly Pro Ala Arg
 1               5               10               15
Ile Lys Gly Ala Gln Ala Gly Trp Ala Phe His Arg Pro Ser Ala Leu
                20                25                30
Cys Ser Arg Gly Ala Gly Gln Ala Xaa Ala Ser Glu Leu Ala Ser Arg
          35                   40                   45
His Arg Gly Gly Ala Ala Ala Val Arg Thr Arg Gln Ala Asn Pro Thr
      50                   55                   60
Gln Lys Ser Pro Pro Pro Asp Ser Gln Val Ala Ala Ala Ser Leu Ala
 65               70               75               80
His Ala Glu Ser Gly Gly Ala Gly Ser Pro Leu Arg Pro Ala Ser Ala
                85                   90                   95
Leu Ser Ser Ser Pro Phe Pro Phe Phe Ser Leu Ser Ser Pro Leu Ser
          100                   105                   110
Leu Pro Ala Phe Ala Gln Pro Arg Ala Met Ser Asp Ala Ser Leu Arg
      115                   120                   125
Ser Thr Ser Thr Met Glu Arg Leu Val Ala Arg Gly Thr Phe Pro Val
      130                   135                   140
Leu Val Arg Thr Ser Ala Cys Arg Ser Leu Phe Gly Pro Val Asp His
145               150               155               160
Glu Glu Leu Ser Arg Glu Leu Gln Ala Arg Leu Ala Glu Leu Asn Ala
                165                   170                   175
Glu Asp Gln Asn Arg Trp Asp Tyr Asp Phe Gln Gln Asp Met Pro Leu

```

180 185 190
 Arg Gly Pro Gly Arg Leu Gln Trp Thr Glu Val Asp Ser Asp Ser Val
 195 200 205
 Pro Ala Phe Tyr Arg Glu Thr Val Gln Ile Phe Phe Ala Lys Arg Lys
 210 215 220
 Arg Ser Ala Pro Glu Lys Ser Ser Gly Asp Val Pro Ala Pro Cys Pro
 225 230 235 240
 Ser Pro Ser Ala Ala Pro Gly Val Gly Ser Val Glu Gln Thr Pro Arg
 245 250 255
 Lys Arg Leu Arg
 260

<210> 116
 <211> 582
 <212> PRT
 <213> Homo sapiens

<400> 116
 Met Met Thr Leu Arg His Leu Pro Phe Ile Leu Leu Leu Ile Leu Ser
 1 5 10 15
 Gly Glu Leu Tyr Ala Glu Glu Lys Gln Cys Asp Phe Pro Thr Val Glu
 20 25 30
 Asn Gly Arg Ile Ala Gln Tyr Tyr Tyr Thr Phe Lys Ser Phe Tyr Phe
 35 40 45
 Pro Met Ser Val Asp Lys Lys Leu Ser Phe Phe Cys Leu Ala Gly Tyr
 50 55 60
 Ala Thr Glu Ser Gly Lys Gln Glu Glu Gln Ile Arg Cys Thr Ala Glu
 65 70 75 80
 Gly Trp Ser Pro Asn Pro Arg Cys Tyr Lys Lys Cys Leu Lys Pro Asp
 85 90 95
 Leu Arg Asn Gly Tyr Val Ser Asn Asp Lys Val Leu Tyr Lys Leu Gln
 100 105 110
 Glu Arg Met Ser Tyr Gly Cys Ser Ser Gly Tyr Lys Thr Thr Gly Gly
 115 120 125
 Lys Asp Glu Glu Val Val His Cys Leu Ser Ala Gly Trp Ser Ser Gln
 130 135 140
 Pro Ser Cys Arg Lys Glu Gln Glu Thr Cys Leu Ala Pro Glu Leu Glu
 145 150 155 160
 His Gly Asn Tyr Ser Thr Thr Gln Arg Thr Phe Lys Val Lys Asp Ile
 165 170 175
 Val Ala Tyr Thr Cys Thr Ala Gly Tyr Tyr Thr Thr Thr Gly Lys Gln
 180 185 190
 Thr Gly Glu Ala Glu Cys Gln Ala Asn Gly Trp Ser Leu Thr Pro Gln

195	200	205
Cys Asn Lys Leu Met Cys Ser Ser Leu Arg Leu Ile Glu Asn Gly Tyr		
210	215	220
Phe His Pro Val Lys Gln Thr Tyr Glu Glu Gly Asp Val Val Gln Phe		
225	230	235
Phe Cys His Glu Asn Tyr Tyr Leu Ser Gly Ser Asp Leu Ile Gln Cys		
245	250	255
Tyr Asn Phe Gly Trp Tyr Pro Glu Ser Pro Ile Cys Glu Gly Arg Arg		
260	265	270
Asn Arg Cys Pro Pro Pro Pro Val Pro Leu Asn Ser Lys Ile Gln Pro		
275	280	285
His Ser Thr Thr Tyr Arg His Gly Glu Arg Val His Ile Glu Cys Glu		
290	295	300
Leu Asn Phe Val Ile Gln Gly Ser Glu Glu Leu Leu Cys Glu Asn Gly		
305	310	315
Lys Trp Thr Glu Pro Pro Lys Cys Ile Glu Glu Lys Glu Lys Val Ala		
325	330	335
Cys Glu Gln Pro Pro Ser Val Glu Asn Gly Val Ala His Pro His Ser		
340	345	350
Glu Ile Tyr Tyr Ser Gly Asp Lys Val Thr Tyr Arg Cys Gly Gly Gly		
355	360	365
Tyr Ser Leu Arg Gly Ser Ser Thr Ile Thr Cys Asn Arg Gly Arg Trp		
370	375	380
Thr Leu Pro Pro Glu Cys Val Glu Asn Ile Glu Asn Cys Lys Pro Pro		
385	390	395
Pro Asp Ile Ala Asn Gly Val Val Val Asp Gly Leu Leu Ala Ser Tyr		
405	410	415
Thr Thr Gly Ser Ser Val Glu Tyr Arg Cys Asn Glu Tyr Tyr Leu Leu		
420	425	430
Lys Gly Ser Glu Thr Ser Arg Cys Glu Gln Gly Ala Trp Ser Ser Pro		
435	440	445
Pro Val Cys Leu Glu Pro Cys Thr Ile Asp Val Asp His Met Asn Arg		
450	455	460
Asn Asn Ile Gln Leu Lys Trp Lys Tyr Glu Gly Lys Ile Leu His Gly		
465	470	475
Asp Leu Ile Asp Phe Val Cys Lys Gln Gly Tyr Asn Leu Ser Pro Ser		
485	490	495
Ile Pro Leu Ser Glu Ile Ser Ala Gln Cys Asn Arg Gly Asp Val Arg		
500	505	510
Tyr Pro Met Cys Ile Arg Lys Glu Ser Lys Gly Met Cys Ala Ser Pro		
515	520	525

Pro Val Ile Arg Asn Gly Asp Ile Val Ser Ser Ala Ala Arg Thr Tyr
 530 535 540

Glu Asn Gly Ser Ser Val Glu Tyr Arg Cys Phe Asp Asn His Phe Leu
 545 550 555 560

Gln Gly Ser Gln Asn Val Tyr Cys Val Asp Gly Val Trp Thr Thr Pro
 565 570 575

Pro Ser Cys Leu Glu Pro
 580

<210> 117

<211> 576

<212> PRT

<213> Homo sapiens

<400> 117

Met Pro Trp Gly Arg Arg Pro Thr Trp Leu Leu Leu Ala Phe Leu Leu
 1 5 10 15

Val Phe Leu Lys Ile Ser Ile Leu Ser Val Thr Ala Trp Gln Thr Gly
 20 25 30

Asn Cys Gln Pro Gly Pro Leu Glu Arg Ser Glu Arg Ser Gly Thr Cys
 35 40 45

Ala Gly Pro Ala Pro Phe Leu Val Phe Ser Gln Gly Lys Ser Ile Ser
 50 55 60

Arg Ile Trp Ala Ile Pro Ser Val Ile Arg Val Asn Lys Arg Thr Gly
 65 70 75 80

Gln Asn Arg Val Arg Leu Gln Gly Ser Met Leu Lys Pro Ser Ser Leu
 85 90 95

Val Val Val His Pro Leu Ala Lys Pro Gly Ala Asp Pro Cys Leu Tyr
 100 105 110

Arg Asn Gly Gly Cys Glu His Ile Cys Gln Glu Ser Leu Gly Thr Ala
 115 120 125

Arg Cys Leu Cys Arg Glu Gly Phe Val Lys Ala Trp Asp Gly Lys Met
 130 135 140

Cys Leu Pro Gln Asp Tyr Pro Ile Leu Ser Gly Glu Asn Ala Asp Leu
 145 150 155 160

Ser Lys Glu Val Thr Ser Leu Ser Asn Ser Thr Gln Ala Glu Val Pro
 165 170 175

Asp Asp Asp Gly Thr Glu Ser Ser Thr Leu Val Ala Glu Ile Met Val
 180 185 190

Ser Gly Met Asn Tyr Glu Asp Asp Cys Gly Pro Gly Gly Cys Gly Ser
 195 200 205

His Ala Arg Cys Val Ser Asp Gly Glu Thr Ala Glu Cys Gln Cys Leu
 210 215 220

Lys Gly Phe Ala Arg Asp Gly Asn Leu Cys Ser Asp Ile Asp Glu Cys
 225 230 235 240
 Val Leu Ala Arg Ser Asp Cys Pro Ser Thr Ser Ser Arg Cys Ile Asn
 245 250 255
 Thr Glu Gly Gly Tyr Val Cys Arg Cys Ser Glu Gly Tyr Glu Gly Asp
 260 265 270
 Gly Ile Ser Cys Phe Asp Ile Asp Glu Cys Gln Arg Gly Ala His Asn
 275 280 285
 Cys Ala Glu Asn Ala Ala Cys Thr Asn Thr Glu Gly Gly Tyr Asn Cys
 290 295 300
 Thr Cys Ala Gly Arg Pro Ser Ser Pro Gly Leu Ser Cys Pro Asp Ser
 305 310 315 320
 Thr Ala Pro Ser Leu Leu Gly Glu Asp Gly His His Leu Asp Arg Asn
 325 330 335
 Ser Tyr Pro Gly Cys Pro Ser Ser Tyr Asp Gly Tyr Cys Leu Asn Gly
 340 345 350
 Gly Val Cys Met His Ile Glu Ser Leu Asp Ser Tyr Thr Cys Asn Cys
 355 360 365
 Val Ile Gly Tyr Ser Gly Asp Arg Cys Gln Thr Arg Asp Leu Arg Trp
 370 375 380
 Trp Glu Leu Arg His Ala Gly Tyr Gly Gln Lys His Asp Ile Met Val
 385 390 395 400
 Val Ala Val Cys Met Val Ala Leu Val Leu Leu Leu Leu Gly Met
 405 410 415
 Trp Gly Thr Tyr Tyr Tyr Arg Thr Arg Lys Gln Leu Ser Asn Pro Pro
 420 425 430
 Lys Asn Pro Cys Asp Glu Pro Ser Gly Ser Val Ser Ser Ser Gly Pro
 435 440 445
 Asp Ser Ser Ser Gly Ala Ala Val Ala Ser Cys Pro Gln Pro Trp Phe
 450 455 460
 Val Val Leu Glu Lys His Gln Asp Pro Lys Asn Gly Ser Leu Pro Ala
 465 470 475 480
 Asp Gly Thr Asn Gly Ala Val Val Asp Ala Gly Leu Ser Pro Ser Leu
 485 490 495
 Gln Leu Gly Ser Val His Leu Thr Ser Trp Arg Gln Lys Pro His Ile
 500 505 510
 Asp Gly Met Gly Thr Gly Gln Ser Cys Trp Ile Pro Pro Ser Ser Asp
 515 520 525
 Arg Gly Pro Gln Glu Ile Glu Gly Asn Ser His Leu Pro Ser Tyr Arg
 530 535 540

Pro Val Gly Pro Glu Lys Leu His Ser Leu Gln Ser Ala Asn Gly Ser
 545 550 555 560

Cys His Glu Arg Ala Pro Asp Leu Pro Arg Gln Thr Glu Pro Val Gln
 565 570 575

<210> 118

<211> 550

<212> PRT

<213> Homo sapiens

<400> 118

Met Pro Trp Gly Arg Arg Pro Thr Trp Leu Leu Leu Ala Phe Leu Leu
 1 5 10 15

Val Phe Leu Lys Ile Ser Ile Leu Ser Val Thr Ala Trp Gln Thr Gly
 20 25 30

Asn Cys Gln Pro Gly Pro Leu Glu Arg Ser Glu Arg Ser Gly Thr Cys
 35 40 45

Ala Gly Pro Ala Pro Phe Leu Val Phe Ser Gln Gly Lys Ser Ile Ser
 50 55 60

Arg Ile Asp Pro Asp Gly Thr Asn His Gln Gln Leu Val Val Asp Ala
 65 70 75 80

Gly Ile Ser Ala Asp Met Asp Ile His Tyr Lys Lys Glu Arg Leu Tyr
 85 90 95

Trp Val Asp Val Glu Arg Gln Val Leu Leu Arg Val Phe Leu Asn Gly
 100 105 110

Thr Gly Leu Glu Lys Val Cys Asn Val Glu Arg Lys Val Ser Gly Leu
 115 120 125

Ala Ile Asp Trp Ile Asp Asp Glu Val Leu Trp Val Asp Gln Gln Asn
 130 135 140

Gly Val Ile Thr Val Thr Asp Met Thr Gly Lys Asn Ser Arg Val Leu
 145 150 155 160

Leu Ser Ser Leu Lys His Pro Ser Asn Ile Ala Val Asp Pro Ile Glu
 165 170 175

Arg Leu Met Phe Trp Ser Ser Glu Val Thr Gly Ser Leu His Arg Ala
 180 185 190

His Leu Lys Gly Val Asp Val Lys Thr Leu Leu Glu Thr Gly Gly Ile
 195 200 205

Ser Val Leu Thr Leu Asp Val Leu Asp Lys Arg Leu Phe Trp Val Gln
 210 215 220

Asp Ser Gly Glu Gly Ser His Ala Tyr Ile His Ser Cys Asp Tyr Glu
 225 230 235 240

Gly Gly Ser Val Arg Leu Ile Arg His Gln Ala Arg His Ser Leu Ser
 245 250 255
 Ser Met Ala Phe Phe Gly Asp Arg Ile Phe Tyr Ser Val Leu Lys Ser
 260 265 270
 Lys Ala Ile Trp Ile Ala Asn Lys His Thr Gly Lys Asp Thr Val Arg
 275 280 285
 Ile Asn Leu His Pro Ser Phe Val Thr Pro Gly Lys Leu Met Val Val
 290 295 300
 His Pro Arg Ala Gln Pro Arg Thr Glu Asp Ala Ala Lys Asp Pro Asp
 305 310 315 320
 Pro Glu Leu Leu Lys Gln Arg Gly Arg Pro Cys Arg Phe Gly Leu Cys
 325 330 335
 Glu Arg Asp Pro Lys Ser His Ser Ser Ala Cys Ala Glu Gly Tyr Thr
 340 345 350
 Leu Ser Arg Asp Arg Lys Tyr Cys Glu Asp Val Asn Glu Cys Ala Thr
 355 360 365
 Gln Asn His Gly Cys Thr Leu Gly Cys Glu Asn Thr Pro Gly Ser Tyr
 370 375 380
 His Cys Thr Cys Pro Thr Gly Phe Val Leu Leu Pro Asp Gly Lys Gln
 385 390 395 400
 Cys His Glu Leu Val Ser Cys Pro Gly Asn Val Ser Lys Cys Ser His
 405 410 415
 Gly Cys Val Leu Thr Ser Asp Gly Pro Arg Cys Ile Cys Pro Ala Gly
 420 425 430
 Ser Val Leu Gly Arg Asp Gly Lys Thr Cys Thr Gly Cys Ser Ser Pro
 435 440 445
 Asp Asn Gly Gly Cys Ser Gln Ile Cys Leu Pro Leu Arg Pro Gly Ser
 450 455 460
 Trp Glu Cys Asp Cys Phe Pro Gly Tyr Asp Leu Gln Ser Asp Arg Lys
 465 470 475 480
 Ser Cys Ala Ala Ser Gly Pro Gln Pro Leu Leu Leu Phe Ala Asn Ser
 485 490 495
 Gln Asp Ile Arg His Met His Phe Asp Gly Thr Asp Tyr Lys Val Leu
 500 505 510
 Leu Ser Arg Gln Met Gly Met Val Phe Ala Leu Asp Tyr Asp Pro Val
 515 520 525
 Glu Ser Lys Ile Tyr Phe Ala Gln Thr Ala Leu Lys Trp Ile Glu Arg
 530 535 540
 Ala Asn Met Asp Gly Ser
 545 550

<210> 119
 <211> 163
 <212> PRT
 <213> Homo sapiens

<400> 119
 Met Pro Trp Gly Arg Arg Pro Thr Trp Leu Leu Leu Ala Phe Leu Leu
 1 5 10 15
 Val Phe Leu Lys Ile Ser Ile Leu Ser Val Thr Ala Trp Gln Thr Gly
 20 25 30
 Asn Cys Gln Pro Gly Pro Leu Glu Arg Ser Glu Arg Ser Gly Thr Cys
 35 40 45
 Ala Gly Pro Ala Pro Phe Leu Val Phe Ser Gln Gly Lys Ser Ile Ser
 50 55 60
 Arg Ile Trp Ala Ile Pro Ser Val Ile Arg Val Asn Lys Arg Thr Gly
 65 70 75 80
 Gln Asn Arg Val Arg Leu Gln Gly Ser Met Leu Lys Pro Ser Ser Leu
 85 90 95
 Val Val Val His Pro Leu Ala Lys Pro Gly Ala Asp Pro Cys Leu Tyr
 100 105 110
 Arg Asn Gly Gly Cys Glu His Ile Cys Gln Glu Ser Leu Gly Thr Ala
 115 120 125
 Arg Cys Leu Cys Arg Glu Gly Phe Val Lys Ala Trp Asp Gly Lys Met
 130 135 140
 Cys Leu Pro Gln Asp Tyr Pro Ile Leu Ser Gly Glu Asn Ala His Asn
 145 150 155 160
 Cys Ala Phe

<210> 120
 <211> 376
 <212> PRT
 <213> Homo sapiens

<400> 120
 Met Pro Trp Gly Arg Arg Pro Thr Trp Leu Leu Leu Ala Phe Leu Leu
 1 5 10 15
 Val Ser Ala Glu Cys Gln Cys Leu Lys Gly Phe Ala Arg Asp Gly Asn
 20 25 30
 Leu Cys Ser Asp Ile Asp Glu Cys Val Leu Ala Arg Ser Asp Cys Pro
 35 40 45
 Ser Thr Ser Ser Arg Cys Ile Asn Thr Glu Gly Gly Tyr Val Cys Arg
 50 55 60
 Cys Ser Glu Gly Tyr Glu Gly Asp Gly Ile Ser Cys Phe Asp Ile Asp
 65 70 75 80


```
<210> 121
<211> 444
<212> PRT
```

<213> Homo sapiens

<400> 121

Met Pro Trp Gly Arg Lys Ala Trp Asp Gly Lys Met Cys Leu Pro Gln
 1 5 10 15

Asp Tyr Pro Ile Leu Ser Gly Glu Asn Ala Asp Leu Ser Lys Glu Val
 20 25 30

Thr Ser Leu Ser Asn Ser Thr Gln Ala Glu Val Pro Asp Asp Asp Gly
 35 40 45

Thr Glu Ser Ser Thr Leu Val Ala Glu Ile Met Val Ser Gly Met Asn
 50 55 60

Tyr Glu Asp Asp Cys Gly Pro Gly Gly Cys Gly Ser His Ala Arg Cys
 65 70 75 80

Val Ser Asp Gly Glu Thr Ala Glu Cys Gln Cys Leu Lys Gly Phe Ala
 85 90 95

Arg Asp Gly Asn Leu Cys Ser Asp Ile Asp Glu Cys Val Leu Ala Arg
 100 105 110

Ser Asp Cys Pro Ser Thr Ser Ser Arg Cys Ile Asn Thr Glu Gly Gly
 115 120 125

Tyr Val Cys Arg Cys Ser Glu Gly Tyr Glu Gly Asp Gly Ile Ser Cys
 130 135 140

Phe Asp Ile Asp Glu Cys Gln Arg Gly Ala His Asn Cys Ala Glu Asn
 145 150 155 160

Ala Ala Cys Thr Asn Thr Glu Gly Gly Tyr Asn Cys Thr Cys Ala Gly
 165 170 175

Arg Pro Ser Ser Pro Gly Leu Ser Cys Pro Asp Ser Thr Ala Pro Ser
 180 185 190

Leu Leu Gly Glu Asp Gly His His Leu Asp Arg Asn Ser Tyr Pro Gly
 195 200 205

Cys Pro Ser Ser Tyr Asp Gly Tyr Cys Leu Asn Gly Gly Val Cys Met
 210 215 220

His Ile Glu Ser Leu Asp Ser Tyr Thr Cys Asn Cys Val Ile Gly Tyr
 225 230 235 240

Ser Gly Asp Arg Cys Gln Thr Arg Asp Leu Arg Trp Trp Glu Leu Arg
 245 250 255

His Ala Gly Tyr Gly Gln Lys His Asp Ile Met Val Val Ala Val Cys
 260 265 270

Met Val Ala Leu Val Leu Leu Leu Leu Gly Met Trp Gly Thr Tyr
 275 280 285

Tyr Tyr Arg Thr Arg Lys Gln Leu Ser Asn Pro Pro Lys Asn Pro Cys
 290 295 300

Asp Glu Pro Ser Gly Ser Val Ser Ser Ser Gly Pro Asp Ser Ser Ser

305 310 315 320
 Gly Ala Ala Val Ala Ser Cys Pro Gln Pro Trp Phe Val Val Leu Glu
 325 330 335
 Lys His Gln Asp Pro Lys Asn Gly Ser Leu Pro Ala Asp Gly Thr Asn
 340 345 350
 Gly Ala Val Val Asp Ala Gly Leu Ser Pro Ser Leu Gln Leu Gly Ser
 355 360 365
 Val His Leu Thr Ser Trp Arg Gln Lys Pro His Ile Asp Gly Met Gly
 370 375 380
 Thr Gly Gln Ser Cys Trp Ile Pro Pro Ser Ser Asp Arg Gly Pro Gln
 385 390 395 400
 Glu Ile Glu Gly Asn Ser His Leu Pro Ser Tyr Arg Pro Val Gly Pro
 405 410 415
 Glu Lys Leu His Ser Leu Gln Ser Ala Asn Gly Ser Cys His Glu Arg
 420 425 430
 Ala Pro Asp Leu Pro Arg Gln Thr Glu Pro Val Gln
 435 440

<210> 122
 <211> 54
 <212> PRT
 <213> Homo sapiens

<400> 122
 Met Phe Arg Glu Leu Asn Glu Ala Leu Glu Leu Lys Asp Ala His Ala
 1 5 10 15
 Thr Glu Glu Ser Gly Asp Ser Arg Ala His Ser Ser Tyr Leu Lys Thr
 20 25 30
 Lys Lys Gly Gln Ser Thr Ser Arg His Lys Lys Thr Met Val Lys Lys
 35 40 45
 Val Gly Pro Asp Ser Asp
 50

<210> 123
 <211> 855
 <212> PRT
 <213> Homo sapiens

<400> 123
 Met Lys Tyr Pro Val Trp Pro Arg Tyr Ser Ala Ser Leu Gln Pro Val
 1 5 10 15
 Val Asp Ser Arg His Leu Thr Val Ala Thr Leu Glu Glu Arg Pro Phe
 20 25 30
 Val Ile Val Glu Ser Pro Asp Pro Gly Thr Gly Gly Cys Val Pro Asn
 35 40 45

Thr Val Pro Cys Arg Arg Gln Ser Asn His Thr Phe Ser Ser Gly Asp
 50 55 60
 Val Ala Pro Tyr Thr Lys Leu Cys Cys Lys Gly Phe Cys Ile Asp Ile
 65 70 75 80
 Leu Lys Lys Leu Ala Arg Val Val Lys Phe Ser Tyr Asp Leu Tyr Leu
 85 90 95
 Val Thr Asn Gly Lys His Gly Lys Arg Val Arg Gly Val Trp Asn Gly
 100 105 110
 Met Ile Gly Glu Val Tyr Tyr Lys Arg Ala Asp Met Ala Ile Gly Ser
 115 120 125
 Leu Thr Ile Asn Glu Glu Arg Ser Glu Ile Val Asp Phe Ser Val Pro
 130 135 140
 Phe Val Glu Thr Gly Ile Ser Val Met Val Ala Arg Ser Asn Gly Thr
 145 150 155 160
 Val Ser Pro Ser Ala Phe Leu Glu Pro Tyr Ser Pro Ala Val Trp Val
 165 170 175
 Met Met Phe Val Met Cys Leu Thr Val Val Ala Ile Thr Val Phe Met
 180 185 190
 Phe Glu Tyr Phe Ser Pro Val Ser Tyr Asn Gln Asn Leu Thr Arg Gly
 195 200 205
 Lys Lys Ser Gly Gly Pro Ala Phe Thr Ile Gly Lys Ser Val Trp Leu
 210 215 220
 Leu Trp Ala Leu Val Phe Asn Asn Ser Val Pro Ile Glu Asn Pro Arg
 225 230 235 240
 Gly Thr Thr Ser Lys Ile Met Val Leu Val Trp Ala Phe Phe Ala Val
 245 250 255
 Ile Phe Leu Ala Ser Tyr Thr Ala Asn Leu Ala Ala Phe Met Ile Gln
 260 265 270
 Glu Gln Tyr Ile Asp Thr Val Ser Gly Leu Ser Asp Lys Lys Phe Gln
 275 280 285
 Arg Pro Gln Asp Gln Tyr Pro Pro Phe Arg Phe Gly Thr Val Pro Asn
 290 295 300
 Gly Ser Thr Glu Arg Asn Ile Arg Ser Asn Tyr Arg Asp Met His Thr
 305 310 315 320
 His Met Val Lys Phe Asn Gln Arg Ser Val Glu Asp Ala Leu Thr Ser
 325 330 335
 Leu Lys Met Gly Lys Leu Asp Ala Phe Ile Tyr Asp Ala Ala Val Leu
 340 345 350
 Asn Tyr Met Ala Gly Lys Asp Glu Gly Cys Lys Leu Val Thr Ile Gly
 355 360 365
 Ser Gly Lys Val Phe Ala Thr Thr Gly Tyr Gly Ile Ala Met Gln Lys

370	375	380
Asp Ser His Trp Lys Arg Ala Ile Asp Leu Ala Leu Leu Gln Phe Leu		
385	390	395 400
Gly Asp Gly Glu Thr Gln Lys Leu Glu Thr Val Trp Leu Ser Gly Ile		
	405	410 415
Cys Gln Asn Glu Lys Asn Glu Val Met Ser Ser Lys Leu Asp Ile Asp		
	420	425 430
Asn Met Ala Gly Val Phe Tyr Met Leu Leu Val Ala Met Gly Leu Ala		
	435	440 445
Leu Leu Val Phe Ala Trp Glu His Leu Val Tyr Trp Lys Leu Arg His		
	450	455 460
Ser Val Pro Asn Ser Ser Gln Leu Asp Phe Leu Leu Ala Phe Ser Arg		
465	470	475 480
Gly Ile Tyr Ser Cys Phe Ser Gly Val Gln Ser Leu Ala Ser Pro Pro		
	485	490 495
Arg Gln Ala Ser Pro Asp Leu Thr Ala Ser Ser Ala Gln Ala Ser Val		
	500	505 510
Leu Lys Met Leu Gln Ala Ala Arg Asp Met Val Thr Thr Ala Gly Val		
	515	520 525
Ser Ser Ser Leu Asp Arg Ala Thr Arg Thr Ile Glu Asn Trp Gly Gly		
530	535	540
Gly Arg Arg Ala Pro Pro Pro Ser Pro Cys Pro Thr Pro Arg Ser Gly		
545	550	555 560
Pro Ser Pro Cys Leu Pro Thr Pro Asp Pro Pro Pro Glu Pro Ser Pro		
	565	570 575
Thr Gly Trp Gly Pro Pro Asp Gly Gly Arg Ala Ala Leu Val Arg Arg		
	580	585 590
Ala Pro Gln Pro Pro Gly Arg Pro Pro Thr Pro Gly Pro Pro Leu Ser		
	595	600 605
Asp Val Ser Arg Val Ser Arg Arg Pro Ala Trp Glu Ala Arg Trp Pro		
610	615	620
Val Arg Thr Gly His Cys Gly Arg His Leu Ser Ala Ser Glu Arg Pro		
625	630	635 640
Leu Ser Pro Ala Arg Cys His Tyr Ser Ser Phe Pro Arg Ala Asp Arg		
	645	650 655
Ser Gly Arg Pro Phe Leu Pro Leu Phe Pro Glu Pro Pro Glu Leu Glu		
	660	665 670
Asp Leu Pro Leu Leu Gly Pro Glu Gln Leu Ala Arg Arg Glu Ala Leu		
	675	680 685
Leu His Ala Ala Trp Ala Arg Gly Ser Arg Pro Arg His Ala Ser Leu		
690	695	700

Pro Ser Ser Val Ala Glu Ala Phe Ala Arg Pro Ser Ser Leu Pro Ala
 705 710 715 720
 Gly Cys Thr Gly Pro Ala Cys Ala Arg Pro Asp Gly His Ser Ala Cys
 725 730 735
 Arg Arg Leu Ala Gln Ala Gln Ser Met Cys Leu Pro Ile Tyr Arg Glu
 740 745 750
 Ala Cys Gln Glu Gly Glu Gln Ala Gly Ala Pro Ala Trp Gln His Arg
 755 760 765
 Gln His Val Cys Leu His Ala His Ala His Leu Pro Phe Cys Trp Gly
 770 775 780
 Ala Val Cys Pro His Leu Pro Pro Cys Ala Ser His Gly Ser Trp Leu
 785 790 795 800
 Ser Gly Ala Trp Gly Pro Leu Gly His Arg Gly Arg Thr Leu Gly Leu
 805 810 815
 Gly Thr Gly Tyr Arg Asp Ser Gly Gly Leu Asp Glu Ile Ser Xaa Val
 820 825 830
 Ala Arg Gly Thr Gln Gly Phe Pro Gly Pro Cys Thr Trp Arg Arg Ile
 835 840 845
 Ser Ser Leu Glu Ser Glu Val
 850 855

 <210> 124
 <211> 665
 <212> PRT
 <213> Homo sapiens

 <400> 124
 Met Arg Leu Ala Val Gly Ala Leu Leu Val Cys Ala Val Leu Gly Leu
 1 5 10 15
 Cys Leu Ala Val Pro Asp Lys Thr Val Arg Trp Cys Ala Val Ser Glu
 20 25 30
 His Glu Ala Thr Lys Cys Gln Ser Phe Arg Asp His Met Lys Ser Val
 35 40 45
 Ile Pro Ser Asp Gly Pro Ser Val Ala Cys Val Lys Lys Ala Ser Tyr
 50 55 60
 Leu Asp Cys Ile Arg Ala Ile Ala Ala Asn Glu Ala Asp Ala Val Thr
 65 70 75 80
 Leu Asp Ala Gly Leu Val Tyr Asp Ala Tyr Leu Ala Pro Asn Asn Leu
 85 90 95
 Lys Pro Val Val Ala Glu Phe Tyr Gly Ser Lys Glu Asp Pro Gln Thr
 100 105 110
 Phe Tyr Tyr Ala Val Ala Val Val Lys Lys Asp Ser Gly Phe Gln Met
 115 120 125

Asn Gln Leu Arg Gly Lys Lys Ser Cys His Thr Gly Leu Gly Arg Ser
 130 135 140
 Ala Gly Trp Asn Ile Pro Ile Gly Leu Leu Tyr Cys Asp Leu Pro Glu
 145 150 155 160
 Pro Arg Lys Pro Leu Glu Lys Ala Val Ala Asn Phe Phe Ser Gly Ser
 165 170 175
 Cys Ala Pro Cys Ala Asp Gly Thr Asp Phe Pro Gln Leu Cys Gln Leu
 180 185 190
 Cys Pro Gly Cys Gly Cys Ser Thr Leu Asn Gln Tyr Phe Gly Tyr Ser
 195 200 205
 Gly Ala Phe Lys Cys Leu Lys Asp Gly Ala Gly Asp Val Ala Phe Val
 210 215 220
 Lys His Ser Thr Ile Phe Glu Asn Leu Ala Asn Lys Ala Asp Arg Asp
 225 230 235 240
 Gln Tyr Glu Leu Leu Cys Leu Asp Asn Thr Arg Lys Pro Val Asp Glu
 245 250 255
 Tyr Lys Asp Cys His Leu Ala Gln Val Pro Ser His Thr Val Val Ala
 260 265 270
 Arg Ser Met Gly Gly Lys Glu Asp Leu Ile Trp Glu Leu Leu Asn Gln
 275 280 285
 Ala Gln Glu His Phe Gly Lys Asp Lys Ser Lys Glu Phe Gln Leu Phe
 290 295 300
 Ser Ser Pro His Gly Lys Asp Leu Leu Phe Lys Asp Ser Ala His Gly
 305 310 315 320
 Phe Leu Lys Val Pro Pro Arg Met Asp Ala Lys Met Tyr Leu Gly Tyr
 325 330 335
 Glu Tyr Val Thr Ala Ile Arg Asn Leu Arg Glu Gly Thr Cys Pro Glu
 340 345 350
 Ala Pro Thr Asp Glu Cys Lys Pro Val Lys Trp Cys Ala Leu Ser His
 355 360 365
 His Glu Arg Leu Lys Cys Asp Glu Trp Ser Val Asn Ser Val Gly Lys
 370 375 380
 Ile Glu Cys Val Ser Ala Glu Thr Thr Glu Asp Cys Ile Ala Lys Ile
 385 390 395 400
 Met Asn Gly Glu Ala Asp Ala Met Ser Leu Asp Gly Gly Phe Val Tyr
 405 410 415
 Ile Ala Gly Lys Cys Gly Leu Val Pro Val Leu Ala Glu Asn Tyr Asn
 420 425 430
 Lys Ser Asp Asn Cys Glu Asp Thr Pro Glu Ala Gly Tyr Phe Ala Val
 435 440 445

Ala Val Val Lys Lys Ser Ala Ser Asp Leu Thr Trp Asp Asn Leu Lys
 450 455 460

Gly Lys Lys Ser Cys His Thr Ala Phe Gly Arg Thr Ala Gly Trp Asn
 465 470 475 480

Ile Pro Met Gly Leu Leu Tyr Asn Lys Ile Asn His Cys Arg Phe Asp
 485 490 495

Glu Phe Phe Ser Glu Gly Cys Ala Pro Gly Ser Lys Lys Asp Ser Ser
 500 505 510

Leu Cys Lys Leu Cys Met Gly Ser Gly Leu Asn Leu Cys Glu Pro Asn
 515 520 525

Asn Lys Glu Gly Tyr Tyr Gly Tyr Thr Gly Ala Phe Arg Cys Leu Val
 530 535 540

Glu Lys Gly Asp Val Ala Phe Val Lys His Gln Thr Val Pro Gln Asn
 545 550 555 560

Thr Gly Gly Lys Asn Pro Asp Pro Trp Ala Lys Asn Leu Asn Glu Lys
 565 570 575

Asp Tyr Glu Leu Leu Cys Leu Asp Gly Thr Arg Lys Pro Val Glu Glu
 580 585 590

Tyr Ala Asn Cys His Leu Ala Arg Ala Pro Asn His Ala Val Val Thr
 595 600 605

Arg Lys Asp Lys Glu Ala Cys Val His Lys Ile Leu Arg Gln Gln Gln
 610 615 620

His Leu Phe Gly Ser Asn Val Thr Asp Cys Ser Gly Asn Phe Cys Leu
 625 630 635 640

Phe Arg Ser Glu Thr Lys Asp Leu Leu Phe Arg Asp Asp Thr His Leu
 645 650 655

Leu Glu Ala Cys Thr Phe Arg Arg Pro :
 660 665

<210> 125

<211> 646

<212> PRT

<213> Homo sapiens

<400> 125

Met Arg Leu Ala Val Gly Ala Leu Leu Val Cys Ala Val Leu Gly Leu
 1 5 10 15

Cys Leu Ala Val Pro Asp Lys Thr Val Arg Trp Cys Ala Val Ser Glu
 20 25 30

His Glu Ala Thr Lys Cys Gln Ser Phe Arg Asp His Met Lys Ser Val
 35 40 45

Ile Pro Ser Asp Gly Pro Ser Val Ala Cys Val Lys Lys Ala Ser Tyr
 50 55 60

Leu Asp Cys Ile Arg Ala Ile Ala Ala Asn Glu Ala Asp Ala Val Thr
 65 70 75 80
 Leu Asp Ala Gly Leu Val Tyr Asp Ala Tyr Leu Ala Pro Asn Asn Leu
 85 90 95
 Lys Pro Val Val Ala Glu Phe Tyr Gly Ser Lys Glu Asp Pro Gln Thr
 100 105 110
 Phe Tyr Tyr Ala Val Ala Val Val Lys Lys Asp Ser Gly Phe Gln Met
 115 120 125
 Asn Gln Leu Arg Gly Lys Lys Ser Cys His Thr Gly Leu Gly Arg Ser
 130 135 140
 Ala Gly Trp Asn Ile Pro Ile Gly Leu Leu Tyr Cys Asp Leu Pro Glu
 145 150 155 160
 Pro Arg Lys Pro Leu Glu Lys Ala Val Ala Asn Phe Phe Ser Gly Ser
 165 170 175
 Cys Ala Pro Cys Ala Asp Gly Thr Asp Phe Pro Gln Leu Cys Gln Leu
 180 185 190
 Cys Pro Gly Cys Gly Cys Ser Thr Leu Asn Gln Tyr Phe Gly Tyr Ser
 195 200 205
 Gly Ala Phe Lys Cys Leu Lys Asp Gly Ala Gly Asp Val Ala Phe Val
 210 215 220
 Lys His Ser Thr Ile Phe Glu Asn Leu Ala Asn Lys Ala Asp Arg Asp
 225 230 235 240
 Gln Tyr Glu Leu Leu Cys Leu Asp Asn Thr Arg Lys Pro Val Asp Glu
 245 250 255
 Tyr Lys Asp Cys His Leu Ala Gln Val Pro Ser His Thr Val Val Ala
 260 265 270
 Arg Ser Met Gly Gly Lys Glu Asp Leu Ile Trp Glu Leu Leu Asn Gln
 275 280 285
 Ala Gln Glu His Phe Gly Lys Asp Lys Ser Lys Glu Phe Gln Leu Phe
 290 295 300
 Ser Ser Pro His Gly Lys Asp Leu Leu Phe Lys Asp Ser Ala His Gly
 305 310 315 320
 Phe Leu Lys Val Pro Pro Arg Met Asp Ala Lys Met Tyr Leu Gly Tyr
 325 330 335
 Glu Tyr Val Thr Ala Ile Arg Asn Leu Arg Glu Gly Thr Cys Pro Glu
 340 345 350
 Ala Pro Thr Asp Glu Cys Lys Pro Val Lys Trp Cys Ala Leu Ser His
 355 360 365
 His Glu Arg Leu Lys Cys Asp Glu Trp Ser Val Asn Ser Val Gly Lys
 370 375 380
 Ile Glu Cys Val Ser Ala Glu Thr Thr Glu Asp Cys Ile Ala Lys Ile

385 390 395 400
 Met Asn Gly Glu Ala Asp Ala Met Ser Leu Asp Gly Gly Phe Val Tyr
 405 410 415
 Ile Ala Gly Lys Cys Gly Leu Val Pro Val Leu Ala Glu Asn Tyr Asn
 420 425 430
 Lys Ser Asp Asn Cys Glu Asp Thr Pro Glu Ala Gly Tyr Phe Ala Glu
 435 440 445
 Glu Gly Cys Ala Pro Gly Ser Lys Lys Asp Ser Ser Leu Cys Lys Leu
 450 455 460
 Cys Met Gly Ser Gly Leu Asn Leu Cys Glu Pro Asn Asn Lys Glu Gly
 465 470 475 480
 Tyr Tyr Gly Tyr Thr Gly Ala Phe Arg Cys Leu Val Glu Lys Gly Asp
 485 490 495
 Val Ala Phe Val Lys His Gln Thr Val Pro Gln Asn Thr Gly Gly Lys
 500 505 510
 Asn Pro Asp Pro Trp Ala Lys Asn Leu Asn Glu Lys Asp Tyr Glu Leu
 515 520 525
 Leu Cys Leu Asp Gly Thr Arg Lys Pro Val Glu Glu Tyr Ala Asn Cys
 530 535 540
 His Leu Ala Arg Ala Pro Asn His Ala Val Val Thr Arg Lys Asp Lys
 545 550 555 560
 Glu Ala Cys Val His Lys Ile Leu Arg Gln Gln Gln His Leu Phe Gly
 565 570 575
 Ser Asn Val Thr Asp Cys Ser Gly Asn Phe Cys Leu Phe Arg Ser Glu
 580 585 590
 Thr Lys Asp Leu Leu Phe Arg Asp Asp Thr Val Cys Leu Ala Lys Leu
 595 600 605
 His Asp Arg Asn Thr Tyr Glu Lys Tyr Leu Gly Glu Glu Tyr Val Lys
 610 615 620
 Ala Val Gly Asn Leu Arg Lys Cys Ser Thr Ser Ser Leu Leu Glu Ala
 625 630 635 640
 Cys Thr Phe Arg Arg Pro
 645

<210> 126

<211> 4787

<212> PRT

<213> Homo sapiens

<400> 126

Met Ala Glu Gly Gly Glu Gly Gly Glu Asp Glu Ile Gln Phe Leu Arg
 1 5 10 15

Thr Glu Asp Glu Val Val Leu Gln Cys Ile Ala Thr Ile His Lys Glu

20 25 30

Gln Arg Lys Phe Cys Leu Ala Ala Glu Gly Leu Gly Asn Arg Leu Cys
35 40 45

Phe Leu Glu Pro Thr Ser Glu Ala Lys Tyr Ile Pro Pro Asp Leu Cys
50 55 60

Val Cys Asn Phe Val Leu Glu Gln Ser Leu Ser Val Arg Ala Leu Gln
65 70 75 80

Glu Met Leu Ala Asn Thr Gly Glu Asn Gly Gly Glu Gly Ala Ala Gln
85 90 95

Gly Gly Gly His Arg Thr Leu Leu Tyr Gly His Ala Val Leu Leu Arg
100 105 110

His Ser Phe Ser Gly Met Tyr Leu Thr Cys Leu Thr Thr Ser Arg Ser
115 120 125

Gln Thr Asp Lys Leu Ala Phe Asp Val Gly Leu Arg Glu His Ala Thr
130 135 140

Gly Glu Ala Cys Trp Trp Thr Ile His Pro Ala Ser Lys Gln Arg Ser
145 150 155 160

Glu Gly Glu Lys Val Arg Ile Gly Asp Asp Leu Ile Leu Val Ser Val
165 170 175

Ser Ser Glu Arg Tyr Leu His Leu Ser Val Ser Asn Gly Asn Ile Gln
180 185 190

Val Asp Ala Ser Phe Met Gln Thr Leu Trp Asn Val His Pro Thr Cys
195 200 205

Ser Gly Ser Ser Ile Glu Glu Gly Tyr Leu Leu Gly Gly His Val Val
210 215 220

Arg Leu Phe His Gly His Asp Glu Cys Leu Thr Ile Pro Ser Thr Asp
225 230 235 240

Gln Asn Asp Ser Gln His Arg Arg Ile Phe Tyr Glu Ala Gly Gly Ala
245 250 255

Gly Thr Arg Ala Xaa Ser Leu Trp Arg Val Glu Pro Leu Arg Ile Ser
260 265 270

Trp Ser Gly Ser Asn Ile Arg Trp Gly Gln Ala Phe Arg Leu Arg His
275 280 285

Leu Thr Thr Gly His Tyr Leu Ala Leu Thr Glu Asp Gln Gly Leu Ile
290 295 300

Leu Gln Asp Arg Ala Lys Ser Asp Thr Lys Ser Thr Ala Phe Ser Phe
305 310 315 320

Arg Ala Ser Lys Glu Leu Lys Glu Lys Leu Asp Ser Ser His Lys Arg
325 330 335

Asp Ile Glu Gly Met Gly Val Pro Glu Ile Lys Tyr Gly Asp Ser Val
340 345 350

Cys Phe Val Gln His Ile Ala Ser Gly Leu Trp Val Thr Tyr Lys Ala
 355 360 365
 Gln Asp Ala Lys Thr Ser Arg Leu Gly Pro Leu Lys Arg Lys Val Ile
 370 375 380
 Leu His Gln Glu Gly His Met Asp Asp Gly Leu Thr Leu Gln Arg Cys
 385 390 395 400
 Gln Arg Glu Glu Ser Gln Ala Ala Arg Ile Ile Arg Asn Thr Thr Ala
 405 410 415
 Leu Phe Ser Gln Phe Val Ser Gly Asn Asn Arg Thr Ala Ala Pro Ile
 420 425 430
 Thr Leu Pro Ile Glu Glu Val Leu Gln Thr Leu Gln Asp Leu Ile Ala
 435 440 445
 Tyr Phe Gln Pro Pro Glu Glu Glu Met Arg His Glu Asp Lys Gln Asn
 450 455 460
 Lys Leu Arg Ser Leu Lys Asn Arg Gln Asn Leu Phe Lys Glu Glu Gly
 465 470 475 480
 Met Leu Ala Leu Val Leu Asn Cys Ile Asp Arg Leu Asn Xaa Tyr Asn
 485 490 495
 Ser Val Ala His Phe Ala Gly Ile Ala Arg Glu Glu Ser Gly Met Ala
 500 505 510
 Trp Lys Glu Ile Leu Asn Leu Leu Tyr Lys Leu Leu Ala Ala Leu Ile
 515 520 525
 Arg Gly Asn Arg Asn Asn Cys Ala Gln Phe Ser Asn Asn Leu Asp Trp
 530 535 540
 Leu Ile Ser Lys Leu Asp Arg Leu Glu Ser Ser Ser Gly Ile Leu Glu
 545 550 555 560
 Val Leu His Cys Ile Leu Thr Glu Ser Pro Glu Ala Leu Asn Leu Ile
 565 570 575
 Ala Glu Gly His Ile Lys Ser Ile Ile Ser Leu Leu Asp Lys His Gly
 580 585 590
 Arg Asn His Lys Val Leu Asp Ile Leu Cys Ser Leu Cys Leu Cys Asn
 595 600 605
 Gly Val Ala Val Arg Ala Asn Gln Asn Leu Ile Cys Asp Asn Leu Leu
 610 615 620
 Pro Arg Arg Asn Leu Leu Leu Gln Thr Arg Leu Ile Asn Asp Val Thr
 625 630 635 640
 Ser Ile Arg Pro Asn Ile Phe Leu Gly Val Ala Glu Gly Ser Ala Gln
 645 650 655
 Tyr Lys Lys Trp Tyr Phe Glu Leu Ile Ile Asp Gln Val Asp Pro Phe
 660 665 670

Leu Thr Ala Glu Pro Thr His Leu Arg Val Gly Trp Ala Ser Ser Ser
 675 680 685
 Gly Tyr Ala Pro Xaa Pro Gly Gly Gly Glu Gly Trp Gly Gly Asn Gly
 690 695 700
 Val Gly Asp Asp Leu Tyr Ser Tyr Gly Phe Asp Gly Leu His Leu Trp
 705 710 715 720
 Ser Gly Arg Ile Pro Arg Ala Val Ala Ser Xaa Asn Gln His Leu Leu
 725 730 735
 Arg Ser Asp Asp Val Val Ser Cys Cys Leu Asp Leu Gly Cys Pro Ala
 740 745 750
 Ser His Ser Ala Ser Met Gly Ser Pro Cys Arg Gly Cys Leu Arg Asn
 755 760 765
 Phe Asn Thr Asp Gly Leu Phe Phe Pro Val Met Ser Phe Ser Ala Gly
 770 775 780
 Val Lys Val Arg Phe Leu Met Gly Gly Arg His Gly Glu Phe Lys Phe
 785 790 795 800
 Leu Pro Pro Ser Gly Tyr Ala Pro Cys Tyr Glu Ala Leu Leu Pro Lys
 805 810 815
 Glu Lys Met Arg Leu Glu Pro Val Lys Glu Tyr Lys Arg Asp Ala Asp
 820 825 830
 Gly Ile Arg Asp Leu Leu Gly Thr Thr Gln Phe Leu Ser Gln Ala Ser
 835 840 845
 Phe Ile Pro Cys Pro Val Asp Thr Ser Gln Val Ile Leu Pro Pro His
 850 855 860
 Leu Glu Lys Ile Arg Asp Arg Leu Ala Glu Asn Ile His Glu Leu Trp
 865 870 875 880
 Gly Met Asn Lys Ile Glu Leu Gly Trp Thr Phe Gly Lys Ile Arg Asp
 885 890 895
 Asp Asn Lys Arg Gln His Pro Cys Leu Val Glu Phe Ser Lys Leu Pro
 900 905 910
 Glu Thr Glu Lys Asn Tyr Asn Leu Gln Met Ser Thr Glu Thr Leu Lys
 915 920 925
 Thr Leu Leu Xaa Leu Gly Cys His Ile Ala His Val Asn Pro Ala Ala
 930 935 940
 Glu Glu Asp Leu Lys Lys Val Lys Leu Pro Lys Asn Tyr Met Met Ser
 945 950 955 960
 Asn Gly Tyr Lys Pro Ala Pro Leu Asp Leu Ser Asp Val Lys Leu Leu
 965 970 975
 Pro Pro Gln Glu Ile Leu Val Asp Lys Leu Ala Glu Asn Ala His Asn
 980 985 990
 Val Trp Ala Lys Asp Arg Ile Lys Gln Gly Trp Thr Tyr Gly Ile Gln

995	1000	1005
Gln Asp Leu Lys Asn Lys Arg Asn Pro Arg Leu Val Pro Tyr Ala Leu		
1010	1015	1020
Leu Asp Glu Arg Thr Lys Lys Ser Asn Arg Asp Ser Leu Arg Glu Ala		
1025	1030	1035 1040
Val Arg Thr Phe Val Gly Tyr Gly Tyr Asn Ile Glu Pro Ser Asp Gln		
	1045	1050 1055
Glu Leu Ala Asp Ser Ala Val Glu Lys Val Ser Ile Asp Lys Ile Arg		
	1060	1065 1070
Phe Phe Arg Val Glu Arg Ser Tyr Xaa Val Arg Ser Gly Lys Trp Tyr		
	1075	1080 1085
Phe Glu Phe Glu Val Val Thr Gly Gly Asp Met Arg Val Gly Trp Ala		
	1090	1095 1100
Arg Pro Gly Cys Arg Pro Asp Val Glu Leu Gly Ala Asp Asp Gln Ala		
	1105	1110 1115 1120
Phe Val Phe Glu Gly Asn Arg Gly Gln Arg Trp His Gln Gly Ser Gly		
	1125	1130 1135
Tyr Phe Gly Arg Thr Trp Gln Pro Gly Asp Val Val Gly Cys Met Ile		
	1140	1145 1150
Asn Leu Asp Asp Ala Ser Met Ile Phe Thr Leu Asn Gly Glu Leu Leu		
	1155	1160 1165
Ile Thr Asn Lys Gly Ser Glu Leu Ala Phe Ala Asp Tyr Glu Ile Glu		
	1170	1175 1180
Asn Gly Phe Val Pro Ile Cys Cys Leu Gly Leu Ser Gln Ile Gly Arg		
	1185	1190 1195 1200
Met Asn Leu Gly Thr Asp Ala Ser Thr Phe Lys Phe Tyr Thr Met Cys		
	1205	1210 1215
Gly Leu Gln Glu Gly Phe Glu Pro Phe Ala Val Asn Met Asn Arg Asp		
	1220	1225 1230
Val Ala Met Trp Phe Ser Lys Arg Leu Pro Thr Phe Val Asn Val Pro		
	1235	1240 1245
Lys Asp His Pro His Ile Glu Val Met Arg Ile Asp Gly Thr Met Asp		
	1250	1255 1260
Ser Pro Pro Cys Leu Lys Val Thr His Lys Thr Phe Gly Thr Gln Asn		
	1265	1270 1275 1280
Ser Asn Ala Asp Met Ile Tyr Cys Arg Leu Ser Met Pro Val Glu Cys		
	1285	1290 1295
His Ser Ser Phe Ser His Ser Pro Cys Leu Asp Ser Glu Ala Phe Gln		
	1300	1305 1310
Lys Arg Lys Gln Met Gln Glu Ile Leu Ser His Thr Thr Thr Gln Cys		
	1315	1320 1325

Tyr Tyr Ala Ile Arg Ile Phe Xaa Gly Gln Asp Pro Ser Cys Val Trp
 1330 1335 1340
 Val Gly Trp Val Thr Pro Asp Tyr His Leu Tyr Ser Glu Lys Phe Asp
 1345 1350 1355 1360
 Leu Asn Lys Asn Cys Thr Val Thr Val Thr Leu Gly Asp Glu Arg Gly
 1365 1370 1375
 Arg Val His Glu Ser Val Lys Arg Ser Asn Cys Tyr Met Val Trp Gly
 1380 1385 1390
 Gly Asp Ile Val Ala Ser Ser Gln Arg Ser Asn Arg Ser Asn Val Asp
 1395 1400 1405
 Leu Glu Ile Gly Cys Leu Val Asp Leu Ala Met Gly Met Leu Ser Phe
 1410 1415 1420
 Ser Ala Asn Gly Lys Glu Leu Gly Thr Cys Tyr Gln Val Glu Pro Asn
 1425 1430 1435 1440
 Thr Lys Val Phe Pro Ala Val Phe Leu Gln Pro Thr Ser Thr Ser Leu
 1445 1450 1455
 Phe Gln Phe Glu Leu Gly Lys Leu Lys Asn Ala Met Pro Leu Ser Ala
 1460 1465 1470
 Ala Ile Phe Arg Ser Glu Glu Xaa Asn Pro Val Pro Gln Cys Pro Pro
 1475 1480 1485
 Arg Leu Asp Val Gln Thr Ile Gln Pro Val Leu Trp Ser Arg Met Pro
 1490 1495 1500
 Asn Ser Phe Leu Lys Val Glu Thr Glu Arg Val Ser Glu Arg His Gly
 1505 1510 1515 1520
 Trp Val Val Gln Cys Leu Glu Pro Leu Gln Met Met Ala Leu His Ile
 1525 1530 1535
 Pro Glu Glu Asn Arg Cys Val Asp Ile Leu Glu Leu Cys Glu Gln Glu
 1540 1545 1550
 Asp Leu Met Arg Phe His Tyr His Thr Leu Arg Leu Tyr Ser Ala Val
 1555 1560 1565
 Cys Ala Leu Gly Asn Ser Arg Val Ala Tyr Ala Leu Cys Ser His Val
 1570 1575 1580
 Asp Leu Ser Gln Leu Phe Tyr Ala Ile Asp Asn Lys Tyr Leu Pro Gly
 1585 1590 1595 1600
 Leu Leu Arg Ser Gly Phe Tyr Asp Leu Leu Ile Ser Ile His Leu Ala
 1605 1610 1615
 Ser Ala Lys Glu Arg Lys Leu Met Met Lys Asn Glu Tyr Ile Ile Pro
 1620 1625 1630
 Ile Thr Ser Thr Thr Arg Asn Ile Cys Leu Phe Pro Asp Glu Ser Lys
 1635 1640 1645

Arg His Gly Leu Pro Gly Val Gly Leu Arg Thr Cys Leu Lys Pro Gly
 1650 1655 1660
 Phe Arg Phe Ser Thr Pro Cys Phe Val Val Thr Gly Glu Asp His Gln
 1665 1670 1675 1680
 Lys Gln Ser Pro Glu Ile Pro Leu Glu Ser Leu Arg Thr Lys Ala Leu
 1685 1690 1695
 Ser Met Leu Thr Glu Ala Val Gln Cys Ser Gly Ala His Ile Arg Asp
 1700 1705 1710
 Pro Val Gly Gly Ser Val Glu Phe Gln Phe Val Pro Val Leu Lys Leu
 1715 1720 1725
 Ile Gly Thr Leu Leu Val Met Gly Val Phe Asp Asp Asp Asp Val Arg
 1730 1735 1740
 Gln Ile Leu Leu Leu Ile Asp Pro Ser Val Phe Gly Glu His Ser Ala
 1745 1750 1755 1760
 Gly Thr Glu Glu Gly Ala Glu Lys Glu Glu Val Thr Gln Val Glu Glu
 1765 1770 1775
 Lys Ala Val Glu Ala Gly Glu Lys Ala Gly Lys Glu Ala Pro Val Lys
 1780 1785 1790
 Gly Leu Leu Gln Thr Arg Leu Pro Glu Ser Val Lys Leu Gln Met Cys
 1795 1800 1805
 Glu Leu Leu Ser Tyr Leu Cys Asp Cys Glu Leu Gln His Arg Val Glu
 1810 1815 1820
 Ala Ile Val Ala Phe Gly Asp Ile Tyr Val Ser Lys Leu Gln Ala Asn
 1825 1830 1835 1840
 Gln Lys Phe Arg Tyr Asn Glu Leu Met Gln Ala Leu Asn Met Ser Ala
 1845 1850 1855
 Ala Leu Thr Ala Arg Lys Thr Lys Glu Phe Arg Ser Pro Pro Gln Glu
 1860 1865 1870
 Gln Ile Asn Met Leu Leu Asn Phe Gln Leu Gly Glu Asn Cys Pro Cys
 1875 1880 1885
 Pro Glu Glu Ile Arg Glu Glu Leu Tyr Asp Phe His Glu Asp Leu Leu
 1890 1895 1900
 Leu His Cys Gly Val Pro Leu Glu Glu Glu Glu Glu Glu Glu Asp
 1905 1910 1915 1920
 Thr Ser Trp Thr Gly Lys Leu Cys Ala Leu Val Tyr Lys Ile Lys Gly
 1925 1930 1935
 Pro Pro Lys Pro Glu Lys Glu Gln Pro Thr Glu Glu Glu Glu Arg Cys
 1940 1945 1950
 Pro Thr Thr Leu Lys Glu Leu Ile Ser Gln Thr Met Ile Cys Trp Ala
 1955 1960 1965
 Gln Glu Asp Gln Ile Gln Asp Ser Glu Leu Val Arg Met Met Phe Asn

1970	1975	1980
Leu Leu Arg Arg Gln Tyr Asp Ser Ile Gly Glu Leu Leu Gln Ala Leu 1985	1990	1995 2000
Arg Lys Thr Tyr Thr Ile Ser His Thr Ser Val Ser Asp Thr Ile Asn 2005	2010	2015
Leu Leu Ala Ala Leu Gly Gln Ile Arg Ser Leu Leu Ser Val Arg Met 2020	2025	2030
Gly Lys Glu Glu Glu Leu Leu Met Ile Asn Gly Leu Gly Asp Ile Met 2035	2040	2045
Asn Asn Lys Val Phe Tyr Gln His Pro Asn Leu Met Arg Val Leu Gly 2050	2055	2060
Met His Glu Thr Val Met Glu Val Met Val Asn Val Leu Gly Thr Glu 2065	2070	2075 2080
Lys Ser Gln Ile Ala Phe Pro Lys Met Val Ala Ser Cys Cys Arg Phe 2085	2090	2095
Leu Cys Tyr Phe Cys Arg Ile Ser Arg Gln Asn Gln Lys Ala Met Phe 2100	2105	2110
Glu His Leu Ser Tyr Leu Leu Glu Asn Ser Ser Val Gly Leu Ala Ser 2115	2120	2125
Pro Ser Met Arg Gly Ser Thr Pro Leu Asp Val Ala Ala Ser Ser Val 2130	2135	2140
Met Asp Asn Asn Glu Leu Ala Leu Ser Leu Glu Glu Pro Asp Leu Glu 2145	2150	2155 2160
Lys Val Val Thr Tyr Leu Ala Gly Cys Gly Leu Gln Ser Cys Pro Met 2165	2170	2175
Leu Leu Ala Lys Gly Tyr Pro Asp Val Gly Trp Asn Pro Ile Glu Gly 2180	2185	2190
Glu Arg Tyr Leu Ser Phe Leu Arg Phe Ala Val Phe Val Asn Ser Glu 2195	2200	2205
Ser Val Glu Glu Asn Ala Ser Val Val Val Lys Leu Leu Ile Arg Arg 2210	2215	2220
Pro Glu Cys Phe Gly Pro Ala Leu Arg Gly Glu Gly Gly Asn Gly Leu 2225	2230	2235 2240
Leu Ala Ala Met Gln Gly Ala Ile Lys Ile Ser Glu Asn Pro Ala Leu 2245	2250	2255
Asp Leu Pro Ser Gln Gly Tyr Lys Arg Glu Val Ser Thr Glu Asp Asp 2260	2265	2270
Glu Glu Glu Glu Glu Ile Val His Met Gly Asn Ala Ile Met Ser Phe 2275	2280	2285
Tyr Ser Ala Leu Ile Asp Leu Leu Gly Arg Cys Ala Pro Glu Met His 2290	2295	2300

Leu Ile Gln Thr Gly Lys Gly Glu Ala Ile Arg Ile Arg Ser Ile Leu
 2305 2310 2315 2320
 Arg Ser Leu Val Pro Thr Glu Asp Leu Val Gly Ile Ile Ser Ile Pro
 2325 2330 2335
 Leu Lys Leu Pro Ser Leu Asn Lys Asp Gly Ser Val Ser Glu Pro Asp
 2340 2345 2350
 Met Ala Xaa Asn Phe Cys Pro Asp His Lys Ala Pro Met Val Leu Phe
 2355 2360 2365
 Leu Asp Arg Val Tyr Gly Ile Lys Asp Gln Thr Phe Leu Leu His Leu
 2370 2375 2380
 Leu Glu Val Gly Phe Leu Pro Asp Leu Arg Ala Ser Ala Ser Leu Asp
 2385 2390 2395 2400
 Thr Val Ser Leu Ser Thr Thr Glu Ala Ala Leu Ala Leu Asn Arg Tyr
 2405 2410 2415
 Ile Cys Ser Ala Val Leu Pro Leu Leu Thr Arg Cys Ala Pro Leu Phe
 2420 2425 2430
 Xaa Gly Thr Glu His Cys Thr Ser Leu Ile Asp Ser Thr Leu Gln Thr
 2435 2440 2445
 Ile Tyr Arg Leu Ser Lys Gly Arg Ser Leu Thr Lys Ala Gln Arg Asp
 2450 2455 2460
 Thr Ile Glu Glu Cys Leu Leu Ala Ile Cys Asn His Leu Arg Pro Ser
 2465 2470 2475 2480
 Met Leu Gln Gln Leu Leu Arg Arg Leu Val Phe Asp Val Pro Gln Leu
 2485 2490 2495
 Asn Glu Tyr Cys Lys Met Pro Leu Lys Leu Leu Thr Asn His Tyr Glu
 2500 2505 2510
 Gln Cys Trp Lys Tyr Tyr Cys Leu Pro Ser Gly Trp Gly Ser Tyr Gly
 2515 2520 2525
 Leu Ala Val Glu Glu Glu Leu His Leu Thr Glu Lys Leu Phe Trp Gly
 2530 2535 2540
 Ile Xaa Asp Ser Leu Ser His Lys Lys Tyr Asp Pro Asp Leu Phe Arg
 2545 2550 2555 2560
 Met Ala Leu Pro Cys Leu Ser Ala Ile Ala Gly Ala Leu Pro Pro Asp
 2565 2570 2575
 Tyr Leu Asp Xaa Arg Ile Thr Ala Thr Leu Glu Lys Gln Ile Ser Val
 2580 2585 2590
 Asp Ala Asp Gly Asn Phe Asp Pro Lys Pro Ile Asn Thr Met Asn Phe
 2595 2600 2605
 Ser Leu Pro Glu Lys Leu Glu Tyr Ile Val Thr Lys Tyr Ala Glu His
 2610 2615 2620

Ser His Asp Lys Trp Ala Cys Asp Lys Ser Gln Ser Gly Trp Lys Tyr
 2625 2630 2635 2640
 Gly Ile Ser Leu Asp Glu Asn Val Lys Thr His Pro Leu Ile Arg Pro
 2645 2650 2655
 Phe Lys Thr Leu Thr Glu Lys Glu Lys Glu Ile Tyr Arg Trp Pro Ala
 2660 2665 2670
 Arg Glu Ser Leu Lys Thr Met Leu Ala Val Gly Trp Thr Val Glu Arg
 2675 2680 2685
 Thr Lys Glu Gly Glu Ala Leu Val Gln Gln Arg Glu Asn Glu Lys Leu
 2690 2695 2700
 Arg Ser Val Ser Gln Ala Asn Gln Gly Asn Ser Tyr Ser Pro Ala Pro
 2705 2710 2715 2720
 Leu Asp Leu Ser Asn Val Val Leu Ser Arg Glu Leu Gln Gly Met Val
 2725 2730 2735
 Glu Val Val Ala Glu Asn Tyr His Asn Ile Trp Ala Lys Lys Lys Lys
 2740 2745 2750
 Leu Glu Leu Glu Ser Lys Gly Gly Gly Ser His Pro Leu Leu Val Pro
 2755 2760 2765
 Tyr Asp Thr Leu Thr Ala Lys Glu Lys Phe Lys Asp Arg Glu Lys Ala
 2770 2775 2780
 Gln Asp Leu Phe Lys Phe Leu Gln Val Asn Gly Ile Ile Val Ser Arg
 2785 2790 2795 2800
 Gly Met Lys Asp Met Glu Leu Asp Ala Ser Ser Met Glu Lys Arg Phe
 2805 2810 2815
 Xaa Tyr Lys Phe Leu Lys Lys Ile Leu Lys Tyr Val Asp Ser Ala Gln
 2820 2825 2830
 Glu Phe Ile Ala His Leu Glu Ala Ile Val Ser Ser Gly Lys Thr Glu
 2835 2840 2845
 Lys Ser Pro Arg Asp Gln Glu Ile Lys Phe Phe Ala Lys Val Leu Leu
 2850 2855 2860
 Pro Leu Val Asp Gln Tyr Phe Thr Ser His Cys Leu Tyr Phe Leu Ser
 2865 2870 2875 2880
 Ser Pro Leu Lys Pro Leu Ser Ser Ser Gly Tyr Ala Ser His Lys Glu
 2885 2890 2895
 Lys Glu Met Val Ala Gly Leu Phe Cys Lys Leu Ala Ala Leu Val Arg
 2900 2905 2910
 His Arg Ile Ser Leu Phe Gly Ser Asp Ser Thr Thr Met Val Ser Cys
 2915 2920 2925
 Leu His Ile Leu Ala Gln Thr Leu Asp Thr Arg Thr Val Met Lys Ser
 2930 2935 2940
 Gly Ser Glu Leu Val Lys Ala Gly Leu Arg Ala Phe Phe Glu Asn Ala

2945	2950	2955	2960
Ala Glu Asp Leu Glu Lys Thr Ser Glu Asn Leu Lys Leu Gly Lys Phe			
2965	2970	2975	
Thr His Ser Arg Thr Gln Ile Lys Gly Val Ser Gln Asn Ile Asn Tyr			
2980	2985	2990	
Thr Thr Val Ala Leu Leu Pro Ile Leu Thr Ser Ile Phe Glu His Val			
2995	3000	3005	
Thr Gln His Gln Phe Gly Met Asp Leu Leu Leu Gly Asp Val Gln Ile			
3010	3015	3020	
Ser Cys Tyr His Ile Leu Cys Ser Leu Tyr Ser Leu Gly Thr Gly Lys			
3025	3030	3035	3040
Asn Ile Tyr Val Glu Arg Gln Arg Pro Ala Leu Gly Glu Cys Leu Ala			
3045	3050	3055	
Ser Leu Ala Ala Ala Ile Pro Val Ala Phe Leu Glu Pro Thr Leu Asn			
3060	3065	3070	
Arg Tyr Asn Pro Leu Ser Val Phe Asn Thr Lys Thr Pro Arg Glu Arg			
3075	3080	3085	
Ser Ile Leu Gly Met Pro Asp Thr Val Glu Asp Met Cys Pro Asp Ile			
3090	3095	3100	
Pro Gln Leu Glu Gly Leu Met Lys Glu Ile Asn Asp Leu Ala Glu Ser			
3105	3110	3115	3120
Gly Ala Arg Tyr Thr Glu Met Pro His Val Ile Glu Val Ile Leu Pro			
3125	3130	3135	
Met Leu Cys Asn Tyr Leu Ser Tyr Trp Trp Glu Arg Gly Pro Glu Asn			
3140	3145	3150	
Leu Pro Pro Ser Thr Gly Pro Cys Cys Thr Lys Val Thr Ser Glu His			
3155	3160	3165	
Leu Ser Leu Ile Leu Gly Asn Ile Leu Lys Ile Ile Asn Asn Asn Leu			
3170	3175	3180	
Gly Ile Asp Glu Ala Ser Trp Met Lys Arg Ile Ala Val Tyr Ala Gln			
3185	3190	3195	3200
Pro Ile Ile Ser Lys Ala Arg Pro Asp Leu Leu Arg Ser His Phe Ile			
3205	3210	3215	
Pro Thr Leu Glu Lys Leu Lys Lys Lys Ala Val Lys Thr Val Gln Glu			
3220	3225	3230	
Glu Glu Gln Leu Lys Ala Asp Gly Lys Gly Asp Thr Gln Glu Ala Glu			
3235	3240	3245	
Leu Leu Ile Leu Asp Glu Phe Ala Val Leu Cys Arg Asp Leu Tyr Ala			
3250	3255	3260	
Phe Tyr Pro Met Leu Ile Arg Tyr Val Asp Asn Asn Arg Ser Asn Trp			
3265	3270	3275	3280

Leu Lys Ser Pro Asp Ala Asp Ser Asp Gln Leu Phe Arg Met Val Ala
 3285 3290 3295
 Glu Val Phe Ile Leu Trp Cys Lys Ser His Asn Phe Lys Arg Glu Glu
 3300 3305 3310
 Gln Asn Phe Val Ile Gln Asn Glu Ile Asn Asn Leu Ala Phe Leu Thr
 3315 3320 3325
 Gly Asp Ser Lys Ser Lys Met Ser Lys Ser Gly Gly Gln Asp Gln Glu
 3330 3335 3340
 Arg Lys Lys Thr Lys Arg Arg Gly Asp Leu Tyr Ser Ile Gln Thr Ser
 3345 3350 3355 3360
 Leu Ile Val Ala Ala Leu Lys Lys Met Leu Pro Ile Gly Leu Asn Met
 3365 3370 3375
 Cys Thr Pro Gly Asp Gln Glu Leu Ile Ser Leu Ala Lys Ser Arg Tyr
 3380 3385 3390
 Ser His Arg Asp Thr Asp Glu Glu Val Arg Glu His Leu Arg Asn Asn
 3395 3400 3405
 Leu His Leu Gln Glu Lys Ser Asp Asp Pro Ala Val Lys Trp Gln Leu
 3410 3415 3420
 Asn Leu Tyr Lys Asp Val Leu Lys Ser Glu Glu Pro Phe Asn Pro Glu
 3425 3430 3435 3440
 Lys Thr Val Glu Arg Val Gln Arg Ile Ser Ala Ala Val Phe His Leu
 3445 3450 3455
 Glu Gln Val Glu Gln Pro Leu Arg Ser Lys Lys Ala Val Trp His Lys
 3460 3465 3470
 Leu Leu Ser Lys Gln Arg Lys Arg Ala Val Val Ala Cys Phe Arg Met
 3475 3480 3485
 Ala Pro Leu Tyr Asn Leu Pro Arg His Arg Ser Ile Asn Leu Phe Leu
 3490 3495 3500
 His Gly Tyr Gln Arg Phe Trp Ile Glu Thr Glu Glu Tyr Ser Phe Glu
 3505 3510 3515 3520
 Glu Lys Leu Val Gln Asp Leu Ala Lys Ser Pro Lys Val Glu Glu Glu
 3525 3530 3535
 Glu Glu Glu Glu Thr Glu Lys Gln Pro Asp Pro Leu His Gln Ile Ile
 3540 3545 3550
 Leu Tyr Phe Ser Arg Asn Ala Leu Thr Glu Arg Ser Lys Leu Glu Asp
 3555 3560 3565
 Asp Pro Leu Tyr Thr Ser Tyr Ser Ser Met Met Ala Lys Ser Cys Gln
 3570 3575 3580
 Ser Gly Glu Asp Glu Glu Glu Asp Glu Asp Lys Glu Lys Thr Phe Glu
 3585 3590 3595 3600

3605	3610	3615
His Glu Arg Gly Ala Ala Glu Met Val Leu Gln Met Ile Ser Ala Ser		
3620	3625	3630
Lys Gly Glu Met Ser Pro Met Val Val Glu Thr Leu Lys Leu Gly Ile		
3635	3640	3645
Ala Ile Leu Asn Gly Gly Asn Ala Gly Val Gln Gln Lys Met Leu Asp		
3650	3655	3660
Tyr Leu Lys Glu Lys Lys Asp Ala Gly Phe Phe Gln Ser Leu Xaa Gly		
3665	3670	3680
Leu Met Gln Ser Cys Ser Val Leu Asp Leu Asn Ala Xaa Glu Arg Gln		
3685	3690	3695
Asn Lys Ala Glu Gly Leu Gly Met Val Thr Glu Glu Gly Thr Leu Ile		
3700	3705	3710
Val Arg Glu Arg Gly Glu Lys Val Leu Gln Asn Asp Glu Phe Thr Arg		
3715	3720	3725
Asp Leu Phe Arg Phe Leu Gln Leu Leu Cys Glu Gly His Asn Ser Asp		
3730	3735	3740
Phe Gln Asn Phe Leu Arg Thr Gln Met Gly Asn Thr Thr Thr Val Asn		
3745	3750	3760
Val Ile Ile Ser Thr Val Asp Tyr Leu Leu Arg Leu Gln Glu Ser Ile		
3765	3770	3775
Ser Asp Phe Tyr Trp Tyr Tyr Ser Gly Lys Asp Ile Ile Asp Glu Ser		
3780	3785	3790
Gly Gln His Asn Phe Ser Lys Ala Leu Ala Val Thr Lys Gln Ile Phe		
3795	3800	3805
Asn Ser Leu Thr Glu Tyr Ile Gln Gly Pro Cys Ile Gly Asn Gln Gln		
3810	3815	3820
Ser Leu Ala His Ser Arg Leu Trp Asp Ala Val Val Gly Phe Leu His		
3825	3830	3840
Val Phe Ala Asn Met Gln Met Lys Leu Ser Gln Asp Ser Ser Gln Ile		
3845	3850	3855
Glu Leu Leu Lys Glu Leu Leu Asp Leu Leu Gln Asp Met Val Val Met		
3860	3865	3870
Leu Leu Ser Leu Leu Glu Gly Asn Val Val Asn Gly Thr Ile Gly Lys		
3875	3880	3885
Gln Met Val Asp Thr Leu Val Glu Ser Ser Thr Asn Val Glu Met Ile		
3890	3895	3900
Leu Lys Phe Phe Asp Met Phe Leu Lys Leu Lys Asp Leu Thr Ser Ser		
3905	3910	3920
Asp Thr Phe Lys Glu Tyr Asp Pro Asp Gly Lys Gly Ile Ile Ser Lys		

3925	3930	3935
Lys Glu Phe Gln Lys Ala Met Glu Gly Gln Lys Gln Tyr Thr Gln Ser		
3940	3945	3950
Glu Ile Asp Phe Leu Leu Ser Cys Ala Glu Ala Asp Glu Asn Asp Met		
3955	3960	3965
Phe Asn Tyr Val Asp Phe Val Asp Arg Phe His Glu Pro Ala Lys Asp		
3970	3975	3980
Ile Gly Phe Asn Val Ala Val Leu Leu Thr Asn Leu Ser Glu His Met		
3985	3990	4000
Pro Asn Asp Ser Arg Leu Lys Cys Leu Leu Asp Pro Ala Glu Ser Val		
4005	4010	4015
Leu Asn Tyr Phe Xaa Pro Tyr Leu Gly Arg Ile Glu Ile Met Gly Gly		
4020	4025	4030
Ala Lys Lys Ile Glu Arg Val Tyr Phe Glu Ile Ser Glu Ser Ser Arg		
4035	4040	4045
Thr Gln Trp Glu Lys Pro Gln Val Lys Glu Ser Lys Arg Gln Phe Ile		
4050	4055	4060
Phe Asp Val Val Asn Glu Gly Gly Glu Gln Glu Lys Met Xaa Leu Phe		
4065	4070	4075
Val Asn Phe Cys Glu Asp Thr Ile Phe Glu Met Gln Leu Ala Ser Gln		
4085	4090	4095
Ile Ser Glu Ser Asp Ser Ala Asp Arg Pro Glu Glu Glu Glu Glu Asp		
4100	4105	4110
Glu Asp Ser Ser Tyr Val Leu Glu Ile Ala Gly Glu Glu Glu Glu Asp		
4115	4120	4125
Gly Ser Leu Glu Pro Ala Ser Ala Phe Ala Met Ala Cys Ala Ser Val		
4130	4135	4140
Lys Arg Asn Val Thr Asp Phe Leu Lys Arg Ala Thr Leu Lys Asn Leu		
4145	4150	4155
Arg Lys Gln Tyr Arg Asn Val Lys Lys Met Thr Ala Lys Glu Leu Val		
4165	4170	4175
Lys Val Leu Phe Ser Phe Phe Trp Met Leu Phe Val Gly Leu Phe Gln		
4180	4185	4190
Leu Leu Phe Thr Ile Leu Gly Gly Ile Phe Gln Ile Leu Trp Ser Thr		
4195	4200	4205
Val Phe Gly Gly Gly Leu Val Glu Gly Ala Lys Asn Ile Arg Val Thr		
4210	4215	4220
Lys Ile Leu Gly Asp Met Pro Asp Pro Thr Gln Phe Gly Ile His Asp		
4225	4230	4235
Asp Thr Met Glu Ala Glu Arg Ala Glu Val Met Glu Pro Gly Ile Thr		
4245	4250	4255

Thr Glu Leu Val His Phe Ile Lys Gly Glu Lys Gly Asp Thr Asp Ile
 4260 4265 4270
 Met Ser Asp Leu Phe Gly Leu His Pro Lys Lys Glu Gly Ser Leu Lys
 4275 4280 4285
 His Gly Pro Glu Val Gly Leu Gly Asp Leu Ser Glu Ile Ile Gly Lys
 4290 4295 4300
 Asp Glu Pro Pro Thr Leu Glu Ser Thr Val Gln Lys Lys Arg Lys Ala
 4305 4310 4315 4320
 Gln Ala Ala Glu Met Lys Ala Ala Asn Glu Ala Glu Gly Lys Val Glu
 4325 4330 4335
 Ser Glu Lys Ala Asp Met Glu Asp Gly Glu Lys Glu Asp Lys Asp Lys
 4340 4345 4350
 Glu Glu Glu Gln Ala Glu Tyr Leu Trp Thr Glu Val Thr Lys Lys Lys
 4355 4360 4365
 Lys Arg Arg Cys Gly Gln Lys Val Glu Lys Pro Glu Ala Phe Thr Ala
 4370 4375 4380
 Asn Phe Phe Lys Gly Leu Glu Ile Tyr Gln Thr Lys Leu Leu His Tyr
 4385 4390 4395 4400
 Leu Ala Arg Asn Phe Tyr Asn Leu Arg Phe Leu Ala Leu Phe Val Ala
 4405 4410 4415
 Phe Ala Ile Asn Phe Ile Leu Leu Phe Tyr Lys Val Thr Glu Glu Pro
 4420 4425 4430
 Leu Glu Glu Glu Thr Glu Asp Val Ala Asn Leu Trp Asn Ser Phe Asn
 4435 4440 4445
 Asp Glu Glu Glu Glu Glu Ala Met Val Phe Phe Val Leu Gln Glu Ser
 4450 4455 4460
 Thr Gly Tyr Met Ala Pro Thr Leu Arg Ala Leu Ala Ile Ile His Thr
 4465 4470 4475 4480
 Ile Ile Ser Leu Val Cys Val Val Gly Tyr Tyr Cys Leu Lys Val Pro
 4485 4490 4495
 Leu Val Val Phe Lys Arg Glu Lys Glu Ile Ala Arg Lys Leu Glu Phe
 4500 4505 4510
 Asp Gly Leu Tyr Ile Thr Glu Gln Pro Ser Glu Asp Asp Ile Lys Gly
 4515 4520 4525
 Gln Trp Asp Xaa Leu Val Ile Asn Thr Pro Ser Phe Pro Asn Asn Tyr
 4530 4535 4540
 Trp Asp Lys Phe Val Lys Arg Lys Val Ile Asn Lys Tyr Gly Asp Leu
 4545 4550 4555 4560
 Tyr Gly Ala Glu Arg Ile Ala Glu Leu Leu Gly Leu Asp Lys Asn Ala
 4565 4570 4575

Leu Asp Phe Ser Pro Val Glu Glu Thr Lys Ala Glu Ala Ala Ser Leu
 4580 4585 4590
 Val Ser Trp Leu Ser Ser Xaa Asp Met Lys Tyr His Ile Trp Lys Leu
 4595 4600 4605
 Gly Val Val Phe Thr Asp Asn Ser Phe Leu Tyr Leu Ala Trp Tyr Thr
 4610 4615 4620
 Thr Met Ser Val Leu Gly His Tyr Asn Asn Phe Phe Phe Ala Ala His
 4625 4630 4635 4640
 Leu Leu Asp Ile Ala Met Gly Phe Lys Thr Leu Arg Thr Ile Leu Ser
 4645 4650 4655
 Ser Val Thr His Asn Gly Lys Gln Leu Val Leu Thr Val Gly Leu Leu
 4660 4665 4670
 Ala Val Val Val Tyr Leu Tyr Thr Val Val Ala Phe Asn Phe Phe Arg
 4675 4680 4685
 Lys Phe Tyr Asn Lys Ser Glu Asp Asp Asp Glu Pro Asp Met Lys Cys
 4690 4695 4700
 Asp Asp Met Met Thr Cys Tyr Leu Phe His Met Tyr Val Gly Val Arg
 4705 4710 4715 4720
 Ala Gly Gly Gly Ile Gly Asp Glu Ile Glu Asp Pro Ala Gly Asp Pro
 4725 4730 4735
 Tyr Glu Met Tyr Arg Ile Val Phe Asp Ile Thr Phe Phe Phe Phe Val
 4740 4745 4750
 Ile Val Ile Leu Leu Ala Ile Ile Gln Gly Leu Ile Ile Asp Ala Phe
 4755 4760 4765
 Gly Glu Leu Arg Asp Gln Gln Glu Gln Val Arg Glu Asp Met Glu Val
 4770 4775 4780
 Met Leu Leu
 4785

<210> 127
 <211> 374
 <212> PRT
 <213> Homo sapiens

<400> 127
 Met Arg Thr Leu Leu Pro Pro Ala Leu Leu Thr Cys Trp Leu Leu Ala
 1 5 10 15
 Pro Val Asn Ser Ile His Pro Glu Cys Arg Phe His Leu Glu Ile Gln
 20 25 30
 Glu Glu Glu Thr Lys Cys Xaa Glu Leu Leu Arg Ser Gln Thr Glu Lys
 35 40 45
 His Lys Ala Cys Ser Gly Val Trp Asp Asn Ile Thr Cys Trp Arg Pro
 50 55 60

Ala Asn Val Gly Glu Thr Val Thr Val Pro Cys Pro Lys Val Phe Ser
 65 70 75 80
 Asn Phe Tyr Ser Lys Ala Gly Asn Ile Ser Lys Asn Cys Thr Ser Asp
 85 90 95
 Gly Trp Ser Glu Thr Phe Pro Asp Phe Val Asp Ala Cys Gly Tyr Ser
 100 105 110
 Asp Pro Glu Asp Glu Ser Lys Ile Thr Phe Tyr Ile Leu Val Lys Ala
 115 120 125
 Ile Tyr Thr Leu Gly Tyr Ser Val Ser Leu Met Ser Leu Ala Thr Gly
 130 135 140
 Ser Ile Ile Leu Cys Leu Phe Arg Lys Leu His Cys Thr Arg Asn Tyr
 145 150 155 160
 Ile His Leu Asn Leu Phe Leu Ser Phe Ile Leu Arg Ala Ile Ser Val
 165 170 175
 Leu Val Lys Asp Asp Val Leu Tyr Ser Ser Ser Gly Thr Leu His Cys
 180 185 190
 Pro Asp Gln Pro Ser Ser Trp Val Gly Cys Lys Leu Ser Leu Val Phe
 195 200 205
 Leu Gln Tyr Cys Ile Met Ala Asn Phe Phe Trp Leu Leu Val Glu Gly
 210 215 220
 Leu Tyr Leu His Thr Leu Leu Val Ala Met Leu Pro Pro Arg Arg Cys
 225 230 235 240
 Phe Leu Ala Tyr Leu Leu Ile Gly Trp Gly Leu Pro Thr Val Cys Ile
 245 250 255
 Gly Ala Trp Thr Ala Ala Arg Leu Tyr Leu Glu Asp Thr Gly Cys Trp
 260 265 270
 Asp Thr Asn Asp His Ser Val Pro Trp Trp Val Ile Arg Ile Pro Ile
 275 280 285
 Leu Ile Ser Ile Ile Val Asn Phe Val Leu Phe Ile Ser Ile Ile Arg
 290 295 300
 Ile Leu Leu Gln Lys Leu Thr Ser Pro Asp Val Gly Gly Asn Asp Gln
 305 310 315 320
 Ser Gln Tyr Lys Arg Leu Ala Lys Ser Thr Leu Leu Leu Ile Pro Leu
 325 330 335
 Phe Gly Val His Tyr Met Val Phe Ala Val Phe Pro Ile Ser Ile Ser
 340 345 350
 Ser Lys Tyr Gln Ile Leu Phe Glu Leu Cys Leu Gly Ser Phe Gln Val
 355 360 365
 Gly Val Arg Arg Arg Pro
 370

<210> 128
 <211> 447
 <212> PRT
 <213> Homo sapiens

<400> 128
 Met Ala Gly Val Val His Val Ser Leu Ala Ala Leu Leu Leu Leu Pro
 1 5 10 15
 Met Ala Pro Ala Met His Ser Asp Cys Ile Phe Lys Lys Glu Gln Ala
 20 25 30
 Met Cys Leu Glu Lys Ile Gln Arg Ala Asn Glu Leu Met Gly Phe Asn
 35 40 45
 Asp Ser Ser Pro Gly Cys Pro Gly Met Trp Asp Asn Ile Thr Cys Trp
 50 55 60
 Lys Pro Ala His Val Gly Glu Met Val Leu Val Ser Cys Pro Glu Leu
 65 70 75 80
 Phe Arg Ile Phe Asn Pro Asp Gln Asp Met Gly Val Val Ser Arg Asn
 85 90 95
 Cys Thr Glu Asp Gly Trp Ser Glu Pro Phe Pro His Tyr Phe Asp Ala
 100 105 110
 Cys Gly Phe Asp Glu Tyr Glu Ser Glu Thr Gly Asp Gln Asp Tyr Tyr
 115 120 125
 Tyr Leu Ser Val Lys Ala Leu Tyr Thr Val Gly Tyr Ser Thr Ser Leu
 130 135 140
 Val Thr Leu Thr Thr Ala Met Val Ile Leu Cys Arg Phe Arg Lys Leu
 145 150 155 160
 His Cys Thr Arg Asn Phe Ile His Met Asn Leu Phe Val Ser Phe Met
 165 170 175
 Leu Arg Ala Ile Ser Val Phe Ile Lys Asp Trp Ile Leu Tyr Ala Glu
 180 185 190
 Gln Asp Ser Asn His Cys Phe Ile Ser Thr Val Glu Cys Lys Ala Val
 195 200 205
 Met Val Phe Phe His Tyr Cys Val Val Ser Asn Tyr Phe Trp Leu Phe
 210 215 220
 Ile Glu Gly Leu Tyr Leu Phe Thr Leu Leu Val Glu Thr Phe Phe Pro
 225 230 235 240
 Glu Arg Arg Tyr Phe Tyr Trp Tyr Thr Ile Ile Gly Trp Gly Thr Pro
 245 250 255
 Thr Val Cys Val Thr Val Trp Ala Thr Leu Arg Leu Tyr Phe Asp Asp
 260 265 270
 Thr Gly Cys Trp Asp Met Asn Asp Ser Thr Ala Leu Trp Trp Val Ile
 275 280 285

290 295 300
 Gly Ile Ile Val Ile Leu Val Gln Lys Leu Gln Ser Pro Asp Met Gly
 305 310 315 320
 Gly Asn Glu Ser Ser Ile Tyr Leu Arg Leu Ala Arg Ser Thr Leu Leu
 325 330 335
 Leu Ile Pro Leu Phe Gly Ile His Tyr Thr Val Phe Ala Phe Ser Pro
 340 345 350
 Glu Asn Val Ser Lys Arg Glu Arg Leu Val Phe Glu Leu Gly Leu Gly
 355 360 365
 Ser Phe Gln Gly Phe Val Val Ala Val Leu Tyr Cys Phe Leu Asn Gly
 370 375 380
 Glu Val Gln Ala Glu Ile Lys Arg Lys Trp Arg Ser Trp Lys Val Asn
 385 390 395 400
 Arg Tyr Phe Ala Val Asp Phe Lys His Arg His Pro Ser Leu Ala Ser
 405 410 415
 Ser Gly Val Asn Gly Gly Thr Gln Leu Ser Ile Leu Ser Lys Ser Ser
 420 425 430
 Ser Gln Ile Arg Met Ser Gly Leu Pro Ala Asp Asn Leu Ala Thr
 435 440 445

 <210> 129
 <211> 381
 <212> PRT
 <213> Homo sapiens

 <400> 129
 Met Glu Arg Gly Leu Pro Leu Leu Cys Ala Val Leu Ala Leu Val Leu
 1 5 10 15
 Ala Pro Ala Gly Ala Phe Arg Asn Asp Lys Cys Gly Asp Thr Ile Lys
 20 25 30
 Ile Glu Ser Pro Gly Tyr Leu Thr Ser Pro Gly Tyr Pro His Ser Tyr
 35 40 45
 His Pro Ser Glu Lys Cys Glu Trp Leu Ile Gln Ala Pro Asp Pro Tyr
 50 55 60
 Gln Arg Ile Met Ile Asn Phe Asn Pro His Phe Asp Leu Glu Asp Arg
 65 70 75 80
 Asp Cys Lys Tyr Asp Tyr Val Glu Val Phe Asp Gly Glu Asn Glu Asn
 85 90 95
 Gly His Phe Arg Gly Lys Phe Cys Gly Lys Ile Ala Pro Pro Pro Val
 100 105 110
 Val Ser Ser Gly Pro Phe Leu Phe Ile Lys Phe Val Ser Asp Tyr Glu
 115 120 125

130 135 140
 Pro Glu Cys Ser Gln Asn Tyr Thr Thr Pro Ser Gly Val Ile Lys Ser
 145 150 155 160
 Pro Gly Phe Pro Glu Lys Tyr Pro Asn Ser Leu Glu Cys Thr Tyr Ile
 165 170
 Val Phe Ala Pro Lys Met Ser Glu Ile Ile Leu Glu Phe Glu Ser Phe
 180 185 190
 Asp Leu Glu Pro Asp Ser Asn Pro Pro Gly Gly Met Phe Cys Arg Tyr
 195 200 205
 Asp Arg Leu Glu Ile Trp Asp Gly Phe Pro Asp Val Gly Pro His Ile
 210 215 220
 Gly Arg Tyr Cys Gly Gln Lys Thr Pro Gly Arg Ile Arg Ser Ser Ser
 225 230 235 240
 Gly Ile Leu Ser Met Val Phe Tyr Thr Asp Ser Ala Ile Ala Lys Glu
 245 250 255
 Gly Phe Ser Ala Asn Tyr Ser Val Leu Gln Ser Ser Val Ser Glu Asp
 260 265 270
 Phe Lys Cys Met Glu Ala Leu Gly Met Glu Ser Gly Glu Ile His Ser
 275 280 285
 Asp Gln Ile Thr Ala Ser Ser Gln Tyr Ser Thr Asn Trp Ser Ala Glu
 290 295 300
 Arg Ser Arg Leu Asn Tyr Pro Glu Asn Gly Trp Thr Pro Gly Glu Asp
 305 310 315 320
 Ser Tyr Arg Glu Trp Ile Gln Val Asp Leu Gly Leu Leu Arg Phe Val
 325 330 335
 Thr Ala Val Gly Thr Gln Gly Ala Ile Ser Lys Glu Thr Lys Lys Lys
 340 345 350
 Tyr Tyr Val Lys Thr Tyr Lys Ile Asp Val Ser Ser Asn Gly Glu Asp
 355 360 365
 Trp Ile Thr Ile Lys Glu Gly Asn Lys Pro Val Val Ser
 370 375 380

<210> 130

<211> 339

<212> PRT

<213> Homo sapiens

<400> 130

Met Glu Arg Gly Leu Pro Leu Leu Cys Ala Val Leu Ala Leu Val Leu
 1 5 10 15

Ala Pro Ala Gly Ala Phe Arg Asn Asp Lys Cys Gly Asp Thr Ile Lys
 20 25 30

35	40	45
His Pro Ser Glu Lys Cys Glu Trp Leu Ile Gln Ala Pro Asp Pro Tyr 50 55 60		
Gln Arg Ile Met Ile Asn Phe Asn Pro His Phe Asp Leu Glu Asp Arg 65 70 75 80		
Asp Cys Lys Tyr Asp Tyr Val Glu Val Phe Asp Gly Glu Asn Glu Asn 85 90 95		
Gly His Phe Arg Gly Lys Phe Cys Gly Lys Ile Ala Pro Pro Pro Val 100 105 110		
Val Ser Ser Gly Pro Phe Leu Phe Ile Lys Phe Val Ser Asp Tyr Glu 115 120 125		
Thr His Gly Ala Gly Phe Ser Ile Arg Tyr Glu Ile Phe Lys Arg Gly 130 135 140		
Pro Glu Cys Ser Gln Asn Tyr Thr Thr Pro Ser Gly Val Ile Lys Ser 145 150 155 160		
Pro Gly Phe Pro Glu Lys Tyr Pro Asn Ser Leu Glu Cys Thr Tyr Ile 165 170 175		
Val Phe Ala Pro Lys Met Ser Glu Ile Ile Leu Glu Phe Glu Ser Phe 180 185 190		
Asp Leu Glu Pro Asp Ser Asn Pro Pro Gly Gly Met Phe Cys Arg Tyr 195 200 205		
Asp Arg Leu Glu Ile Trp Asp Gly Phe Pro Asp Val Gly Pro His Ile 210 215 220		
Gly Arg Tyr Cys Gly Gln Lys Thr Pro Gly Arg Ile Arg Ser Ser Ser 225 230 235 240		
Gly Ile Leu Ser Met Val Phe Tyr Thr Asp Ser Ala Ile Ala Lys Glu 245 250 255		
Gly Phe Ser Ala Asn Tyr Ser Val Leu Gln Ser Ser Val Ser Glu Asp 260 265 270		
Phe Lys Cys Met Glu Ala Leu Gly Met Glu Ser Gly Glu Ile His Ser 275 280 285		
Asp Gln Ile Thr Ala Ser Ser Gln Tyr Ser Thr Asn Trp Ser Ala Glu 290 295 300		
Arg Ser Arg Leu Asn Tyr Pro Glu Asn Gly Trp Thr Pro Gly Glu Asp 305 310 315 320		
Ser Tyr Arg Glu Trp Ile Gln Val Cys Ser Ile Arg Ser Ser Leu Ser 325 330 335		
Arg Ile Glu		

<211> 1350

<212> PRT

<213> Homo sapiens

<400> 131

Met Gly Arg Val Gly Tyr Trp Thr Leu Leu Val Leu Pro Ala Leu Leu
 1 5 10 15

Val Trp Arg Gly Pro Ala Pro Ser Ala Ala Ala Glu Lys Gly Pro Pro
 20 25 30

Ala Leu Asn Ile Ala Val Met Leu Gly His Ser His Asp Val Thr Glu
 35 40 45

Arg Glu Leu Arg Thr Leu Trp Gly Pro Glu Gln Ala Ala Gly Leu Pro
 50 55 60

Leu Asp Val Asn Val Val Ala Leu Leu Met Asn Arg Thr Asp Pro Lys
 65 70 75 80

Ser Leu Ile Thr His Val Cys Asp Leu Met Ser Gly Ala Arg Ile His
 85 90 95

Gly Leu Val Phe Gly Asp Asp Thr Asp Gln Glu Ala Val Ala Gln Met
 100 105 110

Leu Asp Phe Ile Ser Ser His Thr Phe Val Pro Ile Leu Gly Ile His
 115 120 125

Gly Gly Ala Ser Met Ile Met Ala Asp Lys Asp Pro Thr Ser Thr Phe
 130 135 140

Phe Gln Phe Gly Ala Ser Ile Gln Gln Gln Ala Thr Val Met Leu Lys
 145 150 155 160

Ile Met Gln Asp Tyr Asp Trp His Val Phe Ser Leu Val Thr Thr Ile
 165 170 175

Phe Pro Gly Tyr Arg Glu Phe Ile Ser Phe Val Lys Thr Thr Val Asp
 180 185 190

Asn Ser Phe Val Gly Trp Asp Met Gln Asn Val Ile Thr Leu Asp Thr
 195 200 205

Ser Phe Glu Asp Ala Lys Thr Gln Val Gln Leu Lys Lys Ile His Ser
 210 215 220

Ser Val Ile Leu Leu Tyr Cys Ser Lys Asp Glu Ala Val Leu Ile Leu
 225 230 235 240

Ser Glu Ala Arg Ser Leu Gly Leu Thr Gly Tyr Asp Phe Phe Trp Ile
 245 250 255

Val Pro Ser Leu Val Ser Gly Asn Thr Glu Leu Ile Pro Lys Glu Phe
 260 265 270

Pro Ser Gly Leu Ile Ser Val Ser Tyr Asp Asp Trp Asp Tyr Ser Leu
 275 280 285

Glu Ala Arg Val Arg Asp Gly Ile Gly Ile Leu Thr Thr Ala Ala Ser

Ser Met Leu Glu Lys Phe Ser Tyr Ile Pro Glu Ala Lys Ala Ser Cys
 305 310 315 320
 Tyr Gly Gln Met Glu Arg Pro Glu Val Pro Met His Thr Leu His Pro
 325 330 335
 Phe Met Val Asn Val Thr Trp Asp Gly Lys Asp Leu Ser Phe Thr Glu
 340 345 350
 Glu Gly Tyr Gln Val His Pro Arg Leu Val Val Ile Val Leu Asn Lys
 355 360 365
 Asp Arg Glu Trp Glu Lys Val Gly Lys Trp Glu Asn His Thr Leu Ser
 370 375 380
 Leu Arg His Ala Val Trp Pro Arg Tyr Lys Ser Phe Ser Asp Cys Glu
 385 390 395 400
 Pro Asp Asp Asn His Leu Ser Ile Val Thr Leu Glu Glu Ala Pro Phe
 405 410 415
 Val Ile Val Glu Asp Ile Asp Pro Leu Thr Glu Thr Cys Val Arg Asn
 420 425 430
 Thr Val Pro Cys Arg Lys Phe Val Lys Ile Asn Asn Ser Thr Asn Glu
 435 440 445
 Gly Met Asn Val Lys Lys Cys Cys Lys Gly Phe Cys Ile Asp Ile Leu
 450 455 460
 Lys Lys Leu Ser Arg Thr Val Lys Phe Thr Tyr Asp Leu Tyr Leu Val
 465 470 475 480
 Thr Asn Gly Lys His Gly Lys Lys Val Asn Asn Val Trp Asn Gly Met
 485 490 495
 Ile Gly Glu Val Val Tyr Gln Arg Ala Val Met Ala Val Gly Ser Leu
 500 505 510
 Thr Ile Asn Glu Glu Arg Ser Glu Val Val Asp Phe Ser Val Pro Phe
 515 520 525
 Val Glu Thr Gly Ile Ser Val Met Val Ser Arg Ser Asn Gly Thr Val
 530 535 540
 Ser Pro Ser Ala Phe Leu Glu Pro Phe Ser Ala Ser Val Trp Val Met
 545 550 555 560
 Met Phe Val Met Leu Leu Ile Val Ser Ala Ile Ala Val Phe Val Phe
 565 570 575
 Glu Tyr Phe Ser Pro Val Gly Tyr Asn Arg Asn Leu Ala Lys Gly Lys
 580 585 590
 Ala Pro His Gly Pro Ser Phe Thr Ile Gly Lys Ala Ile Trp Leu Leu
 595 600 605
 Trp Gly Leu Val Phe Asn Asn Ser Val Pro Val Gln Asn Pro Lys Gly
 610 615 620

Thr Thr Ser Lys Ile Met Val Ser Val Trp Ala Phe Phe Ala Val Ile
 625 630 635 640
 Phe Leu Ala Ser Tyr Thr Ala Asn Leu Ala Ala Phe Met Ile Gln Glu
 645 650 655
 Glu Phe Val Asp Gln Val Thr Gly Leu Ser Asp Lys Lys Phe Gln Arg
 660 665 670
 Pro His Asp Tyr Ser Pro Pro Phe Arg Phe Gly Thr Val Pro Asn Gly
 675 680 685
 Ser Thr Glu Arg Asn Ile Arg Asn Asn Tyr Pro Tyr Met His Gln Tyr
 690 695 700
 Met Thr Lys Phe Asn Gln Lys Gly Val Glu Asp Ala Leu Val Ser Leu
 705 710 715 720
 Lys Thr Gly Lys Leu Asp Ala Phe Ile Tyr Asp Ala Ala Val Leu Asn
 725 730 735
 Tyr Lys Ala Gly Arg Asp Glu Gly Cys Lys Leu Val Thr Ile Gly Ser
 740 745 750
 Gly Tyr Ile Phe Ala Thr Thr Gly Tyr Gly Ile Ala Leu Gln Lys Gly
 755 760 765
 Ser Pro Trp Lys Arg Gln Ile Asp Leu Ala Leu Leu Gln Phe Val Gly
 770 775 780
 Asp Gly Glu Met Glu Glu Leu Glu Thr Leu Trp Leu Thr Gly Ile Cys
 785 790 795 800
 His Asn Glu Lys Asn Glu Val Met Ser Ser Gln Leu Asp Ile Asp Asn
 805 810 815
 Met Ala Gly Val Phe Tyr Met Leu Ala Ala Ala Met Ala Leu Ser Leu
 820 825 830
 Ile Thr Phe Ile Trp Glu His Leu Phe Tyr Trp Lys Leu Arg Phe Cys
 835 840 845
 Phe Thr Gly Val Cys Ser Asp Arg Pro Gly Leu Leu Phe Ser Ile Ser
 850 855 860
 Arg Gly Ile Tyr Ser Cys Ile His Gly Val His Ile Glu Glu Lys Lys
 865 870 875 880
 Lys Ser Pro Asp Phe Asn Leu Thr Gly Ser Gln Ser Asn Met Leu Lys
 885 890 895
 Leu Leu Arg Ser Ala Lys Asn Ile Ser Ser Met Ser Asn Met Asn Ser
 900 905 910
 Ser Arg Met Asp Ser Pro Lys Arg Ala Ala Asp Phe Ile Gln Arg Gly
 915 920 925
 Ser Leu Ile Met Asp Met Val Ser Asp Lys Gly Asn Leu Met Tyr Ser
 930 935 940
 Asp Asn Arg Ser Phe Gln Gly Lys Glu Ser Ile Phe Gly Asp Asn Met

945	950	955	960
Asn Glu Leu Gln Thr Phe Val Ala Asn Arg Gln Lys Asp Asn Leu Asn	965	970	975
Asn Tyr Val Phe Gln Gly Gln His Pro Leu Thr Leu Asn Glu Ser Asn	980	985	990
Pro Asn Thr Val Glu Val Ala Val Ser Thr Glu Ser Lys Ala Asn Ser	995	1000	1005
Arg Pro Arg Gln Leu Trp Lys Lys Ser Val Asp Ser Ile Arg Gln Asp	1010	1015	1020
Ser Leu Ser Gln Asn Pro Val Ser Gln Arg Asp Glu Ala Thr Ala Glu	1025	1030	1035
Asn Arg Thr His Ser Leu Lys Ser Pro Arg Tyr Leu Pro Glu Glu Met	1045	1050	1055
Ala His Ser Asp Ile Ser Glu Thr Ser Asn Arg Ala Thr Cys His Arg	1060	1065	1070
Glu Pro Asp Asn Ser Lys Asn His Lys Thr Lys Asp Asn Phe Lys Arg	1075	1080	1085
Ser Val Ala Ser Lys Tyr Pro Lys Asp Cys Ser Glu Val Glu Arg Thr	1090	1095	1100
Tyr Leu Lys Thr Lys Ser Ser Ser Pro Arg Asp Lys Ile Tyr Thr Ile	1105	1110	1115
Asp Gly Glu Lys Glu Pro Gly Phe His Leu Asp Pro Pro Gln Phe Val	1125	1130	1135
Glu Asn Val Thr Leu Pro Glu Asn Val Asp Phe Pro Asp Pro Tyr Gln	1140	1145	1150
Asp Pro Ser Glu Asn Phe Arg Lys Gly Asp Ser Thr Leu Pro Met Asn	1155	1160	1165
Arg Asn Pro Leu His Asn Glu Gly Leu Ser Asn Asn Asp Gln Tyr	1170	1175	1180
Lys Leu Tyr Ser Lys His Phe Thr Leu Lys Asp Lys Gly Ser Pro His	1185	1190	1195
Ser Glu Thr Ser Glu Arg Tyr Arg Gln Asn Ser Thr His Cys Arg Ser	1205	1210	1215
Cys Leu Ser Asn Met Pro Thr Tyr Ser Gly His Phe Thr Met Arg Ser	1220	1225	1230
Pro Phe Lys Cys Asp Ala Cys Leu Arg Met Gly Asn Leu Tyr Asp Ile	1235	1240	1245
Asp Glu Asp Gln Met Leu Gln Glu Thr Arg Asp Asp Gln Arg Leu Val	1250	1255	1260
Ile Gly Arg Cys Pro Ser Asp Pro Tyr Lys His Ser Leu Pro Ser Gln	1265	1270	1275
			1280

Ala Val Asn Asp Ser Tyr Leu Arg Ser Ser Leu Arg Ser Thr Ala Ser
1285 1290 1295

Tyr Cys Ser Arg Asp Ser Arg Gly His Asn Asp Val Tyr Ile Ser Glu
1300 1305 1310

His Val Met Pro Tyr Ala Ala Asn Lys Asn Asn Met Tyr Ser Thr Pro
1315 1320 1325

Arg Val Leu Asn Ser Cys Ser Asn Arg Arg Val Tyr Lys Lys Met Pro
1330 1335 1340

Ser Ile Glu Ser Asp Val
1345 1350

<210> 132
<211> 455
<212> PRT
<213> Homo sapiens

<400> 132
Met Arg Thr Leu Leu Pro Pro Ala Leu Leu Thr Cys Trp Leu Leu Ala
1 5 10 15

Pro Val Asn Ser Ile His Pro Glu Cys Arg Phe His Leu Glu Ile Gln
20 25 30

Glu Glu Glu Thr Lys Cys Xaa Glu Leu Leu Arg Ser Gln Thr Glu Lys
35 40 45

His Lys Ala Cys Ser Gly Val Trp Asp Asn Ile Thr Cys Trp Arg Pro
50 55 60

Ala Asn Val Gly Glu Thr Val Thr Val Pro Cys Pro Lys Val Phe Ser
65 70 75 80

Asn Phe Tyr Ser Lys Ala Gly Asn Ile Ser Lys Asn Cys Thr Ser Asp
85 90 95

Gly Trp Ser Glu Thr Phe Pro Asp Phe Val Asp Ala Cys Gly Tyr Ser
100 105 110

Asp Pro Glu Asp Glu Ser Lys Ile Thr Phe Tyr Ile Leu Val Lys Ala
115 120 125

Ile Tyr Thr Leu Gly Tyr Ser Val Ser Leu Met Ser Leu Ala Thr Gly
130 135 140

Ser Ile Ile Leu Cys Leu Phe Arg Lys Leu His Cys Thr Arg Asn Tyr
145 150 155 160

Ile His Leu Asn Leu Phe Leu Ser Phe Ile Leu Arg Ala Ile Ser Val
165 170 175

Leu Val Lys Asp Asp Val Leu Tyr Ser Ser Ser Gly Thr Leu His Cys
180 185 190

Pro Asp Gln Pro Ser Ser Trp Val Gly Cys Lys Leu Ser Leu Val Phe
195 200 205

Leu Gln Tyr Cys Ile Met Ala Asn Phe Phe Trp Leu Leu Val Glu Gly
 210 215 220
 Leu Tyr Leu His Thr Leu Leu Val Ala Met Leu Pro Pro Arg Arg Cys
 225 230 235 240
 Phe Leu Ala Tyr Leu Leu Ile Gly Trp Gly Leu Pro Thr Val Cys Ile
 245 250 255
 Gly Ala Trp Thr Ala Ala Arg Leu Tyr Leu Glu Asp Thr Gly Cys Trp
 260 265 270
 Asp Thr Asn Asp His Ser Val Pro Trp Trp Val Ile Arg Ile Pro Ile
 275 280 285
 Leu Ile Ser Ile Ile Val Asn Phe Val Leu Phe Ile Ser Ile Ile Arg
 290 295 300
 Ile Leu Leu Gln Lys Leu Thr Ser Pro Asp Val Gly Gly Asn Asp Gln
 305 310 315 320
 Ser Gln Tyr Lys Arg Leu Ala Lys Ser Thr Leu Leu Leu Ile Pro Leu
 325 330 335
 Phe Gly Val His Tyr Met Val Phe Ala Val Phe Pro Ile Ser Ile Ser
 340 345 350
 Ser Lys Tyr Gln Ile Leu Phe Glu Leu Cys Leu Gly Ser Phe Gln Gly
 355 360 365
 Leu Val Val Ala Val Leu Tyr Cys Phe Leu Asn Ser Glu Val Ser Ser
 370 375 380
 Trp Pro Pro Trp Asn Gln Ala Gln Val Leu Thr Cys Phe Leu Arg Cys
 385 390 395 400
 Cys Pro Ala Trp Cys Arg Ser Pro His Thr Cys Leu Ser Ser Ala Gly
 405 410 415
 Ser Ser Tyr Cys Pro Gly Pro His Ser Ser Val Ser Pro Ser Glu Asn
 420 425 430
 Pro Gln Arg His Arg Gln Thr His Ser Ser Gly Pro Ser Phe Gln Thr
 435 440 445
 Pro Pro Ser Phe Arg Pro Pro
 450 455

 <210> 133
 <211> 452
 <212> PRT
 <213> Homo sapiens

 <400> 133
 Met Arg Thr Leu Leu Pro Pro Ala Leu Leu Thr Cys Trp Leu Leu Ala
 1 5 10 15
 Pro Val Asn Ser Ile His Pro Glu Cys Arg Phe His Leu Glu Ile Gln
 20 25 30

Glu	Glu	Glu	Thr	Lys	Cys	Xaa	Glu	Leu	Leu	Arg	Ser	Gln	Thr	Glu	Lys	
35						40						45				
His	Lys	Ala	Cys	Ser	Gly	Val	Trp	Asp	Asn	Ile	Thr	Cys	Trp	Arg	Pro	
50						55				60						
Ala	Asn	Val	Gly	Glu	Thr	Val	Thr	Val	Pro	Cys	Pro	Lys	Val	Phe	Ser	
65				70						75				80		
Asn	Phe	Tyr	Ser	Lys	Ala	Gly	Asn	Ile	Ser	Lys	Asn	Cys	Thr	Ser	Asp	
			85						90						95	
Gly	Trp	Ser	Glu	Thr	Phe	Pro	Asp	Phe	Val	Asp	Ala	Cys	Gly	Tyr	Ser	
			100						105						110	
Asp	Pro	Glu	Asp	Glu	Ser	Lys	Ile	Thr	Phe	Tyr	Ile	Leu	Val	Lys	Ala	
		115				120						125				
Ile	Tyr	Thr	Leu	Gly	Tyr	Ser	Val	Ser	Leu	Met	Ser	Leu	Ala	Thr	Gly	
130						135				140						
Ser	Ile	Ile	Leu	Cys	Leu	Phe	Arg	Lys	Leu	His	Cys	Thr	Arg	Asn	Tyr	
145				150						155				160		
Ile	His	Leu	Asn	Leu	Phe	Leu	Ser	Phe	Ile	Leu	Arg	Ala	Ile	Ser	Val	
			165						170						175	
Leu	Val	Lys	Asp	Asp	Val	Leu	Tyr	Ser	Ser	Ser	Gly	Thr	Leu	His	Cys	
		180						185				190				
Pro	Asp	Gln	Pro	Ser	Ser	Trp	Val	Gly	Cys	Lys	Leu	Ser	Leu	Val	Phe	
		195				200						205				
Leu	Gln	Tyr	Cys	Ile	Met	Ala	Asn	Phe	Phe	Trp	Leu	Leu	Val	Glu	Gly	
210						215				220						
Leu	Tyr	Leu	His	Thr	Leu	Leu	Val	Ala	Met	Leu	Pro	Pro	Arg	Arg	Cys	
225				230						235				240		
Phe	Leu	Ala	Tyr	Leu	Leu	Ile	Gly	Trp	Gly	Leu	Pro	Thr	Val	Cys	Ile	
			245						250				255			
Gly	Ala	Trp	Thr	Ala	Ala	Arg	Leu	Tyr	Leu	Glu	Asp	Thr	Gly	Cys	Trp	
			260						265				270			
Asp	Thr	Asn	Asp	His	Ser	Val	Pro	Trp	Trp	Val	Ile	Arg	Ile	Pro	Ile	
		275				280						285				
Leu	Ile	Ser	Ile	Ile	Val	Asn	Phe	Val	Leu	Phe	Ile	Ser	Ile	Ile	Arg	
290						295				300						
Ile	Leu	Leu	Gln	Lys	Leu	Thr	Ser	Pro	Asp	Val	Gly	Gly	Asn	Asp	Gln	
305				310						315				320		
Ser	Gln	Tyr	Lys	Arg	Leu	Ala	Lys	Ser	Thr	Leu	Leu	Leu	Ile	Pro	Leu	
			325						330				335			
Phe	Gly	Val	His	Tyr	Met	Val	Phe	Ala	Val	Phe	Pro	Ile	Ser	Ile	Ser	
			340						345				350			

Ser Lys Tyr Gln Ile Leu Phe Glu Leu Cys Leu Gly Ser Phe Gln Gly
 355 360 365
 Leu Val Val Ala Val Leu Tyr Cys Phe Leu Asn Ser Glu Val Ser Ser
 370 375 380
 Trp Pro Pro Trp Asn Gln Ala Gln Val Leu Thr Cys Phe Leu Arg Cys
 385 390 395 400
 Cys Pro Ala Trp Cys Arg Ser Pro His Thr Cys Leu Ser Ser Ala Gly
 405 410 415
 Ser Ser Tyr Cys Pro Gly Pro His Ser Ser Val Ser Pro Ser Glu Asn
 420 425 430
 Pro Gln Arg His Arg Gln Thr His Ser Ser Gly Trp Gly Val Gly Leu
 435 440 445
 His Ser Val Leu
 450

<210> 134
 <211> 1344
 <212> PRT
 <213> Homo sapiens

<400> 134
 Met Lys Ser Gly Ser Gly Gly Gly Ser Pro Thr Ser Leu Trp Gly Leu
 1 5 10 15
 Leu Phe Leu Ser Ala Ala Leu Ser Leu Trp Pro Thr Ser Gly Glu Ile
 20 25 30
 Cys Gly Pro Gly Ile Asp Ile Arg Asn Asp Tyr Gln Gln Leu Lys Arg
 35 40 45
 Leu Glu Asn Cys Thr Val Ile Glu Gly Tyr Leu His Ile Leu Leu Ile
 50 55 60
 Ser Lys Ala Glu Asp Tyr Arg Ser Tyr Arg Phe Pro Lys Leu Thr Val
 65 70 75 80
 Ile Thr Glu Tyr Leu Leu Leu Phe Arg Val Ala Gly Leu Glu Ser Leu
 85 90 95
 Gly Asp Leu Phe Pro Asn Leu Thr Val Ile Arg Gly Trp Lys Leu Phe
 100 105 110
 Tyr Asn Tyr Ala Leu Val Ile Phe Glu Met Thr Asn Leu Lys Asp Ile
 115 120 125
 Gly Leu Tyr Asn Leu Arg Asn Ile Thr Arg Gly Ala Ile Arg Ile Glu
 130 135 140
 Lys Asn Ala Asp Leu Cys Tyr Leu Ser Thr Val Asp Trp Ser Leu Ile
 145 150 155 160
 Leu Asp Ala Val Ser Asn Asn Tyr Ile Val Gly Asn Lys Pro Pro Lys
 165 170 175

Glu Cys Gly Asp Leu Cys Pro Gly Thr Met Glu Glu Lys Pro Met Cys
 180 185 190
 Glu Lys Thr Thr Ile Asn Asn Glu Tyr Asn Tyr Arg Cys Trp Thr Thr
 195 200 205
 Asn Arg Cys Gln Lys Met Cys Pro Ser Thr Cys Gly Lys Arg Ala Cys
 210 215 220
 Thr Glu Asn Asn Glu Cys Cys His Pro Glu Cys Leu Gly Ser Cys Ser
 225 230 235 240
 Ala Pro Asp Asn Asp Thr Ala Cys Val Ala Cys Arg His Tyr Tyr Tyr
 245 250 255
 Ala Gly Val Cys Val Pro Ala Cys Pro Pro Asn Thr Tyr Arg Phe Glu
 260 265 270
 Gly Trp Arg Cys Val Asp Arg Asp Phe Cys Ala Asn Ile Leu Ser Ala
 275 280 285
 Glu Ser Ser Asp Ser Glu Gly Phe Val Ile His Asp Gly Glu Cys Met
 290 295 300
 Gln Glu Cys Pro Ser Gly Phe Ile Arg Asn Gly Ser Gln Ser Met Tyr
 305 310 315 320
 Cys Ile Pro Cys Glu Gly Pro Cys Pro Lys Val Cys Glu Glu Glu Lys
 325 330 335
 Lys Thr Lys Thr Ile Asp Ser Val Thr Ser Ala Gln Met Leu Gln Gly
 340 345 350
 Cys Thr Ile Phe Lys Gly Asn Leu Leu Ile Asn Ile Arg Arg Gly Asn
 355 360 365
 Asn Ile Ala Ser Glu Leu Glu Asn Phe Met Gly Leu Ile Glu Val Val
 370 375 380
 Thr Gly Tyr Val Lys Ile Arg His Ser His Ala Leu Val Ser Leu Ser
 385 390 395 400
 Phe Leu Lys Asn Leu Arg Leu Ile Leu Gly Glu Glu Gln Leu Glu Gly
 405 410 415
 Asn Tyr Ser Phe Tyr Val Leu Asp Asn Gln Asn Leu Gln Gln Leu Trp
 420 425 430
 Asp Trp Asp His Arg Asn Leu Thr Ile Lys Ala Gly Lys Met Tyr Phe
 435 440 445
 Ala Phe Asn Pro Lys Leu Cys Val Ser Glu Ile Tyr Arg Met Glu Glu
 450 455 460
 Val Thr Gly Thr Lys Gly Arg Gln Ser Lys Gly Asp Ile Asn Thr Arg
 465 470 475 480
 Asn Asn Gly Glu Arg Ala Ser Cys Glu Ser Asp Val Leu His Phe Thr
 485 490 495
 Ser Thr Thr Thr Ser Lys Asn Arg Ile Ile Ile Thr Trp His Arg Tyr

500	505	510
Arg Pro Pro Asp Tyr Arg Asp Leu Ile Ser Phe Thr Val Tyr Tyr Lys		
515	520	525
Glu Ala Pro Phe Lys Asn Val Thr Glu Tyr Asp Gly Gln Asp Ala Cys		
530	535	540
Gly Ser Asn Ser Trp Asn Met Val Asp Val Asp Leu Pro Pro Asn Lys		
545	550	555
560		
Asp Val Glu Pro Gly Ile Leu Leu His Gly Leu Lys Pro Trp Thr Gln		
565	570	575
Tyr Ala Val Tyr Val Lys Ala Val Thr Leu Thr Met Val Glu Asn Asp		
580	585	590
His Ile Arg Gly Ala Lys Ser Glu Ile Leu Tyr Ile Arg Thr Asn Ala		
595	600	605
Ser Val Pro Ser Ile Pro Leu Asp Val Leu Ser Ala Ser Asn Ser Ser		
610	615	620
Ser Gln Leu Ile Val Lys Trp Asn Pro Pro Ser Leu Pro Asn Gly Asn		
625	630	635
640		
Leu Ser Tyr Tyr Ile Val Arg Trp Gln Arg Gln Pro Gln Asp Gly Tyr		
645	650	655
Leu Tyr Arg His Asn Tyr Cys Ser Lys Asp Lys Ile Pro Ile Arg Lys		
660	665	670
Tyr Ala Asp Gly Thr Ile Asp Ile Glu Glu Val Thr Glu Asn Pro Lys		
675	680	685
Thr Glu Val Cys Gly Gly Glu Lys Gly Pro Cys Cys Ala Cys Pro Lys		
690	695	700
Thr Glu Ala Glu Lys Gln Ala Glu Lys Glu Glu Ala Glu Tyr Arg Lys		
705	710	715
720		
Val Phe Glu Asn Phe Leu His Asn Ser Ile Phe Val Pro Arg Pro Glu		
725	730	735
Arg Lys Arg Arg Asp Val Met Gln Val Ala Asn Thr Thr Met Ser Ser		
740	745	750
Arg Ser Arg Asn Thr Thr Ala Ala Asp Thr Tyr Asn Ile Thr Asp Pro		
755	760	765
Glu Glu Leu Glu Thr Glu Tyr Pro Phe Phe Glu Ser Arg Val Asp Asn		
770	775	780
Lys Glu Arg Thr Val Ile Ser Asn Leu Arg Pro Phe Thr Leu Tyr Arg		
785	790	795
800		
Ile Asp Ile His Ser Cys Asn His Glu Ala Glu Lys Leu Gly Cys Ser		
805	810	815
Ala Ser Asn Phe Val Phe Ala Arg Thr Met Pro Ala Glu Gly Ala Asp		
820	825	830

Asp Ile Pro Gly Pro Val Thr Trp Glu Pro Arg Pro Glu Asn Ser Ile
 835 840 845
 Phe Leu Lys Trp Pro Glu Pro Glu Asn Pro Asn Gly Leu Ile Leu Met
 850 855 860
 Tyr Glu Ile Lys Tyr Gly Ser Gln Val Glu Asp Gln Arg Glu Cys Val
 865 870 875 880
 Ser Arg Gln Glu Tyr Arg Lys Tyr Gly Gly Ala Lys Leu Asn Arg Leu
 885 890 895
 Asn Pro Gly Asn Tyr Thr Ala Arg Ile Gln Ala Thr Ser Leu Ser Gly
 900 905 910
 Asn Gly Ser Trp Thr Asp Pro Val Phe Phe Tyr Val Gln Ala Lys Thr
 915 920 925
 Gly Tyr Glu Asn Phe Ile His Leu Ile Ile Ala Leu Pro Val Ala Val
 930 935 940
 Leu Leu Ile Val Gly Gly Leu Val Ile Met Leu Tyr Val Phe His Arg
 945 950 955 960
 Lys Arg Asn Asn Ser Arg Leu Gly Asn Gly Val Leu Tyr Ala Ser Val
 965 970 975
 Asn Pro Glu Tyr Phe Ser Ala Ala Asp Val Tyr Val Pro Asp Glu Trp
 980 985 990
 Glu Val Ala Arg Glu Lys Ile Thr Met Ser Arg Glu Leu Gly Gln Gly
 995 1000 1005
 Ser Phe Gly Met Val Tyr Glu Gly Val Ala Lys Gly Val Val Lys Asp
 1010 1015 1020
 Glu Pro Glu Thr Arg Val Ala Ile Lys Thr Val Asn Glu Ala Ala Ser
 1025 1030 1035 1040
 Met Arg Glu Arg Ile Glu Phe Leu Asn Glu Ala Ser Val Met Lys Glu
 1045 1050 1055
 Phe Asn Cys His His Val Val Arg Leu Leu Gly Val Val Ser Gln Gly
 1060 1065 1070
 Gln Pro Thr Leu Val Ile Met Glu Leu Met Thr Arg Gly Asp Leu Lys
 1075 1080 1085
 Ser Tyr Leu Arg Ser Leu Arg Pro Glu Met Glu Asn Asn Pro Val Leu
 1090 1095 1100
 Ala Pro Pro Ser Leu Ser Lys Met Ile Gln Met Ala Gly Glu Ile Ala
 1105 1110 1115 1120
 Asp Gly Met Ala Tyr Leu Asn Ala Asn Lys Phe Val His Arg Asp Leu
 1125 1130 1135
 Ala Ala Arg Asn Cys Met Val Ala Glu Asp Phe Thr Val Lys Ile Gly
 1140 1145 1150

Asp Phe Gly Met Thr Arg Asp Ile Tyr Glu Thr Asp Tyr Tyr Arg Lys
 1155 1160 1165
 Gly Gly Lys Gly Leu Leu Pro Val Arg Trp Met Ser Pro Glu Ser Leu
 1170 1175 1180
 Lys Asp Gly Val Phe Thr Thr Tyr Ser Asp Val Trp Ser Phe Gly Val
 1185 1190 1195 1200
 Val Leu Trp Glu Ile Ala Thr Leu Ala Glu Gln Pro Tyr Gln Gly Leu
 1205 1210 1215
 Ser Asn Glu Gln Val Leu Arg Phe Val Met Glu Gly Gly Leu Leu Asp
 1220 1225 1230
 Lys Pro Asp Asn Cys Pro Asp Met Leu Phe Glu Leu Met Arg Met Cys
 1235 1240 1245
 Trp Gln Tyr Asn Pro Lys Met Arg Pro Ser Phe Leu Glu Ile Ile Ser
 1250 1255 1260
 Ser Ile Lys Glu Glu Leu Asp Leu Glu Pro Glu Asn Met Glu Ser Val
 1265 1270 1275 1280
 Pro Leu Asp Pro Ser Ala Ser Ser Ser Ser Leu Pro Leu Pro Asp Arg
 1285 1290 1295
 His Ser Gly His Lys Ala Glu Asn Gly Pro Gly Pro Gly Val Leu Val
 1300 1305 1310
 Leu Arg Ala Ser Phe Asp Glu Arg Gln Pro Tyr Ala His Met Asn Gly
 1315 1320 1325
 Gly Arg Lys Asn Glu Arg Ala Leu Pro Leu Pro Gln Ser Ser Thr Cys
 1330 1335 1340

<210> 135
 <211> 600
 <212> PRT
 <213> Homo sapiens

<400> 135
 Met Glu Arg Gly Leu Pro Leu Leu Cys Ala Val Leu Ala Leu Val Leu
 1 5 10 15
 Ala Pro Ala Gly Ala Phe Arg Asn Asp Lys Cys Gly Asp Thr Ile Lys
 20 25 30
 Ile Glu Ser Pro Gly Tyr Leu Thr Ser Pro Gly Tyr Pro His Ser Tyr
 35 40 45
 His Pro Ser Glu Lys Cys Glu Trp Leu Ile Gln Ala Pro Asp Pro Tyr
 50 55 60
 Gln Arg Ile Met Ile Asn Phe Asn Pro His Phe Asp Leu Glu Asp Arg
 65 70 75 80

Asp Cys Lys Tyr Asp Tyr Val Glu Val Phe Asp Gly Glu Asn Glu Asn
 85 90 95
 Gly His Phe Arg Gly Lys Phe Cys Gly Lys Ile Ala Pro Pro Pro Val
 100 105 110
 Val Ser Ser Gly Pro Phe Leu Phe Ile Lys Phe Val Ser Asp Tyr Glu
 115 120 125
 Thr His Gly Ala Gly Phe Ser Ile Arg Tyr Glu Ile Phe Lys Arg Gly
 130 135 140
 Pro Glu Cys Ser Gln Asn Tyr Thr Thr Pro Ser Gly Val Ile Lys Ser
 145 150 155 160
 Pro Gly Phe Pro Glu Lys Tyr Pro Asn Ser Leu Glu Cys Thr Tyr Ile
 165 170 175
 Val Phe Ala Pro Lys Met Ser Glu Ile Ile Leu Glu Phe Glu Ser Phe
 180 185 190
 Asp Leu Glu Pro Asp Ser Asn Pro Pro Gly Gly Met Phe Cys Arg Tyr
 195 200 205
 Asp Arg Leu Glu Ile Trp Asp Gly Phe Pro Asp Val Gly Pro His Ile
 210 215 220
 Gly Arg Tyr Cys Gly Gln Lys Thr Pro Gly Arg Ile Arg Ser Ser Ser
 225 230 235 240
 Gly Ile Leu Ser Met Val Phe Tyr Thr Asp Ser Ala Ile Ala Lys Glu
 245 250 255
 Gly Phe Ser Ala Asn Tyr Ser Val Leu Gln Ser Ser Val Ser Glu Asp
 260 265 270
 Phe Lys Cys Met Glu Ala Leu Gly Met Glu Ser Gly Glu Ile His Ser
 275 280 285
 Asp Gln Ile Thr Ala Ser Ser Gln Tyr Ser Thr Asn Trp Ser Ala Glu
 290 295 300
 Arg Ser Arg Leu Asn Tyr Pro Glu Asn Gly Trp Thr Pro Gly Glu Asp
 305 310 315 320
 Ser Tyr Arg Glu Trp Ile Gln Val Asp Leu Gly Leu Leu Arg Phe Val
 325 330 335
 Thr Ala Val Gly Thr Gln Gly Ala Ile Ser Lys Glu Thr Lys Lys Lys
 340 345 350
 Tyr Tyr Val Lys Thr Tyr Lys Ile Asp Val Ser Ser Asn Gly Glu Asp
 355 360 365
 Trp Ile Thr Ile Lys Glu Gly Asn Lys Pro Val Leu Phe Gln Gly Asn
 370 375 380
 Thr Asn Pro Thr Asp Val Val Val Ala Val Phe Pro Lys Pro Leu Ile
 385 390 395 400
 Thr Arg Phe Val Arg Ile Lys Pro Ala Thr Trp Glu Thr Gly Ile Ser

405										410					415				
Met	Arg	Phe	Glu	Val	Tyr	Gly	Cys	Lys	Ile	Thr	Asp	Tyr	Pro	Cys	Ser				
			420					425					430						
Gly	Met	Leu	Gly	Met	Val	Ser	Gly	Leu	Ile	Ser	Asp	Ser	Gln	Ile	Thr				
		435					440					445							
Ser	Ser	Asn	Gln	Gly	Asp	Arg	Asn	Trp	Met	Pro	Glu	Asn	Ile	Arg	Leu				
		450				455					460								
Val	Thr	Ser	Arg	Ser	Gly	Trp	Ala	Leu	Pro	Pro	Ala	Pro	His	Ser	Tyr				
465					470					475					480				
Ile	Asn	Glu	Trp	Leu	Gln	Ile	Asp	Leu	Gly	Glu	Glu	Lys	Ile	Val	Arg				
				485					490					495					
Gly	Ile	Ile	Ile	Gln	Gly	Gly	Lys	His	Arg	Glu	Asn	Lys	Val	Phe	Met				
			500				505						510						
Arg	Lys	Phe	Lys	Ile	Gly	Tyr	Ser	Asn	Asn	Gly	Ser	Asp	Trp	Lys	Met				
		515					520					525							
Ile	Met	Asp	Asp	Ser	Lys	Arg	Lys	Ala	Lys	Ser	Phe	Glu	Gly	Asn	Asn				
	530					535					540								
Asn	Tyr	Asp	Thr	Pro	Glu	Leu	Arg	Thr	Phe	Pro	Ala	Leu	Ser	Thr	Arg				
545					550				555						560				
Phe	Ile	Arg	Ile	Tyr	Pro	Glu	Arg	Ala	Thr	His	Gly	Gly	Leu	Gly	Leu				
				565				570						575					
Arg	Met	Glu	Leu	Leu	Gly	Cys	Glu	Val	Glu	Ala	Pro	Thr	Ala	Gly	Pro				
			580				585						590						
Thr	Thr	Pro	Asn	Gly	Asn	Leu	Val												
		595				600													

<210> 136

<211> 840

<212> PRT

<213> Homo sapiens

<400> 136

Met	Glu	Arg	Gly	Leu	Pro	Leu	Leu	Cys	Ala	Val	Leu	Ala	Leu	Val	Leu
1				5					10					15	

Ala	Pro	Ala	Gly	Ala	Phe	Arg	Asn	Asp	Lys	Cys	Gly	Asp	Thr	Ile	Lys
			20					25					30		

Ile	Glu	Ser	Pro	Gly	Tyr	Leu	Thr	Ser	Pro	Gly	Tyr	Pro	His	Ser	Tyr
		35					40					45			

His	Pro	Ser	Glu	Lys	Cys	Glu	Trp	Leu	Ile	Gln	Ala	Pro	Asp	Pro	Tyr
	50					55					60				

Gln	Arg	Ile	Met	Ile	Asn	Phe	Asn	Pro	His	Phe	Asp	Leu	Glu	Asp	Arg
65					70					75					80

Asp	Cys	Lys	Tyr	Asp	Tyr	Val	Glu	Val	Phe	Asp	Gly	Glu	Asn	Glu	Asn
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

				85				90				95			
Gly	His	Phe	Arg	Gly	Lys	Phe	Cys	Gly	Lys	Ile	Ala	Pro	Pro	Pro	Val
100								105				110			
Val	Ser	Ser	Gly	Pro	Phe	Leu	Phe	Ile	Lys	Phe	Val	Ser	Asp	Tyr	Glu
115								120				125			
Thr	His	Gly	Ala	Gly	Phe	Ser	Ile	Arg	Tyr	Glu	Ile	Phe	Lys	Arg	Gly
130								135				140			
Pro	Glu	Cys	Ser	Gln	Asn	Tyr	Thr	Thr	Pro	Ser	Gly	Val	Ile	Lys	Ser
145				150				155				160			
Pro	Gly	Phe	Pro	Glu	Lys	Tyr	Pro	Asn	Ser	Leu	Glu	Cys	Thr	Tyr	Ile
				165				170				175			
Val	Phe	Ala	Pro	Lys	Met	Ser	Glu	Ile	Ile	Leu	Glu	Phe	Glu	Ser	Phe
				180				185				190			
Asp	Leu	Glu	Pro	Asp	Ser	Asn	Pro	Pro	Gly	Gly	Met	Phe	Cys	Arg	Tyr
195								200				205			
Asp	Arg	Leu	Glu	Ile	Trp	Asp	Gly	Phe	Pro	Asp	Val	Gly	Pro	His	Ile
210								215				220			
Gly	Arg	Tyr	Cys	Gly	Gln	Lys	Thr	Pro	Gly	Arg	Ile	Arg	Ser	Ser	Ser
225				230				235				240			
Gly	Ile	Leu	Ser	Met	Val	Phe	Tyr	Thr	Asp	Ser	Ala	Ile	Ala	Lys	Glu
				245				250				255			
Gly	Phe	Ser	Ala	Asn	Tyr	Ser	Val	Leu	Gln	Ser	Ser	Val	Ser	Glu	Asp
				260				265				270			
Phe	Lys	Cys	Met	Glu	Ala	Leu	Gly	Met	Glu	Ser	Gly	Glu	Ile	His	Ser
275								280				285			
Asp	Gln	Ile	Thr	Ala	Ser	Ser	Gln	Tyr	Ser	Thr	Asn	Trp	Ser	Ala	Glu
290								295				300			
Arg	Ser	Arg	Leu	Asn	Tyr	Pro	Glu	Asn	Gly	Trp	Thr	Pro	Gly	Glu	Asp
305				310				315				320			
Ser	Tyr	Arg	Glu	Trp	Ile	Gln	Val	Asp	Leu	Gly	Leu	Leu	Arg	Phe	Val
				325				330				335			
Thr	Ala	Val	Gly	Thr	Gln	Gly	Ala	Ile	Ser	Lys	Glu	Thr	Lys	Lys	Lys
				340				345				350			
Tyr	Tyr	Val	Lys	Thr	Tyr	Lys	Ile	Asp	Val	Ser	Ser	Asn	Gly	Glu	Asp
355								360				365			
Trp	Ile	Thr	Ile	Lys	Glu	Gly	Asn	Lys	Pro	Val	Leu	Phe	Gln	Gly	Asn
370				375				380							
Thr	Asn	Pro	Thr	Asp	Val	Val	Val	Ala	Val	Phe	Pro	Lys	Pro	Leu	Ile
385				390				395				400			
Thr	Arg	Phe	Val	Arg	Ile	Lys	Pro	Ala	Thr	Trp	Glu	Thr	Gly	Ile	Ser
				405				410				415			

Met Arg Phe Glu Val Tyr Gly Cys Lys Ile Thr Asp Tyr Pro Cys Ser
 420 425 430
 Gly Met Leu Gly Met Val Ser Gly Leu Ile Ser Asp Ser Gln Ile Thr
 435 440 445
 Ser Ser Asn Gln Gly Asp Arg Asn Trp Met Pro Glu Asn Ile Arg Leu
 450 455 460
 Val Thr Ser Arg Ser Gly Trp Ala Leu Pro Pro Ala Pro His Ser Tyr
 465 470 475 480
 Ile Asn Glu Trp Leu Gln Ile Asp Leu Gly Glu Glu Lys Ile Val Arg
 485 490 495
 Gly Ile Ile Ile Gln Gly Gly Lys His Arg Glu Asn Lys Val Phe Met
 500 505 510
 Arg Lys Phe Lys Ile Gly Tyr Ser Asn Asn Gly Ser Asp Trp Lys Met
 515 520 525
 Ile Met Asp Asp Ser Lys Arg Lys Ala Lys Gly Gly Thr Thr Val Leu
 530 535 540
 Ala Thr Glu Lys Pro Thr Val Ile Asp Ser Thr Ile Gln Ser Glu Phe
 545 550 555 560
 Pro Thr Tyr Gly Phe Asn Cys Glu Phe Gly Trp Gly Ser His Lys Thr
 565 570 575
 Phe Cys His Trp Glu His Asp Asn His Val Gln Leu Lys Trp Ser Val
 580 585 590
 Leu Thr Ser Lys Thr Gly Pro Ile Gln Asp His Thr Gly Asp Gly Asn
 595 600 605
 Phe Ile Tyr Ser Gln Ala Asp Glu Asn Gln Lys Gly Lys Val Ala Arg
 610 615 620
 Leu Val Ser Pro Val Val Tyr Ser Gln Asn Ser Ala His Cys Met Thr
 625 630 635 640
 Phe Trp Tyr His Met Ser Gly Ser His Val Gly Thr Leu Arg Val Lys
 645 650 655
 Leu Arg Tyr Gln Lys Pro Glu Glu Tyr Asp Gln Leu Val Trp Met Ala
 660 665 670
 Ile Gly His Gln Gly Asp His Trp Lys Glu Gly Arg Val Leu Leu His
 675 680 685
 Lys Ser Leu Lys Leu Tyr Gln Val Ile Phe Glu Gly Glu Ile Gly Lys
 690 695 700
 Gly Asn Leu Gly Gly Ile Ala Val Asp Asp Ile Ser Ile Asn Asn His
 705 710 715 720
 Ile Ser Gln Glu Asp Cys Ala Lys Pro Ala Asp Leu Asp Lys Lys Asn
 725 730 735

ro Glu Ile Lys Ile Asp Glu Thr Gly Ser Thr Pro Gly Tyr Glu Gly
 740 745 750
 lu Gly Glu Gly Asp Lys Asn Ile Ser Arg Lys Pro Gly Asn Val Leu
 755 760 765
 ys Thr Leu Xaa Pro Ile Leu Ile Thr Ile Ile Ala Met Ser Ala Leu
 770 775 780
 ly Val Leu Leu Gly Ala Val Cys Gly Val Val Leu Tyr Cys Ala Cys
 785 790 795 800
 Trp His Asn Gly Met Ser Glu Arg Asn Leu Ser Ala Leu Glu Asn Tyr
 805 810 815
 Asn Phe Glu Leu Val Asp Gly Val Lys Leu Lys Lys Asp Lys Leu Asn
 820 825 830
 Thr Gln Ser Thr Tyr Ser Glu Ala
 835 840

<210> 137
 <211> 538
 <212> PRT
 <213> Homo sapiens

<400> 137
 Met Glu Arg Gly Leu Pro Leu Leu Cys Ala Val Leu Ala Leu Val Leu
 1 5 10 15
 Ala Pro Ala Gly Ala Phe Arg Asn Asp Lys Cys Gly Asp Thr Ile Lys
 20 25 30
 Ile Glu Ser Pro Gly Tyr Leu Thr Ser Pro Gly Tyr Pro His Ser Tyr
 35 40 45
 His Pro Ser Glu Lys Cys Glu Trp Leu Ile Gln Ala Pro Asp Pro Tyr
 50 55 60
 Gln Arg Ile Met Ile Asn Phe Asn Pro His Phe Asp Leu Glu Asp Arg
 65 70 75 80
 Asp Cys Lys Tyr Asp Tyr Val Glu Val Phe Asp Gly Glu Asn Glu Asn
 85 90 95
 Gly His Phe Arg Gly Lys Phe Cys Gly Lys Ile Ala Pro Pro Pro Val
 100 105 110
 Val Ser Ser Gly Pro Phe Leu Phe Ile Lys Phe Val Ser Asp Tyr Glu
 115 120 125
 Thr His Gly Ala Gly Phe Ser Ile Arg Tyr Glu Ile Phe Lys Arg Gly
 130 135 140
 Pro Glu Cys Ser Gln Asn Tyr Thr Thr Pro Ser Gly Val Ile Lys Ser
 145 150 155 160
 Pro Gly Phe Pro Glu Lys Tyr Pro Asn Ser Leu Glu Cys Thr Tyr Ile
 165 170 175

Val Phe Ala Pro Lys Met Ser Glu Ile Ile Leu Glu Phe Glu Ser Phe
 180 185 190
 Asp Leu Glu Pro Asp Ser Asn Pro Pro Gly Gly Met Phe Cys Arg Tyr
 195 200 205
 Asp Arg Leu Glu Ile Trp Asp Gly Phe Pro Asp Val Gly Pro His Ile
 210 215 220
 Gly Arg Tyr Cys Gly Gln Lys Thr Pro Gly Arg Ile Arg Ser Ser Ser
 225 230 235 240
 Gly Ile Leu Ser Met Val Phe Tyr Thr Asp Ser Ala Ile Ala Lys Glu
 245 250 255
 Gly Phe Ser Ala Asn Tyr Ser Val Leu Gln Ser Ser Val Ser Glu Asp
 260 265 270
 Phe Lys Cys Met Glu Ala Leu Gly Met Glu Ser Gly Glu Ile His Ser
 275 280 285
 Asp Gln Ile Thr Ala Ser Ser Gln Tyr Ser Thr Asn Trp Ser Ala Glu
 290 295 300
 Arg Ser Arg Leu Asn Tyr Pro Glu Asn Gly Trp Thr Pro Gly Glu Asp
 305 310 315 320
 Ser Tyr Arg Glu Trp Ile Gln Val Asp Leu Gly Leu Leu Arg Phe Val
 325 330 335
 Thr Ala Val Gly Thr Gln Gly Ala Ile Ser Lys Glu Thr Lys Lys Lys
 340 345 350
 Tyr Tyr Val Lys Thr Tyr Lys Ile Asp Val Ser Ser Asn Gly Glu Asp
 355 360 365
 Trp Ile Thr Ile Lys Glu Gly Asn Lys Pro Val Leu Phe Gln Gly Asn
 370 375 380
 Thr Asn Pro Thr Asp Val Val Val Ala Val Phe Pro Lys Pro Leu Ile
 385 390 395 400
 Thr Arg Phe Val Arg Ile Lys Pro Ala Thr Trp Glu Thr Gly Ile Ser
 405 410 415
 Met Arg Phe Glu Val Tyr Gly Cys Lys Ile Thr Asp Tyr Pro Cys Ser
 420 425 430
 Gly Met Leu Gly Met Val Ser Gly Leu Ile Ser Asp Ser Gln Ile Thr
 435 440 445
 Ser Ser Asn Gln Gly Asp Arg Asn Trp Met Pro Glu Asn Ile Arg Leu
 450 455 460
 Val Thr Ser Arg Ser Gly Trp Ala Leu Pro Pro Ala Pro His Ser Tyr
 465 470 475 480
 Ile Asn Glu Trp Leu Gln Ile Asp Leu Gly Glu Glu Lys Ile Val Arg
 485 490 495
 Gly Ile Ile Ile Gln Gly Gly Lys His Arg Glu Asn Lys Val Phe Met

500 505 510
 Arg Lys Phe Lys Ile Gly Tyr Ser Asn Asn Gly Ser Asp Trp Lys Met
 515 520 525
 Ile Met Asp Asp Ser Lys Arg Lys Ala Arg
 530 535
 <210> 138
 <211> 389
 <212> PRT
 <213> Homo sapiens
 <400> 138
 Met Gly Ala Pro Ala Cys Ala Leu Ala Leu Cys Val Ala Val Ala Ile
 1 5 10 15
 Val Ala Gly Ala Ser Ser Glu Ser Leu Gly Thr Glu Gln Arg Val Val
 20 25 30
 Gly Arg Ala Ala Glu Val Pro Gly Pro Glu Pro Gly Gln Gln Glu Gln
 35 40 45
 Leu Val Phe Gly Ser Gly Asp Ala Val Glu Leu Ser Cys Pro Pro Pro
 50 55 60
 Gly Gly Gly Pro Met Gly Pro Thr Val Trp Val Lys Asp Gly Thr Gly
 65 70 75 80
 Leu Val Pro Ser Glu Arg Val Leu Val Gly Pro Gln Arg Leu Gln Val
 85 90 95
 Leu Asn Ala Ser His Glu Asp Ser Gly Ala Tyr Ser Cys Arg Gln Arg
 100 105 110
 Leu Thr Gln Arg Val Leu Cys His Phe Ser Val Arg Val Thr Asp Ala
 115 120 125
 Pro Ser Ser Gly Asp Asp Glu Asp Gly Glu Asp Glu Ala Glu Asp Thr
 130 135 140
 Gly Val Asp Thr Gly Ala Pro Tyr Trp Thr Arg Pro Glu Arg Met Asp
 145 150 155 160
 Lys Lys Leu Leu Ala Val Pro Ala Ala Asn Thr Val Arg Phe Arg Cys
 165 170 175
 Pro Ala Ala Gly Asn Pro Thr Pro Ser Ile Ser Trp Leu Lys Asn Gly
 180 185 190
 Arg Glu Phe Arg Gly Glu His Arg Ile Gly Gly Ile Lys Leu Arg His
 195 200 205
 Gln Gln Trp Ser Leu Val Met Glu Ser Val Val Pro Ser Asp Arg Gly
 210 215 220
 Asn Tyr Thr Cys Val Val Glu Asn Lys Phe Gly Ser Ile Arg Gln Thr
 225 230 235 240
 Tyr Thr Leu Asp Val Leu Glu Arg Ser Pro His Arg Pro Ile Leu Gln

130 135 140
 Ser Cys Arg Lys Glu Gln Glu Thr Cys Leu Ala Pro Glu Leu Glu His
 145 150 155 160
 Gly Asn Tyr Ser Thr Thr Gln Arg Thr Phe Lys Val Lys Asp Ile Val
 165 170 175
 Ala Tyr Thr Cys Thr Ala Gly Tyr Tyr Thr Thr Thr Gly Lys Gln Thr
 180 185 190
 Gly Glu Ala Glu Cys Gln Ala Asn Gly Trp Ser Leu Thr Pro Gln Cys
 195 200 205
 Asn Lys Leu Met Cys Ser Ser Leu Arg Leu Ile Glu Asn Gly Tyr Phe
 210 215 220
 His Pro Val Lys Gln Thr Tyr Glu Glu Gly Asp Val Val Gln Phe Phe
 225 230 235 240
 Cys His Glu Asn Tyr Tyr Leu Ser Gly Ser Asp Leu Ile Gln Cys Tyr
 245 250 255
 Asn Phe Gly Trp Tyr Pro Glu Ser Pro Ile Cys Glu Gly Arg Arg Asn
 260 265 270
 Arg Cys Pro Pro Pro Pro Val Pro Leu Asn Ser Lys Ile Gln Pro His
 275 280 285
 Ser Thr Thr Tyr Arg His Gly Glu Arg Val His Ile Glu Cys Glu Leu
 290 295 300
 Asn Phe Val Ile Gln Gly Ser Glu Glu Leu Leu Cys Glu Asn Gly Lys
 305 310 315 320
 Trp Thr Glu Pro Pro Lys Cys Ile Gly Trp
 325 330

<210> 140
 <211> 1073
 <212> PRT
 <213> Mouse

<400> 140
 Met Pro Trp Gly Arg Arg Pro Thr Trp Leu Leu Leu Ala Phe Leu Leu
 1 5 10 15
 Val Phe Leu Lys Ile Ser Ile Leu Ser Val Thr Ala Trp Gln Thr Gly
 20 25 30
 Asn Cys Gln Pro Gly Pro Leu Glu Arg Ser Glu Arg Ser Gly Thr Cys
 35 40 45
 Ala Gly Pro Ala Pro Phe Leu Val Phe Ser Gln Gly Lys Ser Ile Ser
 50 55 60
 Arg Ile Asp Pro Asp Gly Thr Asn His Gln Gln Leu Val Val Asp Ala
 65 70 75 80
 Gly Ile Ser Ala Asp Met Asp Ile His Tyr Lys Lys Glu Arg Leu Tyr

				85					90					95		
Trp	Val	Asp	Val	Glu	Arg	Gln	Val	Leu	Leu	Arg	Val	Phe	Leu	Asn	Gly	
			100					105					110			
Thr	Gly	Leu	Glu	Lys	Val	Cys	Asn	Val	Glu	Arg	Lys	Val	Ser	Gly	Leu	
		115					120					125				
Ala	Ile	Asp	Trp	Ile	Asp	Asp	Glu	Val	Leu	Trp	Val	Asp	Gln	Gln	Asn	
	130					135					140					
Gly	Val	Ile	Thr	Val	Thr	Asp	Met	Thr	Gly	Lys	Asn	Ser	Arg	Val	Leu	
145					150					155					160	
Leu	Ser	Ser	Leu	Lys	His	Pro	Ser	Asn	Ile	Ala	Val	Asp	Pro	Ile	Glu	
				165					170					175		
Arg	Leu	Met	Phe	Trp	Ser	Ser	Glu	Val	Thr	Gly	Ser	Leu	His	Arg	Ala	
			180					185					190			
His	Leu	Lys	Gly	Val	Asp	Val	Lys	Thr	Leu	Leu	Glu	Thr	Gly	Gly	Ile	
		195					200					205				
Ser	Val	Leu	Thr	Leu	Asp	Val	Leu	Asp	Lys	Arg	Leu	Phe	Trp	Val	Gln	
	210					215					220					
Asp	Ser	Gly	Glu	Gly	Ser	His	Ala	Tyr	Ile	His	Ser	Cys	Asp	Tyr	Glu	
225					230					235					240	
Gly	Gly	Ser	Val	Arg	Leu	Ile	Arg	His	Gln	Ala	Arg	His	Ser	Leu	Ser	
				245					250					255		
Ser	Met	Ala	Phe	Phe	Gly	Asp	Arg	Ile	Phe	Tyr	Ser	Val	Leu	Lys	Ser	
			260					265					270			
Lys	Ala	Ile	Trp	Ile	Ala	Asn	Lys	His	Thr	Gly	Lys	Asp	Thr	Val	Arg	
		275					280					285				
Ile	Asn	Leu	His	Pro	Ser	Phe	Val	Thr	Pro	Gly	Lys	Leu	Met	Val	Val	
	290					295					300					
His	Pro	Arg	Ala	Gln	Pro	Arg	Thr	Glu	Asp	Ala	Ala	Lys	Asp	Pro	Asp	
305					310					315					320	
Pro	Glu	Leu	Leu	Lys	Gln	Arg	Gly	Arg	Pro	Cys	Arg	Phe	Gly	Leu	Cys	
				325					330					335		
Glu	Arg	Asp	Pro	Lys	Ser	His	Ser	Ser	Ala	Cys	Ala	Glu	Gly	Tyr	Thr	
			340					345					350			
Leu	Ser	Arg	Asp	Arg	Lys	Tyr	Cys	Glu	Asp	Val	Asn	Glu	Cys	Ala	Thr	
		355					360					365				
Gln	Asn	His	Gly	Cys	Thr	Leu	Gly	Cys	Glu	Asn	Thr	Pro	Gly	Ser	Tyr	
	370					375					380					
His	Cys	Thr	Cys	Pro	Thr	Gly	Phe	Val	Leu	Leu	Pro	Asp	Gly	Lys	Gln	
385					390					395					400	
Cys	His	Glu	Leu	Val	Ser	Cys	Pro	Gly	Asn	Val	Ser	Lys	Cys	Ser	His	
				405					410					415		

Gly Cys Val Leu Thr Ser Asp Gly Pro Arg Cys Ile Cys Pro Ala Gly
 420 425 430
 Ser Val Leu Gly Arg Asp Gly Lys Thr Cys Thr Gly Cys Ser Ser Pro
 435 440 445
 Asp Asn Gly Gly Cys Ser Gln Ile Cys Leu Pro Leu Arg Pro Gly Ser
 450 455 460
 Trp Glu Cys Asp Cys Phe Pro Gly Tyr Asp Leu Gln Ser Asp Arg Lys
 465 470 475 480
 Ser Cys Ala Ala Ser Gly Pro Gln Pro Leu Leu Leu Phe Ala Asn Ser
 485 490 495
 Gln Asp Ile Arg His Met His Phe Asp Gly Thr Asp Tyr Lys Val Leu
 500 505 510
 Leu Ser Arg Gln Met Gly Met Val Phe Ala Leu Asp Tyr Asp Pro Val
 515 520 525
 Glu Ser Lys Ile Tyr Phe Ala Gln Thr Ala Leu Lys Trp Ile Glu Arg
 530 535 540
 Ala Asn Met Asp Gly Ser Gln Arg Glu Arg Leu Ile Thr Glu Gly Val
 545 550 555 560
 Asp Thr Leu Glu Gly Leu Ala Leu Asp Trp Ile Gly Arg Arg Ile Tyr
 565 570 575
 Trp Thr Asp Ser Gly Lys Ser Val Val Gly Gly Ser Asp Leu Ser Gly
 580 585 590
 Lys His His Arg Ile Ile Ile Gln Glu Arg Ile Ser Arg Pro Arg Gly
 595 600 605
 Ile Ala Val His Pro Arg Ala Arg Arg Leu Phe Trp Thr Asp Val Gly
 610 615 620
 Met Ser Pro Arg Ile Glu Ser Ala Ser Leu Gln Gly Ser Asp Arg Val
 625 630 635 640
 Leu Ile Ala Ser Ser Asn Leu Leu Glu Pro Ser Gly Ile Thr Ile Asp
 645 650 655
 Tyr Leu Thr Asp Thr Leu Tyr Trp Cys Asp Thr Lys Arg Ser Val Ile
 660 665 670
 Glu Met Ala Asn Leu Asp Gly Ser Lys Arg Arg Arg Leu Ile Gln Asn
 675 680 685
 Asp Val Gly His Pro Phe Ser Leu Ala Val Phe Glu Asp His Leu Trp
 690 695 700
 Val Ser Asp Trp Ala Ile Pro Ser Val Ile Arg Val Asn Lys Arg Thr
 705 710 715 720
 Gly Gln Asn Arg Val Arg Leu Gln Gly Ser Met Leu Lys Pro Ser Ser
 725 730 735

Leu Val Val Val His Pro Leu Ala Lys Pro Gly Ala Asp Pro Cys Leu
 740 745 750
 Tyr Arg Asn Gly Gly Cys Glu His Ile Cys Gln Glu Ser Leu Gly Thr
 755 760 765
 Ala Arg Cys Leu Cys Arg Glu Gly Phe Val Lys Ala Trp Asp Gly Lys
 770 775 780
 Met Cys Leu Pro Gln Asp Tyr Pro Ile Leu Ser Gly Glu Asn Ala Asp
 785 790 795 800
 Leu Ser Lys Glu Val Thr Ser Leu Ser Asn Ser Thr Gln Ala Glu Val
 805 810 815
 Pro Asp Asp Asp Gly Thr Glu Ser Ser Thr Leu Val Ala Glu Ile Met
 820 825 830
 Val Ser Gly Met Asn Tyr Glu Asp Asp Cys Gly Pro Gly Gly Cys Gly
 835 840 845
 Ser His Ala Arg Cys Val Ser Asp Gly Glu Thr Ala Glu Cys Gln Cys
 850 855 860
 Leu Lys Gly Phe Ala Arg Asp Gly Asn Leu Cys Ser Asp Ile Asp Glu
 865 870 875 880
 Cys Val Leu Ala Arg Ser Asp Cys Pro Ser Thr Ser Ser Arg Cys Ile
 885 890 895
 Asn Thr Glu Gly Gly Tyr Val Cys Arg Cys Ser Glu Gly Tyr Glu Gly
 900 905 910
 Asp Gly Ile Ser Cys Phe Asp Ile Asp Glu Cys Gln Arg Gly Ala His
 915 920 925
 Asn Cys Ala Glu Asn Ala Ala Cys Thr Asn Thr Glu Gly Gly Tyr Asn
 930 935 940
 Cys Thr Cys Ala Gly Arg Pro Ser Ser Pro Gly Leu Ser Cys Pro Asp
 945 950 955 960
 Ser Thr Ala Pro Ser Leu Leu Gly Glu Asp Gly His His Leu Asp Arg
 965 970 975
 Asn Ser Tyr Pro Gly Cys Pro Ser Ser Tyr Asp Gly Tyr Cys Leu Asn
 980 985 990
 Gly Gly Val Cys Met His Ile Glu Ser Leu Asp Ser Tyr Thr Cys Asn
 995 1000 1005
 Cys Val Ile Gly Tyr Ser Gly Asp Arg Cys Gln Thr Pro Pro Ser Ser
 1010 1015 1020
 Asp Arg Gly Pro Gln Glu Ile Glu Gly Asn Ser His Leu Pro Ser Tyr
 1025 1030 1035 1040
 Arg Pro Val Gly Pro Glu Lys Leu His Ser Leu Gln Ser Ala Asn Gly
 1045 1050 1055
 Ser Cys His Glu Arg Ala Pro Asp Leu Pro Arg Gln Thr Glu Pro Val

1060

1065

1070

Gln

<210> 141

<211> 804

<212> PRT

<213> Homo sapiens

<400> 141

Met Pro Trp Gly Arg Arg Pro Thr Trp Leu Leu Leu Ala Phe Leu Leu
 1 5 10 15

Val Phe Leu Lys Ile Ser Ile Leu Ser Val Thr Ala Trp Gln Thr Gly
 20 25 30

Asn Cys Gln Pro Gly Pro Leu Glu Arg Ser Glu Arg Ser Gly Thr Cys
 35 40 45

Ala Gly Pro Ala Pro Phe Leu Val Phe Ser Gln Gly Lys Ser Ile Ser
 50 55 60

Arg Ile Asp Pro Asp Gly Thr Asn His Gln Gln Leu Val Val Asp Ala
 65 70 75 80

Gly Ile Ser Ala Asp Met Asp Ile His Tyr Lys Lys Glu Arg Leu Tyr
 85 90 95

Trp Val Asp Val Glu Arg Gln Val Leu Leu Arg Val Phe Leu Asn Gly
 100 105 110

Thr Gly Leu Glu Lys Val Cys Asn Val Glu Arg Lys Val Ser Gly Leu
 115 120 125

Ala Ile Asp Trp Ile Asp Asp Glu Val Leu Trp Val Asp Gln Gln Asn
 130 135 140

Gly Val Ile Thr Val Thr Asp Met Thr Gly Lys Asn Ser Arg Val Leu
 145 150 155 160

Leu Ser Ser Leu Lys His Pro Ser Asn Ile Ala Val Asp Pro Ile Glu
 165 170 175

Arg Leu Met Phe Trp Ser Ser Glu Val Thr Gly Ser Leu His Arg Ala
 180 185 190

His Leu Lys Gly Val Asp Val Lys Thr Leu Leu Glu Thr Gly Gly Ile
 195 200 205

Ser Val Leu Thr Leu Asp Val Leu Asp Lys Arg Leu Phe Trp Val Gln
 210 215 220

Asp Ser Gly Glu Gly Ser His Ala Tyr Ile His Ser Cys Asp Tyr Glu
 225 230 235 240

Gly Gly Ser Val Arg Leu Ile Arg His Gln Ala Arg His Ser Leu Ser
 245 250 255

Ser Met Ala Phe Phe Gly Asp Arg Ile Phe Tyr Ser Val Leu Lys Ser

162

Lys His His Arg Ile Ile Ile Gln Glu Arg Ile Ser Arg Pro Arg Gly
 595 600 605
 Ile Ala Val His Pro Arg Ala Arg Arg Leu Phe Trp Thr Asp Val Gly
 610 615 620
 Met Ser Pro Arg Ile Glu Ser Ala Ser Leu Gln Gly Ser Asp Arg Val
 625 630 635 640
 Leu Ile Ala Ser Ser Asn Leu Leu Glu Pro Ser Gly Ile Thr Ile Asp
 645 650 655
 Tyr Leu Thr Asp Thr Leu Tyr Trp Cys Asp Thr Lys Arg Ser Val Ile
 660 665 670
 Glu Met Ala Asn Leu Asp Gly Ser Lys Arg Arg Arg Leu Ile Gln Asn
 675 680 685
 Asp Val Gly His Pro Phe Ser Leu Ala Val Phe Glu Asp His Leu Trp
 690 695 700
 Val Ser Asp Trp Ala Ile Pro Ser Val Ile Arg Val Asn Lys Arg Thr
 705 710 715 720
 Gly Gln Asn Arg Val Arg Leu Gln Gly Ser Met Leu Lys Pro Ser Ser
 725 730 735
 Leu Val Val Val His Pro Leu Ala Lys Pro Gly Ala Asp Pro Cys Leu
 740 745 750
 Tyr Arg Asn Gly Gly Cys Glu His Ile Cys Gln Glu Ser Leu Gly Thr
 755 760 765
 Ala Arg Cys Leu Cys Arg Glu Gly Phe Val Lys Ala Trp Asp Gly Lys
 770 775 780
 Met Cys Leu Pro Gln Asp Tyr Pro Ile Leu Ser Gly Glu Asn Ala His
 785 790 795 800
 Asn Cys Ala Phe

<210> 142
 <211> 576
 <212> PRT
 <213> Homo sapiens

<400> 142
 Met Pro Trp Gly Arg Arg Pro Thr Trp Leu Leu Leu Ala Phe Leu Leu
 1 5 10 15
 Val Phe Leu Lys Ile Ser Ile Leu Ser Val Thr Ala Trp Gln Thr Gly
 20 25 30
 Asn Cys Gln Pro Gly Pro Leu Glu Arg Ser Glu Arg Ser Gly Thr Cys
 35 40 45
 Ala Gly Pro Ala Pro Phe Leu Val Phe Ser Gln Gly Lys Ser Ile Ser
 50 55 60

Arg Ile Trp Ala Ile Pro Ser Val Ile Arg Val Asn Lys Arg Thr Gly
 65 70 75 80
 Gln Asn Arg Val Arg Leu Gln Gly Ser Met Leu Lys Pro Ser Ser Leu
 85 90 95
 Val Val Val His Pro Leu Ala Lys Pro Gly Ala Asp Pro Cys Leu Tyr
 100 105 110
 Arg Asn Gly Gly Cys Glu His Ile Cys Gln Glu Ser Leu Gly Thr Ala
 115 120 125
 Arg Cys Leu Cys Arg Glu Gly Phe Val Lys Ala Trp Asp Gly Lys Met
 130 135 140
 Cys Leu Pro Gln Asp Tyr Pro Ile Leu Ser Gly Glu Asn Ala Asp Leu
 145 150 155 160
 Ser Lys Glu Val Thr Ser Leu Ser Asn Ser Thr Gln Ala Glu Val Pro
 165 170 175
 Asp Asp Asp Gly Thr Glu Ser Ser Thr Leu Val Ala Glu Ile Met Val
 180 185 190
 Ser Gly Met Asn Tyr Glu Asp Asp Cys Gly Pro Gly Gly Cys Gly Ser
 195 200 205
 His Ala Arg Cys Val Ser Asp Gly Glu Thr Ala Glu Cys Gln Cys Leu
 210 215 220
 Lys Gly Phe Ala Arg Asp Gly Asn Leu Cys Ser Asp Ile Asp Glu Cys
 225 230 235 240
 Val Leu Ala Arg Ser Asp Cys Pro Ser Thr Ser Ser Arg Cys Ile Asn
 245 250 255
 Thr Glu Gly Gly Tyr Val Cys Arg Cys Ser Glu Gly Tyr Glu Gly Asp
 260 265 270
 Gly Ile Ser Cys Phe Asp Ile Asp Glu Cys Gln Arg Gly Ala His Asn
 275 280 285
 Cys Ala Glu Asn Ala Ala Cys Thr Asn Thr Glu Gly Gly Tyr Asn Cys
 290 295 300
 Thr Cys Ala Gly Arg Pro Ser Ser Pro Gly Leu Ser Cys Pro Asp Ser
 305 310 315 320
 Thr Ala Pro Ser Leu Leu Gly Glu Asp Gly His His Leu Asp Arg Asn
 325 330 335
 Ser Tyr Pro Gly Cys Pro Ser Ser Tyr Asp Gly Tyr Cys Leu Asn Gly
 340 345 350
 Gly Val Cys Met His Ile Glu Ser Leu Asp Ser Tyr Thr Cys Asn Cys
 355 360 365
 Val Ile Gly Tyr Ser Gly Asp Arg Cys Gln Thr Arg Asp Leu Arg Trp
 370 375 380

Trp Glu Leu Arg His Ala Gly Tyr Gly Gln Lys His Asp Ile Met Val
 385 390 395 400
 Val Ala Val Cys Met Val Ala Leu Val Leu Leu Leu Leu Gly Met
 405 410 415
 Trp Gly Thr Tyr Tyr Tyr Arg Thr Arg Lys Gln Leu Ser Asn Pro Pro
 420 425 430
 Lys Asn Pro Cys Asp Glu Pro Ser Gly Ser Val Ser Ser Ser Gly Pro
 435 440 445
 Asp Ser Ser Ser Gly Ala Ala Val Ala Ser Cys Pro Gln Pro Trp Phe
 450 455 460
 Val Val Leu Glu Lys His Gln Asp Pro Lys Asn Gly Ser Leu Pro Ala
 465 470 475 480
 Asp Gly Thr Asn Gly Ala Val Val Asp Ala Gly Leu Ser Pro Ser Leu
 485 490 495
 Gln Leu Gly Ser Val His Leu Thr Ser Trp Arg Gln Lys Pro His Ile
 500 505 510
 Asp Gly Met Gly Thr Gly Gln Ser Cys Trp Ile Pro Pro Ser Ser Asp
 515 520 525
 Arg Gly Pro Gln Glu Ile Glu Gly Asn Ser His Leu Pro Ser Tyr Arg
 530 535 540
 Pro Val Gly Pro Glu Lys Leu His Ser Leu Gln Ser Ala Asn Gly Ser
 545 550 555 560
 Cys His Glu Arg Ala Pro Asp Leu Pro Arg Gln Thr Glu Pro Val Gln
 565 570 575

<210> 143
 <211> 376
 <212> PRT
 <213> Homo sapiens

<400> 143
 Met Pro Trp Gly Arg Arg Pro Thr Trp Leu Leu Leu Ala Phe Leu Leu
 1 5 10 15
 Val Ser Ala Glu Cys Gln Cys Leu Lys Gly Phe Ala Arg Asp Gly Asn
 20 25 30
 Leu Cys Ser Asp Ile Asp Glu Cys Val Leu Ala Arg Ser Asp Cys Pro
 35 40 45
 Ser Thr Ser Ser Arg Cys Ile Asn Thr Glu Gly Gly Tyr Val Cys Arg
 50 55 60
 Cys Ser Glu Gly Tyr Glu Gly Asp Gly Ile Ser Cys Phe Asp Ile Asp
 65 70 75 80

Glu Cys Gln Arg Gly Ala His Asn Cys Ala Glu Asn Ala Ala Cys Thr
 85 90 95
 Asn Thr Glu Gly Gly Tyr Asn Cys Thr Cys Ala Gly Arg Pro Ser Ser
 100 105 110
 Pro Gly Leu Ser Cys Pro Asp Ser Thr Ala Pro Ser Leu Leu Gly Glu
 115 120 125
 Asp Gly His His Leu Asp Arg Asn Ser Tyr Pro Gly Cys Pro Ser Ser
 130 135 140
 Tyr Asp Gly Tyr Cys Leu Asn Gly Gly Val Cys Met His Ile Glu Ser
 145 150 155 160
 Leu Asp Ser Tyr Thr Cys Asn Cys Val Ile Gly Tyr Ser Gly Asp Arg
 165 170 175
 Cys Gln Thr Arg Asp Leu Arg Trp Trp Glu Leu Arg His Ala Gly Tyr
 180 185 190
 Gly Gln Lys His Asp Ile Met Val Val Ala Val Cys Met Val Ala Leu
 195 200 205
 Val Leu Leu Leu Leu Leu Gly Met Trp Gly Thr Tyr Tyr Tyr Arg Thr
 210 215 220
 Arg Lys Gln Leu Ser Asn Pro Pro Lys Asn Pro Cys Asp Glu Pro Ser
 225 230 235 240
 Gly Ser Val Ser Ser Ser Gly Pro Asp Ser Ser Ser Gly Ala Ala Val
 245 250 255
 Ala Ser Cys Pro Gln Pro Trp Phe Val Val Leu Glu Lys His Gln Asp
 260 265 270
 Pro Lys Asn Gly Ser Leu Pro Ala Asp Gly Thr Asn Gly Ala Val Val
 275 280 285
 Asp Ala Gly Leu Ser Pro Ser Leu Gln Leu Gly Ser Val His Leu Thr
 290 295 300
 Ser Trp Arg Gln Lys Pro His Ile Asp Gly Met Gly Thr Gly Gln Ser
 305 310 315 320
 Cys Trp Ile Pro Pro Ser Ser Asp Arg Gly Pro Gln Glu Ile Glu Gly
 325 330 335
 Asn Ser His Leu Pro Ser Tyr Arg Pro Val Gly Pro Glu Lys Leu His
 340 345 350
 Ser Leu Gln Ser Ala Asn Gly Ser Cys His Glu Arg Ala Pro Asp Leu
 355 360 365
 Pro Arg Gln Thr Glu Pro Val Gln
 370 375

<210> 144

<211> 1249

<212> PRT

<213> Homo sapiens

<400> 144

Met Gly Ala Ala Ser Gly Gln Arg Gly Arg Trp Pro Leu Ser Pro Pro
 1 5 10 15
 Leu Leu Met Leu Ser Leu Leu Val Leu Leu Leu Gln Pro Ser Pro Ala
 20 25 30
 Pro Ala Leu Asp Pro Gly Leu Gln Pro Gly Asn Phe Ser Pro Asp Glu
 35 40 45
 Ala Gly Ala Gln Leu Phe Ala Glu Ser Tyr Asn Ser Ser Ala Glu Val
 50 55 60
 Val Met Phe Gln Ser Thr Val Ala Ser Trp Ala His Asp Thr Asn Ile
 65 70 75 80
 Thr Glu Glu Asn Ala Arg Arg Gln Glu Glu Ala Ala Leu Val Ser Gln
 85 90 95
 Glu Phe Ala Glu Val Trp Gly Lys Lys Ala Lys Glu Leu Tyr Glu Ser
 100 105 110
 Ile Trp Gln Asn Phe Thr Asp Ser Lys Leu Arg Arg Ile Ile Gly Ser
 115 120 125
 Ile Arg Thr Leu Gly Pro Ala Asn Leu Pro Leu Ala Gln Arg Gln Gln
 130 135 140
 Tyr Asn Ser Leu Leu Ser Asn Met Ser Arg Ile Tyr Ser Thr Gly Lys
 145 150 155 160
 Val Cys Phe Pro Asn Lys Thr Ala Thr Cys Trp Ser Leu Asp Pro Glu
 165 170 175
 Leu Thr Asn Ile Leu Ala Ser Ser Arg Ser Tyr Ala Lys Leu Leu Phe
 180 185 190
 Ala Trp Glu Gly Trp His Asp Ala Val Gly Ile Pro Leu Lys Pro Leu
 195 200 205
 Tyr Gln Asp Phe Thr Ala Ile Ser Asn Glu Ala Tyr Arg Gln Asp Asp
 210 215 220
 Phe Ser Asp Thr Gly Ala Phe Trp Arg Ser Trp Tyr Glu Ser Pro Ser
 225 230 235 240
 Phe Glu Glu Ser Leu Glu His Ile Tyr His Gln Leu Glu Pro Leu Tyr
 245 250 255
 Leu Asn Leu His Ala Tyr Val Arg Arg Ala Leu His Arg Arg Tyr Gly
 260 265 270
 Asp Lys Tyr Val Asn Leu Arg Gly Pro Ile Pro Ala His Leu Leu Gly
 275 280 285
 Asp Met Trp Ala Gln Ser Trp Glu Asn Ile Tyr Asp Met Val Val Pro
 290 295 300
 Phe Pro Asp Lys Pro Asn Leu Asp Val Thr Ser Thr Met Val Gln Lys

305		310		315		320
Gly Trp Asn Ala Thr	His Met Phe Arg Val Ser Glu Glu Phe Phe Thr					
	325		330			335
Ser Leu Gly Leu Ser Pro Met Pro Pro Glu Phe Trp Ala Glu Ser Met						
	340		345			350
Leu Glu Lys Pro Thr Asp Gly Arg Glu Val Val Cys His Ala Ser Ala						
	355		360			365
Trp Asp Phe Tyr Asn Arg Lys Asp Phe Arg Ile Lys Gln Cys Thr Arg						
	370		375			380
Val Thr Met Glu Gln Leu Ala Thr Val His His Glu Met Gly His Val						
	385		390			395
Gln Tyr Tyr Leu Gln Tyr Lys Asp Leu His Val Ser Leu Arg Arg Gly						
	405		410			415
Ala Asn Pro Gly Phe His Glu Ala Ile Gly Asp Val Leu Ala Leu Ser						
	420		425			430
Val Ser Thr Pro Ala His Leu His Lys Ile Gly Leu Leu Asp His Val						
	435		440			445
Thr Asn Asp Ile Glu Ser Asp Ile Asn Tyr Leu Leu Lys Met Ala Leu						
	450		455			460
Glu Lys Ile Ala Phe Leu Pro Phe Gly Tyr Leu Val Asp Gln Trp Arg						
	465		470			475
Trp Gly Val Phe Ser Gly Arg Thr Pro Pro Ser Arg Tyr Asn Phe Asp						
	485		490			495
Trp Trp Tyr Leu Arg Thr Lys Tyr Gln Gly Ile Cys Pro Pro Val Ala						
	500		505			510
Arg Asn Glu Thr His Phe Asp Ala Gly Ala Lys Phe His Ile Pro Asn						
	515		520			525
Val Thr Pro Tyr Ile Arg Tyr Phe Val Ser Phe Val Leu Gln Phe Gln						
	530		535			540
Phe His Gln Ala Leu Cys Lys Glu Ala Gly His Gln Gly Pro Leu His						
	545		550			555
Gln Cys Asp Ile Tyr Gln Ser Xaa Gln Ala Gly Ala Lys Leu Lys Gln						
	565		570			575
Val Leu Gln Ala Gly Cys Ser Arg Pro Trp Gln Glu Val Leu Lys Asp						
	580		585			590
Leu Val Gly Ser Asp Ala Leu Asp Ala Lys Ala Leu Leu Glu Tyr Phe						
	595		600			605
Gln Pro Val Ser Gln Trp Leu Glu Glu Gln Asn Gln Arg Asn Gly Glu						
	610		615			620
Val Leu Gly Trp Pro Glu Asn Gln Trp Arg Pro Pro Leu Pro Asp Asn						
	625		630			635
						640

Tyr Pro Glu Gly Ile Asp Leu Glu Thr Asp Glu Ala Lys Ala Asp Arg
 645 650 655
 Phe Val Glu Glu Tyr Asp Arg Thr Ala Gln Val Leu Leu Asn Glu Tyr
 660 665 670
 Ala Glu Ala Asn Trp Gln Tyr Asn Thr Asn Ile Thr Ile Glu Gly Ser
 675 680 685
 Lys Ile Leu Leu Glu Lys Ser Thr Glu Val Ser Asn His Thr Leu Lys
 690 695 700
 Tyr Gly Thr Arg Ala Lys Thr Phe Asp Val Ser Asn Phe Gln Asn Ser
 705 710 715 720
 Ser Ile Lys Arg Ile Ile Lys Lys Leu Gln Asn Leu Asp Arg Ala Val
 725 730 735
 Leu Pro Pro Lys Glu Leu Glu Glu Tyr Asn Gln Ile Leu Leu Asp Met
 740 745 750
 Glu Thr Thr Tyr Ser Leu Ser Asn Ile Cys Tyr Thr Asn Gly Thr Cys
 755 760 765
 Met Pro Leu Glu Pro Asp Leu Thr Asn Met Met Ala Thr Ser Arg Lys
 770 775 780
 Tyr Glu Glu Leu Leu Trp Ala Trp Lys Ser Trp Arg Asp Lys Val Gly
 785 790 795 800
 Arg Ala Ile Leu Pro Phe Phe Pro Lys Tyr Val Glu Phe Ser Asn Lys
 805 810 815
 Ile Ala Lys Leu Asn Gly Tyr Thr Asp Ala Gly Asp Ser Trp Arg Ser
 820 825 830
 Leu Tyr Glu Ser Asp Asn Leu Glu Gln Asp Leu Glu Lys Leu Tyr Gln
 835 840 845
 Glu Leu Gln Pro Leu Tyr Leu Asn Leu His Ala Tyr Val Arg Arg Ser
 850 855 860
 Leu His Arg His Tyr Gly Ser Glu Tyr Ile Asn Leu Asp Gly Pro Ile
 865 870 875 880
 Pro Ala His Leu Leu Gly Asn Met Trp Ala Gln Thr Trp Ser Asn Ile
 885 890 895
 Tyr Asp Leu Val Ala Pro Phe Pro Ser Ala Pro Asn Ile Asp Ala Thr
 900 905 910
 Glu Ala Met Ile Lys Gln Gly Trp Thr Pro Arg Arg Ile Phe Lys Glu
 915 920 925
 Ala Asp Asn Phe Phe Thr Ser Leu Gly Leu Leu Pro Val Pro Pro Glu
 930 935 940
 Phe Trp Asn Lys Ser Met Leu Glu Lys Pro Thr Asp Gly Arg Glu Val
 945 950 955 960

Val Cys His Pro Ser Ala Trp Asp Phe Tyr Asn Gly Lys Asp Phe Arg
 965 970 975
 Ile Lys Gln Cys Thr Ser Val Asn Met Glu Asp Leu Val Ile Ala His
 980 985 990
 His Glu Met Gly His Ile Gln Tyr Phe Met Gln Tyr Lys Asp Leu Pro
 995 1000 1005
 Val Thr Phe Arg Glu Gly Ala Asn Pro Gly Phe His Glu Ala Ile Gly
 1010 1015 1020
 Asp Ile Met Ala Leu Ser Val Ser Thr Pro Lys His Leu Tyr Ser Leu
 1025 1030 1035 1040
 Asn Leu Leu Ser Thr Glu Gly Ser Gly Tyr Glu Tyr Asp Ile Asn Phe
 1045 1050 1055
 Leu Met Lys Met Ala Leu Asp Lys Ile Ala Phe Ile Pro Phe Ser Tyr
 1060 1065 1070
 Leu Ile Asp Gln Trp Arg Trp Arg Val Phe Asp Gly Ser Ile Thr Lys
 1075 1080 1085
 Glu Asn Tyr Asn Gln Glu Trp Trp Ser Leu Arg Leu Lys Tyr Gln Gly
 1090 1095 1100
 Leu Cys Pro Pro Val Pro Arg Ser Gln Gly Asp Phe Asp Pro Gly Ser
 1105 1110 1115 1120
 Lys Phe His Val Pro Ala Asn Val Pro Tyr Val Arg Tyr Phe Val Ser
 1125 1130 1135
 Phe Ile Ile Gln Phe Gln Phe His Glu Ala Leu Cys Arg Ala Ala Gly
 1140 1145 1150
 His Thr Gly Pro Leu His Lys Cys Asp Ile Tyr Gln Ser Lys Glu Ala
 1155 1160 1165
 Gly Lys Leu Leu Ala Asp Ala Met Lys Leu Gly Tyr Ser Lys Pro Trp
 1170 1175 1180
 Pro Glu Ala Met Lys Leu Ile Thr Gly Gln Pro Asn Met Ser Ala Ser
 1185 1190 1195 1200
 Ala Met Met Asn Tyr Phe Lys Pro Leu Thr Glu Trp Leu Val Thr Glu
 1205 1210 1215
 Asn Arg Arg His Gly Glu Thr Leu Gly Trp Pro Glu Tyr Asn Trp Ala
 1220 1225 1230
 Pro Asn Thr Gly Thr Thr Pro Thr Leu Pro Pro Ala Pro Gly Pro Ser
 1235 1240 1245

Ser

<210> 145
 <211> 382
 <212> PRT

<213> Homo sapiens

<400> 145

Met	Thr	Met	Thr	Leu	His	Thr	Lys	Ala	Ser	Gly	Met	Ala	Leu	Leu	His
1				5					10					15	
Gln	Ile	Gln	Gly	Asn	Glu	Leu	Glu	Pro	Leu	Asn	Arg	Pro	Gln	Leu	Lys
			20					25					30		
Met	Pro	Met	Glu	Arg	Ala	Leu	Gly	Glu	Val	Tyr	Val	Asp	Asn	Ser	Lys
		35					40					45			
Pro	Thr	Val	Phe	Asn	Tyr	Pro	Glu	Gly	Ala	Ala	Tyr	Glu	Phe	Asn	Ala
	50					55					60				
Ala	Ala	Ala	Ala	Ala	Ala	Ala	Ala	Ser	Ala	Pro	Val	Tyr	Gly	Gln	Ser
65					70					75					80
Gly	Ile	Ala	Tyr	Gly	Pro	Gly	Ser	Glu	Ala	Ala	Ala	Phe	Ser	Ala	Asn
				85					90					95	
Ser	Leu	Gly	Ala	Phe	Pro	Gln	Leu	Asn	Ser	Val	Ser	Pro	Ser	Pro	Leu
			100					105					110		
Met	Leu	Leu	His	Pro	Pro	Pro	Gln	Leu	Ser	Pro	Phe	Leu	His	Pro	His
	115						120					125			
Gly	Gln	Gln	Val	Pro	Tyr	Tyr	Leu	Glu	Asn	Glu	Pro	Ser	Ala	Tyr	Ala
	130						135				140				
Val	Arg	Asp	Thr	Gly	Pro	Pro	Ala	Phe	Tyr	Arg	Ser	Asn	Ser	Asp	Asn
145					150					155					160
Arg	Arg	Gln	Asn	Gly	Arg	Glu	Arg	Leu	Ser	Ser	Ser	Asn	Glu	Lys	Gly
				165					170					175	
Asn	Met	Ile	Met	Glu	Ser	Ala	Lys	Glu	Thr	Arg	Tyr	Cys	Ala	Val	Cys
			180					185					190		
Asn	Asp	Tyr	Ala	Ser	Gly	Tyr	His	Tyr	Gly	Val	Trp	Ser	Cys	Glu	Gly
		195					200					205			
Cys	Lys	Ala	Phe	Phe	Lys	Arg	Ser	Ile	Gln	Gly	His	Asn	Asp	Tyr	Met
	210					215					220				
Cys	Pro	Ala	Thr	Asn	Gln	Cys	Thr	Ile	Asp	Lys	Asn	Arg	Arg	Lys	Ser
225					230					235					240
Cys	Gln	Ala	Cys	Arg	Leu	Arg	Lys	Cys	Tyr	Glu	Val	Gly	Met	Met	Lys
				245					250					255	
Gly	Gly	Ile	Arg	Lys	Asp	Arg	Arg	Gly	Gly	Arg	Met	Leu	Lys	His	Lys
			260					265					270		
Arg	Gln	Arg	Asp	Asp	Leu	Glu	Gly	Arg	Asn	Glu	Met	Gly	Ala	Ser	Gly
		275					280					285			
Asp	Met	Arg	Ala	Ala	Asn	Leu	Trp	Pro	Ser	Pro	Leu	Val	Ile	Lys	His
	290					295					300				
Thr	Lys	Lys	Asn	Ser	Pro	Ala	Leu	Ser	Leu	Thr	Ala	Asp	Gln	Met	Val

305					310						315					320
Ser	Ala	Leu	Leu	Asp	Ala	Glu	Pro	Pro	Met	Ile	Tyr	Ser	Glu	Tyr	Asp	
				325					330					335		
Pro	Ser	Arg	Pro	Phe	Ser	Glu	Ala	Ser	Met	Met	Gly	Leu	Leu	Thr	Asn	
			340					345					350			
Leu	Ala	Asp	Arg	Glu	Leu	Val	His	Met	Ile	Asn	Trp	Ala	Lys	Arg	Val	
		355					360					365				
Pro	Gly	Lys	Asp	Ala	Lys	Leu	Asn	Phe	Tyr	Val	Lys	Ser	Glu			
	370					375					380					

```
<210> 146
<211> 345
<212> PRT
<213> Homo sapiens
```

```

<400> 146
Met Val Pro Gln Ala His Gly Leu Leu Leu Leu Cys Phe Leu Leu Gln
  1              5              10              15

Leu Gln Gly Pro Leu Gly Thr Ala Val Phe Ile Thr Gln Glu Glu Ala
          20              25              30

His Gly Val Leu His Arg Gln Arg Arg Ala Asn Ser Leu Leu Glu Glu
    35              40              45

Leu Trp Pro Gly Ser Leu Glu Arg Glu Cys Asn Glu Glu Gln Cys Ser
    50              55              60

Phe Glu Glu Ala Arg Glu Ile Phe Lys Ser Pro Glu Arg Thr Lys Gln
    65              70              75              80

Phe Trp Ile Val Tyr Ser Asp Gly Asp Gln Cys Ala Ser Asn Pro Cys
          85              90              95

Gln Asn Gly Gly Thr Cys Gln Asp His Leu Lys Ser Tyr Val Cys Phe
          100              105              110

Cys Leu Leu Asp Phe Glu Gly Ala Val Leu Leu Asp Ala Arg Trp Ile
    115              120              125

Val Thr Ala Ala His Cys Phe Asp Asn Ile Arg Tyr Trp Gly Asn Ile
    130              135              140

Thr Val Val Met Gly Glu His Asp Phe Ser Glu Lys Asp Gly Asp Glu
    145              150              155              160

Gln Val Arg Arg Val Thr Gln Val Ile Met Pro Asp Lys Tyr Ile Arg
          165              170              175

Gly Lys Ile Asn His Asp Ile Ala Leu Leu Arg Leu His Arg Pro Val
          180              185              190

Thr Phe Thr Asp Tyr Val Val Pro Leu Cys Leu Pro Glu Lys Ser Phe
    195              200              205

Ser Glu Asn Thr Leu Ala Arg Ile Arg Phe Ser Arg Val Ser Gly Trp

```


Met Ala Thr Leu Leu Arg Ser Lys Leu Thr Asn Val Ala Thr Ser Val
 1 5 10 15
 Ser Asn Lys Ser Gln Ala Lys Val Ser Gly Met Phe Ala Arg Met Gly
 20 25 30
 Phe Gln Ala Ala Thr Asp Glu Glu Ala Val Gly Phe Ala His Cys Asp
 35 40 45
 Asp Leu Asp Phe Glu His Arg Gln Gly Leu Gln Met Asp Ile Leu Lys
 50 55 60
 Ser Glu Gly Glu Pro Cys Gly Asp Glu Gly Ala Glu Ala Pro Val Glu
 65 70 75 80
 Gly Asp Ile His Tyr Gln Arg Gly Gly Ala Pro Leu Pro Pro Ser Gly
 85 90 95
 Ser Lys Asp Gln Ala Val Gly Ala Gly Gly Glu Phe Gly Gly His Asp
 100 105 110
 Lys Pro Lys Ile Thr Ala Trp Glu Ala Gly Trp Asn Val Thr Asn Ala
 115 120 125
 Ile Gln Gly Met Phe Val Leu Gly Leu Pro Tyr Ala Ile Leu His Gly
 130 135 140
 Gly Tyr Leu Gly Leu Phe Leu Ile Ile Phe Ala Ala Val Val Cys Cys
 145 150 155 160
 Tyr Thr Gly Lys Ile Leu Ile Ala Cys Leu Tyr Glu Glu Asn Glu Asp
 165 170 175
 Gly Glu Val Val Arg Val Arg Asp Ser Tyr Val Ala Ile Ala Asn Ala
 180 185 190
 Cys Cys Ala Pro Arg Phe Pro Thr Leu Gly Gly Arg Val Val Asn Val
 195 200 205
 Ala Gln Ile Ile Glu Leu Val Met Thr Cys Ile Leu Tyr Val Val Val
 210 215 220
 Ser Gly Asn Leu Met Tyr Asn Ser Phe Pro Gly Leu Pro Val Ser Gln
 225 230 235 240
 Lys Ser Trp Ser Ile Ile Ala Thr Ala Val Leu Leu Pro Cys Ala Phe
 245 250 255
 Leu Lys Asn Leu Lys Ala Val Ser Lys Phe Ser Leu Leu Cys Thr Leu
 260 265 270
 Ala His Phe Val Ile Asn Ile Leu Val Ile Ala Tyr Cys Leu Ser Arg
 275 280 285
 Ala Arg Asp Trp Ala Trp Glu Lys Val Lys Phe Tyr Ile Asp Val Lys
 290 295 300
 Lys Phe Pro Ile Ser Ile Gly Ile Ile Val Phe Ser Tyr Thr Ser Gln
 305 310 315 320
 Ile Phe Leu Pro Ser Leu Glu Gly Asn Met Gln Gln Pro Ser Glu Phe

176

<210> 150
 <211> 372
 <212> PRT
 <213> Homo sapiens

<400> 150

```

Met Asp Val Leu Ala Glu Ala Asn Gly Thr Phe Ala Leu Asn Leu Leu
 1           5           10           15

Lys Thr Leu Gly Lys Asp Asn Ser Lys Asn Val Phe Phe Ser Pro Met
      20           25           30

Ser Met Ser Cys Ala Leu Ala Met Val Tyr Met Gly Ala Lys Gly Asn
      35           40           45

Thr Ala Ala Gln Met Ala Gln Ile Leu Ser Phe Asn Lys Ser Gly Gly
      50           55           60

Gly Gly Asp Ile His Gln Gly Phe Gln Ser Leu Leu Thr Glu Val Asn
      65           70           75           80

Lys Thr Gly Thr Gln Tyr Leu Leu Arg Val Ala Asn Arg Leu Phe Gly
      85           90           95

Glu Lys Ser Cys Asp Phe Leu Ser Ser Phe Arg Asp Ser Cys Gln Lys
      100          105          110

Phe Tyr Gln Ala Glu Met Glu Glu Leu Asp Phe Ile Ser Ala Val Glu
      115          120          125

Lys Ser Arg Lys His Ile Asn Thr Trp Val Ala Glu Lys Thr Glu Gly
      130          135          140

Lys Ile Ala Glu Leu Leu Ser Pro Gly Ser Val Asp Pro Leu Thr Arg
      145          150          155          160

Leu Val Leu Val Asn Ala Val Tyr Phe Arg Gly Asn Trp Asp Glu Gln
      165          170          175

Phe Asp Lys Glu Asn Thr Glu Glu Arg Leu Phe Lys Val Ser Lys Asn
      180          185          190

Glu Glu Lys Pro Val Gln Met Met Phe Lys Gln Ser Thr Phe Lys Lys
      195          200          205

Thr Tyr Ile Gly Glu Ile Phe Thr Gln Ile Leu Val Leu Pro Tyr Val
      210          215          220

Gly Lys Glu Leu Asn Met Ile Ile Met Leu Pro Asp Glu Thr Thr Asp
      225          230          235          240

Leu Arg Thr Val Glu Lys Glu Leu Thr Tyr Glu Lys Phe Val Glu Trp
      245          250          255

Thr Arg Leu Asp Met Met Asp Glu Glu Glu Val Glu Val Ser Leu Pro
      260          265          270

Arg Phe Lys Leu Glu Glu Ser Tyr Asp Met Glu Ser Val Leu Arg Asn
      275          280          285
  
```

Leu Gly Met Thr Asp Ala Phe Glu Leu Gly Lys Ala Asp Phe Ser Gly
 290 295 300
 Met Ser Gln Thr Asp Leu Ser Leu Ser Lys Val Val His Lys Ser Phe
 305 310 315 320
 Val Glu Val Asn Glu Glu Gly Thr Glu Ala Ala Ala Ala Thr Ala Ala
 325 330 335
 Ile Met Met Met Arg Cys Ala Arg Phe Val Pro Arg Phe Cys Ala Asp
 340 345 350
 His Pro Phe Leu Phe Phe Ile Gln Gln Arg Ile Pro Leu Val Leu Leu
 355 360 365
 Cys Trp Ser Thr
 370
 <210> 151
 <211> 560
 <212> PRT
 <213> Homo sapiens
 <400> 151
 Met Phe Pro Asp Leu Val Gln Leu Ile Cys Ala Tyr Cys His Thr Arg
 1 5 10 15
 Asp Ile Leu Leu Leu Pro Leu Gln Leu Pro Arg Ala Ile His His Ala
 20 25 30
 Ala Thr His Lys Glu Leu Glu Ala Ile Ser His Leu Gly Ile Glu Phe
 35 40 45
 Trp Ser Ser Ser Leu Asn Ile Lys Ala Gln Arg Gly Pro Ala Gly Gly
 50 55 60
 Pro Val Leu Pro Gln Leu Lys Ala Arg Ser Pro Gln Glu Leu Asp Gln
 65 70 75 80
 Gly Thr Gly Ala Ala Leu Cys Phe Phe Asn Pro Leu Phe Pro Gly Asp
 85 90 95
 Leu Gly Pro Thr Lys Arg Glu Lys Phe Lys Arg Ser Phe Lys Val Arg
 100 105 110
 Val Ser Thr Glu Thr Ser Ser Pro Leu Ser Pro Pro Ala Val Pro Pro
 115 120 125
 Pro Pro Val Pro Val Leu Pro Gly Ala Val Pro Ser Gln Thr Glu Arg
 130 135 140
 Leu Pro Pro Cys Gln Leu Leu Arg Arg Glu Ser Ser Val Gly Tyr Arg
 145 150 155 160
 Val Pro Ala Gly Ser Gly Pro Ser Leu Pro Pro Met Pro Ser Leu Gln
 165 170 175
 Glu Val Asp Cys Gly Ser Pro Ser Ser Ser Glu Glu Glu Gly Val Pro
 180 185 190

Gly Ser Arg Gly Ser Pro Ala Thr Ser Pro His Leu Gly Arg Arg Arg
 195 200 205
 Pro Leu Leu Arg Ser Met Ser Ala Ala Phe Cys Ser Leu Leu Ala Pro
 210 215 220
 Glu Arg Gln Val Gly Arg Ala Ala Ala Ala Leu Met Gln Asp Arg His
 225 230 235 240
 Thr Ala Ala Gly Gln Leu Val Gln Asp Leu Leu Thr Gln Val Arg Asp
 245 250 255
 Gly Gln Arg Pro Gln Glu Leu Glu Gly Ile Arg Gln Ala Leu Ser Arg
 260 265 270
 Ala Arg Ala Met Leu Ser Ala Glu Leu Gly Pro Glu Lys Leu Val Ser
 275 280 285
 Pro Lys Arg Leu Glu His Val Leu Glu Lys Ser Leu His Cys Ser Val
 290 295 300
 Leu Lys Pro Leu Arg Pro Ile Leu Ala Ala Arg Leu Arg Arg Arg Leu
 305 310 315 320
 Ala Ala Asp Gly Ser Leu Gly Arg Leu Ala Glu Gly Leu Arg Leu Ala
 325 330 335
 Arg Ala Gln Gly Pro Gly Ala Phe Gly Ser His Leu Ser Leu Pro Ser
 340 345 350
 Pro Val Glu Leu Glu Gln Val Arg Gln Lys Leu Leu Gln Leu Val Arg
 355 360 365
 Thr Tyr Ser Pro Ser Ala Gln Val Lys Arg Leu Leu Gln Ala Cys Lys
 370 375 380
 Leu Leu Tyr Met Ala Leu Arg Thr Gln Glu Gly Glu Gly Ser Gly Ala
 385 390 395 400
 Asp Gly Phe Leu Pro Leu Leu Ser Leu Val Leu Ala His Cys Asp Leu
 405 410 415
 Pro Glu Leu Leu Leu Glu Ala Glu Tyr Met Ser Glu Leu Leu Glu Pro
 420 425 430
 Ser Leu Leu Thr Gly Glu Gly Gly Tyr Tyr Leu Thr Ser Leu Ser Ala
 435 440 445
 Ser Leu Ala Leu Leu Ser Gly Leu Gly Gln Ala His Thr Leu Pro Leu
 450 455 460
 Ser Pro Val Gln Glu Leu Arg Arg Ser Leu Ser Leu Trp Glu Gln Arg
 465 470 475 480
 Arg Leu Pro Ala Thr His Cys Phe Gln Val Thr Gly Pro Pro Pro Cys
 485 490 495
 Pro Gln Ser Gln Thr Pro Ser Pro Pro Xaa Thr Phe Leu Ser Leu Val
 500 505 510

Lys Ser Pro Asp Ser Val Asp Arg Ser Trp Val Leu Ile Leu Ala Leu
 515 520 525

His Trp Val Val Gly Thr Trp Ala Ser Tyr Leu Thr Thr Ser Cys Leu
 530 535 540

Ser Phe Leu Ile Ser Lys Met Gly Val Ile Gly Pro Thr Ser Trp Gly
 545 550 555 560

<210> 152
 <211> 437
 <212> PRT
 <213> Homo sapiens

<400> 152
 Met Leu Ile Ala Ala Gly Pro Ala Arg Thr Gly Val Gly Pro Ala Arg
 1 5 10 15

Ile Lys Gly Ala Gln Ala Gly Trp Ala Phe His Arg Pro Ser Ala Leu
 20 25 30

Cys Ser Arg Gly Ala Gly Gln Ala Xaa Ala Ser Glu Leu Ala Ser Arg
 35 40 45

His Arg Gly Gly Ala Ala Ala Val Arg Thr Arg Gln Ala Asn Pro Thr
 50 55 60

Gln Lys Ser Pro Pro Pro Asp Ser Gln Val Ala Ala Ala Ser Leu Ala
 65 70 75 80

His Ala Glu Ser Gly Gly Ala Gly Ser Pro Leu Arg Pro Ala Ser Ala
 85 90 95

Leu Ser Ser Ser Pro Phe Pro Phe Phe Ser Leu Ser Ser Pro Leu Ser
 100 105 110

Leu Pro Ala Phe Ala Gln Pro Arg Ala Met Ser Asp Ala Ser Leu Arg
 115 120 125

Ser Thr Ser Thr Met Glu Arg Leu Val Ala Arg Gly Thr Phe Pro Val
 130 135 140

Leu Val Arg Thr Ser Ala Cys Arg Ser Leu Phe Gly Pro Val Asp His
 145 150 155 160

Glu Glu Leu Ser Arg Glu Leu Gln Ala Arg Leu Ala Glu Leu Asn Ala
 165 170 175

Glu Asp Gln Asn Arg Trp Asp Tyr Asp Phe Gln Gln Asp Met Pro Leu
 180 185 190

Arg Gly Pro Gly Arg Leu Gln Trp Thr Glu Val Asp Ser Asp Ser Val
 195 200 205

Pro Ala Phe Tyr Arg Glu Thr Val Gln Val Gly Arg Cys Arg Leu Leu
 210 215 220

Leu Ala Pro Arg Pro Val Ala Val Ala Val Ala Val Ser Pro Pro Leu
 225 230 235 240
 Glu Pro Ala Ala Glu Ser Leu Asp Gly Leu Glu Glu Ala Pro Glu Gln
 245 250 255
 Leu Pro Ser Val Pro Val Pro Ala Pro Ala Ser Thr Pro Pro Pro Val
 260 265 270
 Pro Val Leu Ala Pro Ala Pro Ala Pro Ala Pro Ala Pro Val Ala Ala
 275 280 285
 Pro Val Ala Ala Pro Val Ala Val Pro Val Leu Ala Pro Ala Pro Ala
 290 295 300
 Pro Ala Pro Ala Pro Ala Pro Ala Pro Ala Pro Val Ala Ala Pro Ala
 305 310 315 320
 Pro Ala Pro Ala Pro Ala Pro Ala Pro Ala Pro Ala Pro Ala Pro Ala
 325 330 335
 Pro Asp Ala Ala Pro Gln Glu Ser Ala Glu Gln Gly Ala Asn Gln Gly
 340 345 350
 Gln Arg Gly Gln Glu Pro Leu Ala Asp Gln Leu His Ser Gly Ile Ser
 355 360 365
 Gly Arg Pro Ala Ala Gly Thr Ala Ala Ala Ser Ala Asn Gly Ala Ala
 370 375 380
 Ile Lys Lys Leu Ser Gly Pro Leu Ile Ser Asp Phe Phe Ala Lys Arg
 385 390 395 400
 Lys Arg Ser Ala Pro Glu Lys Ser Ser Gly Asp Val Pro Ala Pro Cys
 405 410 415
 Pro Ser Pro Ser Ala Ala Pro Gly Val Gly Ser Val Glu Gln Thr Pro
 420 425 430
 Arg Lys Arg Leu Arg
 435

<210> 153
 <211> 172
 <212> PRT
 <213> Homo sapiens

<400> 153
 Met Glu Pro Ala Ala Gly Ser Ser Met Glu Pro Ser Ala Asp Trp Leu
 1 5 10 15
 Ala Ser Ala Ala Ala Arg Gly Leu Val Glu Lys Val Arg Gln Leu Leu
 20 25 30
 Glu Ala Gly Ala Asp Pro Asn Ala Pro Asn Ser Tyr Gly Arg Arg Pro
 35 40 45
 Ile Gln Val Met Met Met Gly Ser Ala Arg Val Ala Glu Leu Leu Leu
 50 55 60

Leu His Gly Ala Glu Pro Asn Cys Ala Asp Pro Ala Thr Leu Thr Arg
 65 70 75 80
 Pro Val His Asp Ala Ala Arg Glu Gly Phe Leu Asp Thr Leu Val Val
 85 90 95
 Leu His Arg Ala Gly Ala Arg Leu Asp Val Arg Asp Ala Trp Gly Arg
 100 105 110
 Leu Pro Val Asp Leu Ala Glu Glu Leu Gly His Arg Asp Val Ala Arg
 115 120 125
 Tyr Leu Arg Ala Ala Ala Gly Gly Thr Arg Gly Ser Asn His Ala Arg
 130 135 140
 Ile Asp Ala Ala Glu Gly Pro Ser Val Thr Ala Ser Ile Gln Val Pro
 145 150 155 160
 Gly Gly Glu Glu Gly Asp Phe Gly Ser Ser Tyr Ser
 165 170

 <210> 154
 <211> 174
 <212> PRT
 <213> Homo sapiens

 <400> 154
 Met Arg Glu Glu Asn Lys Gly Met Pro Ser Gly Gly Gly Ser Asp Glu
 1 5 10 15
 Gly Leu Ala Ser Ala Ala Ala Arg Gly Leu Val Glu Lys Val Arg Gln
 20 25 30
 Leu Leu Glu Ala Gly Ala Asp Pro Asn Gly Val Asn Arg Phe Gly Arg
 35 40 45
 Arg Ala Ile Gln Val Met Met Met Gly Ser Ala Arg Val Ala Glu Leu
 50 55 60
 Leu Leu Leu His Gly Ala Glu Pro Asn Cys Ala Asp Pro Ala Thr Leu
 65 70 75 80
 Thr Arg Pro Val His Asp Ala Ala Arg Glu Gly Phe Leu Asp Thr Leu
 85 90 95
 Val Val Leu His Arg Ala Gly Ala Arg Leu Asp Val Arg Asp Ala Trp
 100 105 110
 Gly Arg Leu Pro Val Asp Leu Ala Glu Glu Leu Gly His Arg Asp Val
 115 120 125
 Ala Arg Tyr Leu Arg Ala Ala Ala Gly Gly Thr Arg Gly Ser Asn His
 130 135 140
 Ala Arg Ile Asp Ala Ala Glu Gly Pro Ser Val Thr Ala Ser Ile Gln
 145 150 155 160
 Val Pro Gly Gly Glu Glu Gly Asp Phe Gly Ser Ser Tyr Ser
 165 170

<210> 155
 <211> 349
 <212> PRT
 <213> Homo sapiens

 <400> 155
 Met Lys His Ser Leu Asn Ala Leu Leu Ile Phe Leu Ile Ile Thr Ser
 1 5 10 15
 Ala Trp Gly Gly Ser Lys Gly Pro Leu Asp Gln Leu Glu Lys Gly Gly
 20 25 30
 Glu Thr Ala Gln Ser Ala Asp Pro Gln Trp Glu Gln Leu Asn Asn Lys
 35 40 45
 Asn Leu Ser Met Pro Leu Leu Pro Ala Asp Phe His Lys Glu Asn Thr
 50 55 60
 Val Thr Asn Asp Trp Ile Pro Glu Gly Glu Glu Asp Asp Asp Tyr Leu
 65 70 75 80
 Asp Leu Glu Lys Ile Phe Ser Glu Asp Asp Asp Tyr Ile Asp Ile Val
 85 90 95
 Asp Ser Leu Ser Val Ser Pro Thr Asp Ser Asp Val Ser Ala Gly Asn
 100 105 110
 Ile Leu Gln Leu Phe His Gly Lys Ser Arg Ile Gln Arg Leu Asn Ile
 115 120 125
 Leu Asn Ala Lys Phe Ala Phe Asn Leu Tyr Arg Val Leu Lys Asp Gln
 130 135 140
 Val Asn Thr Phe Asp Asn Ile Phe Ile Ala Pro Val Gly Ile Ser Thr
 145 150 155 160
 Ala Met Gly Met Ile Ser Leu Gly Leu Lys Gly Glu Thr His Glu Gln
 165 170 175
 Val His Ser Ile Leu His Phe Lys Asp Phe Val Asn Ala Ser Ser Lys
 180 185 190
 Tyr Glu Ile Thr Thr Ile His Asn Leu Phe Arg Lys Leu Thr His Arg
 195 200 205
 Leu Phe Arg Arg Asn Phe Gly Tyr Thr Leu Arg Ser Val Asn Asp Leu
 210 215 220
 Tyr Ile Gln Lys Gln Phe Pro Ile Leu Leu Asp Phe Lys Thr Lys Val
 225 230 235 240
 Arg Glu Tyr Tyr Phe Ala Glu Ala Gln Ile Ala Asp Phe Ser Asp Pro
 245 250 255
 Ala Phe Ile Ser Lys Thr Asn Asn His Ile Met Lys Leu Thr Lys Gly
 260 265 270
 Leu Ile Lys Asp Ala Leu Glu Asn Ile Asp Pro Ala Thr Gln Met Met
 275 280 285

Ile Leu Asn Cys Ile Tyr Phe Lys Gly Ser Trp Val Asn Lys Phe Pro
 290 295 300

Val Glu Met Thr His Asn His Asn Phe Arg Leu Asn Glu Arg Glu Val
 305 310 315 320

Val Lys Val Ser Met Met Gln Thr Lys Gly Asn Phe Leu Ala Ser Cys
 325 330 335

Leu Leu Phe Met Gly Arg Val Ala Asn Pro Ser Arg Ser
 340 345

<210> 156

<211> 211

<212> PRT

<213> Homo sapiens

<400> 156

Met Asp Pro Ala Arg Pro Leu Gly Leu Ser Ile Leu Leu Leu Phe Leu
 1 5 10 15

Thr Glu Ala Ala Leu Gly Asp Ala Ala Gln Glu Pro Thr Gly Asn Asn
 20 25 30

Ala Glu Ile Cys Leu Leu Pro Leu Asp Tyr Gly Pro Cys Arg Ala Leu
 35 40 45

Leu Leu Arg Tyr Tyr Tyr Asp Arg Tyr Thr Gln Ser Cys Arg Gln Phe
 50 55 60

Leu Tyr Gly Gly Cys Glu Gly Asn Ala Asn Asn Phe Tyr Thr Trp Glu
 65 70 75 80

Ala Cys Asp Asp Ala Cys Trp Arg Ile Glu Lys Val Pro Lys Val Cys
 85 90 95

Arg Leu Gln Val Ser Val Asp Asp Gln Cys Glu Gly Ser Thr Glu Lys
 100 105 110

Tyr Phe Phe Asn Leu Ser Ser Met Thr Cys Glu Lys Phe Phe Ser Gly
 115 120 125

Gly Cys His Arg Asn Arg Ile Glu Asn Arg Phe Pro Asp Glu Ala Thr
 130 135 140

Cys Met Gly Phe Cys Ala Pro Lys Lys Ile Pro Ser Phe Cys Tyr Ser
 145 150 155 160

Pro Lys Asp Glu Gly Leu Cys Ser Ala Asn Val Thr Arg Tyr Tyr Phe
 165 170 175

Asn Pro Arg Tyr Arg Thr Cys Asp Ala Phe Thr Tyr Thr Gly Cys Gly
 180 185 190

Gly Asn Asp Asn Asn Phe Val Thr Val Gln Lys Met Arg Asp Cys Ala
 195 200 205

Leu Pro Met
 210

<210> 157
 <211> 210
 <212> PRT
 <213> Homo sapiens

<400> 157

```

Met Asp Pro Ala Arg Pro Leu Gly Leu Ser Ile Leu Leu Leu Phe Leu
 1           5           10           15

Thr Glu Ala Ala Leu Gly Asp Ala Ala Gln Glu Pro Thr Gly Asn Asn
          20           25           30

Ala Glu Ile Cys Leu Leu Pro Leu Asp Tyr Gly Pro Cys Arg Ala Leu
          35           40           45

Leu Leu Arg Tyr Tyr Tyr Asp Arg Tyr Thr Gln Ser Cys Arg Gln Phe
          50           55           60

Leu Tyr Gly Gly Cys Glu Gly Asn Ala Asn Asn Phe Tyr Thr Trp Glu
          65           70           75           80

Ala Cys Asp Asp Ala Cys Trp Arg Ile Glu Lys Val Pro Lys Val Cys
          85           90           95

Arg Leu Gln Val Ser Val Asp Asp Gln Cys Glu Gly Ser Thr Glu Lys
          100          105          110

Tyr Phe Phe Asn Leu Ser Ser Met Thr Cys Glu Lys Phe Phe Ser Gly
          115          120          125

Gly Cys His Arg Asn Arg Ile Glu Asn Arg Phe Pro Asp Glu Ala Thr
          130          135          140

Cys Met Gly Phe Cys Ala Pro Lys Lys Lys Tyr Arg Thr Cys Asp Ala
          145          150          155          160

Phe Thr Tyr Thr Gly Cys Gly Gly Asn Asp Asn Asn Phe Val Ser Arg
          165          170          175

Glu Asp Cys Lys Arg Ala Cys Ala Lys Ala Leu Lys Lys Lys Lys Lys
          180          185          190

Met Pro Lys Leu Arg Phe Ala Ser Arg Ile Arg Lys Ile Arg Lys Lys
          195          200          205

Gln Phe
          210

```

<210> 158
 <211> 225
 <212> PRT
 <213> Homo sapiens

<400> 158

```

Met Ile Tyr Thr Met Lys Lys Val His Ala Leu Trp Ala Ser Val Cys
 1           5           10           15

Leu Leu Leu Asn Leu Ala Pro Ala Pro Leu Asn Ala Asp Ser Glu Glu
          20           25           30

```

Asp Glu Glu His Thr Ile Ile Thr Asp Thr Glu Leu Pro Pro Leu Lys
 35 40 45
 Leu Met His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly Pro Cys Lys
 50 55 60
 Ala Ile Met Lys Arg Phe Phe Phe Asn Ile Phe Thr Arg Gln Cys Glu
 65 70 75 80
 Glu Phe Ile Tyr Gly Gly Cys Glu Gly Asn Gln Asn Arg Phe Glu Ser
 85 90 95
 Leu Glu Glu Cys Lys Lys Met Cys Thr Arg Asp Asn Ala Asn Arg Ile
 100 105 110
 Ile Lys Thr Thr Leu Gln Gln Glu Lys Pro Asp Phe Cys Phe Leu Glu
 115 120 125
 Glu Asp Pro Gly Ile Cys Arg Gly Tyr Ile Thr Arg Tyr Phe Tyr Asn
 130 135 140
 Asn Gln Thr Lys Gln Cys Glu Arg Phe Lys Tyr Gly Gly Cys Leu Gly
 145 150 155 160
 Asn Met Asn Asn Phe Glu Thr Leu Glu Glu Cys Lys Asn Ile Cys Glu
 165 170 175
 Asp Gly Pro Asn Gly Phe Gln Val Asp Asn Tyr Gly Thr Gln Leu Asn
 180 185 190
 Ala Val Asn Asn Ser Leu Thr Pro Gln Ser Thr Lys Val Pro Ser Leu
 195 200 205
 Phe Gly Lys Asn Leu Val Asp Phe Ile Ala Ser Arg Lys Leu Leu Ser
 210 215 220

Cys
 225

<210> 159
 <211> 636
 <212> PRT
 <213> Homo sapiens

<400> 159
 Met Ala Ser Arg Leu Thr Leu Leu Thr Leu Leu Leu Leu Leu Ala
 1 5 10 15
 Gly Asp Arg Ala Ser Ser Asn Pro Asn Ala Thr Ser Ser Ser Ser Gln
 20 25 30
 Asp Pro Glu Ser Leu Gln Asp Arg Gly Glu Gly Lys Val Ala Thr Thr
 35 40 45
 Val Ile Ser Lys Met Leu Phe Val Glu Pro Ile Leu Glu Val Ser Ser
 50 55 60
 Leu Pro Thr Thr Asn Ser Thr Thr Asn Ser Ala Thr Lys Ile Thr Ala
 65 70 75 80

Asn Thr Thr Asp Glu Pro Thr Thr Gln Pro Thr Thr Glu Pro Thr Thr
 85 90 95
 Gln Pro Thr Ile Gln Pro Thr Gln Pro Thr Thr Gln Leu Pro Thr Asp
 100 105 110
 Ser Pro Thr Gln Pro Thr Thr Gly Ser Phe Cys Pro Gly Pro Val Thr
 115 120 125
 Leu Cys Ser Asp Leu Glu Ser His Ser Thr Glu Ala Val Leu Gly Asp
 130 135 140
 Ala Leu Val Asp Phe Ser Leu Lys Leu Tyr His Ala Phe Ser Ala Met
 145 150 155 160
 Lys Lys Val Glu Thr Asn Met Ala Phe Ser Pro Phe Ser Ile Ala Ser
 165 170 175
 Leu Leu Thr Gln Val Leu Leu Gly Ala Gly Glu Asn Thr Lys Thr Asn
 180 185 190
 Leu Glu Ser Ile Leu Ser Tyr Pro Lys Asp Phe Thr Cys Val His Gln
 195 200 205
 Ala Leu Lys Gly Phe Thr Thr Lys Gly Val Thr Ser Val Ser Gln Ile
 210 215 220
 Phe His Ser Pro Val Asp Trp Arg Leu Leu Gln Ser Lys Ser Gln Glu
 225 230 235 240
 Val Leu Ser Gln Thr Ser Thr Lys Ala Arg Lys Gln Ser Leu Phe Arg
 245 250 255
 Ala Lys Ile Lys Gly Arg Lys Glu Gly Lys Ser Arg Gln Met Glu Phe
 260 265 270
 Asn Ile Ser Lys Arg Leu Ser Cys Arg Ala Ile Val His Ser Lys Leu
 275 280 285
 Arg Gln Arg Arg Leu Gly Ala Thr Ser Leu Val Leu Gly Ser Gly Phe
 290 295 300
 Thr Phe Phe Gly Pro Tyr Leu Pro His Leu Glu Glu Glu Trp Ala Gly
 305 310 315 320
 Pro Arg Ser Thr Met Pro Tyr Ser Leu Ser Glu Gln Ile Glu Pro Lys
 325 330 335
 Lys Ala Cys Ser Leu Ser Asn Cys Ala His Gly Lys Asn Asp Val Phe
 340 345 350
 Arg Thr Tyr Cys Phe Pro Phe Leu Lys Tyr Pro Pro Asp Leu Ala Ile
 355 360 365
 Arg Asp Thr Phe Val Asn Ala Ser Arg Thr Leu Tyr Ser Ser Ser Pro
 370 375 380
 Arg Val Leu Ser Asn Asn Ser Asp Ala Asn Leu Glu Leu Ile Asn Thr
 385 390 395 400

Trp Val Ala Lys Asn Thr Asn Asn Lys Ile Ser Arg Leu Leu Asp Ser
 405 410 415
 Leu Pro Ser Asp Thr Arg Leu Val Leu Leu Asn Ala Ile Tyr Leu Ser
 420 425 430
 Ala Lys Trp Lys Thr Thr Phe Asp Pro Lys Lys Thr Arg Met Glu Pro
 435 440 445
 Phe His Phe Lys Asn Ser Val Ile Lys Val Pro Met Met Asn Ser Lys
 450 455 460
 Lys Tyr Pro Val Ala His Phe Ile Asp Gln Thr Leu Lys Ala Lys Val
 465 470 475 480
 Gly Gln Leu Gln Leu Ser His Asn Leu Ser Leu Val Ile Leu Val Pro
 485 490 495
 Gln Asn Leu Lys His Arg Leu Glu Asp Met Glu Gln Ala Leu Ser Pro
 500 505 510
 Ser Val Phe Lys Ala Ile Met Glu Lys Leu Glu Met Ser Lys Phe Gln
 515 520 525
 Pro Thr Leu Leu Thr Leu Pro Arg Ile Lys Val Thr Thr Ser Gln Asp
 530 535 540
 Met Leu Ser Ile Met Glu Lys Leu Glu Phe Phe Asp Phe Ser Tyr Asp
 545 550 555 560
 Leu Asn Leu Cys Gly Leu Thr Glu Asp Pro Asp Leu Gln Val Ser Ala
 565 570 575
 Met Gln His Gln Thr Val Leu Glu Leu Thr Glu Thr Gly Val Glu Ala
 580 585 590
 Ala Ala Ala Ser Ala Ile Ser Val Ala Arg Thr Leu Leu Val Phe Glu
 595 600 605
 Val Gln Gln Pro Phe Leu Phe Val Leu Trp Asp Gln Gln His Lys Phe
 610 615 620
 Pro Val Phe Met Gly Arg Val Tyr Asp Pro Arg Ala
 625 630 635

<210> 160

<211> 389

<212> PRT

<213> Homo sapiens

<400> 160

Met Asp Val Leu Ala Glu Ala Asn Gly Thr Phe Ala Leu Asn Leu Leu
 1 5 10 15

Lys Thr Leu Gly Lys Asp Asn Ser Lys Asn Val Phe Phe Ser Pro Met
 20 25 30

Ser Met Ser Cys Ala Leu Ala Met Val Tyr Met Gly Ala Lys Gly Asn
 35 40 45

Thr Ala Ala Gln Met Ala Gln Ile Leu Ser Phe Asn Lys Ser Gly Gly
 50 55 60
 Gly Gly Asp Ile His Gln Gly Phe Gln Ser Leu Leu Thr Glu Val Asn
 65 70 75 80
 Lys Thr Gly Thr Gln Tyr Leu Leu Arg Met Ala Asn Arg Leu Phe Gly
 85 90 95
 Glu Lys Ser Cys Asp Phe Leu Ser Ser Phe Arg Asp Ser Cys Gln Lys
 100 105 110
 Phe Tyr Gln Ala Glu Met Glu Glu Leu Asp Phe Ile Ser Ala Val Glu
 115 120 125
 Lys Ser Arg Lys His Ile Asn Thr Trp Val Ala Glu Lys Thr Glu Gly
 130 135 140
 Lys Ile Ala Glu Leu Leu Ser Pro Gly Ser Val Asp Pro Leu Thr Arg
 145 150 155 160
 Leu Val Leu Val Asn Ala Val Tyr Phe Arg Gly Asn Trp Asp Glu Gln
 165 170 175
 Phe Asp Lys Glu Asn Thr Glu Glu Arg Leu Phe Lys Val Ser Lys Asn
 180 185 190
 Glu Glu Lys Pro Val Gln Met Met Phe Lys Gln Ser Thr Phe Lys Lys
 195 200 205
 Thr Tyr Ile Gly Glu Ile Phe Thr Gln Ile Leu Val Leu Pro Tyr Val
 210 215 220
 Gly Lys Glu Leu Asn Met Ile Ile Met Leu Pro Asp Glu Thr Thr Asp
 225 230 235 240
 Leu Arg Thr Val Glu Lys Glu Leu Thr Tyr Glu Lys Phe Val Glu Trp
 245 250 255
 Thr Arg Leu Asp Met Met Asp Glu Glu Glu Val Glu Val Ser Leu Pro
 260 265 270
 Arg Phe Lys Leu Glu Glu Ser Tyr Asp Met Glu Ser Val Leu Arg Asn
 275 280 285
 Leu Gly Met Thr Asp Ala Phe Glu Leu Gly Lys Ala Asp Phe Ser Gly
 290 295 300
 Met Ser Gln Thr Asp Leu Ser Leu Ser Lys Val Val His Lys Ser Phe
 305 310 315 320
 Val Glu Val Asn Glu Glu Gly Thr Glu Ala Ala Ala Ala Thr Ala Ala
 325 330 335
 Ile Met Met Met Arg Cys Ala Arg Phe Val Pro Arg Phe Cys Ala Asp
 340 345 350
 His Pro Phe Leu Phe Phe Ile Gln His Ser Cys Pro Leu Thr Leu His
 355 360 365
 Ser Val Pro Ala Thr Gln Val Ala Leu Ser Val Gln Trp Trp Gln Phe

370

375

380

Arg Asn Lys Gly Pro
385

<210> 161
<211> 204
<212> PRT
<213> Homo sapiens

<400> 161

Met Asp Val Leu Ala Glu Ala Asn Gly Thr Phe Ala Leu Asn Leu Leu
1 5 10 15

Lys Thr Leu Gly Lys Asp Asn Ser Lys Asn Val Phe Phe Ser Pro Met
20 25 30

Ser Met Ser Cys Ala Leu Ala Met Val Tyr Met Gly Ala Lys Gly Asn
35 40 45

Thr Ala Ala Gln Met Ala Gln Ile Leu Ser Phe Asn Lys Ser Gly Gly
50 55 60

Gly Gly Asp Ile His Gln Gly Phe Gln Ser Leu Leu Thr Glu Val Asn
65 70 75 80

Lys Thr Gly Thr Gln Tyr Leu Leu Arg Met Ala Asn Arg Leu Phe Gly
85 90 95

Glu Lys Ser Cys Asp Phe Leu Ser Ser Phe Arg Asp Ser Cys Gln Lys
100 105 110

Phe Tyr Gln Ala Glu Met Glu Glu Leu Asp Phe Ile Ser Ala Val Glu
115 120 125

Lys Ser Arg Lys His Ile Asn Thr Trp Val Ala Glu Lys Thr Glu Gly
130 135 140

Lys Ile Ala Glu Leu Leu Ser Pro Gly Ser Val Asp Pro Leu Thr Arg
145 150 155 160

Leu Val Leu Val Asn Ala Val Tyr Phe Arg Gly Asn Trp Asp Glu Gln
165 170 175

Phe Asp Lys Glu Asn Thr Glu Glu Arg Leu Phe Lys Val Ser Lys Thr
180 185 190

Asn Gly Ile Leu Phe Cys Gly Arg Phe Ser Ser Pro
195 200

<210> 162
<211> 156
<212> PRT
<213> Homo sapiens

<400> 162

Met Asp Val Leu Ala Glu Ala Asn Gly Thr Phe Ala Leu Asn Leu Leu
1 5 10 15

Lys Thr Leu Gly Lys Asp Asn Ser Lys Asn Val Phe Phe Ser Pro Met
 20 25 30
 Ser Met Ser Cys Ala Leu Ala Met Val Tyr Met Gly Ala Lys Gly Asn
 35 40 45
 Thr Ala Ala Gln Met Ala Gln Ile Leu Ser Phe Asn Lys Ser Gly Gly
 50 55 60
 Gly Gly Asp Ile His Gln Gly Phe Gln Ser Leu Leu Thr Glu Val Asn
 65 70 75 80
 Lys Thr Gly Thr Gln Tyr Leu Leu Arg Met Ala Asn Arg Leu Phe Gly
 85 90 95
 Glu Lys Ser Cys Asp Phe Leu Ser Ser Phe Arg Asp Ser Cys Gln Lys
 100 105 110
 Phe Tyr Gln Ala Glu Met Glu Glu Leu Asp Phe Ile Ser Ala Val Glu
 115 120 125
 Lys Ser Arg Lys His Ile Asn Thr Trp Val Ala Glu Lys Thr Glu Gly
 130 135 140
 Lys Met Tyr Cys Tyr Ser Thr Phe Val Ile Thr Ser
 145 150 155

<210> 163

<211> 517

<212> PRT

<213> Homo sapiens

<400> 163

Met Ala Ala Leu Met Thr Pro Gly Thr Gly Ala Pro Pro Ala Pro Gly
 1 5 10 15
 Asp Phe Ser Gly Glu Gly Ser Gln Gly Leu Pro Asp Pro Ser Pro Glu
 20 25 30
 Pro Lys Gln Leu Pro Glu Leu Ile Arg Met Lys Arg Asp Gly Gly Arg
 35 40 45
 Leu Ser Glu Ala Asp Ile Arg Gly Phe Val Ala Ala Val Val Asn Gly
 50 55 60
 Ser Ala Gln Gly Ala Gln Ile Gly Ala Met Leu Met Ala Ile Arg Leu
 65 70 75 80
 Arg Gly Met Asp Leu Glu Glu Thr Ser Val Leu Thr Gln Ala Leu Ala
 85 90 95
 Gln Ser Gly Gln Gln Leu Glu Trp Pro Glu Ala Trp Arg Gln Gln Leu
 100 105 110
 Val Asp Lys His Ser Thr Gly Gly Val Gly Asp Lys Val Ser Leu Val
 115 120 125
 Leu Ala Pro Ala Leu Ala Ala Cys Gly Cys Lys Val Pro Met Ile Ser
 130 135 140

Gly Arg Gly Leu Gly His Thr Gly Gly Thr Leu Asp Lys Leu Glu Ser
 145 150 155 160
 Ile Pro Gly Phe Asn Val Ile Gln Ser Pro Glu Gln Met Gln Val Leu
 165 170 175
 Leu Asp Gln Ala Gly Cys Cys Ile Val Gly Gln Ser Glu Gln Leu Val
 180 185 190
 Pro Ala Asp Gly Ile Leu Tyr Ala Ala Arg Asp Val Thr Ala Thr Val
 195 200 205
 Asp Ser Leu Pro Leu Ile Thr Ala Ser Ile Leu Ser Lys Lys Leu Val
 210 215 220
 Glu Gly Leu Ser Ala Leu Val Val Asp Val Lys Phe Gly Gly Ala Ala
 225 230 235 240
 Val Phe Pro Asn Gln Glu Gln Ala Arg Glu Leu Ala Lys Thr Leu Val
 245 250 255
 Gly Val Gly Ala Ser Leu Gly Leu Arg Val Ala Ala Ala Leu Thr Ala
 260 265 270
 Met Asp Lys Pro Leu Gly Arg Cys Val Gly His Ala Leu Glu Val Glu
 275 280 285
 Glu Ala Leu Leu Cys Met Asp Gly Ala Gly Pro Pro Asp Leu Arg Asp
 290 295 300
 Leu Val Thr Thr Leu Gly Gly Ala Leu Leu Trp Leu Ser Gly His Ala
 305 310 315 320
 Gly Thr Gln Ala Gln Gly Ala Ala Arg Val Ala Ala Ala Leu Asp Asp
 325 330 335
 Gly Ser Ala Leu Gly Arg Phe Glu Arg Met Leu Ala Ala Gln Gly Val
 340 345 350
 Asp Pro Gly Leu Ala Arg Ala Leu Cys Ser Gly Ser Pro Ala Glu Arg
 355 360 365
 Arg Gln Leu Leu Pro Arg Ala Arg Glu Gln Glu Glu Leu Leu Ala Pro
 370 375 380
 Ala Asp Gly Glu Arg Ser Gly Glu Ser Pro Ser Phe Arg Leu Arg His
 385 390 395 400
 Pro Leu Pro Phe Pro Arg Pro Arg Pro Phe Pro Ser Pro Arg Leu Ser
 405 410 415
 Ala Pro Leu Pro Ala Gly Thr Val Glu Leu Val Arg Ala Leu Pro Leu
 420 425 430
 Ala Leu Val Leu His Glu Leu Gly Ala Gly Arg Ser Arg Ala Gly Glu
 435 440 445
 Pro Leu Arg Leu Gly Val Gly Ala Glu Leu Leu Val Asp Val Gly Gln
 450 455 460
 Arg Leu Arg Arg Gly Thr Pro Trp Leu Arg Val His Arg Asp Gly Pro

[illegible]

```
<210> 164
<211> 142
<212> PRT
<213> Homo sapiens
```

```

<400> 164
Met Ser Asp Ala Ser Leu Arg Ser Thr Ser Thr Met Glu Arg Leu Val
  1                      5                      10                      15
Ala Arg Gly Thr Phe Pro Val Leu Val Arg Thr Ser Ala Cys Arg Ser
      20                      25                      30
Leu Phe Gly Pro Val Asp His Glu Glu Leu Ser Arg Glu Leu Gln Ala
      35                      40                      45
Arg Leu Ala Glu Leu Asn Ala Glu Asp Gln Asn Arg Trp Asp Tyr Asp
      50                      55                      60
Phe Gln Gln Asp Met Pro Leu Arg Gly Pro Gly Arg Leu Gln Trp Thr
      65                      70                      75                      80
Glu Val Asp Ser Asp Ser Val Pro Ala Phe Tyr Arg Glu Thr Val Gln
      85                      90                      95
Ile Ser Ser Pro Ser Ala Arg Asp Gln Arg Leu Arg Ser Arg Arg Ala
      100                      105                      110
Met Ser Pro Arg Arg Val Pro Leu Gln Ala Pro Pro Leu Ala Trp Ala
      115                      120                      125
Arg Trp Ser Arg Pro Arg Ala Arg Gly Cys Gly Glu Pro Ile
      130                      135                      140

```

```
<210> 165
<211> 561
<212> PRT
<213> Homo sapiens
```

<400> 165
Met Gly Ala Pro Ala Cys Ala Leu Ala Leu Cys Val Ala Val Ala Ile
1 5 10 15
Val Ala Gly Ala Ser Ser Glu Ser Leu Gly Thr Glu Gln Arg Val Val
20 25 30
Gly Arg Ala Ala Glu Val Pro Gly Pro Glu Pro Gly Gln Gln Glu Gln
35 40 45

Leu Val Phe Gly Ser Gly Asp Ala Val Glu Leu Ser Cys Pro Pro Pro
 50 55 60
 Gly Gly Gly Pro Met Gly Pro Thr Val Trp Val Lys Asp Gly Thr Gly
 65 70 75 80
 Leu Val Pro Ser Glu Arg Val Leu Val Gly Pro Gln Arg Leu Gln Val
 85 90 95
 Leu Asn Ala Ser His Glu Asp Ser Gly Ala Tyr Ser Cys Arg Gln Arg
 100 105 110
 Leu Thr Gln Arg Val Leu Cys His Phe Ser Val Arg Val Thr Asp Ala
 115 120 125
 Pro Ser Ser Gly Asp Asp Glu Asp Gly Glu Asp Glu Ala Glu Asp Thr
 130 135 140
 Gly Val Asp Thr Gly Ala Pro Tyr Trp Thr Arg Pro Glu Arg Met Asp
 145 150 155 160
 Lys Lys Leu Leu Ala Val Pro Ala Ala Asn Thr Val Arg Phe Arg Cys
 165 170 175
 Pro Ala Ala Gly Asn Pro Thr Pro Ser Ile Ser Trp Leu Lys Asn Gly
 180 185 190
 Arg Glu Phe Arg Gly Glu His Arg Ile Gly Gly Ile Lys Leu Arg His
 195 200 205
 Gln Gln Trp Ser Leu Val Met Glu Ser Val Val Pro Ser Asp Arg Gly
 210 215 220
 Asn Tyr Thr Cys Val Val Glu Asn Lys Phe Gly Ser Ile Arg Gln Thr
 225 230 235 240
 Tyr Thr Leu Asp Val Leu Glu Arg Ser Pro His Arg Pro Ile Leu Gln
 245 250 255
 Ala Gly Leu Pro Ala Asn Gln Thr Ala Val Leu Gly Ser Asp Val Glu
 260 265 270
 Phe His Cys Lys Val Tyr Ser Asp Ala Gln Pro His Ile Gln Trp Leu
 275 280 285
 Lys His Val Glu Val Asn Gly Ser Lys Val Gly Pro Asp Gly Thr Pro
 290 295 300
 Tyr Val Thr Val Leu Lys Thr Ala Gly Ala Asn Thr Thr Asp Lys Glu
 305 310 315 320
 Leu Glu Val Leu Ser Leu His Asn Val Thr Phe Glu Asp Ala Gly Glu
 325 330 335
 Tyr Thr Cys Leu Ala Gly Asn Ser Ile Gly Phe Ser His His Ser Ala
 340 345 350
 Trp Leu Val Val Leu Pro Ala Glu Glu Glu Leu Val Glu Ala Asp Glu
 355 360 365
 Ala Gly Ser Val Tyr Ala Gly Ile Leu Ser Tyr Gly Val Gly Phe Phe

370 375 380
 Leu Phe Ile Leu Val Val Ala Ala Val Thr Xaa Cys Arg Leu Arg Ser
 385 390 395 400
 Pro Pro Lys Lys Gly Leu Gly Ser Pro Thr Val His Lys Ile Ser Arg
 405 410 415
 Phe Pro Leu Lys Arg Gln Val Ser Leu Glu Ser Asn Ala Ser Met Ser
 420 425 430
 Ser Asn Thr Pro Leu Val Arg Ile Ala Arg Leu Ser Ser Gly Glu Gly
 435 440 445
 Pro Thr Leu Ala Asn Val Ser Glu Leu Glu Leu Pro Ala Asp Pro Lys
 450 455 460
 Trp Glu Leu Ser Arg Ala Arg Leu Thr Leu Gly Lys Pro Leu Gly Glu
 465 470 475 480
 Gly Cys Phe Gly Gln Val Val Met Ala Glu Ala Ile Gly Ile Asp Lys
 485 490 495
 Asp Arg Ala Ala Lys Pro Val Thr Val Ala Val Lys Met Leu Lys Asp
 500 505 510
 Asp Ala Thr Asp Lys Asp Leu Ser Asp Leu Val Ser Glu Met Glu Met
 515 520 525
 Met Lys Met Ile Gly Lys His Lys Asn Ile Ile Asn Leu Leu Gln Val
 530 535 540
 Pro Met Leu Leu Asp Val Thr Ser Leu Tyr Ile Ser Ile Tyr Ile Ile
 545 550 555 560
 Tyr

<210> 166
 <211> 188
 <212> PRT
 <213> Homo sapiens

<400> 166
 Met Asp Pro Ala Arg Pro Leu Gly Leu Ser Ile Leu Leu Leu Phe Leu
 1 5 10 15
 Thr Glu Ala Ala Leu Gly Asp Ala Ala Gln Glu Pro Thr Gly Asn Asn
 20 25 30
 Ala Glu Ile Cys Leu Leu Pro Leu Asp Tyr Gly Pro Cys Arg Ala Leu
 35 40 45
 Leu Leu Arg Tyr Tyr Tyr Asp Arg Tyr Thr Gln Ser Cys Arg Gln Phe
 50 55 60
 Leu Tyr Gly Gly Cys Glu Gly Asn Arg Asn Asn Phe Tyr Thr Trp Glu
 65 70 75 80
 Ala Cys Asp Asp Ala Cys Trp Arg Ile Glu Lys Val Pro Lys Val Cys

85 90 95
 Arg Leu Gln Val Ser Val Asp Asp Gln Cys Glu Gly Ser Thr Glu Lys
 100 105 110
 Tyr Phe Phe Asn Leu Ser Ser Met Thr Cys Glu Lys Phe Phe Ser Gly
 115 120 125
 Gly Cys His Arg Asn Arg Ile Glu Asn Arg Phe Pro Asp Glu Ala Thr
 130 135 140
 Cys Met Gly Phe Cys Ala Pro Lys Lys Ile Pro Ser Phe Cys Tyr Ser
 145 150 155 160
 Pro Lys Asp Glu Gly Leu Cys Ser Ala Asn Val Thr Arg Tyr Tyr Phe
 165 170 175
 Asn Ile Asp Val Ser Ile Ser Thr Ala Val Lys Leu
 180 185

 <210> 167
 <211> 539
 <212> PRT
 <213> Homo sapiens

 <400> 167
 Met Asn Gln Leu Arg Gly Lys Lys Ser Cys His Thr Gly Leu Gly Arg
 1 5 10 15
 Ser Ala Gly Trp Asn Ile Pro Ile Gly Leu Leu Tyr Cys Asp Leu Pro
 20 25 30
 Glu Pro Arg Lys Pro Leu Glu Lys Ala Val Ala Asn Phe Phe Ser Gly
 35 40 45
 Ser Cys Ala Pro Cys Ala Asp Gly Thr Asp Phe Pro Gln Leu Cys Gln
 50 55 60
 Leu Cys Pro Gly Cys Gly Cys Ser Thr Leu Asn Gln Tyr Phe Gly Tyr
 65 70 75 80
 Ser Gly Ala Phe Lys Cys Leu Lys Asp Gly Ala Gly Asp Val Ala Phe
 85 90 95
 Val Lys His Ser Thr Ile Phe Glu Asn Leu Ala Asn Lys Ala Asp Arg
 100 105 110
 Asp Gln Tyr Glu Leu Leu Cys Leu Asp Asn Thr Arg Lys Pro Val Asp
 115 120 125
 Glu Tyr Lys Asp Cys His Leu Ala Gln Val Pro Ser His Thr Val Val
 130 135 140
 Ala Arg Ser Met Gly Gly Lys Glu Asp Leu Ile Trp Glu Leu Leu Asn
 145 150 155 160
 Gln Ala Gln Glu His Phe Gly Lys Asp Lys Ser Lys Glu Phe Gln Leu
 165 170 175
 Phe Ser Ser Pro His Gly Lys Asp Leu Leu Phe Lys Asp Ser Ala His

180					185					190					
Gly	Phe	Leu	Lys	Val	Pro	Pro	Arg	Met	Asp	Ala	Lys	Met	Tyr	Leu	Gly
		195					200					205			
Tyr	Glu	Tyr	Val	Thr	Ala	Ile	Arg	Asn	Leu	Arg	Glu	Gly	Thr	Cys	Pro
	210					215					220				
Glu	Ala	Pro	Thr	Asp	Glu	Cys	Lys	Pro	Val	Lys	Trp	Cys	Ala	Leu	Ser
225					230					235					240
His	His	Glu	Arg	Leu	Lys	Cys	Asp	Glu	Trp	Ser	Val	Asn	Ser	Val	Gly
				245					250					255	
Lys	Ile	Glu	Cys	Val	Ser	Ala	Glu	Thr	Thr	Glu	Asp	Cys	Ile	Ala	Lys
			260					265					270		
Ile	Met	Asn	Gly	Glu	Ala	Asp	Ala	Met	Ser	Leu	Asp	Gly	Gly	Phe	Val
		275					280					285			
Tyr	Ile	Ala	Gly	Lys	Cys	Gly	Leu	Val	Pro	Val	Leu	Ala	Glu	Asn	Tyr
	290					295					300				
Asn	Lys	Ser	Asp	Asn	Cys	Glu	Asp	Thr	Pro	Glu	Ala	Gly	Tyr	Phe	Ala
305					310					315					320
Val	Ala	Val	Val	Lys	Lys	Ser	Ala	Ser	Asp	Leu	Thr	Trp	Asp	Asn	Leu
				325					330					335	
Lys	Gly	Lys	Lys	Ser	Cys	His	Thr	Ala	Val	Gly	Arg	Thr	Ala	Gly	Trp
			340					345					350		
Asn	Ile	Pro	Met	Gly	Leu	Leu	Tyr	Asn	Lys	Ile	Asn	His	Cys	Glu	Pro
		355					360					365			
Asn	Asn	Lys	Glu	Gly	Tyr	Tyr	Gly	Tyr	Thr	Gly	Ala	Phe	Arg	Cys	Leu
	370					375					380				
Val	Glu	Lys	Gly	Asp	Val	Ala	Phe	Val	Lys	His	Gln	Thr	Val	Pro	Gln
385					390					395					400
Asn	Thr	Gly	Gly	Lys	Asn	Pro	Asp	Pro	Trp	Ala	Lys	Asn	Leu	Asn	Glu
				405					410					415	
Lys	Asp	Tyr	Glu	Leu	Leu	Cys	Leu	Asp	Gly	Thr	Arg	Lys	Pro	Val	Glu
			420					425					430		
Glu	Tyr	Ala	Asn	Cys	His	Leu	Ala	Arg	Ala	Pro	Asn	His	Ala	Val	Val
		435					440					445			
Thr	Arg	Lys	Asp	Lys	Glu	Ala	Cys	Val	His	Lys	Ile	Leu	Arg	Gln	Gln
	450					455					460				
Gln	His	Leu	Phe	Gly	Ser	Asn	Val	Thr	Asp	Cys	Ser	Gly	Asn	Phe	Cys
465					470					475					480
Leu	Phe	Arg	Ser	Glu	Thr	Lys	Asp	Leu	Leu	Phe	Arg	Asp	Asp	Thr	Val
				485					490					495	
Cys	Leu	Ala	Lys	Leu	His	Asp	Arg	Asn	Thr	Tyr	Glu	Lys	Tyr	Leu	Gly
			500					505					510		

Glu Glu Tyr Val Lys Ala Val Gly Asn Leu Arg Lys Cys Ser Thr Ser
 515 520 525

Ser Leu Leu Glu Ala Cys Thr Phe Arg Arg Pro
 530 535

<210> 168
 <211> 77
 <212> PRT
 <213> Homo sapiens

<400> 168
 Met Arg Thr Leu Leu Pro Pro Ala Leu Leu Thr Cys Trp Leu Leu Ala
 1 5 10 15

Pro Val Asn Ser Ile His Pro Glu Cys Arg Phe His Leu Glu Ile Gln
 20 25 30

Glu Glu Glu Thr Lys Cys Ala Glu Leu Leu Arg Ser Gln Thr Glu Lys
 35 40 45

His Lys Gly His Thr Lys Gly Phe Ile Leu Ile His Ala Gly Gly Leu
 50 55 60

Lys Arg Ile Leu Asp Pro His Thr Tyr Pro Leu Ala Pro
 65 70 75

<210> 169
 <211> 161
 <212> PRT
 <213> Homo sapiens

<400> 169
 Met Lys Leu Pro Glu Val Cys Phe Phe Asn Cys Cys Thr Leu His Glu
 1 5 10 15

Ser Lys Tyr Glu Ile Val Thr Met Phe Ile Tyr Phe Asn Trp Leu Tyr
 20 25 30

Phe Phe Pro Ala Asn Gly Phe Gln Val Asp Asn Tyr Gly Thr Gln Leu
 35 40 45

Asn Ala Val Asn Asn Ser Leu Thr Pro Gln Ser Thr Lys Val Pro Ser
 50 55 60

Leu Phe Glu Phe His Gly Pro Ser Trp Cys Leu Thr Pro Ala Asp Arg
 65 70 75 80

Gly Leu Cys Arg Ala Asn Glu Asn Arg Phe Tyr Tyr Asn Ser Val Ile
 85 90 95

Gly Lys Cys Arg Pro Phe Lys Tyr Ser Gly Cys Gly Gly Asn Glu Asn
 100 105 110

Asn Phe Thr Ser Lys Gln Glu Cys Leu Arg Ala Cys Lys Lys Gly Phe
 115 120 125

Ile Gln Arg Ile Ser Lys Gly Gly Leu Ile Lys Thr Lys Arg Lys Arg

130 135 140
 Lys Lys Gln Arg Val Lys Ile Ala Tyr Glu Glu Ile Phe Val Lys Asn
 145 150 155 160

Met

<210> 170
 <211> 157
 <212> PRT
 <213> Mouse

<400> 170
 Met Tyr Asn Thr Ser Xaa Met Xaa Pro Xaa Asn Pro Arg Pro Ile Leu
 1 5 10 15
 Thr Ile Ile Thr Leu Glu Asp Ser Ser Gly Asn Leu Leu Gly Arg Asp
 20 25 30
 Ser Phe Glu Val Arg Val Cys Ala Ser Pro Gly Arg Asp Pro Arg Thr
 35 40 45
 Glu Glu Glu Asn Phe Arg Lys Lys Glu Val Leu Cys Pro Glu Leu Pro
 50 55 60
 Pro Gly Ser Ala Lys Arg Ala Leu Pro Thr Cys Thr Ser Ala Ser Pro
 65 70 75 80
 Pro Gln Lys Lys Lys Pro Leu Asp Gly Glu Tyr Phe Thr Leu Lys Ile
 85 90 95
 Arg Gly Arg Lys Arg Phe Glu Met Phe Arg Glu Leu Asn Glu Ala Leu
 100 105 110
 Glu Leu Lys Asp Ala His Ala Thr Glu Glu Ser Gly Asp Ser Arg Ala
 115 120 125
 His Ser Ser Tyr Leu Lys Thr Lys Lys Gly Gln Ser Thr Ser Arg His
 130 135 140
 Lys Lys Thr Met Val Lys Lys Val Gly Pro Asp Ser Asp
 145 150 155

<210> 171
 <211> 157
 <212> PRT
 <213> Mouse

<400> 171
 Met Phe Asn Arg Ser Cys Leu Arg Gly Met Asn Pro Arg Pro Ile Leu
 1 5 10 15
 Thr Ile Ile Thr Leu Glu Asp Ser Ser Gly Asn Leu Leu Gly Arg Asp
 20 25 30
 Ser Phe Glu Val Arg Val Cys Ala Ser Pro Gly Arg Asp Pro Arg Thr
 35 40 45

Glu Glu Glu Asn Phe Arg Lys Lys Glu Val Leu Cys Pro Glu Leu Pro
 50 55 60
 Pro Gly Ser Ala Lys Arg Ala Leu Pro Thr Cys Thr Ser Ala Ser Pro
 65 70 75 80
 Pro Gln Lys Lys Lys Pro Leu Asp Gly Glu Tyr Phe Thr Leu Lys Ile
 85 90 95
 Arg Gly Arg Lys Arg Phe Glu Met Phe Arg Glu Leu Asn Glu Ala Leu
 100 105 110
 Glu Leu Lys Asp Ala His Ala Thr Glu Glu Ser Gly Asp Ser Arg Ala
 115 120 125
 His Ser Ser Tyr Leu Lys Thr Lys Lys Gly Gln Ser Thr Ser Arg His
 130 135 140
 Lys Lys Thr Met Val Lys Lys Val Gly Pro Asp Ser Asp
 145 150 155

<210> 172
 <211> 1252
 <212> PRT
 <213> Mouse

<400> 172

Met Gly Ala Ala Ser Gly Gln Arg Gly Arg Trp Pro Leu Ser Pro Pro
 1 5 10 15
 Leu Leu Met Leu Ser Leu Leu Val Leu Leu Leu Gln Pro Ser Pro Ala
 20 25 30
 Pro Ala Leu Asp Pro Gly Leu Gln Pro Gly Asn Phe Ser Pro Asp Glu
 35 40 45
 Ala Gly Ala Gln Leu Phe Ala Glu Ser Tyr Asn Ser Ser Ala Glu Val
 50 55 60
 Val Met Phe Gln Ser Thr Val Ala Ser Trp Ala His Asp Thr Asn Ile
 65 70 75 80
 Thr Glu Glu Asn Ala Arg Arg Gln Glu Glu Ala Ala Leu Val Ser Gln
 85 90 95
 Glu Phe Ala Glu Val Trp Gly Lys Lys Ala Lys Glu Leu Tyr Glu Ser
 100 105 110
 Ile Trp Gln Asn Phe Thr Asp Ser Lys Leu Arg Arg Ile Ile Gly Ser
 115 120 125
 Ile Arg Thr Leu Gly Pro Ala Asn Leu Pro Leu Ala Gln Arg Gln Gln
 130 135 140
 Tyr Asn Ser Leu Leu Ser Asn Met Ser Arg Ile Tyr Ser Thr Gly Lys
 145 150 155 160
 Val Cys Phe Pro Asn Lys Thr Ala Thr Cys Trp Ser Leu Asp Pro Glu
 165 170 175

Leu Thr Asn Ile Leu Ala Ser Ser Arg Ser Tyr Ala Lys Leu Leu Phe
 180 185 190
 Ala Trp Glu Gly Trp His Asp Ala Val Gly Ile Pro Leu Lys Pro Leu
 195 200 205
 Tyr Gln Asp Phe Thr Ala Ile Ser Asn Glu Ala Tyr Arg Gln Asp Asp
 210 215 220
 Phe Ser Asp Thr Gly Ala Phe Trp Arg Ser Trp Tyr Glu Ser Pro Ser
 225 230 235 240
 Phe Glu Glu Ser Leu Glu His Ile Tyr His Gln Leu Glu Pro Leu Tyr
 245 250 255
 Leu Asn Leu His Ala Tyr Val Arg Arg Ala Leu His Arg Arg Tyr Gly
 260 265 270
 Asp Lys Tyr Val Asn Leu Arg Gly Pro Ile Pro Ala His Leu Leu Gly
 275 280 285
 Asp Met Trp Ala Gln Ser Trp Glu Asn Ile Tyr Asp Met Val Val Pro
 290 295 300
 Phe Pro Asp Lys Pro Asn Leu Asp Val Thr Ser Thr Met Val Gln Lys
 305 310 315 320
 Gly Trp Asn Ala Thr His Met Phe Arg Val Ser Glu Glu Phe Phe Thr
 325 330 335
 Ser Leu Gly Leu Ser Pro Met Pro Pro Glu Phe Trp Ala Glu Ser Met
 340 345 350
 Leu Glu Lys Pro Thr Asp Gly Arg Glu Val Val Cys His Ala Ser Ala
 355 360 365
 Trp Asp Phe Tyr Asn Arg Lys Asp Phe Arg Ile Lys Gln Cys Thr Arg
 370 375 380
 Val Thr Met Glu Gln Leu Ala Thr Val His His Glu Met Gly His Val
 385 390 395 400
 Gln Tyr Tyr Leu Gln Tyr Lys Asp Leu His Val Ser Leu Arg Arg Gly
 405 410 415
 Ala Asn Pro Gly Phe His Glu Ala Ile Gly Asp Val Leu Ala Leu Ser
 420 425 430
 Val Ser Thr Pro Ala His Leu His Lys Ile Gly Leu Leu Asp His Val
 435 440 445
 Thr Asn Asp Ile Glu Ser Asp Ile Asn Tyr Leu Leu Lys Met Ala Leu
 450 455 460
 Glu Lys Ile Ala Phe Leu Pro Phe Gly Tyr Leu Val Asp Gln Trp Arg
 465 470 475 480
 Trp Gly Val Phe Ser Gly Arg Thr Pro Pro Ser Arg Tyr Asn Phe Asp
 485 490 495
 Trp Trp Tyr Leu Arg Thr Lys Tyr Gln Gly Ile Cys Pro Pro Val Ala

500	505	510
Arg Asn Glu Thr His Phe Asp Ala Gly Ala Lys Phe His Ile Pro Asn 515	520	525
Val Thr Pro Tyr Ile Arg Tyr Phe Val Ser Phe Val Leu Gln Phe Gln 530	535	540
Phe His Gln Ala Leu Cys Lys Glu Ala Gly His Gln Gly Pro Leu His 545	550	555 560
Gln Cys Asp Ile Tyr Gln Ser Ala Gln Ala Gly Ala Lys Leu Lys Gln 565	570	575
Val Leu Gln Ala Gly Cys Ser Arg Pro Trp Gln Glu Val Leu Lys Asp 580	585	590
Leu Val Gly Ser Asp Ala Leu Asp Ala Lys Ala Leu Leu Glu Tyr Phe 595	600	605
Gln Pro Val Ser Gln Trp Leu Glu Glu Gln Asn Gln Arg Asn Gly Glu 610	615	620
Val Leu Gly Trp Pro Glu Asn Gln Trp Arg Pro Pro Leu Pro Asp Asn 625	630	635 640
Tyr Pro Glu Gly Ile Asp Leu Glu Thr Asp Glu Ala Lys Ala Asp Arg 645	650	655
Phe Val Glu Glu Tyr Asp Arg Thr Ala Gln Val Leu Leu Asn Glu Tyr 660	665	670
Ala Glu Ala Asn Trp Gln Tyr Asn Thr Asn Ile Thr Ile Glu Gly Ser 675	680	685
Lys Ile Leu Leu Glu Lys Ser Thr Glu Val Ser Asn His Thr Leu Lys 690	695	700
Tyr Gly Thr Arg Ala Lys Thr Phe Asp Val Ser Asn Phe Gln Asn Ser 705	710	715 720
Ser Ile Lys Arg Ile Ile Lys Lys Leu Gln Asn Leu Asp Arg Ala Val 725	730	735
Leu Pro Pro Lys Glu Leu Glu Glu Tyr Asn Gln Ile Leu Leu Asp Met 740	745	750
Glu Thr Thr Tyr Ser Leu Ser Asn Ile Cys Tyr Thr Asn Gly Thr Cys 755	760	765
Met Pro Leu Glu Pro Asp Leu Thr Asn Met Met Ala Thr Ser Arg Lys 770	775	780
Tyr Glu Glu Leu Leu Trp Ala Trp Lys Ser Trp Arg Asp Lys Val Gly 785	790	795 800
Arg Ala Ile Leu Pro Phe Phe Pro Lys Tyr Val Glu Phe Ser Asn Lys 805	810	815
Ile Ala Lys Leu Asn Gly Tyr Thr Asp Ala Gly Asp Ser Trp Arg Ser 820	825	830

Leu Tyr Glu Ser Asp Asn Leu Glu Gln Asp Leu Glu Lys Leu Tyr Gln
 835 840 845
 Glu Leu Gln Pro Leu Tyr Leu Asn Leu His Ala Tyr Val Arg Arg Ser
 850 855 860
 Leu His Arg His Tyr Gly Ser Glu Tyr Ile Asn Leu Asp Gly Pro Ile
 865 870 875 880
 Pro Ala His Leu Leu Gly Asn Met Trp Ala Gln Thr Trp Ser Asn Ile
 885 890 895
 Tyr Asp Leu Val Ala Pro Phe Pro Ser Ala Pro Asn Ile Asp Ala Thr
 900 905 910
 Glu Ala Met Ile Lys Gln Gly Trp Thr Pro Arg Arg Ile Phe Lys Glu
 915 920 925
 Ala Asp Asn Phe Phe Thr Ser Leu Gly Leu Leu Pro Val Pro Pro Glu
 930 935 940
 Phe Trp Asn Lys Ser Met Leu Glu Lys Pro Thr Asp Gly Arg Glu Val
 945 950 955 960
 Val Cys His Pro Ser Ala Trp Asp Phe Tyr Asn Gly Lys Asp Phe Arg
 965 970 975
 Ile Lys Gln Cys Thr Ser Val Asn Met Glu Asp Leu Val Ile Ala His
 980 985 990
 His Glu Met Gly His Ile Gln Tyr Phe Met Gln Tyr Lys Asp Leu Pro
 995 1000 1005
 Val Thr Phe Arg Glu Gly Ala Asn Pro Gly Phe His Glu Ala Ile Gly
 1010 1015 1020
 Asp Ile Met Ala Leu Ser Val Ser Thr Pro Lys His Leu Tyr Ser Leu
 1025 1030 1035 1040
 Asn Leu Leu Ser Thr Glu Gly Ser Gly Tyr Glu Tyr Asp Ile Asn Phe
 1045 1050 1055
 Leu Met Lys Met Ala Leu Asp Lys Ile Ala Phe Ile Pro Phe Ser Tyr
 1060 1065 1070
 Leu Ile Asp Gln Trp Arg Trp Arg Val Phe Asp Gly Ser Ile Thr Lys
 1075 1080 1085
 Glu Asn Tyr Asn Gln Glu Trp Trp Ser Leu Arg Leu Lys Tyr Gln Gly
 1090 1095 1100
 Leu Cys Pro Pro Val Pro Arg Ser Gln Gly Asp Phe Asp Pro Gly Ser
 1105 1110 1115 1120
 Lys Phe His Val Pro Ala Asn Val Pro Tyr Val Arg Tyr Phe Val Ser
 1125 1130 1135
 Phe Ile Ile Gln Phe Gln Phe His Glu Ala Leu Cys Arg Ala Ala Gly
 1140 1145 1150

His Thr Gly Pro Leu His Lys Cys Asp Ile Tyr Gln Ser Lys Glu Ala
 1155 1160 1165
 Gly Lys Leu Leu Ala Asp Ala Met Lys Leu Gly Tyr Ser Lys Pro Trp
 1170 1175 1180
 Pro Glu Ala Met Lys Leu Ile Thr Gly Gln Pro Asn Met Ser Ala Ser
 1185 1190 1195 1200
 Ala Met Met Asn Tyr Phe Lys Pro Leu Thr Glu Trp Leu Val Thr Glu
 1205 1210 1215
 Asn Arg Arg His Gly Glu Thr Leu Gly Trp Pro Glu Tyr Asn Trp Ala
 1220 1225 1230
 Pro Asn Thr Gly Thr Thr Pro Thr Leu Pro Pro Ala Pro Ile Leu Trp
 1235 1240 1245
 Ile Pro Ser Val
 1250

<210> 173
 <211> 374
 <212> PRT
 <213> Mouse

<400> 173
 Met Thr Met Thr Leu His Thr Lys Ala Ser Gly Met Ala Leu Leu His
 1 5 10 15
 Gln Ile Gln Gly Asn Glu Leu Glu Pro Leu Asn Arg Pro Gln Leu Lys
 20 25 30
 Met Pro Met Glu Arg Ala Leu Gly Glu Val Tyr Val Asp Asn Ser Lys
 35 40 45
 Pro Thr Val Phe Asn Tyr Pro Glu Gly Ala Ala Tyr Glu Phe Asn Ala
 50 55 60
 Ala Ala Ala Ala Ala Ala Ala Ser Ala Pro Val Tyr Gly Gln Ser
 65 70 75 80
 Gly Ile Ala Tyr Gly Pro Gly Ser Glu Ala Ala Ala Phe Ser Ala Asn
 85 90 95
 Ser Leu Gly Ala Phe Pro Gln Leu Asn Ser Val Ser Pro Ser Pro Leu
 100 105 110
 Met Leu Leu His Pro Pro Pro Gln Leu Ser Pro Phe Leu His Pro His
 115 120 125
 Gly Gln Gln Val Pro Tyr Tyr Leu Glu Asn Glu Pro Ser Ala Tyr Ala
 130 135 140
 Val Arg Asp Thr Gly Pro Pro Ala Phe Tyr Arg Ser Asn Ser Asp Asn
 145 150 155 160
 Arg Arg Gln Asn Gly Arg Glu Arg Leu Ser Ser Asn Glu Lys Gly
 165 170 175

Asn Met Ile Met Glu Ser Ala Lys Glu Thr Arg Tyr Cys Ala Val Cys
 180 185 190
 Asn Asp Tyr Ala Ser Gly Tyr His Tyr Gly Val Trp Ser Cys Glu Gly
 195 200 205
 Cys Lys Ala Phe Phe Lys Arg Ser Ile Gln Gly His Asn Asp Tyr Met
 210 215 220
 Cys Pro Ala Thr Asn Gln Cys Thr Ile Asp Lys Asn Arg Arg Lys Ser
 225 230 235 240
 Cys Gln Ala Cys Arg Leu Arg Lys Cys Tyr Glu Val Gly Met Met Lys
 245 250 255
 Gly Gly Ile Arg Lys Asp Arg Arg Gly Gly Arg Met Leu Lys His Lys
 260 265 270
 Arg Gln Arg Asp Asp Leu Glu Gly Arg Asn Glu Met Gly Ala Ser Gly
 275 280 285
 Asp Met Arg Ala Ala Asn Leu Trp Pro Ser Pro Leu Val Ile Lys His
 290 295 300
 Thr Lys Lys Asn Ser Pro Ala Leu Ser Leu Thr Ala Asp Gln Met Val
 305 310 315 320
 Ser Ala Leu Leu Asp Ala Glu Pro Pro Met Ile Tyr Ser Glu Tyr Asp
 325 330 335
 Pro Ser Arg Pro Phe Ser Glu Ala Ser Met Met Gly Leu Leu Thr Asn
 340 345 350
 Leu Ala Asp Arg Glu Leu Val His Met Ile Asn Trp Ala Lys Arg Val
 355 360 365
 Pro Gly Gly Asn Ser Leu
 370

<210> 174
 <211> 468
 <212> PRT
 <213> Mouse

<400> 174
 Met Ala Thr Leu Leu Arg Ser Lys Leu Thr Asn Val Ala Thr Ser Val
 1 5 10 15
 Ser Asn Lys Ser Gln Ala Lys Val Ser Gly Met Phe Ala Arg Met Gly
 20 25 30
 Phe Gln Ala Ala Thr Asp Glu Glu Ala Val Gly Phe Ala His Cys Asp
 35 40 45
 Asp Leu Asp Phe Glu His Arg Gln Gly Leu Gln Met Asp Ile Leu Lys
 50 55 60
 Ser Glu Gly Glu Pro Cys Gly Asp Glu Gly Ala Glu Ala Pro Val Glu
 65 70 75 80

Gly Asp Ile His Tyr Gln Arg Gly Gly Ala Pro Leu Pro Pro Ser Gly
 85 90 95
 Ser Lys Asp Gln Ala Val Gly Ala Gly Gly Glu Phe Gly Gly His Asp
 100 105 110
 Lys Pro Lys Ile Thr Ala Trp Glu Ala Gly Trp Asn Val Thr Asn Ala
 115 120 125
 Ile Gln Gly Met Phe Val Leu Gly Leu Pro Tyr Ala Ile Leu His Gly
 130 135 140
 Gly Tyr Leu Gly Leu Phe Leu Ile Ile Phe Ala Ala Val Val Cys Cys
 145 150 155 160
 Tyr Thr Gly Lys Ile Leu Ile Ala Cys Leu Tyr Glu Glu Asn Glu Asp
 165 170 175
 Gly Glu Val Val Arg Val Arg Asp Ser Tyr Val Ala Ile Ala Asn Ala
 180 185 190
 Cys Cys Ala Pro Arg Phe Pro Thr Leu Gly Gly Arg Val Val Asn Val
 195 200 205
 Ala Gln Ile Ile Glu Leu Val Met Thr Cys Ile Leu Tyr Val Val Val
 210 215 220
 Ser Gly Asn Leu Met Tyr Asn Ser Phe Pro Gly Leu Pro Val Ser Gln
 225 230 235 240
 Lys Ser Trp Ser Ile Ile Ala Thr Ala Val Leu Leu Pro Cys Ala Phe
 245 250 255
 Leu Lys Asn Leu Lys Ala Val Ser Lys Phe Ser Leu Leu Cys Thr Leu
 260 265 270
 Ala His Phe Val Ile Asn Ile Leu Val Ile Ala Tyr Cys Leu Ser Arg
 275 280 285
 Ala Arg Asp Trp Ala Trp Glu Lys Val Lys Phe Tyr Ile Asp Val Lys
 290 295 300
 Lys Phe Pro Ile Ser Ile Gly Ile Ile Val Phe Ser Tyr Thr Ser Gln
 305 310 315 320
 Ile Phe Leu Pro Ser Leu Glu Gly Asn Met Gln Gln Pro Ser Glu Phe
 325 330 335
 His Cys Met Met Asn Trp Thr His Ile Ala Ala Cys Val Leu Lys Gly
 340 345 350
 Leu Phe Ala Leu Val Ala Tyr Leu Thr Trp Ala Asp Glu Thr Lys Glu
 355 360 365
 Val Ile Thr Asp Asn Leu Pro Gly Ser Ile Arg Ala Val Val Asn Leu
 370 375 380
 Phe Leu Val Ala Lys Ala Leu Leu Ser Tyr Pro Leu Pro Phe Phe Ala
 385 390 395 400
 Ala Val Glu Val Leu Glu Lys Ser Leu Phe Gln Glu Gly Ser Arg Ala

405										410					415				
Phe	Phe	Pro	Ala	Cys	Tyr	Gly	Gly	Asp	Gly	Arg	Leu	Lys	Ser	Trp	Gly				
			420					425					430						
Leu	Thr	Leu	Arg	Cys	Ala	Leu	Val	Val	Phe	Thr	Leu	Leu	Met	Ala	Ile				
		435					440					445							
Ser	Ser	Cys	Ala	Met	Tyr	Pro	Phe	Val	Glu	Leu	Tyr	Thr	Val	Arg	Val				
	450					455					460								
Val	Cys	Ser	Trp																
465																			

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 May 2001 (25.05.2001)

PCT

(10) International Publication Number
WO 01/36632 A3

- (51) International Patent Classification⁷: C12N 15/12, 15/57, C07K 14/47, 14/705, C12N 9/48, C12Q 1/68, G01N 33/68, 33/50, A61K 38/17, 38/48
- (21) International Application Number: PCT/IL00/00766
- (22) International Filing Date:
17 November 2000 (17.11.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
132978 17 November 1999 (17.11.1999) IL
133455 10 December 1999 (10.12.1999) IL
- (71) Applicant (for all designated States except US): COMPU-GEN LTD. [IL/IL]; 72 Pinchas Rozen Street, 69512 Tel Aviv (IL).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): LEVINE, Zurit [IL/IL]; 5 Hakozrim Street, 46360 Herzliya (IL). DAVID, Anat [IL/IL]; 11 Afner Street, 53292 Givatayim (IL). AZAR, Idit [IL/IL]; 2 Hankin Street, 76354 Rehovot (IL). KHOSRAVI, Rami [IL/IL]; 36 Yehuda Halevy Street, 46490 Herzliya (IL). BERNSTEIN, Jeanne [IL/IL]; 23 Harimon Street, 40300 Kfar Yona (IL).
- (74) Agent: REINHOLD COHN AND PARTNERS; P.O.B. 4060, 61040 Tel Aviv (IL).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the international search report:
3 January 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: VARIANTS OF ALTERNATIVE SPLICING

(57) Abstract: The present invention concerns novel variants, amino acid and nucleic acid sequences obtained by alternative splicing of known sequences, expression vectors and host cells containing the variants' nucleic acid sequence, and antibodies reactive with the variants' products. The invention also concerns pharmaceutical compositions containing any of the above as well as methods of detection. A preferred example is the angiotensin converting enzyme (ACE) variant.

WO 01/36632 A3

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C12N15/57 C07K14/47 C07K14/705 C12N9/48
C12Q1/68 G01N33/68 G01N33/50 A61K38/17 A61K38/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N A61K C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EMBASE, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 2 264 948 A (MERCK & CO INC) 15 September 1993 (1993-09-15) figure 3 page 41 -page 42, line 7	2,8,9, 20-22
A	claims 9-14 ---	1-30
X	WO 93 25677 A (GARVAN INST MED RES ;PIERCE KERRIE DIANE (AU); SELBIE LISA (AU); F) 23 December 1993 (1993-12-23)	2,8,9, 20-22
A	the whole document ---	1-30
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

30 July 2001

Date of mailing of the international search report

13.08.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Andres, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IL 00/00766

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FURLONG T J ET AL: "MOLECULAR CHARACTERIZATION OF A HUMAN BRAIN ADENOSINE A2 RECEPTOR" MOLECULAR BRAIN RESEARCH, vol. 15, no. 1/02, 1 September 1992 (1992-09-01), pages 62-66, XP000615546 ISSN: 0169-328X the whole document ---	2,8,9
X	DATABASE EM_HUM 'Online! EMBL; Accession number : U40771; ID : HS2AAR02, 15 December 1995 (1995-12-15) "Human A2a adenosine receptor subtype (ADORA2A) gene" XP002165717 abstract ---	2
A	GELFAND M S ET AL: "ASDB: Database of alternatively spliced genes." NUCLEIC ACIDS RESEARCH, vol. 27, no. 1, 1 January 1999 (1999-01-01), pages 301-302, XP002165716 ISSN: 0305-1048 cited in the application ---	
A	CHU Y Y ET AL: "Characterization of the rat A2a adenosine receptor gene." DNA AND CELL BIOLOGY, (1996 APR) 15 (4) 329-37., XP000992998 ---	
X	BERNSTEIN K E ET AL: "THE ISOLATION OF ANGIOTENSIN-CONVERTING ENZYME CDNA" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 263, no. 23, 15 August 1988 (1988-08-15), pages 11021-11024, XP000095152 ISSN: 0021-9258 the whole document ---	2,8,9, 32,38,39
Y		1-22, 25-53, 56-61
Y	SUGIMURA K ET AL.: "Alternative splicing of the mRNA coding for the human endothelial angiotensin-converting enzyme: a new mechanism for solubilization." BIOCHEM BIOPHYS RES COMMUN 1998 JUN 18;247(2):466-72., XP002173427 the whole document ---	1-22, 25-53, 56-61

-/-

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BERNSTEIN K E ET AL: "MOUSE ANGIOTENSIN-CONVERTING ENZYME IS A PROTEIN COMPOSED OF TWO HOMOLOGOUS DOMAINS" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 264, no. 20, 1989, pages 11945-11951, XP002173428 ISSN: 0021-9258 the whole document ---	2,8,9, 32,38,39
X	WO 90 03435 A (INST NAT SANTE RECH MED) 5 April 1990 (1990-04-05) the whole document ---	2,8-13, 32,38-44
X	WO 85 00369 A (CHIRON CORP) 31 January 1985 (1985-01-31) the whole document ---	2,8,9
X	DATABASE EM_EST 'Online! EMBL; Accession number : AI790464, 4 July 1999 (1999-07-04) MARRA, M. ET AL.: "u101e02.x1 Sugano mouse kidney mkia Mus musculus cDNA clone IMAGE:2064794 3' " XP002173429 abstract ---	2
Y	WHITE R ET AL: "STRUCTURAL ORGANIZATION AND EXPRESSION OF THE MOUSE ESTROGEN RECEPTOR" MOLECULAR ENDOCRINOLOGY, vol. 1, no. 10, 1987, pages 735-744, XP001002989 ISSN: 0888-8809 the whole document ---	1-22, 25-30
Y	LU B ET AL: "Estrogen receptor-beta mRNA variants in human and murine tissues." MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 138, no. 1-2, 16 March 1998 (1998-03-16), pages 199-203, XP001002992 ISSN: 0303-7207 the whole document ---	1-22, 25-30
X	KOIKE S ET AL: "MOLECULAR CLONING AND CHARACTERIZATION OF RAT ESTROGEN RECEPTOR CDNA" NUCLEIC ACIDS RESEARCH, vol. 15, no. 6, 25 March 1987 (1987-03-25), pages 2499-2513, XP002026307 ISSN: 0305-1048 the whole document ---	2,8,9

-/-

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PFEFFER ULRICH ET AL: "Alternative splicing of the estrogen receptor primary transcript normally occurs in estrogen receptor positive tissues and cell lines." JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 56, no. 1-6, 1996, pages 99-105, XP001002991 ISSN: 0960-0760 the whole document -----	1-22, 25-30
T	WO 01 00823 A (EUROP MOLECULAR BIOLOGY LAB ;DINGER STEFANIE (IT); FLOURIOT GILLES) 4 January 2001 (2001-01-04) -----	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IL 00/00766

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 23 24 54 55
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
1-61 (inventions 1, 30 and 31)

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 23 24 54 55

Present claims 23, 24, 54 and 55 relate to compounds defined by reference to a desirable characteristic or property, namely their capacity to be an activator or deactivator of a particular protein.

The claims cover all compounds having this characteristic or property, whereas the application provides no support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for any of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search impossible. Consequently, no search has been carried out for these claims.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: Invention 1: Claims 1-30 (all partially)

A nucleic acid sequence defined by SEQ ID 1 and its corresponding aminoacid sequence SEQ ID 88. An antibody binding specifically to the protein, vectors and hosts expressing the nucleic acid, pharmaceutical compositions containing them and their uses in therapy or diagnostic.

2. Claims: Invention 2: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 2 and 89.

3. Claims: Invention 3: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 3 and 90.

4. Claims: Invention 4: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 4,5,91 and 92.

5. Claims: Invention 5: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 6 and 93.

6. Claims: Invention 6: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 7 and 94.

7. Claims: Invention 7: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 8 and 95.

8. Claims: Invention 8: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 9,10,96 and 97.

9. Claims: Invention 9: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 11 and 98.

10. Claims: Invention 10: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 12 and 99.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

11. Claims: Invention 11: Claims 1-30 (all partially)
As for subject 1, but concerning SEQ IDs 13-16 and 100-103.
12. Claims: Invention 12: Claims 1-30 (all partially)
As for subject 1, but concerning SEQ IDs 17-19, 104-106 and 163.
13. Claims: Invention 13: Claims 1-30 (all partially)
As for subject 1, but concerning SEQ IDs 20, 107 and 159.
14. Claims: Invention 14: Claims 1-30 (all partially)
As for subject 1, but concerning SEQ IDs 21-24, 61, 62, 108-111, 149, 150 and 160-162.
15. Claims: Invention 15: Claims 1-30 (all partially)
As for subject 1, but concerning SEQ IDs 25 and 112.
16. Claims: Invention 16: Claims 1-30 (all partially)
As for subject 1, but concerning SEQ IDs 26, 27, 113 and 114.
17. Claims: Invention 17: Claims 1-30 (all partially)
As for subject 1, but concerning SEQ IDs 28, 64, 115, 152 and 164.
18. Claims: Invention 18: Claims 1-30 (all partially)
As for subject 1, but concerning SEQ IDs 29, 116 and 139.
19. Claims: Invention 19: Claims 1-30 (all partially)
As for subject 1, but concerning SEQ IDs 30-34, 52-55, 117-121 and 140-143.
20. Claims: Invention 20: Claims 1-30 (all partially)
As for subject 1, but concerning SEQ IDs 35, 122, 170 and 171.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

21. Claims: Invention 21: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 36 and 123.

22. Claims: Invention 22: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 37,38,124,125 and 167.

23. Claims: Invention 23: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 39 and 126.

24. Claims: Invention 24: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 40,45,46,127, 132,133 and 168.

25. Claims: Invention 25: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 41 and 128.

26. Claims: Invention 26: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 42,43,48-50, 129,130 and 135-137.

27. Claims: Invention 27: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 44 and 131.

28. Claims: Invention 28: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 47 and 134.

29. Claims: Invention 29: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 51,138 and 165.

30. Claims: Invention 30: Claims 1-30 (all partially) and
claims 31-61

As for subject 1, but concerning SEQ IDs 56,85,144 and 172.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

31. Claims: Invention 31: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 57,145 and 173.

32. Claims: Invention 32: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 58 and 146.

33. Claims: Invention 33: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 59 and 147.

34. Claims: Invention 34: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 60,148 and 174.

35. Claims: Invention 35: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 63 and 151.

36. Claims: Invention 36: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 65 and 153.

37. Claims: Invention 37: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 66 and 154.

38. Claims: Invention 38: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 67 and 155.

39. Claims: Invention 39: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 68,69,156,157 and 166.

40. Claims: Invention 40: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 70,158 and 169.

41. Claims: Inventions 41 to 56: Claims 1-30 (all partially)

As for subject 1, but concerning SEQ IDs 71-84, 86 and 87

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

respectively.

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
GB 2264948	A	15-09-1993	US 6166181 A	26-12-2000
			US 5599671 A	04-02-1997
			US 5817760 A	06-10-1998
WO 9325677	A	23-12-1993	AU 4296693 A	04-01-1994
			EP 0644935 A	29-03-1995
			JP 8500967 T	06-02-1996
WO 9003435	A	05-04-1990	FR 2636968 A	30-03-1990
			AT 121457 T	15-05-1995
			DE 68922297 D	24-05-1995
			DE 68922297 T	14-09-1995
			EP 0388466 A	26-09-1990
			JP 2854062 B	03-02-1999
			JP 3502643 T	20-06-1991
			US 5480793 A	02-01-1996
			US 5359045 A	25-10-1994
WO 8500369	A	31-01-1985	DE 148922 T	05-12-1985
			EP 0148922 A	24-07-1985
			US 4783412 A	08-11-1988
WO 0100823	A	04-01-2001	AU 6152700 A	31-01-2001